source_type,name,id,target_gene,exon_or_intron,number_exon_intron,target_variant,species,cell_line,delivery_approach,aso_type,oligo_sequence,modification,modification_mask,concentration,concentration_unit,type_of_efficiency,efficiency,efficiency_units,efficiency_text,comment,DNA.RNA,link,top1_hit,top1_real,top1_predicted
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.11e+19,5,nM,skip,16,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.11e+19,10,nM,skip,24,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.11e+19,25,nM,skip,43,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.11e+19,50,nM,skip,51,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.11e+19,100,nM,skip,63,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.11e+19,5,nM,skip,44,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.11e+19,10,nM,skip,52,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.11e+19,25,nM,skip,67,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.11e+19,50,nM,skip,70,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.11e+19,100,nM,skip,60,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.01e+19,5,nM,skip,36,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.01e+19,10,nM,skip,52,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.01e+19,25,nM,skip,62,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.01e+19,50,nM,skip,74,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.01e+19,100,nM,skip,69,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.01e+18,5,nM,skip,31,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.01e+18,10,nM,skip,38,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.01e+18,25,nM,skip,65,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.01e+18,50,nM,skip,70,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,US 2020/0308586 A1,DMD,exon,23,NA,mouse,H2K mdx myotubes,"lipofectamine,lipofectin",SSO,ggccaaacctcggcttaccu,"PMO,2'-OMe,TMO",1.01e+18,100,nM,skip,71,%,NA,NA,RNA,https://patents.google.com/patent/US2020/0308586A1,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,25,nM,NA,32.46,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,50,nM,NA,58.69,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,100,nM,NA,60.33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,300,nM,NA,81.31,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,600,nM,NA,84.1,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,25,nM,NA,26.97,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,50,nM,NA,36.51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,100,nM,NA,63.49,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,300,nM,NA,50.66,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,600,nM,NA,91.78,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,25,nM,NA,19.71,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,25,nM,NA,51.19,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,50,nM,NA,47.62,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,100,nM,NA,70.24,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,300,nM,NA,88.69,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,600,nM,NA,92.86,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping Restores Dystrophin Expression In Dmd Patient Derived Muscle Cells,PMID 11468272,DMD,exon,46,NA,mouse,C2C12 mouse myotubes,"PEI, AON linked to PEI at a ratio of 3",NA,uuagcugcugcucau,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11468272,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping Restores Dystrophin Expression In Dmd Patient Derived Muscle Cells,PMID 11468272,DMD,exon,46,NA,mouse,C2C12 mouse myotubes,"PEI, AON linked to PEI at a ratio of 3",NA,cugcugcucaucucc,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11468272,ERROR,ERROR,ERROR
journal article,Modification Of Splicing In The Dystrophin Gene In Cultured Mdx Muscle Cells By Antisense Oligoribonucleotides,PMID 9618164,DMD,exon,23,NA,mouse,primary mdx myotubes,"PEI, 9:1 phosphate:nitrogen",NA,gaaguucauuuaca,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/9618164,ERROR,ERROR,ERROR
journal article,Modification Of Splicing In The Dystrophin Gene In Cultured Mdx Muscle Cells By Antisense Oligoribonucleotides,PMID 9618164,DMD,exon,23,NA,mouse,primary mdx myotubes,"PEI, 9:1 phosphate:nitrogen",NA,gcagagccucaa,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/9618164,ERROR,ERROR,ERROR
journal article,Modification Of Splicing In The Dystrophin Gene In Cultured Mdx Muscle Cells By Antisense Oligoribonucleotides,PMID 9618164,DMD,exon,23,NA,mouse,primary mdx myotubes,"PEI, 9:1 phosphate:nitrogen",NA,gcuuaccugaaauu,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/9618164,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping And Synthesis Of Dystrophin In The Mdx Mouse,PMID 11120883,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2 ug",NA,guuuauacgcacaaucacauuuacu,2OMe,NA,1,uM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11120883,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping And Synthesis Of Dystrophin In The Mdx Mouse,PMID 11120883,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2 ug",NA,ugaagauaaauuaaaacuccgagacguuu,2OMe,NA,1,uM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11120883,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping And Synthesis Of Dystrophin In The Mdx Mouse,PMID 11120883,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2 ug",NA,cgaaaatttcaggtaagccg,2OMe,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/11120883,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping And Synthesis Of Dystrophin In The Mdx Mouse,PMID 11120883,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2 ug",NA,gcuuuuaaaguccauucggctccaa,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11120883,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping And Synthesis Of Dystrophin In The Mdx Mouse,PMID 11120883,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2 ug",NA,gcuuuuaaaguccauucggc,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11120883,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping And Synthesis Of Dystrophin In The Mdx Mouse,PMID 11120883,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2 ug",NA,gcuuuuaaaguccauucggc,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11120883,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping Restores Dystrophin Expression In Dmd Patient Derived Muscle Cells,PMID 11468272,DMD,exon,46,NA,mouse,C2C12 mouse myotubes,"PEI, AON linked to PEI at a ratio of 3",NA,cugcuucuuccagcc,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11468272,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping Restores Dystrophin Expression In Dmd Patient Derived Muscle Cells,PMID 11468272,DMD,exon,46,NA,mouse,C2C12 mouse myotubes,"PEI, AON linked to PEI at a ratio of 3",NA,guuaucugcuucuuccagcc,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11468272,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping Restores Dystrophin Expression In Dmd Patient Derived Muscle Cells,PMID 11468272,DMD,exon,46,NA,mouse,C2C12 mouse myotubes,"PEI, AON linked to PEI at a ratio of 3",NA,guuguucuuuuagcugcugc,2OMe,NA,1,uM,Null,no reproducible induction,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11468272,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping Restores Dystrophin Expression In Dmd Patient Derived Muscle Cells,PMID 11468272,DMD,exon,46,NA,human,"Primary human myotubes (healthy, del45)","PEI, AON linked to PEI at a ratio of 3.5",NA,guuaucugcuuccuccaacc,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11468272,ERROR,ERROR,ERROR
journal article,Antisense-Induced Exon Skipping Restores Dystrophin Expression In Dmd Patient Derived Muscle Cells,PMID 11468272,DMD,exon,46,NA,human,"Primary human myotubes (healthy, del45)","PEI, AON linked to PEI at a ratio of 3.5",NA,uugcugcucuuuucc,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/11468272,ERROR,ERROR,ERROR
journal article,Target Selection For Antisense Oligonucleotide Induced Exon Skipping In The Dystrophin Gene.,PMID 12797117,DMD,exon,19,NA,human/mouse,"healthy/mdx H2K myoblast cells, primary healthy human myotubes","Lipofectin, 2:1 ratio of Lipofectin:AO",NA,ucugcuggcaucuugcaguu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/12797117,ERROR,ERROR,ERROR
journal article,Target Selection For Antisense Oligonucleotide Induced Exon Skipping In The Dystrophin Gene.,PMID 12797117,DMD,exon,19,NA,human/mouse,"healthy/mdx H2K myoblast cells, primary healthy human myotubes","Lipofectin, 2:1 ratio of Lipofectin:AO",NA,gccugagcugaucugcuggc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/12797117,ERROR,ERROR,ERROR
journal article,Target Selection For Antisense Oligonucleotide Induced Exon Skipping In The Dystrophin Gene.,PMID 12797117,DMD,exon,19,NA,human/mouse,"healthy/mdx H2K myoblast cells, primary healthy human myotubes","Lipofectin, 2:1 ratio of Lipofectin:AO",NA,gccugagcugaucugcu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/12797117,ERROR,ERROR,ERROR
journal article,Target Selection For Antisense Oligonucleotide Induced Exon Skipping In The Dystrophin Gene.,PMID 12797117,DMD,exon,19,NA,human/mouse,"healthy/mdx H2K myoblast cells, primary healthy human myotubes","Lipofectin, 2:1 ratio of Lipofectin:AO",NA,gccugagcugaucu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/12797117,ERROR,ERROR,ERROR
journal article,Target Selection For Antisense Oligonucleotide Induced Exon Skipping In The Dystrophin Gene.,PMID 12797117,DMD,exon,19,NA,human/mouse,"healthy/mdx H2K myoblast cells, primary healthy human myotubes","Lipofectin, 2:1 ratio of Lipofectin:AO",NA,aucuugcaguuuuc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/12797117,ERROR,ERROR,ERROR
journal article,Target Selection For Antisense Oligonucleotide Induced Exon Skipping In The Dystrophin Gene.,PMID 12797117,DMD,exon,19,NA,human/mouse,"healthy/mdx H2K myoblast cells, primary healthy human myotubes","Lipofectin, 2:1 ratio of Lipofectin:AO",NA,ugaucugcuggc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/12797117,ERROR,ERROR,ERROR
journal article,Target Selection For Antisense Oligonucleotide Induced Exon Skipping In The Dystrophin Gene.,PMID 12797117,DMD,exon,19,NA,human/mouse,"healthy/mdx H2K myoblast cells, primary healthy human myotubes","Lipofectin, 2:1 ratio of Lipofectin:AO",NA,auggccugcagcaugagagcaaagg,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/12797117,ERROR,ERROR,ERROR
journal article,Target Selection For Antisense Oligonucleotide Induced Exon Skipping In The Dystrophin Gene.,PMID 12797117,DMD,exon,19,NA,human/mouse,"healthy/mdx H2K myoblast cells, primary healthy human myotubes","Lipofectin, 2:1 ratio of Lipofectin:AO",NA,aaucaacuucauguaauuaccauuu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/12797117,ERROR,ERROR,ERROR
journal article,Target Selection For Antisense Oligonucleotide Induced Exon Skipping In The Dystrophin Gene.,PMID 12797117,DMD,exon,19,NA,human/mouse,"healthy/mdx H2K myoblast cells, primary healthy human myotubes","Lipofectin, 2:1 ratio of Lipofectin:AO",NA,gcucuauggccugcagcaugagagcaaaga,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/12797117,ERROR,ERROR,ERROR
journal article,Target Selection For Antisense Oligonucleotide Induced Exon Skipping In The Dystrophin Gene.,PMID 12797117,DMD,exon,19,NA,human/mouse,"healthy/mdx H2K myoblast cells, primary healthy human myotubes","Lipofectin, 2:1 ratio of Lipofectin:AO",NA,aacucguguaauuaccauucaccau,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/12797117,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary healthy human myotubes,"PEI, 3.5 ul per ug AO",NA,gcttttcttttagttgctgctc,unmodified PMO,NA,1,uM,Skip,6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary healthy human myotubes,"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (LNA),NA,500,nM,Skip,85,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary healthy human myotubes,"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (PNA),NA,20,uM,Null,data not shown,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary patient myotubes (del45),"PEI, 3.5 ul per ug AO",NA,gcttttcttttagttgctgctc,unmodified PMO,NA,1,uM,Skip,5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary patient myotubes (del45),"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (LNA),NA,500,nM,Skip,98,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary patient myotubes (del45),"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (PNA),NA,20,uM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary healthy human myotubes,"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (LNA),NA,400,nM,Skip,30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary healthy human myotubes,"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (LNA),NA,300,nM,Skip,15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary healthy human myotubes,"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (LNA),NA,200,nM,Skip,3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary healthy human myotubes,"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (LNA),NA,100,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary patient myotubes (del45),"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (LNA),NA,400,nM,Skip,93,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary patient myotubes (del45),"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (LNA),NA,300,nM,Skip,86,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary patient myotubes (del45),"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (LNA),NA,200,nM,Skip,41,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Comparative Analysis Of Antisense Oligonucleotide Analogs For Targeted Dmd Exon 46 Skipping In Muscle Cells,PMID 15229633,DMD,exon,46,NA,human,Primary patient myotubes (del45),"PEI, 3.5 ul per ug AO",NA,cttttagttgctgc,Others (LNA),NA,100,nM,Skip,10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/15229633,ERROR,ERROR,ERROR
journal article,Targeted Exon Skipping In Transgenic Hdmd Mice: A Model For Direct Preclinical Screening Of Human-Specific Antisense Oligonucleotides,PMID 15294170,DMD,exon,46,NA,mouse,"Wild-type mice (C57Bl/6NCrL), i.m. GAS",Null,NA,cugcuucuuccagcc,2OMe,NA,5.4,nmol,Skip,2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/15294170,ERROR,ERROR,ERROR
journal article,Targeted Exon Skipping In Transgenic Hdmd Mice: A Model For Direct Preclinical Screening Of Human-Specific Antisense Oligonucleotides,PMID 15294170,DMD,exon,46,NA,mouse,"Wild-type mice (C57Bl/6NCrL), i.m. GAS",Null,NA,cugcuucuuccagcc,2OMe,NA,3.6,nmol,Skip,2.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/15294170,ERROR,ERROR,ERROR
journal article,Targeted Exon Skipping In Transgenic Hdmd Mice: A Model For Direct Preclinical Screening Of Human-Specific Antisense Oligonucleotides,PMID 15294170,DMD,exon,46,NA,mouse,"Wild-type mice (C57Bl/6NCrL), i.m. GAS",Null,NA,cugcuucuuccagcc,2OMe,NA,1.8,nmol,Skip,1.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/15294170,ERROR,ERROR,ERROR
journal article,Targeted Exon Skipping In Transgenic Hdmd Mice: A Model For Direct Preclinical Screening Of Human-Specific Antisense Oligonucleotides,PMID 15294170,DMD,exon,46,NA,mouse,"Wild-type mice (C57Bl/6NCrL), i.m. GAS",Null,NA,cugcuucuuccagcc,2OMe,NA,0.9,nmol,Skip,0.75,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/15294170,ERROR,ERROR,ERROR
journal article,Targeted Exon Skipping In Transgenic Hdmd Mice: A Model For Direct Preclinical Screening Of Human-Specific Antisense Oligonucleotides,PMID 15294170,DMD,exon,46,NA,mouse,"mdx-BL10 mice, i.m. GAS",Null,NA,cugcuucuuccagcc,2OMe,NA,3.6,nmol,Skip,8.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/15294170,ERROR,ERROR,ERROR
journal article,Targeted Exon Skipping In Transgenic Hdmd Mice: A Model For Direct Preclinical Screening Of Human-Specific Antisense Oligonucleotides,PMID 15294170,DMD,exon,46,NA,mouse,"mdx-BL10 mice, i.m. GAS",Null,NA,cugcuucuuccagcc,2OMe,NA,1.8,nmol,Skip,8.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/15294170,ERROR,ERROR,ERROR
journal article,Targeted Exon Skipping In Transgenic Hdmd Mice: A Model For Direct Preclinical Screening Of Human-Specific Antisense Oligonucleotides,PMID 15294170,DMD,exon,46,NA,mouse,"mdx-BL10 mice, i.m. GAS",Null,NA,cugcuucuuccagcc,2OMe,NA,0.9,nmol,Skip,4,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/15294170,ERROR,ERROR,ERROR
journal article,Targeted Exon Skipping In Transgenic Hdmd Mice: A Model For Direct Preclinical Screening Of Human-Specific Antisense Oligonucleotides,PMID 15294170,DMD,exon,46,NA,mouse,"mdx-BL10 mice, i.m. GAS",Null,NA,cugcuucuuccagcc,2OMe,NA,0.36,nmol,Skip,2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/15294170,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,6,NA,dog,Primary GRMD myotubes,"L2K, 1:1 AO:lipoplex ratio",NA,catttttgacctacatggga,2OMe,NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,6,NA,dog,Primary GRMD myotubes,"L2K, 1:1 AO:lipoplex ratio",NA,tttgacctacatgggaaaga,2OMe,NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,6,NA,dog,Primary GRMD myotubes,"L2K, 1:1 AO:lipoplex ratio",NA,tacgagttgattgtcggacccag,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,6,NA,dog,Primary GRMD myotubes,"L2K, 1:1 AO:lipoplex ratio",NA,atctcagtggtctccttacctatgac,2OMe,NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,6,NA,dog,Primary GRMD myotubes,"L2K, 1:1 AO:lipoplex ratio",NA,tggtctccttacctatgactgtgg,2OMe,NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,8,NA,dog,Primary GRMD myotubes,"L2K, 1:1 AO:lipoplex ratio",NA,gataagtggtggcaacatctgt,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,8,NA,dog,Primary GRMD myotubes,"L2K, 1:1 AO:lipoplex ratio",NA,gtggcaacatctgtaagcac,2OMe,NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,8,NA,dog,Primary GRMD myotubes,"L2K, 1:1 AO:lipoplex ratio",NA,tactttacctgttgaga,2OMe,NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,8,NA,dog,Primary GRMD myotubes,"L2K, 1:1 AO:lipoplex ratio",NA,tgatactttacctgttgagaatagtg,2OMe,NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,8/6,NA,dog,Primary GRMD myotubes,"L2K, 1:1 AO:lipoplex ratio",NA,tacgagttgattgtcggacccag/gataagtggtggcaacatctgt,2OMe,NA,20-600,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,8/6,NA,dog,Primary GRMD myotubes,Null,NA,tacgagttgattgtcggacccag/gataagtggtggcaacatctgt,unmodified PMO,NA,50-20000,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro In A Canine Model Of Dmd,PMID 16724091,DMD,exon,8/6,NA,dog,Primary GRMD myotubes,Null,NA,tacgagttgattgtcggacccag/gataagtggtggcaacatctgt,modified PMO (PPMO),NA,50-10000,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16724091,ERROR,ERROR,ERROR
journal article,Intraperitoneal Administration Of Phosphorothioate Antisense Oligodeoxynucleotide Against Splicing Enhancer Sequence Induced Exon Skipping In Dystrophin Mrna Expressed In Mdx Skeletal Muscle,PMID 16198206,DMD,exon,19,NA,mouse,"mdx mice, i.p.",Null,NA,gcctgagctgatctgctggcatcttgcagtt,Others (DNA-PS),NA,0.2-200,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16198206,ERROR,ERROR,ERROR
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,"2,5,10",ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,ERROR,ERROR,ERROR
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ggccaaacctcggcttacctgaaat,2OMe,NA,"5, 10",ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,ERROR,ERROR,ERROR
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ccaaacctcggctta,Others (PNA),NA,"5, 10",ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,ERROR,ERROR,ERROR
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ccaaacctcggctta,Others (PNA),NA,"5, 10",ug,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,NA,NA,NA
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ggccaaacctcggctta,Others (PNA),NA,"5, 10",ug,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,NA,NA,NA
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ggccaaacctcggcttacctgaaat,Others (PMO (leashed)),NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,NA,NA,NA
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ggccaaacctcggcttacctgaaat,2OMe,NA,2,ug,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,NA,NA,NA
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ccaaacctcggctta,Others (PNA (leashed)),NA,2,ug,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,NA,NA,NA
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ccaaacctcggctta,Others (PNA (leashed)),NA,2,ug,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,NA,NA,NA
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ggccaaacctcggctta,Others (PNA (leashed)),NA,2,ug,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,NA,NA,NA
journal article,Dystrophin Expression In The Mdx Mouse After Localised And Systemic Administration Of A Morpholino Antisense Oligonucleotide,PMID 16285002,DMD,exon,23,NA,mouse,"mdx mice, i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16285002,NA,NA,NA
journal article,Antisense-Induced Multiexon Skipping For Duchenne Muscular Dystrophy Makes More Sense,PMID 14681829,DMD,exon,43/44,NA,human,DMD human primary myotubes (MyoD-converted fibroblast),"PEI, 3.5 ul per ug AO",NA,cuguagcuucacccuuucc/cgccgccauuucucaacag,2OMe,NA,200,nM,Skip,30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/14681829,NA,NA,NA
journal article,Antisense-Induced Multiexon Skipping For Duchenne Muscular Dystrophy Makes More Sense,PMID 14681829,DMD,exon,45/51,NA,human,DMD human primary myotubes,"PEI, 3.5 ul per ug AO",NA,gcccaaugccauccugg/ccucugugauuuuauaacuugau,2OMe,NA,200,nM,Skip,75,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/14681829,NA,NA,NA
journal article,Antisense-Induced Multiexon Skipping For Duchenne Muscular Dystrophy Makes More Sense,PMID 14681829,DMD,exon,45/51,NA,human,healthy human myotubes (KM109),"PEI, 3.5 ul per ug AO",NA,gcccaaugccauccugg/ccucugugauuuuauaacuugau,2OMe,NA,200,nM,Skip,15.78,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/14681829,NA,NA,NA
journal article,Antisense-Induced Multiexon Skipping For Duchenne Muscular Dystrophy Makes More Sense,PMID 14681829,DMD,exon,45/51,NA,human,healthy human myotubes (KM109),"PEI, 3.5 ul per ug AO",NA,gcccaaugccauccugg-ccucugugauuuuauaacuugau,2OMe,NA,200,nM,Skip,26.13,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/14681829,NA,NA,NA
journal article,Antisense-Induced Multiexon Skipping For Duchenne Muscular Dystrophy Makes More Sense,PMID 14681829,DMD,exon,45/51,NA,human,DMD human primary myotubes,"PEI, 3.5 ul per ug AO",NA,gcccaaugccauccugg/ccucugugauuuuauaacuugau,2OMe,NA,200,nM,Skip,64.17,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/14681829,NA,NA,NA
journal article,Antisense-Induced Multiexon Skipping For Duchenne Muscular Dystrophy Makes More Sense,PMID 14681829,DMD,exon,45/51,NA,human,DMD human primary myotubes,"PEI, 3.5 ul per ug AO",NA,gcccaaugccauccugg-ccucugugauuuuauaacuugau,2OMe,NA,200,nM,Skip,3.62,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/14681829,NA,NA,NA
journal article,Antisense-Induced Multiexon Skipping For Duchenne Muscular Dystrophy Makes More Sense,PMID 14681829,DMD,exon,45/51,NA,human,DMD human primary myotubes,"PEI, 3.5 ul per ug AO",NA,gcccaaugccauccugg/ccucugugauuuuauaacuugau,2OMe,NA,200,nM,Skip,5.69,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/14681829,NA,NA,NA
journal article,Antisense-Induced Multiexon Skipping For Duchenne Muscular Dystrophy Makes More Sense,PMID 14681829,DMD,exon,45/51,NA,human,DMD human primary myotubes,"PEI, 3.5 ul per ug AO",NA,gcccaaugccauccugg-ccucugugauuuuauaacuugau,2OMe,NA,200,nM,Skip,21.99,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/14681829,NA,NA,NA
journal article,Enhanced In Vivo Delivery Of Antisense Oligonucleotides To Restore Dystrophin Expression In Adult Mdx Mouse Muscle,PMID 14527677,DMD,exon,23,NA,mouse,"mdx mice, im, TA",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,8,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/14527677,NA,NA,NA
journal article,Vivo-Morpholinos: A Non-Peptide Transporter Delivers Morpholinos Into A Wide Array Of Mouse Tissues,PMID 19238792,DMD,exon,23,NA,mouse,"mdx mice, im, soleus",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-Morpholinos),NA,12.5,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19238792,NA,NA,NA
journal article,Vivo-Morpholinos: A Non-Peptide Transporter Delivers Morpholinos Into A Wide Array Of Mouse Tissues,PMID 19238792,DMD,exon,23,NA,mouse,"mdx mice, im, gastro",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-Morpholinos),NA,25,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19238792,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, im, gastro",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,58 (two consecutive days),uM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, im, gastro",Null,NA,uaaaguccauucggcuccaaaccgg,2OMe,NA,58 (two consecutive days),uM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, im, gastro",Null,NA,taaagtccattcggctccaaaccgg,unmodified PMO,NA,58 (two consecutive days),uM,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,44,NA,mouse,"hDMD mice, im, gastro",Null,NA,cccuuguacgauuuauguuu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:human exon 44,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,44,NA,mouse,"hDMD mice, im, gastro",Null,NA,cuuaacccuuguacgauuuauguuu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:human exon 44,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,44,NA,mouse,"hDMD mice, im, gastro",Null,NA,cttaacccttgtacgatttatgttt,unmodified PMO,NA,58 (two consecutive days),uM,Skip[%]:human exon 44,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,44,NA,mouse,"hDMD mice, im, gastro",Null,NA,cccuuguacgauuuauguuu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 44,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,44,NA,mouse,"hDMD mice, im, gastro",Null,NA,cuuaacccuuguacgauuuauguuu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 44,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,44,NA,mouse,"hDMD mice, im, gastro",Null,NA,cttaacccttgtacgatttatgttt,unmodified PMO,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 44,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,45,NA,mouse,"hDMD mice, im, gastro",Null,NA,gguccuaccguaacccg,2OMe,NA,58 (two consecutive days),uM,Skip[%]:human exon 45,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uugucagcaauccauugcuugaaggc,2OMe,NA,10,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,45,NA,mouse,"hDMD mice, im, gastro",Null,NA,guccuaccguaacccgucgccguuu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:human exon 45,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,45,NA,mouse,"hDMD mice, im, gastro",Null,NA,gtcctaccgtaacccgtcgccgttt,unmodified PMO,NA,58 (two consecutive days),uM,Skip[%]:human exon 45,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,45,NA,mouse,"hDMD mice, im, gastro",Null,NA,gguccuaccguaacccg,2OMe,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 45,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,45,NA,mouse,"hDMD mice, im, gastro",Null,NA,guccuaccguaacccgucgccguuu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 45,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,45,NA,mouse,"hDMD mice, im, gastro",Null,NA,gtcctaccgtaacccgtcgccgttt,unmodified PMO,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 45,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,46,NA,mouse,"hDMD mice, im, gastro",Null,NA,aucauagggugaacuugga,2OMe,NA,58 (two consecutive days),uM,Skip[%]:human exon 46,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,46,NA,mouse,"hDMD mice, im, gastro",Null,NA,aucauagggugaacuuggaccuuuu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:human exon 46,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,46,NA,mouse,"hDMD mice, im, gastro",Null,NA,atcatagggtgaacttggacctttt,unmodified PMO,NA,58 (two consecutive days),uM,Skip[%]:human exon 46,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,46,NA,mouse,"hDMD mice, im, gastro",Null,NA,aucauagggugaacuugga,2OMe,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 46,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,46,NA,mouse,"hDMD mice, im, gastro",Null,NA,aucauagggugaacuuggaccuuuu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 46,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,46,NA,mouse,"hDMD mice, im, gastro",Null,NA,atcatagggtgaacttggacctttt,unmodified PMO,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 46,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,51,NA,mouse,"hDMD mice, im, gastro",Null,NA,ucuuuacgguagaaggaacu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:human exon 51,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,51,NA,mouse,"hDMD mice, im, gastro",Null,NA,uuugaucuuuacgguagaaggaacu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:human exon 51,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,51,NA,mouse,"hDMD mice, im, gastro",Null,NA,tttgatctttacggtagaaggaact,unmodified PMO,NA,58 (two consecutive days),uM,Skip[%]:human exon 51,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,51,NA,mouse,"hDMD mice, im, gastro",Null,NA,ucuuuacgguagaaggaacu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 51,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,51,NA,mouse,"hDMD mice, im, gastro",Null,NA,uuugaucuuuacgguagaaggaacu,2OMe,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 51,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,51,NA,mouse,"hDMD mice, im, gastro",Null,NA,tttgatctttacggtagaaggaact,unmodified PMO,NA,58 (two consecutive days),uM,Skip[%]:mouse exon 51,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:gastro,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uaaaguccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:gastro,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,taaagtccattcggctccaaaccgg,unmodified PMO,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:gastro,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Quad,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uaaaguccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Quad,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,taaagtccattcggctccaaaccgg,unmodified PMO,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Quad,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Triceps,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uaaaguccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Triceps,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,taaagtccattcggctccaaaccgg,unmodified PMO,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Triceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:TA,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uaaaguccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:TA,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,taaagtccattcggctccaaaccgg,unmodified PMO,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Diaphragm,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uaaaguccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Diaphragm,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,taaagtccattcggctccaaaccgg,unmodified PMO,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Diaphragm,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Heart,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,uaaaguccauucggcuccaaaccgg,2OMe,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Heart,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,In Vivo Comparison Of 2'-O-Methyl Phosphorothioate And Morpholino Antisense Oligonucleotides For Duchenne Muscular Dystrophy Exon Skipping,PMID 19140108,DMD,exon,23,NA,mouse,"mdx mice, iv",Null,NA,taaagtccattcggctccaaaccgg,unmodified PMO,NA,14.52 (three times a week for 3 weeks),umol/kg,Skip[%]:Heart,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19140108,NA,NA,NA
journal article,Proteomic Profiling Of Antisense-Induced Exon Skipping Reveals Reversal Of Pathobiochemical Abnormalities In Dystrophic Mdx Diaphragm,PMID 19132684,DMD,exon,23,NA,mouse,"MDX mice, intraperitoneal",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (P007-PMO),NA,10 (per week),mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19132684,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,uccaauugggggcgucucuguucca,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,aucuugcaguguugccugaaagaaaaaaaa,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,cauuaagagacuuacuucgaucaguaauga,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,gggcagcaguaaugaguucuuccaauuggg,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,uucaaauucugggcagcaguaaugaguucu,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,cauucaacuguugucuccuguucugcagcug,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,ucugaauucuuucaacuggaauaaaaauaa,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,augcuugacacuaaccuugguuucugugau,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,ugucuccuguucugcagcuguucuugaacc,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,uuaacauuucauucaacuguugucuccugu,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,guugaauccuuuaacauuucauucaacugu,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,cagccauuguguugaauccuuuaacauuuc,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,ucugcagcuguucuugaaccucaucccacu,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,uucaacuggaauaaaaauaagaauaaagaa,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,ccaugagucaagcuugccucugaccugucc,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,cuacugugugaggaccuucuuuccaugagu,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,ucugugaucuucuuuuggauugcaucuacu,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,uuuuaaagauaugcuugacacuaaccuugg,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,cuggaauaaaaauaagaauaaagaa,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,uucaacuggaauaaaaauaagaaua,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,auuguguugaauccuuuaacauuuc,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,cagccauuguguugaauccuuuaac,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,53,NA,mouse,H-2K mdx immortalised myogenic cells,"Lipofectin, OptiMEM",NA,ccuguucggcuucuuccuuagcuuc,2OMe,NA,unspecified,unspecified,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,4CV cultured primary myoblasts,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,2OMe,NA,600,mM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,4CV cultured primary myoblasts,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,2OMe,NA,600,mM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,4CV cultured primary myoblasts,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,2OMe,NA,600,mM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,4CV cultured primary myoblasts,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,2OMe,NA,600,mM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,4CV cultured primary myoblasts,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,2OMe,NA,600,mM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,"4CV mice, TA, im",No,NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,2OMe,NA,100,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,"4CV mice, diaphragm, intraperitoneal",No,NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,2OMe,NA,100,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,4CV cultured primary myoblasts,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,modified PMO (P007-PMO),NA,10,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,4CV cultured primary myoblasts,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,modified PMO (P007-PMO),NA,10,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,4CV cultured primary myoblasts,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,modified PMO (P007-PMO),NA,10,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,4CV cultured primary myoblasts,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,modified PMO (P007-PMO),NA,10,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,4CV cultured primary myoblasts,"Lipofectin, OptiMEM",NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,modified PMO (P007-PMO),NA,10,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,"4CV mice, TA, im",No,NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,modified PMO (P007-PMO),NA,40,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,"4CV mice, TA, im",No,NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,modified PMO (P007-PMO),NA,40,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,"4CV mice, TA, im",No,NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,modified PMO (P007-PMO),NA,40,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,"4CV mice, TA, im",No,NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,modified PMO (P007-PMO),NA,40,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,By-Passing The Nonsense Mutation In The 4cv Mouse Model Of Muscular Dystrophy By Induced Exon Skipping,PMID 19006096,DMD,exon,52/53,NA,mouse,"4CV mice, TA, im",No,NA,aaugaguucuuccaauugggggcgucucug/ucugaauucuuucaacuggaauaaaaauaa/augcuugacacuaaccuugguuucugugau/cagccauuguguugaauccuuuaacauuuc,modified PMO (P007-PMO),NA,40,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19006096,NA,NA,NA
journal article,Effective Rescue Of Dystrophin Improves Cardiac Function In Dystrophin-Deficient Mice By A Modified Morpholino Oligomer,PMID 18806224,DMD,exon,23,NA,mouse,"mdx mice, iv",No,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,30,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/18806224,NA,NA,NA
journal article,Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides Restore Systemic Muscle And Cardiac Dystrophin Expression And Function,PMID 18784278,DMD,exon,23,NA,mouse,"mdx mice, iv",No,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/18784278,NA,NA,NA
journal article,Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides Restore Systemic Muscle And Cardiac Dystrophin Expression And Function,PMID 18784278,DMD,exon,23,NA,mouse,"mdx mice, iv",No,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/18784278,NA,NA,NA
journal article,Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides Restore Systemic Muscle And Cardiac Dystrophin Expression And Function,PMID 18784278,DMD,exon,23,NA,mouse,"mdx mice, iv",No,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/18784278,NA,NA,NA
journal article,Long-Term Benefit Of Adeno-Associated Virus/Antisense-Mediated Exon Skipping In Dystrophic Mice,PMID 18500943,DMD,exon,23,NA,mouse,"mdx mice, iv",No,NA,mu1anti5'(cgaaatttcaggtaagccgaggttatgagatcttgggcctctgc)andmu1anti3'(gaactttgcagagcctcaaaattaaatagggcaggggagataccatgatc),Others (AAV1/U1-antisense RNA),NA,310^12,genome copies,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18500943,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,gggacagagguugcagugagcugagau,2OMe,NA,10,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,cucacgaggcugaggcaggagaau,2OMe,NA,10,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,gggacagagguugcagugagcugagau/cucacgaggcugaggcaggagaau,2OMe,NA,10,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,gggacagagguugcagugagcugagau,2OMe,NA,30,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,cucacgaggcugaggcaggagaau,2OMe,NA,30,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,gggacagagguugcagugagcugagau/cucacgaggcugaggcaggagaau,2OMe,NA,30,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,gggacagagguugcagugagcugagau,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,cucacgaggcugaggcaggagaau,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,gggacagagguugcagugagcugagau/cucacgaggcugaggcaggagaau,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,gggacagagguugcagugagcugagau,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,cucacgaggcugaggcaggagaau,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 11,NA,human,BMD myoblasts,ExGen500,NA,gggacagagguugcagugagcugagau/cucacgaggcugaggcaggagaau,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uaccacugccuugcuuccgucuccca,2OMe,NA,10,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uugucagcaauccauugcuugaaggc/uaccacugccuugcuuccgucuccca,2OMe,NA,10,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uugucagcaauccauugcuugaaggc,2OMe,NA,30,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uaccacugccuugcuuccgucuccca,2OMe,NA,30,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uugucagcaauccauugcuugaaggc/uaccacugccuugcuuccgucuccca,2OMe,NA,30,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uugucagcaauccauugcuugaaggc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uaccacugccuugcuuccgucuccca,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uugucagcaauccauugcuugaaggc/uaccacugccuugcuuccgucuccca,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uugucagcaauccauugcuugaaggc,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uaccacugccuugcuuccgucuccca,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,"Dmd Pseudoexon Mutations: Splicing Efficiency, Phenotype, And Potential Therapy",PMID 18059005,DMD,intron,intron 45,NA,human,DMD myoblasts,ExGen500,NA,uugucagcaauccauugcuugaaggc/uaccacugccuugcuuccgucuccca,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/18059005,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA),NA,250,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA),NA,2.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA),NA,25,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,2.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,25,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,2.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,25,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,2.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,25,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,2.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,H2K mdx myoblasts,"Opti-MEM, lipofectin",NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,25,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA),NA,10,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA),NA,20,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,10,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,20,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,10,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,20,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,10,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,20,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,10,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Effective Exon Skipping And Restoration Of Dystrophin Expression By Peptide Nucleic Acid Antisense Oligonucleotides In Mdx Mice,PMID 17968354,DMD,exon,23,NA,mouse,"mdx mice, TA, im",No,NA,ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,20,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17968354,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,tttgatctttacggtagaaggaact,unmodified PMO,NA,100,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cgtcttccatactcttttttactat,unmodified PMO,NA,100,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,uaguucgucuuccauacucu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,uucgucuuccauacucuuuu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,gucuuccauacucuuuuuua,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,uuccauacucuuuuucua,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cauacucuuuuuuacuauuu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,acucuuuuuuacuauuuuca,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,400,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exons 48 to 50,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exons 48 to 50,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exons 48 to 50,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exons 48 to 50,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,45,NA,human,primary myoblasts from a DMD patient with an exon 45 duplication,ExGen500,NA,gcccaaugccauccugg,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exons 48 to 50,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,400,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exons 48 to 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exons 48 to 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exons 48 to 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exons 48 to 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exons 48 to 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,400,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exon 50,Lipofectin,NA,ucaaggaagauggcauuucu,2OMe,NA,100,nM,Skip,13,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exon 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,100,nM,Skip,73,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,500,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectamine,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,500,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,ExGen,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,500,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Oligofectamine,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,500,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,HFM cells,Lipofectin,NA,tttgatctttacggtagaaggaact,unmodified PMO,NA,50,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,HFM cells,Lipofectin,NA,tttgatctttacggtagaaggaact,unmodified PMO,NA,100,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,HFM cells,Lipofectin,NA,tttgatctttacggtagaaggaact,unmodified PMO,NA,200,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,HFM cells,Lipofectin,NA,tttgatctttacggtagaaggaact,unmodified PMO,NA,300,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,HFM cells,Lipofectin,NA,tttgatctttacggtagaaggaact,unmodified PMO,NA,400,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,HFM cells,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,HFM cells,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,HFM cells,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,HFM cells,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,HFM cells,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,400,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,250,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,500,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,tttgatctttacggtagaaggaact,unmodified PMO,NA,500,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,human skeletal muscle cell,Lipofectin,NA,cgtcttccatactcttttttactat,unmodified PMO,NA,500,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exon 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exon 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exon 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exon 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,400,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,cultured myogenic cells from a DMD patient with a deletion in exon 50,Lipofectin,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,500,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,human,Muscle explants from a DMD patient (3-11),Opti-MEM,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,400,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,mouse,"transgenic human DMD mice, gastro, im",Null,NA,cgtcttccatactcttttttactat,unmodified PMO,NA,2.9,nmol,Skip,1.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,mouse,"transgenic human DMD mice, gastro, im",Null,NA,tttgatctttacggtagaaggaact,unmodified PMO,NA,2.9,nmol,Skip,5.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Comparative Analysis Of Antisense Oligonucleotide Sequences For Targeted Skippingg Of Exon 51 During Dystrophin Pre-Mrna Splicing In Human Muscle,PMID 17767400,DMD,exon,51,NA,mouse,"transgenic human DMD mice, gastro, im",Null,NA,cuccaacaucaaggaagauggcauuucuag,unmodified PMO,NA,2.9,nmol,Skip,22.1,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17767400,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,45,NA,human,primary myoblasts from a DMD patient with an exon 45 duplication,ExGen500,NA,gcccaaugccauccugg,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,45,NA,human,primary myoblasts from a DMD patient with an exon 45 duplication,ExGen500,NA,gcccaaugccauccugg,2OMe,NA,150,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,45,NA,human,primary myoblasts from a DMD patient with an exon 45 duplication,ExGen500,NA,gcccaaugccauccugg,2OMe,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,45,NA,human,primary myoblasts from a DMD patient with an exon 45 duplication,ExGen500,NA,gcccaaugccauccugg,2OMe,NA,250,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,44,NA,human,primary myoblasts from a DMD patient with an exon 44 duplication,ExGen500,NA,uuuguauuuagcauguuccc,2OMe,NA,20,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,44,NA,human,primary myoblasts from a DMD patient with an exon 44 duplication,ExGen500,NA,uuuguauuuagcauguuccc,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,44,NA,human,primary myoblasts from a DMD patient with an exon 44 duplication,ExGen500,NA,uuuguauuuagcauguuccc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,44,NA,human,primary myoblasts from a DMD patient with an exon 44 duplication,ExGen500,NA,cgccgccauuucucaacag,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,44,NA,human,primary myoblasts from a DMD patient with an exon 44 duplication,ExGen500,NA,cgccgccauuucucaacag,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Antisense-Induced Exon Skipping For Duplications In Duchenne Muscular Dystrophy,PMID 17612397,DMD,exon,52/62,NA,human,primary myoblasts from a DMD patient with an exon 52-62 duplication,ExGen501,NA,uugcuggucuuguuuuuc/uggcucucucccaggg,2OMe,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17612397,NA,NA,NA
journal article,Morpholino Oligomer-Mediated Exon Skipping Averts The Onset Of Dystrophic Pathology In The Mdx Mouse,PMID 17579573,DMD,exon,23,NA,mouse,"mdx mouse, intraperitoneal",No,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPP),NA,1,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17579573,NA,NA,NA
journal article,Morpholino Oligomer-Mediated Exon Skipping Averts The Onset Of Dystrophic Pathology In The Mdx Mouse,PMID 17579573,DMD,exon,23,NA,mouse,"mdx mouse, intraperitoneal",No,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPP),NA,2,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17579573,NA,NA,NA
journal article,Morpholino Oligomer-Mediated Exon Skipping Averts The Onset Of Dystrophic Pathology In The Mdx Mouse,PMID 17579573,DMD,exon,23,NA,mouse,"mdx mouse, intraperitoneal",No,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPP),NA,5,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17579573,NA,NA,NA
journal article,Morpholino Oligomer-Mediated Exon Skipping Averts The Onset Of Dystrophic Pathology In The Mdx Mouse,PMID 17579573,DMD,exon,23,NA,mouse,"mdx mouse, intraperitoneal",No,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPP),NA,10,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17579573,NA,NA,NA
journal article,Morpholino Oligomer-Mediated Exon Skipping Averts The Onset Of Dystrophic Pathology In The Mdx Mouse,PMID 17579573,DMD,exon,23,NA,mouse,"mdx mouse, intraperitoneal",No,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPP),NA,25,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17579573,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], quadriceps",30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], abdominal",30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], intercostal",30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], TA",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], diaphragm",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], heart",0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], heart",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], diaphragm",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], abdominal",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], intercostal",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], biceps",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], triceps",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], TA",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], quadriceps",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Systemic Delivery Of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide And Improves Dystrophic Pathology,PMID 16444267,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,mg,"Skip[%], GAS",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/16444267,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], heart",5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], GAS",17,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], quadriceps",15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], TA",15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], triceps",15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], diaphragm",20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx/utrn+/- mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], heart",5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx/utrn+/- mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], GAS",20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx/utrn+/- mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], quadriceps",15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx/utrn+/- mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], TA",15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx/utrn+/- mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], triceps",15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,Long-term Exon Skipping Studies With 2-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models,PMID 23344236,DMD,exon,23,NA,mouse,"mdx/utrn+/- mice, 24x weekly s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,"Skip[%], diaphragm",15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344236,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.125,uM,Skip,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.25,uM,Skip,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,60,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.125,uM,Skip,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.25,uM,Skip,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.125,uM,Skip,10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.25,uM,Skip,30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.125,uM,Skip,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.25,uM,Skip,35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.125,uM,Skip,15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.25,uM,Skip,35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.125,uM,Skip,10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.25,uM,Skip,35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.125,uM,Skip,10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.25,uM,Skip,35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,60,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,auauucacagaccugcaauu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], quadriceps",20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], diaphragm",10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], heart",7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], quadriceps",15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], diaphragm",10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], heart",10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], quadriceps",15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], diaphragm",10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], heart",10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], quadriceps",15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], diaphragm",15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], heart",10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], quadriceps",15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], diaphragm",20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], heart",7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], quadriceps",12.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], diaphragm",10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], heart",2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], quadriceps",7.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], diaphragm",7.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], heart",2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], quadriceps",5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], diaphragm",5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], heart",5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], quadriceps",5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], diaphragm",5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,"Pip6-Pmo, A New Generation Of Peptide-Oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity For Dmd Treatment",PMID 23344180,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,"Skip[%], heart",5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23344180,NA,NA,NA
journal article,Cationic Pmma Nanoparticles Bind And Deliver Antisense Oligoribonucleotides Allowing Restoration Of Dystrophin Expression In The Mdx Mouse,PMID 19240694,DMD,exon,23,NA,mouse,"mdx mice, single i.p. with 2.5 mg T1 nanoparticles",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,45,ug,"Skip[%], skeletal muscles (GAS, QUA)",6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19240694,NA,NA,NA
journal article,Cationic Pmma Nanoparticles Bind And Deliver Antisense Oligoribonucleotides Allowing Restoration Of Dystrophin Expression In The Mdx Mouse,PMID 19240694,DMD,exon,23,NA,mouse,"mdx mice, single i.p. with 2.5 mg T1 nanoparticles",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,45,ug,"Skip[%], heart",16,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19240694,NA,NA,NA
journal article,Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice,PMID 23091362,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p, evaluate 90 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], quadriceps",2.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23091362,NA,NA,NA
journal article,Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice,PMID 23091362,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p, evaluate 90 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], diaphragm",6.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23091362,NA,NA,NA
journal article,Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice,PMID 23091362,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p, evaluate 90 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], heart",3.3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23091362,NA,NA,NA
journal article,Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice,PMID 23091362,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. with 2.5 mg ZM2 nanoparticles, evaluate 90 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], quadriceps",6.3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23091362,NA,NA,NA
journal article,Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice,PMID 23091362,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. with 2.5 mg ZM2 nanoparticles, evaluate 90 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], diaphragm",9.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23091362,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 10x i.p. every other day",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,15,mg/kg,"Skip[%], diaphragm",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice,PMID 23091362,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. with 2.5 mg ZM2 nanoparticles, evaluate 90 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], heart",7.8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23091362,NA,NA,NA
journal article,"Dystrophin Restoration In Skeletal, Heart And Skin Arrector Pili Smooth Muscle Of Mdx Mice By Zm2 Np?Aon Complexes",PMID 19907501,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. evaluate 7 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], heart",0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19907501,NA,NA,NA
journal article,"Dystrophin Restoration In Skeletal, Heart And Skin Arrector Pili Smooth Muscle Of Mdx Mice By Zm2 Np?Aon Complexes",PMID 19907501,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. evaluate 7 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], quadriceps",2.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19907501,NA,NA,NA
journal article,"Dystrophin Restoration In Skeletal, Heart And Skin Arrector Pili Smooth Muscle Of Mdx Mice By Zm2 Np?Aon Complexes",PMID 19907501,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. evaluate 7 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], GAS",2.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19907501,NA,NA,NA
journal article,"Dystrophin Restoration In Skeletal, Heart And Skin Arrector Pili Smooth Muscle Of Mdx Mice By Zm2 Np?Aon Complexes",PMID 19907501,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. evaluate 7 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], diaphragm",2.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19907501,NA,NA,NA
journal article,"Dystrophin Restoration In Skeletal, Heart And Skin Arrector Pili Smooth Muscle Of Mdx Mice By Zm2 Np?Aon Complexes",PMID 19907501,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. with 2.5 mg ZM2 nanoparticles, evaluate 7 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], heart",3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19907501,NA,NA,NA
journal article,"Dystrophin Restoration In Skeletal, Heart And Skin Arrector Pili Smooth Muscle Of Mdx Mice By Zm2 Np?Aon Complexes",PMID 19907501,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. with 2.5 mg ZM2 nanoparticles, evaluate 7 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], quadriceps",10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19907501,NA,NA,NA
journal article,"Dystrophin Restoration In Skeletal, Heart And Skin Arrector Pili Smooth Muscle Of Mdx Mice By Zm2 Np?Aon Complexes",PMID 19907501,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. with 2.5 mg ZM2 nanoparticles, evaluate 7 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], GAS",5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19907501,NA,NA,NA
journal article,"Dystrophin Restoration In Skeletal, Heart And Skin Arrector Pili Smooth Muscle Of Mdx Mice By Zm2 Np?Aon Complexes",PMID 19907501,DMD,exon,23,NA,mouse,"mdx mice, 7x weekly i.p. with 2.5 mg ZM2 nanoparticles, evaluate 7 days post-final injection",Null,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,7.5,mg/kg,"Skip[%], diaphragm",25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19907501,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, single i.p.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,6,mg/kg,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, single i.p.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,30,mg/kg,"Skip[%], TA",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 10x i.p. every other day",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,15,mg/kg,"Skip[%], abdominal",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 10x i.p. every other day",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,15,mg/kg,"Skip[%], intercostal",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 10x i.p. every other day",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,15,mg/kg,"Skip[%], diaphragm",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 10x i.p. every other day",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,15,mg/kg,"Skip[%], heart",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 10x i.p. every other day",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,15,mg/kg,"Skip[%], TA",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 10x i.p. every other day",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,15,mg/kg,"Skip[%], abdominal",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 10x i.p. every other day",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,15,mg/kg,"Skip[%], intercostal",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 10x i.p. every other day",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,15,mg/kg,"Skip[%], heart",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,6,mg/kg,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,300,mg/kg,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 5x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,6,mg/kg,"Skip[%], TA",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 5x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,6,mg/kg,"Skip[%], abdominal",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 5x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,6,mg/kg,"Skip[%], intercostal",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 5x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,6,mg/kg,"Skip[%], diaphragm",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 5x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,6,mg/kg,"Skip[%], heart",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 5x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,6,mg/kg,"Skip[%], quadriceps",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 5x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,6,mg/kg,"Skip[%], GAS",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Octa-Guanidine Morpholino Restores Dystrophin Expression In Cardiac And Skeletal Muscles And Ameliorates Pathology In Dystrophic Mdx Mice,PMID 19277018,DMD,exon,23,NA,mouse,"mdx mice, 5x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (Vivo-PMO),NA,6,mg/kg,"Skip[%], biceps",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19277018,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,Primary mdx cardiac myoblasts,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2.5,ug/ml,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,Primary mdx cardiac myoblasts,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,10,ug/ml,Skip,30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,Primary mdx cardiac myoblasts,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,ug/ml,Skip,50,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,C2C12 myoblasts,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2.5,ug/ml,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,C2C12 myoblasts,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,10,ug/ml,Skip,30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,C2C12 myoblasts,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,ug/ml,Skip,50,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,Fresh mdx cardiomyocytes,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,ug/ml,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,Fresh mdx heart muscle,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,ug/ml,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,Fresh mdx TA,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,ug/ml,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.03,g/kg,"Skip[%], muscle unspecified",0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.06,g/kg,"Skip[%], muscle unspecified",0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.15,g/kg,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.3,g/kg,"Skip[%], TA/diaphragm/heart",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.6,g/kg,"Skip[%], TA/diaphragm/heart",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,1.5,g/kg,"Skip[%], TA/diaphragm/heart",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,3,g/kg,"Skip[%], TA/diaphragm",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Dose-Dependent Restoration Of Dystrophin Expression In Cardiac Muscle Of Dystrophic Mice By Systemically Delivered Morpholino,PMID 19759562,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,3,g/kg,"Skip[%], heart",30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19759562,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with EPC at molar charge ratios of 0.1:0,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with EPC at molar charge ratios of 0.05:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with EPC at molar charge ratios of 0.25:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with EPC at molar charge ratios of 0.5:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,0.79,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with C20-20 at molar charge ratios of 0.05:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,1.18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with C20-20 at molar charge ratios of 0.1:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,4.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with C20-20 at molar charge ratios of 0.25:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,29.7,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with C20-20 at molar charge ratios of 0.5:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with C30-20 at molar charge ratios of 0.05:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with C30-20 at molar charge ratios of 0.1:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,0.13,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with C30-20 at molar charge ratios of 0.25:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,8.28,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Novel Cationic Carotenoid Lipids As Delivery Vectors Of Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 22274137,DMD,exon,45,NA,human,normal human skeletal muscle primary cells with C30-20 at molar charge ratios of 0.5:1,Null,NA,"sequenceavailableonrequest,purchasedfromgenetools",unmodified PMO,NA,250,nM,Skip,68.3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22274137,NA,NA,NA
journal article,Combination Antisense Treatment For Destructive Exon Skipping Of Myostatin And Open Reading Frame Rescue Of Dystrophin In Neonatal Mdx Mice,PMID 25959011,DMD,exon,23,NA,mouse,Mdx neonates,Null,NA,ggccaaacctcggcttacctgaaat/agcccatcttctcctggtcctgggaagg,modified PMO (BPMO),NA,10,mg/kg,Skip,29.72,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25959011,NA,NA,NA
journal article,Combination Antisense Treatment For Destructive Exon Skipping Of Myostatin And Open Reading Frame Rescue Of Dystrophin In Neonatal Mdx Mice,PMID 25959011,DMD,exon,23,NA,mouse,Mdx neonates,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (BPMO),NA,10,mg/kg,Skip,35.38,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25959011,NA,NA,NA
journal article,Dual Myostatin And Dystrophin Exon Skipping By Morpholino Nucleic Acid Oligomers Conjugated To A Cell-Penetrating Peptide Is A Promising Therapeutic Strategy For The Treatment Of Duchenne Muscular Dystrophy,PMID 23250360,DMD,exon,23,NA,mouse,Mdx mice,Null,NA,ggccaaacctcggcttacctgaaat/agcccatcttctcctggtcctgggaagg,modified PMO (BPMO),NA,10,ug,Skip,51.16,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23250360,NA,NA,NA
journal article,Dual Myostatin And Dystrophin Exon Skipping By Morpholino Nucleic Acid Oligomers Conjugated To A Cell-Penetrating Peptide Is A Promising Therapeutic Strategy For The Treatment Of Duchenne Muscular Dystrophy,PMID 23250360,DMD,exon,23,NA,mouse,Mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (BPMO),NA,10,ug,Skip,40.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23250360,NA,NA,NA
journal article,Systemic Antisense Therapeutics For Dystrophin And Myostatin Exon Splice Modulation Improve Muscle Pathology Of Adult Mdx Mice,PMID 28325281,DMD,exon,23,NA,mouse,Mdx mice,Null,NA,ggccaaacctcggcttacctgaaat/cagcccatcttctcctggtcctgggaaggt,modified PMO (BPMO),NA,10,mg/kg,Skip,65.12,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28325281,NA,NA,NA
journal article,Systemic Antisense Therapeutics For Dystrophin And Myostatin Exon Splice Modulation Improve Muscle Pathology Of Adult Mdx Mice,PMID 28325281,DMD,exon,23,NA,mouse,Mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (BPMO),NA,10,mg/kg,Skip,62.79,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28325281,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,DMD,exon,50 (DMD)/ 2(MSTN),NA,human,DMD del51-55 primary myoblasts (DL589.2),polyethyleneimine 2.5 ul/ug of AON,NA,cucagagcucagaucuu/guuugaugagucucaggauu,2OMe,NA,400,nM,Skip,"not quantified, but skipped bands range are strong for exon 50 dys , faint for exon 2 MSTN",NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,DMD,exon,51 (DMD)/ 2(MSTN),NA,human,DMD del51-55 primary myoblasts (DL589.2),polyethyleneimine 2.5 ul/ug of AON,NA,cucagagcucagaucuu/guuugaugagucucaggauu,2OMe,NA,200,nM,Skip,"not quantified, but skipped bands range are strong for exon 50 dys , faint for exon 2 MSTN",NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,DMD,exon,51 (DMD)/ 2(MSTN),NA,human,DMD del51-55 primary myoblasts (DL589.2),polyethyleneimine 2.5 ul/ug of AON,NA,cucagagcucagaucuu/guuugaugagucucaggauu,2OMe,NA,100,nM,Skip,"not quantified, but skipped bands range are moderate-strong for exon 23 dys , faint for exon 2 MSTN",NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,DMD,exon,52 (DMD)/ 2(MSTN),NA,mouse,"mdx mice, i.m. GAS",Null,NA,ggccaaaccucggcuuaccu/guuugaugagucucaggauu,2OMe,NA,40,ug each,Skip,"not quantified, but skipped bands range are moderate-strong for exon 23 dys , faint for exon 2 MSTN",NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cugcaauuccccgagucucugc,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cugcaauuccccgagucucugc,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cugcaauuccccgagucucugc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cugcaauuccccgagucucugc,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cugcaauuccccgagucucugc,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,auauucacagaccugcaauu,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,auauucacagaccugcaauu,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,auauucacagaccugcaauu,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,auauucacagaccugcaauu,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,mouse,H-2K mdx cells,Lipofectin,NA,cuguaauuucccgagucucucc,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,mouse,H-2K mdx cells,Lipofectin,NA,cuguaauuucccgagucucucc,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,mouse,H-2K mdx cells,Lipofectin,NA,cuguaauuucccgagucucucc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,mouse,H-2K mdx cells,Lipofectin,NA,cuguaauuucccgagucucucc,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,mouse,H-2K mdx cells,Lipofectin,NA,cuguaauuucccgagucucucc,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,mouse,H-2K mdx cells,Lipofectin,NA,auguccacagaccuguaauu,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,mouse,H-2K mdx cells,Lipofectin,NA,auguccacagaccuguaauu,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,mouse,H-2K mdx cells,Lipofectin,NA,auguccacagaccuguaauu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,mouse,H-2K mdx cells,Lipofectin,NA,auguccacagaccuguaauu,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,22,NA,mouse,H-2K mdx cells,Lipofectin,NA,auguccacagaccuguaauu,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cggcuaauuucagagggcgcuuucuucgac,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cggcuaauuucagagggcgcuuucuucgac,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cggcuaauuucagagggcgcuuucuucgac,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cggcuaauuucagagggcgcuuucuucgac,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cggcuaauuucagagggcgcuuucuucgac,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,aguaaaaucuugaauuaccugaauu,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,aguaaaaucuugaauuaccugaauu,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,aguaaaaucuugaauuaccugaauu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,aguaaaaucuugaauuaccugaauu,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,aguaaaaucuugaauuaccugaauu,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,mouse,H-2K mdx cells,Lipofectin,NA,uggcauauuucugaaggugcuuucuuggcc,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,mouse,H-2K mdx cells,Lipofectin,NA,uggcauauuucugaaggugcuuucuuggcc,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,mouse,H-2K mdx cells,Lipofectin,NA,uggcauauuucugaaggugcuuucuuggcc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,mouse,H-2K mdx cells,Lipofectin,NA,uggcauauuucugaaggugcuuucuuggcc,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,mouse,H-2K mdx cells,Lipofectin,NA,uggcauauuucugaaggugcuuucuuggcc,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,mouse,H-2K mdx cells,Lipofectin,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,mouse,H-2K mdx cells,Lipofectin,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,mouse,H-2K mdx cells,Lipofectin,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,mouse,H-2K mdx cells,Lipofectin,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,23,NA,mouse,H-2K mdx cells,Lipofectin,NA,ggccaaaccucggcuuaccugaaau,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,caagggcaggccauuccuccuuc,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,caagggcaggccauuccuccuuc,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,caagggcaggccauuccuccuuc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,caagggcaggccauuccuccuuc,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,caagggcaggccauuccuccuuc,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,caacuucagccauccauuucuucag/cagcugcuuuuuuagaauuucugaa,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,caacuucagccauccauuucuucag/cagcugcuuuuuuagaauuucugaa,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,caacuucagccauccauuucuucag/cagcugcuuuuuuagaauuucugaa,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,caacuucagccauccauuucuucag/cagcugcuuuuuuagaauuucugaa,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,caacuucagccauccauuucuucag/cagcugcuuuuuuagaauuucugaa,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,mouse,H-2K mdx cells,Lipofectin,NA,ccagggcaggccauuccucuuuc,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,mouse,H-2K mdx cells,Lipofectin,NA,ccagggcaggccauuccucuuuc,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,mouse,H-2K mdx cells,Lipofectin,NA,ccagggcaggccauuccucuuuc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,mouse,H-2K mdx cells,Lipofectin,NA,ccagggcaggccauuccucuuuc,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,mouse,H-2K mdx cells,Lipofectin,NA,ccagggcaggccauuccucuuuc,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,mouse,H-2K mdx cells,Lipofectin,NA,caacuucagccauccauuucuguaa/gagcuguuuuuucaggauuucagca,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,mouse,H-2K mdx cells,Lipofectin,NA,caacuucagccauccauuucuguaa/gagcuguuuuuucaggauuucagca,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,mouse,H-2K mdx cells,Lipofectin,NA,caacuucagccauccauuucuguaa/gagcuguuuuuucaggauuucagca,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,mouse,H-2K mdx cells,Lipofectin,NA,caacuucagccauccauuucuguaa/gagcuguuuuuucaggauuucagca,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,24,NA,mouse,H-2K mdx cells,Lipofectin,NA,caacuucagccauccauuucuguaa/gagcuguuuuuucaggauuucagca,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cuggcagaauucgauccaccggcuguuc/cagcaguaguugucaucugcuc,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cuggcagaauucgauccaccggcuguuc/cagcaguaguugucaucugcuc,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cuggcagaauucgauccaccggcuguuc/cagcaguaguugucaucugcuc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cuggcagaauucgauccaccggcuguuc/cagcaguaguugucaucugcuc,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cuggcagaauucgauccaccggcuguuc/cagcaguaguugucaucugcuc,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,guucaguuguucugaggcuuguuug/aguaguugucaucugcuccaauugu,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,guucaguuguucugaggcuuguuug/aguaguugucaucugcuccaauugu,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,guucaguuguucugaggcuuguuug/aguaguugucaucugcuccaauugu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,guucaguuguucugaggcuuguuug/aguaguugucaucugcuccaauugu,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,guucaguuguucugaggcuuguuug/aguaguugucaucugcuccaauugu,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,mouse,H-2K mdx cells,Lipofectin,NA,uuggcagaauucuguccaccggcuguuc/cggcaguaguugucaucuguuc,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,mouse,H-2K mdx cells,Lipofectin,NA,uuggcagaauucuguccaccggcuguuc/cggcaguaguugucaucuguuc,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,mouse,H-2K mdx cells,Lipofectin,NA,uuggcagaauucuguccaccggcuguuc/cggcaguaguugucaucuguuc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,mouse,H-2K mdx cells,Lipofectin,NA,uuggcagaauucuguccaccggcuguuc/cggcaguaguugucaucuguuc,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,mouse,H-2K mdx cells,Lipofectin,NA,uuggcagaauucuguccaccggcuguuc/cggcaguaguugucaucuguuc,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,mouse,H-2K mdx cells,Lipofectin,NA,guucaguuguucugaggcuuguuug/aguaguugucaucugcuccaauugu,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,mouse,H-2K mdx cells,Lipofectin,NA,guucaguuguucugaggcuuguuug/aguaguugucaucugcuccaauugu,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,mouse,H-2K mdx cells,Lipofectin,NA,guucaguuguucugaggcuuguuug/aguaguugucaucugcuccaauugu,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,mouse,H-2K mdx cells,Lipofectin,NA,guucaguuguucugaggcuuguuug/aguaguugucaucugcuccaauugu,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,20,NA,mouse,H-2K mdx cells,Lipofectin,NA,guucaguuguucugaggcuuguuug/aguaguugucaucugcuccaauugu,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cagccauuguguugaauccuuuaacauuuc/uuaaaaagguaucuuugauacuaaccuugg,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cagccauuguguugaauccuuuaacauuuc/uuaaaaagguaucuuugauacuaaccuugg,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cagccauuguguugaauccuuuaacauuuc/uuaaaaagguaucuuugauacuaaccuugg,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cagccauuguguugaauccuuuaacauuuc/uuaaaaagguaucuuugauacuaaccuugg,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cagccauuguguugaauccuuuaacauuuc/uuaaaaagguaucuuugauacuaaccuugg,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cauucaacuguugucuccuguucugcagcug,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cauucaacuguugucuccuguucugcagcug,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cauucaacuguugucuccuguucugcagcug,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cauucaacuguugucuccuguucugcagcug,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cauucaacuguugucuccuguucugcagcug,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cagccauuguguugaauccuuuaacauuuc/uuuuaaagauaugcuugacacuaaccuugg,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cagccauuguguugaauccuuuaacauuuc/uuuuaaagauaugcuugacacuaaccuugg,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cagccauuguguugaauccuuuaacauuuc/uuuuaaagauaugcuugacacuaaccuugg,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cagccauuguguugaauccuuuaacauuuc/uuuuaaagauaugcuugacacuaaccuugg,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cagccauuguguugaauccuuuaacauuuc/uuuuaaagauaugcuugacacuaaccuugg,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cuacugugugaggaccuucuuuccaugagu/ucugugaucuucuuuuggauugcaucuacu,2OMe,NA,150,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cuacugugugaggaccuucuuuccaugagu/ucugugaucuucuuuuggauugcaucuacu,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,53,NA,mouse,H-2K mdx cells,Lipofectin,NA,cuacugugugaggaccuucuuuccaugagu/ucugugaucuucuuuuggauugcaucuacu,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,52,NA,mouse,H-2K mdx cells,Lipofectin,NA,uccaauugggggcgucucuguuccaaaucu,2OMe,NA,12.5,nM,Skip,47.2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,52,NA,mouse,H-2K mdx cells,Lipofectin,NA,uccaauugggggcgucucuguuccaaaucu,2OMe,NA,25,nM,Skip,43.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,52,NA,mouse,H-2K mdx cells,Lipofectin,NA,uccaauugggggcgucucuguuccaaaucu,2OMe,NA,50,nM,Skip,36.8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,52,NA,mouse,H-2K mdx cells,Lipofectin,NA,uccaauugggggcgucucuguucca/uucaaauucugggcagcaguaaugaguucu,2OMe,NA,12.5,nM,Skip,96,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,52,NA,mouse,H-2K mdx cells,Lipofectin,NA,uccaauugggggcgucucuguucca/uucaaauucugggcagcaguaaugaguucu,2OMe,NA,25,nM,Skip,69.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,52,NA,mouse,H-2K mdx cells,Lipofectin,NA,uccaauugggggcgucucuguucca/uucaaauucugggcagcaguaaugaguucu,2OMe,NA,50,nM,Skip,95.2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,65,NA,mouse,H-2K mdx cells,Lipofectin,NA,ucugcaggauauccaugggcugguc,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,65,NA,mouse,H-2K mdx cells,Lipofectin,NA,ucugcaggauauccaugggcugguc,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,65,NA,mouse,H-2K mdx cells,Lipofectin,NA,ucugcaggauauccaugggcugguc,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,65,NA,mouse,H-2K mdx cells,Lipofectin,NA,ucugcaggauauccaugggcugguc,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,65,NA,mouse,H-2K mdx cells,Lipofectin,NA,ucugcaggauauccaugggcugguc,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,65,NA,mouse,H-2K mdx cells,Lipofectin,NA,gcucaagagauccacugcaaaaaag/guugugcugguccagggcaucacau,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,65,NA,mouse,H-2K mdx cells,Lipofectin,NA,gcucaagagauccacugcaaaaaag/guugugcugguccagggcaucacau,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,65,NA,mouse,H-2K mdx cells,Lipofectin,NA,gcucaagagauccacugcaaaaaag/guugugcugguccagggcaucacau,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,65,NA,mouse,H-2K mdx cells,Lipofectin,NA,gcucaagagauccacugcaaaaaag/guugugcugguccagggcaucacau,2OMe,NA,300,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,65,NA,mouse,H-2K mdx cells,Lipofectin,NA,gcucaagagauccacugcaaaaaag/guugugcugguccagggcaucacau,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,10,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,10,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,normal human myogenic cells,Lipofectamine 2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,myogenic cells from a DMD patient with a mutation (IVS16+1G>T;c.1992+1G>T) in dystrophin exon 16,Lipofectamine 2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,10,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,myogenic cells from a DMD patient with a mutation (IVS16+1G>T;c.1992+1G>T) in dystrophin exon 16,Lipofectamine 2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,myogenic cells from a DMD patient with a mutation (IVS16+1G>T;c.1992+1G>T) in dystrophin exon 16,Lipofectamine 2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,myogenic cells from a DMD patient with a mutation (IVS16+1G>T;c.1992+1G>T) in dystrophin exon 16,Lipofectamine 2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,myogenic cells from a DMD patient with a mutation (IVS16+1G>T;c.1992+1G>T) in dystrophin exon 16,Lipofectamine 2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,myogenic cells from a DMD patient with a mutation (IVS16+1G>T;c.1992+1G>T) in dystrophin exon 16,Lipofectamine 2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,10,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,myogenic cells from a DMD patient with a mutation (IVS16+1G>T;c.1992+1G>T) in dystrophin exon 16,Lipofectamine 2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,25,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,myogenic cells from a DMD patient with a mutation (IVS16+1G>T;c.1992+1G>T) in dystrophin exon 16,Lipofectamine 2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,50,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,myogenic cells from a DMD patient with a mutation (IVS16+1G>T;c.1992+1G>T) in dystrophin exon 16,Lipofectamine 2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,100,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,Rational Design Of Antisense Oligomers To Induce Dystrophin Exon Skipping,PMID 19293776,DMD,exon,16,NA,human,myogenic cells from a DMD patient with a mutation (IVS16+1G>T;c.1992+1G>T) in dystrophin exon 16,Lipofectamine 2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,200,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19293776,NA,NA,NA
journal article,A Fusion Peptide Directs Enhanced Systemic Dystrophin Exon Skipping And Functional Restoration In Dystrophin-Deficient Mdx Mice,PMID 19692354,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPPs),NA,25,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19692354,NA,NA,NA
journal article,A Fusion Peptide Directs Enhanced Systemic Dystrophin Exon Skipping And Functional Restoration In Dystrophin-Deficient Mdx Mice,PMID 19692354,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPPs),NA,25,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19692354,NA,NA,NA
journal article,A Fusion Peptide Directs Enhanced Systemic Dystrophin Exon Skipping And Functional Restoration In Dystrophin-Deficient Mdx Mice,PMID 19692354,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPPs),NA,30,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19692354,NA,NA,NA
journal article,A Fusion Peptide Directs Enhanced Systemic Dystrophin Exon Skipping And Functional Restoration In Dystrophin-Deficient Mdx Mice,PMID 19692354,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPPs),NA,40,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19692354,NA,NA,NA
journal article,A Fusion Peptide Directs Enhanced Systemic Dystrophin Exon Skipping And Functional Restoration In Dystrophin-Deficient Mdx Mice,PMID 19692354,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPPs),NA,3,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19692354,NA,NA,NA
journal article,A Fusion Peptide Directs Enhanced Systemic Dystrophin Exon Skipping And Functional Restoration In Dystrophin-Deficient Mdx Mice,PMID 19692354,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPPs),NA,3,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19692354,NA,NA,NA
journal article,A Fusion Peptide Directs Enhanced Systemic Dystrophin Exon Skipping And Functional Restoration In Dystrophin-Deficient Mdx Mice,PMID 19692354,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPPs),NA,3,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19692354,NA,NA,NA
journal article,A Fusion Peptide Directs Enhanced Systemic Dystrophin Exon Skipping And Functional Restoration In Dystrophin-Deficient Mdx Mice,PMID 19692354,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPPs),NA,6,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19692354,NA,NA,NA
journal article,A Fusion Peptide Directs Enhanced Systemic Dystrophin Exon Skipping And Functional Restoration In Dystrophin-Deficient Mdx Mice,PMID 19692354,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PMO conjugated to CPPs),NA,6,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19692354,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12E50 myoblasts with DMSO,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.3,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12E50 myoblasts with 60 ?mol/l 6TG,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.3,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12E50 myoblasts with 90 ?mol/l 6TG,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.3,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.2,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts with 60 ?mol/l 6TG,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.2,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts with 90 ?mol/l 6TG,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.2,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.4,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts with 60 ?mol/l 6TG,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.4,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts with 90 ?mol/l 6TG,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.4,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.6,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts with 60 ?mol/l 6TG,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.6,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts with 90 ?mol/l 6TG,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.6,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12 myoblasts,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12 myoblasts with 30 ?M Guanine-hydro,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12 myoblasts with 60 ?M Guanine-hydro,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12 myoblasts with 90 ?M Guanine-hydro,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts with 30 ?M Guanine-hydro,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts with 60 ?M Guanine-hydro,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,C2C12E23 myoblasts with 90 ?M Guanine-hydro,Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12 myoblasts,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12 myoblasts with 30 ?M Guanine-hydro,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12 myoblasts with 60 ?M Guanine-hydro,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12 myoblasts with 90 ?M Guanine-hydro,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12E23 myoblasts,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12E23 myoblasts with 30 ?M Guanine-hydro,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12E23 myoblasts with 60 ?M Guanine-hydro,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,C2C12E23 myoblasts with 90 ?M Guanine-hydro,Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"C2C12 myoblasts with 30 ?M 2,8-Dim-6-hydro",Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"C2C12 myoblasts with 60 ?M 2,8-Dim-6-hydro",Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"C2C12 myoblasts with 90 ?M 2,8-Dim-6-hydro",Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"C2C12E23 myoblasts with 30 ?M 2,8-Dim-6-hydro",Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"C2C12E23 myoblasts with 60 ?M 2,8-Dim-6-hydro",Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"C2C12E23 myoblasts with 90 ?M 2,8-Dim-6-hydro",Endoporter,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12 myoblasts with 30 ?M 2,4,6-Triaminoquinazoline",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12 myoblasts with 60 ?M 2,4,6-Triaminoquinazoline",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12 myoblasts with 90 ?M 2,4,6-Triaminoquinazoline",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12E23 myoblasts with 30 ?M 2,4,6-Triaminoquinazoline",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12E23 myoblasts with 60 ?M 2,4,6-Triaminoquinazoline",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12E23 myoblasts with 90 ?M 2,4,6-Triaminoquinazoline",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12 myoblasts with 30 ?M 2,6-Dithiopurine",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12 myoblasts with 60 ?M 2,6-Dithiopurine",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12 myoblasts with 90 ?M 2,6-Dithiopurine",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12E23 myoblasts with 30 ?M 2,6-Dithiopurine",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12E23 myoblasts with 60 ?M 2,6-Dithiopurine",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,50,NA,mouse,"C2C12E23 myoblasts with 90 ?M 2,6-Dithiopurine",Endoporter,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"mdx mouse, TA, im",No,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"mdx mouse, TA, im, with 1?g 2,6-Dithiopurine",No,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"mdx mouse, TA, im, with 10?g 2,6-Dithiopurine",No,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"mdx mouse, TA, im, with 1?g 2,4,6-Triaminoquinazoline",No,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"mdx mouse, TA, im, with 10?g 2,4,6-Triaminoquinazoline",No,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"mdx mouse, TA, im, with 1?g 6TG",No,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"mdx mouse, TA, im, with 10?g 6TG",No,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"mdx mouse, TA, im, with 1?g Guanine",No,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping In Dystrophin Gene In Vitro And In Vivo,PMID 20087314,DMD,exon,23,NA,mouse,"mdx mouse, TA, im, with 10?g Guanine",No,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20087314,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacct,Others (P-PNA),NA,"1, 2",uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacct,Others (P-PNA),NA,"1, 2",uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacct,Others (P-PNA),NA,"1, 2",uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,45,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,50,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,45,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,60,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,50,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,uM,Skip,60,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,uM,Skip,50,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,55,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,uM,Skip,75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,0.5,uM,Skip,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,uM,Skip,35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,H2K mdx myotubes,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,uM,Skip,65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: quadriceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: GAS,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: biceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: diaphragm,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: abdominal,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: heart,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: quadriceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: GAS,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: biceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: diaphragm,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: abdominal,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: heart,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: quadriceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: GAS,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: biceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: diaphragm,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: abdominal,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-Mediated Dystrophin Exon Skipping In Heart And Phenotypic Correction In Mdx Mice,PMID 21505427,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,mg/kg,Skip[%]: heart,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21505427,NA,NA,NA
journal article,Prevention Of Exercised Induced Cardiomyopathy Following Pip-Pmo Treatment In Dystrophic Mdx Mice,PMID 25758104,DMD,exon,23,NA,mouse,"mdx mice, 4x everyday followed by 5 doses every 2 weeks i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,10,mg/kg,Skip[%]: heart,32,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25758104,NA,NA,NA
journal article,Prevention Of Exercised Induced Cardiomyopathy Following Pip-Pmo Treatment In Dystrophic Mdx Mice,PMID 25758104,DMD,exon,23,NA,mouse,"mdx mice, 4x everyday followed by 5 doses every 2 weeks i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,10,mg/kg,Skip[%]: diaphragm,77,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25758104,NA,NA,NA
journal article,Prevention Of Exercised Induced Cardiomyopathy Following Pip-Pmo Treatment In Dystrophic Mdx Mice,PMID 25758104,DMD,exon,23,NA,mouse,"mdx mice, 4x everyday followed by 5 doses every 2 weeks i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,10,mg/kg,Skip[%]: TA,86,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25758104,NA,NA,NA
journal article,Prevention Of Exercised Induced Cardiomyopathy Following Pip-Pmo Treatment In Dystrophic Mdx Mice,PMID 25758104,DMD,exon,23,NA,mouse,"mdx mice, 4x everyday followed by 5 doses every 2 weeks i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,10,mg/kg,Skip[%]: intercostal,86,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25758104,NA,NA,NA
journal article,Prevention Of Exercised Induced Cardiomyopathy Following Pip-Pmo Treatment In Dystrophic Mdx Mice,PMID 25758104,DMD,exon,23,NA,mouse,"mdx mice, 4x everyday followed by 5 doses every 2 weeks i.v.",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,10,mg/kg,Skip[%]: sternomastoid,86,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25758104,NA,NA,NA
journal article,Bubble Liposomes And Ultrasound Exposure Improve Localized Morpholino Oligomer Delivery Into The Skeletal Muscles Of Dystrophic Mdx Mice,PMID 24433046,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA, with bubble liposomes/ultrasound",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,5,ug,Skip,65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24433046,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,Skip[%]: TA,28,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,Skip[%]: GAS,28,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,Skip[%]: quadriceps,32,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,Skip[%]: triceps,28,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,Skip[%]: biceps,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,Skip[%]: diaphragm,34,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,Skip[%]: heart,24,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,Skip[%]: hippocampus,2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,Skip[%]: cortex,2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,Skip[%]: cerebellum,5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,Skip[%]: TA,8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,Skip[%]: GAS,8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,Skip[%]: quadriceps,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,Skip[%]: triceps,8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,Skip[%]: biceps,6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,Skip[%]: diaphragm,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,Skip[%]: heart,4,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,Skip[%]: hippocampus,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,Skip[%]: cortex,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,200,mg/kg,Skip[%]: cerebellum,0.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200,mg/kg,Skip[%]: TA,6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200,mg/kg,Skip[%]: GAS,6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200,mg/kg,Skip[%]: quadriceps,6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200,mg/kg,Skip[%]: triceps,8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200,mg/kg,Skip[%]: biceps,4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200,mg/kg,Skip[%]: diaphragm,10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200,mg/kg,Skip[%]: heart,2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200,mg/kg,Skip[%]: hippocampus,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200,mg/kg,Skip[%]: cortex,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200,mg/kg,Skip[%]: cerebellum,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,80,mg/kg,Skip[%]: TA,14,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,80,mg/kg,Skip[%]: GAS,18,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,80,mg/kg,Skip[%]: quadriceps,16,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,80,mg/kg,Skip[%]: triceps,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,80,mg/kg,Skip[%]: biceps,14,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,80,mg/kg,Skip[%]: diaphragm,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,80,mg/kg,Skip[%]: heart,6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,100,mg/kg,Skip[%]: TA,6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,100,mg/kg,Skip[%]: GAS,4,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,100,mg/kg,Skip[%]: quadriceps,4,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,100,mg/kg,Skip[%]: triceps,6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,100,mg/kg,Skip[%]: biceps,6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,100,mg/kg,Skip[%]: diaphragm,8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,100,mg/kg,Skip[%]: heart,2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,125,mg/kg,Skip[%]: TA,8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,125,mg/kg,Skip[%]: GAS,6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,125,mg/kg,Skip[%]: quadriceps,6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,125,mg/kg,Skip[%]: triceps,8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,125,mg/kg,Skip[%]: biceps,6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,125,mg/kg,Skip[%]: diaphragm,8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx mice, 12x weekly i.v.",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,125,mg/kg,Skip[%]: heart,2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: TA, 5 wks",25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: TA, 11 wks",30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: TA, 18 wks",35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: TA, 20 wks",50,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: GAS, 5 wks",25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: GAS, 11 wks",40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: GAS, 18 wks",40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: GAS, 20 wks",50,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: diaphragm, 5 wks",30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: diaphragm, 11 wks",60,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: diaphragm, 18 wks",70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: diaphragm, 20 wks",110,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: heart, 5 wks",10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: heart, 11 wks",15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: heart, 18 wks",25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: heart, 20 wks",30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: brain, 5 wks",2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: brain, 11 wks",3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: brain, 18 wks",2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Functional Correction In Mouse Models Of Muscular Dystrophy Using Exon-Skipping Tricyclo-Dna Oligomers,PMID 25642938,DMD,exon,23,NA,mouse,"mdx/utrn dKO mice, 5-20x weekly i.v.",Null,NA,aacctcggcttacct,Others (tcDNA),NA,200,mg/kg,"Skip[%]: brain, 20 wks",6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25642938,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,50,mg/kg,Skip[%]: TA,10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,50,mg/kg,Skip[%]: GAS,15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,50,mg/kg,Skip[%]: quadriceps,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,50,mg/kg,Skip[%]: triceps,10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,50,mg/kg,Skip[%]: abdominal,5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,50,mg/kg,Skip[%]: diaphragm,2.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 3x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,50,mg/kg,Skip[%]: heart,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 5x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: TA,10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 5x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: GAS,65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 5x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: quadriceps,60,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 5x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: triceps,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 5x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: abdominal,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 5x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: diaphragm,20,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, 5x weekly i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: heart,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: TA,10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: GAS,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: quadriceps,25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: triceps,5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: abdominal,5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: diaphragm,5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Peptide Nucleic Acid Promotes Systemic Dystrophin Expression And Functional Rescue In Dystrophin-Deficient Mdx Mice,PMID 26440599,DMD,exon,23,NA,mouse,"mdx mice, single i.v.",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,100,mg/kg,Skip[%]: heart,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26440599,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,50,NA,mouse,C2C12E50 myotubes,"PQ-1, 40 ?g/ml",NA,aacttcctctttaacagaaaagcatac,unmodified PMO,NA,10,ug/ml,Skip,90,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,50,NA,mouse,C2C12E50 myotubes,"PQ-2, 20 ?g/ml",NA,aacttcctctttaacagaaaagcatac,unmodified PMO,NA,10,ug/ml,Skip,90,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,50,NA,mouse,C2C12E50 myotubes,"PQ-3, 200 ?g/ml",NA,aacttcctctttaacagaaaagcatac,unmodified PMO,NA,10,ug/ml,Skip,90,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,50,NA,mouse,C2C12E50 myotubes,"PQ-4, 200 ?g/ml",NA,aacttcctctttaacagaaaagcatac,unmodified PMO,NA,10,ug/ml,Skip,35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,23,NA,mouse,C2C12E23 myotubes,"PQ-1, 100 ?g/ml",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,10,ug/ml,Skip,64.8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,23,NA,mouse,C2C12E23 myotubes,"PQ-3, 100 ?g/ml",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,10,ug/ml,Skip,61.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,23,NA,mouse,C2C12E23 myotubes,"PQ-4, 100 ?g/ml",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,10,ug/ml,Skip,45.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,23,NA,mouse,C2C12E23 myotubes,"PQ-2, 20 ?g/ml",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,10,ug/ml,Skip,57.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA with 20 ?g PQ-1",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Skip,37.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA with 20 ?g PQ-2",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Skip,25.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA with 20 ?g PQ-3",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Skip,42.8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,23,NA,mouse,"mdx mice, i.m. TA with 20 ?g PQ-4",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Skip,31.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,23,NA,mouse,"mdx mice, single i.v. with 0.5 mg PQ-1",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,1,mg,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,Polyquaternium-Mediated Delivery Of Morpholino Oligonucleotides For Exon-Skipping In Vitro And In Mdx Mice,PMID 28633548,DMD,exon,23,NA,mouse,"mdx mice, single i.v. with 0.5 mg PQ-3",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,1,mg,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28633548,NA,NA,NA
journal article,A Dystrophic Duchenne Mouse Model For Testing Human Antisense Oligonucleotides,PMID 29466448,DMD,exon,51,NA,human,"hDMDdel45 mice, i.m. GAS and triceps",Null,NA,tcaaggaagatggcatttctagttt,modified PMO (vivo-PMO),NA,40,ug,"Skip[%]: GAS, triceps",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/29466448,NA,NA,NA
journal article,A Dystrophic Duchenne Mouse Model For Testing Human Antisense Oligonucleotides,PMID 29466448,DMD,exon,53,NA,human,"hDMDdel45 mice, i.m. GAS and triceps",Null,NA,ttgcctccggttctgaaggtgttct,modified PMO (vivo-PMO),NA,40,ug,"Skip[%]: GAS, triceps",unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/29466448,NA,NA,NA
journal article,Peptide-Conjugated Phosphodiamidate Oligomer-Mediated Exon Skipping Has Benefits For Cardiac Function In Mdx And Cmah-/-Mdx Mouse Models Of Duchenne Muscular Dystrophy,PMID 29912990,DMD,exon,23,NA,mouse,"mdx mice, 4x i.v. at 18 mg/kg, 6x i.v. at 12 mg/kg, biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12/18,mg/kg,Skip[%]: heart,18,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/29912990,NA,NA,NA
journal article,Peptide-Conjugated Phosphodiamidate Oligomer-Mediated Exon Skipping Has Benefits For Cardiac Function In Mdx And Cmah-/-Mdx Mouse Models Of Duchenne Muscular Dystrophy,PMID 29912990,DMD,exon,23,NA,mouse,"mdx mice, 4x i.v. at 18 mg/kg, 6x i.v. at 12 mg/kg, biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12/18,mg/kg,Skip[%]: TA,50-70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/29912990,NA,NA,NA
journal article,Peptide-Conjugated Phosphodiamidate Oligomer-Mediated Exon Skipping Has Benefits For Cardiac Function In Mdx And Cmah-/-Mdx Mouse Models Of Duchenne Muscular Dystrophy,PMID 29912990,DMD,exon,23,NA,mouse,"mdx mice, 4x i.v. at 18 mg/kg, 6x i.v. at 12 mg/kg, biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12/18,mg/kg,Skip[%]: diaphragm,35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/29912990,NA,NA,NA
journal article,A Platform For Discovery Of Functional Cell-Penetrating Peptides For Efficient Multi-Cargo Intracellular Delivery,PMID 30135446,DMD,exon,23,NA,mouse,H2K tsA58 myotubes,unspecified,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,25,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30135446,NA,NA,NA
journal article,A Platform For Discovery Of Functional Cell-Penetrating Peptides For Efficient Multi-Cargo Intracellular Delivery,PMID 30135446,DMD,exon,23,NA,mouse,H2K tsA58 myotubes,unspecified,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,50,nM,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30135446,NA,NA,NA
journal article,A Platform For Discovery Of Functional Cell-Penetrating Peptides For Efficient Multi-Cargo Intracellular Delivery,PMID 30135446,DMD,exon,23,NA,mouse,H2K tsA58 myotubes,unspecified,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,100,nM,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30135446,NA,NA,NA
journal article,A Platform For Discovery Of Functional Cell-Penetrating Peptides For Efficient Multi-Cargo Intracellular Delivery,PMID 30135446,DMD,exon,23,NA,mouse,H2K tsA58 myotubes,unspecified,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,250,nM,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30135446,NA,NA,NA
journal article,A Platform For Discovery Of Functional Cell-Penetrating Peptides For Efficient Multi-Cargo Intracellular Delivery,PMID 30135446,DMD,exon,23,NA,mouse,H2K tsA58 myotubes,unspecified,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,500,nM,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30135446,NA,NA,NA
journal article,A Platform For Discovery Of Functional Cell-Penetrating Peptides For Efficient Multi-Cargo Intracellular Delivery,PMID 30135446,DMD,exon,23,NA,mouse,H2K tsA58 myotubes,unspecified,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1000,nM,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30135446,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,100,nM,Skip,52,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,200,nM,Skip,57,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,400,nM,Skip,65,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,100,nM,Skip,49,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,200,nM,Skip,53,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,400,nM,Skip,64,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcuuac,2OMe,NA,100,nM,Skip,23,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcuuac,2OMe,NA,200,nM,Skip,30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcuuac,2OMe,NA,400,nM,Skip,39,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,200,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,400,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcuu,2OMe,NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcuu,2OMe,NA,200,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcuu,2OMe,NA,400,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaacctcggctuacc,2OMe,NA,100,nM,Skip,51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaacctcggctuacc,2OMe,NA,200,nM,Skip,61,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaacctcggctuacc,2OMe,NA,400,nM,Skip,65,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggctuacc,2OMe,NA,100,nM,Skip,55,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggctuacc,2OMe,NA,200,nM,Skip,66,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggctuacc,2OMe,NA,400,nM,Skip,72,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,100,nM,Skip,56,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,200,nM,Skip,59,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,400,nM,Skip,56,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaacctcggctuac,2OMe,NA,100,nM,Skip,44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaacctcggctuac,2OMe,NA,200,nM,Skip,53,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaacctcggctuac,2OMe,NA,400,nM,Skip,61,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcutac,2OMe,NA,100,nM,Skip,48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcutac,2OMe,NA,200,nM,Skip,60,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcutac,2OMe,NA,400,nM,Skip,75,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcuuac,2OMe,NA,100,nM,Skip,50,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcuuac,2OMe,NA,200,nM,Skip,59,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcuuac,2OMe,NA,400,nM,Skip,63,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaacctcggctua,2OMe,NA,100,nM,Skip,33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaacctcggctua,2OMe,NA,200,nM,Skip,44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaacctcggctua,2OMe,NA,400,nM,Skip,58,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,100,nM,Skip,43,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,200,nM,Skip,57,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,400,nM,Skip,66,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuta,2OMe,NA,100,nM,Skip,37,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuta,2OMe,NA,200,nM,Skip,48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuta,2OMe,NA,400,nM,Skip,56,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaacctcggcut,2OMe,NA,100,nM,Skip,6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaacctcggcut,2OMe,NA,200,nM,Skip,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaacctcggcut,2OMe,NA,400,nM,Skip,9,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcut,2OMe,NA,100,nM,Skip,14,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcut,2OMe,NA,200,nM,Skip,24,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcut,2OMe,NA,400,nM,Skip,29,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggctt,2OMe,NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggctt,2OMe,NA,200,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggctt,2OMe,NA,400,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,12.5,nM,Skip,41,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,25,nM,Skip,55,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,50,nM,Skip,55,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggctuacc,2OMe,NA,12.5,nM,Skip,50,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggctuacc,2OMe,NA,25,nM,Skip,60,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggctuacc,2OMe,NA,50,nM,Skip,74,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcuuac,2OMe,NA,12.5,nM,Skip,16,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcuuac,2OMe,NA,25,nM,Skip,32,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcuuac,2OMe,NA,50,nM,Skip,34,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcutac,2OMe,NA,12.5,nM,Skip,44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcutac,2OMe,NA,25,nM,Skip,58,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaaccucggcutac,2OMe,NA,50,nM,Skip,68,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,12.5,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,25,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,50,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,12.5,nM,Skip,31,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,25,nM,Skip,54,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,caaaccucggcuua,2OMe,NA,50,nM,Skip,55,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcuu,2OMe,NA,12.5,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcuu,2OMe,NA,25,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcuu,2OMe,NA,50,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcut,2OMe,NA,12.5,nM,Skip,20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcut,2OMe,NA,25,nM,Skip,20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaaccucggcut,2OMe,NA,50,nM,Skip,7,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,25,nM,Skip,29.18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,50,nM,Skip,47.87,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,100,nM,Skip,70.49,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,300,nM,Skip,80,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,600,nM,Skip,86.39,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,25,nM,Skip,43.61,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,50,nM,Skip,51.15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,100,nM,Skip,57.38,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,300,nM,Skip,67.21,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,600,nM,Skip,76.72,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,25,nM,Skip,53.93,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,50,nM,Skip,52.46,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,100,nM,Skip,61.8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,300,nM,Skip,76.39,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,Normal human myoblasts,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,600,nM,Skip,79.51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,25,nM,Skip,22.37,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,50,nM,Skip,46.22,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,100,nM,Skip,72.2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,300,nM,Skip,78.45,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,600,nM,Skip,90.95,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,25,nM,Skip,57.89,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,50,nM,Skip,61.02,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,100,nM,Skip,63.65,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,300,nM,Skip,64.97,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,600,nM,Skip,80.76,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,25,nM,Skip,65.46,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,50,nM,Skip,75.33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,100,nM,Skip,67.27,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,300,nM,Skip,84.21,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 17 nonsense mutation,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,600,nM,Skip,94.57,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,25,nM,Skip,34.15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,50,nM,Skip,41.95,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,100,nM,Skip,77.07,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,300,nM,Skip,65.37,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,600,nM,Skip,96.59,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,50,nM,Skip,45.07,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,100,nM,Skip,51.32,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,300,nM,Skip,84.88,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,600,nM,Skip,92.29,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,25,nM,Skip,11.12,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,50,nM,Skip,18.93,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,100,nM,Skip,32.59,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,300,nM,Skip,34.93,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,600,nM,Skip,44.68,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,25,nM,Skip,36.88,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,50,nM,Skip,35.32,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,100,nM,Skip,42.73,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,300,nM,Skip,42.93,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with 20 base intra-exonic deletion in exon 18,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,600,nM,Skip,51.71,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,25,nM,Skip,48.51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,50,nM,Skip,55.51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,100,nM,Skip,62.2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,300,nM,Skip,92.26,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,agugauggcugagugguggugacagc/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,600,nM,Skip,89.14,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,25,nM,Skip,48.51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,50,nM,Skip,55.36,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,100,nM,Skip,52.08,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,300,nM,Skip,61.9,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cagcuucugagcgaguaauccagcugugaa,2OMe,NA,600,nM,Skip,84.82,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,25,nM,Skip,68.15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,50,nM,Skip,83.04,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,100,nM,Skip,85.42,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,300,nM,Skip,92.56,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Personalized Exon Skipping Strategies To Address Clustered Non-Deletion Dystrophin Mutations,PMID 20817455,DMD,exon,17/18,NA,human,myoblasts from a DMD patient with exon 18 duplication,"Lipofectamine 2000, opti-MEM",NA,uguucccuuguggucaccguaguuac/cugcaacacagcuucugagcgaguaauccag,2OMe,NA,600,nM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20817455,NA,NA,NA
journal article,Dosing Regimen Has A Significant Impact On The Efficiency Of Morpholino Oligomer-Induced Exon Skipping In Mdx Mice,PMID 19469709,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,1,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19469709,NA,NA,NA
journal article,Dosing Regimen Has A Significant Impact On The Efficiency Of Morpholino Oligomer-Induced Exon Skipping In Mdx Mice,PMID 19469709,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,10,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19469709,NA,NA,NA
journal article,Dosing Regimen Has A Significant Impact On The Efficiency Of Morpholino Oligomer-Induced Exon Skipping In Mdx Mice,PMID 19469709,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,100,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19469709,NA,NA,NA
journal article,Dosing Regimen Has A Significant Impact On The Efficiency Of Morpholino Oligomer-Induced Exon Skipping In Mdx Mice,PMID 19469709,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,200 single injection,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19469709,NA,NA,NA
journal article,Dosing Regimen Has A Significant Impact On The Efficiency Of Morpholino Oligomer-Induced Exon Skipping In Mdx Mice,PMID 19469709,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50 4 injections weekly,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19469709,NA,NA,NA
journal article,Dosing Regimen Has A Significant Impact On The Efficiency Of Morpholino Oligomer-Induced Exon Skipping In Mdx Mice,PMID 19469709,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,20 single injection,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19469709,NA,NA,NA
journal article,Dosing Regimen Has A Significant Impact On The Efficiency Of Morpholino Oligomer-Induced Exon Skipping In Mdx Mice,PMID 19469709,DMD,exon,23,NA,mouse,"mdx mouse, iv",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,5 4 injections weekly,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19469709,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,50,nM,Skip,12.86,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,100,nM,Skip,18.86,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,300,nM,Skip,21.43,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,500,nM,Skip,25.86,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,1,uM,Skip,30.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,50,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,300,nM,Skip,7.71,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,500,nM,Skip,9.29,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,1,uM,Skip,10.14,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,50,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,100,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,500,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,1,uM,Skip,0.68,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,50,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,100,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,300,nM,Skip,8.23,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,500,nM,Skip,9.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,1,uM,Skip,10.43,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,50,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,100,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,300,nM,Skip,3.92,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,500,nM,Skip,4.94,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,1,uM,Skip,23.85,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,100,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,300,nM,Skip,3.92,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,500,nM,Skip,4.94,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,1,uM,Skip,23.85,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,50,nM,Skip,2.87,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,100,nM,Skip,3.65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,300,nM,Skip,9.64,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,500,nM,Skip,29.19,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,1,uM,Skip,32.05,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 12 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,not described,Null,Skip,40.53,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 24 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,not described,Null,Skip,37.89,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 48 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,not described,Null,Skip,42.63,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 72 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,not described,Null,Skip,54.74,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 12 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,not described,Null,Skip,2.63,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 24 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,not described,Null,Skip,8.42,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 48 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,not described,Null,Skip,39.47,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 72 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,not described,Null,Skip,55.79,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 12 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,not described,Null,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 24 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,not described,Null,Skip,3.16,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 48 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,not described,Null,Skip,2.11,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 72 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,not described,Null,Skip,1.05,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 12 hr after transfection,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,not described,Null,Skip,12.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 24 hr after transfection,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,not described,Null,Skip,47.09,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 48 hr after transfection,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,not described,Null,Skip,40.74,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 72 hr after transfection,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,not described,Null,Skip,36.51,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 12 hr after transfection,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,not described,Null,Skip,8.47,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 24 hr after transfection,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,not described,Null,Skip,20.11,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 48 hr after transfection,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,not described,Null,Skip,8.47,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 72 hr after transfection,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,not described,Null,Skip,12.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 12 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,not described,Null,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 24 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,not described,Null,Skip,16.84,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 48 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,not described,Null,Skip,7.37,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 72 hr after transfection,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,not described,Null,Skip,16.32,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 12 hr after transfection,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,not described,Null,Skip,8.47,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 24 hr after transfection,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,not described,Null,Skip,20.11,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 48 hr after transfection,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,not described,Null,Skip,8.47,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells at 72 hr after transfection,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,not described,Null,Skip,13.23,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,10,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,1,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,5,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,10,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,1,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,10,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,1,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,10,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,1,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,10,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,1,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,10,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,1,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,10,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,300,nM,Skip,21.9,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,300,nM,Skip,8.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,5,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ygrkkrrqrrrpggccaaaccucggcuuaccu,Others (2OMePS-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,No,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,300,nM,Skip,8.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,No,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,300,nM,Skip,2.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aacctcggcttacct,Others (PNA),NA,1,uM,Skip,2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,aaacctcggcttacct,Others (PNA),NA,1,uM,Skip,0.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggctta,Others (PNA),NA,1,uM,Skip,0.05,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttac,Others (PNA),NA,1,uM,Skip,3.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ccaaacctcggcttacct,Others (PNA),NA,1,uM,Skip,1.8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (PNA),NA,1,uM,Skip,1.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (PNA),NA,1,uM,Skip,10.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,aacctcggcttacct,Others (PNA),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,aaacctcggcttacct,Others (PNA),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaacctcggctta,Others (PNA),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaacctcggcttac,Others (PNA),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ccaaacctcggcttacct,Others (PNA),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaacctcggcttacct,Others (PNA),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaacctcggcttacctgaaat,Others (PNA),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (PNA),NA,300,nM,Skip,1.65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (PNA),NA,500,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,500,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,300,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,500,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaacctcggcttacctgaaat,Others (PNA),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,(rxr)4xbggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,300,nM,Skip,0.92,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,300,nM,Skip,6.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,300,nM,Skip,19.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,(rxr)4xbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,asslniaxrxrrbrrxrrbrbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,300,nM,Skip,10.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,rxrrbrrxrrbrbasslniaxggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,300,nM,Skip,59,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,H2K mdx cells,Null,NA,rxrrbrrxrrbrxbggccaaacctcggcttacctgaaat,modified PMO (PMO-peptide conjugates),NA,300,nM,Skip,45.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,mdx mouse cardiomyocytes,RNAiMAX,NA,ggccaaaccucggcuuaccu,2OMe,NA,300,nM,Skip,5.34,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,mdx mouse cardiomyocytes,RNAiMAX,NA,((rxr)3ihilfqndrrmkwhkbc)ggccaaacctcggcttacct,Others (PNA-peptide conjugates),NA,300,nM,Skip,7.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,In Vitro Evaluation Of Novel Antisense Oligonucleotides Is Predictive Of In Vivo Exon Skipping Activity For Duchenne Muscular Dystrophy,PMID 20235089,DMD,exon,23,NA,mouse,mdx mouse cardiomyocytes,RNAiMAX,NA,(rxr)4xbggccaaacctcggcttacct,modified PMO (PMO-peptide conjugates),NA,300,nM,Skip,22.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20235089,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,uucuuuaagauugaagaacgcc,2OMe,NA,100,nM,Skip,10.9,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,cauccuuuucuuuaagauug,2OMe,NA,100,nM,Skip,11.06,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,uuacuauuaaugaaaguaauuuu,2OMe,NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,uuuugcuauuuccuuucugguug,2OMe,NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,uuaucauugguacguuaaggacu,2OMe,NA,100,nM,Skip,5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,uuuuauguaccugaguacauu,2OMe,NA,100,nM,Skip,1.8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,ccuuucugguuguuuuguggcc,2OMe,NA,100,nM,Skip,2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,cuuaaacacuucccauuuug,2OMe,NA,100,nM,Skip,1.2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,ucauucucucuuuccuucgug,2OMe,NA,100,nM,Skip,0.8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,cauccuuuucuuuaagauug,2OMe,NA,50,nM,Skip,6.22,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,cauccuuuucuuuaagauug,2OMe,NA,75,nM,Skip,10.24,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,cauccuuuucuuuaagauug,2OMe,NA,100,nM,Skip,11.08,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,uuaucauugguacguuaaggacu,2OMe,NA,50,nM,Skip,0.82,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,uuaucauugguacguuaaggacu,2OMe,NA,75,nM,Skip,2.08,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Antisense Modulation Of Both Exonic And Intronic Splicing Motifs Induces Skipping Of A Dmd Pseudo-Exon Responsible For X-Linked Dilated Cardiomyopathy,PMID 20486769,DMD,intron,Alu-exon (intron 11),NA,human,MyoD converted human fibroblasts from XLDC patient,"ExGen500, 2?l/ug of AON",NA,uuaucauugguacguuaaggacu,2OMe,NA,100,nM,Skip,6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20486769,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,C2C12hE50 GFP reporter myoblasts,Endo Porter,NA,ccactcagagctcagatcttctaacttcc,unmodified PMO,NA,1,uM,Skip,9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,C2C12hE50 GFP reporter myoblasts,Endo Porter,NA,aacttcctctttaacagaaaagcatac,unmodified PMO,NA,1,uM,Skip,26,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,C2C12hE50 GFP reporter myoblasts,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,1,uM,Skip,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,C2C12hE50 GFP reporter myoblasts,Lipofectamine,NA,ccacucagagcucagaucuucuaacuucc,2OMe,NA,1,uM,Skip,8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,C2C12hE50 GFP reporter myoblasts,Lipofectamine,NA,aacuuccucuuuaacagaaaagcauac,2OMe,NA,1,uM,Skip,21,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,C2C12hE50 GFP reporter myoblasts,Lipofectamine,NA,gggauccaguauacuuacaggcucc,2OMe,NA,1,uM,Skip,28,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,normal human myoblasts,Lipofectamine,NA,cuucuaacuuccucuuuaacagaaaagcauac,2OMe,NA,1,uM,Skip,<1,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,normal human myoblasts,Lipofectamine,NA,ccacucagagcucagaucuucuaacuucc,2OMe,NA,1,uM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,normal human myoblasts,Lipofectamine,NA,aacuuccucuuuaacagaaaagcauac,2OMe,NA,1,uM,Skip,29,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,normal human myoblasts,Lipofectamine,NA,gggauccaguauacuuacaggcucc,2OMe,NA,1,uM,Skip,65,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,normal human myoblasts,Lipofectamine,NA,ccucuuuaacagaaaagcauac,2OMe,NA,1,uM,Skip,3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,normal human myoblasts,Endo Porter,NA,gatccagtatacttacaggctccaatag,unmodified PMO,NA,1,uM,Skip,5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,normal human myoblasts,Endo Porter,NA,ccactcagagctcagatcttctaacttcc,unmodified PMO,NA,1,uM,Skip,45,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,normal human myoblasts,Endo Porter,NA,gctcttgaagtaaacgg,unmodified PMO,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,normal human myoblasts,Endo Porter,NA,acttcctctttaacagaaaagcatac,unmodified PMO,NA,1,uM,Skip,29,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,normal human myoblasts,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,1,uM,Skip,65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,gctcttgaagtaaacgg,unmodified PMO,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,tccactcagagctcagatcttctaa,unmodified PMO,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,ccactcagagctcagatcttctaacttcc,unmodified PMO,NA,1,uM,Skip,25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,acttcctctttaacagaaaagcatac,unmodified PMO,NA,1,uM,Skip,34,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,1,uM,Skip,62,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,normal human myoblasts,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,50,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,normal human myoblasts,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.1,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,normal human myoblasts,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.2,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,normal human myoblasts,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.4,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,normal human myoblasts,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.8,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,normal human myoblasts,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,1.6,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,50,nM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.1,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.2,uM,Skip,64,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.4,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.8,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,human,fibroblasts from a DMD patient with exon 51 deletion,Endo Porter,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,1.6,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"C57 mice, im, TA",Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,10,ug,Skip,2.68,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"C57 mice, im, TA",Null,NA,gggatccagtatacttacaggctcc,modified PMO (Vivo-PMO),NA,10,ug,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, im, TA",Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,10,ug,Skip,4.58,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, im, TA",Null,NA,ccactcagagctcagatcttctaacttcc,modified PMO (Vivo-PMO),NA,10,ug,Skip,25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, im, TA",Null,NA,acttcctctttaacagaaaagcatac,modified PMO (Vivo-PMO),NA,10,ug,Skip,34,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, im, TA",Null,NA,gggatccagtatacttacaggctcc,modified PMO (Vivo-PMO),NA,10,ug,Skip,65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,gggatccagtatacttacaggctcc,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:TA,66.95,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,gggatccagtatacttacaggctcc,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Quad,69.49,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,gggatccagtatacttacaggctcc,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Gastro,65.25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,gggatccagtatacttacaggctcc,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Abdom,66.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,gggatccagtatacttacaggctcc,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Diaph,61.44,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,gggatccagtatacttacaggctcc,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Heart,5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,gggatccagtatacttacaggctcc,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Biceps,41.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,acttcctctttaacagaaaagcatac,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:TA,19.92,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,acttcctctttaacagaaaagcatac,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Quad,17.8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,acttcctctttaacagaaaagcatac,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Gastro,18.22,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,acttcctctttaacagaaaagcatac,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Abdom,20.76,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,acttcctctttaacagaaaagcatac,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Diaph,19.49,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,acttcctctttaacagaaaagcatac,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Heart,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Targeted Skipping Of Human Dystrophin Exons In Transgenic Mouse Model Systemically For Antisense Drug Development,PMID 21611204,DMD,exon,50,NA,mouse,"hDMD/mdx mice, iv",Null,NA,acttcctctttaacagaaaagcatac,modified PMO (Vivo-PMO),NA,15,mg/kg,Skip[%]:Biceps,19.07,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/21611204,NA,NA,NA
journal article,Cmah-Dystrophin Deficient Mdx Mice Display An Accelerated Cardiac Phenotype That Is Improved Following Peptide-Pmo Exon Skipping Treatment,PMID 30281092,DMD,exon,23,NA,mouse,"Cmah-/-;mdx mice, 10x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,Skip[%]: heart,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30281092,NA,NA,NA
journal article,Cmah-Dystrophin Deficient Mdx Mice Display An Accelerated Cardiac Phenotype That Is Improved Following Peptide-Pmo Exon Skipping Treatment,PMID 30281092,DMD,exon,23,NA,mouse,"Cmah-/-;mdx mice, 10x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,Skip[%]: TA,80,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30281092,NA,NA,NA
journal article,Cmah-Dystrophin Deficient Mdx Mice Display An Accelerated Cardiac Phenotype That Is Improved Following Peptide-Pmo Exon Skipping Treatment,PMID 30281092,DMD,exon,23,NA,mouse,"Cmah-/-;mdx mice, 10x i.v. biweekly",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,12.5,mg/kg,Skip[%]: diaphragm,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30281092,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex45-54 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,1,uM,Skip,50,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex45-54 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,5,uM,Skip,85,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex45-54 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,10,uM,Skip,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"MYOD1-converted fibroblast derived myotubes, ex45-54 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,1,uM,Skip,60,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"MYOD1-converted fibroblast derived myotubes, ex45-54 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,5,uM,Skip,90,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"MYOD1-converted fibroblast derived myotubes, ex45-54 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,10,uM,Skip,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex45 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,1,uM,Skip,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex45 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,5,uM,Skip,80,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex45 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,10,uM,Skip,90,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"MYOD1-converted fibroblast derived myotubes, ex45 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,1,uM,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"MYOD1-converted fibroblast derived myotubes, ex45 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,5,uM,Skip,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,44,NA,human,"MYOD1-converted fibroblast derived myotubes, ex45 del",Endoporter,NA,tgttcagcttctgttagccactga,unmodified PMO,NA,10,uM,Skip,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,51,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex50 del",Endoporter,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,1,uM,Skip,10,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,51,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex50 del",Endoporter,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,5,uM,Skip,30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,50,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex51 del",Endoporter,NA,aacttcctctttaacagaaaagcatac,unmodified PMO,NA,5,uM,Skip,60,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,50,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex51 del",Endoporter,NA,aacttcctctttaacagaaaagcatac,unmodified PMO,NA,10,uM,Skip,80,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,55,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex54 del",Endoporter,NA,tcttccaaagcagcctct,unmodified PMO,NA,5,uM,Skip,80,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Modelling Duchenne Muscular Dystrophy In Myod1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydrochloride,PMID 30846748,DMD,exon,55,NA,human,"DZNep-treated MYOD1-converted urine derived myotubes, ex54 del",Endoporter,NA,tcttccaaagcagcctct,unmodified PMO,NA,10,uM,Skip,80,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30846748,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,12.5,nM,Skip,43,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,25,nM,Skip,47,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,50,nM,Skip,51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*u*c*g*g*c*u*u*a*c*c*,Others (2'-F-PS),NA,12.5,nM,Skip,50,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*u*c*g*g*c*u*u*a*c*c*,Others (2'-F-PS),NA,25,nM,Skip,44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*u*c*g*g*c*u*u*a*c*c*,Others (2'-F-PS),NA,50,nM,Skip,51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,2OMe,NA,12.5,nM,Skip,26,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,2OMe,NA,25,nM,Skip,42,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,2OMe,NA,50,nM,Skip,42,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,2OMe,NA,12.5,nM,Skip,46,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,2OMe,NA,25,nM,Skip,46,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,2OMe,NA,50,nM,Skip,47,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*uc*g*gc*u*ua*c*c,2OMe,NA,12.5,nM,Skip,43,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*uc*g*gc*u*ua*c*c,2OMe,NA,25,nM,Skip,50,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*uc*g*gc*u*ua*c*c,2OMe,NA,50,nM,Skip,49,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,12.5,nM,Skip,56,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,25,nM,Skip,58,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,50,nM,Skip,53,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,12.5,nM,Skip,51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,25,nM,Skip,54,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,50,nM,Skip,47,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*tc*g*gc*u*ta*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,12.5,nM,Skip,44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*tc*g*gc*u*ta*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,25,nM,Skip,51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*tc*g*gc*u*ta*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,50,nM,Skip,63,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,2.5,nM,Skip,13,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,5,nM,Skip,19,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gccaaaccucggcuuacc,2OMe,NA,12.5,nM,Skip,33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,2OMe,NA,2.5,nM,Skip,14,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,2OMe,NA,5,nM,Skip,26,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,2OMe,NA,12.5,nM,Skip,20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,2OMe,NA,2.5,nM,Skip,31,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,2OMe,NA,5,nM,Skip,34,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,2OMe,NA,12.5,nM,Skip,39,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*uc*g*gc*u*ua*c*c,2OMe,NA,2.5,nM,Skip,24,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*uc*g*gc*u*ua*c*c,2OMe,NA,5,nM,Skip,32,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*uc*g*gc*u*ua*c*c,2OMe,NA,12.5,nM,Skip,41,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,2.5,nM,Skip,33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,5,nM,Skip,40,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gcc*a*a*a*c*c*u*c*g*g*c*u*u*a*cc,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,12.5,nM,Skip,51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,2.5,nM,Skip,33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,5,nM,Skip,40,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,gc*c*a*a*a*cc*u*c*g*gc*u*u*a*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,12.5,nM,Skip,48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*tc*g*gc*u*ta*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,2.5,nM,Skip,18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*tc*g*gc*u*ta*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,5,nM,Skip,32,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Systematic evaluation of 2-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro,PMID 30988454,DMD,exon,23,NA,mouse,H2K mdx myotubes,"Lipofectin, 2:1 w/w Lipofectin:AO",NA,g*c*c*a*a*a*c*c*tc*g*gc*u*ta*c*c,"Others (LNA (lowercase), 2'-F-PS (N*))",NA,12.5,nM,Skip,44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30988454,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., unexercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: diaphragm,91,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., exercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: diaphragm,79,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., unexercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: heart,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., exercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: heart,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., unexercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: abdominal,49,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., exercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: abdominal,72,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., unexercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., exercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., unexercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: intercostal,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., exercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: intercostal,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., unexercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: sternomastoid,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Implications For Cardiac Function Following Rescue Of The Dystrophic Diaphragm In A Mouse Model Of Duchenne Muscular Dystrophy,PMID 26113184,DMD,exon,23,NA,mouse,"mdx mice, i.p., exercised",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,19,mg/kg,Skip[%]: sternomastoid,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26113184,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,45,NA,human,human control myotubes,Null,NA,ugccgcugcccaaugccauccug,Others (2'-OMePS conjugated to cyclic peptide),NA,2,uM,Skip,6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,45,NA,human,human control myotubes,Null,NA,ugccgcugcccaaugccauccug,Others (2'-OMePS conjugated to cyclic peptide),NA,4,uM,Skip,5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,45,NA,human,human control myotubes,Null,NA,ugccgcugcccaaugccauccug,2OMe,NA,2,uM,Skip,2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,45,NA,human,human control myotubes,Null,NA,ugccgcugcccaaugccauccug,2OMe,NA,4,uM,Skip,6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,45,NA,human,"hDMD mice, 2x i.m. GAS and triceps (pre-treated with cardiotoxin)",Null,NA,ugccgcugcccaaugccauccug,2OMe,NA,20,ug,Skip[%]: GAS,2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,45,NA,human,"hDMD mice, 2x i.m. GAS and triceps (pre-treated with cardiotoxin)",Null,NA,ugccgcugcccaaugccauccug,2OMe,NA,20,ug,Skip[%]: triceps,3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,45,NA,human,"hDMD mice, 2x i.m. GAS and triceps (pre-treated with cardiotoxin)",Null,NA,ugccgcugcccaaugccauccug,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 20 ?g h45AON,Null,Skip[%]: GAS,2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,45,NA,human,"hDMD mice, 2x i.m. GAS and triceps (pre-treated with cardiotoxin)",Null,NA,ugccgcugcccaaugccauccug,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 20 ?g h45AON,Null,Skip[%]: triceps,2.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,50,mg/kg,Skip[%]: GAS,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,50,mg/kg,Skip[%]: quadriceps,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,50,mg/kg,Skip[%]: TA,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,50,mg/kg,Skip[%]: triceps,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,50,mg/kg,Skip[%]: diaphragm,15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,50,mg/kg,Skip[%]: heart,2.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: GAS,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: quadriceps,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: TA,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: triceps,10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: diaphragm,15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: heart,2.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: GAS,20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: quadriceps,20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: TA,20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,728.6,mg/kg/week,Skip[%]:Quadriceps,13.74,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: triceps,20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: diaphragm,30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Cyclic Peptides To Improve Delivery And Exon Skipping Of Antisense Oligonucleotides In A Mouse Model For Duchenne Muscular Dystrophy,PMID 29103911,DMD,exon,23,NA,mouse,"mdx mice, 4x per week for 8 weeks s.c.",Null,NA,ggccaaaccucggcuuaccu,Others (2'-OMePS conjugated to cyclic peptide),NA,equimolar to 50 mg/kg 23AON,Null,Skip[%]: heart,5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29103911,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,300,nM,Skip,48.63,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip,67.12,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,1,uM,Skip,90.07,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,300,nM,Skip,46.58,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip,88.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,1,uM,Skip,92.29,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (MOE),NA,300,nM,Skip,29.45,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (MOE),NA,500,nM,Skip,40.75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (MOE),NA,1,uM,Skip,56.16,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,10,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,10,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (MOE),NA,5,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (MOE),NA,10,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip[%]:24hr after transfection,65.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip[%]:48hr after transfection,78.49,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip[%]:72hr after transfection,57.85,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip[%]:96hr after transfection,40.26,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip[%]:24hr after transfection,45.81,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip[%]:48hr after transfection,91.24,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip[%]:72hr after transfection,71.72,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip[%]:96hr after transfection,21.76,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip[%]:48hr after transfection,67.64,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,500,nM,Skip[%]:48hr after transfection,89.21,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,500,nM,Skip[%]:48hr after transfection,33.24,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,H2K mdx cells,"Lipofectin, 2.5:1 w/w Lipofectin:AO",NA,ggccaaacctcggcttacct,Others (MOE),NA,500,nM,Skip[%]:48hr after transfection,40.82,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaacctcggcttacct,Others (MOE),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaacctcggcttacctgaaat,Others (MOE),NA,5,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Effective Exon Skipping And Dystrophin Restoration By 2'-O-Methoxyethyl Antisense Oligonucleotide In Dystrophin-Deficient Mice,PMID 23658612,DMD,exon,23,NA,mouse,"mdx mouse, im, TA",Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,5,ug,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23658612,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1200,mg/kg/week,Skip[%]:Gastro,15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100,mg/kg/week,Skip[%]:Gastro,12.48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,728.6,mg/kg/week,Skip[%]:Gastro,12.98,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1200,mg/kg/week,Skip[%]:Quadriceps,11.85,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100,mg/kg/week,Skip[%]:Quadriceps,11.47,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1200,mg/kg/week,Skip[%]:TA,8.82,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100,mg/kg/week,Skip[%]:TA,7.82,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,728.6,mg/kg/week,Skip[%]:TA,11.85,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1200,mg/kg/week,Skip[%]:Triceps,11.09,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100,mg/kg/week,Skip[%]:Triceps,11.09,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,728.6,mg/kg/week,Skip[%]:Triceps,14.37,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1200,mg/kg/week,Skip[%]:Heart,1.64,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100,mg/kg/week,Skip[%]:Heart,2.14,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,728.6,mg/kg/week,Skip[%]:Heart,4.03,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1200,mg/kg/week,Skip[%]:Diaphragm,8.07,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100,mg/kg/week,Skip[%]:Diaphragm,9.33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,728.6,mg/kg/week,Skip[%]:Diaphragm,18.03,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:Gastro,14.3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:Gastro,7.45,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:Gastro,3.98,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:Gastro,6.52,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,No further injection after an initial treatment with 5250mg/kg in the first week,Null,Skip[%]:Gastro,2.54,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:Quadriceps,12.75,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:Quadriceps,6.79,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uuugcagaccuccugcc,Others (2FPS),NA,200,nM,Skip,58.58,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:Quadriceps,3.75,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:Quadriceps,2.65,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,No further injection after an initial treatment with 5250mg/kg in the first week,Null,Skip[%]:Quadriceps,1.33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:TA,10.82,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:TA,5.69,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:TA,3.59,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:TA,3.53,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,No further injection after an initial treatment with 5250mg/kg in the first week,Null,Skip[%]:TA,2.21,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:Triceps,11.37,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:Triceps,4.69,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:Triceps,3.7,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:Triceps,4.47,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,No further injection after an initial treatment with 5250mg/kg in the first week,Null,Skip[%]:Triceps,2.21,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:Heart,3.64,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:Heart,2.26,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:Heart,0.88,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:Heart,1.44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,No further injection after an initial treatment with 5250mg/kg in the first week,Null,Skip[%]:Heart,1.05,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:Diaphragm,11.93,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/week,Skip[%]:Diaphragm,6.96,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,2100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:Diaphragm,3.42,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,1100 after an initial treatment with 5250mg/kg in the first week,mg/kg/month,Skip[%]:Diaphragm,2.93,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Dose-Dependent Pharmacokinetic Profiles Of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotidesin Mdx Mice,PMID 23634945,DMD,exon,23,NA,mouse,"mdx mouse, injected subcutaneously",Null,NA,uccauucggcuccaaaccgg,2OMe,NA,No further injection after an initial treatment with 5250mg/kg in the first week,Null,Skip[%]:Diaphragm,2.15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23634945,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,gcccaaugccauccugg,2OMe,NA,100,nM,Skip,3.3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,gcccaaugccauccugg,2OMe,NA,100,nM,Skip,97.69,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,gcccaaugccauccugg,2OMe,NA,200,nM,Skip,5.94,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,gcccaaugccauccugg,2OMe,NA,200,nM,Skip,98.68,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,gcccaaugccauccugg,2OMe,NA,500,nM,Skip,3.63,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,gcccaaugccauccugg,2OMe,NA,500,nM,Skip,98.84,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uugccgcugcccaaugccauccugg,2OMe,NA,100,nM,Skip,64.36,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uugccgcugcccaaugccauccugg,Others (2FPS),NA,100,nM,Skip,99.01,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uugccgcugcccaaugccauccugg,2OMe,NA,200,nM,Skip,83.83,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uugccgcugcccaaugccauccugg,Others (2FPS),NA,200,nM,Skip,98.35,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uugccgcugcccaaugccauccugg,2OMe,NA,500,nM,Skip,80.86,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uugccgcugcccaaugccauccugg,Others (2FPS),NA,500,nM,Skip,99.7,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uuugcagaccuccugcc,2OMe,NA,100,nM,Skip,4.95,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uuugcagaccuccugcc,Others (2FPS),NA,100,nM,Skip,20.3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uuugcagaccuccugcc,2OMe,NA,200,nM,Skip,18.48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uuugcagaccuccugcc,2OMe,NA,500,nM,Skip,44.88,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,uuugcagaccuccugcc,Others (2FPS),NA,500,nM,Skip,70.46,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,guugcauucaauguucugac,2OMe,NA,100,nM,Skip,17.16,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,guugcauucaauguucugac,Others (2FPS),NA,100,nM,Skip,97.69,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,guugcauucaauguucugac,2OMe,NA,200,nM,Skip,13.86,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,guugcauucaauguucugac,Others (2FPS),NA,200,nM,Skip,94.06,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,guugcauucaauguucugac,2OMe,NA,500,nM,Skip,10.56,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,guugcauucaauguucugac,Others (2FPS),NA,500,nM,Skip,94.72,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,auuguguugaauccuuuaac,2OMe,NA,100,nM,Skip,2.52,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,auuguguugaauccuuuaac,Others (2FPS),NA,100,nM,Skip,7.55,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,auuguguugaauccuuuaac,2OMe,NA,200,nM,Skip,2.68,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,auuguguugaauccuuuaac,Others (2FPS),NA,200,nM,Skip,36.07,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,auuguguugaauccuuuaac,2OMe,NA,500,nM,Skip,1.01,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,auuguguugaauccuuuaac,Others (2FPS),NA,500,nM,Skip,9.4,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,cuguugccuccgguucug,2OMe,NA,100,nM,Skip,24.66,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,cuguugccuccgguucug,Others (2FPS),NA,100,nM,Skip,32.21,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,cuguugccuccgguucug,2OMe,NA,200,nM,Skip,42.11,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,cuguugccuccgguucug,Others (2FPS),NA,200,nM,Skip,66.78,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,cuguugccuccgguucug,2OMe,NA,500,nM,Skip,24.33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,cuguugccuccgguucug,Others (2FPS),NA,500,nM,Skip,25.34,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,ccuaagaccugcucagcuucuuccu,2OMe,NA,100,nM,Skip,7.89,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,ccuaagaccugcucagcuucuuccu,Others (2FPS),NA,100,nM,Skip,66.28,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,ccuaagaccugcucagcuucuuccu,2OMe,NA,200,nM,Skip,16.28,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,ccuaagaccugcucagcuucuuccu,Others (2FPS),NA,200,nM,Skip,84.73,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,ccuaagaccugcucagcuucuuccu,2OMe,NA,500,nM,Skip,9.9,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,ccuaagaccugcucagcuucuuccu,Others (2FPS),NA,500,nM,Skip,42.95,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,agcuuccagccauuguguugaaucc,2OMe,NA,100,nM,Skip,26.17,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,agcuuccagccauuguguugaaucc,Others (2FPS),NA,100,nM,Skip,64.77,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,agcuuccagccauuguguugaaucc,2OMe,NA,200,nM,Skip,18.79,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,agcuuccagccauuguguugaaucc,Others (2FPS),NA,200,nM,Skip,39.43,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,agcuuccagccauuguguugaaucc,2OMe,NA,500,nM,Skip,8.05,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,human control myotubes,6ul of Lipofectamin 2000 per well,NA,agcuuccagccauuguguugaaucc,Others (2FPS),NA,500,nM,Skip,54.7,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,myotubes from a DMD patient with deletion of exon 45-52,6ul of Lipofectamin 2000 per well,NA,cuguugccuccgguucug,2OMe,NA,200,nM,Skip,90.8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,myotubes from a DMD patient with deletion of exon 45-52,6ul of Lipofectamin 2000 per well,NA,cuguugccuccgguucug,Others (2FPS),NA,200,nM,Skip,99.82,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,myotubes from a DMD patient with deletion of exon 45-52,6ul of Lipofectamin 2000 per well,NA,ccuaagaccugcucagcuucuuccu,2OMe,NA,200,nM,Skip,14.69,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,53,NA,human,myotubes from a DMD patient with deletion of exon 45-52,6ul of Lipofectamin 2000 per well,NA,ccuaagaccugcucagcuucuuccu,Others (2FPS),NA,200,nM,Skip,80.53,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,mouse control myotubes,6ul of Lipofectamin 2000 per well,NA,cgccaaaccucggcuuaccu,2OMe,NA,200,nM,Skip,68.18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,mouse control myotubes,6ul of Lipofectamin 2000 per well,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,200,nM,Skip,68.18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,mouse control myotubes,6ul of Lipofectamin 2000 per well,NA,cgccaaaccucggcuuaccu,2OMe,NA,500,nM,Skip,76.22,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,mouse control myotubes,6ul of Lipofectamin 2000 per well,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,500,nM,Skip,99.48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,primary myoblasts from extensor digitorum longus muscles of an mdx mouse,Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,2,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,primary myoblasts from extensor digitorum longus muscles of an mdx mouse,Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,4,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,primary myoblasts from extensor digitorum longus muscles of an mdx mouse,Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,2,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,primary myoblasts from extensor digitorum longus muscles of an mdx mouse,Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,4,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, im, gastro",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, im, gastro",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,2.9,nmol/day  2 consecutive days,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, im, triceps",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,2.9,nmol/day  2 consecutive days,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, im, triceps",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, im, gastro",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,2.9,nmol/day  2 consecutive days,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, im, gastro",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, im, gastro",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, im, triceps",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,2.9,nmol/day  2 consecutive days,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,Others (2FPS),NA,450,mg/kg/week  8 weeks,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,23,NA,mouse,"mdx mouse, subcutaneous injection",Null,NA,cgccaaaccucggcuuaccu,2OMe,NA,450,mg/kg/week  8 weeks,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,mouse,"hDMD mouse, im, gastro",Null,NA,uugccgcugcccaaugccauccugg,Others (2FPS),NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,mouse,"hDMD mouse, im, gastro",Null,NA,uugccgcugcccaaugccauccugg,2OMe,NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,mouse,"hDMD mouse, im, triceps",Null,NA,uugccgcugcccaaugccauccugg,2OMe,NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,mouse,"hDMD mouse, im, triceps",Null,NA,uugccgcugcccaaugccauccugg,Others (2FPS),NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,mouse,"hDMD mouse, im, gastro",Null,NA,uugccgcugcccaaugccauccugg,2OMe,NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,mouse,"hDMD mouse, im, gastro",Null,NA,uugccgcugcccaaugccauccugg,Others (2FPS),NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,mouse,"hDMD mouse, im, triceps",Null,NA,uugccgcugcccaaugccauccugg,Others (2FPS),NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,Evaluation Of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides For Exon Skipping In Duchenne Muscular Dystrophy,PMID 26623937,DMD,exon,45,NA,mouse,"hDMD mouse, im, triceps",Null,NA,uugccgcugcccaaugccauccugg,2OMe,NA,2.9,nmol/day  2 consecutive days,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/26623937,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 20-29 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 11 injections),Skip[%]:TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 20-29 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 11 injections),Skip[%]:Quadriceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 20-29 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 11 injections),Skip[%]:Gastrocnemius,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 20-29 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 11 injections),Skip[%]:Diaphragm,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 20-29 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 11 injections),Skip[%]:Heart,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 20-29 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 11 injections),Skip[%]:Biceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,58 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Quadriceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 30-39 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 10 injections),Skip[%]:TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 30-39 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 10 injections),Skip[%]:Quadriceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 30-39 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 10 injections),Skip[%]:Gastrocnemius,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 30-39 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 10 injections),Skip[%]:Diaphragm,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 30-39 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 10 injections),Skip[%]:Heart,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 30-39 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 10 injections),Skip[%]:Biceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 40-49 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 9 injections),Skip[%]:TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 40-49 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 9 injections),Skip[%]:Quadriceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 40-49 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 9 injections),Skip[%]:Gastrocnemius,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 40-49 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 9 injections),Skip[%]:Diaphragm,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 40-49 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 9 injections),Skip[%]:Heart,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 40-49 days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 9 injections),Skip[%]:Biceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 50+ days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 2 injections),Skip[%]:TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 50+ days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 2 injections),Skip[%]:Quadriceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 50+ days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 2 injections),Skip[%]:Gastrocnemius,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 50+ days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 2 injections),Skip[%]:Diaphragm,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 50+ days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 2 injections),Skip[%]:Heart,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,"Exon Skipping Restores Dystrophin Expression, But Fails To Prevent Disease Progression In Later Stage Dystrophic Dko Mice",PMID 24942628,DMD,exon,23,NA,mouse,"utrophin-dystrophin-deficient mice, iv, treatment started at 50+ days",Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (peptide-PMO conjugate),NA,15,mg/kg biweekly (total 2 injections),Skip[%]:Biceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/24942628,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 5.7% Glucose:2.86% fructose:1.4% xylitol",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 5% Mannose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 5% glucose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/week  3 weeks,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/week  3 weeks,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/week  3 weeks,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 5% Mannose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/week  3 weeks,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,51 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Quadriceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,52 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Gastrocnemius,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,53 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Triceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,54 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Diaphragm,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,55 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Heart,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,56 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Abdominal,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,57 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:TA,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,59 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Gastrocnemius,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,60 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Triceps,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,61 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Diaphragm,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,62 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Heart,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,63 mg/kg/week  3 weeks50 mg/kg/month  5 months,Null,Skip[%]:Abdominal,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, 16hr after PMO",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with Saline",Null,NA,ggccaaacctcggcttacct,2OMe,NA,100,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 2.5% Glucose:2.5% fructose",Null,NA,ggccaaacctcggcttacct,2OMe,NA,100,mg/kg,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 2.5% D-Glucose:2.5% D-fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 2.5% L-Glucose:2.5% L-fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 2.5% D-Glucose:2.5% L-fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 2.5% Glucose:2.5% fructose: 0.5 mM phloretin",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 2.5% L-Glucose:2.5% D-fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 5% 2-deoxyglucose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 2.5% Glucose:2.5% fructose (GF), 40ng oligomycin A before GF administration",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 10mM ATP",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 2.5% Glucose:2.5% fructose (GF):10mM ATP",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 2.5% Glucose:2.5% fructose (GF) iv",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,C2C12 cells incubated for 1 hr at 37,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,20,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,C2C12 cells incubated for 1 hr at 4,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,20,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"C2C12 cells, with 100ng/ml Oligomycin A",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,20,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"C2C12 cells, with 15uM CPM",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,20,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"C2C12 cells, with 5mM MCD",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,20,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,starving C2C12 myoblasts (cultured in glucose- and pyruvate-free DMEM),Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,20,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"starving C2C12 myoblasts (cultured in glucose- and pyruvate-free DMEM), with 4.5g/l GF",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,20,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Hexose Enhances Oligonucleotide Delivery And Exon Skipping In Dystrophin-Deficient Mdx Mice,PMID 26964641,DMD,exon,23,NA,mouse,"starving C2C12 myoblasts (cultured in glucose- and pyruvate-free DMEM), with 4.5g/l 2-deoxyglucose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,20,uM,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/26964641,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,Others (PNA),NA,5,ug,Skip,26.67,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul 5% galactose",Null,NA,ggccaaacctcggcttacctgaaat,Others (PNA),NA,5,ug,Skip,56.43,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul GF(2.5% glucose and 2.5% fructose)",Null,NA,ggccaaacctcggcttacctgaaat,Others (PNA),NA,5,ug,Skip,46.19,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul 5% mannose",Null,NA,ggccaaacctcggcttacctgaaat,Others (PNA),NA,5,ug,Skip,45.95,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,Others (PNA),NA,5,ug,Skip,49.64,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul Saline",Null,NA,ggccaaacctcggcttacct,2OMe,NA,5,ug,Skip,2.98,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul 5% galactose",Null,NA,ggccaaacctcggcttacct,2OMe,NA,5,ug,Skip,10.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul GF(2.5% glucose and 2.5% fructose)",Null,NA,ggccaaacctcggcttacct,2OMe,NA,5,ug,Skip,10.36,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul 5% mannose",Null,NA,ggccaaacctcggcttacct,2OMe,NA,5,ug,Skip,5.24,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul 5% fructose",Null,NA,ggccaaacctcggcttacct,2OMe,NA,5,ug,Skip,12.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul Saline",Null,NA,rrqpprsisshp-ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,ug,Skip,63.74,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul 5% fructose",Null,NA,rrqpprsisshp-ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,2,ug,Skip,76.02,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul Saline",Null,NA,rxrrbrrxrrbrb-asslniax-ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,ug,Skip,27.29,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul 5% fructose",Null,NA,rxrrbrrxrrbrb-asslniax-ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,ug,Skip,51.66,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul Saline",Null,NA,rxrrxrrxrrxrxb-ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,ug,Skip,45.42,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul 5% fructose",Null,NA,rxrrxrrxrrxrxb-ggccaaacctcggcttacctgaaat,modified PMO (PPMO),NA,1,ug,Skip,61.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Skip,33.91,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, im, TA, with 40 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,2,ug,Skip,69.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Skip[%]:abdominal muscle,6.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Skip[%]:abdominal muscle,36.16,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Skip[%]:Quadriceps,9.86,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Skip[%]:Quadriceps,55.07,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Skip[%]:TA,6.03,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Skip[%]:TA,17.26,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Skip[%]:gastrocnemius,7.12,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Skip[%]:gastrocnemius,60.27,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Skip[%]:triceps,5.21,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,25,mg/kg/day  3 days,Skip[%]:triceps,10.96,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:TA,28.57,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,51 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:TA,23.11,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,52 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:Quadriceps,41.24,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,53 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:Quadriceps,21.49,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,54 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:gastrocnemius,11.93,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,55 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:gastrocnemius,48.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,56 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:triceps,23.85,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,57 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:triceps,22.36,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,58 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:diaphragm,6.71,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,59 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:diaphragm,11.43,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul Saline",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,60 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:abdominal muscle,25.34,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,Fructose Promotes Uptake And Activity Of Oligonucleotides With Different Chemistries In A Context-Dependent Manner In Mdx Mice,PMID 27351681,DMD,exon,23,NA,mouse,"mdx mouse, iv, with 100 ul 5% fructose",Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,61 mg/kg/week for 3 weeks and 50 mg/kg/month for 5 months,Null,Skip[%]:abdominal muscle,24.84,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27351681,NA,NA,NA
journal article,A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides,PMID 25493284,DYSF,pseudoexon,44.1,NA,human,"P1 (ID 8597) iFDM (inducible fibroblast-derived myogenic cells), Roswell ParkMemorial Institute (RPMI) c.4886+1249 (G>T)",Oligofectamine,NA,ccagggcugguucaccuucaaa,2OMe,NA,600 (2 days),nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25493284,NA,NA,NA
journal article,A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides,PMID 25493284,DYSF,pseudoexon,44.1,NA,human,"P1 (ID 8597) iFDM (inducible fibroblast-derived myogenic cells), Roswell ParkMemorial Institute (RPMI) c.4886+1249 (G>T)",Oligofectamine,NA,cuccaaucccugcuuggugg,2OMe,NA,600 (2 days),nM,Skip,Moderate skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25493284,NA,NA,NA
journal article,A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides,PMID 25493284,DYSF,pseudoexon,44.1,NA,human,"P2 (ID 8601) iFDM (inducible fibroblast-derived myogenic cells), Roswell ParkMemorial Institute (RPMI) c.4886+1249 (G>T)),",Oligofectamine,NA,ccagggcugguucaccuucaaa,2OMe,NA,600 (2 days),nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25493284,NA,NA,NA
journal article,A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides,PMID 25493284,DYSF,pseudoexon,44.1,NA,human,"P2 (ID 8601) iFDM (inducible fibroblast-derived myogenic cells), Roswell ParkMemorial Institute (RPMI) c.4886+1249 (G>T)),",Oligofectamine,NA,cuccaaucccugcuuggugg,2OMe,NA,600 (2 days),nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25493284,NA,NA,NA
journal article,Therapeutic Exon Skipping For Dysferlinopathies,PMID 20145676,DYSF,exon,19,NA,human,Human myoblasts,"Polyethyleneimine, 2.5 ul per ug of AO",NA,gaagccggccacgauaagcc,2OMe,NA,500,nM,Skip,No skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20145676,NA,NA,NA
journal article,Therapeutic Exon Skipping For Dysferlinopathies,PMID 20145676,DYSF,exon,19,NA,human,Human myoblasts,"Polyethyleneimine, 2.5 ul per ug of AO",NA,ccuucuguucacugugcucc,2OMe,NA,500,nM,Skip,15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20145676,NA,NA,NA
journal article,Therapeutic Exon Skipping For Dysferlinopathies,PMID 20145676,DYSF,exon,24,NA,human,Human myoblasts,"Polyethyleneimine, 2.5 ul per ug of AO",NA,gcauccagaugacgauguccg,2OMe,NA,500,nM,Skip,53,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20145676,NA,NA,NA
journal article,Therapeutic Exon Skipping For Dysferlinopathies,PMID 20145676,DYSF,exon,24,NA,human,Human myoblasts,"Polyethyleneimine, 2.5 ul per ug of AO",NA,gcuucccacaauucuugcca,2OMe,NA,500,nM,Skip,24,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20145676,NA,NA,NA
journal article,Therapeutic Exon Skipping For Dysferlinopathies,PMID 20145676,DYSF,exon,30,NA,human,Human myoblasts,"Polyethyleneimine, 2.5 ul per ug of AO",NA,ccgucuucuccaguggcucc,2OMe,NA,500,nM,Skip,92,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20145676,NA,NA,NA
journal article,Therapeutic Exon Skipping For Dysferlinopathies,PMID 20145676,DYSF,exon,30,NA,human,Human myoblasts,"Polyethyleneimine, 2.5 ul per ug of AO",NA,cggcggaaggcaucugucuug,2OMe,NA,500,nM,Skip,96,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20145676,NA,NA,NA
journal article,Therapeutic Exon Skipping For Dysferlinopathies,PMID 20145676,DYSF,exon,32,NA,human,Human myoblasts,"Polyethyleneimine, 2.5 ul per ug of AO",NA,uccguuccagacucgguucac,2OMe,NA,500,nM,Skip,No skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20145676,NA,NA,NA
journal article,Therapeutic Exon Skipping For Dysferlinopathies,PMID 20145676,DYSF,exon,34,NA,human,Human myoblasts,"Polyethyleneimine, 2.5 ul per ug of AO",NA,cgacggcuggcugccccucguc,2OMe,NA,500,nM,Skip,17,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20145676,NA,NA,NA
journal article,Therapeutic Exon Skipping For Dysferlinopathies,PMID 20145676,DYSF,exon,34,NA,human,Human myoblasts,"Polyethyleneimine, 2.5 ul per ug of AO",NA,gcagcguagaugguagcggu,2OMe,NA,500,nM,Skip,No skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20145676,NA,NA,NA
journal article,Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-2 chain-null congenital muscular dystrophy mice,PMID 23882132,LAMA2,exon,4,NA,mouse,(dy3k/dy3k ) mice for myotonic congenital dystrophy laminin-2 chain-null dy3K/dy3K mice: a model of merosin-deficient congenital muscular dystrophy (MDC1A),intramuscular injection,NA,ttccaaaatccagtttccaggccga/tgtcaccgcatgatactgccagggt,unmodified PMO,NA,400,ug/kg body weight,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-2 chain-null congenital muscular dystrophy mice,PMID 23882132,LAMA2,exon,4,NA,mouse,(dy3k/dy3k ) mice for myotonic congenital dystrophy laminin-2 chain-null dy3K/dy3K mice: a model of merosin-deficient congenital muscular dystrophy (MDC1A),intraperitoneal injection,NA,ttccaaaatccagtttccaggccga/tgtcaccgcatgatactgccagggt,unmodified PMO,NA,150,mg/kg body weight,Skip,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,1,NA,human,Human neuroblastoma IMR32,Nucleofector-II,NA,gccatcctggttcaaagttcacctg,unmodified PMO,NA,Null,Null,Skip,22,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,1,NA,human,Human neuroblastoma SH-SY5Y,Nucleofector-II,NA,gccatcctggttcaaagttcacctg,unmodified PMO,NA,Null,Null,Skip,28,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,1,NA,human,Human neuroblastoma SH-SY5Y,Nucleofector-II,NA,tcagccatcctggttcaaagttcac,unmodified PMO,NA,Null,Null,Skip,9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,1,NA,human,Human neuroblastoma IMR32,Nucleofector-II,NA,tggctgtccactaacctttcaggcc,unmodified PMO,NA,Null,Null,Skip,51,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,1,NA,human,Human neuroblastoma IMR32,Nucleofector-II,NA,gcatggctgtccactaacctttcag,unmodified PMO,NA,Null,Null,Skip,52,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,1,NA,human,Human neuroblastoma SH-SY5Y,Nucleofector-II,NA,gcatggctgtccactaacctttcag,unmodified PMO,NA,Null,Null,Skip,59,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,1,NA,human,Human neuroblastoma IMR32,Nucleofector-II,NA,gtgcatggctgtccactaacctttc,unmodified PMO,NA,Null,Null,Skip,41,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,1,NA,human,Human neuroblastoma IMR32,Nucleofector-II,NA,ctgtccactaacctttcaggccagc,unmodified PMO,NA,Null,Null,Skip,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,5,NA,human,Human neuroblastoma IMR32,Nucleofector-II,NA,ttgcttttactgaccatgcgagctg,unmodified PMO,NA,Null,Null,Skip,35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,5,NA,human,Human neuroblastoma SH-SY5Y,Nucleofector-II,NA,ttgcttttactgaccatgcgagctg,unmodified PMO,NA,Null,Null,Skip,17,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,5,NA,human,Human neuroblastoma IMR32,Nucleofector-II,NA,tcgtcagcttaccttggcttttttg,unmodified PMO,NA,Null,Null,Skip,36,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,5,NA,human,Human neuroblastoma SH-SY5Y,Nucleofector-II,NA,tcgtcagcttaccttggcttttttg,unmodified PMO,NA,Null,Null,Skip,31,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,5,NA,human,Human neuroblastoma IMR32,Nucleofector-II,NA,cgtggcatcgtcagcttaccttggc,unmodified PMO,NA,Null,Null,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies,PMID 25072694,MAPT,exon,5,NA,human,Human neuroblastoma SH-SY5Y,Nucleofector-II,NA,cgtggcatcgtcagcttaccttggc,unmodified PMO,NA,Null,Null,Skip,54,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25072694,NA,NA,NA
journal article,Development of Novel Chemically-Modified Nucleic Acid Molecules for Efficient Inhibition of Human MAPT Gene Expression,PMID 32575375,MAPT,exon,4,NA,human,Human neuroblastoma SH-SY5Y,Lipofectamine 3000,NA,gtgtctccaatgcctgcttcttcag,2OMe,NA,50,uM,Skip,92,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/32575375,NA,NA,NA
journal article,Development of Novel Chemically-Modified Nucleic Acid Molecules for Efficient Inhibition of Human MAPT Gene Expression,PMID 32575375,MAPT,exon,4,NA,human,Human neuroblastoma SH-SY5Y,Lipofectamine 3000,NA,agcagcttcgtcttccaggctgggg,2OMe,NA,50,uM,Skip,83,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/32575375,NA,NA,NA
journal article,Development of Novel Chemically-Modified Nucleic Acid Molecules for Efficient Inhibition of Human MAPT Gene Expression,PMID 32575375,MAPT,exon,5,NA,human,Human neuroblastoma SH-SY5Y,Lipofectamine 3000,NA,tcgcttccagtcccgtctttgcttt,2OMe,NA,50,uM,Skip,93,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/32575375,NA,NA,NA
journal article,Development of Novel Chemically-Modified Nucleic Acid Molecules for Efficient Inhibition of Human MAPT Gene Expression,PMID 32575375,MAPT,exon,12,NA,human,Human neuroblastoma SH-SY5Y,Lipofectamine 3000,NA,tacttccacctggccacctcctaga,2OMe,NA,50,uM,Skip,74,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/32575375,NA,NA,NA
journal article,Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation,PMID 27802265,USH2A,pseudoexon,40,NA,human,Usher syndrome patient fibroblasts (USH2A c.7595-2144A>G),FuGENE HD Transfection Reagent,NA,gugugauucuggagaggaagcug,2OMe,NA,1.5,umol/l,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27802265,NA,NA,NA
journal article,Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation,PMID 27802265,USH2A,pseudoexon,40,NA,human,Usher syndrome patient fibroblasts (USH2A c.7595-2144A>G),FuGENE HD Transfection Reagent,NA,cccuuaaaagccagcauaca,2OMe,NA,1.5,umol/l,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27802265,NA,NA,NA
journal article,Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation,PMID 27802265,USH2A,pseudoexon,40,NA,human,Usher syndrome patient fibroblasts (USH2A c.7595-2144A>G),FuGENE HD Transfection Reagent,NA,gugugauucuggagaggaagcug/cccuuaaaagccagcauaca,2OMe,NA,1.5,umol/l,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27802265,NA,NA,NA
journal article,Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations,PMID 33895329,USH2A,exon,13,NA,human,Usher syndrome patient fibroblasts (USH2A c.2299delG) -reprogrammed into iPSCs-differentiated into retinal organoids,Null,NA,not specfied. 21-mer sequence. orphan drug status,2OMe,NA,1,uM,Skip,42,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33895329,NA,NA,NA
journal article,Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations,PMID 33895329,USH2A,exon,13,NA,human,Usher syndrome patient fibroblasts (USH2A c.2299delG) -reprogrammed into iPSCs-differentiated into retinal organoids,Null,NA,not specfied. 21-mer sequence. orphan drug status,2OMe,NA,2,uM,Skip,40,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33895329,NA,NA,NA
journal article,Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations,PMID 33895329,USH2A,exon,13,NA,human,Usher syndrome patient fibroblasts (USH2A c.2299delG) -reprogrammed into iPSCs-differentiated into retinal organoids,Null,NA,not specfied. 21-mer sequence. orphan drug status,2OMe,NA,5,uM,Skip,45,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33895329,NA,NA,NA
journal article,Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations,PMID 33895329,USH2A,exon,13,NA,human,Usher syndrome patient fibroblasts (USH2A c.2299delG) -reprogrammed into iPSCs-differentiated into retinal organoids,Null,NA,not specfied. 21-mer sequence. orphan drug status,2OMe,NA,10,uM,Skip,63,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33895329,NA,NA,NA
journal article,Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations,PMID 33895329,USH2A,exon,12,NA,monkey,monkey,IVT (bilateral) administration,NA,not specfied. 21-mer sequence. orphan drug status,2OMe,NA,low,Null,Skip,26,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33895329,NA,NA,NA
journal article,Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations,PMID 33895329,USH2A,exon,12,NA,monkey,monkey,IVT (bilateral) administration,NA,not specfied. 21-mer sequence. orphan drug status,2OMe,NA,mid,Null,Skip,48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33895329,NA,NA,NA
journal article,Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations,PMID 33895329,USH2A,exon,12,NA,monkey,monkey,IVT (bilateral) administration,NA,not specfied. 21-mer sequence. orphan drug status,2OMe,NA,high,Null,Skip,69,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33895329,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,10,NA,human,Healthy human fibroblasts,Lipofectamine 3000,NA,cgggccucaggcaccaaguuc,2OMe,NA,50,nM,Skip,34,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,10,NA,human,Healthy human fibroblasts,Lipofectamine 3000,NA,cgggccucaggcaccaaguuc,2OMe,NA,10,nM,Skip,26,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,10,NA,human,Healthy human fibroblasts,Lipofectamine 3001,NA,cuucccccgcacugaccagucuc,2OMe,NA,50,nM,Skip,34,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,10,NA,human,Healthy human fibroblasts,Lipofectamine 3002,NA,cuucccccgcacugaccagucuc,2OMe,NA,10,nM,Skip,19,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,10,NA,human,Healthy human fibroblasts,Lipofectamine 3003,NA,cgggccucaggcaccaaguuc/cuucccccgcacugaccagucuc,2OMe,NA,50 (25 each),nM,Skip,64,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,10,NA,human,Healthy human fibroblasts,Lipofectamine 3004,NA,cgggccucaggcaccaaguuc/cuucccccgcacugaccagucuc,2OMe,NA,10 (5 each),nM,Skip,48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,10,NA,human,Healthy human fibroblasts,Null,NA,cgggccucaggcaccaaguuc,unmodified PMO,NA,150,uM,Skip,50,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,10,NA,human,Healthy human fibroblasts,Null,NA,cuucccccgcacugaccagucuc,unmodified PMO,NA,150,uM,Skip,95,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,10,NA,human,Healthy human fibroblasts,Null,NA,cgggccucaggcaccaaguuc/cuucccccgcacugaccagucuc,unmodified PMO,NA,150 (75 each),uM,Skip,84,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,73,NA,human,Healthy human fibroblasts,Null,NA,cgcccuucagcccgcguucuccagg,unmodified PMO,NA,150,uM,Skip,22,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,73,NA,human,Healthy human fibroblasts,Null,NA,uucagcccgcguucuccagg,unmodified PMO,NA,150,uM,Skip,32,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1,PMID 33081018,COL7A1,exon,73,NA,human,Healthy human fibroblasts,Null,NA,cgcccuucagcccgcguucu,unmodified PMO,NA,150,uM,Skip,85,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33081018,NA,NA,NA
journal article,Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients,PMID 16778792,COL7A1,exon,70,NA,human,HaCat keratinocytes or normal human epidermal keratinocytes,Lipofectamine 2000,NA,ccacgcucuccagggag,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/16778792,NA,NA,NA
journal article,Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients,PMID 16778792,COL7A1,exon,70,NA,human,HaCat keratinocytes,Lipofectamine 2000,NA,cuuccaggcucuccucgc,2OMe,NA,unspecified,Null,Skip,18.2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/16778792,NA,NA,NA
journal article,Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients,PMID 16778792,COL7A1,exon,70,NA,human,Normal human epidermal keratinocytes,Lipofectamine 2000,NA,cuuccaggcucuccucgc,2OMe,NA,unspecified,Null,Skip,28.1,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/16778792,NA,NA,NA
journal article,Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients,PMID 16778792,COL7A1,exon,70,NA,human and nude rat,Transplanatation of human skin onto nude rat,Null,NA,cuuccaggcucuccucgc,2OMe,NA,30,ug,Skip,12.2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/16778792,NA,NA,NA
journal article,Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva,PMID 23861958,ACVR1(ALK2),exon,8,NA,mouse,mouse C2C12 myoblasts,DharmaFect Duo,NA,ggguuaucuggcgagccaccguucu,2OMe,NA,500,nM,Skip,faint skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23861958,NA,NA,NA
journal article,Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva,PMID 23861958,ACVR1(ALK2),exon,8,NA,mouse,mouse endothelial cells,ExGen 500,NA,ggguuaucuggcgagccaccguucu,2OMe,NA,200,nM,Skip,moderate skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23861958,NA,NA,NA
journal article,Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva,PMID 23861958,ACVR1(ALK2),exon,8,NA,mouse,mouse endothelial cells,ExGen 500,NA,ggguuaucuggcgagccaccguucu,2OMe,NA,500,nM,Skip,moderate skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23861958,NA,NA,NA
journal article,Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva,PMID 23861958,ACVR1(ALK2),exon,8,NA,mouse,mouse osteoprogenitor cells KS483,ExGen 500,NA,ggguuaucuggcgagccaccguucu,2OMe,NA,200,nM,Skip,faint skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23861958,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,11,NA,human,Hep3B cells,Lipofectamine 2000,NA,gtaaggtgaggtggt,Others (LNA),NA,50,nmol/l,Skip,53,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,11,NA,human,Hep3B cells,Lipofectamine 2000,NA,gtaaggtgaggtggt,Others (LNA),NA,84,nmol/l,Skip,52,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,11,NA,human,Hep3B cells,Lipofectamine 2000,NA,gtaaggtgaggtggt,Others (LNA),NA,100,nmol/l,Skip,57,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,human,Hep3B cells,Endo-Porter,NA,gtaaggtgaggtggtgacaaaggtga,unmodified PMO,NA,2.5,uM/l,Skip,99,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,human,Hep3B cells,Endo-Porter,NA,gtaaggtgaggtggtgacaaaggtga,unmodified PMO,NA,5,uM/l,Skip,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,human,Hep3B cells,Endo-Porter,NA,gtaaggtgaggtggtgacaaaggtga,unmodified PMO,NA,10,uM/l,Skip,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,human,Hep3B cells,Endo-Porter,NA,gtaaggtgaggtggtgacaaaggtga,unmodified PMO,NA,20,uM/l,Skip,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,11,NA,"mouse, TA muscles of male C57Bl/6 mice",Null,Null,NA,gtgaggtgattaccaaagaggatc,modified PMO,NA,50,mg/kg,Skip,95,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,"mouse, TA muscles of male C57Bl/6 mice",Null,Null,NA,taatagtaagtagctcacacctgctg,modified PMO,NA,25,mg/kg,Skip,96,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,"mouse, TA muscles of male C57Bl/6 mice",Hep3B cells,Endo-Porter,NA,taacagtaagtaatttacaccttacg,unmodified PMO,NA,2.5,uM/l,Skip,21,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,"mouse, TA muscles of male C57Bl/6 mice",Hep3B cells,Endo-Porter,NA,taacagtaagtaatttacaccttacg,unmodified PMO,NA,5,uM/l,Skip,37,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,"mouse, TA muscles of male C57Bl/6 mice",Hep3B cells,Endo-Porter,NA,taacagtaagtaatttacaccttacg,unmodified PMO,NA,10,uM/l,Skip,84,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,"mouse, TA muscles of male C57Bl/6 mice",Hep3B cells,Endo-Porter,NA,taacagtaagtaatttacaccttacg,unmodified PMO,NA,20,uM/l,Skip,70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,"mouse, TA muscles of male C57Bl/6 mice",Hep3B cells,Endo-Porter,NA,agcctgtggttttggtcttaggaac,unmodified PMO,NA,2.5,uM/l,Skip,7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,"mouse, TA muscles of male C57Bl/6 mice",Hep3B cells,Endo-Porter,NA,agcctgtggttttggtcttaggaac,unmodified PMO,NA,5,uM/l,Skip,11,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,"mouse, TA muscles of male C57Bl/6 mice",Hep3B cells,Endo-Porter,NA,agcctgtggttttggtcttaggaac,unmodified PMO,NA,10,uM/l,Skip,27,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
journal article,A Sensitive Assay System To Test Antisense Oligonucleotides For Splice Suppression Therapy In The Mouse Liver,PMID 25226162,PAH,exon,12,NA,"mouse, TA muscles of male C57Bl/6 mice",Hep3B cells,Endo-Porter,NA,agcctgtggttttggtcttaggaac,unmodified PMO,NA,20,uM/l,Skip,46,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25226162,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,acaguuugccgcugcccaaugccau,unmodified PMO,NA,0.1,uM,Skip,3.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,ugacaacaguuugccgcugcccaau,unmodified PMO,NA,0.03,uM,Skip,1.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,ugacaacaguuugccgcugcccaau,unmodified PMO,NA,0.1,uM,Skip,6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uguucugacaacaguuugccgcugc,unmodified PMO,NA,0.03,uM,Skip,11.4,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uguucugacaacaguuugccgcugc,unmodified PMO,NA,0.1,uM,Skip,21.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uucaauguucugacaacaguuugcc,unmodified PMO,NA,0.03,uM,Skip,9.4,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uucaauguucugacaacaguuugcc,unmodified PMO,NA,0.1,uM,Skip,12,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uugcauucaauguucugacmcagu,unmodified PMO,NA,0.03,uM,Skip,2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uugcauucaauguucugacmcagu,unmodified PMO,NA,0.1,uM,Skip,12,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uugccgcugcccaaugccauccugg,unmodified PMO,NA,0.03,uM,Skip,53.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uugccgcugcccaaugccauccugg,unmodified PMO,NA,0.1,uM,Skip,93.8,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,acaguuugccgcugcccaaugccau,unmodified PMO,NA,0.03,uM,Skip,5.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uuugccgcugcccaaugccauccug,unmodified PMO,NA,0.03,uM,Skip,36.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uuugccgcugcccaaugccauccug,unmodified PMO,NA,0.1,uM,Skip,88.7,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gcugcccaaugccauccuggaguuc,unmodified PMO,NA,0.03,uM,Skip,62.9,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gcugcccaaugccauccuggaguuc,unmodified PMO,NA,0.1,uM,Skip,88.9,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaguugcauucmuguucugaca,unmodified PMO,NA,0.03,uM,Skip,2.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaguugcauucmuguucugaca,unmodified PMO,NA,0.1,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,ucuuccccaguugcauucaauguuc,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,ucuuccccaguugcauucaauguuc,unmodified PMO,NA,0.1,uM,Skip,9.8,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uuauuucuuccccaguugcauucaa,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uuauuucuuccccaguugcauucaa,unmodified PMO,NA,0.1,uM,Skip,3.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cugaauuauuucuuccccaguugca,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cugaauuauuucuuccccaguugca,unmodified PMO,NA,0.1,uM,Skip,22.7,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gauugcugaauuauuucuuccccag,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gauugcugaauuauuucuuccccag,unmodified PMO,NA,0.1,uM,Skip,2.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uugaggauugcugaauuauuucuuc,unmodified PMO,NA,0.03,uM,Skip,1.9,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uugaggauugcugaauuauuucuuc,unmodified PMO,NA,0.1,uM,Skip,6.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uguuuuugaggauugcugaauuauu,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uguuuuugaggauugcugaauuauu,unmodified PMO,NA,0.1,uM,Skip,1.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gcaucuguuuuugaggauugcugaa,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gcaucuguuuuugaggauugcugaa,unmodified PMO,NA,0.1,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uacuggcaucuguuuuugaggauug,unmodified PMO,NA,0.03,uM,Skip,12.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uacuggcaucuguuuuugaggauug,unmodified PMO,NA,0.1,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uuugccgcugcccaaugccauccug,unmodified PMO,NA,0.01,uM,Skip,10,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uuugccgcugcccaaugccauccug,unmodified PMO,NA,0.03,uM,Skip,19.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uuugccgcugcccaaugccauccug,unmodified PMO,NA,0.1,uM,Skip,27.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gcugcccaaugccauccuggaguuc,unmodified PMO,NA,0.01,uM,Skip,25.8,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gcugcccaaugccauccuggaguuc,unmodified PMO,NA,0.03,uM,Skip,35.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gcugcccaaugccauccuggaguuc,unmodified PMO,NA,0.1,uM,Skip,53.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uugccgcugcccaaugccauccugg,unmodified PMO,NA,0.01,uM,Skip,12.7,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uugccgcugcccaaugccauccugg,unmodified PMO,NA,0.03,uM,Skip,31,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,uugccgcugcccaaugccauccugg,unmodified PMO,NA,0.1,uM,Skip,41,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,18.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,54.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,81.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttcctgt,unmodified PMO,NA,1,uM,Skip,14.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttcctgt,unmodified PMO,NA,3,uM,Skip,50.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttcctgt,unmodified PMO,NA,10,uM,Skip,83.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,9.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,32,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,54.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,1,uM,Skip,6.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,3,uM,Skip,26.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,10,uM,Skip,59.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,59.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gcagccucucgcucacucacc,unmodified PMO,NA,0.03,uM,Skip,5.9,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gcagccucucgcucacucacc,unmodified PMO,NA,0.1,uM,Skip,23,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uucuuccaaagcagccucucg,unmodified PMO,NA,0.03,uM,Skip,6.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uucuuccaaagcagccucucg,unmodified PMO,NA,0.1,uM,Skip,33.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,aucuaugaguuucuuccaaag,unmodified PMO,NA,0.03,uM,Skip,8.7,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,aucuaugaguuucuuccaaag,unmodified PMO,NA,0.1,uM,Skip,13.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uguugcaguaaucuaugaguu,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uguugcaguaaucuaugaguu,unmodified PMO,NA,0.1,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,cagggggaacuguugcaguaa,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,cagggggaacuguugcaguaa,unmodified PMO,NA,0.1,uM,Skip,5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuuccagguccagggggaacu,unmodified PMO,NA,0.03,uM,Skip,6.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuuccagguccagggggaacu,unmodified PMO,NA,0.1,uM,Skip,6.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gcaagaaacuuuuccaggucc,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gcaagaaacuuuuccaggucc,unmodified PMO,NA,0.1,uM,Skip,17.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uguaagccaggcaagaaacuu,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uguaagccaggcaagaaacuu,unmodified PMO,NA,0.1,uM,Skip,1.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuucagcuucuguaagccagg,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuucagcuucuguaagccagg,unmodified PMO,NA,0.1,uM,Skip,2.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuggcaguuguuucagcuucu,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuggcaguuguuucagcuucu,unmodified PMO,NA,0.1,uM,Skip,4.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,cuguaggacauuggcaguugu,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,cuguaggacauuggcaguugu,unmodified PMO,NA,0.1,uM,Skip,4.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ggguagcauccuguaggacau,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ggguagcauccuguaggacau,unmodified PMO,NA,0.1,uM,Skip,10.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,cuuuccuuacggguagcaucc,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,cuuuccuuacggguagcaucc,unmodified PMO,NA,0.1,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uucuaggagccuuuccuuacg,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uucuaggagccuuuccuuacg,unmodified PMO,NA,0.1,uM,Skip,1.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ccuuggagucuucuaggagcc,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ccuuggagucuucuaggagcc,unmodified PMO,NA,0.1,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ucuuuuacucccuuggagucu,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ucuuuuacucccuuggagucu,unmodified PMO,NA,0.1,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuucaucagcucuuuuacucc,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuucaucagcucuuuuacucc,unmodified PMO,NA,0.1,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uugccauuguuucaucagcu,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uugccauuguuucaucagcu,unmodified PMO,NA,0.1,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uccuguaggacauuggcagu,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uccuguaggacauuggcagu,unmodified PMO,NA,0.1,uM,Skip,4.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gcagccucucgcucacucacc,unmodified PMO,NA,0.01,uM,Skip,1.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gcagccucucgcucacucacc,unmodified PMO,NA,0.03,uM,Skip,12.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gcagccucucgcucacucacc,unmodified PMO,NA,0.1,uM,Skip,23.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ccaaagcagccucucgcucac,unmodified PMO,NA,0.01,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ccaaagcagccucucgcucac,unmodified PMO,NA,0.03,uM,Skip,9,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ccaaagcagccucucgcucac,unmodified PMO,NA,0.1,uM,Skip,12.8,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uucuuccaaagcagccucucg,unmodified PMO,NA,0.01,uM,Skip,6.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uucuuccaaagcagccucucg,unmodified PMO,NA,0.03,uM,Skip,24.4,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uucuuccaaagcagccucucg,unmodified PMO,NA,0.1,uM,Skip,31.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuuccagguccagggggaacu,unmodified PMO,NA,0.01,uM,Skip,1.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuuccagguccagggggaacu,unmodified PMO,NA,0.03,uM,Skip,6.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uuuccagguccagggggaacu,unmodified PMO,NA,0.1,uM,Skip,12.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uccuguaggacauuggcagu,unmodified PMO,NA,0.01,uM,Skip,1.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uccuguaggacauuggcagu,unmodified PMO,NA,0.03,uM,Skip,1.4,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,uccuguaggacauuggcagu,unmodified PMO,NA,0.1,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agcagcctctcgctcactcac,unmodified PMO,NA,1,uM,Skip,0.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agcagcctctcgctcactcac,unmodified PMO,NA,3,uM,Skip,1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agcagcctctcgctcactcac,unmodified PMO,NA,10,uM,Skip,1.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ttccaaagcagcctctcgctc,unmodified PMO,NA,1,uM,Skip,12.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ttccaaagcagcctctcgctc,unmodified PMO,NA,3,uM,Skip,29.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ttccaaagcagcctctcgctc,unmodified PMO,NA,10,uM,Skip,56.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ttcttccaaagcagcctctcg,unmodified PMO,NA,1,uM,Skip,31.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ttcttccaaagcagcctctcg,unmodified PMO,NA,3,uM,Skip,52,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,ttcttccaaagcagcctctcg,unmodified PMO,NA,10,uM,Skip,84.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,36.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,59.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,90,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cucaacagaucugucaaaucgc,unmodified PMO,NA,0.03,uM,Skip,46.7,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cucaacagaucugucaaaucgc,unmodified PMO,NA,0.1,uM,Skip,51.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cauuucucaacagaucugucaa,unmodified PMO,NA,0.03,uM,Skip,20.7,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cauuucucaacagaucugucaa,unmodified PMO,NA,0.1,uM,Skip,45.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,gccgccauuucucaacagaucu,unmodified PMO,NA,0.03,uM,Skip,41.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,gccgccauuucucaacagaucu,unmodified PMO,NA,0.1,uM,Skip,61.9,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,aaaacgccgccauuucucaaca,unmodified PMO,NA,0.03,uM,Skip,16.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,aaaacgccgccauuucucaaca,unmodified PMO,NA,0.1,uM,Skip,58.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uaaugaaaacgccgccauuucu,unmodified PMO,NA,0.03,uM,Skip,39.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uaaugaaaacgccgccauuucu,unmodified PMO,NA,0.1,uM,Skip,53.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uaucauaaugaaaacgccgcca,unmodified PMO,NA,0.03,uM,Skip,38,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uaucauaaugaaaacgccgcca,unmodified PMO,NA,0.1,uM,Skip,62,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cuuuauaucauaaugaaaacgc,unmodified PMO,NA,0.03,uM,Skip,29.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cuuuauaucauaaugaaaacgc,unmodified PMO,NA,0.1,uM,Skip,50.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,aauaucuuuauaucauaaugaa,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,aauaucuuuauaucauaaugaa,unmodified PMO,NA,0.1,uM,Skip,9.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,gauuaaauaucuuuauaucaua,unmodified PMO,NA,0.03,uM,Skip,6.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,gauuaaauaucuuuauaucaua,unmodified PMO,NA,0.1,uM,Skip,10.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,guuagccacugauuaaauaucu,unmodified PMO,NA,0.03,uM,Skip,15.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,guuagccacugauuaaauaucu,unmodified PMO,NA,0.1,uM,Skip,31.8,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cuucuguuagccacugauuaaa,unmodified PMO,NA,0.03,uM,Skip,25.4,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cuucuguuagccacugauuaaa,unmodified PMO,NA,0.1,uM,Skip,29.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uucagcuucuguuagccacuga,unmodified PMO,NA,0.03,uM,Skip,46.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uucagcuucuguuagccacuga,unmodified PMO,NA,0.1,uM,Skip,48.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,aacuguucagcuucuguuagcc,unmodified PMO,NA,0.03,uM,Skip,36.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,aacuguucagcuucuguuagcc,unmodified PMO,NA,0.1,uM,Skip,39.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ugagaaacuguucagcuucugu,unmodified PMO,NA,0.03,uM,Skip,31.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ugagaaacuguucagcuucugu,unmodified PMO,NA,0.1,uM,Skip,37.4,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cuuucugagaaacuguucagcu,unmodified PMO,NA,0.03,uM,Skip,53,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cuuucugagaaacuguucagcu,unmodified PMO,NA,0.1,uM,Skip,41.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ugugucuuucugagaaacuguu,unmodified PMO,NA,0.03,uM,Skip,35.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ugugucuuucugagaaacuguu,unmodified PMO,NA,0.1,uM,Skip,50.7,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,gaauuugugucuuucugagaaa,unmodified PMO,NA,0.03,uM,Skip,22,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,gaauuugugucuuucugagaaa,unmodified PMO,NA,0.1,uM,Skip,26.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cucaggaauuugugucuuucug,unmodified PMO,NA,0.03,uM,Skip,29.8,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cucaggaauuugugucuuucug,unmodified PMO,NA,0.1,uM,Skip,55.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,caauucucaggaauuugugucu,unmodified PMO,NA,0.03,uM,Skip,56,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,caauucucaggaauuugugucu,unmodified PMO,NA,0.1,uM,Skip,34.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,guucccaauucucaggaauuug,unmodified PMO,NA,0.03,uM,Skip,40.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,guucccaauucucaggaauuug,unmodified PMO,NA,0.1,uM,Skip,55.4,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,agcauguucccaauucucagga,unmodified PMO,NA,0.03,uM,Skip,26.9,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,agcauguucccaauucucagga,unmodified PMO,NA,0.1,uM,Skip,41.9,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uauuuagcauguucccaauucu,unmodified PMO,NA,0.03,uM,Skip,7.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uauuuagcauguucccaauucu,unmodified PMO,NA,0.1,uM,Skip,17.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,auaccauuuguauuuagcaugu,unmodified PMO,NA,0.03,uM,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,auaccauuuguauuuagcaugu,unmodified PMO,NA,0.1,uM,Skip,4.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ucagcuucuguuagccacug,unmodified PMO,NA,0.03,uM,Skip,62.8,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ucagcuucuguuagccacug,unmodified PMO,NA,0.1,uM,Skip,51.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,gccgccauuucucaacagaucu,unmodified PMO,NA,0.01,uM,Skip,31,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,gccgccauuucucaacagaucu,unmodified PMO,NA,0.03,uM,Skip,62.3,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,gccgccauuucucaacagaucu,unmodified PMO,NA,0.1,uM,Skip,46.9,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uaaugaaaacgccgccauuucu,unmodified PMO,NA,0.01,uM,Skip,23.2,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uaaugaaaacgccgccauuucu,unmodified PMO,NA,0.03,uM,Skip,15.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uaaugaaaacgccgccauuucu,unmodified PMO,NA,0.1,uM,Skip,60.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uaucauaaugaaaacgccgcca,unmodified PMO,NA,0.01,uM,Skip,24,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uaucauaaugaaaacgccgcca,unmodified PMO,NA,0.03,uM,Skip,50.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,uaucauaaugaaaacgccgcca,unmodified PMO,NA,0.1,uM,Skip,61.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cuuucugagaaacuguucagcu,unmodified PMO,NA,0.01,uM,Skip,19.7,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cuuucugagaaacuguucagcu,unmodified PMO,NA,0.03,uM,Skip,29.1,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,cuuucugagaaacuguucagcu,unmodified PMO,NA,0.1,uM,Skip,53.5,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,caauucucaggaauuugugucu,unmodified PMO,NA,0.01,uM,Skip,17.6,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,caauucucaggaauuugugucu,unmodified PMO,NA,0.03,uM,Skip,35.7,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,caauucucaggaauuugugucu,unmodified PMO,NA,0.1,uM,Skip,33.8,NA,NA,NA,RNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ataatgaaaacgccgccattt,unmodified PMO,NA,1,uM,Skip,14,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ataatgaaaacgccgccattt,unmodified PMO,NA,3,uM,Skip,27.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ataatgaaaacgccgccattt,unmodified PMO,NA,10,uM,Skip,64.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,1,uM,Skip,15.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,3,uM,Skip,28.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,10,uM,Skip,75.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atatcataatgaaaacgccgc,unmodified PMO,NA,1,uM,Skip,8.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atatcataatgaaaacgccgc,unmodified PMO,NA,3,uM,Skip,23.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atatcataatgaaaacgccgc,unmodified PMO,NA,10,uM,Skip,48.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatatcataatgaaaacgccg,unmodified PMO,NA,1,uM,Skip,8.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatatcataatgaaaacgccg,unmodified PMO,NA,3,uM,Skip,30.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatatcataatgaaaacgccg,unmodified PMO,NA,10,uM,Skip,70.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,1,uM,Skip,37.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,3,uM,Skip,69.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,10,uM,Skip,92.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tcataatgaaaacgccgccat,unmodified PMO,NA,1,uM,Skip,23.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tcataatgaaaacgccgccat,unmodified PMO,NA,3,uM,Skip,61.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tcataatgaaaacgccgccat,unmodified PMO,NA,10,uM,Skip,91.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,1,uM,Skip,12.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,3,uM,Skip,45.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,10,uM,Skip,80.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,29.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,54.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,94.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ttatatcataatgaaaacgcc,unmodified PMO,NA,1,uM,Skip,3.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ttatatcataatgaaaacgcc,unmodified PMO,NA,3,uM,Skip,8.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,ttatatcataatgaaaacgcc,unmodified PMO,NA,10,uM,Skip,36.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,1,uM,Skip,39.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,3,uM,Skip,65.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,10,uM,Skip,95.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,tccagtatacttacaggctcc,unmodified PMO,NA,0.1,uM,Skip,1.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,tccagtatacttacaggctcc,unmodified PMO,NA,0.3,uM,Skip,2.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,tccagtatacttacaggctcc,unmodified PMO,NA,1,uM,Skip,7.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,atccagtatacttacaggctc,unmodified PMO,NA,0.1,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,atccagtatacttacaggctc,unmodified PMO,NA,0.3,uM,Skip,3.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,atccagtatacttacaggctc,unmodified PMO,NA,1,uM,Skip,12.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gatccagtatacttacaggct,unmodified PMO,NA,0.1,uM,Skip,1.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gatccagtatacttacaggct,unmodified PMO,NA,0.3,uM,Skip,5.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gatccagtatacttacaggct,unmodified PMO,NA,1,uM,Skip,32.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,ggatccagtatacttacaggc,unmodified PMO,NA,0.1,uM,Skip,1.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,ggatccagtatacttacaggc,unmodified PMO,NA,0.3,uM,Skip,10.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,ggatccagtatacttacaggc,unmodified PMO,NA,1,uM,Skip,59.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,84,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,99.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,cttacaggctccaatagtggtcagt,unmodified PMO,NA,0.1,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,cttacaggctccaatagtggtcagt,unmodified PMO,NA,0.3,uM,Skip,6.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,cttacaggctccaatagtggtcagt,unmodified PMO,NA,1,uM,Skip,41.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.1,uM,Skip,1.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.3,uM,Skip,54.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,1,uM,Skip,97.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,1,uM,Skip,20.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,3,uM,Skip,59.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,10,uM,Skip,91.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,ccaatgccatcctggagttcc,unmodified PMO,NA,1,uM,Skip,19.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,ccaatgccatcctggagttcc,unmodified PMO,NA,3,uM,Skip,63.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,ccaatgccatcctggagttcc,unmodified PMO,NA,10,uM,Skip,92.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,26.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,70.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,93.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gcccaatgccatcctggagtt,unmodified PMO,NA,1,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gcccaatgccatcctggagtt,unmodified PMO,NA,3,uM,Skip,1.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,gcccaatgccatcctggagtt,unmodified PMO,NA,10,uM,Skip,3.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,tgcccaatgccatcctggagt,unmodified PMO,NA,1,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,tgcccaatgccatcctggagt,unmodified PMO,NA,3,uM,Skip,2.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,tgcccaatgccatcctggagt,unmodified PMO,NA,10,uM,Skip,6.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,1,uM,Skip,9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,3,uM,Skip,33.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,10,uM,Skip,80,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,17.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,54.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,84.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,4.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,19.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,49.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,ccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,4.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,ccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,15.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,ccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,44.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagtt,unmodified PMO,NA,1,uM,Skip,4.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagtt,unmodified PMO,NA,3,uM,Skip,20.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,45,NA,human,RD cells,Null,NA,cccaatgccatcctggagtt,unmodified PMO,NA,10,uM,Skip,46.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,tttcttccaaagcagcctctc,unmodified PMO,NA,1,uM,Skip,17.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,tttcttccaaagcagcctctc,unmodified PMO,NA,3,uM,Skip,36.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,tttcttccaaagcagcctctc,unmodified PMO,NA,10,uM,Skip,69.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gtttcttccaaagcagcctct,unmodified PMO,NA,1,uM,Skip,14.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gtttcttccaaagcagcctct,unmodified PMO,NA,3,uM,Skip,34.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gtttcttccaaagcagcctct,unmodified PMO,NA,10,uM,Skip,57.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,25.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,38.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,74.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gagtttcttccaaagcagcct,unmodified PMO,NA,1,uM,Skip,11.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gagtttcttccaaagcagcct,unmodified PMO,NA,3,uM,Skip,27.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gagtttcttccaaagcagcct,unmodified PMO,NA,10,uM,Skip,72,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,tgagtttcttccaaagcagcc,unmodified PMO,NA,1,uM,Skip,13.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,tgagtttcttccaaagcagcc,unmodified PMO,NA,3,uM,Skip,27.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,tgagtttcttccaaagcagcc,unmodified PMO,NA,10,uM,Skip,63.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,1,uM,Skip,1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,3,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,10,uM,Skip,1.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,17.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,32.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,67.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,6.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,45.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,1,uM,Skip,7.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,3,uM,Skip,24.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,10,uM,Skip,67.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,9.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,28.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,58.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,1,uM,Skip,0.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,3,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,10,uM,Skip,1.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,13.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,27.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,68.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,11.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,18.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,55.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgc,unmodified PMO,NA,1,uM,Skip,2.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgc,unmodified PMO,NA,3,uM,Skip,9.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgc,unmodified PMO,NA,10,uM,Skip,30.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,7.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,32.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,61.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,13.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,79.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,98.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,4.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,54.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,95.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,ggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,1.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,ggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,7.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,ggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,37.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacag,unmodified PMO,NA,0.1,uM,Skip,5.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacag,unmodified PMO,NA,0.3,uM,Skip,53.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacag,unmodified PMO,NA,1,uM,Skip,95.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,tgggatccagtatacttacag,unmodified PMO,NA,0.1,uM,Skip,7.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,tgggatccagtatacttacag,unmodified PMO,NA,0.3,uM,Skip,45.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,tgggatccagtatacttacag,unmodified PMO,NA,1,uM,Skip,96.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,atgggatccagtatacttaca,unmodified PMO,NA,0.1,uM,Skip,3.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,atgggatccagtatacttaca,unmodified PMO,NA,0.3,uM,Skip,32.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,atgggatccagtatacttaca,unmodified PMO,NA,1,uM,Skip,90.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,28.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,42.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,70.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,26.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,43.6,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,44,NA,human,RD cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,68.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,7.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.5,uM,Skip,13,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,52.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,5,uM,Skip,67.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,10,uM,Skip,86.1,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,0.1,uM,Skip,5.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,0.5,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,26.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,5,uM,Skip,47.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,70.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,0.1,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,0.5,uM,Skip,2.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,1,uM,Skip,6.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,5,uM,Skip,22.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,10,uM,Skip,59.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,1.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,20.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,10,uM,Skip,77.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,35.7,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.5,uM,Skip,49.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,71.3,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,5,uM,Skip,82.2,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,50,NA,human,RD cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,10,uM,Skip,93.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,0.1,uM,Skip,56.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,75.9,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,78.4,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,0.1,uM,Skip,31.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,1,uM,Skip,55.5,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
patent,Antisense Nucleic Acid,US10870676B2,DMD,exon,55,NA,human,RD cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,10,uM,Skip,73.8,NA,NA,NA,DNA,https://patents.google.com/patent/US10870676B2,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,gatccatggacatttgactggtatt,unmodified PMO,NA,2,uM,Skip,24.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,attcttcatgatccatggacatttg,unmodified PMO,NA,2,uM,Skip,4.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,gtagtaattcttcatgatccatgga,unmodified PMO,NA,2,uM,Skip,5.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,ccggagagaggctccaggagtacgt,unmodified PMO,NA,2,uM,Skip,20.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,gatccatggacatttgactggtatttcc,unmodified PMO,NA,2,uM,Skip,39.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,tgatccatggacatttgactggtatttc,unmodified PMO,NA,2,uM,Skip,28.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,atgatccatggacatttgactggtattt,unmodified PMO,NA,2,uM,Skip,34,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,catgatccatggacatttgactggtatt,unmodified PMO,NA,2,uM,Skip,27.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,attcttcatgatccatggacatttgact,unmodified PMO,NA,2,uM,Skip,16.8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,gtaattcttcatgatccatggacatttg,unmodified PMO,NA,2,uM,Skip,15.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,cttccggagagaggctccaggagtacgt,unmodified PMO,NA,2,uM,Skip,6.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,cttccggagagaggctccaggagtacgt,unmodified PMO,NA,2,uM,Skip,20.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,HEK293,LipoD293 or Lipofectamine 3000,NA,cttttcccttccggagagaggctccagg,unmodified PMO,NA,2,uM,Skip,15.8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,A15 HEK293T(mutation c.1885G>A),LipoD293 or Lipofectamine 3000,NA,gatccatggacatttgactggtatttcc,unmodified PMO,NA,2,uM,Skip,9.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,A15 HEK293T(mutation c.1885G>A),LipoD293 or Lipofectamine 3000,NA,atgatccatggacatttgactggtattt,unmodified PMO,NA,2,uM,Skip,6.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Targeted Exon Skipping Of Nf1 Exon 17 As A Therapeutic For Neurofibromatosis Type I,PMID 35433111,NF1,exon,17,NA,human,A15 HEK293T(mutation c.1885G>A),LipoD293 or Lipofectamine 3000,NA,gtaattcttcatgatccatggacatttg,unmodified PMO,NA,2,uM,Skip,15.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35433111,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 46/ 47/ 48/ 49/ 50/ 51/ 52/ 53/ 54/ 55,NA,human,healthy immortalized patient-derived KM155 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,34.38,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 47/ 49/ 51/ 53/ 55,NA,human,healthy immortalized patient-derived KM155 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtttgagaattccctggcgcaggggcaact/atctcttccacatccggttgtttagcttga/gtgtcaccagagtaacagtctgagtaggag/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,24.48,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 47/ 49/ 53/ 55,NA,human,healthy immortalized patient-derived KM155 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtttgagaattccctggcgcaggggcaact/atctcttccacatccggttgtttagcttga/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,21.88,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 49/ 50/ 52/ 53/ 55,NA,human,healthy immortalized patient-derived KM155 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,29.27,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,mouse,DIA,Null,NA,gtgtcaccagagtaacagtctgagtaggag,modified PMO,NA,64,mg/kg,Skip,69.38,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 50/ 55,NA,human,healthy immortalized patient-derived KM155 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtaaacggtttaccgccttccactcagagc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,33.65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 46/ 47/ 48/ 49/ 50/ 51/ 52/ 53/ 54/ 55,NA,human,healthy immortalized patient-derived KM571 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,24.79,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 47/ 49/ 51/ 53/ 55,NA,human,healthy immortalized patient-derived KM571 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtttgagaattccctggcgcaggggcaact/atctcttccacatccggttgtttagcttga/gtgtcaccagagtaacagtctgagtaggag/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,20.21,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 47/ 49/ 53/ 55,NA,human,healthy immortalized patient-derived KM571 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtttgagaattccctggcgcaggggcaact/atctcttccacatccggttgtttagcttga/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,24.17,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 49/ 50/ 52/ 53/ 55,NA,human,healthy immortalized patient-derived KM571 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,34.69,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 50/ 55,NA,human,healthy immortalized patient-derived KM571 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtaaacggtttaccgccttccactcagagc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,30.21,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 46/ 47/ 48/ 49/ 50/ 51/ 52/ 53/ 54/ 55,NA,human,healthy immortalized patient-derived 6594 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,16.15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 47/ 49/ 51/ 53/ 55,NA,human,healthy immortalized patient-derived 6594 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtttgagaattccctggcgcaggggcaact/atctcttccacatccggttgtttagcttga/gtgtcaccagagtaacagtctgagtaggag/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,6.25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 47/ 49/ 53/ 55,NA,human,healthy immortalized patient-derived 6594 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtttgagaattccctggcgcaggggcaact/atctcttccacatccggttgtttagcttga/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,16.15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 49/ 50/ 52/ 53/ 55,NA,human,healthy immortalized patient-derived 6594 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,21.56,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 50/ 55,NA,human,healthy immortalized patient-derived 6594 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtaaacggtttaccgccttccactcagagc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,24.38,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 46/ 47/ 48/ 49/ 50/ 51/ 52/ 53/ 54/ 55,NA,human,healthy immortalized patient-derived 6311 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,33.23,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 47/ 49/ 51/ 53/ 55,NA,human,healthy immortalized patient-derived 6311 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtttgagaattccctggcgcaggggcaact/atctcttccacatccggttgtttagcttga/gtgtcaccagagtaacagtctgagtaggag/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,0.83,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 50/ 55,NA,human,healthy immortalized patient-derived 6311 myotubes,Gene tools,NA,gacaacagtttgccgctgcccaatgccatc/gtaaacggtttaccgccttccactcagagc/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,0.31,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,human,TA,Null,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,50,mg/kg,Skip,31.8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,human,GAS,Null,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,50,mg/kg,Skip,7.25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,human,QUA,Null,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,50,mg/kg,Skip,26.48,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,human,DIA,Null,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,50,mg/kg,Skip,5.18,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,human,HRT,Null,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,50,mg/kg,Skip,4.29,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,mouse,TA,Null,NA,gtgtcaccagagtaacagtctgagtaggag,modified PMO,NA,64,mg/kg,Skip,71.15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,mouse,GAS,Null,NA,gtgtcaccagagtaacagtctgagtaggag,modified PMO,NA,64,mg/kg,Skip,72.93,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,mouse,QUA,Null,NA,gtgtcaccagagtaacagtctgagtaggag,modified PMO,NA,64,mg/kg,Skip,74.41,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,mouse,HRT,Null,NA,gtgtcaccagagtaacagtctgagtaggag,modified PMO,NA,64,mg/kg,Skip,73.52,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,mouse,TA,Null,NA,gtgtcaccagagtaacagtctgagtaggag,modified PMO,NA,30,mg/kg,Skip,54.65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,mouse,QUA,Null,NA,gtgtcaccagagtaacagtctgagtaggag,modified PMO,NA,30,mg/kg,Skip,58.05,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,mouse,DIA,Null,NA,gtgtcaccagagtaacagtctgagtaggag,modified PMO,NA,30,mg/kg,Skip,57.14,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,51,NA,mouse,HRT,Null,NA,gtgtcaccagagtaacagtctgagtaggag,modified PMO,NA,30,mg/kg,Skip,70.27,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,Development Of Dg9 Peptide-Conjugated Single- And Multi-Exon Skipping Therapies For The Treatment Of Duchenne Muscular Dystrophy,PMID 35193974,DMD,exon,45/ 49/ 50/ 52/ 53/ 55,NA,mouse,hDMDdel52;mdx mice,Null,NA,gacaacagtttgccgctgcccaatgccatc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/tcttccaaagcagcctctcgctcactcacc,modified PMO,NA,"5 ug/DG9-PMO,25 ug total dose",Null,Skip,9.33,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/35193974,NA,NA,NA
journal article,"Akr1a1 Variant Associated With Schizophrenia Causes Exon Skipping, Leading To Loss Of Enzymatic Activity",PMID 34938315,AKR1A1,exon,8,NA,human,HEK293(MT),Null,NA,not applicable,Null,NA,Null,Null,Skip,9.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/34938315,NA,NA,NA
journal article,"Akr1a1 Variant Associated With Schizophrenia Causes Exon Skipping, Leading To Loss Of Enzymatic Activity",PMID 34938315,AKR1A1,exon,8,NA,human,HEK293(WT),Null,NA,not applicable,Null,NA,Null,Null,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/34938315,NA,NA,NA
journal article,"Akr1a1 Variant Associated With Schizophrenia Causes Exon Skipping, Leading To Loss Of Enzymatic Activity",PMID 34938315,AKR1A1,exon,8,NA,human,SHSY5YMT,Null,NA,not applicable,Null,NA,Null,Null,Skip,8.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/34938315,NA,NA,NA
journal article,"Akr1a1 Variant Associated With Schizophrenia Causes Exon Skipping, Leading To Loss Of Enzymatic Activity",PMID 34938315,AKR1A1,exon,8,NA,human,SHSY5YWT,Null,NA,not applicable,Null,NA,Null,Null,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/34938315,NA,NA,NA
journal article,"Akr1a1 Variant Associated With Schizophrenia Causes Exon Skipping, Leading To Loss Of Enzymatic Activity",PMID 34938315,AKR1A1,exon,8,NA,human,1321N1MT,Null,NA,not applicable,Null,NA,Null,Null,Skip,1.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/34938315,NA,NA,NA
journal article,"Akr1a1 Variant Associated With Schizophrenia Causes Exon Skipping, Leading To Loss Of Enzymatic Activity",PMID 34938315,AKR1A1,exon,8,NA,human,1321N1WT,Null,NA,not applicable,Null,NA,Null,Null,Skip,0.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/34938315,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,accactgigccagigigicctc,2OMe,NA,10,uM,Null,13.73,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,accactgigccagigigicctc,2OMe,NA,3,uM,Null,2.41,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,acaggtgaaggttcttgggtac,2OMe,NA,10,uM,Null,1.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,acaggtgaaggttcttgggtac,2OMe,NA,3,uM,Null,1.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,ggcctcttggaccctgcagaccct,2OMe,NA,10,uM,Null,44.9,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,ggcctcttggaccctgcagaccct,2OMe,NA,3,uM,Null,9.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,ggcctcttggaccctgcagaccct,2OMe,NA,0.3,uM,Null,1.86,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,aaggttcttgggtactcaccac,2OMe,NA,10,uM,Null,95.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,aaggttcttgggtactcaccac,2OMe,NA,3,uM,Null,95.37,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,aaggttcttgggtactcaccac,2OMe,NA,1,uM,Null,82.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,aaggttcttgggtactcaccac,2OMe,NA,0.3,uM,Null,51.63,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,gttcttgggtactcaccactgg,2OMe,NA,10,uM,Null,95.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,gttcttgggtactcaccactgg,2OMe,NA,3,uM,Null,92.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,gttcttgggtactcaccactgg,2OMe,NA,1,uM,Null,74.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,gttcttgggtactcaccactgg,2OMe,NA,0.3,uM,Null,29.5,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ggtactcaccactgggccagig,2OMe,NA,10,uM,Null,82.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ggtactcaccactgggccagig,2OMe,NA,3,uM,Null,58.49,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ggtactcaccactgggccagig,2OMe,NA,1,uM,Null,13.89,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ggtactcaccactgggccagig,2OMe,NA,0.3,uM,Null,5.15,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ttgggtactcaccactgggcca,2OMe,NA,10,uM,Null,80.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ttgggtactcaccactgggcca,2OMe,NA,3,uM,Null,50.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ttgggtactcaccactgggcca,2OMe,NA,1,uM,Null,15.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ttgggtactcaccactgggcca,2OMe,NA,0.3,uM,Null,1.72,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,ggtactcaccactgggccagig,2OMe,NA,3,uM,Null,8.35,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,aaggttcttgggtactcaccac,2OMe,NA,10,uM,Null,96.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,aaggttcttgggtactcaccac,2OMe,NA,3,uM,Null,95.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,aaggttcttgggtactcaccac,2OMe,NA,1,uM,Null,54.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,aaggttcttgggtactcaccac,2OMe,NA,0.3,uM,Null,24.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,gttcttgggtactcaccactgg,2OMe,NA,10,uM,Null,94.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,gttcttgggtactcaccactgg,2OMe,NA,3,uM,Null,89.98,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,gttcttgggtactcaccactgg,2OMe,NA,1,uM,Null,35.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,gttcttgggtactcaccactgg,2OMe,NA,0.3,uM,Null,1.67,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,ttgggtactcaccactgggcca,2OMe,NA,10,uM,Null,70.87,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,ttgggtactcaccactgggcca,2OMe,NA,3,uM,Null,13.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,ttgggtactcaccactgggcca,2OMe,NA,1,uM,Null,3.15,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HDFa cells,nucleofector,NA,ggtactcaccactgggccagig,2OMe,NA,10,uM,Null,58.44,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,accactgigccagigigicctc,2OMe,NA,10,uM,Null,41.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,accactgigccagigigicctc,2OMe,NA,3,uM,Null,18.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,accactgigccagigigicctc,2OMe,NA,1,uM,Null,6.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,acaggtgaaggttcttgggtac,2OMe,NA,Null,uM,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ggcctcttggaccctgcagaccct,2OMe,NA,10,uM,Null,81.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ggcctcttggaccctgcagaccct,2OMe,NA,3,uM,Null,28.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
journal article,Antisense-Induced Exon Exclusion In Type Vii Collagen,JP2018518167A,COL7A1,exon,80,NA,human,HEKa cells,nucleofector,NA,ggcctcttggaccctgcagaccct,2OMe,NA,1,uM,Null,14.58,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018518167A,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US/2021/254071,DMD,exon,45,NA,human,human  control  myotubes,UNIFectylin,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,72,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/254071,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US/2021/254071,DMD,exon,45,NA,human,human  control  myotubes,UNIFectylin,NA,uuugccncugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,63,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/254071,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US/2021/254071,DMD,exon,45,NA,human,human  control  myotubes,UNIFectylin,NA,ucaauguucugacaacaguuugccg,2OMe,NA,0.2,uM,Skip,9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/254071,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US/2021/254071,DMD,exon,45,NA,human,human  control  myotubes,UNIFectylin,NA,caauguucugacaacaguuugccgc,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/254071,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US/2021/254071,DMD,exon,45,NA,human,human  control  myotubes,UNIFectylin,NA,aauguucugacaacaguuugccgcu,2OMe,NA,0.2,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/254071,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US/2021/254071,DMD,exon,45,NA,human,human  control  myotubes,UNIFectylin,NA,auguucugacaacaguuugccgcug,2OMe,NA,0.2,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/254071,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US/2021/254071,DMD,exon,45,NA,human,human  control  myotubes,UNIFectylin,NA,uguucugacaacaguuugccicugc,2OMe,NA,0.2,uM,Skip,20,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/254071,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US/2021/254071,DMD,exon,45,NA,human,human  control  myotubes,UNIFectylin,NA,guucugacaacaguuugccgcugcc,2OMe,NA,0.2,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/254071,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US/2021/254071,DMD,exon,45,NA,human,human  control  myotubes,UNIFectylin,NA,uucugacaacaguuugccgcugccc,2OMe,NA,0.2,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/254071,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US/2021/254071,DMD,exon,45,NA,human,human  control  myotubes,UNIFectylin,NA,ucugacaacaguuugccgcugccca,2OMe,NA,0.2,uM,Skip,12,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/254071,NA,NA,NA
patent,Combination Therapies For Treating Muscular Dystrophy,US/2021/145852,DMD,exon,45,NA,mouse,Quadriceps,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,Mdx mice treated with the M23D PMO in combination with CAT-1004. Mice were dosed weekly with M23D PMO (AVI-4225)  at  40  mg/kg  by  IV injection  and  treated  with CAT-1004  (1%)  in  their  diet.,Null,Skip,45.59,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/145852,NA,NA,NA
patent,Combination Therapies For Treating Muscular Dystrophy,US/2021/145852,DMD,exon,45,NA,mouse,Quadriceps,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO,NA,Mdx mice treated with the M23D PMO in combination with CAT-1004. Mice were dosed weekly with M23D PMO (AVI-4225)  at  40  mg/kg  by  IV injection  and  treated  with CAT-1004  (1%)  in  their  diet.,Null,Skip,59.02,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/145852,NA,NA,NA
patent,Combination Therapies For Treating Muscular Dystrophy,US/2021/145852,DMD,exon,45,NA,mouse,Diaphragm,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,Mdx mice treated with the M23D PMO in combination with CAT-1004. Mice were dosed weekly with M23D PMO (AVI-4225)  at  40  mg/kg  by  IV injection  and  treated  with CAT-1004  (1%)  in  their  diet.,Null,Skip,31.61,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/145852,NA,NA,NA
patent,Combination Therapies For Treating Muscular Dystrophy,US/2021/145852,DMD,exon,45,NA,mouse,Diaphragm,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO,NA,Mdx mice treated with the M23D PMO in combination with CAT-1004. Mice were dosed weekly with M23D PMO (AVI-4225)  at  40  mg/kg  by  IV injection  and  treated  with CAT-1004  (1%)  in  their  diet.,Null,Skip,36.92,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/145852,NA,NA,NA
patent,Combination Therapies For Treating Muscular Dystrophy,US/2021/145852,DMD,exon,45,NA,mouse,Heart,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,Mdx mice treated with the M23D PMO in combination with CAT-1004. Mice were dosed weekly with M23D PMO (AVI-4225)  at  40  mg/kg  by  IV injection  and  treated  with CAT-1004  (1%)  in  their  diet.,Null,Skip,7.27,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/145852,NA,NA,NA
patent,Combination Therapies For Treating Muscular Dystrophy,US/2021/145852,DMD,exon,45,NA,mouse,Heart,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO,NA,Mdx mice treated with the M23D PMO in combination with CAT-1004. Mice were dosed weekly with M23D PMO (AVI-4225)  at  40  mg/kg  by  IV injection  and  treated  with CAT-1004  (1%)  in  their  diet.,Null,Skip,6.15,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/145852,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cattcaactgttgcctccggttctgaaggtg,unmodified PMO,NA,0.1,uM,Skip,17.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,0.1,uM,Skip,62.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ccggttctgaaggtgttcttgt,unmodified PMO,NA,0.1,uM,Skip,57.2,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.1,uM,Skip,86.72,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,tccggttctgaaggtgttcttg,unmodified PMO,NA,0.1,uM,Skip,73.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,tgcctccggttctgaaggtgttctt,unmodified PMO,NA,0.1,uM,Skip,71.46,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,54,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,62.24,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,91.76,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,14.15,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.1,uM,Skip,13.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,gcctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,8.09,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,0.1,uM,Skip,6.14,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.1,uM,Skip,37.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,gcctccggttctgaaggtgttcttg,unmodified PMO,NA,0.1,uM,Skip,18.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,37.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,gcctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,17.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,0.1,uM,Skip,3.9,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,fibroblasts from human DMD patient,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,89.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,fibroblasts from human DMD patient,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.1,uM,Skip,80.49,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,fibroblasts from human DMD patient,Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,0.1,uM,Skip,64.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,fibroblasts from human DMD patient,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,94.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,fibroblasts from human DMD patient,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.1,uM,Skip,94.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,fibroblasts from human DMD patient,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,94.05,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,fibroblasts from human DMD patient,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,Skip,71.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,fibroblasts from human DMD patient,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.1,uM,Skip,88.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,fibroblasts from human DMD patient,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.1,uM,Skip,80.17,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,41.17,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucccacugauucugaauucuuucaa,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuucaucccacugauucugaauucu,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuguacuucaucccacugauucuga,2OMe,NA,0.1,uM,Skip,22.4,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguucuuguacuucaucccacugau,2OMe,NA,0.1,uM,Skip,32.65,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gaagguguucuuguacuucauccca,2OMe,NA,0.1,uM,Skip,11.99,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guucugaagguguucuuguacuuca,2OMe,NA,0.1,uM,Skip,24.61,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuccgguucugaagguguucuugua,2OMe,NA,0.1,uM,Skip,42.27,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guugccuccgguucugaagguguuc,2OMe,NA,0.1,uM,Skip,73.34,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caacuguugccuccgguucugaagg,2OMe,NA,0.1,uM,Skip,28.86,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucauucaacuguugccuccgguucu,2OMe,NA,0.1,uM,Skip,28.71,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,81.85,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,acauuucauucaacuguugccuccg,2OMe,NA,0.1,uM,Skip,1.82,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuuuaacauuucauucaacuguugc,2OMe,NA,0.1,uM,Skip,1.98,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gaauccuuuaacauuucauucaacu,2OMe,NA,0.1,uM,Skip,3.14,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guguugaauccuuuaacauuucauu,2OMe,NA,0.1,uM,Skip,3.14,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccauuguguugaauccuuuaacauu,2OMe,NA,0.1,uM,Skip,4.79,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uccagccauuguguugaauccuuua,2OMe,NA,0.1,uM,Skip,3.8,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uagcuuccagccauuguguugaauc,2OMe,NA,0.1,uM,Skip,6.93,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuccuuagcuuccagccauuguguu,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gcuucuuccuuagcuuccagccauu,2OMe,NA,0.1,uM,Skip,8.91,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,46.38,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gaccugcucagcuucuuccuuagcu,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuaagaccugcucagcuucuuccu,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuguccuaagaccugcucagcuuc,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucuggccuguccuaagaccugcuca,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuggcucuggccuguccuaagaccu,2OMe,NA,0.1,uM,Skip,27.17,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caagcuuggcucuggccuguccuaa,2OMe,NA,0.1,uM,Skip,39.13,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugacucaagcuuggcucuggccugu,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuccaugacucaagcuuggcucugg,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuccuuccaugacucaagcuuggc,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,90.21,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gggacccuccuuccaugacucaagc,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guauagggacccuccuuccaugacu,2OMe,NA,0.1,uM,Skip,13.64,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuacuguauagggacccuccuucca,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugcaucuacuguauagggacccucc,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uggauugcaucuacuguauagggac,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucuuuuggauugcaucuacuguaua,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gauuuucuuuuggauugcaucuacu,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucugugauuuucuuuuggauugcau,2OMe,NA,0.1,uM,Skip,1.05,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugguuucugugauuuucuuuuggau,2OMe,NA,0.1,uM,Skip,2.1,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,64.51,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuccgguucugaagguguucuugua,2OMe,NA,0.1,uM,Skip,58.36,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guugccuccgguucugaagguguuc,2OMe,NA,0.1,uM,Skip,87.03,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caacuguugccuccgguucugaagg,2OMe,NA,0.1,uM,Skip,28.33,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuccuuagcuuccagccauuguguu,2OMe,NA,0.1,uM,Skip,11.6,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caagcuuggcucuggccuguccuaa,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guauagggacccuccuuccaugacu,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugguuucugugauuuucuuuuggau,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,90.92,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uagcuuccagccauuguguugaauc,2OMe,NA,0.1,uM,Skip,15.92,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuuagcuuccagccauuguguuga,2OMe,NA,0.1,uM,Skip,18.49,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuccuuagcuuccagccauuguguu,2OMe,NA,0.1,uM,Skip,14.04,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucuuccuuagcuuccagccauugug,2OMe,NA,0.1,uM,Skip,27.23,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gcuucuuccuuagcuuccagccauu,2OMe,NA,0.1,uM,Skip,9.76,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ggcucuggccuguccuaagaccugc,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuggcucuggccuguccuaagaccu,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,agcuuggcucuggccuguccuaaga,2OMe,NA,0.1,uM,Skip,22.09,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caagcuuggcucuggccuguccuaa,2OMe,NA,0.1,uM,Skip,32.71,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cucaagcuuggcucuggccugucc,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gacccuccuuccaugacucaagcuu,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gggacccuccuuccaugacucaagc,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,auagggacccuccuuccaugacuca,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guauagggacccuccuuccaugacu,2OMe,NA,0.1,uM,Skip,11.67,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuguauagggacccuccuuccauga,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugugauuuucuuuuggauugcaucu,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucugugauuuucuuuuggauugcau,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guuucugugauuuucuuuuggauug,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugguuucugugauuuucuuuuggau,2OMe,NA,0.1,uM,Skip,16.48,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,71.29,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuguugccuccgguucug,2OMe,NA,0.1,uM,Skip,52.74,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccgguucugaagguguucuuguacu,2OMe,NA,0.1,uM,Skip,57.26,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uccgguucugaagguguucuuguac,2OMe,NA,0.1,uM,Skip,67.42,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuccgguucugaagguguucuugua,2OMe,NA,0.1,uM,Skip,74.68,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuccgguucugaagguguucuugu,2OMe,NA,0.1,uM,Skip,66.94,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gccuccgguucugaagguguucuug,2OMe,NA,0.1,uM,Skip,78.71,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugccuccgguucugaagguguucuu,2OMe,NA,0.1,uM,Skip,85.32,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uugccuccgguucugaagguguucu,2OMe,NA,0.1,uM,Skip,93.87,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guugccuccgguucugaagguguuc,2OMe,NA,0.1,uM,Skip,87.42,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguugccuccgguucugaagguguu,2OMe,NA,0.1,uM,Skip,83.39,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuguugccuccgguucugaaggugu,2OMe,NA,0.1,uM,Skip,51.77,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,acuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,47.42,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,aacuguugccuccgguucugaaggu,2OMe,NA,0.1,uM,Skip,53.39,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caacuguugccuccgguucugaagg,2OMe,NA,0.1,uM,Skip,80.32,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,76.24,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuguugccuccgguucug,2OMe,NA,0.1,uM,Skip,41.67,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguugccuccgguucugaagguguucuugu,2OMe,NA,0.1,uM,Skip,91.17,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuccgguucugaagguguucuugu,2OMe,NA,0.1,uM,Skip,78.11,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gccuccgguucugaagguguucuug,2OMe,NA,0.1,uM,Skip,95.27,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugccuccgguucugaagguguucuu,2OMe,NA,0.1,uM,Skip,95.02,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uugccuccgguucugaagguguucu,2OMe,NA,0.1,uM,Skip,93.16,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guugccuccgguucugaagguguuc,2OMe,NA,0.1,uM,Skip,86.69,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguugccuccgguucugaagguguu,2OMe,NA,0.1,uM,Skip,84.2,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gguucugaagguguucuugu,2OMe,NA,0.1,uM,Skip,9.2,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uccgguucugaagguguucu,2OMe,NA,0.1,uM,Skip,54.85,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuccgguucugaagguguu,2OMe,NA,0.1,uM,Skip,20.77,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uugccuccgguucugaaggu,2OMe,NA,0.1,uM,Skip,42.04,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguugccuccgguucugaag,2OMe,NA,0.1,uM,Skip,58.33,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uucugaagguguucuugu,2OMe,NA,0.1,uM,Skip,13.43,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cgguucugaagguguucu,2OMe,NA,0.1,uM,Skip,26.37,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuccgguucugaaggugu,2OMe,NA,0.1,uM,Skip,23.76,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugccuccgguucugaagg,2OMe,NA,0.1,uM,Skip,58.83,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguugccuccgguucuga,2OMe,NA,0.1,uM,Skip,48.88,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uucugaagguguucu,2OMe,NA,0.1,uM,Skip,7.71,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uccgguucugaaggu,2OMe,NA,0.1,uM,Skip,4.98,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uugccuccgguucug,2OMe,NA,0.1,uM,Skip,23.13,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.3,uM,Skip,3.15,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,1,uM,Skip,8.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,3,uM,Skip,24.37,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,60.08,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,30,uM,Skip,72.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,0.3,uM,Skip,1.05,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,1,uM,Skip,5.46,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,3,uM,Skip,12.82,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,10,uM,Skip,30.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,30,uM,Skip,52.31,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,0.3,uM,Skip,1.26,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,1,uM,Skip,2.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,3,uM,Skip,8.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,10,uM,Skip,18.49,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,30,uM,Skip,39.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.3,uM,Skip,18.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,1,uM,Skip,18.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,3,uM,Skip,40.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,65.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,30,uM,Skip,80.9,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.3,uM,Skip,12.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,1,uM,Skip,22.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,3,uM,Skip,38.41,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,63.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,30,uM,Skip,73.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.3,uM,Skip,14.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,1,uM,Skip,10.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,3,uM,Skip,16.74,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,28.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,30,uM,Skip,47.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.3,uM,Skip,13.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,1,uM,Skip,16.74,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,3,uM,Skip,19.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,28.86,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP6867636B1,DMD,exon,53,NA,human,RD Cells,Nucleofector II,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,30,uM,Skip,36.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,43,NA,human,human  control  myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,cgaccugagcuuuguuguag,2OMe,NA,0.5,uM,Skip,66,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,43,NA,human,human  control  myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,cgaccugagcuuuguuguagacuau,2OMe,NA,0.5,uM,Skip,13,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,43,NA,human,human  control  myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,cguugcacuuugcaaugcugcug,2OMe,NA,0.5,uM,Skip,36,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,46,NA,human,myotubes from a DMD patient with an exon 45 deletion,UNIFectylin Prosensa  Therapeutics  BV,NA,ucuuuuccagguucaagugg,2OMe,NA,0.05,uM,Skip,21,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,46,NA,human,myotubes from a DMD patient with an exon 45 deletion,UNIFectylin Prosensa  Therapeutics  BV,NA,ucuuuuccagguucaagugg,2OMe,NA,0.15,uM,Skip,55,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,46,NA,human,myotubes from a DMD patient with an exon 45 deletion,UNIFectylin Prosensa  Therapeutics  BV,NA,gcuuuucuuuuaguugcugcucuuu,2OMe,NA,0.05,uM,Skip,53,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,46,NA,human,myotubes from a DMD patient with an exon 45 deletion,UNIFectylin Prosensa  Therapeutics  BV,NA,gcuuuucuuuuaguugcugcucuuu,2OMe,NA,0.15,uM,Skip,58,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,46,NA,human,myotubes from a DMD patient with an exon 45 deletion,UNIFectylin Prosensa  Therapeutics  BV,NA,ggauacuagcaauguuaucugcuuc,2OMe,NA,0.05,uM,Skip,46,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,modified PMO,NA,1.25,uM,Skip,2.46,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,46,NA,human,myotubes from a DMD patient with an exon 45 deletion,UNIFectylin Prosensa  Therapeutics  BV,NA,ggauacuagcaauguuaucugcuuc,2OMe,NA,0.15,uM,Skip,42,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,46,NA,human,myotubes from a DMD patient with an exon 45 deletion,UNIFectylin Prosensa  Therapeutics  BV,NA,agcaauguuaucugcuuccuccaac,2OMe,NA,0.05,uM,Skip,48,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,46,NA,human,myotubes from a DMD patient with an exon 45 deletion,UNIFectylin Prosensa  Therapeutics  BV,NA,agcaauguuaucugcuuccuccaac,2OMe,NA,0.15,uM,Skip,74,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,50,NA,human,human control myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,cucagcucuugaaguaaacg,2OMe,NA,0.5,uM,Skip,14,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,50,NA,human,human control myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,ccucagcucuugaaguaaac,2OMe,NA,0.5,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,50,NA,human,human control myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,ccucagcucuugaaguaaacg,2OMe,NA,0.5,uM,Skip,14,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,50,NA,human,human control myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,auaguggucaguccaggagcu,2OMe,NA,0.5,uM,Skip,35,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,52,NA,human,human control myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,cucuugauugcuggucuuguuuuuc,2OMe,NA,0.2,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,52,NA,human,human control myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,cucuugauugcuggucuuguuuuuc,2OMe,NA,0.5,uM,Skip,59,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,52,NA,human,human control myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,uuccaacuggggacgccucuguucc,2OMe,NA,0.2,uM,Skip,88,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2021/0139904,DMD,exon,52,NA,human,human control myotubes,UNIFectylin Prosensa  Therapeutics  BV,NA,uuccaacuggggacgccucuguucc,2OMe,NA,0.5,uM,Skip,91,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/0139904,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,1.25,uM,Skip,0.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,2.5,uM,Skip,1.36,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,5,uM,Skip,2.19,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,10,uM,Skip,4.05,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,20,uM,Skip,6.94,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,40,uM,Skip,12.94,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,modified PMO,NA,2.5,uM,Skip,4.75,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,modified PMO,NA,5,uM,Skip,5.72,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,modified PMO,NA,10,uM,Skip,10.54,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,modified PMO,NA,20,uM,Skip,19.02,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2021/0138079,DMD,exon,52,NA,human,human myoblasts,Null,NA,ctgttccaaatcctgcattgttgcc,modified PMO,NA,40,uM,Skip,47.11,NA,NA,NA,DNA,https://patents.google.com/patent/US/2021/0138079,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cccacccccccucucuucagca,2OMe,NA,0.25,uM,Skip,89.94,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cagggaaguaggacuguuggaaac,2OMe,NA,0.25,uM,Skip,95.14,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cucacaggacagcacagggcaa,2OMe,NA,0.25,uM,Skip,59.07,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cccagggcccaugcuccaugggc,2OMe,NA,0.25,uM,Skip,57.21,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,ccagaugcucucacaggacagca,2OMe,NA,0.25,uM,Skip,70.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,ugcuccaugggccucggcuacca,2OMe,NA,0.25,uM,Skip,38.14,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gggcccaugcuccaugggccucgg,2OMe,NA,0.25,uM,Skip,51.16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cagcagguggggcccagaugcu,2OMe,NA,0.25,uM,Skip,90.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,caaaccccacccccccucucuu,2OMe,NA,0.25,uM,Skip,97.34,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,guaggacuguuggaaacgggg,2OMe,NA,0.25,uM,Skip,96.99,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,agcgucugaaacagggaa,2OMe,NA,0.25,uM,Skip,99.77,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gaaccugagcagcgucugaaa,2OMe,NA,0.25,uM,Skip,99.54,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,guaacccucccagcuuugga,2OMe,NA,0.25,uM,Skip,94.57,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gagcccccccgguaacccuccca,2OMe,NA,0.25,uM,Skip,95.72,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,agcaccagccccugccacaguc,2OMe,NA,0.25,uM,Skip,97.69,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,ugccacagucugaugcaggagcc,2OMe,NA,0.25,uM,Skip,98.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gguggggcccagaugcucucaca,2OMe,NA,0.25,uM,Skip,90.64,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,ccccucucuucagcaggugggg,2OMe,NA,0.25,uM,Skip,87.05,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,agcgucugaaacagggaaguagg,2OMe,NA,0.25,uM,Skip,99.19,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,guugaaccugagcagcgucugaa,2OMe,NA,0.25,uM,Skip,99.77,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cccucccagcuuuggacccgggc,2OMe,NA,0.25,uM,Skip,91.21,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gcaggagcccccccgguaacccu,2OMe,NA,0.25,uM,Skip,88.55,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,ugagcagcuuccucagcacgg,2OMe,NA,0.25,uM,Skip,91.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cccaggcagaagugggggaag,2OMe,NA,0.25,uM,Skip,87.62,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gugcaaggucaaugaggcccc,2OMe,NA,0.25,uM,Skip,87.27,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,caaaccgggcauagacaucu,2OMe,NA,0.25,uM,Skip,80.99,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cucggcuaccacccaccaaacc,2OMe,NA,0.25,uM,Skip,78.02,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gggaagacaaugagcagcuuccu,2OMe,NA,0.25,uM,Skip,87.97,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,aggccccggcccaggcagaagug,2OMe,NA,0.25,uM,Skip,86.57,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gccuggcucagugcaaggucaau,2OMe,NA,0.25,uM,Skip,82.21,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,accacccaccaaaccgggcauaga,2OMe,NA,0.25,uM,Skip,84.48,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cucacaggacagcacagggcaa,2OMe,NA,0.25,uM,Skip,79.71,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cagcagguggggcccagaugcu,2OMe,NA,0.25,uM,Skip,87.25,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,caaaccccacccccccucucuu,2OMe,NA,0.25,uM,Skip,77.97,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,guaggacuguuggaaacgggg,2OMe,NA,0.25,uM,Skip,76.43,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,agcgucugaaacagggaa,2OMe,NA,0.25,uM,Skip,90.34,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gaaccugagcagcgucugaaa,2OMe,NA,0.25,uM,Skip,87.63,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,ugagcagcuuccucagcacgg,2OMe,NA,0.25,uM,Skip,86.86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cccaggcagaagugggggaag,2OMe,NA,0.25,uM,Skip,94.78,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gugcaaggucaaugaggcccc,2OMe,NA,0.25,uM,Skip,78.74,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,caaaccgggcauagacaucu,2OMe,NA,0.25,uM,Skip,86.86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cucggcuaccacccaccaaacc,2OMe,NA,0.25,uM,Skip,94.98,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cccagggcccaugcuccaugggc,2OMe,NA,0.25,uM,Skip,74.88,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,guaacccucccagcuuugga,2OMe,NA,0.25,uM,Skip,87.63,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gagcccccccgguaacccuccca,2OMe,NA,0.25,uM,Skip,90.34,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,agcaccagccccugccacaguc,2OMe,NA,0.25,uM,Skip,87.25,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,ugccacagucugaugcaggagcc,2OMe,NA,0.25,uM,Skip,90.53,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,ccagaugcucucacaggacagca,2OMe,NA,0.25,uM,Skip,81.26,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gguggggcccagaugcucucaca,2OMe,NA,0.25,uM,Skip,86.86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,ccccucucuucagcaggugggg,2OMe,NA,0.25,uM,Skip,89.18,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cccacccccccucucuucagca,2OMe,NA,0.25,uM,Skip,86.86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cagggaaguaggacuguuggaaac,2OMe,NA,0.25,uM,Skip,94.78,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,agcgucugaaacagggaaguagg,2OMe,NA,0.25,uM,Skip,74.88,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,guugaaccugagcagcgucugaa,2OMe,NA,0.25,uM,Skip,81.45,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gggaagacaaugagcagcuuccu,2OMe,NA,0.25,uM,Skip,89.37,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,aggccccggcccaggcagaagug,2OMe,NA,0.25,uM,Skip,91.88,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gccuggcucagugcaaggucaau,2OMe,NA,0.25,uM,Skip,91.69,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,accacccaccaaaccgggcauaga,2OMe,NA,0.25,uM,Skip,63.86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,ugcuccaugggccucggcuacca,2OMe,NA,0.25,uM,Skip,63.67,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gggcccaugcuccaugggccucgg,2OMe,NA,0.25,uM,Skip,51.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cccucccagcuuuggacccgggc,2OMe,NA,0.25,uM,Skip,87.83,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gcaggagcccccccgguaacccu,2OMe,NA,0.25,uM,Skip,85.51,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cucacaggacagcacagggcaa,2OMe,NA,0.25,uM,Skip,76.03,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,cucacaggacagcacagggcaa,2MOe,NA,0.25,uM,Skip,60.31,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gggcccaugcuccaugggccucgg,2OMe,NA,0.25,uM,Skip,55.18,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Antisense Oligonucleotides For The Treatment Of Stargardt Disease,US/2021/115439,ABCA4,exon,39,NA,human,HEK293  cells,LipofectlAMINE  2000,NA,gggcccaugcuccaugggccucgg,2MOe,NA,0.25,uM,Skip,41.95,NA,NA,NA,RNA,https://patents.google.com/patent/US/2021/115439,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gttctgaaggtgttcttgtact,unmodified PMO,NA,2.5,uM,Skip,2.1,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggtgt,unmodified PMO,NA,10,uM,Skip,2.5,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggtgt,unmodified PMO,NA,5,uM,Skip,3.3,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggtgt,unmodified PMO,NA,2.5,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaagg,unmodified PMO,NA,10,uM,Skip,2.4,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaagg,unmodified PMO,NA,5,uM,Skip,2.1,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaagg,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctga,unmodified PMO,NA,10,uM,Skip,0.7,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctga,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctga,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggtt,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggtt,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,9.6,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ggttctgaaggtgttcttgt,unmodified PMO,NA,5,uM,Skip,6.7,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ggttctgaaggtgttcttgt,unmodified PMO,NA,2.5,uM,Skip,5.5,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgtt,unmodified PMO,NA,10,uM,Skip,17.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgtt,unmodified PMO,NA,5,uM,Skip,10.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgtt,unmodified PMO,NA,2.5,uM,Skip,5.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggt,unmodified PMO,NA,10,uM,Skip,7.3,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggt,unmodified PMO,NA,5,uM,Skip,2.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggt,unmodified PMO,NA,2.5,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,20.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,5,uM,Skip,9.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,2.5,uM,Skip,8.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,aaggtgttcttgtacttcatcc,unmodified PMO,NA,10,uM,Skip,11.3,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,aaggtgttcttgtacttcatcc,unmodified PMO,NA,5,uM,Skip,5.9,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,aaggtgttcttgtacttcatcc,unmodified PMO,NA,2.5,uM,Skip,4.3,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gttctgaaggtgttcttgtact,unmodified PMO,NA,10,uM,Skip,6.7,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gttctgaaggtgttcttgtact,unmodified PMO,NA,5,uM,Skip,4.4,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggtt,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,10.3,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tccggttctgaaggtgttcttgt,unmodified PMO,NA,5,uM,Skip,5.7,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tccggttctgaaggtgttcttgt,unmodified PMO,NA,2.5,uM,Skip,1.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttc,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttc,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttc,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,21.6,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,5,uM,Skip,17.5,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,2.5,uM,Skip,16.3,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ggtgttcttgtacttcatcc,unmodified PMO,NA,10,uM,Skip,13.7,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ggtgttcttgtacttcatcc,unmodified PMO,NA,5,uM,Skip,7.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ggtgttcttgtacttcatcc,unmodified PMO,NA,2.5,uM,Skip,2.1,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gaaggtgttcttgtacttca,unmodified PMO,NA,10,uM,Skip,12.7,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gaaggtgttcttgtacttca,unmodified PMO,NA,5,uM,Skip,4,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gaaggtgttcttgtacttca,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tctgaaggtgttcttgtact,unmodified PMO,NA,10,uM,Skip,10.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tctgaaggtgttcttgtact,unmodified PMO,NA,5,uM,Skip,5.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tctgaaggtgttcttgtact,unmodified PMO,NA,2.5,uM,Skip,2.9,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gcctccggttctgaaggtgt,unmodified PMO,NA,10,uM,Skip,3.6,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gcctccggttctgaaggtgt,unmodified PMO,NA,5,uM,Skip,4.5,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gcctccggttctgaaggtgt,unmodified PMO,NA,2.5,uM,Skip,1,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaagg,unmodified PMO,NA,10,uM,Skip,7.4,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaagg,unmodified PMO,NA,5,uM,Skip,2.5,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaagg,unmodified PMO,NA,2.5,uM,Skip,5.1,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,actgttgcctccggttctga,unmodified PMO,NA,10,uM,Skip,2.9,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,actgttgcctccggttctga,unmodified PMO,NA,5,uM,Skip,3.7,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,actgttgcctccggttctga,unmodified PMO,NA,2.5,uM,Skip,1,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tcaactgttgcctccggttc,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tcaactgttgcctccggttc,unmodified PMO,NA,5,uM,Skip,0.5,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tcaactgttgcctccggttc,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,aggtgttcttgtacttcatcc,unmodified PMO,NA,10,uM,Skip,11.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,aggtgttcttgtacttcatcc,unmodified PMO,NA,5,uM,Skip,8.1,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,aggtgttcttgtacttcatcc,unmodified PMO,NA,2.5,uM,Skip,7.9,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttca,unmodified PMO,NA,10,uM,Skip,16,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttca,unmodified PMO,NA,5,uM,Skip,8.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttca,unmodified PMO,NA,2.5,uM,Skip,1.6,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttctgaaggtgttcttgtact,unmodified PMO,NA,10,uM,Skip,7.9,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttctgaaggtgttcttgtact,unmodified PMO,NA,5,uM,Skip,3.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttctgaaggtgttcttgtact,unmodified PMO,NA,2.5,uM,Skip,1.1,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,18.4,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cggttctgaaggtgttcttgt,unmodified PMO,NA,5,uM,Skip,5.4,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,cggttctgaaggtgttcttgt,unmodified PMO,NA,2.5,uM,Skip,6.3,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgcctccggttctgaaggtgt,unmodified PMO,NA,10,uM,Skip,9.6,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgcctccggttctgaaggtgt,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgcctccggttctgaaggtgt,unmodified PMO,NA,2.5,uM,Skip,3.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgttgcctccggttctgaagg,unmodified PMO,NA,10,uM,Skip,5.5,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgttgcctccggttctgaagg,unmodified PMO,NA,5,uM,Skip,1.7,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgttgcctccggttctgaagg,unmodified PMO,NA,2.5,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,aactgttgcctccggttctga,unmodified PMO,NA,10,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,aactgttgcctccggttctga,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,aactgttgcctccggttctga,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tcaactgttgcctccggttct,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tcaactgttgcctccggttct,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tcaactgttgcctccggttct,unmodified PMO,NA,2.5,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ccggttctgaaggtgttcttgta,unmodified PMO,NA,10,uM,Skip,10.6,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ccggttctgaaggtgttcttgta,unmodified PMO,NA,5,uM,Skip,6.4,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ccggttctgaaggtgttcttgta,unmodified PMO,NA,2.5,uM,Skip,2.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgcctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,15.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgcctccggttctgaaggtgttc,unmodified PMO,NA,5,uM,Skip,4.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgcctccggttctgaaggtgttc,unmodified PMO,NA,2.5,uM,Skip,5.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgttgcctccggttctgaaggtg,unmodified PMO,NA,10,uM,Skip,3.3,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgttgcctccggttctgaaggtg,unmodified PMO,NA,5,uM,Skip,2.6,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,tgttgcctccggttctgaaggtg,unmodified PMO,NA,2.5,uM,Skip,2.5,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggt,unmodified PMO,NA,10,uM,Skip,5.9,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggt,unmodified PMO,NA,5,uM,Skip,3.4,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggt,unmodified PMO,NA,2.5,uM,Skip,2.4,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttcaactgttgcctccggttctg,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttcaactgttgcctccggttctg,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,ttcaactgttgcctccggttctg,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,attcaactgttgcctccggttct,unmodified PMO,NA,10,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,attcaactgttgcctccggttct,unmodified PMO,NA,5,uM,Skip,3,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exon Skipping Oligomers And Oligomer Conjugates For Muscular Dystrophy,US2021102205,DMD,exon,53,NA,human,RD Cells,Null,NA,attcaactgttgcctccggttct,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2021102205,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc,unmodified PMO,NA,10,uM,Skip,24.88,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD muscle cell,Gene Tools,NA,tgccgctgcccaatgccatcctgga,unmodified PMO,NA,5,uM,Skip,4.83,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gtttgccgctgcccaatgccatcctggagt,unmodified PMO,NA,5,uM,Skip,3.07,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc,unmodified PMO,NA,5,uM,Skip,9.07,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gccgctgcccaatgccatcctggagttcct,unmodified PMO,NA,5,uM,Skip,4.54,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD muscle cell,Gene Tools,NA,tgaggattgctgaattatttcttccccagt,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttatttcttccccagttgcattcaatgttc,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/tgaggattgctgaattatttcttccccagt,unmodified PMO,NA,5,uM,Skip,12.73,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/ttatttcttccccagttgcattcaatgttc,unmodified PMO,NA,5,uM,Skip,12.29,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gttatctgcttcctccaaccataaaacaaa,unmodified PMO,NA,5,uM,Skip,6.88,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,human,immortalized DMD muscle cell,Gene Tools,NA,cttttagttgctgctcttttccagg,unmodified PMO,NA,5,uM,Skip,22.98,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gctgctcttttccaggttcaagtgggatac,unmodified PMO,NA,5,uM,Skip,24.88,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,human,immortalized DMD muscle cell,Gene Tools,NA,agttgctgctcttttccaggttcaagtggg,unmodified PMO,NA,5,uM,Skip,32.05,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,human,immortalized DMD muscle cell,Gene Tools,NA,agttgctgctcttttccaggttcaagtggg,unmodified PMO,NA,10,uM,Skip,40.1,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,human,immortalized DMD muscle cell,Gene Tools,NA,tccaggttcaagtgggatactagcaatgtt,unmodified PMO,NA,5,uM,Skip,4.24,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gttatctgcttcctccaaccataaaacaaa/gctgctcttttccaggttcaagtgggatac,unmodified PMO,NA,5,uM,Skip,33.07,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gttatctgcttcctccaaccataaaacaaa/agttgctgctcttttccaggttcaagtggg,unmodified PMO,NA,5,uM,Skip,36.15,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gttatctgcttcctccaaccataaaacaaa/cttttagttgctgctcttttccagg,unmodified PMO,NA,5,uM,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttccctggcgcaggggcaactcttccacca,unmodified PMO,NA,5,uM,Skip,1.76,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttccctggcgcaggggcaactcttccacca,unmodified PMO,NA,10,uM,Skip,6,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gcacttacaagcacgggtcctccagtttca,unmodified PMO,NA,5,uM,Skip,0.29,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,attgtttgagaattccctggcgcag,unmodified PMO,NA,5,uM,Skip,1.17,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttccaccagtaactgaaacagacaaatgca,unmodified PMO,NA,5,uM,Skip,1.46,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gggcaactcttccaccagtaactgaaacag,unmodified PMO,NA,5,uM,Skip,5.41,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,cttatgggagcacttacaagcacgggtcct,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gtttgagaattccctggcgcaggggcaact,unmodified PMO,NA,5,uM,Skip,11.56,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gtttgagaattccctggcgcaggggcaact,unmodified PMO,NA,10,uM,Skip,22.24,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttccctggcgcaggggcaactcttccacca/cttatgggagcacttacaagcacgggtcct,unmodified PMO,NA,5,uM,Skip,20.2,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttccctggcgcaggggcaactcttccacca/gcacttacaagcacgggtcctccagtttca,unmodified PMO,NA,5,uM,Skip,18,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gggcaactcttccaccagtaactgaaacag/cttatgggagcacttacaagcacgggtcct,unmodified PMO,NA,5,uM,Skip,21.66,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gtttgagaattccctggcgcaggggcaact/cttatgggagcacttacaagcacgggtcct,unmodified PMO,NA,5,uM,Skip,22.83,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gggcaactcttccaccagtaactgaaacag/gcacttacaagcacgggtcctccagtttca,unmodified PMO,NA,5,uM,Skip,18.15,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gtttgagaattccctggcgcaggggcaact/gcacttacaagcacgggtcctccagtttca,unmodified PMO,NA,5,uM,Skip,16.1,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,48,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttctccttgtttctcaggtaaagctctgga,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,48,NA,human,immortalized DMD muscle cell,Gene Tools,NA,caatttctccttgtttctcaggtaaagctc,unmodified PMO,NA,10,uM,Skip,0.41,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,48,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttctcaggtaaagctctggaaacct,unmodified PMO,NA,10,uM,Skip,0.62,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,48,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttcaagctgcccaaggtcttttatttgagc,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,48,NA,human,immortalized DMD muscle cell,Gene Tools,NA,cagatgatttaactgctcttcaaggtcttc,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,48,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttctccttgtttctcaggtaaagctctgga/ttcaagctgcccaaggtcttttatttgagc,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,48,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttctccttgtttctcaggtaaagctctgga/cagatgatttaactgctcttcaaggtcttc,unmodified PMO,NA,10,uM,Skip,39.59,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,48,NA,human,immortalized DMD muscle cell,Gene Tools,NA,caatttctccttgtttctcaggtaaagctc/ttcaagctgcccaaggtcttttatttgagc,unmodified PMO,NA,10,uM,Skip,7.05,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,48,NA,human,immortalized DMD muscle cell,Gene Tools,NA,caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc,unmodified PMO,NA,10,uM,Skip,55.34,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,48,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ttcaagctgcccaaggtcttttatttgagc/cagatgatttaactgctcttcaaggtcttc,unmodified PMO,NA,10,uM,Skip,0.83,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,49,NA,human,immortalized DMD muscle cell,Gene Tools,NA,atctcttccacatccggttgtttagcttga,unmodified PMO,NA,5,uM,Skip,24.04,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,49,NA,human,immortalized DMD muscle cell,Gene Tools,NA,aatctcttccacatccggttgttta,unmodified PMO,NA,5,uM,Skip,15.13,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,49,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gccctttagacaaaatctcttccacatccg,unmodified PMO,NA,5,uM,Skip,8.5,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,49,NA,human,immortalized DMD muscle cell,Gene Tools,NA,cactggctgagtggctggtttttcc,unmodified PMO,NA,5,uM,Skip,9.12,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,49,NA,human,immortalized DMD muscle cell,Gene Tools,NA,atctcttccacatccggttgtttagcttga/cactggctgagtggctggtttttcc,unmodified PMO,NA,5,uM,Skip,15.34,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,50,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ccactcagagctcagatcttctaacttcct,unmodified PMO,NA,5,uM,Skip,33.37,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,50,NA,human,immortalized DMD muscle cell,Gene Tools,NA,acggtttaccgccttccactcagagctcag,unmodified PMO,NA,5,uM,Skip,35.03,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,50,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ctgctttgccctcagctcttgaagt,unmodified PMO,NA,5,uM,Skip,15.34,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,51,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,10,uM,Skip,71.3,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,51,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,39.59,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,51,NA,human,immortalized DMD muscle cell,Gene Tools,NA,aggttgtgtcaccagagtaacagtctgagt,unmodified PMO,NA,10,uM,Skip,34.82,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,51,NA,human,immortalized DMD muscle cell,Gene Tools,NA,aggttgtgtcaccagagtaacagtctgagt,unmodified PMO,NA,5,uM,Skip,37.72,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,51,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,18.24,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,51,NA,human,immortalized DMD muscle cell,Gene Tools,NA,acatcaaggaagatggcatttctag,unmodified PMO,NA,5,uM,Skip,13.68,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,52,NA,human,immortalized DMD muscle cell,Gene Tools,NA,acgcctctgttccaaatcctgcattgttgc,unmodified PMO,NA,5,uM,Skip,20.31,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,52,NA,human,immortalized DMD muscle cell,Gene Tools,NA,ccaactggggacgcctctgttccaaatcct,unmodified PMO,NA,5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,52,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gcctctgttccaaatcctgcattgt,unmodified PMO,NA,5,uM,Skip,22.38,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,53,NA,human,immortalized DMD muscle cell,Gene Tools,NA,cctccggttctgaaggtgttcttgtacttc,unmodified PMO,NA,10,uM,Skip,40.62,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,53,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gttcttgtacttcatcccactgattctgaa,unmodified PMO,NA,5,uM,Skip,33.37,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,53,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gttcttgtacttcatcccactgattctgaa,unmodified PMO,NA,10,uM,Skip,31.5,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,53,NA,human,immortalized DMD muscle cell,Gene Tools,NA,attcaactgttgcctccggttctga,unmodified PMO,NA,5,uM,Skip,12.85,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,54,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gagaagtttcagggccaagtcatttgccac,unmodified PMO,NA,5,uM,Skip,45.6,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,54,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gccacatctacatttgtctgccact,unmodified PMO,NA,5,uM,Skip,30.47,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,55,NA,human,immortalized DMD muscle cell,Gene Tools,NA,tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,5,uM,Skip,48.5,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,55,NA,human,immortalized DMD muscle cell,Gene Tools,NA,gcagttgtttcagcttctgtaagcc,unmodified PMO,NA,5,uM,Skip,1.87,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/gttatctgcttcctccaaccataaaacaaa/gcacttacaagcacgggtcctccagtttca/caatttctccttgtttctcaggtaaagctc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/aggttgtgtcaccagagtaacagtctgagt/ggtaatgagttcttccaactggggacgcct/gttcttgtacttcatcccactgattctgaa/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,1,uM,Skip,4.97,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/gttatctgcttcctccaaccataaaacaaa/gcacttacaagcacgggtcctccagtttca/caatttctccttgtttctcaggtaaagctc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/aggttgtgtcaccagagtaacagtctgagt/ggtaatgagttcttccaactggggacgcct/gttcttgtacttcatcccactgattctgaa/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,3,uM,Skip,36.89,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/gttatctgcttcctccaaccataaaacaaa/gcacttacaagcacgggtcctccagtttca/caatttctccttgtttctcaggtaaagctc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/aggttgtgtcaccagagtaacagtctgagt/ggtaatgagttcttccaactggggacgcct/gttcttgtacttcatcccactgattctgaa/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,10,uM,Skip,54.51,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,tgcctgcccaatgccatcctgga/cttttagttgctgctcttttccagg/attgtttgagaattccctggcgcag/ttctcaggtaaagctctggaaacct/aatctcttccacatccggttgttta/ctgctttgccctcagctcttgaagt/acatcaaggaagatggcatttctag/gcctctgttccaaatcctgcattgt/attcaactgttgcctccggttctga/gccacatctacatttgtctgccact/gcagttgtttcagcttctgtaagcc,unmodified PMO,NA,1,uM,Skip,0.41,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,tgcctgcccaatgccatcctgga/cttttagttgctgctcttttccagg/attgtttgagaattccctggcgcag/ttctcaggtaaagctctggaaacct/aatctcttccacatccggttgttta/ctgctttgccctcagctcttgaagt/acatcaaggaagatggcatttctag/gcctctgttccaaatcctgcattgt/attcaactgttgcctccggttctga/gccacatctacatttgtctgccact/gcagttgtttcagcttctgtaagcc,unmodified PMO,NA,3,uM,Skip,2.69,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,tgcctgcccaatgccatcctgga/cttttagttgctgctcttttccagg/attgtttgagaattccctggcgcag/ttctcaggtaaagctctggaaacct/aatctcttccacatccggttgttta/ctgctttgccctcagctcttgaagt/acatcaaggaagatggcatttctag/gcctctgttccaaatcctgcattgt/attcaactgttgcctccggttctga/gccacatctacatttgtctgccact/gcagttgtttcagcttctgtaagcc,unmodified PMO,NA,10,uM,Skip,6.63,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,1,uM,Skip,6.22,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,3,uM,Skip,36.27,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,10,uM,Skip,62.18,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/gttatctgcttcctccaaccataaaacaaa/gcacttacaagcacgggtcctccagtttca/caatttctccttgtttctcaggtaaagctc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/aggttgtgtcaccagagtaacagtctgagt/ggtaatgagttcttccaactggggacgcct/gttcttgtacttcatcccactgattctgaa/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,1,uM,Skip,1.27,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/gttatctgcttcctccaaccataaaacaaa/gcacttacaagcacgggtcctccagtttca/caatttctccttgtttctcaggtaaagctc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/aggttgtgtcaccagagtaacagtctgagt/ggtaatgagttcttccaactggggacgcct/gttcttgtacttcatcccactgattctgaa/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,3,uM,Skip,9.02,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/gttatctgcttcctccaaccataaaacaaa/gcacttacaagcacgggtcctccagtttca/caatttctccttgtttctcaggtaaagctc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/aggttgtgtcaccagagtaacagtctgagt/ggtaatgagttcttccaactggggacgcct/gttcttgtacttcatcccactgattctgaa/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,10,uM,Skip,24.7,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,tgcctgcccaatgccatcctgga/cttttagttgctgctcttttccagg/attgtttgagaattccctggcgcag/ttctcaggtaaagctctggaaacct/aatctcttccacatccggttgttta/ctgctttgccctcagctcttgaagt/acatcaaggaagatggcatttctag/gcctctgttccaaatcctgcattgt/attcaactgttgcctccggttctga/gccacatctacatttgtctgccact/gcagttgtttcagcttctgtaagcc,unmodified PMO,NA,1,uM,Skip,1.27,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,actagcaatgttatctgcttcctccaacca,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,6.06,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,tgcctgcccaatgccatcctgga/cttttagttgctgctcttttccagg/attgtttgagaattccctggcgcag/ttctcaggtaaagctctggaaacct/aatctcttccacatccggttgttta/ctgctttgccctcagctcttgaagt/acatcaaggaagatggcatttctag/gcctctgttccaaatcctgcattgt/attcaactgttgcctccggttctga/gccacatctacatttgtctgccact/gcagttgtttcagcttctgtaagcc,unmodified PMO,NA,3,uM,Skip,3.17,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,tgcctgcccaatgccatcctgga/cttttagttgctgctcttttccagg/attgtttgagaattccctggcgcag/ttctcaggtaaagctctggaaacct/aatctcttccacatccggttgttta/ctgctttgccctcagctcttgaagt/acatcaaggaagatggcatttctag/gcctctgttccaaatcctgcattgt/attcaactgttgcctccggttctga/gccacatctacatttgtctgccact/gcagttgtttcagcttctgtaagcc,unmodified PMO,NA,10,uM,Skip,13.3,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,1,uM,Skip,2.22,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,3,uM,Skip,10.13,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,10,uM,Skip,44.01,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/gttatctgcttcctccaaccataaaacaaa/gcacttacaagcacgggtcctccagtttca/caatttctccttgtttctcaggtaaagctc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/aggttgtgtcaccagagtaacagtctgagt/ggtaatgagttcttccaactggggacgcct/gttcttgtacttcatcccactgattctgaa/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,1,uM,Skip,1.41,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/gttatctgcttcctccaaccataaaacaaa/gcacttacaagcacgggtcctccagtttca/caatttctccttgtttctcaggtaaagctc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/aggttgtgtcaccagagtaacagtctgagt/ggtaatgagttcttccaactggggacgcct/gttcttgtacttcatcccactgattctgaa/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,3,uM,Skip,6.23,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/gttatctgcttcctccaaccataaaacaaa/gcacttacaagcacgggtcctccagtttca/caatttctccttgtttctcaggtaaagctc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/aggttgtgtcaccagagtaacagtctgagt/ggtaatgagttcttccaactggggacgcct/gttcttgtacttcatcccactgattctgaa/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,10,uM,Skip,13.47,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,47,NA,mouse,unspecified,Null,NA,tcatttaaatctctttgaaattctgacaag,unmodified PMO,NA,Null,Null,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,tgcctgcccaatgccatcctgga/cttttagttgctgctcttttccagg/attgtttgagaattccctggcgcag/ttctcaggtaaagctctggaaacct/aatctcttccacatccggttgttta/ctgctttgccctcagctcttgaagt/acatcaaggaagatggcatttctag/gcctctgttccaaatcctgcattgt/attcaactgttgcctccggttctga/gccacatctacatttgtctgccact/gcagttgtttcagcttctgtaagcc,unmodified PMO,NA,1,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,tgcctgcccaatgccatcctgga/cttttagttgctgctcttttccagg/attgtttgagaattccctggcgcag/ttctcaggtaaagctctggaaacct/aatctcttccacatccggttgttta/ctgctttgccctcagctcttgaagt/acatcaaggaagatggcatttctag/gcctctgttccaaatcctgcattgt/attcaactgttgcctccggttctga/gccacatctacatttgtctgccact/gcagttgtttcagcttctgtaagcc,unmodified PMO,NA,3,uM,Skip,1.71,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,tgcctgcccaatgccatcctgga/cttttagttgctgctcttttccagg/attgtttgagaattccctggcgcag/ttctcaggtaaagctctggaaacct/aatctcttccacatccggttgttta/ctgctttgccctcagctcttgaagt/acatcaaggaagatggcatttctag/gcctctgttccaaatcctgcattgt/attcaactgttgcctccggttctga/gccacatctacatttgtctgccact/gcagttgtttcagcttctgtaagcc,unmodified PMO,NA,10,uM,Skip,6.13,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,1,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,3,uM,Skip,4.62,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,human,immortalized DMD- patient derived skeletal muscle cells,Gene Tools,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,10,uM,Skip,27.54,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,mouse,humanized mouse model with the normal human DMD gene and without the entire mouse Dmd gene (hDMD/Dmd-null mouse),Null,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,20 ug,Null,Skip,14.65,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45,NA,mouse,humanized mouse model with the normal human DMD gene and without the entire mouse Dmd gene (hDMD/Dmd-null mouse),Null,NA,gacaacagtttgccgctgcccaatgccatc/agttgctgctcttttccaggttcaagtggg/gtttgagaattccctggcgcaggggcaact/caatttctccttgtttctcaggtaaagctc/cagatgatttaactgctcttcaaggtcttc/atctcttccacatccggttgtttagcttga/gtaaacggtttaccgccttccactcagagc/gtgtcaccagagtaacagtctgagtaggag/ggtaatgagttcttccaactggggacgcct/cctccggttctgaaggtgttcttgtacttc/gagaagtttcagggccaagtcatttgccac/tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,100 ug,Null,Skip,21.78,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,ccttgacttgctcaagcttttcttttagtt,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,18.34,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,gttatctgcttcctccaaccataaaacaaa,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,6.57,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,cttttagttgctgctcttttccagg,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,22.94,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,gctgctcttttccaggttcaagtgggatac,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,24.65,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,agttgctgctcttttccaggttcaagtggg,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,31.81,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,46,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,tccaggttcaagtgggatactagcaatgtt,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,4.18,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,51,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,aggttgtgtcaccagagtaacagtctgagt,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,51.39,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,50,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,gtggtcagtccaggagctaggtcaggctgc,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,43.76,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,50,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,gccctcagctcttgaagtaaacggtttacc,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,27.95,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,44/45,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,unspecified,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,30.64,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,50,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,ccactcagagctcagatcttctaacttcct,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,33.04,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,50,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,acggtttaccgccttccactcagagctcag,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,34.87,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,50,NA,mouse,Immortalized healthy (KM155) myoblasts,Null,NA,ctgctttgccctcagctcttgaagt,unmodified PMO,NA,"At 3 days post-differentiation, myotubes were transfected with 5 mM",Null,Skip,15.39,NA,NA,NA,DNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/46/47/48/49/50/51/52/53/54/55,NA,human,Immortalized healthy (KM155) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,34.08,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/47/49/51/53/55,NA,human,Immortalized healthy (KM155) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,24.49,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/47/49/53/55,NA,human,Immortalized healthy (KM155) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,21.84,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/49/50/52/53/55,NA,human,Immortalized healthy (KM155) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,29.18,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/50/55,NA,human,Immortalized healthy (KM155) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,33.47,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/46/47/48/49/50/51/52/53/54/55,NA,human,Immortalized healthy (KM155) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,6.94,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/47/49/53/55,NA,human,Immortalized healthy (KM571) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,24.8,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/49/50/52/53/55,NA,human,Immortalized healthy (KM571) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,20.41,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/50/55,NA,human,Immortalized healthy (KM571) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,24.18,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/46/47/48/49/50/51/52/53/54/55,NA,human,Immortalized healthy (KM571) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,34.8,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/47/49/51/53/55,NA,human,Immortalized healthy (KM571) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,30.31,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/47/49/53/55,NA,human,Immortalized healthy (KM571) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,8.78,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/50/55,NA,human,Immortalized healthy (6594) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,16.39,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/46/47/48/49/50/51/52/53/54/55,NA,human,Immortalized healthy (6594) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,6.43,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/47/49/51/53/55,NA,human,Immortalized healthy (6594) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,16.32,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/47/49/53/55,NA,human,Immortalized healthy (6594) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,21.68,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/49/50/52/53/55,NA,human,Immortalized healthy (6594) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,24.52,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/50/55,NA,human,Immortalized healthy (6594) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,0.57,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/47/49/51/53/55,NA,human,Immortalized healthy (6311) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,27.35,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/47/49/53/55,NA,human,Immortalized healthy (6311) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,1.01,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/49/50/52/53/55,NA,human,Immortalized healthy (6311) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,0.5,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Exons 45-55 Skipping Using Mutation-Tailored Cocktails Of Antisense Morpholinos In The Dmd Gene,EP3997228A1,DMD,exon,45/50/55,NA,human,Immortalized healthy (6311) myoblasts,Null,NA,unspecified,unmodified PMO,NA,unspecified,Null,Skip,0.5,NA,NA,NA,RNA,https://patents.google.com/patent/EP3997228A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caggttgtgtcaccagagtaacagtctgag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,acaggttgtgtcaccagagtaacagtctga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,26.26,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,36.96,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,10,uM,Skip,75.14,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,1,uM,Skip,15.81,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,3,uM,Skip,21.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,10,uM,Skip,40.36,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,tccaacatcaaggaagatggcatttctag,unmodified PMO,NA,1,uM,Skip,3.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,tccaacatcaaggaagatggcatttctag,unmodified PMO,NA,3,uM,Skip,6.08,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,tccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,15.32,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,tcaaggaagatggcatttct,unmodified PMO,NA,1,uM,Skip,0.49,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,tcaaggaagatggcatttct,unmodified PMO,NA,3,uM,Skip,0.97,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,KM571,Gene Tools,NA,tcaaggaagatggcatttct,unmodified PMO,NA,10,uM,Skip,2.43,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,30.14,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,38.26,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,10,uM,Skip,67.83,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,1,uM,Skip,19.13,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,3,uM,Skip,26.67,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,10,uM,Skip,51.88,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,tccaacatcaaggaagatggcatttctag,unmodified PMO,NA,1,uM,Skip,4.06,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,tccaacatcaaggaagatggcatttctag,unmodified PMO,NA,3,uM,Skip,7.83,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,tccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,21.45,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,tcaaggaagatggcatttct,unmodified PMO,NA,1,uM,Skip,1.16,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,tcaaggaagatggcatttct,unmodified PMO,NA,3,uM,Skip,1.74,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,6594 Cell,Gene Tools,NA,tcaaggaagatggcatttct,unmodified PMO,NA,10,uM,Skip,4.93,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aggttgtgtcaccagagtaacagtctgagt,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggcagtttccttagtaaccacaggttgtgt,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agatggcagtttccttagtaaccacaggtt,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcaccagagtaacagtctgagtaggag,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caccagagtaacagtctgagtaggag,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,accagagtaacagtctgagtaggag,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccacaggttgtgtcaccagagtaacagtct,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttataacttgatcaagcagagaaagccagt,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ataccttctgcttgatgatcatctcgttga,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,49,NA,human,Null,Null,NA,cagccagtgaagaggaagttag,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,53,NA,human,Null,Null,NA,ccagccattgtgttgaatcc,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,47,NA,human,Null,Null,NA,aggacccgtgcttgtaagtg,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,52,NA,human,Null,Null,NA,gattgttctagcctcttgattgc,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,43,NA,human,Null,Null,NA,gacaagggcgatttgacag,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caagcactcagccagtgaag,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tccagccattgtgttgaatc,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tccctgagctgaacgggaag,unmodified PMO,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,accacaggttgtgtcaccagagtaacagtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cacaggttgtgtcaccagagtaacagtctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgtgtcaccagagtaacagtctgagtagga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttgtgtcaccagagtaacagtctgagtagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aaccacaggttgtgtcaccagagtaacagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggttgtgtcaccagagtaacagtctgagta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccttagtaaccacaggttgtgtcaccagag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tccttagtaaccacaggttgtgtcaccaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tggcagtttccttagtaaccacaggttgtg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,taaccacaggttgtgtcaccagagtaacag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtaaccacaggttgtgtcaccagagtaaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcagtttccttagtaaccacaggttgtgtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatggcagtttccttagtaaccacaggttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agtaaccacaggttgtgtcaccagagtaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agtttccttagtaaccacaggttgtgtcac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gttgtgtcaccagagtaacagtctgagtag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cttagtaaccacaggttgtgtcaccagagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cagtttccttagtaaccacaggttgtgtca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttccttagtaaccacaggttgtgtcaccag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttagtaaccacaggttgtgtcaccagagta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tagtaaccacaggttgtgtcaccagagtaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtttccttagtaaccacaggttgtgtcacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atggcagtttccttagtaaccacaggttgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tttccttagtaaccacaggttgtgtcacca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gagatggcagtttccttagtaaccacaggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggagatggcagtttccttagtaaccacagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccaagcccggttgaaatctgccagagcagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cagagcaggtacctccaacatcaaggaaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggcatttctagtttggagatggcagtttcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctgtccaagcccggttgaaatctgccagag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctgtccaagcccggttgaaatctgccaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccagagcaggtacctccaacatcaaggaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtccaagcccggttgaaatctgccagagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgtccaagcccggttgaaatctgccagagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggaagatggcatttctagtttggagatggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tccaagcccggttgaaatctgccagagcag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agttctgtccaagcccggttgaaatctgcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tggagatggcagtttccttagtaaccacag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gttctgtccaagcccggttgaaatctgcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttctgtccaagcccggttgaaatctgccag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gccagtcggtaagttctgtccaagcccggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgaaatctgccagagcaggtacctccaaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agtttggagatggcagtttccttagtaacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caagcccggttgaaatctgccagagcaggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctagtttggagatggcagtttccttagta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agagcaggtacctccaacatcaaggaagat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctgccagagcaggtacctccaacatcaagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agcccggttgaaatctgccagagcaggtac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gaaatctgccagagcaggtacctccaacat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgccagagcaggtacctccaacatcaagga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aagcccggttgaaatctgccagagcaggta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gccagagcaggtacctccaacatcaaggaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,taagttctgtccaagcccggttgaaatctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggttgaaatctgccagagcaggtacctcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agatggcatttctagtttggagatggcagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gttgaaatctgccagagcacgtacctccaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcccggttgaaatctgccagagcaggtacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttgaaatctgccagagcagctacctccaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttggacatgccactttccttagtaaccaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctccaacatcaaggaagatggcatttctag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tttggagatggcagtttccttagtaaccac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cggttgaaatctgccagagcaggtacctcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcatttctagtttggagatggcagtttcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcaaggaagatggcatttctagtttgcaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agccagtcggtaagttctgtccaagcccgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctgccagagcaggtacctccaacatcaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cccggttgaaatctgccagagcaggtacct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aagttctgtccaagcccggttgaaatctgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccagtcggtaagttctgtccaagcccggtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtaagttctgtccaagcccggttgaaatct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggtaagttctgtccaagcccggttgaaatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccggttgaaatctgccagagcaggtacctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtttggagatggcagtttccttagtaacca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caaggaagatggcatttctagtttggagat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gagcaggtacctccaacatcaaggaagatg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctagtttggagatggcagtttccttagtaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tccaacatcaaggaagatggcatttctagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cagtcggtaagttctgtccaagcccggttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gaagatggcatttctagtttggagatggca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccaacatcaaggaagatggcatttctagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cggtaagttctgtccaagcccggttgaaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttctagtttggagatggcagtttccttagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aatctgccagagcaggtacctccaacatca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtcggtaagttctgtccaagcccggttgaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agtcggtaagttctgtccaagcccggttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcaggtacctccaacatcaaggaagatggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tagtttggagatggcagtttccttagtaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aagccagtcggtaagttctgtccaagcccg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,acctccaacatcaaggaagatggcatttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atctgccagagcaggtacctccaacatcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atcaaggaagatggcatttctagtttggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcggtaagttctgtccaagcccggttgaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aggaagatggcatttctagtttggagatgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aaatctgccagagcaggtacctccaacatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cctccaacatcaaggaagatggcatttcta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatggcatttctagtttggagatggcagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tttctagtttggagatggcagtttccttag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,catttctagtttggagatggcagtttcctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aagatggcatttctagtttggagatggcag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aaggaagatggcatttctagtttggagatg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tacctccaacatcaaggaagatggcatttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gaaagccagtcggtaagttctgtccaagcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aaagccagtcggtaagttctgtccaagccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agcaggtacctccaacatcaaggaagatgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agaaagccagtcggtaagttctgtccaagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,catcaaggaagatggcatttctagtttgga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gagaaagccagtcggtaagttctgtccaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtacctccaacatcaaggaagatggcattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,acatcaaggaagatggcatttctagtttgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caggtacctccaacatcaaggaagatggca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agagaaagccagtcggtaagttctgtccaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggtacctccaacatcaaggaagatggcatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aggtacctccaacatcaaggaagatggcat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caacatcaaggaagatggcatttctagttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aacatcaaggaagatggcatttctagtttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcagagaaagccagtcggtaagttctgtcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cagagaaagccagtcggtaagttctgtcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atttctagtttggagatggcagtttcctta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tggcatttctagtttggagatggcagtttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caagcagagaaagccagtcggtaagttctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcaagcagagaaagccagtcggtaagttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aagcagagaaagccagtcggtaagttctgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atcaagcagagaaagccagtcggtaagttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agcagagaaagccagtcggtaagttctgtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,acttgatcaagcagagaaagccagtcggta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aacttgatcaagcagagaaagccagtcggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,taacttgatcaagcagagaaagccagtcgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatcaagcagagaaagccagtcggtaagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tataacttgatcaaccagagaaagccagtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgatcaagcagagaaagccagtcggtaagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttgatcaagcagagaaagccagtcggtaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ataacttgatcaagcagagaaagccagtcg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cttgatcaagcagagaaagccagtcggtaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tttataacttgatcaagcagagaaagccag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgattttataacttgatcaagcagagaaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gattttataacttgatcaagcagagaaagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcaccctctgtgattttataacttgatcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtcacccaccatcaccctctgtgattttat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttttataacttgatcaagcagagaaagcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cctcaaggtcacccaccatcaccctctgtg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,attttataacttgatcaagcagagaaagcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caccctctgtgattttataacttgatcaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggtcacccaccatcaccctctgtgatttta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcctcaaggtcacccaccatcaccctctgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atcaccctctgtgattttataacttgatca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctcaaggtcacccaccatcaccctctgtga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atcctcaaggtcacccaccatcaccctctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcaaggtcacccaccatcaccctctgtgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcacccaccatcaccctctgtgattttata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cccaccatcaccctctgtgattttataact,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caccatcaccctctgtgattttataacttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtgattttataacttgatcaagcagagaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,acccaccatcaccctctgtgattttataac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caaggtcacccaccatcaccctctgtgatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aggtcacccaccttcaccctctgtgajttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccctctgtgattttataacttgatcaagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cacccaccatcaccctctgtgattttataa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atatcctcaaggtcacccaccatcaccctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,accatcaccctctgtgaatttataacttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tatcctcaaggtcacccaccatcaccctct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,accctctgtgattttataacttgatcaagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aaggtcacccaccatcaccctctgtgattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccaccatcaccctctgtgattttataactt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccatcaccctctgtgattttataacttgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,catcaccctctgtgattttaraacttgatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatatcctcaaggtcacccaccatcaccct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cctctgtgattttataacttgatcaagcag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctgtgattttataacttgatcaagcagaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgatatcctcaaggtcacccaccatcaccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttgatatcctcaaggtcacccaccatcacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgtgattttataacttgatcaagcagagaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gttgatatcctcaaggtcacccaccatcac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cgttgatatcctcaaggtcacccaccatca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcgttgatatcctcaaggtcacccaccatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctcgttgatatccrcaaggtcacccaccat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctcgttgatatcctcaaggtcacccacca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,catctcgttgatatcctcaaggtcacccac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcatctcgttgatatcctcaaggtcaccca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atctcgttgatatgctcaaggtcacccacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atcatctcgttgatatcctcaaggtcaccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatcatctcgttgatatcctcaaggtcacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctctgtgattttataacttgatcaagcaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgatcatctcgttgatatcctcaaggtcac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctgtgattttataacttgatcaagcagag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atgatcatctcgttgatatcctcaaggtca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatgatcatctcgttgatatcctcaaggtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgatgatcatctcgttgatatcctcaaggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttgatgatcatctcgttgatatcctcaagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcttgatgatcarctcgttgatatcctcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cttgatgatcatctcgttgatatcctcaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgcttgatgatcatctcgttgatatcctca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctgcttgatgatcatctcgttgatatcctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctgcttgatgatcatctcgttgatatcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttctgcttgatgatcatctcgttgatatcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cttctgcttgatgatcatctcgttgatatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctgtgattttataacttgatcaagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atcaccctctgtgattttataactt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtgattttataacttgatcaagcag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgattttataacttgatcaagcaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgtgattttataacttgatcaagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtaaccacaggttgtgtcaccagag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aaccacaggttgtgtcaccagagta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,acaggttgtgtcaccagagtaacag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccacaggttgtgtcaccagagtaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,accacaggttgtgtcaccagagtaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggcagtttccttagtaaccacaggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cacaggttgtgtcaccagagtaaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aggttgtgtcaccagagtaacagtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caggttgtgtcaccagagtaacagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggttgtgtcaccagagtaacagtct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,taaccacaggttgtgtcaccagagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tggcagtttccttagtaaccacagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcagtttccttagtaaccacaggtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agtaaccacaggttgtgtcaccaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccttagtaaccacaggttgtgtcac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtgtcaccagagtaacagtctgagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caccagagtaacagtctgagtagga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgtgtcaccagagtaacagtctgag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tccttagtaaccacaggttgtgtca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcaccagagtaacagtctgagtagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtcaccagagtaacagtctgagtag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttccttagtaaccacaggttgtgtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtttccttagtaaccacaggttgtg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cagtttccttagtaaccacaggttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatggcagtttccttagtaaccaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gttgtgtcaccagagtaacagtctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttgtgtcaccagagtaacagtctga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgtcaccagagtaacagtctgagta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tttccttagtaaccacaggttgtgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cttagtaaccacaggttgtgtcacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atggcagtttccttagtaaccacag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctgtccaagcccggttgaaatctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctgccagagcaggtacctccaaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cccggttgaaatctgccagagcagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agtttccttagtaaccacaggttgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agatggcagtttccttagtaaccac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tagtaaccacaggttgtgtcaccag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccagagcaggtacctccaacatcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctgccagagcaggtacctccaacat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cagagcaggtacctccaacatcaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gccagagcaggtacctccaacatca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgccagagcaggtacctccaacatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gttctgtccaagcccggttgaaatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctgtccaagcccggttgaaatctgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttctgtccaagcccggttgaaatct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcccggttgaaatctgccagagcag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agagcaggtacctccaacatcaagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gagatggcagtttccttagtaacca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggcatttctagtttggagatggcag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agttctgtccaagcccggttgaaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttagtaaccacaggttgtgtcacca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgtccaagcccggttgaaatctgcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aagttctgtccaagcccggttgaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggtaagttctgtccaagcccggttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcatttctagtttggagatggcagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aagcccggttgaaatctgccagagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccaagcccggttgaaatctggcaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,taagttctgtccaagcccggttgaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtccaagcccggttgaaatctgcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atggcatttctagtttggagatggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agcccggttgaaatctgccagagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cggtaagttctgtccaagcccggtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccggttgaaatctgccagagcaggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcggtaagttctgtccaagcccggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caagcccggttgaaatctgccagag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtaagttctgtccaagcccggttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tccaaggccggttgaaatctgccag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gaaatctgccagagcaggtacctcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggagatggcagtttccttagtaacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atctgccagagcaggtacctccaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtcggtaagttctgtccaagcccgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggttgaaatctgccagagcaggtac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gaagatggcatttctagtttggaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttctagtttggagatggcagtttcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tttctagtttggagatggcagtttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aatctgccagagcaggtacctccaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggaagatggcatttctagtttggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cggttgaaatctgccagagcaggta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcagagaaagccagtcggtaagttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gagcaggtacctccaacatcaagga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cagtcggtaagttctgtccaagccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gagaaagccagtcggtaagttctgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agtcggtaagttctgtccaagcccg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgaaatctgccagagcaggtacctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tttggagatggcagtttccttagta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aaatctgccagagcaggtacctcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agagaaagccagtcggtaagttctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccagtcggtaagttctgtccaagcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gccagtcggtaagttctgtccaagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tggagatggcagtttccttagtaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctagtttggagatggcagtttcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcaggtacctccaacatcaaggaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atttctagtttggagatggcagttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aaagccagtcggtaagttctgtcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gaaagccagtcggtaagttctgtcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttggagatggcagtttccttagtaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caagcagagaaagccagtcggtaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agcagagaaagccagtcggtaagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatcaagcagagaaagccagtcggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aagcagagaaagccagtcggtaagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgatcaagcagagaaagccagtcgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agaaagccagtcggtaagttctgtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atcaagcagagaaagccagtcggta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,acctccaacatcaaggaagatggca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agcaggtacctccaacatcaaggaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cagagaaagccagtcggtaagttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gttgaaatctgccagagcaggtacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aggaagatggcatttctagtttgga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aagatggcatttctagtttggagat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttgaaatctgccagagcaggtacct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cttgatcaagcagagaaagccagtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctccaacatcaaggaagatggcatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cctccaacatcaaggaagatggcat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tggcatttctagtttggagatggca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atcaaggaagatggcatttctagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agtttggagatggcagtttccttag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatggcatttctagtttggagatgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,catttctagtttggagatggcagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcaagcagagaaagccagtcggtaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agccagtcggtaagttctgtccaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,acttgatcaagcagagaaagccagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccaacatcaaggaagatggcatttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aagccagtcggtaagttctgtccaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aaggaagatggcatttctagtttgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,agatggcatttctagtttggagatg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aacttgatcaagcagagaaagccag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tacctccaacatcaaggaagatggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttgatcaagcagagaaagccagtcg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtttggagatggcagtttccttagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtacctccaacatcaaggaagatgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,catcaaggaagatggcatttctagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,acatcaaggaagatggcatttctag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctagtttggagatggcagtttcctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caaggaagatggcatttctagtttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gtcacccaccatcaccctctgtgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tccaacatcaaggaagatggcattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,taacttgatcaagcagagaaagcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcaaggaagatggcatttctagttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caggtacctccaacatcaaggaaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caacatcaaggaagatggcatttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggtcacccaccatcaccctctgtga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ataacttgatcaagcagagaaagcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ggtacctccaacatcaaggaagatg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aggtcacccaccatcaccctctgtg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aacatcaaggaagatggcatttcta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tagtttggagatggcagtttcctta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttataacttgatcaagcagagaaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcacccaccatcaccctctgtgatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cacccaccatcaccctctgtgattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tttataacttgatcaagcagagaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caaggtcacccaccatcaccctctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tataacttgatcaagcagagaaagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cccaccatcaccctctgtgatttta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,acccaccatcaccctctgtgatttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcaaggtcacccaccatcaccctct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atcctcaaggtcacccaccatcacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aaggtcacccaccatcaccctctgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcctcaaggtcacccaccatcaccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cctcaagctcacccaccatcaccct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atatcctcaaggtcacccaccatca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctcaaggtcacccaccatcaccctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,aggtacctccaacatcaaggaagat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tatcctcaaggtcacccaccatcac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctctgtgattttataacttgatcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccaccatcaccctctgtgattttat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cctctgtgattttataacttgatca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatatcctcaaggtcacccaccatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttttataacttgatcaagcagagaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctcgttgatatcctcaaggtcaccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcgttgatatcctcaaggtcaccca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgatatcctcaaggtcacccaccat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cgttgatatcctcaaggtcacccac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,attttataacttgatcaagcagaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctcgttgatatcctcaaggtcacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caccctctgtgattttataacttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gttgatatcctcaaggtcagccacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctgtgattttataacttgatcaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccctctgtgattttataacttgatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atctcgttgatatcctcaaggtcac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttgatatcctcaaggtcacccacca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,catctcgttgatatcctcaaggtca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcaccctctgtgattttataacttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,caccatcaccctctgtgattttata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tcatctcgttgatatcctcaaggtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatcatctcgttgatatcctcaagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gattttataacttgatcaagcagag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgatcatctcgttgatatcctcaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gatgatcatctcgttgatatcctca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atgatcatctcgttgatatcctcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgatgatcatctcgttgatatcctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttgatgatcatctcgttgatatcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,atcatctcgttgatatcctcaaggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cttgatgatcatctcgttgatatcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,accctctgtgattttataacttgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tgcttgatgatcatctcgttgatat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,gcttgatgatcatctcgttgatatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ccarcaccctctgtgattttataac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ctgcttgatgatcatctcgttgata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,accatcaccctctgtgattttataa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,catcaccctctgtgattttataact,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,tctgcttgatgatcatctcgttgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,ttctgctrgatgatcatctcgttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Null,Null,NA,cttctgcttgatgatcatctcgttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,5,uM,Skip,4.73,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,10,uM,Skip,7.08,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,uM,Skip,9.45,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,uM,Skip,12.08,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,2.5,uM,Skip,2.45,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,1.25,uM,Skip,1.21,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,2.5,uM,Skip,2.22,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,5,uM,Skip,3.03,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,10,uM,Skip,5.86,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,uM,Skip,10.51,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,uM,Skip,19.19,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,1.25,uM,Skip,1.82,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,2.5,uM,Skip,3.23,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,5,uM,Skip,6.06,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,10,uM,Skip,9.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,uM,Skip,16.57,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,uM,Skip,26.26,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,1.25,uM,Skip,1.45,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,2.5,uM,Skip,2.63,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,5,uM,Skip,3.33,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,10,uM,Skip,4.78,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,uM,Skip,8.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,uM,Skip,12.98,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,1.25,uM,Skip,3.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,human,cynomolgus monkeys having intact muscle tissues,Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,mg/kg,Skip,35.33,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Quadriceps",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,72.28,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Quadriceps",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,80,mg/kg,Skip,95.11,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Quadriceps",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,2.17,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Diaphragm",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,mg/kg,Skip,63.68,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Diaphragm",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,95.75,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Diaphragm",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,80,mg/kg,Skip,99.06,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Diaphragm",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,1.89,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Biceps",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,mg/kg,Skip,28.12,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Biceps",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,70.67,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Biceps",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,80,mg/kg,Skip,91.35,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Biceps",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,0.96,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Deltoid",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,mg/kg,Skip,35.54,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Deltoid",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,92.94,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Deltoid",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,80,mg/kg,Skip,96.13,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Deltoid",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,1.82,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Heart",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,mg/kg,Skip,47.15,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Heart",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,87.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Heart",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,80,mg/kg,Skip,96.93,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Heart",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,2.19,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Aorta",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,mg/kg,Skip,53.13,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Aorta",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,73.09,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Aorta",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,80,mg/kg,Skip,73.13,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Aorta",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,30.16,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Duodenum",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,mg/kg,Skip,15.28,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Duodenum",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,46.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Duodenum",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,80,mg/kg,Skip,74.07,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Duodenum",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,6.25,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Colon",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,20,mg/kg,Skip,27.55,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Colon",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,67.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Colon",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,80,mg/kg,Skip,87.17,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2020/0377886,DMD,exon,53,NA,monkey,"cynomolgus monkeys having intact muscle tissues,Colon",Null,NA,gttgcctccggttctgaaggtgttc,Null,NA,40,mg/kg,Skip,8.31,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/0377886,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,atatatagtttgttatta,2MOE,NA,20,uM,Skip,56.25,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,cytoplasmic RNA from DMSO-treated (CHX?)  mouse Neuro 2A cells,Null,NA,unspecified,unspecified,NA,unspecified,Null,Skip,66.27,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,human,cytoplasmic RNA from cycloheximide-treated (CHX+)  mouse Neuro 2A cells,Null,NA,unspecified,unspecified,NA,unspecified,Null,Skip,15.66,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,cytoplasmic RNA from DMSO-treated (CHX?)  RenCell VM (human neuroprogenitor cells),Null,NA,unspecified,unspecified,NA,unspecified,Null,Skip,54.8,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,cytoplasmic RNA from cycloheximide-treated (CHX+)  RenCell VM (human neuroprogenitor cells),Null,NA,unspecified,unspecified,NA,unspecified,Null,Skip,11.48,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,gatgctctccgtctgttt,2MOE,NA,20,uM,Skip,25,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ttcatgatgctctccgtc,2MOE,NA,20,uM,Skip,36.25,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ttttgttcatgatgctct,2MOE,NA,20,uM,Skip,34.69,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ttactttttgttcatgat,2MOE,NA,20,uM,Skip,30.94,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,tggtgttactttttgttc,2MOE,NA,20,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,acatttggtgttactttt,2MOE,NA,20,uM,Skip,34.38,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,acagaacatttggtgtta,2MOE,NA,20,uM,Skip,41.56,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,atatgacagaacatttgg,2MOE,NA,20,uM,Skip,30.31,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,atctgatatgacagaaca,2MOE,NA,20,uM,Skip,45.31,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,tagaaatctgatatgaca,2MOE,NA,20,uM,Skip,38.44,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ttagttagaaatctgata,2MOE,NA,20,uM,Skip,44.38,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,tgttattagttagaaatc,2MOE,NA,20,uM,Skip,81.25,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,tagtttgttattagttag,2MOE,NA,20,uM,Skip,80.63,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,tagaaatatatagtttgt,2MOE,NA,20,uM,Skip,54.38,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,caaaatagaaatatatag,2MOE,NA,20,uM,Skip,32.5,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,atacaaaatagaaatata,2MOE,NA,20,uM,Skip,35,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ctatacaaaatagaaata,2MOE,NA,20,uM,Skip,38.44,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,tcctatacaaaatagaaa,2MOE,NA,20,uM,Skip,46.56,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,tatcctatacaaaataga,2MOE,NA,20,uM,Skip,41.88,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,attatcctatacaaaata,2MOE,NA,20,uM,Skip,36.88,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,agttggagcaagattatc,2MOE,NA,20,uM,Skip,96.25,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,atccaagttggagcaaga,2MOE,NA,20,uM,Skip,80.94,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,accccatccaagttggag,2MOE,NA,20,uM,Skip,57.5,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,gctccaccccatccaagt,2MOE,NA,20,uM,Skip,96.25,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ccagcgctccaccccatc,2MOE,NA,20,uM,Skip,94.06,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,gaaccagcgctccacccc,2MOE,NA,20,uM,Skip,95.63,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,gggaggaaccagcgctcc,2MOE,NA,20,uM,Skip,94.69,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ataataaagggctcaggg,2MOE,NA,20,uM,Skip,41.88,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ccataataaagggctcag,2MOE,NA,20,uM,Skip,55.94,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,gtaatacagtacccataa,2MOE,NA,20,uM,Skip,69.06,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,gggtaatacagtacccat,2MOE,NA,20,uM,Skip,39.38,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ttaaaggtagcaaaaggg,2MOE,NA,20,uM,Skip,36.56,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,aaggattaaaggtagcaa,2MOE,NA,20,uM,Skip,94.06,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,agtgcaaggattaaaggt,2MOE,NA,20,uM,Skip,88.75,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,gtcacagtgcaaggatta,2MOE,NA,20,uM,Skip,80,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,cataagtcacagtgcaag,2MOE,NA,20,uM,Skip,85.31,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ctacacataagtcacagt,2MOE,NA,20,uM,Skip,75.63,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ccccactacacataagtc,2MOE,NA,20,uM,Skip,65.94,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,cctcaccccactacacat,2MOE,NA,20,uM,Skip,40.63,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ccctccctcaccccacta,2MOE,NA,20,uM,Skip,43.75,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ccaatccctccctcaccc,2MOE,NA,20,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ccttcccaatccctccct,2MOE,NA,20,uM,Skip,30.94,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,agtacccttcccaatccc,2MOE,NA,20,uM,Skip,36.88,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ataatagtacccttccca,2MOE,NA,20,uM,Skip,51.56,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,gtgcaataatagtaccct,2MOE,NA,20,uM,Skip,46.56,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,RenCell VM cells by gymnotic uptake,Null,NA,ctgtggtgcaataatagt,2MOE,NA,20,uM,Skip,40.94,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,SMN,Null,NA,unspecified,2MOE,NA,20,uM,Skip,33.44,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,20,NA,human,Sham,Null,NA,unspecified,2MOE,NA,20,uM,Skip,34.69,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,Neuro 2A (mouse neuroblastoma) cells,Null,NA,agttggagcaagattatc,2MOE,NA,0.03,uM,Skip,74.92,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,Neuro 2A (mouse neuroblastoma) cells,Null,NA,agttggagcaagattatc,2MOE,NA,0.08,uM,Skip,92.15,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,Neuro 2A (mouse neuroblastoma) cells,Null,NA,agttggagcaagattatc,2MOE,NA,0.2,uM,Skip,95.77,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,Sham,Null,NA,unspecified,2MOE,NA,unspecified,Null,Skip,13.9,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,human,Right eye (+),Null,NA,tagtttattattagttag,2MOE,NA,Null,Right eye (+) at 10 mM concentration,Skip,94.12,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,Right eye (+),Null,NA,agttggagcaagattatc,2MOE,NA,Null,Right eye (+) at 10 mM concentration,Skip,98.4,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,Right eye (+),Null,NA,aaggattaaaggtagcaa,2MOE,NA,Null,Right eye (+) at 10 mM concentration,Skip,96.26,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,Right eye (+),Null,NA,cataagtcacagtgcaag,2MOE,NA,Null,Right eye (+) at 10 mM concentration,Skip,96.54,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,Right eye (+),Null,NA,unspecified,2MOE,NA,Null,Right eye (+) at 10 mM concentration,Skip,92.63,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,human,left eye (?),Null,NA,tagtttattattagttag,2MOE,NA,1,(1 uL) left eye (?),Skip,91.35,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,left eye (?),Null,NA,agttggagcaagattatc,2MOE,NA,1,(1 uL) left eye (?),Skip,93.25,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,left eye (?),Null,NA,aaggattaaaggtagcaa,2MOE,NA,1,(1 uL) left eye (?),Skip,92.09,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,left eye (?),Null,NA,cataagtcacagtgcaag,2MOE,NA,1,(1 uL) left eye (?),Skip,92.28,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,left eye (?),Null,NA,unspecified,2MOE,NA,1,(1 uL) left eye (?),Skip,93.15,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,"mouse Scn1a, 2'-MOE ASO-injected brains",Null,NA,tagtttattattagttag,2MOE,NA,300,ug,Skip,98.92,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,"mouse Scn1a, 2'-MOE ASO-injected brains",Null,NA,aaggattaaaggtagcaa,2MOE,NA,300,ug,Skip,98.76,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,"mouse Scn1a, 2'-MOE ASO-injected brains",Null,NA,cataagtcacagtgcaag,2MOE,NA,300,ug,Skip,98.61,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,"300 ug, injected brains",Null,NA,unspecified,2MOE,NA,300,ug,Skip,96.61,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,"uninjected (-, no ASO control)",Null,NA,unspecified,2MOE,NA,300,ug,Skip,96.51,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,"intracerebroventricular (ICV) injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,unspecified,2MOE,NA,300,ug,Skip,94.46,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,"intracerebroventricular (ICV) injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,tagtttattattagttag,2MOE,NA,30,ug,Skip,97.08,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,"intracerebroventricular (ICV) injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,tagtttattattagttag,2MOE,NA,100,ug,Skip,98.13,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,"intracerebroventricular (ICV) injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,tagtttattattagttag,2MOE,NA,300,ug,Skip,98.74,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,C57BL6J mice (postnatal day 2),Null,NA,unspecified,2MOE,NA,20,ug,Skip,58.03,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,C57BL6J mice (postnatal day 2),Null,NA,tagtttattattagttag,2MOE,NA,20,ug,Skip,99.21,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,indicated mouse CNS samples,Null,NA,unspecified,2MOE,NA,unspecified,Null,Skip,63.81,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,indicated mouse CNS samples,Null,NA,unspecified,2MOE,NA,unspecified,Null,Skip,83.85,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,indicated mouse CNS samples,Null,NA,unspecified,2MOE,NA,unspecified,Null,Skip,84.33,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,indicated mouse CNS samples,Null,NA,unspecified,2MOE,NA,unspecified,Null,Skip,80.66,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,mouse,indicated mouse CNS samples,Null,NA,unspecified,2MOE,NA,unspecified,Null,Skip,72.13,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,human,indicated human CNS samples,Null,NA,unspecified,2MOE,NA,unspecified,Null,Skip,96.82,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,human,indicated human CNS samples,Null,NA,unspecified,2MOE,NA,unspecified,Null,Skip,95.71,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,exon,21,NA,human,indicated human CNS samples,Null,NA,unspecified,2MOE,NA,unspecified,Null,Skip,85.29,NA,NA,NA,RNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,30,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,guucugugcucggcuccaccu,2OMe,NA,500,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,30,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,guucugugcucggcuccaccu,2OMe,NA,1000,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,30,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,cggcggaaggcaucugucuug,2OMe,NA,500,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,30,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,cggcggaaggcaucugucuug,2OMe,NA,100,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,30,NA,human,"Patient Line 393 Primary myoblasts, Eurobiobank c.1237insA (exon 9) c.3031 + 2T>G (exon 28)",polyethyleneimine,NA,guucugugcucggcuccaccu,2OMe,NA,500,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,30,NA,human,"Patient Line 393 Primary myoblasts, Eurobiobank c.1237insA (exon 9) c.3031 + 2T>G (exon 28)",polyethyleneimine,NA,guucugugcucggcuccaccu,2OMe,NA,1000,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,30,NA,human,"Patient Line 393 Primary myoblasts, Eurobiobank c.1237insA (exon 9) c.3031 + 2T>G (exon 28)",polyethyleneimine,NA,cggcggaaggcaucugucuug,2OMe,NA,500,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,30,NA,human,"Patient Line 393 Primary myoblasts, Eurobiobank c.1237insA (exon 9) c.3031 + 2T>G (exon 28)",polyethyleneimine,NA,cggcggaaggcaucugucuug,2OMe,NA,100,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,8,NA,human,Jain Foundation Line 107 immortalized human myoblasts c.855 + 1delG (exon 8) c.895G>A (exon 9),Lipofectamine,NA,aggagagucaaacaaguugaa,2OMe,NA,200,nM,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,9,NA,human,Jain Foundation Line 107 immortalized human myoblasts c.855 + 1delG (exon 8) c.895G>A (exon 9),Lipofectamine,NA,aucuguccugagagaacga,2OMe,NA,200,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,34,NA,human,Eurobiobank Line 180 primary human myoblasts c.1663C>T (exon 19) c.3708delA (exon 34),Lipofectamine or PEI,NA,uccguuccagacucgguugac,2OMe,NA,100,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,9,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,aucuguccugagagaacga,2OMe,NA,Null,Null,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,21,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,ucugagucucgauucuaugg,2OMe,NA,Null,Null,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,21,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,caggguagguaguaguagug,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,29,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,uacaucuucucagcagggacc,2OMe,NA,25,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,29,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,uacaucuucucagcagggacc,2OMe,NA,50,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,29,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,uacaucuucucagcagggacc,2OMe,NA,100,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,29,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,uacaucuucucagcagggacc,2OMe,NA,200,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,29,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,uacaucuucucagcagggacc,2OMe,NA,500,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,29,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,cuuccauuuggcugagaucc,2OMe,NA,25,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,29,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,cuuccauuuggcugagaucc,2OMe,NA,50,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,29,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,cuuccauuuggcugagaucc,2OMe,NA,100,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,29,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,cuuccauuuggcugagaucc,2OMe,NA,200,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,29,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,cuuccauuuggcugagaucc,2OMe,NA,500,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,8,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",Lipofectamine,NA,aggagagucaaacaaguugaa,2OMe,NA,Null,Null,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,20,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,gcaggauguggaugaugcca,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,20,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,ggaacaaguucgacaugacc,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,20,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,caaguucgacaugaccugcc,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,20,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,uacuugcgccuccuaaggua,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,20,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,gauggcaucauccacauccu,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,20,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,ucgaacuuguucccguaguuc,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,20,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,ucaugucgaacuuguucccgu,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,38,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,cugguaacucuucauguucc/gguuccugaugacacagga,2OMe,NA,500,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,38,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,cugguaacucuucauguucc/gguuccugaugacacagga,2OMe,NA,1000,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,38,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,cugguaacucuucauguucc,2OMe,NA,500,nM,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,38,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,cugguaacucuucauguucc,2OMe,NA,1000,nM,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,38,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,gguuccugaugacacagga,2OMe,NA,500,nM,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense-Mediated Skipping Of Dysferlin Exons In Control And Dysferlinopathy Patient-Derived Cells,PMID 31873062,DYSF,exon,38,NA,human,"KM155.c25 Immortalized myoblasts, Mouly Lab",polyethyleneimine,NA,gguuccugaugacacagga,2OMe,NA,1000,nM,Skip,no skipping,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31873062,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.03,uM,Skip,36.34,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.1,uM,Skip,88.8,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcugcccaaugccauccuggaguuc,2OMe,NA,0.03,uM,Skip,62.98,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcugcccaaugccauccuggaguuc,2OMe,NA,0.1,uM,Skip,88.8,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugccgcugcccaaugccauccugg,2OMe,NA,0.03,uM,Skip,53.01,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugccgcugcccaaugccauccugg,2OMe,NA,0.1,uM,Skip,93.85,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,acaguuugccgcugcccaaugccau,2OMe,NA,0.03,uM,Skip,5.19,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,acaguuugccgcugcccaaugccau,2OMe,NA,0.1,uM,Skip,3.55,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,ugacaacaguuugccgcugcccaau,2OMe,NA,0.03,uM,Skip,1.09,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,ugacaacaguuugccgcugcccaau,2OMe,NA,0.1,uM,Skip,6.15,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uguucugacaacaguuugccgcugc,2OMe,NA,0.03,uM,Skip,11.48,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uguucugacaacaguuugccgcugc,2OMe,NA,0.1,uM,Skip,21.45,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uucaauguucugacaacaguuugcc,2OMe,NA,0.03,uM,Skip,9.56,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uucaauguucugacaacaguuugcc,2OMe,NA,0.1,uM,Skip,12.02,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugcauucaauguucugacaacagu,2OMe,NA,0.03,uM,Skip,1.91,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugcauucaauguucugacaacagu,2OMe,NA,0.1,uM,Skip,11.89,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,cccaguugcauucaauguucugaca,2OMe,NA,0.03,uM,Skip,2.73,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,cccaguugcauucaauguucugaca,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,ucuuccccaguugcauucaauguuc,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,ucuuccccaguugcauucaauguuc,2OMe,NA,0.1,uM,Skip,9.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuauuucuuccccaguugcauucaa,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuauuucuuccccaguugcauucaa,2OMe,NA,0.1,uM,Skip,3.55,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,cugaauuauuucuuccccaguugca,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,cugaauuauuucuuccccaguugca,2OMe,NA,0.1,uM,Skip,22.68,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gauugcugaauuauuucuuccccag,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gauugcugaauuauuucuuccccag,2OMe,NA,0.1,uM,Skip,2.46,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugaggauugcugaauuauuucuuc,2OMe,NA,0.03,uM,Skip,1.91,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugaggauugcugaauuauuucuuc,2OMe,NA,0.1,uM,Skip,6.28,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uguuuuugaggauugcugaauuauu,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uguuuuugaggauugcugaauuauu,2OMe,NA,0.1,uM,Skip,1.64,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcaucuguuuuugaggauugcugaa,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcaucuguuuuugaggauugcugaa,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uacuggcaucuguuuuugaggauug,2OMe,NA,0.03,uM,Skip,12.43,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uacuggcaucuguuuuugaggauug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.01,uM,Skip,9.94,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.03,uM,Skip,18.84,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.1,uM,Skip,27.12,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcugcccaaugccauccuggaguuc,2OMe,NA,0.01,uM,Skip,25.88,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcugcccaaugccauccuggaguuc,2OMe,NA,0.03,uM,Skip,35.2,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcugcccaaugccauccuggaguuc,2OMe,NA,0.1,uM,Skip,53.83,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugccgcugcccaaugccauccugg,2OMe,NA,0.01,uM,Skip,12.63,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugccgcugcccaaugccauccugg,2OMe,NA,0.03,uM,Skip,30.85,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugccgcugcccaaugccauccugg,2OMe,NA,0.1,uM,Skip,40.79,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,0.01,uM,Skip,18.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,0.03,uM,Skip,54.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,0.1,uM,Skip,81.62,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttcctgt,unmodified PMO,NA,0.01,uM,Skip,14.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttcctgt,unmodified PMO,NA,0.03,uM,Skip,50.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttcctgt,unmodified PMO,NA,0.1,uM,Skip,84.25,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,0.01,uM,Skip,9.39,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,0.03,uM,Skip,32.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,0.1,uM,Skip,54.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,0.01,uM,Skip,6.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,0.03,uM,Skip,26.56,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,0.1,uM,Skip,59.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,the human dystrophin gene in the cells where human MyoD gene is induced into fibroblasts from human DMD patient (GM05017 cells),Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,0.1,uM,Skip,59.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcagccucucgcucacucacc,2OMe,NA,0.03,uM,Skip,5.88,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcagccucucgcucacucacc,2OMe,NA,0.1,uM,Skip,23.01,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuuccaaagcagccucucg,2OMe,NA,0.03,uM,Skip,6.38,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuuccaaagcagccucucg,2OMe,NA,0.1,uM,Skip,33.56,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,aucuaugaguuucuuccaaag,2OMe,NA,0.03,uM,Skip,8.53,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,aucuaugaguuucuuccaaag,2OMe,NA,0.1,uM,Skip,13.59,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uguugcaguaaucuaugaguu,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uguugcaguaaucuaugaguu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,cagggggaacuguugcaguaa,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,cagggggaacuguugcaguaa,2OMe,NA,0.1,uM,Skip,4.93,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuuccagguccagggggaacu,2OMe,NA,0.03,uM,Skip,6.45,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuuccagguccagggggaacu,2OMe,NA,0.1,uM,Skip,6.43,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcaagaaacuuuuccaggucc,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcaagaaacuuuuccaggucc,2OMe,NA,0.1,uM,Skip,17.25,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uguaagccaggcaagaaacuu,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uguaagccaggcaagaaacuu,2OMe,NA,0.1,uM,Skip,1.26,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuucagcuucuguaagccagg,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuucagcuucuguaagccagg,2OMe,NA,0.1,uM,Skip,2.21,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuggcaguuguuucagcuucu,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuggcaguuguuucagcuucu,2OMe,NA,0.1,uM,Skip,4.49,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,cuguaggacauuggcaguugu,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,cuguaggacauuggcaguugu,2OMe,NA,0.1,uM,Skip,4.36,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ggguagcauccuguaggacau,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ggguagcauccuguaggacau,2OMe,NA,0.1,uM,Skip,10.81,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,cuuuccuuacggguagcaucc,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,cuuuccuuacggguagcaucc,2OMe,NA,0.1,uM,Skip,2.91,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuaggagccuuuccuuacg,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuaggagccuuuccuuacg,2OMe,NA,0.1,uM,Skip,1.26,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ccuuggagucuucuaggagcc,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ccuuggagucuucuaggagcc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ucuuuuacucccuuggagucu,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ucuuuuacucccuuggagucu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuucaucagcucuuuuacucc,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuucaucagcucuuuuacucc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,unspecified,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,unspecified,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uccuguaggacauuggcagu,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uccuguaggacauuggcagu,2OMe,NA,0.1,uM,Skip,4.04,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcagccucucgcucacucacc,2OMe,NA,0.01,uM,Skip,1.22,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcagccucucgcucacucacc,2OMe,NA,0.03,uM,Skip,12.43,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcagccucucgcucacucacc,2OMe,NA,0.1,uM,Skip,23.48,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ccaaagcagccucucgcucac,2OMe,NA,0.01,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ccaaagcagccucucgcucac,2OMe,NA,0.03,uM,Skip,8.96,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ccaaagcagccucucgcucac,2OMe,NA,0.1,uM,Skip,12.78,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuuccaaagcagccucucg,2OMe,NA,0.01,uM,Skip,6.78,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuuccaaagcagccucucg,2OMe,NA,0.03,uM,Skip,24.26,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuuccaaagcagccucucg,2OMe,NA,0.1,uM,Skip,31.13,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuuccagguccagggggaacu,2OMe,NA,0.01,uM,Skip,1.39,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuuccagguccagggggaacu,2OMe,NA,0.03,uM,Skip,6.61,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuuccagguccagggggaacu,2OMe,NA,0.1,uM,Skip,12,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uccuguaggacauuggcagu,2OMe,NA,0.01,uM,Skip,1.04,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uccuguaggacauuggcagu,2OMe,NA,0.03,uM,Skip,1.57,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uccuguaggacauuggcagu,2OMe,NA,0.1,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agcagcctctcgctcactcac,unmodified PMO,NA,1,uM,Skip,0.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agcagcctctcgctcactcac,unmodified PMO,NA,3,uM,Skip,0.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agcagcctctcgctcactcac,unmodified PMO,NA,10,uM,Skip,1.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttccaaagcagcctctcgctc,unmodified PMO,NA,1,uM,Skip,12.79,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttccaaagcagcctctcgctc,unmodified PMO,NA,3,uM,Skip,29.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttccaaagcagcctctcgctc,unmodified PMO,NA,10,uM,Skip,56.93,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttcttccaaagcagcctctcg,unmodified PMO,NA,1,uM,Skip,31.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttcttccaaagcagcctctcg,unmodified PMO,NA,3,uM,Skip,51.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttcttccaaagcagcctctcg,unmodified PMO,NA,10,uM,Skip,84.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,35.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,59.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,89.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cucaacagaucugucaaaucgc,2OMe,NA,0.03,uM,Skip,46.42,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cucaacagaucugucaaaucgc,2OMe,NA,0.1,uM,Skip,51.16,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cauuucucaacagaucugucaa,2OMe,NA,0.03,uM,Skip,20.49,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cauuucucaacagaucugucaa,2OMe,NA,0.1,uM,Skip,45.12,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gccgccauuucucaacagaucu,2OMe,NA,0.03,uM,Skip,40.97,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gccgccauuucucaacagaucu,2OMe,NA,0.1,uM,Skip,61.93,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aaaacgccgccauuucucaaca,2OMe,NA,0.03,uM,Skip,15.87,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aaaacgccgccauuucucaaca,2OMe,NA,0.1,uM,Skip,58.5,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaaugaaaacgccgccauuucu,2OMe,NA,0.03,uM,Skip,39.55,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaaugaaaacgccgccauuucu,2OMe,NA,0.1,uM,Skip,53.05,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaucauaaugaaaacgccgcca,2OMe,NA,0.03,uM,Skip,37.89,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaucauaaugaaaacgccgcca,2OMe,NA,0.1,uM,Skip,61.82,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuuauaucauaaugaaaacgc,2OMe,NA,0.03,uM,Skip,29.13,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuuauaucauaaugaaaacgc,2OMe,NA,0.1,uM,Skip,50.09,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aauaucuuuauaucauaaugaa,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aauaucuuuauaucauaaugaa,2OMe,NA,0.1,uM,Skip,9.59,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gauuaaauaucuuuauaucaua,2OMe,NA,0.03,uM,Skip,5.92,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gauuaaauaucuuuauaucaua,2OMe,NA,0.1,uM,Skip,10.42,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,guuagccacugauuaaauaucu,2OMe,NA,0.03,uM,Skip,15.39,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,guuagccacugauuaaauaucu,2OMe,NA,0.1,uM,Skip,31.62,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuucuguuagccacugauuaaa,2OMe,NA,0.03,uM,Skip,25.34,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuucuguuagccacugauuaaa,2OMe,NA,0.1,uM,Skip,29.13,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uucagcuucuguuagccacuga,2OMe,NA,0.03,uM,Skip,46.3,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uucagcuucuguuagccacuga,2OMe,NA,0.1,uM,Skip,48.2,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aacuguucagcuucuguuagcc,2OMe,NA,0.03,uM,Skip,36.36,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aacuguucagcuucuguuagcc,2OMe,NA,0.1,uM,Skip,39.08,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ugagaaacuguucagcuucugu,2OMe,NA,0.03,uM,Skip,31.03,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ugagaaacuguucagcuucugu,2OMe,NA,0.1,uM,Skip,37.3,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuucugagaaacuguucagcu,2OMe,NA,0.03,uM,Skip,52.82,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuucugagaaacuguucagcu,2OMe,NA,0.1,uM,Skip,41.21,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ugugucuuucugagaaacuguu,2OMe,NA,0.03,uM,Skip,34.93,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ugugucuuucugagaaacuguu,2OMe,NA,0.1,uM,Skip,50.45,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gaauuugugucuuucugagaaa,2OMe,NA,0.03,uM,Skip,21.91,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gaauuugugucuuucugagaaa,2OMe,NA,0.1,uM,Skip,26.53,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cucaggaauuugugucuuucug,2OMe,NA,0.03,uM,Skip,29.49,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cucaggaauuugugucuuucug,2OMe,NA,0.1,uM,Skip,55.07,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,caauucucaggaauuugugucu,2OMe,NA,0.03,uM,Skip,55.89,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,caauucucaggaauuugugucu,2OMe,NA,0.1,uM,Skip,34.46,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,guucccaauucucaggaauuug,2OMe,NA,0.03,uM,Skip,40.62,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,guucccaauucucaggaauuug,2OMe,NA,0.1,uM,Skip,55.3,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,agcauguucccaauucucagga,2OMe,NA,0.03,uM,Skip,26.88,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,agcauguucccaauucucagga,2OMe,NA,0.1,uM,Skip,41.68,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uauuuagcauguucccaauucu,2OMe,NA,0.03,uM,Skip,7.11,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uauuuagcauguucccaauucu,2OMe,NA,0.1,uM,Skip,17.29,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,auaccauuuguauuuagcaugu,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,auaccauuuguauuuagcaugu,2OMe,NA,0.1,uM,Skip,4.26,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ucagcuucuguuagccacug,2OMe,NA,0.03,uM,Skip,62.64,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ucagcuucuguuagccacug,2OMe,NA,0.1,uM,Skip,51.16,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gccgccauuucucaacagaucu,2OMe,NA,0.01,uM,Skip,30.96,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gccgccauuucucaacagaucu,2OMe,NA,0.03,uM,Skip,61.91,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gccgccauuucucaacagaucu,2OMe,NA,0.1,uM,Skip,46.76,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaaugaaaacgccgccauuucu,2OMe,NA,0.01,uM,Skip,22.81,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaaugaaaacgccgccauuucu,2OMe,NA,0.03,uM,Skip,15.32,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaaugaaaacgccgccauuucu,2OMe,NA,0.1,uM,Skip,60.29,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaucauaaugaaaacgccgcca,2OMe,NA,0.01,uM,Skip,23.79,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaucauaaugaaaacgccgcca,2OMe,NA,0.03,uM,Skip,49.86,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaucauaaugaaaacgccgcca,2OMe,NA,0.1,uM,Skip,60.94,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuucugagaaacuguucagcu,2OMe,NA,0.01,uM,Skip,19.23,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuucugagaaacuguucagcu,2OMe,NA,0.03,uM,Skip,29.33,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuucugagaaacuguucagcu,2OMe,NA,0.1,uM,Skip,53.44,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,caauucucaggaauuugugucu,2OMe,NA,0.01,uM,Skip,17.27,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,caauucucaggaauuugugucu,2OMe,NA,0.03,uM,Skip,35.19,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,caauucucaggaauuugugucu,2OMe,NA,0.1,uM,Skip,33.24,NA,NA,NA,RNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccattt,unmodified PMO,NA,1,uM,Skip,13.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccattt,unmodified PMO,NA,3,uM,Skip,27.58,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccattt,unmodified PMO,NA,10,uM,Skip,63.98,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,1,uM,Skip,15.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,3,uM,Skip,28.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,10,uM,Skip,75.05,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atatcataatgaaaacgccgc,unmodified PMO,NA,1,uM,Skip,8.63,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atatcataatgaaaacgccgc,unmodified PMO,NA,3,uM,Skip,23.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atatcataatgaaaacgccgc,unmodified PMO,NA,10,uM,Skip,48.59,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatatcataatgaaaacgccg,unmodified PMO,NA,1,uM,Skip,8.63,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatatcataatgaaaacgccg,unmodified PMO,NA,3,uM,Skip,30.02,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatatcataatgaaaacgccg,unmodified PMO,NA,10,uM,Skip,70.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,1,uM,Skip,36.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,3,uM,Skip,69.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,10,uM,Skip,92.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tcataatgaaaacgccgccat,unmodified PMO,NA,1,uM,Skip,22.99,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tcataatgaaaacgccgccat,unmodified PMO,NA,3,uM,Skip,61.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tcataatgaaaacgccgccat,unmodified PMO,NA,10,uM,Skip,91.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,1,uM,Skip,12.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,3,uM,Skip,45.98,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,10,uM,Skip,80.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,29.69,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,54.24,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,94.2,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,ttatatcataatgaaaacgcc,unmodified PMO,NA,1,uM,Skip,3.79,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,ttatatcataatgaaaacgcc,unmodified PMO,NA,3,uM,Skip,8.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,ttatatcataatgaaaacgcc,unmodified PMO,NA,10,uM,Skip,36.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,1,uM,Skip,38.84,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,3,uM,Skip,65.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,10,uM,Skip,95.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,tccagtatacttacaggctcc,unmodified PMO,NA,0.1,uM,Skip,1.09,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,tccagtatacttacaggctcc,unmodified PMO,NA,0.3,uM,Skip,2.17,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,tccagtatacttacaggctcc,unmodified PMO,NA,1,uM,Skip,7.37,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,atccagtatacttacaggctc,unmodified PMO,NA,0.1,uM,Skip,0.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,atccagtatacttacaggctc,unmodified PMO,NA,0.3,uM,Skip,3.62,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,atccagtatacttacaggctc,unmodified PMO,NA,1,uM,Skip,12.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gatccagtatacttacaggct,unmodified PMO,NA,0.1,uM,Skip,1.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gatccagtatacttacaggct,unmodified PMO,NA,0.3,uM,Skip,5.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gatccagtatacttacaggct,unmodified PMO,NA,1,uM,Skip,32.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacaggc,unmodified PMO,NA,0.1,uM,Skip,1.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacaggc,unmodified PMO,NA,0.3,uM,Skip,10.87,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacaggc,unmodified PMO,NA,1,uM,Skip,59.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,6.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,84.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,99.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,cttacaggctccaatagtggtcagt,unmodified PMO,NA,0.1,uM,Skip,1.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,cttacaggctccaatagtggtcagt,unmodified PMO,NA,0.3,uM,Skip,6.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,cttacaggctccaatagtggtcagt,unmodified PMO,NA,1,uM,Skip,41.79,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.1,uM,Skip,1.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.3,uM,Skip,54.11,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,1,uM,Skip,97.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,1,uM,Skip,19.76,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,3,uM,Skip,59.41,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,10,uM,Skip,91.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcc,unmodified PMO,NA,1,uM,Skip,19.35,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcc,unmodified PMO,NA,3,uM,Skip,63.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcc,unmodified PMO,NA,10,uM,Skip,92.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,26.34,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,70.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,93.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,gcccaatgccatcctggagtt,unmodified PMO,NA,1,uM,Skip,0.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,gcccaatgccatcctggagtt,unmodified PMO,NA,3,uM,Skip,1.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,gcccaatgccatcctggagtt,unmodified PMO,NA,10,uM,Skip,2.82,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,tgcccaatgccatcctggagt,unmodified PMO,NA,1,uM,Skip,0.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,tgcccaatgccatcctggagt,unmodified PMO,NA,3,uM,Skip,1.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,tgcccaatgccatcctggagt,unmodified PMO,NA,10,uM,Skip,5.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,1,uM,Skip,8.74,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,3,uM,Skip,33.47,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,10,uM,Skip,79.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,18.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,54.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,84.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,4.93,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,19.47,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,49.87,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,4.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,15.07,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,44.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagtt,unmodified PMO,NA,1,uM,Skip,4.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagtt,unmodified PMO,NA,3,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagtt,unmodified PMO,NA,10,uM,Skip,46.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,tttcttccaaagcagcctctc,unmodified PMO,NA,1,uM,Skip,17.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,tttcttccaaagcagcctctc,unmodified PMO,NA,3,uM,Skip,37.02,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,tttcttccaaagcagcctctc,unmodified PMO,NA,10,uM,Skip,69.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctct,unmodified PMO,NA,1,uM,Skip,14.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctct,unmodified PMO,NA,3,uM,Skip,34.15,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctct,unmodified PMO,NA,10,uM,Skip,57.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,25.55,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,38.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,75.14,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtttcttccaaagcagcct,unmodified PMO,NA,1,uM,Skip,11.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtttcttccaaagcagcct,unmodified PMO,NA,3,uM,Skip,28.14,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtttcttccaaagcagcct,unmodified PMO,NA,10,uM,Skip,71.99,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,tgagtttcttccaaagcagcc,unmodified PMO,NA,1,uM,Skip,13.93,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,tgagtttcttccaaagcagcc,unmodified PMO,NA,3,uM,Skip,28.01,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,tgagtttcttccaaagcagcc,unmodified PMO,NA,10,uM,Skip,63.66,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,1,uM,Skip,0.82,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,3,uM,Skip,1.5,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,10,uM,Skip,1.5,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,17.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,33.05,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,67.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,6.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,45.11,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,1,uM,Skip,7.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,3,uM,Skip,24.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,10,uM,Skip,67.23,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,9.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,28.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,58.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,1,uM,Skip,0.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,3,uM,Skip,0.57,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,10,uM,Skip,1.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,13.26,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,28.1,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,68.73,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,11.82,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,18.59,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,55.33,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgc,unmodified PMO,NA,1,uM,Skip,2.31,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgc,unmodified PMO,NA,3,uM,Skip,9.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgc,unmodified PMO,NA,10,uM,Skip,30.55,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,7.35,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,31.99,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,60.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,13.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,79.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,98.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,4.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,54.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,96.07,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,1.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,7.86,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,37.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacag,unmodified PMO,NA,0.1,uM,Skip,5.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacag,unmodified PMO,NA,0.3,uM,Skip,53.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacag,unmodified PMO,NA,1,uM,Skip,95.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,tgggatccagtatacttacag,unmodified PMO,NA,0.1,uM,Skip,7,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,tgggatccagtatacttacag,unmodified PMO,NA,0.3,uM,Skip,45.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,tgggatccagtatacttacag,unmodified PMO,NA,1,uM,Skip,96.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,atgggatccagtatacttaca,unmodified PMO,NA,0.1,uM,Skip,3.84,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,atgggatccagtatacttaca,unmodified PMO,NA,0.3,uM,Skip,32.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,RD Cells,Null,NA,atgggatccagtatacttaca,unmodified PMO,NA,1,uM,Skip,90.51,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,28.57,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,42.73,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,70.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,26.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,43.91,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,44,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,68.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,7.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,13.31,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,52.02,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,3,uM,Skip,66.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exon 45 (GM05112 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,10,uM,Skip,86.02,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,35.9,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,49.51,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,70.83,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,3,uM,Skip,82.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,50,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,10,uM,Skip,93.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,0.1,uM,Skip,56.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,75.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,78.76,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,0.1,uM,Skip,31.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,1,uM,Skip,55.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
journal article,Antisense Nucleic Acid,JP6867636B1,DMD,exon,55,NA,human,human dystrophin gene in the fibroblasts from human DMD patient with deletion of exons 51-55 (GM04364 cells),Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,10,uM,Skip,73.67,NA,NA,NA,DNA,https://patents.google.com/patent/JP6867636B1,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Huntington disease fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,0.001,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Huntington disease fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,0.025,uM,Skip,92,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Huntington disease fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,0.15,uM,Skip,95,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Huntington disease fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,0.76,SEM,Skip,1.98,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,1.19,SEM,Skip,1.98,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,1.64,SEM,Skip,60.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,1.89,SEM,Skip,90.35,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,2.05,SEM,Skip,90.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,2.17,SEM,Skip,91.09,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,cggugguggucugggagcugucgcugaug,2OMe,NA,2.61,SEM,Skip,88.37,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc/uuucagaacuguccgaaggaguc,2OMe,NA,0,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc/uuucagaacuguccgaaggaguc,2OMe,NA,0.01,uM,Skip,1.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc/uuucagaacuguccgaaggaguc,2OMe,NA,0.02,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc/uuucagaacuguccgaaggaguc,2OMe,NA,0.05,uM,Skip,13.13,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc/uuucagaacuguccgaaggaguc,2OMe,NA,0.1,uM,Skip,31.31,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc/uuucagaacuguccgaaggaguc,2OMe,NA,0.2,uM,Skip,16.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0.01,uM,Skip,12.56,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0.02,uM,Skip,23.06,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0.05,uM,Skip,46.31,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0.1,uM,Skip,46.31,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,Human fibroblasts,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0.2,uM,Skip,46.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,controlcells,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0,uM,Skip,0.22,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,controlcells,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0.01,uM,Skip,26.76,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,controlcells,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0.02,uM,Skip,48.56,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,controlcells,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0.05,uM,Skip,59.78,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,controlcells,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0.1,uM,Skip,59.03,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,controlcells,Lipofectamine 2000,NA,ggcuguccuaucugcaug,2OMe,NA,0.2,uM,Skip,57.73,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,unspecified,NA,human,Null,Lipofectamine 2000,NA,unspecified,2OMe,NA,0.05,uM,Skip,1.28,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human Fibroblasts cells,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc,2OMe,NA,0.05,uM,Skip,62.82,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human Fibroblasts cells,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc/uuucagaacuguccgaaggaguc/ggcuguccuaucugcaug,2OMe,NA,0.05,uM,Skip,62.82,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human Fibroblasts cells,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc,2OMe,NA,0.05,uM,Skip,63.74,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,Human Fibroblasts cells,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc/uuucagaacuguccgaaggaguc/ggcuguccuaucugcaug,2OMe,NA,0.05,uM,Skip,58.22,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,12,NA,mouse,C2C12,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc,2OMe,NA,0.2,uM,Skip,3.15,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,12,NA,mouse,C2C12,Lipofectamine 2000,NA,ggcucaagauguccuccucaucc/uuucagaacuguccgaaggaguc/ggcuguccuaucugcaug,2OMe,NA,0.2,uM,Skip,87.24,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gagauauguuucuggaacuacc,2OMe,NA,0.01,uM,Skip,6.28,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gagauauguuucuggaacuacc,2OMe,NA,0.02,uM,Skip,22.13,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gagauauguuucuggaacuacc,2OMe,NA,0.05,uM,Skip,44.81,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gagauauguuucuggaacuacc,2OMe,NA,0.1,uM,Skip,57.38,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gagauauguuucuggaacuacc,2OMe,NA,0.2,uM,Skip,59.84,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gcuucucgucucuuccgaagc,2OMe,NA,0.01,uM,Skip,24.71,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gcuucucgucucuuccgaagc,2OMe,NA,0.02,uM,Skip,30.59,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gcuucucgucucuuccgaagc,2OMe,NA,0.05,uM,Skip,58.82,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gcuucucgucucuuccgaagc,2OMe,NA,0.1,uM,Skip,60.78,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gcuucucgucucuuccgaagc,2OMe,NA,0.2,uM,Skip,58.43,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,10,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gcuguugcugcuuuugcugcug,2OMe,NA,0.01,uM,Skip,68.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,10,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gcuguugcugcuuuugcugcug,2OMe,NA,0.02,uM,Skip,83.86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,10,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gcuguugcugcuuuugcugcug,2OMe,NA,0.05,uM,Skip,94.49,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,10,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gcuguugcugcuuuugcugcug,2OMe,NA,0.1,uM,Skip,94.88,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,10,NA,human,Control  fibroblasts,Lipofectamine 2000,NA,gcuguugcugcuuuugcugcug,2OMe,NA,0.2,uM,Skip,96.06,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,mouse,unspecified,unspecified,NA,guuccugaaggccuccgaggcuucauca,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,mouse,unspecified,unspecified,NA,gguccuacuucuacuccuucggugu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,mouse,unspecified,unspecified,NA,gucccaucauucagguccau,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,mouse,unspecified,unspecified,NA,cucaagauauccuccucauc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,mouse,unspecified,unspecified,NA,ggcuguccaaucugcagg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,mouse,unspecified,unspecified,NA,ggcucaagauguccuccucaucc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,mouse,unspecified,unspecified,NA,uuucagaacuguccgaaggaguc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,mouse,unspecified,unspecified,NA,ggcuguccuaucugcaug,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,9,NA,mouse,unspecified,unspecified,NA,gcuucucgucuccuccgcagc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,10,NA,mouse,unspecified,unspecified,NA,gaacuuguggucggucuuucac,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,mouse,unspecified,unspecified,NA,cggugguggucugggagcugucgcugaug,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gucgcugcugccaucaucau,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,aagaggaagcaggaggcaga,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,Unknown,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggaggagccuggaacauucg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,6,NA,unspecified,unspecified,unspecified,NA,aagcucgcgcuccuucucgc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,6,NA,unspecified,unspecified,unspecified,NA,cgaguugaagccgcgaucca,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,6,NA,unspecified,unspecified,unspecified,NA,guucaagcucgcgcuccuuc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,APP,exon,15,NA,unspecified,unspecified,unspecified,NA,cuugauauuugucaacccagaac,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,APP,exon,15,NA,unspecified,unspecified,unspecified,NA,cuucacuucagagaucuccuccg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,APP,exon,15,NA,unspecified,unspecified,unspecified,NA,gucaugucggaauucugcauc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,APP,exon,15,NA,unspecified,unspecified,unspecified,NA,gaugaugaacuucauauccugag,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,APP,exon,16,NA,unspecified,unspecified,unspecified,NA,accaugaguccaaugauugc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,APP,exon,16,NA,unspecified,unspecified,unspecified,NA,ucaccaaggugaugacgauc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,APP,exon,16,NA,unspecified,unspecified,unspecified,NA,caccaugaugaauggauguguac,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,APP,exon,16,NA,unspecified,unspecified,unspecified,NA,guuugaacccacaucuucugc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,APP,exon,16,NA,unspecified,unspecified,unspecified,NA,cuguuucuucuucagcaucacc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,APP,exon,16,NA,unspecified,unspecified,unspecified,NA,cuaccuccaccacaccaugauga,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,agggagacuguggccgagggag,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gccaucaucauuaaggcuccgc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,cgauaucccuagggucgcugcu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gggacgugcuucgguuguccu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,cagagucauucuccacacuucca,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gcccugggacaggccagaagau,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ucaaagcuagccucuggcugucg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggaggagccuggaacauucga,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ccaccagugcccccaggauaga,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,cuugggacccauugggggucca,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ccacugaugaggcagccccu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gagcaccacuagccccagagcuu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,cuggagugguaggcggcuuugu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggaaguuggcuggugguggag,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,cagaugaccagguagugguugg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,guugggcccuucucugggcca,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggcgcuggagcagaagaggaa,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,cuagaggaugaauaaggaaac,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gcugauuggagacagagaggc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,cuccacacagccugggaugg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,cgguggacugggccccaguaga,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggcccagaguuuccgugaugc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggagcuaccgcccuccagugg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggccucagagaccccagggag,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gcaggugugcuggcccuggug,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggccugcuuggcuguaggacac,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gugaacauggguaggacccuug,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,guggugaccguaggcaccggug,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,guggaaaggguagccgaagag,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gaagccacgguggcaaugacc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggcucucuuuccguacggugg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gagguuccucgauagcccggugg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggcuugaaggucccugggccug,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,caggggcccaggucccacggugg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,gccugagggccccgcagguggc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,agguggugguggcagcgaugg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,caggggcggcccugaggcagg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,ggucucauacuccucagccggc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,uggguacaucuaccaccuugg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,5,NA,unspecified,unspecified,unspecified,NA,cuggcagacugacuggcauggc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,6,NA,unspecified,unspecified,unspecified,NA,gaguugaagccgcgauccagg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,6,NA,unspecified,unspecified,unspecified,NA,ccuccaguggcacgaaguacagg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,6,NA,unspecified,unspecified,unspecified,NA,cgccgcaccuucuccaccagguc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,6,NA,unspecified,unspecified,unspecified,NA,cgcucgcgcuccuuuucuucgcg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,6,NA,unspecified,unspecified,unspecified,NA,cuuucucgcguucccgcucgc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATN1,exon,6,NA,unspecified,unspecified,unspecified,NA,caagcucgcgcuccuucucgc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,7,NA,unspecified,unspecified,unspecified,NA,gcagaucacccuuaacgacaa,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,7,NA,unspecified,unspecified,unspecified,NA,ucagcuucgcaaucuggcag,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,7,NA,unspecified,unspecified,unspecified,NA,aaucaucugcaggaguugguc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,7,NA,unspecified,unspecified,unspecified,NA,gucgaugcaucuguuggacc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,7,NA,unspecified,unspecified,unspecified,NA,cuuugcucuuuuaguugugc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,8,NA,unspecified,unspecified,unspecified,NA,gagccaucauuugcuucuaac,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,8,NA,unspecified,unspecified,unspecified,NA,cuucgucuaacauuccugag,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,8,NA,unspecified,unspecified,unspecified,NA,gcccucugcaaauccuccuc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,8,NA,unspecified,unspecified,unspecified,NA,cugcggagaucugcuuccuc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,8,NA,unspecified,unspecified,unspecified,NA,cuugcauacuuagcugaauagcc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,unspecified,unspecified,unspecified,NA,gagauauguuucuggaacuacc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,9,NA,unspecified,unspecified,unspecified,NA,gcuucucgucucuuccgaagc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,10,NA,unspecified,unspecified,unspecified,NA,gcuguugcugcuuuugcugcug,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN3,exon,10,NA,unspecified,unspecified,unspecified,NA,gaacucuguccugauagguc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN7,exon,3,NA,unspecified,unspecified,unspecified,NA,gcuccgacauucuuuccgcuc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN7,exon,3,NA,unspecified,unspecified,unspecified,NA,ugacgucauccgcggcccgcu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN7,exon,3,NA,unspecified,unspecified,unspecified,NA,cugcggaggcggcggcugcu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN7,exon,3,NA,unspecified,unspecified,unspecified,NA,cgccguccuccggccgugu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN7,exon,3,NA,unspecified,unspecified,unspecified,NA,cggccgagguggaggcggcgc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN7,exon,3,NA,unspecified,unspecified,unspecified,NA,ucgccauugcggcggccgaggu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN7,exon,3,NA,unspecified,unspecified,unspecified,NA,acuucaggacugggcagaggcc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN7,exon,3,NA,unspecified,unspecified,unspecified,NA,auuccacgacugucccagcauca,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,ATXN7,exon,3,NA,unspecified,unspecified,unspecified,NA,cuucccaggaaguuuggaagccu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,unspecified,unspecified,NA,cggugguggucugggagcugucgcugaug,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,unspecified,unspecified,NA,gccugcagugugugcuguga,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,unspecified,unspecified,NA,augaugucaugaccugcugacc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,unspecified,unspecified,NA,cugaagaagcagccagcucu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,unspecified,unspecified,NA,cucaagauauccuccucauc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,unspecified,unspecified,NA,ccacugaucucauccuucacuga,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,unspecified,unspecified,NA,gucccaucauucagguccau,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,unspecified,unspecified,NA,aucaguggcagagcuuguca,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,unspecified,unspecified,NA,acggcgcugaccuggcugga,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,12,NA,human,unspecified,unspecified,NA,agcuggccagauccacugagu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,unspecified,unspecified,NA,ggcuguccaaucugcagg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,13,NA,human,unspecified,unspecified,NA,aaauacugguugucgguacc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,14,NA,human,unspecified,unspecified,NA,cugccugcagugacucauguu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,14,NA,human,unspecified,unspecified,NA,aucaacacugcugucagaaggc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,HTT,exon,14,NA,human,unspecified,unspecified,NA,caguagcuucaucucucaac,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,uagggauuccgggagucauggc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,gcaucauuggacuaaagauagg,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,guggggucaguccagugccaua,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,cugcugaacggcugcagcugc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,gcugggacguugacugcugaac,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,cuguggugccuggccugagguu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,ugaguggaagagcuguggugc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,gcaguugugagagucugugag,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,agggauacaguggaguggugcc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,agcuggcguggcaggagugaug,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,3,NA,unspecified,unspecified,unspecified,NA,ugcgguacaaucccagaacucu,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,4,NA,unspecified,unspecified,unspecified,NA,accaagauucacuguggauaca,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,4,NA,unspecified,unspecified,unspecified,NA,cuuuaggucaaguuuacaacc,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,"Antisense Oligonucleotide Directed Removal Of Proteolytic Cleavage Sites, The Hchwa-D Mutation, And Trinucleotide Repeat Expansions",US/2020/224203,TBP,exon,4,NA,unspecified,unspecified,unspecified,NA,cguuucgggcacgaagugcaaug,unspecified,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2020/224203,NA,NA,NA
patent,Method For Inducing Muscular Cells Using Cells In Spot Urine,WO/2020/136696,DMD,exon,45,NA,human,the myotubes induced from urine-derived cells,Null,NA,ccaaugccauccuggaguuccuguaa,2OMe,NA,1,uM,Null,38.81,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/136696,NA,NA,NA
patent,Method For Inducing Muscular Cells Using Cells In Spot Urine,WO/2020/136696,DMD,exon,45,NA,human,the myotubes induced from urine-derived cells,Null,NA,ccaaugccauccuggaguuccuguaa,2OMe,NA,5,uM,Null,71.25,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/136696,NA,NA,NA
patent,Method For Inducing Muscular Cells Using Cells In Spot Urine,WO/2020/136696,DMD,exon,45,NA,human,the myotubes induced from urine-derived cells,Null,NA,ccaaugccauccuggaguuccuguaa,2OMe,NA,10,uM,Null,83.98,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/136696,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,c*aaggaagauggc*auuuc*t,2OMe,NA,0.4,uM,Skip,0.62,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,tc*aaggaagauggc*auuuc*t,2OMe,NA,0.4,uM,Skip,2.1,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,gguaaguuc*c*aagc*,2OMe,NA,0.4,uM,Skip,2.23,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,c*aaggaagauggc*auuuc*t,2OMe,NA,0.8,uM,Skip,1.24,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,tc*aaggaagauggc*auuuc*t,2OMe,NA,0.8,uM,Skip,5.56,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,gguaaguuc*c*aagc*,2OMe,NA,0.8,uM,Skip,3.34,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,c*aaggaagauggc*auuuc*t/tc*aaggaagauggc*auuuc*t,2OMe,NA,0.4,uM,Skip,3.09,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,c*aaggaagauggc*auuuc*t/gguaaguuc*c*aagc*,2OMe,NA,0.4,uM,Skip,10.26,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,tc*aaggaagauggc*auuuc*t/gguaaguuc*c*aagc*,2OMe,NA,0.4,uM,Skip,23.86,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,tc*aaggaagauggc*auuuc*t-teg-gguaaguuc*uguc*c*aagc*,2OMe,NA,0.8,uM,Skip,55.51,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,gguaaguuc*uguc*c*aagc*-teg-tc*aaggaagauggc*auuuc*t,2OMe,NA,0.8,uM,Skip,81.47,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,tc*aaggaagauggc*auuuc*t-heg-gguaaguuc*uguc*c*aagc*,2OMe,NA,0.8,uM,Skip,63.67,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,human,muscle cells from a DMD patient with a deletion of exons 48 to 50,Null,NA,gguaaguuc*uguc*c*aagc*-heg-tc*aaggaagauggc*auuuc*t,2OMe,NA,0.8,uM,Skip,73.43,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,mouse,quadriceps muscle from del52hDMD/mdx mice,Null,NA,gguaaguuc*c*aagc*,2OMe,NA,2.7 umol/kg 1x weekly for 12 weeks,Null,Skip,37.42,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,mouse,quadriceps muscle from del52hDMD/mdx mice,Null,NA,gguaaguuc*c*aagc*,2OMe,NA,8.1 umol/kg 1x weekly for 12 weeks,Null,Skip,46.07,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,mouse,quadriceps muscle from del52hDMD/mdx mice,Null,NA,tc*aaggaagauggc*auuuc*t,2OMe,NA,2.7 umol/kg 1x weekly for 12 weeks,Null,Skip,5.84,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,mouse,quadriceps muscle from del52hDMD/mdx mice,Null,NA,tc*aaggaagauggc*auuuc*t,2OMe,NA,8.1 umol/kg 1x weekly for 12 weeks,Null,Skip,8.65,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,mouse,quadriceps muscle from del52hDMD/mdx mice,Null,NA,gguaaguuc*c*aagc*/tc*aaggaagauggc*auuuc*t,2OMe,NA,4.05 umol/kg each,Null,Skip,68.43,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,WO/2020/089325,DMD,exon,51,NA,mouse,quadriceps muscle from del52hDMD/mdx mice,Null,NA,tc*aaggaagauggc*auuuc*t-heg-gguaaguuc*uguc*c*aagc*,2OMe,NA,2.7 umol/kg  starting at 5-6 weeks of age for a total of 12 weeks.,Null,Skip,66.07,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2020/089325,NA,NA,NA
patent,Substances For Targeting Various Selected Organs Or Tissues,JP/2020/510612,DMD,exon,45,NA,human,human control myotubes,Null,NA,ugccgcugcccaaugggauccug,2OMe,NA,2,uM,Skip,1.97,NA,NA,NA,RNA,https://patents.google.com/patent/JP/2020/510612,NA,NA,NA
patent,Substances For Targeting Various Selected Organs Or Tissues,JP/2020/510612,DMD,exon,45,NA,human,human control myotubes,Null,NA,unspecified,2OMe,NA,2,uM,Skip,5.06,NA,NA,NA,RNA,https://patents.google.com/patent/JP/2020/510612,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,1.25,uM,Skip,1.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,2.5,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,2.5,uM,Skip,3.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,5,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,5,uM,Skip,7.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,10,uM,Skip,2.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,10,uM,Skip,13.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,20,uM,Skip,6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,20,uM,Skip,24,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,40,uM,Skip,11.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,40,uM,Skip,39.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,1.25,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,1.25,uM,Skip,3.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,2.5,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,2.5,uM,Skip,12.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,5,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,5,uM,Skip,25,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,10,uM,Skip,2.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,10,uM,Skip,36.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,20,uM,Skip,4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,20,uM,Skip,57.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,unmodified PMO,NA,40,uM,Skip,9.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Oligomer Conjugates For Muscular Dystrophy,US/2020/078465,DMD,exon,45,NA,human,healthy human myoblasts,Null,NA,caatgccatcctggagttcctg,modified PMO (PPMO),NA,40,uM,Skip,72.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2020/078465,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,cccuggcaauccatcctg,2OMe,NA,0.05,uM,Null,high skipping efficiencies,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccuggcaauccauccugu,2OMe,NA,0.05,uM,Null,high skipping efficiencies,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cccuggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ctggcaatccauccugtc,2OMe,NA,0.05,uM,Null,high skipping efficiencies,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccctggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccctggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccctggcaatccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,cccuggcaatccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccctggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccctggcaatccatcctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,DNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccctggcaatccatcctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,DNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccctggcaatccatccug,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccuggcaatccaucctgu,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,high skipping efficiencies,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccuggcaatccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,cctggcaauccaucctgu,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,cctggcaatccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,cctggcaauccaucctgu,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,cctggcaatccatcctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,DNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ctggcaatccatccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ctggcaauccatcctguc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ctggcaatccatccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ctggcaauccatccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ctggcaauccaucctgtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ctggcaatccauccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ctggcaatccatccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ctggcaatccatccuguc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,cccuggcaauccatcctg,2OMe,NA,0.05,uM,Null,high skipping efficiencies,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ccuggcaauccauccugu,2OMe,NA,0.05,uM,Null,high skipping efficiencies,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs (Human Dermal Microvascular Endothelial Cells),Null,NA,ctggcaatccauccugtc,2OMe,NA,0.05,uM,Null,high skipping efficiencies,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,uauagcutactaggagga,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,gcuuacuaggaggaaugu,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,ggagguccaggaatggaa,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,gtccaggaauggaaautc,2OMe,NA,0.05,uM,Null,high skipping efficiencies,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,aggaauggaaauuccagg,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,uaactgcagcccctaaga,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,aauatagcuuacuaggag,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,atauagctuacuaggagg,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,atagcuuacuaggaggaa,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,uagctuacuaggaggaau,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,ctuacuaggaggaaugtg,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,uacuaggaggaaugugag,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,gaggtccaggaauggaaa,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,agguccaggaauggaaau,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,gguccaggaatggaaatu,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,uccaggaauggaaauucc,2OMe,NA,0.05,uM,Null,high skipping efficiencies,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,ccaggaatggaaatucca,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,caggaauggaaautccag,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,ccauaactgcagccccta,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,cauaacugcagccccuaa,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,ataacugcagccccuaag,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,aacugcagccccuaagau,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable of highyield  expression  of COL4A5),Null,NA,acugcagccccuaagatu,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,ctgcagcccctaagautc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaatggaaautc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaatggaaatuc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaatggaaattc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,DNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaatggaaautc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaauggaaautc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaatggaaatuc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaatggaaautc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaatggaaatuc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaauggaaautc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaauggaaatuc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,gtccaggaatggaaautc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,uccaggaatggaaauucc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,tccaggaauggaaatucc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,uccaggaauggaaauucc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,tccaggaatggaaatucc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,uccaggaatggaaatucc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,uccaggaatggaaatucc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,uccaggaauggaaatucc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,tccaggaatggaaatucc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,tccaggaatggaaautcc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,uccaggaauggaaatucc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,uccaggaauggaaauucc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,HMVECs  (cells  capable  of highyield  expression  of COL4A5),Null,NA,uccaggaauggaaautcc,2OMe,NA,0.05,uM,Null,skipping of exon 20 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cccuggcaauccatcctg,2OMe,NA,0.005,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccuggcaauccauccugu,2OMe,NA,0.005,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ctggcaatccauccugtc,2OMe,NA,0.005,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.005,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cccuggcaauccatcctg,2OMe,NA,0.015,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccuggcaauccauccugu,2OMe,NA,0.015,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ctggcaatccauccugtc,2OMe,NA,0.015,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.015,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cccuggcaauccatcctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccuggcaauccauccugu,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ctggcaatccauccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cccuggcaauccatcctg,2OMe,NA,0.1,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccuggcaauccauccugu,2OMe,NA,0.1,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ctggcaatccauccugtc,2OMe,NA,0.1,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.1,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,ccctggcaatccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,ccctggcaatccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cccuggcaatccatcctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,ccctggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cccuggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cccuggcaauccauccug,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,ccctggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cctggcaatccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,ccuggcaauccatccugt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cctggcaauccaucctgu,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cctggcaatccatccugt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,ccuggcaauccatccugt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cuggcaauccauccuguc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cuggcaauccauccuguc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,ctggcaauccauccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cuggcaauccauccuguc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,cuggcaauccatccuguc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,ctggcaauccatccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,ctggcaatccatccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,HMVEC,Null,NA,ctggcaatccaucctgtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccctggcaatccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccctggcaatccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cccuggcaatccatcctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccctggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cccuggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cccuggcaauccauccug,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccctggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cccuggcaauccaucctg,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaatccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccuggcaauccatccugt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgu,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaatccatccugt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccuggcaauccatccugt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cuggcaauccauccuguc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cuggcaauccauccuguc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ctggcaauccauccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cuggcaauccauccuguc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cuggcaauccatccuguc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ctggcaauccatccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ctggcaatccatccugtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ctggcaatccaucctgtc,2OMe,NA,0.05,uM,Null,skipping of exon 24 was confinned,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaatccaucctgt,2OMe,NA,5.00E-06,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaatccaucctgt,2OMe,NA,5.00E-04,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaatccaucctgt,2OMe,NA,0.005,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaatccaucctgt,2OMe,NA,0.015,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaatccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaatccaucctgt,2OMe,NA,0.1,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,5.00E-06,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,5.00E-04,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.005,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.015,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.1,uM,Null,skipping of exon 24 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cccuggcaauccatcctg,2OMe,NA,0.05,uM,Null,confirmation of their effects,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ccuggcaauccauccugu,2OMe,NA,0.05,uM,Null,confirmation of their effects,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,ctggcaatccauccugtc,2OMe,NA,0.05,uM,Null,confirmation of their effects,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaatccaucctgt,2OMe,NA,0.05,uM,Null,confirmation of their effects,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 24,Null,NA,cctggcaauccaucctgt,2OMe,NA,0.05,uM,Null,confirmation of their effects,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ctuggagtcctuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ggagtcctuuaucacctg,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ccuuggaguccuutauca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,utggaguccutuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,uggaguccuutaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ccuuggagucctuuauca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,cctuggagucctuuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ccutggagucctuuauca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,cctuggagtccutuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,cctuggagtccuuuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,cctuggaguccuuuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,cctuggaguccuuuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ccutggagtccuuuauca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ccutggaguccuuuauca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ctuggaguccuutaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,cutggaguccuuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,cutggaguccuuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,cutggagucctuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,utggagtccuutaucacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,utggaguccuuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,tuggaguccuuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,tuggaguccuuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,utggaguccuuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,utggagucctuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,utggagtcctuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,utggagtccutuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,tuggagtcctuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,uggaguccuuuaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,uggaguccuuuaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,uggaguccuutaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,tggaguccuuuaucacct,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,tggaguccuuuatcaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,tggaguccuuuaucacct,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,tggaguccuutaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,tggagtccutuaucacct,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,tggagtccutuaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,uggagtcctutaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ggaguccuuuatcaccug,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ggaguccuutaucacctg,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ggaguccuuuatcacctg,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,HEK293A (a  Cell  Line  Derived  from Human Embryonic Kiduey Cells),Null,NA,ggaguccutuatcaccug,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ctuggagtcctuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ggagtcctuuaucacctg,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ccuuggaguccuutauca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,utggaguccutuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,uggaguccuutaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ccuuggagucctuuauca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,cctuggagucctuuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ccutggagucctuuauca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,cctuggagtccutuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,cctuggagtccuuuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,cctuggaguccuuuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,cctuggaguccuuuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ccutggagtccuuuauca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ccutggaguccuuuauca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ctuggaguccuutaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,cutggaguccuuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,cutggaguccuuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,cutggagucctuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,utggagtccuutaucacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,utggaguccuuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,tuggaguccuuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,tuggaguccuuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,utggaguccuuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,utggagucctuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,utggagtcctuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,utggagtccutuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,tuggagtcctuuatcacc,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,uggaguccuuuaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,uggaguccuuuaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,uggaguccuutaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,tggaguccuuuaucacct,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,tggaguccuuuatcaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,tggaguccuuuaucacct,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,tggaguccuutaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,tggagtccutuaucacct,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,tggagtccutuaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,uggagtcctutaucaccu,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ggaguccuuuatcaccug,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ggaguccuutaucacctg,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ggaguccuuuatcacctg,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,Culture ofHMVECs (human dermal microvascular endothelial  cells),Null,NA,ggaguccutuatcaccug,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,ctuggagtcctuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,ggaguccutuatcaccug,2OMe,NA,0.05,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cctuggagucctuuatca,2OMe,NA,0.00005,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cctuggagucctuuatca,2OMe,NA,0.0005,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cctuggagucctuuatca,2OMe,NA,0.005,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cctuggagucctuuatca,2OMe,NA,0.015,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cctuggagucctuuatca,2OMe,NA,0.05,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cctuggagucctuuatca,2OMe,NA,0.1,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggaguccuuuaucac,2OMe,NA,0.00005,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggaguccuuuaucac,2OMe,NA,0.0005,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggaguccuuuaucac,2OMe,NA,0.005,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggaguccuuuaucac,2OMe,NA,0.015,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggaguccuuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggaguccuuuaucac,2OMe,NA,0.1,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggagucctuuaucac,2OMe,NA,0.00005,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggagucctuuaucac,2OMe,NA,0.0005,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggagucctuuaucac,2OMe,NA,0.005,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggagucctuuaucac,2OMe,NA,0.015,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggagucctuuaucac,2OMe,NA,0.05,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggagucctuuaucac,2OMe,NA,0.1,uM,Null,skipping of exon 21 was observed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,utggaguccutuatcacc,2OMe,NA,0.005,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cctuggagucctuuatca,2OMe,NA,0.005,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggaguccuuuaucac,2OMe,NA,0.005,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,urine exfoliated cells derived from an Alport syndrome patient with a mutation in exon 21,Null,NA,cutggagucctuuaucac,2OMe,NA,0.005,uM,Null,skipping of exon 21 was confirmed,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,tcctuuaucacctgg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ctuuaucacctggag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ctuggagtcctuuaucac,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ggagtcctuuaucacctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ccuuggaguccuutauca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,utggaguccutuatcacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,uggaguccuutaucaccu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ccuuggagucctuuauca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,cctuggagucctuuatca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ccutggagucctuuauca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,cctuggagtccutuatca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,cctuggagtccuuuatca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,cctuggaguccuuuatca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,cctuggaguccuuuatca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ccutggagtccuuuauca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ccutggaguccuuuauca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ctuggaguccuutaucac,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,cutggaguccuuuaucac,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,cutggaguccuuuaucac,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,cutggagucctuuaucac,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,utggagtccuutaucacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,utggaguccuuuatcacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,tuggaguccuuuatcacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,tuggagucctuuatcacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,utggaguccuuuatcacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,utggagucctuuatcacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,utggagtccruuatcacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,utggagtccutuatcacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,tuggagtcctuuatcacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,uggaguccuuuaucaccu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,uggaguccuuuaucaccu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,uggaguccuutaucaccu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,tggaguccuuuaucacct,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,tggaguccuuuatcaccu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,tggaguccuutaucaccu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,tggagtccutuaucacct,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,tggagtccutuaucaccu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,tggagtccutuaucaccu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ggaguccuuuatcaccug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ggaguccuutaucacctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ggaguccuuuatcacctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,21,NA,human,unspecified,Null,NA,ggaguccutuatcaccug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cccuggcaauccatcctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccuggcaauccauccugu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaatccauccugtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccctggcaauccaucctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccctggcaauccaucctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccctggcaatccaucctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cccuggcaatccaucctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccctggcaauccaucctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccctggcaatccatectg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccctggcaatccatectg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccctggcaatccatccug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccuggcaatccaucctgu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaauccaucctgt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccuggcaatccaucctgt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaauccaucctgu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaatccaucctgt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaauccaucctgu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaatccatcctgt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaauccaucctgt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaatccatccugtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaauccatcctguc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaatccatccugtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaauccatccugtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaauccaucctgtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaatccauccugtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaatccatccugtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaatccatccuguc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccctggcaatccaucctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cccuggcaatccaucctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cccuggcaatccatcctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccctggcaauccaucctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cccuggcaauccaucag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cccuggcaauccauccug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccctggcaauccaucctg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cccuggcaauccaucag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaatccaucctgt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaauccaucctgt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaauccaucctgt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaauccaucctgt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccuggcaauccatccugt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaauccaucctgu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cctggcaatccatccugt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ccuggcaauccatccugt,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cuggcaauccauccuguc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cuggcaauccauccuguc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaauccauccugtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cuggcaauccauccuguc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,cuggcaauccatccuguc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaauccatccugtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaatccatccugtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,24,NA,human,unspecified,Null,NA,ctggcaatccaucagtc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uauagcutactaggagga,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gcuuacuaggaggaaugu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,ggagguccaggaatggaa,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaauggaaautc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,aggaauggaaauuccagg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uaactgcagcccctaaga,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,aauatagcuuacuaggag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,atauagctuacuaggagg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,atagcuuacuaggaggaa,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uagctuacuaggaggaau,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,ctuacuaggaggaaugtg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uacuaggaggaaugugag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gaggtccaggaauggaaa,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,agguccaggaauggaaau,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gguccaggaatggaaatu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uccaggaauggaaauucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,ccaggaatggaaatucca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,caggaauggaaautccag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,ccauaactgcagccccta,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,cauaacugcagccccuaa,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,ataacugcagccccuaag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,aacugcagccccuaagau,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,acugcagccccuaagatu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,ctgcagcccctaagautc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaatggaaautc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaatggaaatuc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaatggaaattc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaatggaaautc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaauggaaautc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaauggaaautc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaatggaaautc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaatggaaatuc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaauggaaautc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaauggaaatuc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,gtccaggaatggaaautc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uccaggaatggaaauucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,tccaggaauggaaatucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uccaggaauggaaauucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uccaggaauggaaauucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uccaggaatggaaatucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uccaggaauggaaauucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uccaggaauggaaatucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,tccaggaatggaaatucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,tccaggaatggaaautcc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uccaggaauggaaatucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uccaggaauggaaauucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Therapeutic Drug For Alport's Syndrome,US2020080080,COL4A5,exon,20,NA,human,unspecified,Null,NA,uccaggaauggaaautcc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2020080080,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,53,NA,human,unspecified,Null,NA,gcctccggttctgaaggtgttcttg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,44,NA,human,unspecified,Null,NA,cagatctgtcaaatcgcctgcagg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,44,NA,human,unspecified,Null,NA,caacagatctgtcaaatcgcctgcagg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,44,NA,human,unspecified,Null,NA,ctcaacagatctgtcaaatcgcctgcagg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gtgtctttctgagaaactgttcagc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gagaaactgttcagcttctgttagccac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gaaactgttcagcttctgttagccactg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,44,NA,human,unspecified,Null,NA,ctgttcagcttctgttagccactg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,44,NA,human,unspecified,Null,NA,ctgttcagcttctgttagccactgatt,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gaaactgttcagcttctgttagccactgatt,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,53,NA,human,unspecified,Null,NA,ctccggttctgaaggtgttcttgtac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,53,NA,human,unspecified,Null,NA,cctccggttctgaaggtgttcttgtac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,19,NA,human,unspecified,Null,NA,cugcuggcaucuugcaguu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,20,NA,human,unspecified,Null,NA,auucgauccaccggcuguuc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,20,NA,human,unspecified,Null,NA,cagcaguaguugucaucugc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,45,NA,human,unspecified,Null,NA,cuaccucuuuuuucugucug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,53,NA,human,unspecified,Null,NA,cctccggttctgaaggtgttcttgtac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Compositions For Treating Muscular Dystrophy,US 20200040337 A1,DMD,exon,44,NA,human,unspecified,Null,NA,agaaactgttcagcttctgttagcca,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20200040337A1,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,8,NA,human,Healthy primary human myotubes,ExGen500,NA,gugauguacauuaagauggacuuc,2OMe,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,10,NA,human,Healthy primary human myotubes,ExGen500,NA,cuuccuuccgaaagauugcaaauuc,2OMe,NA,unspecified,Null,Skip,70,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,10,NA,human,Healthy primary human myotubes,ExGen500,NA,gacuugucuucaggagcuucc,2OMe,NA,unspecified,Null,Skip,5,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,10,NA,human,Healthy primary human myotubes,ExGen500,NA,caaaugacuugucuucaggagcuuc,2OMe,NA,unspecified,Null,Skip,38,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,10,NA,human,Healthy primary human myotubes,ExGen500,NA,cugccaaaugacuugucuucaggag,2OMe,NA,unspecified,Null,Skip,66,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,10,NA,human,Healthy primary human myotubes,ExGen500,NA,ccaaaugacuugucu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,10,NA,human,Healthy primary human myotubes,ExGen500,NA,caaaugacuugucuucaggag,2OMe,NA,unspecified,Null,Skip,79,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,10,NA,human,Healthy primary human myotubes,ExGen500,NA,cagucuccugggcagacuggaugcuc,2OMe,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,45,NA,human,Healthy primary human myotubes,ExGen500,NA,uccuguaggauauuggcaguuguuu,2OMe,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,45,NA,human,Healthy primary human myotubes,ExGen500,NA,uccuguaggauauuggcaguugu,2OMe,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Oligonucleotide For The Treatment Of Muscular Dystrophy Patients,EP 3608407,DMD,exon,45,NA,human,Healthy primary human myotubes,ExGen500,NA,uccuguaggacauuggcaguuguuu,2OMe,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/EP3608407,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,8,NA,human,unspecified,Null,NA,uaucuggauaggugguaucaagaucuguaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,8,NA,human,unspecified,Null,NA,auguaacugaaaauguucuucuuua,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,8,NA,human,unspecified,Null,NA,uggauaggugguaucaacaucuguaagcac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,8,NA,human,unspecified,Null,NA,gauaggugguaucaacaucugu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,8,NA,human,unspecified,Null,NA,uaucuggauaggugguaucaacaucuguaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,8,NA,human,unspecified,Null,NA,aaacuuggaagagugaugugaugua,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,8,NA,human,unspecified,Null,NA,gcucacuuguugaggcaaaacuuggaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,8,NA,human,unspecified,Null,NA,gccuuggcaacauuuccacuuccug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,8,NA,human,unspecified,Null,NA,uacacacuuuaccuguugagaauag,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,23,NA,human,unspecified,Null,NA,cggcuaauuucagagggcgcuuucuungac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,23,NA,human,unspecified,Null,NA,ggccaaaccucggcuuaccugaaau,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,35,NA,human,unspecified,Null,NA,ucuucaggugcaccuucuguuucucaaucu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,gagagcuuccuguagcuucacccuuu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,uguguuaccuacccuugucg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,uagacuaucuuuuauauucuguaauau,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,gagagcuuccuguagcuucacccuuucca,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,uuccuguagcuucacccuuuccacaggcguu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,agcuuccuguagcuucacccuuu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,ggagagagcuuccuguagcuucacccuuu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,gagagcuuccuguagcuucaccc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,gcugggagagagcuuccuguagcuucac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,uguuaccuacccuugucgguccuuguac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,cugcugucuucuugcuaugaauaauguc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,ggcguugcacuuugcaaugcugcugucu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,uuggaaaucaagcugggagagagcuucc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,cuacccuugucgguccuuguacauuuug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,gucaauccgaccugagcuuuguuguaga,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,cuugcuaugaauaaugucaauccgacc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,uauauguguuaccuacccuugucggucc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,43,NA,human,unspecified,Null,NA,ucguucuucugucgucguaacguuuc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,uucucaggaauuugugucuuu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gacaacucuuu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,cuguucagcuucuguuagccacugauu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gccacugauuaaauaucuuuauauc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,ucuguuagccacugauuaaauaucuuuaua,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gagaaacuguucagcuucuguuagccacuga,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,ucuuucugagaaacuguucagcuucuguuag,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,cagaucugucaaaucgccugcaggua,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,caacagaucugucaaaucgccugcag,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,aaacuguucagcuucuguuagccacugauuaaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gaaacuguucagcuucuguuagccacugauu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,aaacuguucagcuucuguuagccacuga,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,ugagaaacuguucagcuucuguuagcca,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,uucugagaaacuguucagcuucuguuagccac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,uucugagaaacuguucagcuucuguu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gaucugucaaaucgccugcagguaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,auaaugaaaacgccgccauuucuca,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,aaacuguucagcuucuguuagccac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,uugugucuuucugagaaacuguuca,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,ccaauucucaggaauuugugucuuu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,aucgccugcagguaaaagcauaugg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,ugaaaacgccgccauuucucaacagaucug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,cauaaugaaaacgccgccauuucucaacag,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,uguucagcuucuguuagccacugauuaaau,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,cagaucugucaaaucgccugcagg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,caacagaucugucaaaucgccugcagg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,cucaacagaucugucaaaucgccugcagg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gaucugucaaaucgccugcaggu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gaucugucaaaucgccugcagg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gaucugucaaaucgccugcag,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,cagaucugucaaaucgccugcaggu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,cagaucugucaaaucgccugcag,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gugucuuucugagaaacuguucagc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gagaaacuguucagcuucuguuagccac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gaaacuguucagcuucuguuagccacug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,cuguucagcuucuguuagccacug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,aucugucaaaucgccugcagguaaaag,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,gaucugucaaaucgccugcagguaaaagc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,caccgauugucuucga,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,cccuuguacgauuuaug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,44,NA,human,unspecified,Null,NA,ucuguguuuaaggacucu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,caguuugccgcugccca,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,auuuuuccuguagaauacugg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gcugcccaaugcgauccuggaguuccuguaagau,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gcugcccaaugcgauccuggaguuccug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gcugcccaaugcgauccuggaguuccuguaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,caaugccauccuggaguuccuguaagauacc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,ccaaugccauccuggaguuccuguaagaua,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gcugcccaaugccauccuggaguuccuguaagau,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,caaugccauccuggaguuccuguaaga,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gcccaaugccauccuggaguuccuguaagauacc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,ugccauccuggaguuccuguaagauacc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,ugccauccuggaguuccuguaagau,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,caaugccauccuggaguuccuguaagau,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gcccaaugccauccuggaguuccuguaagau,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gcccaaugccauccuggaguuccuguaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gccgcugcccaaugacauccuggaguuccuguaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gccauccuggaguuccuguaagaua,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,ccaaugccauccuggaguuccugua,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,uuugaggauugcugaauuauuucuu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,caguuugccgcugcccaaugccauccugga,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,uugccgcugcccaaugccauccuggaguuc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,ccaaugccauccuggaguuccu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,cccaaugccauccuggaguuccuguaaga,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,ccgcugcccaaugccauccuggaguucc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,cccaaugccauccuggaguuccuguaagau,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,ccgcugcccaaugccauccuggaguuccug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,ugcccaaugccauccuggaguuccuguaag,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,cccaaugccauccuggaguuccuguaag,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,ugcccaaugccauccuggaguuccugua,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,caaugccauccuggaguuccug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gccgcugcccaaugccauccuggaguuccug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gcccaaugccauccuggaguuccug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,55,NA,human,unspecified,Null,NA,agccucucgcucacucacccugcaaagga,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,cucagaucuucuaacuuccucuuuaac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,cucagagcucagaucuucuaacuuccucu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,cgccuuccacucagagcucagaucuuc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,ucagcucuugaaguaaacgguuuaccg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,uuugcccucagcucuugaaguaaacgg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,ggcugcuuugcccucagcucuugaagu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,aaagagaaugggauccaguauacuuac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,ggcugcuuugcccucagcucuugaaguaaacgg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,aggcugcuuugcccucagcucuugaaguaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,gucaggcugcuuugcccucagcucuugaag,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,aggucaggcugcuuugcccucagcucuuga,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,cagagcucagaucuucuaacuuccu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,cuuacaggcuccaauaguggucagu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,augggauccaguauacuuacaggcu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,agagaaugggauccaguauacuuac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,aacuuccucuuuaacagaaaagcauac,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,50,NA,human,unspecified,Null,NA,gagccucucgcucacucacccugcaaagga,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,51,NA,human,unspecified,Null,NA,gguaccuccaacaucaaggaagauggcauu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,51,NA,human,unspecified,Null,NA,auuucuaguuuggagauggcaguuuc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,51,NA,human,unspecified,Null,NA,caucaaggaagauggcauuucuaguu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,51,NA,human,unspecified,Null,NA,gagcagguaccuccaacaucaaggaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,51,NA,human,unspecified,Null,NA,cuccaacaucaaggaagauggcauuucu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,51,NA,human,unspecified,Null,NA,aucauuuuuucucauaccuucugcuaggagcuaaaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,52,NA,human,unspecified,Null,NA,gcuggucuuguuuuucaa,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,52,NA,human,unspecified,Null,NA,uggucuuguuuuucaaauuu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,52,NA,human,unspecified,Null,NA,gucuuguuuuucaaauuuug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,52,NA,human,unspecified,Null,NA,cuuguuuuucaaauuuuggg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,52,NA,human,unspecified,Null,NA,uguuuuucaauuuugggc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,52,NA,human,unspecified,Null,NA,uccaacuggggacgccucuguuccaaauccugc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,uucaacuguugccuccgguucugaagguguucu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,uacuucaucccacugauucugaauu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,cuguugccuccgguucugaagguguucuug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,caacuguugccuccgguucugaagguguuc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,cuccgguucugaagguguucuug,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,cuccgguucugaagguguucuu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,cuccgguucugaagguguucu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,cuccgguucugaagguguuc,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,cuccgguucugaagguguu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,aaccgagaccggacaggauucu,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Muscle Targeting Complexes And Uses Thereof For Treating Dystrophinopathies,WO 2020028832 A1,DMD,exon,53,NA,human,unspecified,Null,NA,ggaagcuaaggaagaagcugagcagg,Others (unspecified),NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/WO2020028832A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aacatcttctctttcatctaaaatg,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,taaaatgcaaaataaaaaaataaaa,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aacatcttctctttcatctaaaatg,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ttcatctaaaatgcaaaataaaaaa,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ttcatctaaaatgcaaaataaaaaa,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ttctctttcatctaaaatgcaaaat,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ttctctttcatctaaaatgcaaaat,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,atcttctctttcatctaaaatgcaa,unmodified PMO,NA,10,uM,Skip,20-29.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,atcttctctttcatctaaaatgcaa,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ttgaacatcttctctttcatctaaa,unmodified PMO,NA,10,uM,Skip,20-29.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ttgaacatcttctctttcatctaaa,unmodified PMO,NA,10,uM,Skip,20-29.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cttttgaacatcttctctttcatct,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cttttgaacatcttctctttcatct,unmodified PMO,NA,10,uM,Skip,30.0-39.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tttcttttgaacatcttctctttca,unmodified PMO,NA,10,uM,Skip,20-29.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tttcttttgaacatcttctctttca,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgttttcttttgaacatcttctctt,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgttttcttttgaacatcttctctt,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgttttcttttgaacatcttctctt,unmodified PMO,NA,10,uM,Skip,30-39.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgttttcttttgaacatcttctctt,unmodified PMO,NA,10,uM,Skip,20-29.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,gaatgttttcttttgaacatcttct,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,gaatgttttcttttgaacatcttct,unmodified PMO,NA,10,uM,Skip,20-29.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,gaatgttttcttttgaacatcttct,unmodified PMO,NA,10,uM,Skip,30-39.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,gaatgttttcttttgaacatcttct,unmodified PMO,NA,10,uM,Skip,20-29.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgtgaatgttttcttttgaacatct,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgtgaatgttttcttttgaacatct,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgtgaatgttttcttttgaacatct,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgtgaatgttttcttttgaacatct,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ttttgtgaatgttttcttttgaaca,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ttttgtgaatgttttcttttgaaca,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ccattttgtgaatgttttcttttga,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ccattttgtgaatgttttcttttga,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tacccattttgtgaatgttttcttt,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tacccattttgtgaatgttttcttt,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,atttacccattttgtgaatgttttc,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,atttacccattttgtgaatgttttc,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgcatttacccattttgtgaatgtt,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgcatttacccattttgtgaatgtt,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ttgtgcatttacccattttgtgaat,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,ttgtgcatttacccattttgtgaat,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aaattgtgcatttacccattttgtg,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aaattgtgcatttacccattttgtg,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,agaaaattgtgcatttacccatttt,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,agaaaattgtgcatttacccatttt,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cttagaaaattgtgcatttacccat,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cttagaaaattgtgcatttacccat,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cttagaaaattgtgcatttacccat,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cttagaaaattgtgcatttacccat,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,taccttagaaaattgtgcatttacc,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,taccttagaaaattgtgcatttacc,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tcttaccttagaaaattgtgcattt,unmodified PMO,NA,10,uM,Skip,30-39.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tcttaccttagaaaattgtgcattt,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cattcttaccttagaaaattgtgca,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cattcttaccttagaaaattgtgca,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cattcttaccttagaaaattgtgca,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cattcttaccttagaaaattgtgca,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aaccattcttaccttagaaaattgt,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aaccattcttaccttagaaaattgt,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,acaaaccattcttaccttagaaaat,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,acaaaccattcttaccttagaaaat,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,atgttttcttttgaacatcttctct,unmodified PMO,NA,10,uM,Skip,20-29.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,atgttttcttttgaacatcttctct,unmodified PMO,NA,10,uM,Skip,20-29.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,atgttttcttttgaacatcttctct,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,atgttttcttttgaacatcttctct,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aatgttttcttttgaacatcttctc,unmodified PMO,NA,10,uM,Skip,30-39.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aatgttttcttttgaacatcttctc,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgaatgttttcttttgaacatcttc,unmodified PMO,NA,10,uM,Skip,20-29.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgaatgttttcttttgaacatcttc,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,gtgaatgttttcttttgaacatctt,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,gtgaatgttttcttttgaacatctt,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,atctaaaatgcaaaataaaaaaata,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,atctaaaatgcaaaataaaaaaata,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,taaaatgcaaaataaaaaaataaaa,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aatgcaaaataaaaaaataaaagtt,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aatgcaaaataaaaaaataaaagtt,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,gcaaaataaaaaaataaaagttagg,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,gcaaaataaaaaaataaaagttagg,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aaataaaaaaataaaagttaggaag,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aaataaaaaaataaaagttaggaag,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,taaaaaaataaaagttaggaagcaa,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,taaaaaaataaaagttaggaagcaa,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aaaaataaaagttaggaagcaactt,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,aaaaataaaagttaggaagcaactt,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgttttcttttgaacatct,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,tgttttcttttgaacatct,unmodified PMO,NA,10,uM,Skip,19.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,attcttaccttagaaaattgtgc,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,attcttaccttagaaaattgtgc,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cttagaaaattgtgcat,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cttagaaaattgtgcat,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cattcttaccttagaaa,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,WO 2020/023688 A1,DMD,exon,2,NA,human,RD Cells,Null,NA,cattcttaccttagaaa,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2020/023688A1,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,40,uM,Skip,41.93,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,40,uM,Skip,68.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,20,uM,Skip,34.56,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,20,uM,Skip,58.9,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,22.23,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,10,uM,Skip,56.76,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,5,uM,Skip,15.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,5,uM,Skip,37.46,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,2.5,uM,Skip,12.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,2.5,uM,Skip,23.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,1.25,uM,Skip,4.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,differentiated human myocytes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,1.25,uM,Skip,12.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,1.25,uM,Skip,0.66,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,1.25,uM,Skip,2.2,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,2.5,uM,Skip,1.49,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,2.5,uM,Skip,2.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,5,uM,Skip,2.76,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,5,uM,Skip,6.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,2.63,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,10,uM,Skip,8.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,20,uM,Skip,5.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,20,uM,Skip,18.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,40,uM,Skip,8.46,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myoblasts,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,40,uM,Skip,29.24,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,1.25,uM,Skip,0.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,1.25,uM,Skip,1.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,2.5,uM,Skip,0.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,2.5,uM,Skip,2.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,5,uM,Skip,1.23,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,5,uM,Skip,5.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,2.11,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,10,uM,Skip,8.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,20,uM,Skip,2.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,20,uM,Skip,16.08,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,40,uM,Skip,5.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,JP/2020/503009,DMD,exon,51,NA,human,healthy human myotubes,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,40,uM,Skip,27.79,NA,NA,NA,DNA,https://patents.google.com/patent/JP/2020/503009,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Ex45Del patient myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,ucuguuagccacugauuaaau,2OMe,NA,150,nM,Skip,36,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Ex45Del patient myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,ucagcuucuguuagccacug,2OMe,NA,150,nM,Skip,84,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Healthy human myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,ucagcuucuguuagccacug,2OMe,NA,400,nM,Skip,45,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Healthy human myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,agauaccauuuguauuuagc,2OMe,NA,150,nM,Skip,1,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Ex45Del patient myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,gccauuucucaacagaucu,2OMe,NA,150,nM,Skip,72,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Ex45Del patient myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,gccauuucucaacagaucuguca,2OMe,NA,150,nM,Skip,87,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Ex45Del patient myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,auucucaggaauuugugucuuuc,2OMe,NA,150,nM,Skip,86,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Ex45Del patient myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,ucucaggaauuugugucuuuc,2OMe,NA,150,nM,Skip,94,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Healthy human myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,guucagcuucuguuagcc,2OMe,NA,150,nM,Skip,44,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Healthy human myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,guucagcuucuguuagcc,2OMe,NA,400,nM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Healthy human myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,cugauuaaauaucuuuauauc,2OMe,NA,150,nM,Skip,14,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Healthy human myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,cugauuaaauaucuuuauauc,2OMe,NA,400,nM,Skip,12,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Ex45Del patient myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,gccgccauuucucaacag,2OMe,NA,150,nM,Skip,91,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Ex45Del patient myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,guauuuagcauguuccca,2OMe,NA,150,nM,Skip,68,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Healthy human myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,guauuuagcauguuccca,2OMe,NA,150,nM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Healthy human myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,guauuuagcauguuccca,2OMe,NA,400,nM,Skip,9,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,AU 2019/283969 A1,DMD,exon,44,NA,human,Ex45Del patient myotubes,ExGen or UNIFectylin (2 uL per ug AON),NA,caggaauuugugucuuuc,2OMe,NA,150,nM,Skip,35,NA,NA,NA,RNA,https://patents.google.com/patent/AU2019/283969A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US 10533171 B2,DMD,exon,44,NA,human,Healthy primary human myotubes,UNIfectylin,NA,ucacuucuguuaiccacug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US10533171B2,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,US 10533171 B2,DMD,exon,19,NA,human,Healthy primary human myotubes,UNIfectylin,NA,cagcaguaguugucaucugc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US10533171B2,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,accagaguaacagucugaguaggag,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,caccagaguaacagucugaguagga,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,ucaccagaguaacagucugaguagg,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,gucaccagaguaacagucugaguag,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,guugugucaccagaguaacagucug,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,gguugugucaccagaguaacagucu,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,agguugugucaccagaguaacaguc,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,cagguugugucaccagaguaacagu,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,ccacagguugugucaccagaguaac,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,accacagguugugucaccagaguaa,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,aaccacagguugugucaccagagua,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,uaaccacagguugugucaccagagu,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US 2019/0390197 A1,DMD,exon,unspecified,NA,human,Null,Null,NA,guaaccacagguugugucaccagag,"Others (mixed 2'OMe, F, and stereochemistry)",NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US2019/0390197A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,lipofectamine 2000,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,20,uM,Skip,58.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,10,uM,Skip,42.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,5,uM,Skip,37.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,2.5,uM,Skip,23.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,1.25,uM,Skip,17.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,20,uM,Skip,41.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,10,uM,Skip,40.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,5,uM,Skip,23.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,2.5,uM,Skip,18.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,1.25,uM,Skip,5.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,20,uM,Skip,49.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,10,uM,Skip,40.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,5,uM,Skip,40.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,2.5,uM,Skip,26.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,1.25,uM,Skip,20.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,58.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,35.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,31.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,23.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,22.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,61.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,43.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,28.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,34.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,17.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,61.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,51.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,27.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,23,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,69.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,42.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,34.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,22.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,12.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,20,uM,Skip,41.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,10,uM,Skip,37.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,5,uM,Skip,17.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,2.5,uM,Skip,21.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,1.25,uM,Skip,14.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,68.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,45.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,38.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,18.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,16.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,28.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,38.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,32.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,20.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,19.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,76,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,45,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,37.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,30.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,25.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,20,uM,Skip,58.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,10,uM,Skip,42.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,5,uM,Skip,32.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,2.5,uM,Skip,26.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,1.25,uM,Skip,23.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,20,uM,Skip,72,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,10,uM,Skip,62.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,5,uM,Skip,38.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,2.5,uM,Skip,26.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,1.25,uM,Skip,22.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,20,uM,Skip,33.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,10,uM,Skip,32.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,5,uM,Skip,30.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,2.5,uM,Skip,18.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,1.25,uM,Skip,13.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,20,uM,Skip,69.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,10,uM,Skip,53.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,5,uM,Skip,40.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,2.5,uM,Skip,27.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,1.25,uM,Skip,18.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,20,uM,Skip,51.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,10,uM,Skip,46.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,5,uM,Skip,33.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,2.5,uM,Skip,15.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,1.25,uM,Skip,15.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gaagaaaaagaaaaattagaaacac,modified PMO,NA,20,uM,Skip,40.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gaagaaaaagaaaaattagaaacac,modified PMO,NA,10,uM,Skip,21.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gaagaaaaagaaaaattagaaacac,modified PMO,NA,5,uM,Skip,8.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gaagaaaaagaaaaattagaaacac,modified PMO,NA,2.5,uM,Skip,2.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gaagaaaaagaaaaattagaaacac,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaggaaaaaagaagaaaaagaaaaa,modified PMO,NA,20,uM,Skip,22.9,NA,NA,NA,Unknown,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaggaaaaaagaagaaaaagaaaaa,modified PMO,NA,10,uM,Skip,25,NA,NA,NA,Unknown,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaggaaaaaagaagaaaaagaaaaa,modified PMO,NA,5,uM,Skip,9.2,NA,NA,NA,Unknown,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaggaaaaaagaagaaaaagaaaaa,modified PMO,NA,2.5,uM,Skip,13.5,NA,NA,NA,Unknown,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaggaaaaaagaagaaaaagaaaaa,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,Unknown,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaaaaaggaaaaaagaagaaaaag,modified PMO,NA,20,uM,Skip,63.3,NA,NA,NA,Unknown,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaaaaaggaaaaaagaagaaaaag,modified PMO,NA,10,uM,Skip,30.2,NA,NA,NA,Unknown,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaaaaaggaaaaaagaagaaaaag,modified PMO,NA,5,uM,Skip,12,NA,NA,NA,Unknown,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaaaaaggaaaaaagaagaaaaag,modified PMO,NA,2.5,uM,Skip,5.9,NA,NA,NA,Unknown,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaaaaaggaaaaaagaagaaaaag,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,Unknown,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tttttgcaaaaaggaaaaaagaaga,modified PMO,NA,20,uM,Skip,31.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tttttgcaaaaaggaaaaaagaaga,modified PMO,NA,10,uM,Skip,22.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tttttgcaaaaaggaaaaaagaaga,modified PMO,NA,5,uM,Skip,13,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tttttgcaaaaaggaaaaaagaaga,modified PMO,NA,2.5,uM,Skip,3.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tttttgcaaaaaggaaaaaagaaga,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ttgggtttttgcaaaaaggaaaaaa,modified PMO,NA,20,uM,Skip,56.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ttgggtttttgcaaaaaggaaaaaa,modified PMO,NA,10,uM,Skip,48.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ttgggtttttgcaaaaaggaaaaaa,modified PMO,NA,5,uM,Skip,37.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ttgggtttttgcaaaaaggaaaaaa,modified PMO,NA,2.5,uM,Skip,12.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ttgggtttttgcaaaaaggaaaaaa,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atattttgggtttttgcaaaaagga,modified PMO,NA,20,uM,Skip,14.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atattttgggtttttgcaaaaagga,modified PMO,NA,10,uM,Skip,3.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atattttgggtttttgcaaaaagga,modified PMO,NA,5,uM,Skip,4.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atattttgggtttttgcaaaaagga,modified PMO,NA,2.5,uM,Skip,2.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atattttgggtttttgcaaaaagga,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctaaaatattttgggtttttgcaaa,modified PMO,NA,20,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctaaaatattttgggtttttgcaaa,modified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctaaaatattttgggtttttgcaaa,modified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctaaaatattttgggtttttgcaaa,modified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctaaaatattttgggtttttgcaaa,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggagctaaaatattttgggttttt,modified PMO,NA,20,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggagctaaaatattttgggttttt,modified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggagctaaaatattttgggttttt,modified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggagctaaaatattttgggttttt,modified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggagctaaaatattttgggttttt,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tgagtaggagctaaaatattttggg,modified PMO,NA,20,uM,Skip,1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tgagtaggagctaaaatattttggg,modified PMO,NA,10,uM,Skip,0.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tgagtaggagctaaaatattttggg,modified PMO,NA,5,uM,Skip,1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tgagtaggagctaaaatattttggg,modified PMO,NA,2.5,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tgagtaggagctaaaatattttggg,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cagtctgagtaggagctaaaatatt,modified PMO,NA,20,uM,Skip,1.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cagtctgagtaggagctaaaatatt,modified PMO,NA,10,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cagtctgagtaggagctaaaatatt,modified PMO,NA,5,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cagtctgagtaggagctaaaatatt,modified PMO,NA,2.5,uM,Skip,0.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cagtctgagtaggagctaaaatatt,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,agtaacagtctgagtaggagctaaa,modified PMO,NA,20,uM,Skip,8.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,agtaacagtctgagtaggagctaaa,modified PMO,NA,10,uM,Skip,7.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,agtaacagtctgagtaggagctaaa,modified PMO,NA,5,uM,Skip,3.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,agtaacagtctgagtaggagctaaa,modified PMO,NA,2.5,uM,Skip,2.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,agtaacagtctgagtaggagctaaa,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagtaacagtctgagtaggagc,modified PMO,NA,20,uM,Skip,18.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagtaacagtctgagtaggagc,modified PMO,NA,10,uM,Skip,15.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagtaacagtctgagtaggagc,modified PMO,NA,5,uM,Skip,8.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagtaacagtctgagtaggagc,modified PMO,NA,2.5,uM,Skip,8.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagtaacagtctgagtaggagc,modified PMO,NA,1.25,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaaagaaaaattagaaacacaagct,modified PMO,NA,20,uM,Skip,25.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaaagaaaaattagaaacacaagct,modified PMO,NA,10,uM,Skip,10.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaaagaaaaattagaaacacaagct,modified PMO,NA,5,uM,Skip,7.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaaagaaaaattagaaacacaagct,modified PMO,NA,2.5,uM,Skip,6.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaaagaaaaattagaaacacaagct,modified PMO,NA,1.25,uM,Skip,2.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaaaattagaaacacaagctaaaga,modified PMO,NA,20,uM,Skip,21.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaaaattagaaacacaagctaaaga,modified PMO,NA,10,uM,Skip,13.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaaaattagaaacacaagctaaaga,modified PMO,NA,5,uM,Skip,7.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaaaattagaaacacaagctaaaga,modified PMO,NA,2.5,uM,Skip,5.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaaaattagaaacacaagctaaaga,modified PMO,NA,1.25,uM,Skip,3.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ttagaaacacaagctaaagagccaa,modified PMO,NA,20,uM,Skip,35.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ttagaaacacaagctaaagagccaa,modified PMO,NA,10,uM,Skip,7.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ttagaaacacaagctaaagagccaa,modified PMO,NA,5,uM,Skip,3.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ttagaaacacaagctaaagagccaa,modified PMO,NA,2.5,uM,Skip,5.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ttagaaacacaagctaaagagccaa,modified PMO,NA,1.25,uM,Skip,5.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aacacaagctaaagagccaatttca,modified PMO,NA,20,uM,Skip,6.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aacacaagctaaagagccaatttca,modified PMO,NA,10,uM,Skip,3.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aacacaagctaaagagccaatttca,modified PMO,NA,5,uM,Skip,2.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aacacaagctaaagagccaatttca,modified PMO,NA,2.5,uM,Skip,4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aacacaagctaaagagccaatttca,modified PMO,NA,1.25,uM,Skip,3.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aagctaaagagccaatttcaataac,modified PMO,NA,20,uM,Skip,2.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aagctaaagagccaatttcaataac,modified PMO,NA,10,uM,Skip,2.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aagctaaagagccaatttcaataac,modified PMO,NA,5,uM,Skip,2.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aagctaaagagccaatttcaataac,modified PMO,NA,2.5,uM,Skip,2.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aagctaaagagccaatttcaataac,modified PMO,NA,1.25,uM,Skip,3.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaagagccaatttcaataacaataa,modified PMO,NA,20,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaagagccaatttcaataacaataa,modified PMO,NA,10,uM,Skip,2.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaagagccaatttcaataacaataa,modified PMO,NA,5,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaagagccaatttcaataacaataa,modified PMO,NA,2.5,uM,Skip,3.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aaagagccaatttcaataacaataa,modified PMO,NA,1.25,uM,Skip,3.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gccaatttcaataacaataagtcaa,modified PMO,NA,20,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gccaatttcaataacaataagtcaa,modified PMO,NA,10,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gccaatttcaataacaataagtcaa,modified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gccaatttcaataacaataagtcaa,modified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gccaatttcaataacaataagtcaa,modified PMO,NA,1.25,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tttcaataacaataagtcaaattta,modified PMO,NA,20,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tttcaataacaataagtcaaattta,modified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tttcaataacaataagtcaaattta,modified PMO,NA,5,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tttcaataacaataagtcaaattta,modified PMO,NA,2.5,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tttcaataacaataagtcaaattta,modified PMO,NA,1.25,uM,Skip,0.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctccaacatcaaggaagatggcatttctag,modified PMO,NA,20,uM,Skip,46.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctccaacatcaaggaagatggcatttctag,modified PMO,NA,10,uM,Skip,43,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctccaacatcaaggaagatggcatttctag,modified PMO,NA,5,uM,Skip,24.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctccaacatcaaggaagatggcatttctag,modified PMO,NA,2.5,uM,Skip,12.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctccaacatcaaggaagatggcatttctag,modified PMO,NA,1.25,uM,Skip,5.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,20,uM,Skip,76.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,10,uM,Skip,62.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,5,uM,Skip,60.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,2.5,uM,Skip,41.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,1.25,uM,Skip,37.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,80.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,66.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,40.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,36,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,20.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acatcaaggaagatggcatttctagtttgg,modified PMO,NA,20,uM,Skip,48.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acatcaaggaagatggcatttctagtttgg,modified PMO,NA,10,uM,Skip,38.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acatcaaggaagatggcatttctagtttgg,modified PMO,NA,5,uM,Skip,17,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acatcaaggaagatggcatttctagtttgg,modified PMO,NA,2.5,uM,Skip,6.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gagcaggtacctccaacatcaaggaa,modified PMO,NA,20,uM,Skip,13.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gagcaggtacctccaacatcaaggaa,modified PMO,NA,10,uM,Skip,13,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gagcaggtacctccaacatcaaggaa,modified PMO,NA,5,uM,Skip,2.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gagcaggtacctccaacatcaaggaa,modified PMO,NA,2.5,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,20,uM,Skip,36.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,10,uM,Skip,26,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,5,uM,Skip,13.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,2.5,uM,Skip,3.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,20,uM,Skip,28.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,10,uM,Skip,22.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,5,uM,Skip,12.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,2.5,uM,Skip,6.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,20,uM,Skip,41.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,10,uM,Skip,43.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,5,uM,Skip,19,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,2.5,uM,Skip,17.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,catcaaggaagatggcatttctagtt,modified PMO,NA,20,uM,Skip,6.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,catcaaggaagatggcatttctagtt,modified PMO,NA,10,uM,Skip,9.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,catcaaggaagatggcatttctagtt,modified PMO,NA,5,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,catcaaggaagatggcatttctagtt,modified PMO,NA,2.5,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tagtttggagatggcagttt,modified PMO,NA,20,uM,Skip,9.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tagtttggagatggcagttt,modified PMO,NA,10,uM,Skip,7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tagtttggagatggcagttt,modified PMO,NA,5,uM,Skip,3.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tagtttggagatggcagttt,modified PMO,NA,2.5,uM,Skip,5.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtt,modified PMO,NA,20,uM,Skip,6.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtt,modified PMO,NA,10,uM,Skip,7.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtt,modified PMO,NA,5,uM,Skip,2.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtt,modified PMO,NA,2.5,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gaagatggcatttctagtttgg,modified PMO,NA,20,uM,Skip,21.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gaagatggcatttctagtttgg,modified PMO,NA,10,uM,Skip,19,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gaagatggcatttctagtttgg,modified PMO,NA,5,uM,Skip,7.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gaagatggcatttctagtttgg,modified PMO,NA,2.5,uM,Skip,3.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,51.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,43.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,18.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,7.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctgccagagcaggtacctccaacatcaag,modified PMO,NA,20,uM,Skip,22,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctgccagagcaggtacctccaacatcaag,modified PMO,NA,10,uM,Skip,9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctgccagagcaggtacctccaacatcaag,modified PMO,NA,5,uM,Skip,4.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ctgccagagcaggtacctccaacatcaag,modified PMO,NA,2.5,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gagcaggtacctccaacatcaag,modified PMO,NA,20,uM,Skip,5.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gagcaggtacctccaacatcaag,modified PMO,NA,10,uM,Skip,3.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gagcaggtacctccaacatcaag,modified PMO,NA,5,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gagcaggtacctccaacatcaag,modified PMO,NA,2.5,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,20,uM,Skip,29.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,10,uM,Skip,13.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,5,uM,Skip,3.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,2.5,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,1.25,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggcatt,modified PMO,NA,0.625,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,20,uM,Skip,6.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,10,uM,Skip,4.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,5,uM,Skip,1.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,2.5,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,1.25,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,atttctagtttggagatggcagtttc,modified PMO,NA,0.625,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,20,uM,Skip,17.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,10,uM,Skip,12.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,5,uM,Skip,10.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,2.5,uM,Skip,4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,1.25,uM,Skip,1.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggaagatggcatttctagtttggag,modified PMO,NA,0.625,uM,Skip,0.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,4.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,3.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,2.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,1.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,cctccaacatcaaggaagatggc,modified PMO,NA,0.625,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,28.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,15.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,5.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,1.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggc,modified PMO,NA,0.625,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,19.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,14.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,2.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ggtacctccaacatcaaggaagatggc,modified PMO,NA,0.625,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,59.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,37.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,15.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,10.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,2.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,caggtacctccaacatcaaggaagatggc,modified PMO,NA,0.625,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,32.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,15.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,5.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,1.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gcaggtacctccaacatcaaggaagatggc,modified PMO,NA,0.625,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatgg,modified PMO,NA,20,uM,Skip,4.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatgg,modified PMO,NA,10,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatgg,modified PMO,NA,5,uM,Skip,1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatgg,modified PMO,NA,2.5,uM,Skip,0.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatgg,modified PMO,NA,1.25,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatgg,modified PMO,NA,0.625,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatg,modified PMO,NA,20,uM,Skip,1.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatg,modified PMO,NA,10,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatg,modified PMO,NA,5,uM,Skip,0.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatg,modified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatg,modified PMO,NA,1.25,uM,Skip,0.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatg,modified PMO,NA,0.625,uM,Skip,0.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,20,uM,Skip,27.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,10,uM,Skip,7.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,5,uM,Skip,1.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,2.5,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,1.25,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,ccagagcaggtacctccaacatcaaggaag,modified PMO,NA,0.625,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,34.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,14.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,5.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,2.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,0.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,aggtacctccaacatcaaggaagatggc,modified PMO,NA,0.625,uM,Skip,0.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,17.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,5.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,0.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,0.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tacctccaacatcaaggaagatggc,modified PMO,NA,0.625,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,15.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,1.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,acctccaacatcaaggaagatggc,modified PMO,NA,0.625,uM,Skip,0.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tccaacatcaaggaagatggc,modified PMO,NA,20,uM,Skip,1.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tccaacatcaaggaagatggc,modified PMO,NA,10,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tccaacatcaaggaagatggc,modified PMO,NA,5,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tccaacatcaaggaagatggc,modified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tccaacatcaaggaagatggc,modified PMO,NA,1.25,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,tccaacatcaaggaagatggc,modified PMO,NA,0.625,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,20,uM,Skip,20.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,10,uM,Skip,6.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,5,uM,Skip,3.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,2.5,uM,Skip,0.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,1.25,uM,Skip,0.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatttc,modified PMO,NA,0.625,uM,Skip,0.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,20,uM,Skip,8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,10,uM,Skip,4.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,5,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,2.5,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,1.25,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcattt,modified PMO,NA,0.625,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,20,uM,Skip,11.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,10,uM,Skip,5.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,5,uM,Skip,2.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,2.5,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,1.25,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcatt,modified PMO,NA,0.625,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,20,uM,Skip,45.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,10,uM,Skip,19.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,5,uM,Skip,9.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,2.5,uM,Skip,4.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,1.25,uM,Skip,1.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggcat,modified PMO,NA,0.625,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,20,uM,Skip,31.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,10,uM,Skip,12.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,5,uM,Skip,4.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,2.5,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,1.25,uM,Skip,1.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagatggca,modified PMO,NA,0.625,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagat,modified PMO,NA,20,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagat,modified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagat,modified PMO,NA,5,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagat,modified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagat,modified PMO,NA,1.25,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaagat,modified PMO,NA,0.625,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaaga,modified PMO,NA,20,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaaga,modified PMO,NA,10,uM,Skip,0.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaaga,modified PMO,NA,5,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaaga,modified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaaga,modified PMO,NA,1.25,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaaga,modified PMO,NA,0.625,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaag,modified PMO,NA,20,uM,Skip,1.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaag,modified PMO,NA,10,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaag,modified PMO,NA,5,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaag,modified PMO,NA,2.5,uM,Skip,1.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaag,modified PMO,NA,1.25,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystropy,WO2018005805A1,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,gtacctccaacatcaaggaag,modified PMO,NA,0.625,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018005805A1,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,1.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*smc*sma*sma*smg*smg*sma*sma*smg*sma*smu*smg*smg*smc*sma*smu*smu*smu*smc*smu,2OMe,NA,unspecified,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*rmc*rma*rma*rmg*rmg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*rmu*rmu*rmu*rmc*rmu,2OMe,NA,unspecified,uM,Skip,1.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*smc*rma*sma*rmg*smg*rma*sma*rmg*sma*rmu*smg*rmg*smc*rma*smu*rmu*smu*rmc*smu,2OMe,NA,unspecified,uM,Skip,1.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*rmc*rma*rma*smg*smg*sma*sma*smg*sma*smu*smg*smg*smc*sma*smu*smu*rmu*rmc*rmu,2OMe,NA,unspecified,uM,Skip,0.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*smc*sma*sma*rmg*rmg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*rmu*rmu*smu*smc*smu,2OMe,NA,unspecified,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*rmc*rma*rma*rmg*rmg*sma*sma*rmg*sma*smu*rmg*smg*smc*rma*rmu*rmu*rmu*rmc*rmu,2OMe,NA,unspecified,uM,Skip,28.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*smc*sma*sma*smg*smg*rma*rma*smg*rma*rmu*smg*rmg*rmc*sma*smu*smu*smu*smc*smu,2OMe,NA,unspecified,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*rmc*rma*rma*smg*smg*rma*rma*smg*rma*rmu*rmg*smg*rmc*rma*smu*smu*rmu*rmc*rmu,2OMe,NA,unspecified,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*smc*sma*sma*rmg*rmg*sma*sma*rmg*sma*smu*smg*rmg*smc*sma*rmu*rmu*smu*smc*smu,2OMe,NA,unspecified,uM,Skip,0.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*smc*rma*rma*rmg*rmg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*rmu*rmu*rmu*rmc*smu,2OMe,NA,unspecified,uM,Skip,8.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*rmc*sma*sma*smg*smg*sma*sma*smg*sma*smu*smg*smg*smc*sma*smu*smu*smu*smc*rmu,2OMe,NA,unspecified,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*smc*rma*sma*smg*rmg*rma*sma*smg*rma*smu*smg*rmg*rmc*rma*smu*smu*smu*smc*rmu,2OMe,NA,unspecified,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*rmc*sma*rma*rmg*smg*sma*rma*rmg*sma*rmu*rmg*smg*smc*sma*rmu*rmu*rmu*rmc*smu,2OMe,NA,unspecified,uM,Skip,0.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,healthy human myoblasts,Null,NA,mu*smc*sma*rma*rmg*rmg*rma*rma*rmg*rma*rmu*smg*rmg*rmc*sma*rmu*smu*smu*smc*smu,2OMe,NA,unspecified,uM,Skip,4.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mg*mg*mc*mc*ma*ma*ma*mc*mc*mu*mc*mg*mg*mc*mu*mu*ma*mc*mc*mu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*rmc*rma*rma*rmg*rmg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*rmu*rmu*rmu*rmc*rmu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*rma*sma*rmg*smg*rma*sma*rmg*sma*rmu*smg*rmg*smc*rma*smu*rmu*smu*rmc*smu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*rmc*rma*rma*smg*smg*sma*sma*smg*sma*smu*smg*smg*smc*sma*smu*smu*rmu*rmc*rmu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*sma*sma*rmg*rmg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*rmu*rmu*smu*smc*smu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*rmc*rma*rma*rmg*rmg*sma*sma*rmg*sma*smu*rmg*smg*smc*rma*rmu*rmu*rmu*rmc*rmu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*sma*sma*smg*smg*rma*rma*smg*rma*rmu*smg*rmg*rmc*sma*smu*smu*smu*smc*smu,2OMe,NA,10,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*rmc*rma*rma*smg*smg*rma*rma*smg*rma*rmu*rmg*smg*rmc*rma*smu*smu*rmu*rmc*rmu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*sma*sma*rmg*rmg*sma*sma*rmg*sma*smu*smg*rmg*smc*sma*rmu*rmu*smu*smc*smu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*rma*rma*rmg*rmg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*rmu*rmu*rmu*rmc*smu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*rmc*sma*sma*smg*smg*sma*sma*smg*sma*smu*smg*smg*smc*sma*smu*smu*smu*smc*rmu,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*rma*sma*smg*rmg*rma*sma*smg*rma*smu*smg*rmg*rmc*rma*smu*smu*smu*smc*rmu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*rmc*sma*rma*rmg*smg*sma*rma*rmg*sma*rmu*rmg*smg*smc*sma*rmu*rmu*rmu*rmc*smu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mg*mg*mc*mc*ma*ma*ma*mc*mc*mu*mc*mg*mg*mc*mu*mu*ma*mc*mc*mu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*rmc*rma*rma*rmg*rmg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*rmu*rmu*rmu*rmc*rmu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*rma*sma*rmg*smg*rma*sma*rmg*sma*rmu*smg*rmg*smc*rma*smu*rmu*smu*rmc*smu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*rmc*rma*rma*smg*smg*sma*sma*smg*sma*smu*smg*smg*smc*sma*smu*smu*rmu*rmc*rmu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*sma*sma*rmg*rmg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*rmu*rmu*smu*smc*smu,2OMe,NA,10,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*rmc*rma*rma*rmg*rmg*sma*sma*rmg*sma*smu*rmg*smg*smc*rma*rmu*rmu*rmu*rmc*rmu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*sma*sma*smg*smg*rma*rma*smg*rma*rmu*smg*rmg*rmc*sma*smu*smu*smu*smc*smu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*rma*rma*rmg*rmg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*rmu*rmu*rmu*rmc*smu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*smc*sma*rma*rmg*rmg*rma*rma*rmg*rma*rmu*smg*rmg*rmc*sma*rmu*smu*smu*smc*smu,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,Primary human myoblasts from a patient with (dystrophin deletion exon 48-50),Null,NA,mu*rmc*rma*sma*smg*smg*sma*sma*smg*sma*smu*rmg*smg*smc*rma*smu*rmu*rmu*rmc*rmu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,ma*mu*mu*mu*mc*mu*ma*mg*mu*mu*mu*mg*mg*ma*mg*ma*mu*mg*mg*mc,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma*mg*mu*mu*mu*mg*mg*ma*mg*ma,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma*mg*mu*mu*mu*mg*mg*ma,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma*mg*mu*mu*mu*mg*mg,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma*mg*mu*mu*mu*mg,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma*mg*mu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma*mg,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma*mg*mu*mu*mu*mg,2OMe,NA,10,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mc*ma*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma*mg*mu,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,ma*mc*ma*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma*mg,2OMe,NA,10,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,ma*ma*mc*ma*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu*ma,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mc*ma*ma*mc*ma*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mc*mu*mc*mc*ma*ma*mc*ma*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu,2OMe,NA,10,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,ma*mc*mc*mu*mc*mc*ma*ma*mc*ma*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mg*mu*ma*mc*mc*mu*mc*mc*ma*ma*mc*ma*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*mamamgmamumgmgmc*fa*fu*fu*fu*fc*fu,2OMe,NA,unspecified,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*mgmamamgmamumgmgmcma*fu*fu*fu*fc*fu,2OMe,NA,unspecified,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smamamgmamumgmgmc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*smgmamamgmamumgmgmcma*sfu*sfu*sfu*sfc*sfu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sma*rma*rmg*rma*rmu*rmg*rmg*rmc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*smg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*sfu*sfu*sfu*sfc*sfu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo13lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo14lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modoo5lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo16lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo17lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo18lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo19lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modoo6loo1*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,unspecified,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,1.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*rmg*rma*rmu*rmg*rmg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,17.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smg*rma*rmu*rmg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,16.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,31,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfamgmamumgmg*sfc*sfa*sfu*sfu*sfu*5fc*sfu,2OMe,NA,10,uM,Skip,3.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,16.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*smc*sma*sma*smg*smg*sma*rma*rmg*rma*rmu*rmg*rmg*rmc*sma*smu*smu*smu*smc*smu,2OMe,NA,10,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*smc*sma*sma*smg*smg*sma*sma*rmg*rma*rmu*rmg*rmg*smc*sma*smu*smu*smu*smc*smu,2OMe,NA,10,uM,Skip,1.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*smc*sma*sma*smg*smg*sma*sma*smg*rma*rmu*rmg*smg*smc*sma*smu*smu*smu*smc*smu,2OMe,NA,10,uM,Skip,0.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*smc*sma*sma*smg*smg*sma*sma*smg*sma*rmu*smg*smg*smc*sma*smu*smu*smu*smc*smu,2OMe,NA,10,uM,Skip,0.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*smc*sma*sma*smg*smg*sma*ma*mg*ma*mu*mg*mg*mc*sma*smu*smu*smu*smc*smu,2OMe,NA,10,uM,Skip,1.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*fa*fa*fg*fa*fu*fg*fg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*fa*fa*fg*fa*fu*fg*fg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*ma*ma*mg*mg*ma*ma*mg*ma*fu*mg*mg*fc*ma*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*ma*ma*mg*mg*ma*ma*mg*ma*fu*mg*mg*fc*ma*fu*fu*fu*fc*fu,2OMe,NA,3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*fa*fa*fg*fg*fa*fa*fg*fa*mu*fg*fg*mc*fa*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*fa*fa*fg*fg*fa*fa*fg*fa*mu*fg*fg*mc*fa*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*fc*ma*fa*mg*fg*ma*fa*mg*fa*mu*fg*mg*fc*ma*fu*mu*fu*mc*fu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*fc*ma*fa*mg*fg*ma*fa*mg*fa*mu*fg*mg*fc*ma*fu*mu*fu*mc*fu,2OMe,NA,3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*fa*fa*fg*fa*fu*fg*fg*fc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*fa*fa*fg*fa*fu*fg*fg*fc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*ma*ma*mg*ma*mu*mg*mg*mc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*ma*ma*mg*ma*mu*mg*mg*mc*fa*fu*fu*fu*fc*fu,2OMe,NA,3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*fc*ma*ma*fg*fg*ma*ma*fg*ma*mu*fg*fg*fc*ma*mu*mu*mu*fc*mu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*fc*ma*ma*fg*fg*ma*ma*fg*ma*mu*fg*fg*fc*ma*mu*mu*mu*fc*mu,2OMe,NA,3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*mc*fa*fa*mg*mg*fa*fa*mg*fa*fu*mg*mg*mc*fa*fu*fuqu*mcqu,2OMe,NA,10,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*mc*fa*fa*mg*mg*fa*fa*mg*fa*fu*mg*mg*mc*fa*fu*fuqu*mcqu,2OMe,NA,3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sma*rma*rmg*rma*rmu*rmg*rmg*rmc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,0.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sma*rma*rmg*rma*rmu*rmg*rmg*rmc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*smg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*smg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,0.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfamgmamumgmg*sfc*sfa*sfu*sfu*sfu*5fc*sfu,2OMe,NA,10,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfamgmamumgmg*sfc*sfa*sfu*sfu*sfu*5fc*sfu,2OMe,NA,3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,1.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*fa*fa*fg*fa*fu*fg*fg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,8.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*ma*ma*mg*mg*ma*ma*mg*ma*fu*mg*mg*fc*ma*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,4.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*fa*fa*fg*fg*fa*fa*fg*fa*mu*fg*fg*mc*fa*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,4.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*fc*ma*fa*mg*fg*ma*fa*mg*fa*mu*fg*mg*fc*ma*fu*mu*fu*mc*fu,2OMe,NA,10,uM,Skip,2.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*fa*fa*fg*fa*fu*fg*fg*fc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,2.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*ma*ma*mg*ma*mu*mg*mg*mc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,8.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*fc*ma*ma*fg*fg*ma*ma*fg*ma*mu*fg*fg*fc*ma*mu*mu*mu*fc*mu,2OMe,NA,10,uM,Skip,2.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*mc*fa*fa*mg*mg*fa*fa*mg*fa*fu*mg*mg*mc*fa*fu*fuqu*mcqu,2OMe,NA,10,uM,Skip,2.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sma*rma*rmg*rma*rmu*rmg*rmg*rmc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,22.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*smg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,15.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,29.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfamgmamumgmg*sfc*sfa*sfu*sfu*sfu*5fc*sfu,2OMe,NA,10,uM,Skip,4.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,18.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,1.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*fa*fa*fg*fa*fu*fg*fg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,3,uM,Skip,13.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*ma*ma*mg*mg*ma*ma*mg*ma*fu*mg*mg*fc*ma*fu*fu*fu*fc*fu,2OMe,NA,3,uM,Skip,4.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*fa*fa*fg*fg*fa*fa*fg*fa*mu*fg*fg*mc*fa*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,5.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*fc*ma*fa*mg*fg*ma*fa*mg*fa*mu*fg*mg*fc*ma*fu*mu*fu*mc*fu,2OMe,NA,3,uM,Skip,5.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*fa*fa*fg*fa*fu*fg*fg*fc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,2.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*ma*ma*mg*ma*mu*mg*mg*mc*fa*fu*fu*fu*fc*fu,2OMe,NA,3,uM,Skip,9.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*fc*ma*ma*fg*fg*ma*ma*fg*ma*mu*fg*fg*fc*ma*mu*mu*mu*fc*mu,2OMe,NA,3,uM,Skip,3.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*mc*fa*fa*mg*mg*fa*fa*mg*fa*fu*mg*mg*mc*fa*fu*fuqu*mcqu,2OMe,NA,3,uM,Skip,4.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sma*rma*rmg*rma*rmu*rmg*rmg*rmc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,37.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*smg*rma*rma*rmg*rma*rmu*rmg*rmg*rmc*rma*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,28.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,64.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfamgmamumgmg*sfc*sfa*sfu*sfu*sfu*5fc*sfu,2OMe,NA,3,uM,Skip,10.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,33.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,30,uM,Skip,2.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.3,uM,Skip,5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,5.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,16.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,32.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,30,uM,Skip,49.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15l0o1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.3,uM,Skip,0.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15l0o1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15l0o1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,16.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15l0o1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,32.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15l0o1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,30,uM,Skip,81.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.3,uM,Skip,0.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,4.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,46.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,30,uM,Skip,96.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.1,uM,Skip,0.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.3,uM,Skip,1.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,5.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,15.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,34.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*smufg*smgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.1,uM,Skip,1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*smufg*smgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.3,uM,Skip,2.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*smufg*smgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,4.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*smufg*smgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,10,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*smufg*smgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,22.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*sfumgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.1,uM,Skip,0.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*sfumgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.3,uM,Skip,0.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*sfumgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,0.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*sfumgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,1.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*sfumgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.1,uM,Skip,0.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.3,uM,Skip,1.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,4.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,8.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,19.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.1,uM,Skip,1.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.3,uM,Skip,2.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,4.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,12.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,27.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,0.1,uM,Skip,0.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,0.3,uM,Skip,0.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,1,uM,Skip,0.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumgmg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,15.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumgmg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,4.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumgmg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,1.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,22.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,10.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgmamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,4.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*smamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,22.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*smamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,9.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*smamumg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,4.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*smamu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,29.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*smamu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,14.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*smamu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,7.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,30.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,17,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*sfg*sma*rmu*sfg*sfg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,6.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*smufg*smgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,34.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*smufg*smgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,20.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgfa*smufg*smgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,8.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgfa*smufg*smg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,25.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgfa*smufg*smg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,9.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*sfa*sfa*smgfa*smufg*smg*sfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,3.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,1,uM,Skip,0.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,7.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,15.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,33,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,30,uM,Skip,49.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15l0o1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,8.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15l0o1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,15.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15l0o1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,35.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15l0o1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,30,uM,Skip,82.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15loo1*fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15loo1*fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,15.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15loo1*fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,47.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15loo1*fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,30,uM,Skip,82.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,8.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,19,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,55.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,30,uM,Skip,96.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1*fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,6.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1*fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,27.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1*fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,58.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1*fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,30,uM,Skip,90.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*fa*mamgmamumgmg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,1.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*fa*fa*mgmamumg*fg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,1.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*fa*fa*mg*ma*mu*mg*fg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,3.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*fa*fa*fg*ma*mu*fg*fg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,2.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*fa*ma*mg*ma*mu*mg*mg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*mamamgmafu*mgmg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,3.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*fg*fg*ma*ma*mg*ma*fu*mg*mg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,6.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*mg*mg*fa*fa*mg*ma*fu*mg*mg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,1.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*mg*mg*fa*fa*mgmamumg*mg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,0.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*mg*mg*fa*fa*mg*ma*mu*mg*mg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,1.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*mg*mg*ma*ma*mg*ma*fu*mg*mg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,2.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*mg*mg*fa*fa*mg*fa*fu*mg*mg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,1.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*mg*mg*fa*fa*mgmamumgmg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,0.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*mg*mg*fa*fa*mgmafu*mgmg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,0.7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,fu*fc*fa*fa*mg*mg*ma*ma*mgmafu*mgmg*fc*fa*fu*fu*fu*fc*fu,2OMe,NA,10,uM,Skip,1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,2.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo13lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,7.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo13lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,2.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo14lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modoo5lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,7.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modoo5lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,4.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo15lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo16lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,3.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo16lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo17lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,5.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo17lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,1.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo18lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,5.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo18lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,1.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo19lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,4.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo19lo01*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,1.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modoo6loo1*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,6.4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modoo6loo1*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,8.3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Oligonucleotide Compositions And Methods Thereof,US/2019/390197,DMD,exon,51,NA,human,RD Cells,Null,NA,modo2oloo1*mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/390197,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,WO2019231824A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,1.25,uM,Skip,0.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019231824A1,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,WO2019231824A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,2.5,uM,Skip,1.36,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019231824A1,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,WO2019231824A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,5,uM,Skip,2.19,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019231824A1,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,WO2019231824A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,10,uM,Skip,4.05,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019231824A1,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,WO2019231824A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,20,uM,Skip,6.94,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019231824A1,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,WO2019231824A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Null,NA,ctgttccaaatcctgcattgttgcc,unmodified PMO,NA,40,uM,Skip,12.94,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019231824A1,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,WO2019231824A1,DMD,exon,23,NA,mouse,mdx mice (injection at tail vein),Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,40,mg/kg,Skip,Null,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019231824A1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,tgtgtctttctcgccgccat,unmodified PMO,NA,0.3,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,tgtgtctttctcgccgccat,unmodified PMO,NA,1,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,tgtgtctttctcgccgccat,unmodified PMO,NA,3,uM,Skip,60,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,65,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,0.3,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,ccgccatttctc/gtgtctttctgag,unmodified PMO,NA,1,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,cgccgccattt/tctgttagcca,unmodified PMO,NA,1,uM,Skip,1,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,tctgttagccac/ttgtgtctttct,unmodified PMO,NA,1,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,ccgccatttctca/gtgtctttctgag,unmodified PMO,NA,1,uM,Skip,12,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,ctgttagccact/cgccgccatttc,unmodified PMO,NA,1,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,gccactgatt/actgttcagc,unmodified PMO,NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,gccactgatt/actgttcagc,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,ttgtgtctttct/tctgttagccac,unmodified PMO,NA,1,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,tctgttagcca/cgccgccattt,unmodified PMO,NA,1,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,ccgccatttctca/gtgtctttctgag,unmodified PMO,NA,1,uM,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,human,Human Rhabdomyosarcoma Cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,ctgttagccact/cgccgccatttc,unmodified PMO,NA,1,uM,Skip,4,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,attctcaggaatttgtttctcaaca,unmodified PMO,NA,unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,tctcaggaatttgtctcaacagatct,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctgagaaactgtttctcaacagatct,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,tgtgtctttcccgccatttc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,tgttcagcttctgtgttagccactga,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ttagccactgcgccgccatt,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,tgttcagctttagccactga,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctgttagccaccgccatttc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctgttagccactgcataatgaaaac,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,gccactgacctctcagcttctgtta,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,cgccgccatttcttttctgagaaact,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,aacgccgccatttctgagaaactgtt,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,cgccgccatttctgagaaact,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,tgttagccactgattgtgtctttctg,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctgttcagctccactgatta,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,actgttcagcccactgatta,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,tgtctttctgacgccatttctc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctgttcagcttgttagccac,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ttctgagaaactgttagccac,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctgttcagccactgatta,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctgagaaacttgttagccac,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,tgtctttctgaccgccatttct,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctttctgagaacgccatttctc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctttctgagaaacgccgcc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,tgtctttctgttagccatttctc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctttctgttagccatttctc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctttctgagagccatttctc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctgttagccactccgccatttc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctttctgagaaacgccgccatttc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,ctttctgagaaccgccatttc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,tgtctttctgagtcaaatcgcc,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,Unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
patent,Antisense Nucleic Acid For Use In The Treatment Of Duchenne's Muscular Dystrophy,EP3159409B1,DMD,exon,44,NA,unspecified,Null,Null,NA,gtgtctttctgagccgccatttctc,unmodified PMO,NA,unspecified,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/EP3159409B1,NA,NA,NA
journal article,Patient-Customized Oligonucleotide Therapy For A Rare Genetic Disease,PMID 31597037,MFSD8(CLN7),exon ,11,NA,human,Patient skin fibroblasts (c.1102G>C),Lipofectamine 3000,NA,aatgttagtgcttgttgagggc,2MOE,NA,100,nM,fraction of corrected splicing [%] following i6 skipping,34,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/31597037,NA,NA,NA
journal article,Patient-Customized Oligonucleotide Therapy For A Rare Genetic Disease,PMID 31597037,MFSD8(CLN7),exon ,11,NA,human,Patient,intrathecal injection,NA,aatgttagtgcttgttgagggc,2MOE,NA,"3.5 mg, 7 mg, 14 mg, 21 mg, 28 mg, 35 mg, 42 mg, 42 mg, 42 mg (every 2 week interval) followed by maintenance dose of 42 mg every 3 months",mg,unspecified,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/31597037,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,agguggccucaagaugcacaaagcuaaaagg,2OMe,NA,0.1,uM,Skip,10.37,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,auucuccagguggccucaagaugcacaaag,2OMe,NA,0.1,uM,Skip,23.85,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.1,uM,Skip,90.63,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.1,uM,Skip,85.94,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,A549  cells,Null,NA,uugucucuccgaauguguugcucccugguu,2OMe,NA,0.1,uM,Skip,40.25,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,A549  cells,Null,NA,uguugcucccugguuugaagagcaagacg,2OMe,NA,0.1,uM,Skip,16.82,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,A549  cells,Null,NA,gguagccuugucucuccgaauguguugc,2OMe,NA,0.1,uM,Skip,30.29,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,A549  cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.1,uM,Skip,84.18,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,13,NA,human,A549  cells,Null,NA,ugugaacaagggaaaugucuuuauuuuc,2OMe,NA,0.1,uM,Skip,6.86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,13,NA,human,Null,Null,NA,unspecified,2OMe,NA,unspecified,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,13,NA,human,A549  cells,Null,NA,guuucuucauguaccggacaauguuuguuu,2OMe,NA,0.1,uM,Skip,37.61,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,13,NA,human,A549  cells,Null,NA,augucuuuauuuuccaguuucuucaugua,2OMe,NA,0.1,uM,Skip,14.18,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,15,NA,human,Null,Null,NA,unspecified,2OMe,NA,unspecified,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,15,NA,human,Null,Null,NA,unspecified,2OMe,NA,unspecified,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,15,NA,human,Null,Null,NA,unspecified,2OMe,NA,unspecified,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,15,NA,human,Null,Null,NA,unspecified,2OMe,NA,unspecified,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,16,NA,human,Null,Null,NA,unspecified,2OMe,NA,unspecified,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,16,NA,human,A549  cells,Null,NA,uuucugguuuaaguaggcucggauagug,2OMe,NA,0.1,uM,Skip,45.23,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,16,NA,human,Null,Null,NA,unspecified,2OMe,NA,unspecified,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,16,NA,human,Null,Null,NA,unspecified,2OMe,NA,unspecified,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.002,uM,Skip,42.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.005,uM,Skip,51.09,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.01,uM,Skip,77.77,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.02,uM,Skip,90.81,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.04,uM,Skip,94.37,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.08,uM,Skip,93.78,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,A549  cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.002,uM,Skip,14.04,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,A549  cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.005,uM,Skip,41.31,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,A549  cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.01,uM,Skip,69.17,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,A549  cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.02,uM,Skip,77.77,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,A549  cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.08,uM,Skip,87.55,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.002,uM,Skip,20.56,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.005,uM,Skip,41.01,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.01,uM,Skip,61.47,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.02,uM,Skip,76.88,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.04,uM,Skip,95.26,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549  cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.08,uM,Skip,93.18,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.025,uM,Skip,28.53,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.05,uM,Skip,43.09,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.1,uM,Skip,66.38,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.15,uM,Skip,67.71,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.2,uM,Skip,77.24,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.25,uM,Skip,93.65,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.025,uM,Skip,16.88,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.05,uM,Skip,29.06,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.1,uM,Skip,38.06,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.15,uM,Skip,65.85,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.2,uM,Skip,59.76,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,tumour sphere cells,Null,NA,aagcuaaaaggucaguagcacagcaggccagg,2OMe,NA,0.25,uM,Skip,58.71,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,tumour sphere cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.025,uM,Skip,2.85,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,tumour sphere cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.05,uM,Skip,20.32,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,tumour sphere cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.1,uM,Skip,46.26,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,tumour sphere cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.15,uM,Skip,40.97,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,tumour sphere cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.2,uM,Skip,51.82,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,8,NA,human,tumour sphere cells,Null,NA,ucucuccgaauguguugcucccugguuuga,2OMe,NA,0.25,uM,Skip,59.24,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549 with Lipofectamin,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.1,uM,Skip,83.56,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,A549 without Lipofectamin,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.1,uM,Skip,2.01,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,TS32 with Lipofectamin,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.1,uM,Skip,79.86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Oligonucleotides,US/2019/309302,GLDC,exon,7,NA,human,TS32 without Lipofectamin,Null,NA,aaggucaguagcacagcaggccaggcu,2OMe,NA,0.1,uM,Skip,56.04,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/309302,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,17,NA,human,human  muscle  cells,unspecified,NA,ggugacagccugugaaaucugugagaagua,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,17,NA,human,human  muscle  cells,unspecified,NA,gugguggugacagccugugaaaucugugag,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,17,NA,human,human  muscle  cells,unspecified,NA,ugacagccugugaaaucugugag,2OMe,NA,0.2,uM,Skip,Skipping ex17+18,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,17,NA,human,human  muscle  cells,unspecified,NA,agugauggcugagugguggugacagc,2OMe,NA,0.05,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,17,NA,human,human  muscle  cells,unspecified,NA,acaguugucuguguuaguga,2OMe,NA,unspecified,Null,Skip,inconsistent skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,17,NA,human,human  muscle  cells,unspecified,NA,uguucccuuguggucaccguaguuac,2OMe,NA,0.05,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,17,NA,human,human  muscle  cells,unspecified,NA,cagaauccacaguaaucugc,2OMe,NA,0.3,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,2,NA,human,human  muscle  cells,unspecified,NA,ucucuuucaucuaaaaugcaaaau,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,2,NA,human,human  muscle  cells,unspecified,NA,cuuuugaacaucuucucuuucauc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,2,NA,human,human  muscle  cells,unspecified,NA,uuuugugaauguuuucuuuugaacaucuucuc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,2,NA,human,human  muscle  cells,unspecified,NA,auuuugugaauguuuucuuuugaa,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,2,NA,human,human  muscle  cells,unspecified,NA,uagaaaauugugcauuuacccauuuugugaa,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,2,NA,human,human  muscle  cells,unspecified,NA,accauucuuaccuuagaaaauugugcauuu,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,2,NA,human,human  muscle  cells,unspecified,NA,aaaguaacaaaccauucuuaccuu,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,aggucacugaagagguucucaauau,2OMe,NA,0.01,uM,Skip,Moderate skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,guaggucacugaagagguucu,2OMe,NA,0.05,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,aggaggcgucucccauccuguaggucacugaagag,2OMe,NA,unspecified,Null,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,aggucuaggaggcgccuccca,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,cuucgaggaggucuaggaggcgccuc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,gcccugucaggccuucgaggagguc,2OMe,NA,0.3,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,ucacauacaguuuuugcccugucag,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,uacaguuuuugcccugucagg,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,aagucacauacaguuuuugcccug,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,ucacauacaguuuuugccc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,uaggaggcgccucccauccuguaggucacug/gcccugucaggccuucgaggagguc,2OMe,NA,0.1,uM,Skip,Excellent skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,uaggaggcgccucccauccuguaggucacug/gcccugucaggccuucgaggagguc,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,gcccugucaggccuucgaggagguc/gcgccucccauccuguaggucacug,2OMe,NA,0.05,uM,Skip,Very strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,3,NA,human,human  muscle  cells,unspecified,NA,gcccugucaggccuucgaggagguc/aggaggcgucucccauccuguaggucacugaagag,2OMe,NA,0.05,uM,Skip,Very strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,4,NA,human,human  muscle  cells,unspecified,NA,gauccuuuuucuuuuggcugagaac,2OMe,NA,0.01,uM,Skip,Weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,4,NA,human,human  muscle  cells,unspecified,NA,ccgcagugccuuguugacauuguuc,2OMe,NA,0.01,uM,Skip,Good skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,4,NA,human,human  muscle  cells,unspecified,NA,guacuacuuacauuauuguucugca,2OMe,NA,0.01,uM,Skip,Very poor skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,4,NA,human,human  muscle  cells,unspecified,NA,uguucagggcaugaacucuuguggauccuu/guacuacuuacauuauuguucugca,2OMe,NA,0.1,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,4,NA,human,human  muscle  cells,unspecified,NA,uguucagggcaugaacucuuguggauccuu/guacuacuuacauuauuguucugca,2OMe,NA,0.005,uM,Skip,good skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,5,NA,human,human  muscle  cells,unspecified,NA,aaaccaagagucaguuuaugauuuccaucua,2OMe,NA,0.01,uM,Skip,Great skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,5,NA,human,human  muscle  cells,unspecified,NA,cuuaccugccaguggaggauuauauuccaaa,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,6,NA,human,human  muscle  cells,unspecified,NA,uucauuacauuuuugaccuacaugug,2OMe,NA,0.6,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,6,NA,human,human  muscle  cells,unspecified,NA,cuuuucacuguugguuuguugcaauc,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,unspecified,NA,human,human  muscle  cells,unspecified,NA,aauuacgaguugauugucggacccagcuc,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,6,NA,human,human  muscle  cells,unspecified,NA,auaauuacgaguugauugucggacccag,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,6,NA,human,human  muscle  cells,unspecified,NA,ggugaaguugauuacauuaaccugug,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,6,NA,human,human  muscle  cells,unspecified,NA,ucuuaccuaugacuauggaugaga,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,6,NA,human,human  muscle  cells,unspecified,NA,caguaaucuucuuaccuaugac,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,6,NA,human,human  muscle  cells,unspecified,NA,ucaguaaucuucuuaccuaugac,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,6,NA,human,human  muscle  cells,unspecified,NA,ugucucaguaaucuucuuaccuau,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,7,NA,human,human  muscle  cells,unspecified,NA,ucaaauaggucuggccuaaaac,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,7,NA,human,human  muscle  cells,unspecified,NA,ccagucaaauaggucuggccua,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,7,NA,human,human  muscle  cells,unspecified,NA,uguuccagucguuguguggcuga,2OMe,NA,0.05,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,7,NA,human,human  muscle  cells,unspecified,NA,ugcauguuccagucguuguguggcuga,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,7,NA,human,human  muscle  cells,unspecified,NA,uguugaaugcauguuccagucguugugu,2OMe,NA,0.025,uM,Skip,skippking but weak,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,7,NA,human,human  muscle  cells,unspecified,NA,ugaaugcauguuccagucguugu,2OMe,NA,0.025,uM,Skip,good skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,uggauaggugguaucaacaucuguaagcac,2OMe,NA,0.01,uM,Skip,Very weak skipping of 8+9,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,gauaggugguaucaacaucugu,2OMe,NA,0.01,uM,Skip,Very very weak skipping of 8+9,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,uaucuggauaggugguaucaacaucuguaa,2OMe,NA,0.01,uM,Skip,Weak skipping of 8+9,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,gauaggugguaucaacaucugu,2OMe,NA,0.04,uM,Skip,works strongly,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,aaacuuggaagagugaugugaugua,2OMe,NA,0.01,uM,Skip,good skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,gcucacuuguugaggcaaaacuuggaa,2OMe,NA,0.01,uM,Skip,good skipping of 8+9 at high conc,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,gccuuggcaacauuuccacuuccug,2OMe,NA,0.3,uM,Skip,Weak skipping of 8+9,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,auguaacugaaaauguucuucuuua,2OMe,NA,0.1,uM,Skip,Weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,uacacacuuuaccuguugagaauag,2OMe,NA,0.05,uM,Skip,Weak skipping of 8+9 Exon8 Cocktails,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,uaucuggauaggugguaucaacaucuguaa/auguaacugaaaauguucuucuuua,2OMe,NA,0.01,uM,Skip,Good skipping (8+9) but also 8 on its own,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,uaucuggauaggugguaucaacaucuguaa/uacacacuuuaccuguugagaauag,2OMe,NA,0.01,uM,Skip,Good skipping (8+9) but also 8 on its own,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,uaucuggauaggugguaucaacaucuguaa/gcucacuuguugaggcaaaacuuggaa,2OMe,NA,0.01,uM,Skip,Good skipping (8+9) but also 8 on its own,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,8,NA,human,human  muscle  cells,unspecified,NA,uaucuggauaggugguaucaacaucuguaa/gccuuggcaacauuuccacuuccug,2OMe,NA,0.01,uM,Skip,Good skipping (8+9) but also 8 on its own,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,9,NA,human,human  muscle  cells,unspecified,NA,agcagccuguguguaggcauagcucuugaau,2OMe,NA,0.1,uM,Skip,working strongly,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,9,NA,human,human  muscle  cells,unspecified,NA,agaccugugaaggaaaugggcuccguguag,2OMe,NA,0.2,uM,Skip,working strongly,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,10,NA,human,human  muscle  cells,unspecified,NA,caggagcuuccaaaugcugcacaau,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,10,NA,human,human  muscle  cells,unspecified,NA,ugacuugucuucaggagcuu,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,10,NA,human,human  muscle  cells,unspecified,NA,caaugaacugccaaaugacuug,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,10,NA,human,human  muscle  cells,unspecified,NA,acucuccaucaaugaacugccaaau,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,10,NA,human,human  muscle  cells,unspecified,NA,cuguuugauaacgguccagguuuac,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,10,NA,human,human  muscle  cells,unspecified,NA,gccacgauaauacuucuucuaaag,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,10,NA,human,human  muscle  cells,unspecified,NA,uuaguuuaccucaugaguaugaaac,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,10,NA,human,human  muscle  cells,unspecified,NA,caggagcuuccaaaugcugca/uccucagcagaaagaagccacg,2OMe,NA,0.2,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,10,NA,human,human  muscle  cells,unspecified,NA,caggagcuuccaaaugcugca/uuagaaaucucuccuugugc,2OMe,NA,0.2,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,ccaucauguaccccugacaa,2OMe,NA,0.3,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,cccugaggcauucccaucuugaau,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,auuaccaacccggcccugaugggcug,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,uccaaucagcuuacuucccaauuguagaau,2OMe,NA,0.01,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,uccaaucagcuuacuucccaauuguagaau,2OMe,NA,0.0025,uM,Skip,hint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,uccaaucagcuuacuucccaauugua,2OMe,NA,0.01,uM,Skip,Stong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,uccaaucagcuuacuucccaauugua,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,cuguuccaaucagcuuacuucccaauugua,2OMe,NA,0.005,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,cuguuccaaucagcuuacuucccaauugua,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,aguuucuucaucuucugauaauuuuc,2OMe,NA,0.025,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,auuuaggagauucaucugcucuuguacuuc,2OMe,NA,0.025,uM,Skip,Strong skipping (20%),NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,auuuaggagauucaucugcucuugua,2OMe,NA,0.025,uM,Skip,Strong skipping (20%),NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,11,NA,human,human  muscle  cells,unspecified,NA,uugaauuuaggagauucaucugcucuugua,2OMe,NA,0.025,uM,Skip,Strong skipping (20%),NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,12,NA,human,human  muscle  cells,unspecified,NA,cauaagauacaccuaccuuaug,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,12,NA,human,human  muscle  cells,unspecified,NA,ucuucuguuuuuguuagccaguca,2OMe,NA,unspecified,Null,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,12,NA,human,human  muscle  cells,unspecified,NA,cagucauucaacucuuucaguuucugau,2OMe,NA,0.01,uM,Skip,Strong  skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,12,NA,human,human  muscle  cells,unspecified,NA,uuccuuguucuuucuucuguuuuuguua,2OMe,NA,0.025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,12,NA,human,human  muscle  cells,unspecified,NA,agaucagguccaagaggcucuuccucca,2OMe,NA,0.025,uM,Skip,Strong skipping (30%),NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,12,NA,human,human  muscle  cells,unspecified,NA,uguuguuguacuuggcguuuuaggucuu,2OMe,NA,0.025,uM,Skip,Strong skipping (30%),NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,13,NA,human,human  muscle  cells,unspecified,NA,uucuugaagcaccugaaagauaaa,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,14,NA,human,human  muscle  cells,unspecified,NA,gaaggaugucuuguaaaagaacccagcgg,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,16,NA,human,human  muscle  cells,unspecified,NA,cuagauccgcuuuuaaaaccuguuaa,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,16,NA,human,human  muscle  cells,unspecified,NA,gcuuuuucuuuucuagauccgcu,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,16,NA,human,human  muscle  cells,unspecified,NA,cacuaaccugugcuguacucuuuuc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,17,NA,human,human  muscle  cells,unspecified,NA,uguggucaccguaguuacuguuuccauucaa,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,17,NA,human,human  muscle  cells,unspecified,NA,guucccuuguggucaccguaguuacuguuuc,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,18,NA,human,human  muscle  cells,unspecified,NA,caacauccuuccuaagacug,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,18,NA,human,human  muscle  cells,unspecified,NA,gcgaguaauccagcugugaa,2OMe,NA,unspecified,Null,Skip,In consistent skipping of both exon 17+18,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,18,NA,human,human  muscle  cells,unspecified,NA,uucaggacucugcaacagagcuucugagcg,2OMe,NA,0.3,uM,Skip,Skipping exons 17+18,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,18,NA,human,human  muscle  cells,unspecified,NA,uugucugugaaguugccuuccuuccg,2OMe,NA,0.3,uM,Skip,Skipping exons 17+18,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,18,NA,human,human  muscle  cells,unspecified,NA,uuaaugcauaaccuacauug,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,19,NA,human,human  muscle  cells,unspecified,NA,ggcaucuugcaguuuucugaacuucucagc,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,19,NA,human,human  muscle  cells,unspecified,NA,ucugcuggcaucuugcaguuuucugaac,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,19,NA,human,human  muscle  cells,unspecified,NA,ucaacucguguaauuaccgu,2OMe,NA,unspecified,Null,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,20,NA,human,human  muscle  cells,unspecified,NA,guucaguuguucugaggcuuguuug,2OMe,NA,0.6,uM,Skip,faint shadow,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,20,NA,human,human  muscle  cells,unspecified,NA,aguaguugucaucugcuccaauugu,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,23,NA,human,human  muscle  cells,unspecified,NA,cggcuaauuucagagggcgcuuucuuugac,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,24,NA,human,human  muscle  cells,unspecified,NA,caagggcaggccauuccuccuuc,2OMe,NA,0.025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,25,NA,human,human  muscle  cells,unspecified,NA,ugggcugaauugucugaauaucac,2OMe,NA,0.025,uM,Skip,strong but did not reduce the full length product,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,25,NA,human,human  muscle  cells,unspecified,NA,gagauugucuauaccuguug,2OMe,NA,0.025,uM,Skip,very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,25,NA,human,human  muscle  cells,unspecified,NA,agacugggcugaauugucugaauaucacu,2OMe,NA,0.005,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,25,NA,human,human  muscle  cells,unspecified,NA,agacugggcugaauugucugaauaucacu,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,25,NA,human,human  muscle  cells,unspecified,NA,uugaguucuguucucaagucucgaag,2OMe,NA,0.025,uM,Skip,Strong skipping (patient specific),NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,25,NA,human,human  muscle  cells,unspecified,NA,uugaguucuguucucaagucucgaag,2OMe,NA,0.005,uM,Skip,faint (patientspecific),NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,25,NA,human,human  muscle  cells,unspecified,NA,gagauugucuauaccuguuggcacaug,2OMe,NA,0.01,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,ggcauagaccuuccacaaaacaaac,2OMe,NA,0.6,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,ggcauagaccuuccacaaaacaaac,2OMe,NA,0.3,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,aaggccuccuuucuggcauagaccuuccac,2OMe,NA,0.6,uM,Skip,"Faint, multiple exons 26-29 or 27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,aaggccuccuuucuggcauagaccuuccac,2OMe,NA,0.3,uM,Skip,"Faint, multiple exons 26-29 or 27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,cuucaaggccuccuuucuggcauagaccuu,2OMe,NA,0.6,uM,Skip,"Faint, multiple exons 26-29 or 27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,cuucaaggccuccuuucuggcauagaccuu,2OMe,NA,0.3,uM,Skip,"Faint, multiple exons 26-29 or 27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,aaccucccuucaaggccuccuuucuggcau,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,cuuacaguuuucuccaaaccucccuuc,2OMe,NA,0.6,uM,Skip,"Faint, multiple exons 26-29 or2 7-30",NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,cuuacaguuuucuccaaaccucccuuc,2OMe,NA,0.3,uM,Skip,"Faint, multiple exons 26-29 or2 7-30",NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,uuucuuuuuuuuuuuuuaccuucau,2OMe,NA,0.6,uM,Skip,"Faint, multiple exons 26-29 or 27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,uuaccuucaucucuucaacugcuuu,2OMe,NA,unspecified,Null,Skip,multiple exons 26-29 or 27-30,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,uuuuuuuuaccuucaucucu,2OMe,NA,unspecified,Null,Skip,Not skipping 26 other bands,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,26,NA,human,human  muscle  cells,unspecified,NA,ccuccuuucuggcauagaccuuccac/cuuacaguuuucuccaaaccucccuuc/ugugucauccauucgugcaucucug,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,31,NA,human,human  muscle  cells,unspecified,NA,uucugaaauuucauauaccugugcaacauc,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,31,NA,human,human  muscle  cells,unspecified,NA,uaguuucugaaauaacauauaccugugcaa,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,31,NA,human,human  muscle  cells,unspecified,NA,cuuaguuucugaaauaacauauaccugugc,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,31,NA,human,human  muscle  cells,unspecified,NA,uaguuucugaaauaacauauaccu,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,31,NA,human,human  muscle  cells,unspecified,NA,ccuuaguuucugaaauaacauauacc,2OMe,NA,0.3,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,32,NA,human,human  muscle  cells,unspecified,NA,acuuucuuguagacgcugcucaaaauuggc,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,34,NA,human,human  muscle  cells,unspecified,NA,uuucgcaucuuacgggacaauuuc,2OMe,NA,0.2,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,34,NA,human,human  muscle  cells,unspecified,NA,cauucauuuccuuucgcaucuuacgggaca,2OMe,NA,0.2,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,34,NA,human,human  muscle  cells,unspecified,NA,gacauucauuuccuuucgcaucuuacggga,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,34,NA,human,human  muscle  cells,unspecified,NA,ucugucaagacauucauuuccuuucgcauc,2OMe,NA,0.2,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,34,NA,human,human  muscle  cells,unspecified,NA,ugaucucuuugucaauuccauaucuguagc,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,34,NA,human,human  muscle  cells,unspecified,NA,cugaucucuuugucaauuccauaucugugg,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,34,NA,human,human  muscle  cells,unspecified,NA,ugaucucuuugucaauuccauaucug,2OMe,NA,0.025,uM,Skip,Faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,34,NA,human,human  muscle  cells,unspecified,NA,cugcugaucucuuugucaauuccauaucug,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,35,NA,human,human  muscle  cells,unspecified,NA,ucuucaggugcaccuucuguuucucaaucu,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,35,NA,human,human  muscle  cells,unspecified,NA,ucugugauacucuucaggugcaccuucugu,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,cugguauuccuuaauuguacagaga,2OMe,NA,0,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,ccauguguuucugguauucc,2OMe,NA,0.3,uM,Skip,very faint skipping 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,cacauucuggucaaaaguuuccauguguuu,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,ugugaugugguccacauucuggucaaaagu,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,ugugaugugguccacauucugguca,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,cacuuugugaugugguccacauucugguca,2OMe,NA,0.3,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,ugauccacuuugugaugugguccacauucu,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,aagugugucagccugaauga,2OMe,NA,unspecified,Null,Skip,very weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,ucucugauucauccaaaagugugucagccu,2OMe,NA,0.6,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,ucucugauucauccaaaagugugucagccu,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,gcugggguuucuuuuucucugauucaucca,2OMe,NA,0.6,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,gcugggguuucuuuuucucugauucaucca,2OMe,NA,0.025,uM,Skip,skipoping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,uauuugcuaccuuaagcacgucuuc,2OMe,NA,unspecified,Null,Skip,very weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,36,NA,human,human  muscle  cells,unspecified,NA,cugguauuccuuaauuguacagaga/ugugaugugguccacauucuggucaaaagu,2OMe,NA,0.025,uM,Skip,good skipping down to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,38,NA,human,human  muscle  cells,unspecified,NA,cuaaaaaaaaagauagugcua,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,38,NA,human,human  muscle  cells,unspecified,NA,aaaggaauggaggccuaaaaaaaaag,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,38,NA,human,human  muscle  cells,unspecified,NA,aaccaauuuaccauaucuuuauuga,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,39,NA,human,human  muscle  cells,unspecified,NA,acaguaccaucauugucuucauucugauc,2OMe,NA,0.6,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,39,NA,human,human  muscle  cells,unspecified,NA,acaguacccucauugucuucauucugauc,2OMe,NA,0.6,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,39,NA,human,human  muscle  cells,unspecified,NA,cucucgcuuucucucaucugugauucuuug,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,39,NA,human,human  muscle  cells,unspecified,NA,uccucucgcuuucucucaucugugauucuu,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,39,NA,human,human  muscle  cells,unspecified,NA,uauguuuugucuguaacagcugcug,2OMe,NA,0.6,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,41,NA,human,human  muscle  cells,unspecified,NA,auuuccuauugagcaaaacc,2OMe,NA,0.2,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,41,NA,human,human  muscle  cells,unspecified,NA,cauugcggccccauccucagacaag,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,41,NA,human,human  muscle  cells,unspecified,NA,gcugagcuggaucugaguuggcuccacug,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,41,NA,human,human  muscle  cells,unspecified,NA,guugagucuucgaaacugagcaaauuugc,2OMe,NA,unspecified,Null,Skip,No visible skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,41,NA,human,human  muscle  cells,unspecified,NA,ccaguaacaacucacaauuu,2OMe,NA,0.2,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,42,NA,human,human  muscle  cells,unspecified,NA,accuucagagacuccucuugc,2OMe,NA,unspecified,Null,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,uccuguagcuucacccuuuccacaggcg,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,gagagcuuccuguagcuucacccuuu,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,aaucagcugggagagagcuuccuguagcu,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,uguguuaccuacccuugucg,2OMe,NA,0.2,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,uagacuaucuuuuauauucuguaauau,2OMe,NA,0.025,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,gagagcuuccuguagcuucacccuuucca,2OMe,NA,0.025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,gagagcuuccuguagcuucacccuuucca,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,uuccuguagcuucacccuuuccacaggcguu,2OMe,NA,0.05,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,uuccuguagcuucacccuuuccacaggcguu,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,agcuuccuguagcuucacccuuu,2OMe,NA,0.0025,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,ggagagagcuuccuguagcuucacccuuu,2OMe,NA,0.01,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,ggagagagcuuccuguagcuucacccuuu,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,gagagcuuccuguagcuucaccc,2OMe,NA,0.025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,43,NA,human,human  muscle  cells,unspecified,NA,gagagcuuccuguagcuucaccc,2OMe,NA,0.01,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,ucugucaaaucgccugcagguaaaag,2OMe,NA,unspecified,Null,Skip,unspesified,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,uucucaacagaucugucaaaucgccugcag,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,gccacugauuaaauaucuuuauauc,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,ucuguuagccacugauuaaauaucuuuaua,2OMe,NA,0.05,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,uguucagcuucuguuagccacuga,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,gagaaacuguucagcuucuguuagccacuga,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,uguucagcuucuguuagccacuga,2OMe,NA,0.01,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,ucuuucugagaaacuguucagcuucuguuag,2OMe,NA,0.05,uM,Skip,weak,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,cagaucugucaaaucgccugcaggua,2OMe,NA,0.01,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,caacagaucugucaaaucgccugcag,2OMe,NA,0.0025,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,aaacuguucagcuucuguuagccacugauuaaa,2OMe,NA,0.005,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,aaacuguucagcuucuguuagccacugauuaaa,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,cuguucagcuucuguuagccacugauu,2OMe,NA,0.005,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,gaaacuguucagcuucuguuagccacugauu,2OMe,NA,0.01,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,aaacuguucagcuucuguuagccacuga,2OMe,NA,0.025,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,ugagaaacuguucagcuucuguuagcca,2OMe,NA,0.025,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,uucugagaaacuguucagcuucuguuagccac,2OMe,NA,0.025,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,uucugagaaacuguucagcuucuguu,2OMe,NA,0.05,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcugcccaaugccauccuggaguuccuguaag,2OMe,NA,unspecified,Null,Skip,Generates multiple bands,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,ccaaugccauccuggaguuccuguaagaua,2OMe,NA,0.01,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,uugccgcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.01,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,caaugccauccuggaguuccuguaaga,2OMe,NA,0.05,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcugcccaaugccauccuggaguuccuguaag,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,caguuugccgcugcccaaugccaucc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,cuuccccaguugcauucaauguuc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,cuggcaucuguuuuugaggauug,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,uuagaucugucgcccuaccu,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcugcccaaugccauccuggaguuccuguaagauaccaa,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcccaaugccauccuggaguuccuguaagauacc,2OMe,NA,0.005,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcccaaugccauccuggaguuccuguaagauacc,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,cauccuggaguuccuguaagauacc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,ugccauccuggaguuccuguaagauacc,2OMe,NA,0.025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,ugccauccuggaguuccuguaagauacc,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,ugccauccuggaguuccuguaagau,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,caaugccauccuggaguuccuguaagau,2OMe,NA,0.025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,caaugccauccuggaguuccuguaagau,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.01,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,uugccgcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.005,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,uugccgcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcugcccaaugccauccuggaguuccuguaag,2OMe,NA,0.0025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcccaaugccauccuggaguuccuguaa,2OMe,NA,0.005,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcccaaugccauccuggaguuccuguaa,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gccgcugcccaaugacauccuggaguuccuguaa,2OMe,NA,0.0025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,caaugccauccuggaguuccug,2OMe,NA,0.005,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,caaugccauccuggaguuccug,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcccaaugccauccuggaguuccug,2OMe,NA,0.01,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcccaaugccauccuggaguuccug,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcugcccaaugccauccuggaguuccug,2OMe,NA,0.0025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gccgcugcccaaugccauccuggaguuccug,2OMe,NA,0.01,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gccgcugcccaaugccauccuggaguuccug,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,auuagaucugucgcccuaccucuuuuuuc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,ugucgcccuaccucuuuuuucugucug,2OMe,NA,0.0025,uM,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,gcugcccaaugccauccuggaguuccuguaa,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,caaugccauccuggaguuccuguaagauacc,2OMe,NA,unspecified,Null,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,auucuuuuguucuucuagccugga,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,ucucuuugaaauucugacaagauauuc,2OMe,NA,0.025,uM,Skip,"skipping, other bands",NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,uuaaaucucuuugaaauucu,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,aaaacaaauucauuuaaaucucuuug,2OMe,NA,0.05,uM,Skip,very faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,cugcuuccuccaaccauaaaac,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,gcaauguuaucugcuuccuccaacc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,uccagguucaagugggauacuagcaaugu,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,uucaagugggauacuagcaau,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,uccagguucaagugggauac,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,cugcucuuuuccagguucaagugggaua,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,guugcugcucuuuuccagguucaagugg,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,cuuuuaguugcugcucuuuuccagguuc,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,aagcuuuucuuuuaguugcugcuc,2OMe,NA,0.1,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,gcuuuucuuuuaguugcugc,2OMe,NA,0.1,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,gacuugcucaagcuuuucuuuuaguugcug,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,uucagaaaauaaaauuaccu,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,guugcugcucuuuuccagguucaaguggga,2OMe,NA,0.025,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,guugcugcucuuuuccagguucaaguggga,2OMe,NA,0.005,uM,Skip,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,46,NA,human,human  muscle  cells,unspecified,NA,uaguugcugcucuuuuccagguucaagugg,2OMe,NA,0.025,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,44,NA,human,human  muscle  cells,unspecified,NA,agaaacuguucagcuucuguuagcca/ccaaugccauccuggaguuccuguaagaua,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,ccaaugccauccuggaguuccuguaagaua/cugcucuuuuccagguucaggugggaua,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,ccaaugccauccuggaguuccuguaagaua/caagcuuuucuuuuaguugcugcucuuuucc,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,45,NA,human,human  muscle  cells,unspecified,NA,ccaaugcauccuggaguuccuguaagaua/agaaacuguucagcuucuguuagcca/cugcucuuuuccagguucaggugggaua,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,47,NA,human,human  muscle  cells,unspecified,NA,gcaacucuuccaccaguaacugaaac,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,47,NA,human,human  muscle  cells,unspecified,NA,uggcgcaggggcaacucuuccaccaguaa,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,47,NA,human,human  muscle  cells,unspecified,NA,gcacggguccuccaguuucauuuaauu,2OMe,NA,0.6,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,47,NA,human,human  muscle  cells,unspecified,NA,gggcuuaugggagcacuuacaagca,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,47,NA,human,human  muscle  cells,unspecified,NA,cuugcucuucugggcuuaugggagcacuuac,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,47,NA,human,human  muscle  cells,unspecified,NA,cuugcucuucugggcuuaugggagcacu,2OMe,NA,0.2,uM,Skip,"Faint skipping,full length product not reduced",NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,47,NA,human,human  muscle  cells,unspecified,NA,aaugucuaaccuuuauccacuggagau,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,cucagguaaagcucuggaaaccugaaagga,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,cagguaaagcucuggaaaccugaaagg,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,uucucagguaaagcucuggaaaccugaaag,2OMe,NA,0.6,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,uucucagguaaagcucuggaaaccugaaag,2OMe,NA,0.3,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,guuucucagguaaagcucuggaaaccugaa,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,cuuguuucucagguaaagcucuggaaac,2OMe,NA,0.05,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,uucuccuuguuucucagguaaagcucu,2OMe,NA,0.05,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,caagcugcccaaggucuuuuauuugagc,2OMe,NA,unspecified,Null,Skip,No skipping (sporadic),NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,uuaacugcucuucaaggucuucaagc,2OMe,NA,1,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,gauaaccacagcagcagaugauuuaac,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,aguucccuaccugaacgucaaaugguc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,guucccuaccugaacgucaaauggu,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,48,NA,human,human  muscle  cells,unspecified,NA,cuuguuucucagguaaagcucuggaaac/caagcugcccaaggucuuuuauuugagc,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,49,NA,human,human  muscle  cells,unspecified,NA,gaacugcuauuucaguuuccugggga,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,49,NA,human,human  muscle  cells,unspecified,NA,aucucuuccacauccgguuguuuagc,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,49,NA,human,human  muscle  cells,unspecified,NA,acaaaugcugcccuuuagacaaaauc,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,49,NA,human,human  muscle  cells,unspecified,NA,uucauuaccuucacuggcugaguggc,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,cucagaucuucuaacuuccucuuuaac,2OMe,NA,0.025,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,cucagagcucagaucuucuaacuuccucu,2OMe,NA,0.1,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,cgccuuccacucagagcucagaucuuc,2OMe,NA,0.025,uM,Skip,skipping faintly,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,ucagcucuugaaguaaacgguuuaccg,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,uuugcccucagcucuugaaguaaacgg,2OMe,NA,0.025,uM,Skip,reasonable skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,ggcugcuuugcccucagcucuugaagu,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,caggagcuaggucaggcugcuuugcc,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,uccaauaguggucaguccaggagcu,2OMe,NA,unspecified,Null,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,aaagagaaugggauccaguauacuuac,2OMe,NA,0.1,uM,Skip,faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,aaauagcuagagccaaagagaauggga,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,ggcugcuuugcccucagcucuugaaguaaacgg,2OMe,NA,0.01,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,ggcugcuuugcccucagcucuugaaguaaacgg,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,aggcugcuuugcccucagcucuugaaguaa,2OMe,NA,0.025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,aggcugcuuugcccucagcucuugaaguaa,2OMe,NA,0.01,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,gucaggcugcuuugcccucagcucuugaagu,2OMe,NA,0.01,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,gucaggcugcuuugcccucagcucuugaagu,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,aggucaggcugcuuugcccucagcucuuga,2OMe,NA,0.025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,50,NA,human,human  muscle  cells,unspecified,NA,aggucaggcugcuuugcccucagcucuuga,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,49,NA,human,human  muscle  cells,unspecified,NA,aagauaauucaugaacaucuuaaucca,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,uuuggguuuuugcaaaaagg,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,cuaaaauauuuuggguuuuugc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,ugaguaggagcuaaaauauuuugg,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,guuuccuuaguaaccacagguuguguc,2OMe,NA,0.025,uM,Skip,very faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,aguuuggagauggcaguuuccuuaguaa,2OMe,NA,0.025,uM,Skip,skippig also skips 50 or 52 a well,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,uggcauuucuag,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,agauggcauuucuag,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,ggaagauggcauuucuag,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,cuccaacaucaaggaaga,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,cuccaacaucaagga,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,cuccaacaucaa,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,gaaaucugccagagcagguaccuccaa,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,gauggcauuucuaguuuggagauggca,2OMe,NA,0.025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,aaggaagauggcauuucuaguuuggagau,2OMe,NA,0.025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,aaggaagauggcauuucuaguuuggagau,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,gguaccuccaacaucaaggaagauggcauu,2OMe,NA,0.005,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,agcagguaccuccaacaucaaggaagaug,2OMe,NA,0.025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,ccugcauuguugccuguaagaacaa,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,gcauuguugccuguaagaac,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,gggacgccucuguuccaaauccugcau,2OMe,NA,0.05,uM,Skip,skippping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,guucuuccaacuggggacgccucuguucca,2OMe,NA,0.025,uM,Skip,skippping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,acuggggacgccucuguucca,2OMe,NA,0.025,uM,Skip,skippping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,ccucuugauugcuggucuuguuuuucaa,2OMe,NA,0.025,uM,Skip,very very faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,51,NA,human,human  muscle  cells,unspecified,NA,uaccccuuaguaucaggguucuucagc,2OMe,NA,unspecified,Null,Skip,No skipping (SNPCorT),NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,aacuggggacgccucuguuccaaauccugc,2OMe,NA,0.0025,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,uccaacuggggacgccucuguuccaaauccugc,2OMe,NA,0.005,uM,Skip,Strong skipping to 5 nM faint at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,uccaacuggggacgccucuguuccaaauccugc,2OMe,NA,0.005,uM,Skip,Strong skipping to 5 nM faint at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,ucuuccaacuggggacgccucuguuccaaa,2OMe,NA,0.01,uM,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,ucuuccaacuggggacgccucuguuccaaa,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,auaguaguaaaugcuagucuggag,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,gaaaaauaaauauauaguaguaaaug,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,auaaaaggaaaaauaaauauauaguag,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,ucugaauucuuucaacuagaauaaaaggaa,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,caacuguugccuccgguucugaaggug,2OMe,NA,0.05,uM,Skip,sklppping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,sklppping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,cguucaacuguugccuccgguucugaaggug,2OMe,NA,0.025,uM,Skip,sklppping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,ucauucaacuguugccuccgguucugaaggu,2OMe,NA,0.05,uM,Skip,sklppping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,cauucaacuguugccuccgguucugaagg,2OMe,NA,0.05,uM,Skip,sklppping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,cauucaacuguugccuccgguucugaa,2OMe,NA,0.05,uM,Skip,sklppping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,cagccauuguguugaauccuuuaacauuuc,2OMe,NA,0.05,uM,Skip,sklppping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,52,NA,human,human  muscle  cells,unspecified,NA,uauauaguaguaaaugcuagucugg,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,ccuccgguucugaagguguucuuguacuuc,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,ccuccgguucugaagguguucuuguacuuc,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uugccuccgguucugaagguguucuuguacuuc,2OMe,NA,0.01,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uugccuccgguucugaagguguucuuguacuuc,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uugccuccgguucugaagguguucuuguac,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,aacuguugccuccgguucugaagguguucuuguac,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,aacuguugccuccgguucugaagguguucuuguac,2OMe,NA,0.01,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,cauucaacuguugccuccgguucugaagguguucuuguac,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,cauucaacuguugccuccgguucugaagguguucuuguac,2OMe,NA,0.002,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,acuguugccuccgguucugaagguguucuug,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,acuguugccuccgguucugaagguguucuug,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uucaacuguugccuccgguucugaagguguucuug,2OMe,NA,0.05,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uucaacuguugccuccgguucugaagguguucuug,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,caacuguugccuccgguucugaagguguucuug,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,caacuguugccuccgguucugaagguguucuug,2OMe,NA,0.0025,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uucaacuguugccuccgguucugaagguguucu,2OMe,NA,unspecified,Null,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uucaacuguugccuccgguucugaagguguu,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,ucauucaacuguugccuccgguucugaagguguuc,2OMe,NA,0.005,uM,Skip,reasonable sipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uucauucaacuguugccuccgguucugaaggug,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uucauucaacuguugccuccgguucugaag,2OMe,NA,0.1,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,53,NA,human,human  muscle  cells,unspecified,NA,uucauucaacuguugccuccgguucugaag,2OMe,NA,0.005,uM,Skip,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,54,NA,human,human  muscle  cells,unspecified,NA,uugucugccacuggcggagguc,2OMe,NA,0.3,uM,Skip,Skipping brings out 55+54,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,54,NA,human,human  muscle  cells,unspecified,NA,aucugcagaauaaucccggagaaguuucag,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,54,NA,human,human  muscle  cells,unspecified,NA,ucugcagaauaaucccggagaag,2OMe,NA,0.04,uM,Skip,Weak skipping both 54+55,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,54,NA,human,human  muscle  cells,unspecified,NA,uggucucaucugcagaauaaucccggagaag,2OMe,NA,0.01,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,54,NA,human,human  muscle  cells,unspecified,NA,ggacuuuucugguaucaucugcagaauaau,2OMe,NA,0.05,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,54,NA,human,human  muscle  cells,unspecified,NA,uggucucaucugcagaauaaucccggagaag/cucgcucacucacccugcaaagga,2OMe,NA,0.01,uM,Skip,Specific for 54&55 Skipping No additional bands,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,cucgcucacucacccugcaaagga,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,cagccucucgcucacucacccugcaaagga,2OMe,NA,0.01,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,cagggggaacuguugcaguaauc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,ucuuuuacucccuuggagucuucuaggagcc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,ucuguaagccaggcaagaaac,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,ccuuacggguagcauccugauggacauuggc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,cuuacggguagcauccuguaggaca,2OMe,NA,0.1,uM,Skip,very weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,ccuuggagucuucuaggagccuuuccuuac,2OMe,NA,0.2,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,cuuggagucuucuaggagcc,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,cucuuuuacucccuuggagucuucuaggag,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,55,NA,human,human  muscle  cells,unspecified,NA,ccugacuuacuugccauugu,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,gcuucaauuucaccuuggagguccuacag,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,uucaccuuggagguccuacag,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,guugugauaaacaucuguguga,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,ccagggaucucaggauuuuuuggcug,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,cggaaccuuccagggaucucaggau,2OMe,NA,0.2,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,ccaaacgucuuuguaacaggacugcau,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,guuauccaaacgucuuuguaacagg,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,uucauguuauccaaacgucuuuguaacagg,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,ccacuugaaguucauguuauccaaacgucu,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,ucacuccacuugaaguucauguuauccaaa,2OMe,NA,0.025,uM,Skip,skipping weakly,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,cuccacuugaaguucauguuauc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,56,NA,human,human  muscle  cells,unspecified,NA,cuuuuccuaccaaauguugag,2OMe,NA,0.06,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,57,NA,human,human  muscle  cells,unspecified,NA,cuggcuuccaaaugggaccugaaaaagaacagc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,57,NA,human,human  muscle  cells,unspecified,NA,cuggcuuccaaaugggaccugaaaaagaac,2OMe,NA,0.05,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,57,NA,human,human  muscle  cells,unspecified,NA,aacuggcuuccaaaugggaccugaaaaaga,2OMe,NA,0.3,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,57,NA,human,human  muscle  cells,unspecified,NA,ucagaacuggcuuccaaaugggaccugaaa,2OMe,NA,0.3,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,57,NA,human,human  muscle  cells,unspecified,NA,ggugcagacgcuuccacuggucag,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,57,NA,human,human  muscle  cells,unspecified,NA,gcuguagccacaccagaaguuccugcagaga,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,57,NA,human,human  muscle  cells,unspecified,NA,cugccggcuuaauucaucaucuuuc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,57,NA,human,human  muscle  cells,unspecified,NA,cugcuggaaagucgccuccaauaggug,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,uccucaggaggcagcucuaaau,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,uccucgccugcuuucguagaagccgaguga,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,agguucaauuuuucccacucaguauu,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,cuauuuuucucugccagucagcgga,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,cucaucuauuuuucucugccagucagcgga,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,cagggucucaucuauuuuucucugccaguca,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,cauccguggccucuugaaguuccug,2OMe,NA,0.2,uM,Skip,Skipping exon 58&59,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,agguccagcucauccguggccucuu,2OMe,NA,0.3,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,gcgcagcuugagguccagcucaucc,2OMe,NA,0.2,uM,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,gcuuggcgcagcuugagguccagcucaucc,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,caccucagcuuggcgcagcuugagguc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,cccuugaucaccucagcuuggcgca,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,acgggcugccaggaucccuug,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,gagagagucaaugaggagaucgccc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,59,NA,human,human  muscle  cells,unspecified,NA,cucaucuauuuuucucugccagucagcggagugc,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,gcaauuucuccucgaagugccugugugcaa,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,caauuucuccucgaagugccugugugc,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,caaggucauugacguggcucacguucucuu,2OMe,NA,0.05,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,cgagcaaggucauugacguggcucacguuc,2OMe,NA,0.05,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,cuggcgagcaagguccuugacguggcucac,2OMe,NA,0.1,uM,Skip,good skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,cuggcgagcaaggucauugacguggcucac,2OMe,NA,unspecified,Null,Skip,SNP,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,cuggcgagcaagguccuugacguggcuc,2OMe,NA,0.1,uM,Skip,good skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,ugguaagcuggcgagcaagguccuugacgug,2OMe,NA,0.1,uM,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,agugguaagcuggcgugcaagguca,2OMe,NA,0.1,uM,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,uuauacggugagagcugaaugcccaaagug,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,gagguuauacggugagagcugaaugcccaaa,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,ugcugagguuauacggugagagcugaa,2OMe,NA,0.1,uM,Skip,good skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,uccagagugcugagguuauacggugagagc,2OMe,NA,0.1,uM,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,cuuuccugcagaagcuuccaucugguguuc,2OMe,NA,0.6,uM,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,caauuucuccucgaagugccugugugc/cuggcgagcaagguccuugacguggcucac,2OMe,NA,0.01,uM,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,uccagagugcugagguuauacggugagagc/cuggcgagcaagguccuugacguggcucac,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,gcaauuucuccucgaagugccugugugcaa/ugguaagcuggcgagcaagguccuugacgug,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,60,NA,human,human  muscle  cells,unspecified,NA,cuggcgagcaagguccuugacguggcuc/gcaauuucuccucgaagugccugugugcaa,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,61,NA,human,human  muscle  cells,unspecified,NA,cucgguccucgacggccaccugggag,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,61,NA,human,human  muscle  cells,unspecified,NA,caugcagcugccugacucgguccucgccgg,2OMe,NA,0.05,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,61,NA,human,human  muscle  cells,unspecified,NA,gggcuucaugcagcugccugacucgguccuc,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,61,NA,human,human  muscle  cells,unspecified,NA,gggcuucaugcagcugccugacucg,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,61,NA,human,human  muscle  cells,unspecified,NA,ccugugggcuucaugcagcugccugacucg,2OMe,NA,0.05,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,61,NA,human,human  muscle  cells,unspecified,NA,gcugagaugcuggaccaaagucccug,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,61,NA,human,human  muscle  cells,unspecified,NA,gcugaaaaugacuuacuggaaagaaa,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,62,NA,human,human  muscle  cells,unspecified,NA,gacccuggacagacgcugaaaagaagggag,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,62,NA,human,human  muscle  cells,unspecified,NA,ccagggacccuggacagacgcugaaaagaa,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,62,NA,human,human  muscle  cells,unspecified,NA,gacccuggacagacgcugaa,2OMe,NA,0.025,uM,Skip,Faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,62,NA,human,human  muscle  cells,unspecified,NA,cucucccagggacccuggacagacgcug,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,62,NA,human,human  muscle  cells,unspecified,NA,uggcucucucccagggacccuggacagacg,2OMe,NA,0.3,uM,Skip,almost 100% skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,62,NA,human,human  muscle  cells,unspecified,NA,gagauggcucucucccagggacccugg,2OMe,NA,0.3,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,62,NA,human,human  muscle  cells,unspecified,NA,uuguuuggugagauggcucucucccagggac,2OMe,NA,0.025,uM,Skip,Faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,62,NA,human,human  muscle  cells,unspecified,NA,uagggcacuuuguuuggcgagauggcucuc,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,62,NA,human,human  muscle  cells,unspecified,NA,uacuugauauaguagggcac,2OMe,NA,0.1,uM,Skip,Faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,62,NA,human,human  muscle  cells,unspecified,NA,cuuacuugauauaguagggcacuuuguuug,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,63,NA,human,human  muscle  cells,unspecified,NA,gagucucguggcuaaaacacaaaac,2OMe,NA,unspecified,Null,Skip,No visible skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,63,NA,human,human  muscle  cells,unspecified,NA,ugggauggucccagcaaguuguuug,2OMe,NA,0.6,uM,Skip,Possible skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,63,NA,human,human  muscle  cells,unspecified,NA,gagcucugucauuuugggauggucccagca,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,63,NA,human,human  muscle  cells,unspecified,NA,gacugguagagcucugucauuuugg,2OMe,NA,unspecified,Null,Skip,No visible skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,63,NA,human,human  muscle  cells,unspecified,NA,cuaaagacugguagagcucuguc,2OMe,NA,unspecified,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,63,NA,human,human  muscle  cells,unspecified,NA,cauggccauguccuuaccuaaagac,2OMe,NA,unspecified,Null,Skip,No visible skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,64,NA,human,human  muscle  cells,unspecified,NA,cugagaaucugacauuauucaggucagcug,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,64,NA,human,human  muscle  cells,unspecified,NA,cugcagucuucggaguuucauggcagucc,2OMe,NA,0.05,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,64,NA,human,human  muscle  cells,unspecified,NA,aaagggccuucugcagucuucggaguuuca,2OMe,NA,0.05,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,64,NA,human,human  muscle  cells,unspecified,NA,gcaaagggccuucugcagucuucggag,2OMe,NA,0.2,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,64,NA,human,human  muscle  cells,unspecified,NA,caauacuuacagcaaagggccuucu,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,65,NA,human,human  muscle  cells,unspecified,NA,uugaccaaauuguugugcucuugcuc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,66,NA,human,human  muscle  cells,unspecified,NA,gauccucccuguucguccccuauuaug,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,66,NA,human,human  muscle  cells,unspecified,NA,caggacacggauccucccuguucguccccu,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,66,NA,human,human  muscle  cells,unspecified,NA,uaauauacacgacuuacaucuguacuuguc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,66,NA,human,human  muscle  cells,unspecified,NA,caggacacggauccucccuguucguccccu/uaauauacacgacuuacaucuguacuuguc,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,67,NA,human,human  muscle  cells,unspecified,NA,gcgcuggucacaaaauccuguugaacuugc,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,67,NA,human,human  muscle  cells,unspecified,NA,agcuccggacacuuggcucaauguuacu,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,67,NA,human,human  muscle  cells,unspecified,NA,gcagcuccggacacuuggcucaaug,2OMe,NA,0.6,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,67,NA,human,human  muscle  cells,unspecified,NA,uaacuuacaaauuggaagcagcuccggaca,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,68,NA,human,human  muscle  cells,unspecified,NA,gaucucuggcuuauuauuagccugc,2OMe,NA,0.1,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,68,NA,human,human  muscle  cells,unspecified,NA,cauccagucuaggaagagggccgcuuc,2OMe,NA,0.2,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,68,NA,human,human  muscle  cells,unspecified,NA,caccauggacugggguuccagucuc,2OMe,NA,0.2,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,68,NA,human,human  muscle  cells,unspecified,NA,cagcagccacucugugcaggacgggcagcc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,68,NA,human,human  muscle  cells,unspecified,NA,uaccugaauccaaugauuggacacuc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,68,NA,human,human  muscle  cells,unspecified,NA,caccauggacugggguuccagucuc/uaccugaauccaaugauuggacacuc,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,69,NA,human,human  muscle  cells,unspecified,NA,gugcuuuagacuccuguaccugauaaagagc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,69,NA,human,human  muscle  cells,unspecified,NA,uggcagaugucauaauuaaagugcuuuagac,2OMe,NA,0.2,uM,Skip,Skipping 68-71,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,69,NA,human,human  muscle  cells,unspecified,NA,ccagaaaaaaagcagcuuuggcagauguc,2OMe,NA,0.2,uM,Skip,Skipping 68-71  also 68+69 & 69+70,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,69,NA,human,human  muscle  cells,unspecified,NA,ggccuuuugcaacucgaccagaaa,2OMe,NA,unspecified,Null,Skip,Skipping 68-71,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,69,NA,human,human  muscle  cells,unspecified,NA,uuuuauggccuuuugcaacucgaccagaaa,2OMe,NA,0.2,uM,Skip,90% Skipping of 68-71,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,69,NA,human,human  muscle  cells,unspecified,NA,cuggcgucaaacuuaccggagugc,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,70,NA,human,human  muscle  cells,unspecified,NA,uucuccugauguagucuaaaaggg,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,70,NA,human,human  muscle  cells,unspecified,NA,cgaacaucuucuccugauguagucuaaaag,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,70,NA,human,human  muscle  cells,unspecified,NA,guaccuuggcaaagucucgaacauc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,70,NA,human,human  muscle  cells,unspecified,NA,guuuuuuaguaccuuggcaaaguc,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,70,NA,human,human  muscle  cells,unspecified,NA,gguucgaaauuuguuuuuuaguaccuugg,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,70,NA,human,human  muscle  cells,unspecified,NA,gcccauucggggaugcuucgcaaaauaccu,2OMe,NA,unspecified,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,71,NA,human,human  muscle  cells,unspecified,NA,gaucagaguaacgggacugcaaaa,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,71,NA,human,human  muscle  cells,unspecified,NA,acuggccagaaguugaucagagua,2OMe,NA,0.1,uM,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,71,NA,human,human  muscle  cells,unspecified,NA,gcagaaucuacuggccagaaguug,2OMe,NA,0.1,uM,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,71,NA,human,human  muscle  cells,unspecified,NA,cucacgcagaaucuacuggccaga,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,72,NA,human,human  muscle  cells,unspecified,NA,aagcugaggggacgaggcaggccuauaagg,2OMe,NA,0.6,uM,Skip,faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,72,NA,human,human  muscle  cells,unspecified,NA,gugugaaagcugaggggacgaggcagg,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,72,NA,human,human  muscle  cells,unspecified,NA,agucucauaccugcuagcauaaug,2OMe,NA,unspecified,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,73,NA,human,human  muscle  cells,unspecified,NA,augcuaucauuuagauaagauccau,2OMe,NA,unspecified,Null,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,73,NA,human,human  muscle  cells,unspecified,NA,uucugcuagccugauaaaaaacguaa,2OMe,NA,0.025,uM,Skip,Faint,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,73,NA,human,human  muscle  cells,unspecified,NA,cauugcuguuuuccauuucugguag,2OMe,NA,0.025,uM,Skip,Strong,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,73,NA,human,human  muscle  cells,unspecified,NA,acaugcucucauuaggagagaugcu,2OMe,NA,0.025,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,73,NA,human,human  muscle  cells,unspecified,NA,uaucauuuagauaagauccauugcug,2OMe,NA,0.025,uM,Skip,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,74,NA,human,human  muscle  cells,unspecified,NA,guucaaacuuuggcaguaaugcuggau,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,74,NA,human,human  muscle  cells,unspecified,NA,gacuacgaggcuggcucaggggggaguc,2OMe,NA,0.025,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,74,NA,human,human  muscle  cells,unspecified,NA,gcuccccucuuuccucacucucuaagg,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,76,NA,human,human  muscle  cells,unspecified,NA,cauucacuuuggccucugccuggggcu,2OMe,NA,unspecified,Null,Skip,no detectable skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US9758783B2,DMD,exon,76,NA,human,human  muscle  cells,unspecified,NA,gacugccaaccacucggagcagcauag,2OMe,NA,unspecified,Null,Skip,no detectable skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9758783B2,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,23,NA,mouse,Mdx mice (C57B1/10ScSn-mdx/J)  quadriceps (Q) muscles,Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,"100 /wk 4 (5 times), week 5-8 (2 times)",mg/kg,Skip,15.83,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,23,NA,mouse,Mdx mice (C57B1/10ScSn-mdx/J)  tibialis anterior (TA) muscles,Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,"100 /wk 4 (5 times), week 5-8 (2 times)",mg/kg,Skip,29.11,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,23,NA,mouse,Mdx mice (C57B1/10ScSn-mdx/J)  diaphragm (DIA) muscles,Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,"100 /wk 4 (5 times), week 5-8 (2 times)",mg/kg,Skip,14.86,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,23,NA,mouse,Mdx mice (C57B1/10ScSn-mdx/J)  quadriceps (Q) muscles,Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,"100 /wk 4 (5 times), week 5-8 (2 times)",mg/kg,Skip,36.03,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,23,NA,mouse,Mdx mice (C57B1/10ScSn-mdx/J)  tibialis anterior (TA) muscles,Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,"100 /wk 4 (5 times), week 5-8 (2 times)",mg/kg,Skip,37.86,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,23,NA,mouse,Mdx mice (C57B1/10ScSn-mdx/J)  diaphragm (DIA) muscles,Null,NA,ggccaaaccucggcuuaccu,2OMe,NA,"100 /wk 4 (5 times), week 5-8 (2 times)",mg/kg,Skip,22.09,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,44,NA,unspecified,Differentiated muscle cell cultures (myotubes),unifectylin,NA,ucagcuucuguuagccacug,2OMe,NA,"0.25/pentoxyfilline, 0mg/ml",mg/ml,Skip,32.47,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,44,NA,unspecified,Differentiated muscle cell cultures (myotubes),unifectylin,NA,ucagcuucuguuagccacug,2OMe,NA,"0.25/pentoxyfilline, 0.01mg/ml",mg/ml,Skip,38.72,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,44,NA,unspecified,Differentiated muscle cell cultures (myotubes),unifectylin,NA,ucagcuucuguuagccacug,2OMe,NA,"0.25/pentoxyfilline, 0.05mg/ml",mg/ml,Skip,40.1,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,44,NA,unspecified,Differentiated muscle cell cultures (myotubes),unifectylin,NA,ucagcuucuguuagccacug,2OMe,NA,"0.25/pentoxyfilline, 0.1mg/ml",mg/ml,Skip,45.4,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,44,NA,unspecified,Differentiated muscle cell cultures (myotubes),unifectylin,NA,ucagcuucuguuagccacug,2OMe,NA,"0.25/pentoxyfilline, 0.5mg/ml",mg/ml,Skip,38.54,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,45,NA,unspecified,Differentiated muscle cell cultures (myotubes),unifectylin,NA,auucaauguucugacaacaguuugc,2OMe,NA,"0.25/pentoxyfilline, 0mg/ml",mg/ml,Skip,4.28,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,45,NA,unspecified,Differentiated muscle cell cultures (myotubes),unifectylin,NA,auucaauguucugacaacaguuugc,2OMe,NA,"0.25/pentoxyfilline, 0.01mg/ml",mg/ml,Skip,5.72,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,45,NA,unspecified,Differentiated muscle cell cultures (myotubes),unifectylin,NA,auucaauguucugacaacaguuugc,2OMe,NA,"0.25/pentoxyfilline, 0.05mg/ml",mg/ml,Skip,8.07,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,45,NA,unspecified,Differentiated muscle cell cultures (myotubes),unifectylin,NA,auucaauguucugacaacaguuugc,2OMe,NA,"0.25/pentoxyfilline, 0.1mg/ml",mg/ml,Skip,8.95,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
journal article,Means And Methods For Counteracting Muscle Disorders,USRE48468E1,DMD,exon,45,NA,unspecified,Differentiated muscle cell cultures (myotubes),unifectylin,NA,auucaauguucugacaacaguuugc,2OMe,NA,"0.25pentoxyfilline, 0.5mg/ml",mg/ml,Skip,11.17,NA,NA,NA,RNA,https://patents.google.com/patent/USRE48468E1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sflj*sfc*sfu,2OMe,NA,3,uM,Skip,17.37,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sflj*sfc*sfu,2OMe,NA,10,uM,Skip,33.1,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,1,uM,Skip,0.7,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,3,uM,Skip,0.7,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,10,uM,Skip,0.94,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mu*mc*ma*ma*mg*mg*ma*ma*mg*ma*mu*mg*mg*mc*ma*mu*mu*mu*mc*mu,2OMe,NA,30,uM,Skip,3.29,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sflj*sfc*sfu,2OMe,NA,0.3,uM,Skip,5.63,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sflj*sfc*sfu,2OMe,NA,1,uM,Skip,6.81,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sflj*sfc*sfu,2OMe,NA,30,uM,Skip,50.47,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mod015l001fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.3,uM,Skip,1.88,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mod015l001fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,6.34,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mod015l001fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,17.84,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mod015l001fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,33.33,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mod015l001fu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,30,uM,Skip,82.63,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mod020l001ftu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,0.3,uM,Skip,1.41,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mod020l001ftu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,1,uM,Skip,5.63,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mod020l001ftu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,3,uM,Skip,16.9,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mod020l001ftu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,10,uM,Skip,47.89,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,"Oligonucleotides, Compositions And Methods Thereof",WO2021237223A1,DMD,exon,51,NA,human,TLR9 cells,Null,NA,mod020l001ftu*sfc*sfa*sfa*sfg*sfg*smafa*smgma*sfu*smgmgfc*sfa*sfu*sfu*sfu*sfc*sfu,2OMe,NA,30,uM,Skip,97.42,NA,NA,NA,RNA,https://patents.google.com/patent/WO2021237223A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,3,"ug, 12-week-old male human DMD exon 45-knock-in/mouse Dmd exon 44-knock-out mouse,",Skip,8.5,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,3,"ug, 12-week-old male human DMD exon 45-knock-in/mouse Dmd exon 44-knock-out mouse,",Skip,7.7,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,3,"ug, 12-week-old male human DMD exon 45-knock-in/mouse Dmd exon 44-knock-out mouse,",Skip,2.6,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,1,"ug/well,  Human iPS cells derived from a patient with DMD with deletion of dystrophin Ex 45,   Human iPS Cell-Derived Myoblasts(Myogenic Differentiation of Human iPS Cells)",Skip,10.6,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,3,"ug/well,  Human iPS cells derived from a patient with DMD with deletion of dystrophin Ex 45,   Human iPS Cell-Derived Myoblasts(Myogenic Differentiation of Human iPS Cells)",Skip,13.1,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,10,"ug/well,  Human iPS cells derived from a patient with DMD with deletion of dystrophin Ex 45,   Human iPS Cell-Derived Myoblasts(Myogenic Differentiation of Human iPS Cells)",Skip,10.5,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,1,"ug, Human iPS Cell-Derived Myoblasts",Skip,4.8,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,ugucagacagaaaaaagguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,1,"ug, Human iPS Cell-Derived Myoblasts",Skip,1.6,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg/ugucagacagaaaaaagguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,0.5*2,"ug, Human iPS Cell-Derived Myoblasts",Skip,43.6,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg/ugucagacagaaaaaagguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,3,"ug, gastrocnemius muscle of the right lower limb of each 6-week-old male human DMD exon 45-knock-in/mouse Dmd exon 44-knock-out mouse",Skip,52,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg/ugucagacagaaaaaagguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,3,"ug, gastrocnemius muscle of the right lower limb of each 6-week-old male human DMD exon 45-knock-in/mouse Dmd exon 44-knock-out mouse",Skip,40,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg/ugucagacagaaaaaagguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,3,"ug, gastrocnemius muscle of the right lower limb of each 6-week-old male human DMD exon 45-knock-in/mouse Dmd exon 44-knock-out mouse",Skip,59,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Composition For Modifying Target Gene,AU2018397951A1,DMD,exon,45,NA,mouse,Null,Null,NA,uaucuuacaggaacuccguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg/ugucagacagaaaaaagguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucgg,Null,NA,3,"ug, gastrocnemius muscle of the right lower limb of each 6-week-old male human DMD exon 45-knock-in/mouse Dmd exon 44-knock-out mouse",Skip,40,NA,NA,NA,RNA,https://patents.google.com/patent/AU2018397951A1,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,53,NA,human,human healthy control muscle cells,ExGen500,NA,guugx1x1ux1x1gguux1ugaagguguux1,2OMe,NA,0.4,uM,Skip,64.16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,53,NA,human,human healthy control muscle cells,ExGen500,NA,uugx1x1uccgguux1ugaagguguux1,2OMe,NA,0.4,uM,Skip,47.19,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,53,NA,human,human healthy control muscle cells,ExGen500,NA,guugx1x1uccgguucugaagguguuc,2OMe,NA,0.4,uM,Skip,36.2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,53,NA,human,human healthy control muscle cells,ExGen500,NA,guugcx1uccgguux1ugaagguguux1,2OMe,NA,0.4,uM,Skip,44.93,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,53,NA,human,human healthy control muscle cells,ExGen500,NA,ucaaggaagauggcauuucu,2OMe,NA,0.2,uM,Skip,12.73,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,53,NA,human,human healthy control muscle cells,ExGen500,NA,y1caaggaagay1ggcay1y1y1cy1,2OMe,NA,0.2,uM,Skip,18.11,NA,NA,NA,Unknown,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,53,NA,human,human healthy control muscle cells,ExGen500,NA,y1x1aaggaagay1ggx1ay1y1y1x1y1,2OMe,NA,0.2,uM,Skip,23.48,NA,NA,NA,Unknown,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,46,NA,human,human healthy control muscle cells,ExGen500,NA,ucagcuucuguuagccacug,2OMe,NA,0.2,uM,Skip,9.92,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,46,NA,human,human healthy control muscle cells,ExGen500,NA,y1cagcy1y1cy1gy1y1agccacy1g,2OMe,NA,0.2,uM,Skip,29.77,NA,NA,NA,Unknown,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,46,NA,human,human healthy control muscle cells,ExGen500,NA,y1x1agx1y1y1x1y1gy1y1agx1x1ax1y1g,2OMe,NA,0.2,uM,Skip,30,NA,NA,NA,Unknown,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,54,NA,human,human healthy control muscle cells,ExGen500,NA,gguaaugaguucuuccaacugg,2OMe,NA,0.2,uM,Skip,23.86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,54,NA,human,human healthy control muscle cells,ExGen500,NA,ggy1aay1gagy1y1cy1y1ccaacy1gg,2OMe,NA,0.2,uM,Skip,43.33,NA,NA,NA,Unknown,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,23,NA,human,human healthy control muscle cells,ExGen500,NA,ggccaaaccucggcuuaccu,2OMe,NA,0.2,uM,Skip,2.65,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,23,NA,human,human healthy control muscle cells,ExGen500,NA,ggccaaaccncggcnnaccn,2OMe,NA,0.2,uM,Skip,7.38,NA,NA,NA,Unknown,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,53,NA,human,human healthy control muscle cells,ExGen500,NA,ucaaggaagauggcauuucu,2OMe,NA,0.2,uM,Skip,16.68,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,53,NA,human,human healthy control muscle cells,ExGen500,NA,ucz1z1ggzz1gz1uggcz1uuucu,2OMe,NA,0.2,uM,Skip,64.98,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,54,NA,human,human healthy control muscle cells,ExGen500,NA,gguaaugaguucuuccaacugg,2OMe,NA,0.2,uM,Skip,23.95,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,54,NA,human,human healthy control muscle cells,ExGen500,NA,gguz1z1ugz1guucuuccz1z1cugg,2OMe,NA,0.2,uM,Skip,73.05,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,46,NA,human,human healthy control muscle cells,ExGen500,NA,ucagcuucuguuagccacug,2OMe,NA,0.2,uM,Skip,29.87,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,US/2019/194656,DMD,exon,46,NA,human,human healthy control muscle cells,ExGen500,NA,ucz1gcuucuguuz1gccz1cug,2OMe,NA,0.2,uM,Skip,53.95,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/194656,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,healthy human myoblasts,ExGen500,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,healthy human myoblasts,ExGen500,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,healthy human myoblasts,ExGen500,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,42,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,healthy human myoblasts,ExGen500,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.5,uM,Skip,75,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,healthy human myoblasts,ExGen500,NA,gcccaaugccauccugg,2OMe,NA,0.2,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,healthy human myoblasts,ExGen500,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.5,uM,Skip,63,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,Null,Null,NA,auucaauguucugacaacaguuugc,unspecified,NA,Null,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,Null,Null,NA,ccaguugcauucaauguucugacaa,unspecified,NA,Null,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,Null,Null,NA,caguugcauucaauguucugac,unspecified,NA,Null,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,Null,Null,NA,aguugcauucaauguucuga,unspecified,NA,Null,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/2019/0177725,DMD,exon,45,NA,human,Null,Null,NA,gauugcugaauuauuucuucc,unspecified,NA,Null,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2019/0177725,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,5,nM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,10,nM,Skip,24,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,25,nM,Skip,43,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,50,nM,Skip,51,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,100,nM,Skip,63,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,5,nM,Skip,44,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,10,nM,Skip,52,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,25,nM,Skip,67,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,50,nM,Skip,70,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,100,nM,Skip,60,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,5,nM,Skip,36,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,10,nM,Skip,52,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,25,nM,Skip,62,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,50,nM,Skip,74,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,100,nM,Skip,69,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,5,nM,Skip,31,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,10,nM,Skip,38,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,25,nM,Skip,65,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,50,nM,Skip,70,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Thiomorpholino Oligonucleotides For The Treatment Of Muscular Dystrophy,WO2019060522A2,DMD,exon,23,NA,mouse,H2K mdx myotubes,lipofectamine or lipofectin,NA,ggccaaacctcggcttaccu,"Others (PMO (uppercase), DNA (lowercase), 2'-OMe (3' u), TMO linkages)",NA,100,nM,Skip,71,NA,NA,NA,RNA,https://patents.google.com/patent/WO2019060522A2,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,19 or 20,NA,human,Healthy primary human myotubes,Endo-porter,NA,gcagaauucgauccaccggcuguucaagccugagcugaucugcucgcaucuugcagu,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,21,NA,human,Healthy primary human myotubes,Endo-porter,NA,cacaaagucugcauccaggaacauggguc,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,51,NA,human,Healthy primary human myotubes,Endo-porter,NA,aucauuuuuucucauaccuucugcuag,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,cuaccucuuuuuucugucug,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,20,NA,human,Healthy primary human myotubes,Endo-porter,NA,guucaguuguucugaggcuugucug,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,20,NA,human,Healthy primary human myotubes,Endo-porter,NA,uuggcagaauucuguccaccggcuguuc,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,20,NA,human,Healthy primary human myotubes,Endo-porter,NA,aguaguugucaucuguuccaauugu,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,20,NA,human,Healthy primary human myotubes,Endo-porter,NA,cggcaguaguugucaucuguuc,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,21,NA,human,Healthy primary human myotubes,Endo-porter,NA,cugcauccagaaacauuggccc,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,22,NA,human,Healthy primary human myotubes,Endo-porter,NA,auguccacagaccuguaauu,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,22,NA,human,Healthy primary human myotubes,Endo-porter,NA,auauucacagaccugcaauu,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,22,NA,human,Healthy primary human myotubes,Endo-porter,NA,cuguaauuucccgagucucucc,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,23,NA,human,Healthy primary human myotubes,Endo-porter,NA,ggccaaaccucggcuuaccugaaau,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,23,NA,human,Healthy primary human myotubes,Endo-porter,NA,aguaaaaucuugaauuaccugaauu,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,23,NA,human,Healthy primary human myotubes,Endo-porter,NA,uggcauauuucugaaggugcuuucuuggcc,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,24,NA,human,Healthy primary human myotubes,Endo-porter,NA,caacuucagccauccauuucuguaa,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,24,NA,human,Healthy primary human myotubes,Endo-porter,NA,caacuucagccauccauuucuucag,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,24,NA,human,Healthy primary human myotubes,Endo-porter,NA,ccagggcaggccauuccucuuuc,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,24,NA,human,Healthy primary human myotubes,Endo-porter,NA,gagcuguuuuuucaggauuucagca,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,24,NA,human,Healthy primary human myotubes,Endo-porter,NA,cagcugcuuuuuuagaauuucugaa,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,25,NA,human,Healthy primary human myotubes,Endo-porter,NA,cuaaguucugucuccagucuggaug,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,40,NA,human,Healthy primary human myotubes,Endo-porter,NA,uccuuucaucucugggcuc,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,43,NA,human,Healthy primary human myotubes,Endo-porter,NA,uuguuaacuuuuuccauu,unmodified PMO,NA,unspecified,Null,unspecified,Null,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,cgccatttctcaacagatctgtcaaatcgc,unmodified PMO,NA,0.1,uM,Skip,31.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,cgccatttctcaacagatctgtcaaatcgc,unmodified PMO,NA,1,uM,Skip,67.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,cgccatttctcaacagatctgtcaaatcgc,unmodified PMO,NA,3,uM,Skip,79.7,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,cgccatttctcaacagatctgtcaaatcgc,unmodified PMO,NA,10,uM,Skip,83.8,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,ccgccatttctcaacagatctgtcaaatcg,unmodified PMO,NA,0.1,uM,Skip,32,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,ccgccatttctcaacagatctgtcaaatcg,unmodified PMO,NA,1,uM,Skip,68.3,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,ccgccatttctcaacagatctgtcaaatcg,unmodified PMO,NA,3,uM,Skip,79.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,ccgccatttctcaacagatctgtcaaatcg,unmodified PMO,NA,10,uM,Skip,77.7,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,gccgccatttctcaacagatctgtcaaatc,unmodified PMO,NA,0.1,uM,Skip,31,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,gccgccatttctcaacagatctgtcaaatc,unmodified PMO,NA,1,uM,Skip,70,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,gccgccatttctcaacagatctgtcaaatc,unmodified PMO,NA,3,uM,Skip,96,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,gccgccatttctcaacagatctgtcaaatc,unmodified PMO,NA,10,uM,Skip,88.7,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,agccgccatttctcaacagatctgtcaaat,unmodified PMO,NA,0.1,uM,Skip,26,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,agccgccatttctcaacagatctgtcaaat,unmodified PMO,NA,1,uM,Skip,62,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,agccgccatttctcaacagatctgtcaaat,unmodified PMO,NA,3,uM,Skip,89,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,agccgccatttctcaacagatctgtcaaat,unmodified PMO,NA,10,uM,Skip,75,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aagccgccatttctcaacagatctgtcaaa,unmodified PMO,NA,0.1,uM,Skip,23,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aagccgccatttctcaacagatctgtcaaa,unmodified PMO,NA,1,uM,Skip,67,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aagccgccatttctcaacagatctgtcaaa,unmodified PMO,NA,3,uM,Skip,88,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aagccgccatttctcaacagatctgtcaaa,unmodified PMO,NA,10,uM,Skip,84,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaccgccatttctcaacagatctgtcaaa,unmodified PMO,NA,0.1,uM,Skip,18,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaccgccatttctcaacagatctgtcaaa,unmodified PMO,NA,1,uM,Skip,54,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaccgccatttctcaacagatctgtcaaa,unmodified PMO,NA,3,uM,Skip,68,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaccgccatttctcaacagatctgtcaaa,unmodified PMO,NA,10,uM,Skip,63,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaagccgccatttctcaacagatctgtca,unmodified PMO,NA,0.1,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaagccgccatttctcaacagatctgtca,unmodified PMO,NA,1,uM,Skip,58.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaagccgccatttctcaacagatctgtca,unmodified PMO,NA,3,uM,Skip,81,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaagccgccatttctcaacagatctgtca,unmodified PMO,NA,10,uM,Skip,74,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaacgccgccatttctcaacagatctgtc,unmodified PMO,NA,0.1,uM,Skip,23,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaacgccgccatttctcaacagatctgtc,unmodified PMO,NA,1,uM,Skip,59.3,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaacgccgccatttctcaacagatctgtc,unmodified PMO,NA,3,uM,Skip,85,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaaacgccgccatttctcaacagatctgtc,unmodified PMO,NA,10,uM,Skip,84.3,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,gaaaacgccgccatttctcaacagatctgt,unmodified PMO,NA,0.1,uM,Skip,27,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,gaaaacgccgccatttctcaacagatctgt,unmodified PMO,NA,1,uM,Skip,53.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,gaaaacgccgccatttctcaacagatctgt,unmodified PMO,NA,3,uM,Skip,70,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,gaaaacgccgccatttctcaacagatctgt,unmodified PMO,NA,10,uM,Skip,76,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,atgaaaacgccgccatttctcaacagatct,unmodified PMO,NA,0.1,uM,Skip,23,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,atgaaaacgccgccatttctcaacagatct,unmodified PMO,NA,1,uM,Skip,45.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,atgaaaacgccgccatttctcaacagatct,unmodified PMO,NA,3,uM,Skip,79,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,atgaaaacgccgccatttctcaacagatct,unmodified PMO,NA,10,uM,Skip,85,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,cataatgaaaacgccgccatttctcaacag,unmodified PMO,NA,0.1,uM,Skip,31.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,cataatgaaaacgccgccatttctcaacag,unmodified PMO,NA,1,uM,Skip,62,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,cataatgaaaacgccgccatttctcaacag,unmodified PMO,NA,3,uM,Skip,80,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,cataatgaaaacgccgccatttctcaacag,unmodified PMO,NA,10,uM,Skip,86.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,atatcataatgaaaacgccgccatttctca,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,atatcataatgaaaacgccgccatttctca,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,tatatcataatgaaaacgccgccatttctc,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,tgttcagcttctgttagccactgattaaat,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,actgttcagcttctgttagccactgattaa,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,gaaactgttcagcttctgttagccactgat,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,44,NA,human,Healthy primary human myotubes,Endo-porter,NA,gtctttctgagaaactgttcagcttctgtt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,ttgccgctgcccaatgccatcctggagttc,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,tttgccgctgcccaatgccatcctggagtt,unmodified PMO,NA,1,uM,Skip,29.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,tttgccgctgcccaatgccatcctggagtt,unmodified PMO,NA,3,uM,Skip,38.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,tttgccgctgcccaatgccatcctggagtt,unmodified PMO,NA,10,uM,Skip,43.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,agtttgccgctgcccaatgccatcctggag,unmodified PMO,NA,1,uM,Skip,34,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,agtttgccgctgcccaatgccatcctggag,unmodified PMO,NA,3,uM,Skip,56.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,agtttgccgctgcccaatgccatcctggag,unmodified PMO,NA,10,uM,Skip,69.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,acaacagtttgccgctgcccaatgccatcc,unmodified PMO,NA,1,uM,Skip,43.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,acaacagtttgccgctgcccaatgccatcc,unmodified PMO,NA,3,uM,Skip,69.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,acaacagtttgccgctgcccaatgccatcc,unmodified PMO,NA,10,uM,Skip,76,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,gacaacagtttgccgctgcccaatgccatc,unmodified PMO,NA,0.1,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,gacaacagtttgccgctgcccaatgccatc,unmodified PMO,NA,1,uM,Skip,47.3,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,gacaacagtttgccgctgcccaatgccatc,unmodified PMO,NA,3,uM,Skip,62.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,gacaacagtttgccgctgcccaatgccatc,unmodified PMO,NA,10,uM,Skip,73.7,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,tgacaacagtttgccgctgcccaatgccat,unmodified PMO,NA,1,uM,Skip,35.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,tgacaacagtttgccgctgcccaatgccat,unmodified PMO,NA,3,uM,Skip,56.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,tgacaacagtttgccgctgcccaatgccat,unmodified PMO,NA,10,uM,Skip,53,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,tctgacaacagtttgccgctgcccaatgcc,unmodified PMO,NA,1,uM,Skip,26.5,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,tctgacaacagtttgccgctgcccaatgcc,unmodified PMO,NA,3,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,45,NA,human,Healthy primary human myotubes,Endo-porter,NA,tctgacaacagtttgccgctgcccaatgcc,unmodified PMO,NA,10,uM,Skip,52,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,cttcctccaaccataaaacaaattcattta,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,gcttcctccaaccataaaacaaattcattt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,tgcttcctccaaccataaaacaaattcatt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,ctgcttcctccaaccataaaacaaattcat,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,tctgcttcctccaaccataaaacaaattca,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,atctgcttcctccaaccataaaacaaattc,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,tatctgcttcctccaaccataaaacaaatt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,ttatctgcttcctccaaccataaaacaaat,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,gttatctgcttcctccaaccataaaacaaa,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,tgttatctgcttcctccaaccataaaacaa,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,atgttatctgcttcctccaaccataaaaca,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,aatgttatctgcttcctccaaccataaaac,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,caatgttatctgcttcctccaaccataaaa,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,gcaatgttatctgcttcctccaaccataaa,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,agcaatgttatctgcttcctccaaccataa,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,tagcaatgttatctgcttcctccaaccata,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,ctagcaatgttatctgcttcctccaaccat,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,46,NA,human,Healthy primary human myotubes,Endo-porter,NA,actagcaatgttatctgcttcctccaacca,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,48,NA,human,Healthy primary human myotubes,Endo-porter,NA,uuauaaauuuccaacugauuc,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,51,NA,human,Healthy primary human myotubes,Endo-porter,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,51,NA,human,Healthy primary human myotubes,Endo-porter,NA,aggttgtgtcaccagagtaacagtctgagt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,51,NA,human,Healthy primary human myotubes,Endo-porter,NA,ccacaggttgtgtcaccagagtaacagtct,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,51,NA,human,Healthy primary human myotubes,Endo-porter,NA,ggcagtttccttagtaaccacaggttgtgt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,51,NA,human,Healthy primary human myotubes,Endo-porter,NA,agatggcagtttccttagtaaccacaggtt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,51,NA,human,Healthy primary human myotubes,Endo-porter,NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,51,NA,human,Healthy primary human myotubes,Endo-porter,NA,ttataacttgatcaagcagagaaagccagt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,51,NA,human,Healthy primary human myotubes,Endo-porter,NA,ataccttctgcttgatgatcatctcgttga,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Endo-porter,NA,uccaauugggggcgucucuguuccaaaucu,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Endo-porter,NA,uccaauugggggcgucucuguucca,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Endo-porter,NA,ggtaatgagttcttccaactggggacgcct,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Endo-porter,NA,uucaaauucugggcagcaguaaugaguucu,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,52,NA,human,Healthy primary human myotubes,Endo-porter,NA,uucaaauuuugggcagcgguaaugaguucu,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,acttcatcccactgattctgaattctttca,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,tacttcatcccactgattctgaattctttt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,gtacttcatcccactgattctgaattcttt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,tgtacttcatcccactgattctgaattctt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,uuuuaaagauaugcuugacacuaaccuugg,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,uuaaaaagguaucuuugauacuaaccuugg,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,ttgtacttcatcccactgattctgaattct,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,cttgtacttcatcccactgattctgaattc,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,ttcttgtacttcatcccactgattctgaat,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,gttcttgtacttcatcccactgattctgaa,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,tgttcttgtacttcatcccactgattctga,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,gtgttcttgtacttcatcccactgattctg,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,ggtgttcttgtacttcatcccactgattct,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,aggtgttcttgtacttcatcccactgattc,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,aaggtgttcttgtacttcatcccactgatt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,gaaggtgttcttgtacttcatcccactgat,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,tgaaggtgttcttgtacttcatcccactga,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,ctgaaggtgttcttgtacttcatcccactg,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,tctgaaggtgttcttgtacttcatcccact,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,ttctgaaggtgttcttgtacttcatcccac,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,gttctgaaggtgttcttgtacttcatccca,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,ggttctgaaggtgttcttgtacttcatccc,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,ccggttctgaaggtgttcttgtacttcatc,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,tccggttctgaaggtgttcttgtacttcat,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,cctccggttctgaaggtgttcttgtacttc,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,gcctccggttctgaaggtgttcttgtactt,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,gttgcctccggttctgaaggtgttcttgta,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,cauucaacuguugucuccuguucugcagcug,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,cuacugugugaggaccuucuuuccaugagu,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,53,NA,human,Healthy primary human myotubes,Endo-porter,NA,ucugugaucuucuuuuggauugcaucuacu,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,54,NA,human,Healthy primary human myotubes,Endo-porter,NA,gagaagtttcagggccaagtcatttgccac,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,55,NA,human,Healthy primary human myotubes,Endo-porter,NA,tcttccaaagcagcctctcgctcactcacc,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,65,NA,human,Healthy primary human myotubes,Endo-porter,NA,gcucaagagauccacugcaaaaaag,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,65,NA,human,Healthy primary human myotubes,Endo-porter,NA,guugugcugguccaaggcaucacau,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
patent,Nucleic Acid-Polypeptide Compositions And Methods Of Inducing Exon Skipping,AU2023278129A1,DMD,exon,65,NA,human,Healthy primary human myotubes,Endo-porter,NA,guugugcugguccagggcaucacau,unmodified PMO,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/AU2023278129A1,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.1,NA,human,JF196 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,agucuuguucucuguuuucuca,2OMe,NA,600,nM,Skip,Faint skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.1,NA,human,JF196 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,acugaggcuucauggagcaac,2OMe,NA,600,nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.2,NA,human,JF196 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,ggucaucuugggcuuccucccac,2OMe,NA,600,nM,Skip,Slight Faint skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.3,NA,human,JF196 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,acugaggcuucauggagcaac,2OMe,NA,600,nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.4,NA,human,JF196 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,acugaggcuucauggagcaac,2OMe,NA,300,nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.5,NA,human,JF196 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,acugaggcuucauggagcaac,2OMe,NA,150,nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.6,NA,human,JF196 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,acugaggcuucauggagcaac,2OMe,NA,75,nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.7,NA,human,TDM57 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,acugaggcuucauggagcaac,2OMe,NA,600,nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.8,NA,human,TDM57 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,acugaggcuucauggagcaac,2OMe,NA,300,nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.9,NA,human,TDM57 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,acugaggcuucauggagcaac,2OMe,NA,175,nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE50.10,NA,human,TDM57 patient iFDM cells (inducible fibroblast-derived myogenic cells) c.5668-824C>T,Oligofectamine,NA,acugaggcuucauggagcaac,2OMe,NA,50,nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE44.1,NA,human,"P1 (ID 8597) iFDM (inducible fibroblast-derived myogenic cells), Roswell ParkMemorial Institute (RPMI) c.4886+1249 (G>T)",Oligofectamine,NA,gaacaguaggugucuucugcag,2OMe,NA,600 (2 days),nM,Skip,Faint skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE44.1,NA,human,"P1 (ID 8597) iFDM (inducible fibroblast-derived myogenic cells), Roswell ParkMemorial Institute (RPMI) c.4886+1249 (G>T)",Oligofectamine,NA,ccagggcugguucaccuucaaa,2OMe,NA,600 (2 days),nM,Skip,Moderate skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation,PMID 31019989,DYSF,pseudoexon,pseudoexon PE44.1,NA,human,"P1 (ID 8597) iFDM (inducible fibroblast-derived myogenic cells), Roswell ParkMemorial Institute (RPMI) c.4886+1249 (G>T)",Oligofectamine,NA,cuccaaucccugcuuggugg,2OMe,NA,600 (2 days),nM,Skip,Strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31019989,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,atatatagtttgttatta,Others (2'-MOE),NA,20,uM,Inclusion[%],43.37,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,"CA3073515A1
",SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,tagaaatatatagtttgt,Others (2'-MOE),NA,20,uM,Inclusion[%],45.52,NA,NA,NA,DNA,"https://patents.google.com/patent/CA3073515A1
",NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,caaaatagaaatatatag,Others (2'-MOE),NA,20,uM,Inclusion[%],67.38,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,gatgctctccgtctgttt,Others (2'-MOE),NA,20,uM,Inclusion[%],75.27,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ttcatgatgctctccgtc,Others (2'-MOE),NA,20,uM,Inclusion[%],63.44,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ttttgttcatgatgctct,Others (2'-MOE),NA,20,uM,Inclusion[%],65.23,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ttactttttgttcatgat,Others (2'-MOE),NA,20,uM,Inclusion[%],69.53,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,tggtgttactttttgttc,Others (2'-MOE),NA,20,uM,Inclusion[%],80.29,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,acatttggtgttactttt,Others (2'-MOE),NA,20,uM,Inclusion[%],65.59,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,acagaacatttggtgtta,Others (2'-MOE),NA,20,uM,Inclusion[%],58.78,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,atatgacagaacatttgg,Others (2'-MOE),NA,20,uM,Inclusion[%],69.89,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,atctgatatgacagaaca,Others (2'-MOE),NA,20,uM,Inclusion[%],54.84,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,tagaaatctgatatgaca,Others (2'-MOE),NA,20,uM,Inclusion[%],61.29,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ttagttagaaatctgata,Others (2'-MOE),NA,20,uM,Inclusion[%],55.56,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,tgttattagttagaaatc,Others (2'-MOE),NA,20,uM,Inclusion[%],18.64,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,tagtttgttattagttag,Others (2'-MOE),NA,20,uM,Inclusion[%],19.71,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,atacaaaatagaaatata,Others (2'-MOE),NA,20,uM,Inclusion[%],64.87,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ctatacaaaatagaaata,Others (2'-MOE),NA,20,uM,Inclusion[%],61.29,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,tcctatacaaaatagaaa,Others (2'-MOE),NA,20,uM,Inclusion[%],53.41,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,tatcctatacaaaataga,Others (2'-MOE),NA,20,uM,Inclusion[%],58.42,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,attatcctatacaaaata,Others (2'-MOE),NA,20,uM,Inclusion[%],63.08,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,agttggagcaagattatc,Others (2'-MOE),NA,20,uM,Inclusion[%],3.94,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,atccaagttggagcaaga,Others (2'-MOE),NA,20,uM,Inclusion[%],19,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,accccatccaagttggag,Others (2'-MOE),NA,20,uM,Inclusion[%],42.65,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,gctccaccccatccaagt,Others (2'-MOE),NA,20,uM,Inclusion[%],3.94,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ccagcgctccaccccatc,Others (2'-MOE),NA,20,uM,Inclusion[%],5.73,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,gaaccagcgctccacccc,Others (2'-MOE),NA,20,uM,Inclusion[%],4.3,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,gggaggaaccagcgctcc,Others (2'-MOE),NA,20,uM,Inclusion[%],5.02,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ataataaagggctcaggg,Others (2'-MOE),NA,20,uM,Inclusion[%],58.06,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ccataataaagggctcag,Others (2'-MOE),NA,20,uM,Inclusion[%],43.73,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,gtaatacagtacccataa,Others (2'-MOE),NA,20,uM,Inclusion[%],30.82,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,gggtaatacagtacccat,Others (2'-MOE),NA,20,uM,Inclusion[%],60.22,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ttaaaggtagcaaaaggg,Others (2'-MOE),NA,20,uM,Inclusion[%],63.44,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,aaggattaaaggtagcaa,Others (2'-MOE),NA,20,uM,Inclusion[%],5.73,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,agtgcaaggattaaaggt,Others (2'-MOE),NA,20,uM,Inclusion[%],11.11,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,gtcacagtgcaaggatta,Others (2'-MOE),NA,20,uM,Inclusion[%],19.71,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,cataagtcacagtgcaag,Others (2'-MOE),NA,20,uM,Inclusion[%],14.7,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ctacacataagtcacagt,Others (2'-MOE),NA,20,uM,Inclusion[%],24.37,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ccccactacacataagtc,Others (2'-MOE),NA,20,uM,Inclusion[%],33.69,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,cctcaccccactacacat,Others (2'-MOE),NA,20,uM,Inclusion[%],59.14,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ccctccctcaccccacta,Others (2'-MOE),NA,20,uM,Inclusion[%],56.27,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ccaatccctccctcaccc,Others (2'-MOE),NA,20,uM,Inclusion[%],59.86,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ccttcccaatccctccct,Others (2'-MOE),NA,20,uM,Inclusion[%],69.18,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,agtacccttcccaatccc,Others (2'-MOE),NA,20,uM,Inclusion[%],62.72,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ataatagtacccttccca,Others (2'-MOE),NA,20,uM,Inclusion[%],48.39,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,gtgcaataatagtaccct,Others (2'-MOE),NA,20,uM,Inclusion[%],53.41,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 20,NA,human,RenCell VM cells,unspecified,NA,ctgtggtgcaataatagt,Others (2'-MOE),NA,20,uM,Inclusion[%],58.78,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 21,NA,mouse,mouse neuroblastoma,Lipofectamine RNAiMAX Transfection Reagent,NA,agttggagcaagattatc,Others (2'-MOE),NA,0.03,uM,Inclusion[%],24.83,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 21,NA,mouse,mouse neuroblastoma,Lipofectamine RNAiMAX Transfection Reagent,NA,agttggagcaagattatc,Others (2'-MOE),NA,0.08,uM,Inclusion[%],8.16,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 21,NA,mouse,mouse neuroblastoma,Lipofectamine RNAiMAX Transfection Reagent,NA,agttggagcaagattatc,Others (2'-MOE),NA,0.2,uM,Inclusion[%],4.76,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 21,NA,mouse,"intracerebroventricular (ICV) injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,agttggagcaagattatc,Others (2'-MOE),NA,300,ug,Inclusion[%],1.08,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 21,NA,mouse,"intracerebroventricular (ICV) injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,aaggattaaaggtagcaa,Others (2'-MOE),NA,300,ug,Inclusion[%],1.25,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 21,NA,mouse,"intracerebroventricular (ICV) injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,cataagtcacagtgcaag,Others (2'-MOE),NA,300,ug,Inclusion[%],1.4,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 21,NA,mouse,"ICV injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,agttggagcaagattatc,Others (2'-MOE),NA,33,ug,Inclusion[%],2.92,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 21,NA,mouse,"ICV injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,agttggagcaagattatc,Others (2'-MOE),NA,100,ug,Inclusion[%],1.86,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 21,NA,mouse,"ICV injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,agttggagcaagattatc,Others (2'-MOE),NA,300,ug,Inclusion[%],1.24,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
journal article,Antisense Oligomers For Treatment Of Conditions And Diseases,CA3073515A1,SCN1A,pseudoexon,pseudoexon 21,NA,mouse,"ICV injection of selected ASOs in C57BL6J mice (male, 3 months old)",Null,NA,agttggagcaagattatc,Others (2'-MOE),NA,20,ug,Inclusion[%],0.97,NA,NA,NA,DNA,https://patents.google.com/patent/CA3073515A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,10,uM,Skip,71.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,aggttgtgtcaccagagtaacagtctgagt,unmodified PMO,NA,10,uM,Skip,34.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ggcagtttccttagtaaccacaggttgtgt,unmodified PMO,NA,10,uM,Skip,40.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,agatggcagtttccttagtaaccacaggtt,unmodified PMO,NA,10,uM,Skip,35.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,mouse,"hDMD/Dmd-null mice, i.m. TA",Null,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,50,ug,Skip,4.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,10,uM,Skip,37.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,18.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,10,uM,Skip,3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,37.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,55,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,38.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,53.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,29.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,46.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,caccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,31.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,caccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,48.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,accagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,26.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,accagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,42.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,32.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,48.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,32,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,49.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,27.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,43.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,caccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,25,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,caccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,43.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,accagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,27.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,accagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,40.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ccacaggttgtgtcaccagagtaacagtct,unmodified PMO,NA,10,uM,Skip,11.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ttataacttgatcaagcagagaaagccagt,unmodified PMO,NA,10,uM,Skip,4.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ataccttctgcttgatgatcatctcgttga,unmodified PMO,NA,10,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,5,uM,Skip,44.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,5,uM,Skip,27.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,5,uM,Skip,28.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,5,uM,Skip,18.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,5,uM,Skip,10.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,5,uM,Skip,2.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,5,uM,Skip,1.15,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,5,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,23.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,1,uM,Skip,11,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,3,uM,Skip,27.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,1,uM,Skip,2.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,3,uM,Skip,6.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex52del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,3,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,1,uM,Skip,24.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,3,uM,Skip,45.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,10,uM,Skip,65,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,1,uM,Skip,13.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,3,uM,Skip,33.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,10,uM,Skip,50.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,1,uM,Skip,2.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,3,uM,Skip,8.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,20.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,1,uM,Skip,0.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,3,uM,Skip,1.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex48-50del immortalized primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,10,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex45-50del primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,10,uM,Skip,36.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex45-50del primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,10,uM,Skip,26.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex45-50del primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,12.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex45-50del primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,10,uM,Skip,6.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex49-50del primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,10,uM,Skip,14.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex49-50del primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,10,uM,Skip,5.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex49-50del primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Ex49-50del primary DMD human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,10,uM,Skip,1.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Healthy human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,10,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Healthy human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,10,uM,Skip,23.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Healthy human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,15.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,human,Healthy human skeletal muscle cells,Endo-porter transfection reagent (6 ?u),NA,tcaaggaagatggcatttct,unmodified PMO,NA,10,uM,Skip,3.5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,mouse,"hDMD/Dmd-null mice, i.m. TA",Null,NA,gtgtcaccagagtaacagtctgagtaggag,unmodified PMO,NA,50,ug,Skip,7.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,mouse,"hDMD/Dmd-null mice, i.m. TA",Null,NA,atggcatttctagtttggagatggcagttt,unmodified PMO,NA,50,ug,Skip,1.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
patent,Antisense Oligonucleotides That Bind To Exon 51 Of Human Dystrophin Pre-Mrna,WO2019014772A1,DMD,exon,51,NA,mouse,"hDMD/Dmd-null mice, i.m. TA",Null,NA,tcaaggaagatggcatttct,unmodified PMO,NA,50,ug,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/WO2019014772A1,NA,NA,NA
journal article,Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy,PMID 30439648,DYSF,exon,28/29,NA,human,Human fibroblasts c.5077C >T(ID MM-Pt2),"Endoporter, 6 uM",NA,actcaatgtcatccttgggaagcaccttct/ctcagcagggacccagtgcttcggcttccg,unmodified PMO,NA,10,uM,Skip,59.32,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30439648,NA,NA,NA
journal article,Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy,PMID 30439648,DYSF,exon,28/29,NA,human,Human fibroblasts c.5077C >T(ID MM-Pt2),"Endoporter, 6 uM",NA,actcaatgtcatccttgggaagcaccttct/tcttctcagcagggacccagtgcttcggct,unmodified PMO,NA,10,uM,Skip,54.43,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30439648,NA,NA,NA
journal article,Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy,PMID 30439648,DYSF,exon,28/29,NA,human,Human fibroblasts c.5077C >T(ID MM-Pt2),"Endoporter, 6 uM",NA,actcaatgtcatccttgggaagcaccttct/tacatcttctcagcagggacccagtgcttc,unmodified PMO,NA,10,uM,Skip,52.05,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30439648,NA,NA,NA
journal article,Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy,PMID 30439648,DYSF,exon,28/29,NA,human,Human fibroblasts c.5077C >T(ID MM-Pt2),"Endoporter, 6 uM",NA,gggcactcaatgtcatccttgggaagcacc/ctcagcagggacccagtgcttcggcttccg,unmodified PMO,NA,10,uM,Skip,59.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30439648,NA,NA,NA
journal article,Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy,PMID 30439648,DYSF,exon,28/29,NA,human,Human fibroblasts c.5077C >T(ID MM-Pt2),"Endoporter, 6 uM",NA,gggcactcaatgtcatccttgggaagcacc/tcttctcagcagggacccagtgcttcggct,unmodified PMO,NA,10,uM,Skip,58.41,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30439648,NA,NA,NA
journal article,Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy,PMID 30439648,DYSF,exon,28/29,NA,human,Human fibroblasts c.5077C >T(ID MM-Pt2),"Endoporter, 6 uM",NA,gggcactcaatgtcatccttgggaagcacc/tacatcttctcagcagggacccagtgcttc,unmodified PMO,NA,10,uM,Skip,51.59,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30439648,NA,NA,NA
journal article,Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy,PMID 30439648,DYSF,exon,28/29,NA,human,Human fibroblasts c.5077C >T(ID MM-Pt2),"Endoporter, 6 uM",NA,cattcctcatcttcccacttccagcccagt/ctcagcagggacccagtgcttcggcttccg,unmodified PMO,NA,10,uM,Skip,50.45,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30439648,NA,NA,NA
journal article,Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy,PMID 30439648,DYSF,exon,28/29,NA,human,Human fibroblasts c.5077C >T(ID MM-Pt2),"Endoporter, 6 uM",NA,cattcctcatcttcccacttccagcccagt/tcttctcagcagggacccagtgcttcggct,unmodified PMO,NA,10,uM,Skip,56.14,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30439648,NA,NA,NA
journal article,Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy,PMID 30439648,DYSF,exon,28/29,NA,human,Human fibroblasts c.5077C >T(ID MM-Pt2),"Endoporter, 6 uM",NA,cattcctcatcttcccacttccagcccagt/tacatcttctcagcagggacccagtgcttc,unmodified PMO,NA,10,uM,Skip,57.95,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/30439648,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cacttaccagcccatcttctcctgg,unmodified PMO,NA,2,Null,Skip,89.97,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctggtcctgggaaggt,unmodified PMO,NA,2,Null,Skip,79.13,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctg,unmodified PMO,NA,2,Null,Skip,85.44,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,gcccatcttctcctggtcctggg,unmodified PMO,NA,2,Null,Skip,75.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,ccagcccatcttctcctggtcctgg,unmodified PMO,NA,2,Null,Skip,85.44,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctggtcctgggaaggt,unmodified PMO,NA,1,Null,Skip,45.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctg,unmodified PMO,NA,1,Null,Skip,42.56,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,gcccatcttctcctggtcctggg,unmodified PMO,NA,1,Null,Skip,41.59,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,ccagcccatcttctcctggtcctgg,unmodified PMO,NA,1,Null,Skip,49.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cacttaccagcccatcttctcctgg,unmodified PMO,NA,1,Null,Skip,60.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctggtcctgggaaggt,unmodified PMO,NA,0.5,Null,Skip,17.8,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctg,unmodified PMO,NA,0.5,Null,Skip,22.01,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,gcccatcttctcctggtcctggg,unmodified PMO,NA,0.5,Null,Skip,18.61,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,ccagcccatcttctcctggtcctgg,unmodified PMO,NA,0.5,Null,Skip,25.24,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cacttaccagcccatcttctcctgg,unmodified PMO,NA,0.5,Null,Skip,35.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctggtcctgggaaggt,unmodified PMO,NA,0.25,Null,Skip,7.93,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctg,unmodified PMO,NA,0.25,Null,Skip,7.44,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,gcccatcttctcctggtcctggg,unmodified PMO,NA,0.25,Null,Skip,6.63,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,ccagcccatcttctcctggtcctgg,unmodified PMO,NA,0.25,Null,Skip,12.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cacttaccagcccatcttctcctgg,unmodified PMO,NA,0.25,Null,Skip,14.56,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctggtcctgggaaggt,unmodified PMO,NA,1,Null,Skip,45.71,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctg,unmodified PMO,NA,1,Null,Skip,42.35,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,gcccatcttctcctggtcctggg,unmodified PMO,NA,1,Null,Skip,41.34,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,ccagcccatcttctcctggtcctgg,unmodified PMO,NA,1,Null,Skip,49.24,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cacttaccagcccatcttctcctgg,unmodified PMO,NA,1,Null,Skip,60.17,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctg,unmodified PMO,NA,1,Null,Skip,49.08,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,gcccatcttctcctggtcctggg,unmodified PMO,NA,1,Null,Skip,92.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,ccagcccatcttctcctggtcctgg,unmodified PMO,NA,1,Null,Skip,71.09,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,RD Cells,"Life technologies, Carlsbad, Calif.",NA,cacttaccagcccatcttctcctgg,unmodified PMO,NA,1,Null,Skip,74.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,C2C12 Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctggtcctgggaaggt,unmodified PMO,NA,2,Null,Skip,68.74,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,C2C12 Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctg,unmodified PMO,NA,2,Null,Skip,74.63,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,C2C12 Cells,"Life technologies, Carlsbad, Calif.",NA,gcccatcttctcctggtcctggg,unmodified PMO,NA,2,Null,Skip,69.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,C2C12 Cells,"Life technologies, Carlsbad, Calif.",NA,ccagcccatcttctcctggtcctgg,unmodified PMO,NA,2,Null,Skip,75.61,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,C2C12 Cells,"Life technologies, Carlsbad, Calif.",NA,cacttaccagcccatcttctcctgg,unmodified PMO,NA,2,Null,Skip,73.81,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,C2C12 Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctggtcctgggaaggt,unmodified PMO,NA,0.5,Null,Skip,19.15,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,C2C12 Cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctg,unmodified PMO,NA,0.5,Null,Skip,31.1,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,C2C12 Cells,"Life technologies, Carlsbad, Calif.",NA,gcccatcttctcctggtcctggg,unmodified PMO,NA,0.5,Null,Skip,26.68,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,C2C12 Cells,"Life technologies, Carlsbad, Calif.",NA,ccagcccatcttctcctggtcctgg,unmodified PMO,NA,0.5,Null,Skip,16.04,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,C2C12 Cells,"Life technologies, Carlsbad, Calif.",NA,cacttaccagcccatcttctcctgg,unmodified PMO,NA,0.5,Null,Skip,30.93,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctggtcctgggaaggt,unmodified PMO,NA,2,Null,Skip,47.12,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctg,unmodified PMO,NA,2,Null,Skip,64.74,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,gcccatcttctcctggtcctggg,unmodified PMO,NA,2,Null,Skip,54.81,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,ccagcccatcttctcctggtcctgg,unmodified PMO,NA,2,Null,Skip,77.24,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,cacttaccagcccatcttctcctgg,unmodified PMO,NA,2,Null,Skip,57.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctggtcctgggaaggt,unmodified PMO,NA,0.5,Null,Skip,12.18,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,cagcccatcttctcctg,unmodified PMO,NA,0.5,Null,Skip,17.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,gcccatcttctcctggtcctggg,unmodified PMO,NA,0.5,Null,Skip,24.52,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,ccagcccatcttctcctggtcctgg,unmodified PMO,NA,0.5,Null,Skip,10.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,cacttaccagcccatcttctcctgg,unmodified PMO,NA,0.5,Null,Skip,30.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,H2Kb mdx cells,"Life technologies, Carlsbad, Calif.",NA,unspecified,unmodified PMO,NA,0.5,Null,Skip,20.99,NA,NA,NA,RNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,ccatccgcttgcattagaaagtcagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,gcattagaaaatcagctataaatg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,ccacttgcattagaaaatcagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,cttgcattagaaaatcagctataaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,cacttgcattagaaaatcagctata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,ccacttgcattagaaaatcagctat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,tccacttgcattagaaaatcagcta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,atccacttgcattagaaaatcagct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,catccacttgcattagaaaatcagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,ttattttcagttatcacttaccagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,ttttcagttatcacttaccagccca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,tcagttatcacttaccagcccatct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,gttatcacttaccagcccatcttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,atcacttaccagcccatcttctcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,acttaccagcccatcttctcctggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,taccagcccatcttctcctggtcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,atgttattttcagttatcacttacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,tgttattttcagttatcacttacca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,gttattttcagttatcacttaccag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,tattttcagttatcacttaccagcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,attttcagttatcacttaccagccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,tttcagttatcacttaccagcccat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,ttcagttatcacttaccagcccatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,cagttatcacttaccagcccatctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,mouse,Null,Null,NA,agttatcacttaccagcccatcttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,cagcccatcttctcctggtcctgggaaggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,cagcccatcttctcctggtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,tctcctggtcctgggaaggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,ctgggaaggttacagcaaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,tttaaagaagcaacatttgggtttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,tattttagagctaaatttaaagaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,tactttattgtattgtattttagag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,tagttgggcctttactactttattg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,tctcaaatatatccatagttgggcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,acgggtctcaaatatatccatagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,gttgtaggagtctcgacgggtctcaaatat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,acactgttgtaggagtctcgacggg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,taggtttgatgagtctcaggatttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,ccgtctttcataggtttgatgagtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,cagtataccttgtaccgtctttcataggtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,gggttcatgtcaagtttcagagatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,aataccagtgcctgggttcatgtcaagttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,aaataccagtgcctgggttcatgtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,tctgccaaataccagtgcctgggtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,tcttcacatcaatgctctgccaaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,caggttgtttgagccaattttgcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,tgcctaagttggattcaggttgttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,aagcttttatttcaatgcctaagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,gaccattctcatctaaagcttttat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Compositions And Methods For Treating Duchenne Muscular Dystrophy And Related Disorders,US20190177723A1,MSTN,exon,2,NA,human,Null,Null,NA,ttacagcaagatcatgaccattctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US20190177723A1,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,unmodified PMO,NA,1.25,uM,Skip,0.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,modified PMO (PPMO),NA,1.25,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,unmodified PMO,NA,2.5,uM,Skip,1.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,modified PMO (PPMO),NA,2.5,uM,Skip,3.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,unmodified PMO,NA,5,uM,Skip,2.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,modified PMO (PPMO),NA,5,uM,Skip,5.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,6.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,modified PMO (PPMO),NA,10,uM,Skip,9.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,unmodified PMO,NA,20,uM,Skip,10.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,modified PMO (PPMO),NA,20,uM,Skip,16.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,unmodified PMO,NA,40,uM,Skip,19.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Exon Skipping Oligomer Conjugates For Muscular Dystrophy,US/2018/271993,DMD,exon,53,NA,human,healthy human myoblasts,Null,NA,gttgcctccggttctgaaggtgttc,modified PMO (PPMO),NA,40,uM,Skip,26.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2018/271993,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,acggucgcccuucagcccgcguu,2OMe,NA,0.1,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ccccugagggccagggucuccacgg,unspecified,NA,0.1,uM,Skip,10,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,cagaccagguggccccugagggcca,unspecified,NA,0.1,uM,Skip,2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ucuccacggucgcccuucagcccgcguucu,unspecified,NA,0.1,uM,Skip,82,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ucuccacggucgcccuucagcccgc,unspecified,NA,0.1,uM,Skip,80,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ucuccaggaaagccgauggggccc,2OMe,NA,0.1,uM,Skip,67,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,agcccgcguucuccaggaaagccga,2OMe,NA,0.1,uM,Skip,69,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,gucgcccuucagcccgcguucucca,2OMe,NA,0.1,uM,Skip,67,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ccaagggccagaccagguggcccc,unspecified,NA,0.1,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ccagaccagguggccccugagggcc,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ucuccccaagggccagaccagg,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ggaaggcccgggggggccccucuc,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ccggcaaggccggaaggcccgggg,unspecified,NA,0.1,uM,Skip,6,NA,NA,NA,Unknown,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,aggcuuuccaggcuccccggcaag,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,cgggaauaccaggcuuuccaggcu,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ugccugggagcccgggaauacca,unspecified,NA,0.1,uM,Skip,17,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,cccacacccccagcccugccuggg,unspecified,NA,0.1,uM,Skip,8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ccucucccacacccccagcccu,unspecified,NA,0.1,uM,Skip,8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ucucuccuggccuuccugccucu,unspecified,NA,0.1,uM,Skip,9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,cacccucucuccuggccuuccu,unspecified,NA,0.1,uM,Skip,11,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ccagccucacccucucuccugg,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,cuccaggaaagccgauggggccc,2OMe,NA,0.1,uM,Skip,74,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,uccaggaaagccgauggggccc,2OMe,NA,0.1,uM,Skip,58,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ccaggaaagccgauggggccc,2OMe,NA,0.1,uM,Skip,64,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,cuccaggaaauccgauggggcccu,2OMe,NA,0.1,uM,Skip,64,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,uccaggaaagccgauggggcccug,2OMe,NA,0.1,uM,Skip,72,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,uccaggaaagccgauggg,2OMe,NA,0.1,uM,Skip,32,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,uccaggaaagccgaugg,2OMe,NA,0.1,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,uccaggaaagccgaug,2OMe,NA,0.1,uM,Skip,49,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,cuccaggaaagccgaugg,2OMe,NA,0.1,uM,Skip,53,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ucuccaggaaagccgaug,2OMe,NA,0.1,uM,Skip,66,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ccaggaaagccgauggggcccugc,2OMe,NA,0.1,uM,Skip,54,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,aggaaagccgauggggcccugcag,unspecified,NA,0.1,uM,Skip,22,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,gaaagccgauggggcccugcagga,unspecified,NA,0.1,uM,Skip,40,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,aagccgauggggcccugcaggagu,unspecified,NA,0.1,uM,Skip,20,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,gccgauggggcccugcaggagugg,unspecified,NA,0.1,uM,Skip,5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,gauggggcccugcaggaguggaa,unspecified,NA,0.1,uM,Skip,6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,uccaggaaag,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,cguucuccaggaaagccgaug,2OMe,NA,0.1,uM,Skip,76,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,Hela,Null,NA,ccugagggccagggucuccacg,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ucuccacggucgcccuucagcccgcguucu,unspecified,NA,0.1,uM,Skip,96,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ucuccacggucgcccuucagcccgc,unspecified,NA,0.1,uM,Skip,73,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ucuccaggaaagccgauggggccc,2OMe,NA,0.1,uM,Skip,86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,agcccgcguucuccaggaaagccga,2OMe,NA,0.1,uM,Skip,85,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,gucgcccuucagcccgcguucucca,2OMe,NA,0.1,uM,Skip,92,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,acggucgcccuucagcccgcguu,2OMe,NA,0.1,uM,Skip,83,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ccccugagggccagggucuccacgg,unspecified,NA,0.1,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,cagaccagguggccccugagggcca,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ccaagggccagaccagguggcccc,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ccagaccagguggccccugagggcc,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ucuccccaagggccagaccagg,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ggaaggcccgggggggccccucuc,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ccggcaaggccggaaggcccgggg,unspecified,NA,0.1,uM,Skip,6,NA,NA,NA,Unknown,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,aggcuuuccaggcuccccggcaag,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,cgggaauaccaggcuuuccaggcu,unspecified,NA,0.1,uM,Skip,2,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ugccugggagcccgggaauacca,unspecified,NA,0.1,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,cccacacccccagcccugccuggg,unspecified,NA,0.1,uM,Skip,8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ccucucccacacccccagcccu,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ucucuccuggccuuccugccucu,unspecified,NA,0.1,uM,Skip,9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,cacccucucuccuggccuuccu,unspecified,NA,0.1,uM,Skip,13,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ccagccucacccucucuccugg,unspecified,NA,0.1,uM,Skip,7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,cuccaggaaagccgauggggccc,2OMe,NA,0.1,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,uccaggaaagccgauggggccc,2OMe,NA,0.1,uM,Skip,89,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ccaggaaagccgauggggccc,2OMe,NA,0.1,uM,Skip,85,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,cuccaggaaauccgauggggcccu,2OMe,NA,0.1,uM,Skip,83,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,uccaggaaagccgauggggcccug,2OMe,NA,0.1,uM,Skip,93,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,uccaggaaagccgauggg,2OMe,NA,0.1,uM,Skip,73,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,uccaggaaagccgaugg,2OMe,NA,0.1,uM,Skip,88,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,uccaggaaagccgaug,2OMe,NA,0.1,uM,Skip,79,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,cuccaggaaagccgaugg,2OMe,NA,0.1,uM,Skip,86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ucuccaggaaagccgaug,2OMe,NA,0.1,uM,Skip,89,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ccaggaaagccgauggggcccugc,2OMe,NA,0.1,uM,Skip,92,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,aggaaagccgauggggcccugcag,unspecified,NA,0.1,uM,Skip,49,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,gaaagccgauggggcccugcagga,unspecified,NA,0.1,uM,Skip,37,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,aagccgauggggcccugcaggagu,unspecified,NA,0.1,uM,Skip,47,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,gccgauggggcccugcaggagugg,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,gauggggcccugcaggaguggaa,unspecified,NA,0.1,uM,Skip,7,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,uccaggaaag,unspecified,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,cguucuccaggaaagccgaug,2OMe,NA,0.1,uM,Skip,91,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
patent,Oligonucleotides Matching Col7a1 Exon 73 For Epidermolysis Bullosa Therapy,US/2018/216106,COL7A1,exon,73,NA,human,hunian  primary  fibroblasts,Null,NA,ccugagggccagggucuccacg,unspecified,NA,0.1,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2018/216106,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccacatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccacatcctggagttc,unmodified PMO,NA,3,uM,Skip,12.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccacatcctggagttc,unmodified PMO,NA,10,uM,Skip,51.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,1,uM,Skip,5.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,3,uM,Skip,12.62,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,10,uM,Skip,54.57,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gccgctgcccacatcctggagttcct,unmodified PMO,NA,1,uM,Skip,2.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gccgctgcccacatcctggagttcct,unmodified PMO,NA,3,uM,Skip,12.93,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gccgctgcccacatcctggagttcct,unmodified PMO,NA,10,uM,Skip,47.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatgtcctggagttcct,unmodified PMO,NA,1,uM,Skip,3.15,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatgtcctggagttcct,unmodified PMO,NA,3,uM,Skip,10.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatgtcctggagttcct,unmodified PMO,NA,10,uM,Skip,49.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,1,uM,Skip,9.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,3,uM,Skip,38.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,10,uM,Skip,88.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgctggagttcct,unmodified PMO,NA,1,uM,Skip,3.56,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgctggagttcct,unmodified PMO,NA,3,uM,Skip,21.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgctggagttcct,unmodified PMO,NA,10,uM,Skip,70.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctctggagttcct,unmodified PMO,NA,1,uM,Skip,9.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctctggagttcct,unmodified PMO,NA,3,uM,Skip,32.91,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctctggagttcct,unmodified PMO,NA,10,uM,Skip,79.34,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,1,uM,Skip,4.35,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,3,uM,Skip,17.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,10,uM,Skip,49.73,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccatcctggagttcct,unmodified PMO,NA,1,uM,Skip,3.67,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccatcctggagttcct,unmodified PMO,NA,3,uM,Skip,19.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccatcctggagttcct,unmodified PMO,NA,10,uM,Skip,72.69,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgccgctgccatcctggagttcct,unmodified PMO,NA,1,uM,Skip,2.99,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgccgctgccatcctggagttcct,unmodified PMO,NA,3,uM,Skip,16.58,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgccgctgccatcctggagttcct,unmodified PMO,NA,10,uM,Skip,59.1,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,1,uM,Skip,4.57,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,3,uM,Skip,21.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,10,uM,Skip,58.56,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccatcctggagttcct,unmodified PMO,NA,1,uM,Skip,5.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccatcctggagttcct,unmodified PMO,NA,3,uM,Skip,21.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccatcctggagttcct,unmodified PMO,NA,10,uM,Skip,68.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgccgctgcctcctggagttcc,unmodified PMO,NA,1,uM,Skip,2.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgccgctgcctcctggagttcc,unmodified PMO,NA,3,uM,Skip,11.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgccgctgcctcctggagttcc,unmodified PMO,NA,10,uM,Skip,52.2,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tgccgctgcccgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,4.89,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tgccgctgcccgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,24.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tgccgctgcccgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,64.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcct,unmodified PMO,NA,1,uM,Skip,8.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcct,unmodified PMO,NA,3,uM,Skip,24.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcct,unmodified PMO,NA,10,uM,Skip,75.37,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgcccatcctggagttcct,unmodified PMO,NA,1,uM,Skip,14.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgcccatcctggagttcct,unmodified PMO,NA,3,uM,Skip,47.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgcccatcctggagttcct,unmodified PMO,NA,10,uM,Skip,77.98,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,1,uM,Skip,5.87,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,3,uM,Skip,37.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,10,uM,Skip,94.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,7.67,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,17.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,59.05,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,1,uM,Skip,26.35,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,3,uM,Skip,35.56,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,10,uM,Skip,84.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccggagttcct,unmodified PMO,NA,1,uM,Skip,7.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccggagttcct,unmodified PMO,NA,3,uM,Skip,36.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccggagttcct,unmodified PMO,NA,10,uM,Skip,70.79,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcc,unmodified PMO,NA,1,uM,Skip,18.1,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcc,unmodified PMO,NA,3,uM,Skip,47.62,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcc,unmodified PMO,NA,10,uM,Skip,75.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccggagttcctg,unmodified PMO,NA,1,uM,Skip,15.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccggagttcctg,unmodified PMO,NA,3,uM,Skip,32.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccggagttcctg,unmodified PMO,NA,10,uM,Skip,92.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttc,unmodified PMO,NA,1,uM,Skip,23.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttc,unmodified PMO,NA,3,uM,Skip,61.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttc,unmodified PMO,NA,10,uM,Skip,87.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcc,unmodified PMO,NA,1,uM,Skip,26.98,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcc,unmodified PMO,NA,3,uM,Skip,67.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcc,unmodified PMO,NA,10,uM,Skip,99.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,3,uM,Skip,41.2,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tggagttcct,unmodified PMO,NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccc,unmodified PMO,NA,3,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tggagttcct-cagtttgccgctgccc,unmodified PMO,NA,3,uM,Skip,2.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcct,unmodified PMO,NA,3,uM,Skip,32,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgc,unmodified PMO,NA,3,uM,Skip,0.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cctggagttcct,unmodified PMO,NA,3,uM,Skip,0.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgc-cctggagttcct,unmodified PMO,NA,3,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,caguugcauucaacauccuggaguuc,2OMe,NA,0.1,uM,Skip,1.02,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uucuuccccaguucauccuggaguuc,2OMe,NA,0.1,uM,Skip,8.11,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,ugaauuauuucuucauccuggaguuc,2OMe,NA,0.1,uM,Skip,0.34,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,caguugcauucaaaaugccauccugg,2OMe,NA,0.1,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uucuuccccaguuaaugccauccugg,2OMe,NA,0.1,uM,Skip,2.73,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,ugaauuauuucuuaaugccauccugg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,gcagauucaggcucauccuggaguuc,2OMe,NA,0.1,uM,Skip,0.2,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cugccaccgcagacauccuggaguuc,2OMe,NA,0.1,uM,Skip,2.8,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,gcagauucaggcuaaugccauccugg,2OMe,NA,0.1,uM,Skip,11.93,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cugccaccgcagaaaugccauccugg,2OMe,NA,0.1,uM,Skip,0.48,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cagaccuccugccaaugccauccugg,2OMe,NA,0.1,uM,Skip,3.02,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uucaggcuucccagccgcugcccaau,2OMe,NA,0.1,uM,Skip,11.93,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,accgcagauucaggccgcugcccaau,2OMe,NA,0.1,uM,Skip,0.87,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cuccugccaccgcgccgcugcccaau,2OMe,NA,0.1,uM,Skip,0.68,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uucaggcuucccaacaacaguuugcc,2OMe,NA,0.1,uM,Skip,15.61,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,accgcagauucagacaacaguuugcc,2OMe,NA,0.1,uM,Skip,2.25,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cuccugccaccgcacaacaguuugcc,2OMe,NA,0.1,uM,Skip,1.02,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cuucccaauuuuuuuccccaguugca,2OMe,NA,0.1,uM,Skip,1.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,auucaggcuucccuuccccaguugca,2OMe,NA,0.1,uM,Skip,0.34,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,accgcagauucaguuccccaguugca,2OMe,NA,0.1,uM,Skip,5.39,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cuucccaauuuuuaauuauuucuucc,2OMe,NA,0.1,uM,Skip,1.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,auucaggcuucccaauuauuucuucc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,accgcagauucagaauuauuucuucc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cuucccaauuuuugauugcugaauua,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,auucaggcuucccgauugcugaauua,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,accgcagauucaggauugcugaauua,2OMe,NA,0.1,uM,Skip,0.34,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,2.58,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,17.01,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,55.5,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acctcctgccaccgctcttccccagttgca,unmodified PMO,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acctcctgccaccgctcttccccagttgca,unmodified PMO,NA,3,uM,Skip,4.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acctcctgccaccgctcttccccagttgca,unmodified PMO,NA,10,uM,Skip,22.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tggcatctgttttcatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.72,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tggcatctgttttcatcctggagttc,unmodified PMO,NA,3,uM,Skip,4.98,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tggcatctgttttcatcctggagttc,unmodified PMO,NA,10,uM,Skip,16.15,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ctcctgccaccgctggcatctgtttt,unmodified PMO,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ctcctgccaccgctggcatctgtttt,unmodified PMO,NA,3,uM,Skip,0.69,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ctcctgccaccgctggcatctgtttt,unmodified PMO,NA,10,uM,Skip,1.89,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgtagaataccatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgtagaataccatcctggagttc,unmodified PMO,NA,3,uM,Skip,2.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgtagaataccatcctggagttc,unmodified PMO,NA,10,uM,Skip,4.98,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,3,uM,Skip,22.49,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctcctggagttcct,unmodified PMO,NA,10,uM,Skip,62.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctggagttcct,unmodified PMO,NA,3,uM,Skip,0.79,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctggagttcct,unmodified PMO,NA,10,uM,Skip,1.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcc,unmodified PMO,NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcc,unmodified PMO,NA,10,uM,Skip,1.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,22.49,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,56.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gccatcctggagttc,unmodified PMO,NA,3,uM,Skip,1.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gccatcctggagttc,unmodified PMO,NA,10,uM,Skip,7.69,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgc,unmodified PMO,NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgc,unmodified PMO,NA,10,uM,Skip,1.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,23.67,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,76.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccac,unmodified PMO,NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccac,unmodified PMO,NA,10,uM,Skip,1.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccactggagttcct,unmodified PMO,NA,1,uM,Skip,2.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccactggagttcct,unmodified PMO,NA,3,uM,Skip,14.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccactggagttcct,unmodified PMO,NA,10,uM,Skip,35.47,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccactggagttcctgt,unmodified PMO,NA,1,uM,Skip,6.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccactggagttcctgt,unmodified PMO,NA,3,uM,Skip,13.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccactggagttcctgt,unmodified PMO,NA,10,uM,Skip,44.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,1,uM,Skip,15.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,3,uM,Skip,37,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,10,uM,Skip,73.39,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,1,uM,Skip,13.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,3,uM,Skip,43.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcct,unmodified PMO,NA,10,uM,Skip,74.87,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatgtggagttcctgt,unmodified PMO,NA,1,uM,Skip,2.07,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatgtggagttcctgt,unmodified PMO,NA,3,uM,Skip,5.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatgtggagttcctgt,unmodified PMO,NA,10,uM,Skip,23.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatctggagttcct,unmodified PMO,NA,1,uM,Skip,3.11,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatctggagttcct,unmodified PMO,NA,3,uM,Skip,16.58,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatctggagttcct,unmodified PMO,NA,10,uM,Skip,58.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,1,uM,Skip,6.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,3,uM,Skip,32.51,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,10,uM,Skip,65.41,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cagaccuccugccacgccauccuggaguuc,2OMe,NA,0.1,uM,Skip,53.67,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,ccuccugccaccgcacauccuggaguuccu,2OMe,NA,0.1,uM,Skip,49.92,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cagaccuccugccaccauccuggaguuccu,2OMe,NA,0.1,uM,Skip,32.14,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuugcagaccuccugcauccuggaguuccu,2OMe,NA,0.1,uM,Skip,9.98,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,gaccuccugccacaugccauccuggaguuc,2OMe,NA,0.1,uM,Skip,8.42,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cagaccuccugccacaguuccuguaagaua,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uucuuccccaguugcgccauccuggaguuc,2OMe,NA,0.1,uM,Skip,39.94,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uccccaguugcauuccauccuggaguuccu,2OMe,NA,0.1,uM,Skip,53.67,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uucuuccccaguugccauccuggaguuccu,2OMe,NA,0.1,uM,Skip,51.48,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuauuucuuccccagcauccuggaguuccu,2OMe,NA,0.1,uM,Skip,17.16,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cuuccccaguugcaugccauccuggaguuc,2OMe,NA,0.1,uM,Skip,58.97,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uucuuccccaguugcaguuccuguaagaua,2OMe,NA,0.1,uM,Skip,9.05,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,ccuguagaauacugggaggauugcugaauu,2OMe,NA,0.1,uM,Skip,2.18,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uucuuccccaguugcgccauccuggaguuc,2OMe,NA,0.03,uM,Skip,60.91,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uucuuccccaguugcgccauccuggaguuc,2OMe,NA,0.1,uM,Skip,69.26,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uccccaguugcauucgccauccuggaguuc,2OMe,NA,0.03,uM,Skip,62.43,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uccccaguugcauucgccauccuggaguuc,2OMe,NA,0.1,uM,Skip,74.95,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuauuucuuccccaggccauccuggaguuc,2OMe,NA,0.03,uM,Skip,24.1,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuauuucuuccccaggccauccuggaguuc,2OMe,NA,0.1,uM,Skip,36.62,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cagaccuccugccacgccauccuggaguuc,2OMe,NA,0.03,uM,Skip,57.87,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cagaccuccugccacgccauccuggaguuc,2OMe,NA,0.1,uM,Skip,73.81,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,ccuccugccaccgcagccauccuggaguuc,2OMe,NA,0.03,uM,Skip,57.31,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,ccuccugccaccgcagccauccuggaguuc,2OMe,NA,0.1,uM,Skip,64.71,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuugcagaccuccuggccauccuggaguuc,2OMe,NA,0.03,uM,Skip,13.09,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuugcagaccuccuggccauccuggaguuc,2OMe,NA,0.1,uM,Skip,25.61,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cagaccuccugccacgccauccuggaguuc,2OMe,NA,0.1,uM,Skip,61.4,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cuggcaucuguuuuuuugccgcugcccaau,2OMe,NA,0.1,uM,Skip,4.56,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuuuccuguagaauauugccgcugcccaau,2OMe,NA,0.1,uM,Skip,4.21,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cugucugacagcugugccauccuggaguuc,2OMe,NA,0.1,uM,Skip,30.18,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,ggauugcugaauuaugccauccuggaguuc,2OMe,NA,0.1,uM,Skip,31.23,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuuuccuguagaauagccauccuggaguuc,2OMe,NA,0.1,uM,Skip,21.4,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,guuugccgcugcccacauccuggaguuccu,2OMe,NA,0.1,uM,Skip,64.91,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuuuccuguagaauacauccuggaguuccu,2OMe,NA,0.03,uM,Skip,15.41,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuuuccuguagaauacauccuggaguuccu,2OMe,NA,0.1,uM,Skip,14.28,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cuggcaucuguuuuugccauccuggaguuc,2OMe,NA,0.03,uM,Skip,23.31,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cuggcaucuguuuuugccauccuggaguuc,2OMe,NA,0.1,uM,Skip,20.3,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,accuccugccaccgccuggcaucuguuuuu,2OMe,NA,0.03,uM,Skip,10.53,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,accuccugccaccgccuggcaucuguuuuu,2OMe,NA,0.1,uM,Skip,17.29,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuucuuccccaguuguugccgcugcccaau,2OMe,NA,0.03,uM,Skip,15.41,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuucuuccccaguuguugccgcugcccaau,2OMe,NA,0.1,uM,Skip,33.83,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,uuuuccuguagaauauuucuuccccaguug,2OMe,NA,0.1,uM,Skip,1.88,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,accuccugccaccgcuuucuuccccaguug,2OMe,NA,0.03,uM,Skip,18.8,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,accuccugccaccgcuuucuuccccaguug,2OMe,NA,0.1,uM,Skip,40.41,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cagaccuccugccacgccauccuggaguuc,2OMe,NA,0.03,uM,Skip,57.14,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Lipofectamin2000,NA,cagaccuccugccacgccauccuggaguuc,2OMe,NA,0.1,uM,Skip,68.05,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,2.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,11.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,60.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gacctcctgccaccatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.31,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gacctcctgccaccatcctggagttc,unmodified PMO,NA,3,uM,Skip,4.11,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gacctcctgccaccatcctggagttc,unmodified PMO,NA,10,uM,Skip,35.14,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gacctcctgccgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.31,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gacctcctgccgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,5.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gacctcctgccgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,27.1,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cttccccagttgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,2.24,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cttccccagttgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,13.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cttccccagttgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,42.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,1,uM,Skip,2.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,3,uM,Skip,11.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,10,uM,Skip,36.82,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,11.01,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,18.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,59.09,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cctgccaccgcagatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,2.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cctgccaccgcagatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,9.44,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cctgccaccgcagatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,48.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cctcctgccaccgcatcctggagttc,unmodified PMO,NA,1,uM,Skip,0.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cctcctgccaccgcatcctggagttc,unmodified PMO,NA,3,uM,Skip,6.47,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cctcctgccaccgcatcctggagttc,unmodified PMO,NA,10,uM,Skip,16.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acctcctgccacccatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.57,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acctcctgccacccatcctggagttc,unmodified PMO,NA,3,uM,Skip,3.67,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acctcctgccacccatcctggagttc,unmodified PMO,NA,10,uM,Skip,20.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gcagacctcctgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,0.87,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gcagacctcctgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,1.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gcagacctcctgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,18.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgtttgcagacccatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgtttgcagacccatcctggagttc,unmodified PMO,NA,3,uM,Skip,4.2,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgtttgcagacccatcctggagttc,unmodified PMO,NA,10,uM,Skip,20.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgcagacctcctggagttcctgta,unmodified PMO,NA,1,uM,Skip,0.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgcagacctcctggagttcctgta,unmodified PMO,NA,3,uM,Skip,0.87,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgcagacctcctggagttcctgta,unmodified PMO,NA,10,uM,Skip,9.62,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttccccagttgcacatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttccccagttgcacatcctggagttc,unmodified PMO,NA,3,uM,Skip,5.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttccccagttgcacatcctggagttc,unmodified PMO,NA,10,uM,Skip,26.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttcttccccagtcatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttcttccccagtcatcctggagttc,unmodified PMO,NA,3,uM,Skip,6.47,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttcttccccagtcatcctggagttc,unmodified PMO,NA,10,uM,Skip,31.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttatttcttccccagttcctgtaaga,unmodified PMO,NA,1,uM,Skip,0.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttatttcttccccagttcctgtaaga,unmodified PMO,NA,3,uM,Skip,0.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttatttcttccccagttcctgtaaga,unmodified PMO,NA,10,uM,Skip,6.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ggcttcccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ggcttcccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,9.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ggcttcccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,56.99,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gcttcccaatgccatcctggagttcc,unmodified PMO,NA,1,uM,Skip,3.15,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gcttcccaatgccatcctggagttcc,unmodified PMO,NA,3,uM,Skip,20.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gcttcccaatgccatcctggagttcc,unmodified PMO,NA,10,uM,Skip,67.66,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,4.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,27.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,65.33,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccccagttgcatctggagttcct,unmodified PMO,NA,1,uM,Skip,0.34,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccccagttgcatctggagttcct,unmodified PMO,NA,3,uM,Skip,3.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ccccagttgcatctggagttcct,unmodified PMO,NA,10,uM,Skip,21.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgccctggagttcc,unmodified PMO,NA,1,uM,Skip,3.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgccctggagttcc,unmodified PMO,NA,3,uM,Skip,12.73,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgccctggagttcc,unmodified PMO,NA,10,uM,Skip,62.31,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cttccccagttgccatcctggagttcct,unmodified PMO,NA,1,uM,Skip,4.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cttccccagttgccatcctggagttcct,unmodified PMO,NA,3,uM,Skip,21.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cttccccagttgccatcctggagttcct,unmodified PMO,NA,10,uM,Skip,78.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgccaccgcagattttcctgtagaata,unmodified PMO,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgccaccgcagattttcctgtagaata,unmodified PMO,NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgccaccgcagattttcctgtagaata,unmodified PMO,NA,10,uM,Skip,0.5,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,8,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,25.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,72.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,2.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,14.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,61.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttctgtctgacagctcctgccaccgcaga,unmodified PMO,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttctgtctgacagctcctgccaccgcaga,unmodified PMO,NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tttctgtctgacagctcctgccaccgcaga,unmodified PMO,NA,10,uM,Skip,0.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgccaccgcagactggcatctgttttt,unmodified PMO,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgccaccgcagactggcatctgttttt,unmodified PMO,NA,3,uM,Skip,1.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgccaccgcagactggcatctgttttt,unmodified PMO,NA,10,uM,Skip,5.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgccaccgcagagaggattgctgaatt,unmodified PMO,NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgccaccgcagagaggattgctgaatt,unmodified PMO,NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,tcctgccaccgcagagaggattgctgaatt,unmodified PMO,NA,10,uM,Skip,0.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,12.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttcttccccagttgcgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,50.73,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,2.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,12.58,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagacctcctgccacgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,57.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acctcctgccaccgcttgccgctgcccaat,unmodified PMO,NA,1,uM,Skip,0.66,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acctcctgccaccgcttgccgctgcccaat,unmodified PMO,NA,3,uM,Skip,1.99,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acctcctgccaccgcttgccgctgcccaat,unmodified PMO,NA,10,uM,Skip,13.91,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccacatcctggagttc,unmodified PMO,NA,1,uM,Skip,1.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccacatcctggagttc,unmodified PMO,NA,3,uM,Skip,9.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,ttgccgctgcccacatcctggagttc,unmodified PMO,NA,10,uM,Skip,37.09,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,1,uM,Skip,4.62,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,3,uM,Skip,19.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,10,uM,Skip,65.57,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctggagttcct,unmodified PMO,NA,1,uM,Skip,5.66,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctggagttcct,unmodified PMO,NA,3,uM,Skip,24.44,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctggagttcct,unmodified PMO,NA,10,uM,Skip,73.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,aacagtttgcccctggagttcc,unmodified PMO,NA,1,uM,Skip,3.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,aacagtttgcccctggagttcc,unmodified PMO,NA,3,uM,Skip,13.86,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,aacagtttgcccctggagttcc,unmodified PMO,NA,10,uM,Skip,41.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctcctggagttc,unmodified PMO,NA,1,uM,Skip,4.62,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctcctggagttc,unmodified PMO,NA,3,uM,Skip,11.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctcctggagttc,unmodified PMO,NA,10,uM,Skip,23.55,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,1,uM,Skip,4.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,3,uM,Skip,42.74,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,10,uM,Skip,90.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttcc,unmodified PMO,NA,1,uM,Skip,8.79,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttcc,unmodified PMO,NA,3,uM,Skip,34.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttcc,unmodified PMO,NA,10,uM,Skip,82.41,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctggagttcc,unmodified PMO,NA,1,uM,Skip,3.89,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctggagttcc,unmodified PMO,NA,3,uM,Skip,19.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgcctggagttcc,unmodified PMO,NA,10,uM,Skip,79.14,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,agtttgccgctcctggagttc,unmodified PMO,NA,1,uM,Skip,3.07,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,agtttgccgctcctggagttc,unmodified PMO,NA,3,uM,Skip,7.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,agtttgccgctcctggagttc,unmodified PMO,NA,10,uM,Skip,22.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctggagttcc,unmodified PMO,NA,1,uM,Skip,1.84,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctggagttcc,unmodified PMO,NA,3,uM,Skip,10.63,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctggagttcc,unmodified PMO,NA,10,uM,Skip,36.2,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttc,unmodified PMO,NA,1,uM,Skip,1.23,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttc,unmodified PMO,NA,3,uM,Skip,12.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttc,unmodified PMO,NA,10,uM,Skip,30.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcc,unmodified PMO,NA,1,uM,Skip,5.47,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcc,unmodified PMO,NA,3,uM,Skip,31.2,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcc,unmodified PMO,NA,10,uM,Skip,74.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcc,unmodified PMO,NA,1,uM,Skip,2.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcc,unmodified PMO,NA,3,uM,Skip,16.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcc,unmodified PMO,NA,10,uM,Skip,60.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttcc,unmodified PMO,NA,1,uM,Skip,5.11,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttcc,unmodified PMO,NA,3,uM,Skip,20.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttcc,unmodified PMO,NA,10,uM,Skip,68.25,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctggagttcct,unmodified PMO,NA,1,uM,Skip,5.66,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctggagttcct,unmodified PMO,NA,3,uM,Skip,9.49,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgctggagttcct,unmodified PMO,NA,10,uM,Skip,38.14,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcc,unmodified PMO,NA,1,uM,Skip,5.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcc,unmodified PMO,NA,3,uM,Skip,21.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,gtttgccgctgccctggagttcc,unmodified PMO,NA,10,uM,Skip,69.57,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcc,unmodified PMO,NA,1,uM,Skip,6.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcc,unmodified PMO,NA,3,uM,Skip,33.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgccctggagttcc,unmodified PMO,NA,10,uM,Skip,69.57,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,1,uM,Skip,7.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,3,uM,Skip,21.56,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,acagtttgccgcctggagttcc,unmodified PMO,NA,10,uM,Skip,59.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttcc,unmodified PMO,NA,1,uM,Skip,19.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttcc,unmodified PMO,NA,3,uM,Skip,59.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttcc,unmodified PMO,NA,10,uM,Skip,91.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgcctggagttcc,unmodified PMO,NA,3,uM,Skip,47.37,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cctggagttcc,unmodified PMO,NA,3,uM,Skip,1.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccg,unmodified PMO,NA,3,uM,Skip,1.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018183178A,DMD,exon,45,NA,human,RD Cells,Null,NA,cctggagttcc/cagtttgccg,unmodified PMO,NA,3,uM,Skip,1.44,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018183178A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.1,uM,Skip,21-30,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,ggccucuuggacccuacagacccu,2OMe,NA,0.1,uM,Skip,11-20,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,ccugcagacccuacauagag,2OMe,NA,0.1,uM,Skip,1-10,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,cuuggacccugcagacccua,2OMe,NA,0.1,uM,Skip,31-40,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,gggccucuuggacccugcag,2OMe,NA,0.1,uM,Skip,11-20,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,uuggguacucaccacugggccagg,2OMe,NA,0.1,uM,Skip,11-20,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,gguacucaccacugggccagg,2OMe,NA,0.1,uM,Skip,31-40,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,guacucaccacugggccaggg,2OMe,NA,0.1,uM,Skip,61-70,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,uacucaccacugggccagggg,2OMe,NA,0.1,uM,Skip,41-50,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,ggguacucaccacugggccag,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,uggguacucaccacugggcca,2OMe,NA,0.1,uM,Skip,11-20,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,uuggguacucaccacugggcc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,ggcaagacaggugaagguucuugg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,cagggcacaggaugggggcaagaca,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,gucacuggggcagggcacaggaugg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,cuugggccuguucccaaccucuggg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,aucugggccucacuugggccug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,agggcacugaugagccucaaucugg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,cauagagagggcacugaugagccuc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,cacugggccaggggggccucuuggacccugcagacc,2OMe,NA,0.1,uM,Skip,71-80,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,gguacucaccacugggccagg,2OMe,NA,0.1,uM,Skip,61-70,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,guacucaccacugggccaggg,2OMe,NA,0.1,uM,Skip,61-70,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,uacucaccacugggccagggg,2OMe,NA,0.1,uM,Skip,31-40,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,ggguacucaccacugggccag,2OMe,NA,0.1,uM,Skip,1-10,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,uggguacucaccacugggcca,2OMe,NA,0.1,uM,Skip,11-20,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,uuggguacucaccacugggcc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,guacucaccacugggccagg,2OMe,NA,0.1,uM,Skip,41-50,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,gguacucaccacugggccag,2OMe,NA,0.1,uM,Skip,41-50,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,primary  human  fibroblasts,ExGen500,NA,cacugggccaggggggccucuuggacccugcagacc,2OMe,NA,0.1,uM,Skip,71-80,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.1,uM,Skip,31-40,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,ggccucuuggacccuacagacccu,2OMe,NA,0.1,uM,Skip,31-40,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,ccugcagacccuacauagag,2OMe,NA,0.1,uM,Skip,1-10,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,cuuggacccugcagacccua,2OMe,NA,0.1,uM,Skip,31-40,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,gggccucuuggacccugcag,2OMe,NA,0.1,uM,Skip,11-20,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,uuggguacucaccacugggccagg,2OMe,NA,0.1,uM,Skip,21-30,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,gguacucaccacugggccagg,2OMe,NA,0.1,uM,Skip,11-20,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,guacucaccacugggccaggg,2OMe,NA,0.1,uM,Skip,61-70,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,uacucaccacugggccagggg,2OMe,NA,0.1,uM,Skip,31..40,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,ggguacucaccacugggccag,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,uggguacucaccacugggcca,2OMe,NA,0.1,uM,Skip,11-20,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,uuggguacucaccacugggcc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,ggcaagacaggugaagguucuugg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,cagggcacaggaugggggcaagaca,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,gucacuggggcagggcacaggaugg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,cuugggccuguucccaaccucuggg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,aucugggccucacuugggccug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,agggcacugaugagccucaaucugg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,cauagagagggcacugaugagccuc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,cacugggccaggggggccucuuggacccugcagacc,2OMe,NA,0.1,uM,Skip,81..90,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,gguacucaccacugggccagg,2OMe,NA,0.1,uM,Skip,61-70,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,guacucaccacugggccaggg,2OMe,NA,0.1,uM,Skip,61-70,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,uacucaccacugggccagggg,2OMe,NA,0.1,uM,Skip,51-60,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,ggguacucaccacugggccag,2OMe,NA,0.1,uM,Skip,1-10,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,uggguacucaccacugggcca,2OMe,NA,0.1,uM,Skip,11-20,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,uuggguacucaccacugggcc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,guacucaccacugggccagg,2OMe,NA,0.1,uM,Skip,41-50,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,gguacucaccacugggccag,2OMe,NA,0.1,uM,Skip,41-50,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
journal article,Antisense Oligonucleotides To Treat Dystrophic Epidermolysis Bullosa,JP2018515122A,COL7A1,exon,80,NA,human,He La cells,ExGen500,NA,cacugggccaggggggccucuuggacccugcagacc,2OMe,NA,0.1,uM,Skip,81..90,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018515122A,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,TW201811807A,DMD,exon,45,NA,human,Human rhabdomyosarcoma cells,No,NA,ccaatgccatcctggagttcctgtaa,unmodified PMO,NA,12.5,uM,Skip,80,NA,NA,NA,DNA,https://patents.google.com/patent/TW201811807A,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,TW201811807A,DMD,exon,45,NA,human,Human rhabdomyosarcoma cells,No,NA,caatgccatcctggagttcctg,unmodified PMO,NA,12.5,uM,Skip,74,NA,NA,NA,DNA,https://patents.google.com/patent/TW201811807A,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,TW201811807A,DMD,exon,45,NA,human,Human rhabdomyosarcoma cells,No,NA,tgccatcctggagttcctgtaagat,unmodified PMO,NA,12.5,uM,Skip,71,NA,NA,NA,DNA,https://patents.google.com/patent/TW201811807A,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,TW201811807A,DMD,exon,45,NA,human,Human rhabdomyosarcoma cells,No,NA,caatgccatcctggagttcctgtaagat,unmodified PMO,NA,12.5,uM,Skip,68,NA,NA,NA,DNA,https://patents.google.com/patent/TW201811807A,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,TW201811807A,DMD,exon,45,NA,human,Human rhabdomyosarcoma cells,No,NA,tgccatcctggagttcctgtaagatacc,unmodified PMO,NA,12.5,uM,Skip,63,NA,NA,NA,DNA,https://patents.google.com/patent/TW201811807A,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,TW201811807A,DMD,exon,45,NA,human,Human rhabdomyosarcoma cells,No,NA,aatgccatcctggagttcctgtaagatacc,unmodified PMO,NA,12.5,uM,Skip,44,NA,NA,NA,DNA,https://patents.google.com/patent/TW201811807A,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,TW201811807A,DMD,exon,45,NA,human,Human rhabdomyosarcoma cells,No,NA,ccaatgccatcctggagttcctgtaa,unmodified PMO,NA,2.5,uM,Skip,31,NA,NA,NA,DNA,https://patents.google.com/patent/TW201811807A,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,TW201811807A,DMD,exon,45,NA,human,Human rhabdomyosarcoma cells,No,NA,tgccatcctggagttcctgtaagatacc,unmodified PMO,NA,2.5,uM,Skip,18,NA,NA,NA,DNA,https://patents.google.com/patent/TW201811807A,NA,NA,NA
patent,Exon Skipping Oligomers For Muscular Dystrophy,TW201811807A,DMD,exon,45,NA,human,Human rhabdomyosarcoma cells,No,NA,aatgccatcctggagttcctgtaagatacc,unmodified PMO,NA,2.5,uM,Skip,19,NA,NA,NA,DNA,https://patents.google.com/patent/TW201811807A,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,normal human keratinocytes,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.05,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,normal human keratinocytes,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.1,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,normal human keratinocytes,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.2,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,normal human fibroblasts,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.05,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,normal human fibroblasts,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.1,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,normal human fibroblasts,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.2,uM,Skip,70,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,normal human keratinocytes,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.05,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,normal human keratinocytes,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.1,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,normal human keratinocytes,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.2,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,normal human fibroblasts,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,normal human fibroblasts,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.1,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,normal human fibroblasts,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.2,uM,Skip,30,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,normal human keratinocytes,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.05,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,normal human keratinocytes,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.1,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,normal human keratinocytes,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.2,uM,Skip,60,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,normal human fibroblasts,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.05,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,normal human fibroblasts,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.1,uM,Skip,60,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,normal human fibroblasts,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.2,uM,Skip,60,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,RDEB keratinocytes,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.05,uM,Skip,70,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,RDEB keratinocytes,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.1,uM,Skip,70,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,RDEB keratinocytes,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.2,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,RDEB fibroblasts,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.05,uM,Skip,95,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,RDEB fibroblasts,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.1,uM,Skip,95,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,73,NA,human,RDEB fibroblasts,lipofectamine 2000,NA,ucuccacggucgcccuucagcccgcguucu,2OMe,NA,0.2,uM,Skip,95,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,RDEB keratinocytes,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.05,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,RDEB keratinocytes,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.1,uM,Skip,40,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,RDEB keratinocytes,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.2,uM,Skip,30,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,RDEB fibroblasts,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.05,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,RDEB fibroblasts,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.1,uM,Skip,55,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,74,NA,human,RDEB fibroblasts,lipofectamine 2000,NA,ccuuucucuccccguucucccugaa,2OMe,NA,0.2,uM,Skip,30,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,RDEB keratinocytes,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.05,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,RDEB keratinocytes,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.1,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,RDEB keratinocytes,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.2,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,RDEB fibroblasts,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.05,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,RDEB fibroblasts,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.1,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Exon Skipping Therapy For Dystrophic Epidermolysis Bullosa,EP3279324B1,DMD,exon,80,NA,human,RDEB fibroblasts,lipofectamine 2000,NA,ggccucuuggacccugcagacccu,2OMe,NA,0.2,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/EP3279324B1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,ccgccauuucucaacag,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,uucucaggaauuugugucuuu,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,45,NA,human,Null,Null,NA,guugcauucaauguucugac,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,52,NA,human,Null,Null,NA,gcuggucuuguuuuucaa,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,46,NA,human,Null,Null,NA,ttgctgctcttttcc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,ccacaggttgtgtcaccag,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,tttccttagtaaccacaggtt,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,ggtaagttctgtccaagccc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,tcaccctctgtgattttat,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,ccctctgtgatttt,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,tcacccaccatcaccct,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,tgatatcctcaaggtcaccc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,ctgcttgatgatcatctcgtt,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,45,NA,human,Null,Null,NA,uuugccicugcccaaugccauccug,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,46,NA,human,Null,Null,NA,caaguuuucuuuuaguugcugcucuuuucc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,45,NA,human,Null,Null,NA,gccgctgcccaatgc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,45,NA,human,Null,Null,NA,cgctgcccaatgccatcc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,45,NA,human,Null,Null,NA,cagtttgccgctgcccaa,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,45,NA,human,Null,Null,NA,tgttctgacaacagtttg,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,46,NA,human,Null,Null,NA,cttttagttgctgctcttttcc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,46,NA,human,Null,Null,NA,ttttccaggttcaagtgg,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,gaaaacgccgccatuuct,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,ctgutagccactgattaa,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,tgagaaactgtucagcut,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,caggaattugtgucuutc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,gtauttagcatgutccca,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,agcatgttcccaatuctc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,gccgccatuucucaacag,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,cataatgaaaacgccgcc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,tucccaatuctcaggaat,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,44,NA,human,Null,Null,NA,ccautugtauttagcatg,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,50,NA,human,Null,Null,NA,ctcagatcuuctaacuuc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,50,NA,human,Null,Null,NA,accgcctuccactcagag,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,50,NA,human,Null,Null,NA,tcttgaagtaaacggtut,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,50,NA,human,Null,Null,NA,ggctgcttugccctcagc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,50,NA,human,Null,Null,NA,agtccaggagctaggtca,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,50,NA,human,Null,Null,NA,gctccaatagtggtcagt,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,gctaggtcaggctgcttu,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,tgtgtcaccagaguaacagt,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,aggttgugucaccagagtaa,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,agtaaccacagguugtgtca,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,ttgatcaagcagagaaagcc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,cacccucugugauuutataa,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,acccaccaucacccuctgtg,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,cctcaaggucacccaccatc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,taacagucugaguaggag,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,ggcatuucuaguutggag,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,agccagucgguaagttct,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,51,NA,human,Null,Null,NA,agtttggagauggcagtt,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,ctgattctgaattcuutc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,ttcttgtacttcatccca,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,ccuccggttctgaaggtg,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,cattucautcaactgttg,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,ttccttagctuccagcca,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,taagacctgctcagcutc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,cttggctctggcctgucc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,ctcctuccatgactcaag,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,ctgaaggtgttcttgtac,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,ttccagccattgtgttga,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,ctcagctucttccttagc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,gcttcutccutagcutcc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,tgcctccggttctgaaggtgttctt,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,ccggttctgaaggtgttc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,ctccggttctgaaggtgttc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,cctccggttctgaaggtgttc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,53,NA,human,Null,Null,NA,gcctccggttctgaaggtgttc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,50,NA,human,Null,Null,NA,ccactcagagctcagatcttctaacttcc,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
patent,Compounds And Methods For Modulation Of Dystrophin Transcript,WO 2018014042 A1,DMD,exon,45,NA,human,Null,Null,NA,ccaatgccatcctggagttcctgtaa,Others (2'MOE or 2'-O-(N-alkyl acetamide) or 2'-(N-methyl acetamide); with or without peptide conjugate),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/WO2018014042A1,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,ucaaggaagauggcauuucu,2OMe,NA,0.8,uM,Skip,1.05,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,ucaaggaagauggcauuucu,2OMe,NA,4,uM,Skip,5.03,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,tcaaggaagauggcauuucu,2OMe,NA,0.8,uM,Skip,7.85,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,tcaaggaagauggcauuucu,2OMe,NA,4,uM,Skip,26.39,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,tcaaggaagauggcauuucu,2OMe,NA,0.8,uM,Skip,8.17,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,tcaaggaagauggcauuucu,2OMe,NA,4,uM,Skip,31.41,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,tcaaggaagauggcauuuct,2OMe,NA,0.8,uM,Skip,9.63,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,tcaaggaagauggcauuuct,2OMe,NA,4,uM,Skip,37.07,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,ucaaggaagauggcauuucu,2OMe,NA,4,uM,Skip,3.46,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,tcaaggaagauggcauuucu,2OMe,NA,4,uM,Skip,18.96,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,tcaaggaagauggcauuuct,2OMe,NA,4,uM,Skip,23.74,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,ucaaggaagauggcauuucu,2OMe,NA,0.8,uM,Skip,1.56,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,ucaaggaagauggcauuucu,2OMe,NA,4,uM,Skip,4.77,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,tcaaggaagauggcauuucu,2OMe,NA,0.8,uM,Skip,3.75,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,51,NA,human,"Immortalized myoblasts, derived from a DMD patient with a deletion of exons 48-50",Null,NA,tcaaggaagauggcauuucu,2OMe,NA,4,uM,Skip,11.03,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,44,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,ucagcuucuguuagccacug,2OMe,NA,0.8,uM,Skip,1.17,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,44,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,ucagcuucuguuagccacug,2OMe,NA,4,uM,Skip,2.56,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,44,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,tcagcuucuguuagccacug,2OMe,NA,0.8,uM,Skip,3.16,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,44,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,tcagcuucuguuagccacug,2OMe,NA,4,uM,Skip,8.1,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,45,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.8,uM,Skip,0.12,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,45,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,uuugccgcugcccaaugccauccug,2OMe,NA,4,uM,Skip,0.39,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,45,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,tuugccgcugcccaaugccauccug,2OMe,NA,0.8,uM,Skip,0.17,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,45,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,tuugccgcugcccaaugccauccug,2OMe,NA,4,uM,Skip,1.05,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,53,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,guugccuccgguucugaagguguuc,2OMe,NA,0.8,uM,Skip,0.06,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,53,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,guugccuccgguucugaagguguuc,2OMe,NA,4,uM,Skip,0.12,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,53,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,guugccuccgguucugaagguguuc,2OMe,NA,0.8,uM,Skip,0.09,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
journal article,"Pre-Mrna Splice Switching Or Modulating Oligonucleotides Comprising Bicyclic Scaffold Moieties, With Improved Characteristics For The Treatment Of Genetic Disorders",JP2019522972A,DMD,exon,53,NA,human,"Immortalized myoblasts, derived from a healthy donor",Null,NA,guugccuccgguucugaagguguuc,2OMe,NA,4,uM,Skip,0.21,NA,NA,NA,RNA,https://patents.google.com/patent/JP2019522972A,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,52.13,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,48.69,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,92.13,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,94.75,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,2.5,uM,Skip,22.88,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,5,uM,Skip,12.75,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,12.5,uM,Skip,20.59,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,25,uM,Skip,34.64,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,37.05,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,65.9,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,80.66,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,91.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,7.84,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,15.69,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,46.08,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,73.2,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,2.5,uM,Skip,19.67,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,5,uM,Skip,41.97,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,12.5,uM,Skip,50.49,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,25,uM,Skip,65.57,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,12.5,uM,Skip,13.77,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,25,uM,Skip,33.11,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,2.5,uM,Skip,13.11,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,5,uM,Skip,31.15,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,12.5,uM,Skip,44.92,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,25,uM,Skip,74.1,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,2.5,uM,Skip,2.62,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,5,uM,Skip,7.21,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,12.5,uM,Skip,7.54,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,25,uM,Skip,9.18,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,tgttgcctccggttctgaaggt,unmodified PMO,NA,2.5,uM,Skip,10.82,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,tgttgcctccggttctgaaggt,unmodified PMO,NA,5,uM,Skip,11.8,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,tgttgcctccggttctgaaggt,unmodified PMO,NA,12.5,uM,Skip,26.56,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,tgttgcctccggttctgaaggt,unmodified PMO,NA,25,uM,Skip,26.89,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,61.11,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,80.39,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,90.52,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
patent,Exon Skipping Compositions  For Treating Muscular  Dystrophy,US 2017/0369875 A1,DMD,exon,53,NA,human,Human Rhabdomyosarcoma cells (RD Cells),Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,92.16,NA,NA,NA,DNA,https://patents.google.com/patent/US2017/0369875A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgagaaactgttcgccgccatttct,unmodified PMO,NA,1,uM,Skip,6.34,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,1,uM,Skip,45.02,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctcaggaatttgcgccgccatttct,unmodified PMO,NA,1,uM,Skip,2.49,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgatctcaacagatct,unmodified PMO,NA,0.1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgatctcaacagatct,unmodified PMO,NA,0.3,uM,Skip,0.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgatctcaacagatct,unmodified PMO,NA,1,uM,Skip,1.08,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgatctcaacagatct,unmodified PMO,NA,3,uM,Skip,3.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgatctcaacagatct,unmodified PMO,NA,10,uM,Skip,11.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgatctcaacagatct,unmodified PMO,NA,30,uM,Skip,21.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgttctcaacagatct,unmodified PMO,NA,0.1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgttctcaacagatct,unmodified PMO,NA,0.3,uM,Skip,0.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgttctcaacagatct,unmodified PMO,NA,1,uM,Skip,2.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgttctcaacagatct,unmodified PMO,NA,3,uM,Skip,16.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgttctcaacagatct,unmodified PMO,NA,10,uM,Skip,69.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgttctcaacagatct,unmodified PMO,NA,30,uM,Skip,96.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtctcaacagatct,unmodified PMO,NA,0.1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtctcaacagatct,unmodified PMO,NA,0.3,uM,Skip,0.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtctcaacagatct,unmodified PMO,NA,1,uM,Skip,2.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtctcaacagatct,unmodified PMO,NA,3,uM,Skip,8.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtctcaacagatct,unmodified PMO,NA,10,uM,Skip,33.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtctcaacagatct,unmodified PMO,NA,30,uM,Skip,61.01,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgtttctcaacagatct,unmodified PMO,NA,0.1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgtttctcaacagatct,unmodified PMO,NA,0.3,uM,Skip,0.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgtttctcaacagatct,unmodified PMO,NA,1,uM,Skip,16.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgtttctcaacagatct,unmodified PMO,NA,3,uM,Skip,55.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgtttctcaacagatct,unmodified PMO,NA,10,uM,Skip,91.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgtttctcaacagatct,unmodified PMO,NA,30,uM,Skip,96.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgaacgccgccatttct,unmodified PMO,NA,0.1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgaacgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,5.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgaacgccgccatttct,unmodified PMO,NA,1,uM,Skip,42.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgaacgccgccatttct,unmodified PMO,NA,3,uM,Skip,89.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgaacgccgccatttct,unmodified PMO,NA,10,uM,Skip,99.1,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgaacgccgccatttct,unmodified PMO,NA,30,uM,Skip,98.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,0.1,uM,Skip,2.25,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,0.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,1,uM,Skip,44.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,3,uM,Skip,84.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,10,uM,Skip,96.55,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgtcgccgccatttct,unmodified PMO,NA,0.1,uM,Skip,0.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgtcgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,5.55,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgtcgccgccatttct,unmodified PMO,NA,1,uM,Skip,25.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgtcgccgccatttct,unmodified PMO,NA,3,uM,Skip,77.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgtcgccgccatttct,unmodified PMO,NA,10,uM,Skip,97.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgagaaactgttcgccgccatttct,unmodified PMO,NA,0.1,uM,Skip,0.15,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgagaaactgttcgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,1.35,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgagaaactgttcgccgccatttct,unmodified PMO,NA,1,uM,Skip,10.34,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgagaaactgttcgccgccatttct,unmodified PMO,NA,3,uM,Skip,28.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgagaaactgttcgccgccatttct,unmodified PMO,NA,10,uM,Skip,80.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,0.1,uM,Skip,1.05,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,1.2,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,1,uM,Skip,44.83,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,3,uM,Skip,84.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,10,uM,Skip,96.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctcaggaatttgcgccgccatttct,unmodified PMO,NA,0.1,uM,Skip,0.15,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctcaggaatttgcgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,1.05,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctcaggaatttgcgccgccatttct,unmodified PMO,NA,1,uM,Skip,2.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctcaggaatttgcgccgccatttct,unmodified PMO,NA,3,uM,Skip,8.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctcaggaatttgcgccgccatttct,unmodified PMO,NA,10,uM,Skip,55.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,attctcaggaatttgaacgccgccatttct,unmodified PMO,NA,0.1,uM,Skip,0.87,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,attctcaggaatttgaacgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,3.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,attctcaggaatttgaacgccgccatttct,unmodified PMO,NA,1,uM,Skip,18.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,attctcaggaatttgaacgccgccatttct,unmodified PMO,NA,3,uM,Skip,58.89,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,attctcaggaatttgaacgccgccatttct,unmodified PMO,NA,10,uM,Skip,95.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,4.31,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,1,uM,Skip,22.39,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,3,uM,Skip,63.98,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgtcgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,9.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgtcgccgccatttct,unmodified PMO,NA,1,uM,Skip,36.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gttcagcttctgtcgccgccatttct,unmodified PMO,NA,3,uM,Skip,87.9,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,4.17,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,1,uM,Skip,21.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,3,uM,Skip,58.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,attctcaggaatttgaacgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,attctcaggaatttgaacgccgccatttct,unmodified PMO,NA,1,uM,Skip,6.82,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,attctcaggaatttgaacgccgccatttct,unmodified PMO,NA,3,uM,Skip,34.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,14.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgccgccatttctca,unmodified PMO,NA,1,uM,Skip,63.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgccgccatttctca,unmodified PMO,NA,3,uM,Skip,93.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgaacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,10.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgaacgccgccattt,unmodified PMO,NA,1,uM,Skip,38.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgaacgccgccattt,unmodified PMO,NA,3,uM,Skip,81.74,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagcgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,11.34,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagcgccgccatttct,unmodified PMO,NA,1,uM,Skip,50.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagcgccgccatttct,unmodified PMO,NA,3,uM,Skip,80.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttcccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,11.34,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttcccgccatttctca,unmodified PMO,NA,1,uM,Skip,37.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttcccgccatttctca,unmodified PMO,NA,3,uM,Skip,80.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagaacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,8.82,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagaacgccgccattt,unmodified PMO,NA,1,uM,Skip,40.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagaacgccgccattt,unmodified PMO,NA,3,uM,Skip,70.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttcaacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,9.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttcaacgccgccattt,unmodified PMO,NA,1,uM,Skip,33.5,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttcaacgccgccattt,unmodified PMO,NA,3,uM,Skip,76.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgattccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,4.23,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgattccgccatttctca,unmodified PMO,NA,1,uM,Skip,25.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgattccgccatttctca,unmodified PMO,NA,3,uM,Skip,66.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccactcgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,9.59,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccactcgccgccatttct,unmodified PMO,NA,1,uM,Skip,50.44,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccactcgccgccatttct,unmodified PMO,NA,3,uM,Skip,90.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgaccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,17.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgaccgccatttctca,unmodified PMO,NA,1,uM,Skip,65.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgaccgccatttctca,unmodified PMO,NA,3,uM,Skip,76.84,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccactccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,7.72,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccactccgccatttctca,unmodified PMO,NA,1,uM,Skip,37.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccactccgccatttctca,unmodified PMO,NA,3,uM,Skip,84.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgattcgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,4.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgattcgccgccatttct,unmodified PMO,NA,1,uM,Skip,23.91,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgattcgccgccatttct,unmodified PMO,NA,3,uM,Skip,62.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgaaacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,7.35,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgaaacgccgccattt,unmodified PMO,NA,1,uM,Skip,22.91,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgaaacgccgccattt,unmodified PMO,NA,3,uM,Skip,64.76,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccactaacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,2.37,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccactaacgccgccattt,unmodified PMO,NA,1,uM,Skip,23.91,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccactaacgccgccattt,unmodified PMO,NA,3,uM,Skip,44.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgattaacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,8.34,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgattaacgccgccattt,unmodified PMO,NA,1,uM,Skip,21.17,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgattaacgccgccattt,unmodified PMO,NA,3,uM,Skip,63.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,7.82,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,1,uM,Skip,52.01,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgcgccgccatttct,unmodified PMO,NA,3,uM,Skip,66,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctcgccgccatttc,unmodified PMO,NA,0.3,uM,Skip,17.89,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctcgccgccatttc,unmodified PMO,NA,1,uM,Skip,63.51,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctcgccgccatttc,unmodified PMO,NA,3,uM,Skip,89.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctgccgccatttc,unmodified PMO,NA,0.3,uM,Skip,4.86,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctgccgccatttc,unmodified PMO,NA,1,uM,Skip,30.33,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctgccgccatttc,unmodified PMO,NA,3,uM,Skip,60.66,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttccgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,7.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttccgccgccatttct,unmodified PMO,NA,1,uM,Skip,49.17,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttccgccgccatttct,unmodified PMO,NA,3,uM,Skip,80.69,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttctttgtgtctttctg,unmodified PMO,NA,0.3,uM,Skip,19.91,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttctttgtgtctttctg,unmodified PMO,NA,1,uM,Skip,72.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttctttgtgtctttctg,unmodified PMO,NA,3,uM,Skip,94.91,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccacgccgccatt,unmodified PMO,NA,0.3,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccacgccgccatt,unmodified PMO,NA,1,uM,Skip,4.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccacgccgccatt,unmodified PMO,NA,3,uM,Skip,16.79,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctggccatttctcaac,unmodified PMO,NA,0.3,uM,Skip,3.39,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctggccatttctcaac,unmodified PMO,NA,1,uM,Skip,15.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctggccatttctcaac,unmodified PMO,NA,3,uM,Skip,45.79,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.1,uM,Skip,4.08,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,15.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,51.86,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,3,uM,Skip,87.39,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,0.1,uM,Skip,3.24,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,0.3,uM,Skip,8.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,1,uM,Skip,32.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,3,uM,Skip,67.59,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttctgttagccaaaaacgccgcca,unmodified PMO,NA,0.3,uM,Skip,11.56,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttctgttagccaaaaacgccgcca,unmodified PMO,NA,1,uM,Skip,16.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttctgttagccaaaaacgccgcca,unmodified PMO,NA,3,uM,Skip,68.79,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,3.9,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgacgccgccattt,unmodified PMO,NA,1,uM,Skip,6.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttagccactgacgccgccattt,unmodified PMO,NA,3,uM,Skip,59.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,13.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,1,uM,Skip,34.25,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,3,uM,Skip,77.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,actgttcagcgccactgatt,unmodified PMO,NA,0.3,uM,Skip,3.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,actgttcagcgccactgatt,unmodified PMO,NA,1,uM,Skip,36.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,actgttcagcgccactgatt,unmodified PMO,NA,3,uM,Skip,72.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aactgttcagctttagccactgatta,unmodified PMO,NA,0.3,uM,Skip,9.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aactgttcagctttagccactgatta,unmodified PMO,NA,1,uM,Skip,36.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aactgttcagctttagccactgatta,unmodified PMO,NA,3,uM,Skip,69.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,5.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,1,uM,Skip,31.87,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,3,uM,Skip,57.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccacgccgccatttc,unmodified PMO,NA,0.3,uM,Skip,3.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccacgccgccatttc,unmodified PMO,NA,1,uM,Skip,14.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccacgccgccatttc,unmodified PMO,NA,3,uM,Skip,43.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,0.3,uM,Skip,6.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,1,uM,Skip,26.1,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,3,uM,Skip,71.17,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttcaacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,9.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttcaacgccgccattt,unmodified PMO,NA,1,uM,Skip,38.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttcaacgccgccattt,unmodified PMO,NA,3,uM,Skip,81.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aacgccgccatttatttgtgtctttc,unmodified PMO,NA,0.3,uM,Skip,3.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aacgccgccatttatttgtgtctttc,unmodified PMO,NA,1,uM,Skip,10.51,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aacgccgccatttatttgtgtctttc,unmodified PMO,NA,3,uM,Skip,42.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aacgccgccatttgtgtctttc,unmodified PMO,NA,0.3,uM,Skip,10.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aacgccgccatttgtgtctttc,unmodified PMO,NA,1,uM,Skip,53.9,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aacgccgccatttgtgtctttc,unmodified PMO,NA,3,uM,Skip,78.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aaacgccgccatttgtgtctttctga,unmodified PMO,NA,0.3,uM,Skip,5.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aaacgccgccatttgtgtctttctga,unmodified PMO,NA,1,uM,Skip,24.62,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aaacgccgccatttgtgtctttctga,unmodified PMO,NA,3,uM,Skip,53.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctgttagccatttctcaac,unmodified PMO,NA,0.3,uM,Skip,6.01,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctgttagccatttctcaac,unmodified PMO,NA,1,uM,Skip,18.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctgttagccatttctcaac,unmodified PMO,NA,3,uM,Skip,60.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,8.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgccgccatttctca,unmodified PMO,NA,1,uM,Skip,35.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgccgccatttctca,unmodified PMO,NA,3,uM,Skip,64.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctcattgtgtctttctg,unmodified PMO,NA,0.3,uM,Skip,10.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctcattgtgtctttctg,unmodified PMO,NA,1,uM,Skip,31.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctcattgtgtctttctg,unmodified PMO,NA,3,uM,Skip,75.72,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctcgccgccatttc,unmodified PMO,NA,0.3,uM,Skip,8.76,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctcgccgccatttc,unmodified PMO,NA,1,uM,Skip,29.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctcgccgccatttc,unmodified PMO,NA,3,uM,Skip,69.18,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttcttgtgtctttct,unmodified PMO,NA,0.3,uM,Skip,3.99,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttcttgtgtctttct,unmodified PMO,NA,1,uM,Skip,15.41,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttcttgtgtctttct,unmodified PMO,NA,3,uM,Skip,52.33,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgaccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,4.99,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgaccgccatttctca,unmodified PMO,NA,1,uM,Skip,21.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgaccgccatttctca,unmodified PMO,NA,3,uM,Skip,53.33,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctcatgttagccactga,unmodified PMO,NA,0.3,uM,Skip,5.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctcatgttagccactga,unmodified PMO,NA,1,uM,Skip,18.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctcatgttagccactga,unmodified PMO,NA,3,uM,Skip,45.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgagaaactgtttgttagccactga,unmodified PMO,NA,0.3,uM,Skip,4.09,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgagaaactgtttgttagccactga,unmodified PMO,NA,1,uM,Skip,15.8,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgagaaactgtttgttagccactga,unmodified PMO,NA,3,uM,Skip,42.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctttctgagaaactgttagccactga,unmodified PMO,NA,0.3,uM,Skip,3.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctttctgagaaactgttagccactga,unmodified PMO,NA,1,uM,Skip,16.08,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctttctgagaaactgttagccactga,unmodified PMO,NA,3,uM,Skip,48.23,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctttctgttagccactgaac,unmodified PMO,NA,0.3,uM,Skip,2.86,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctttctgttagccactgaac,unmodified PMO,NA,1,uM,Skip,3.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctttctgttagccactgaac,unmodified PMO,NA,3,uM,Skip,8.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cccagcttctgttagccactgacc,unmodified PMO,NA,0.3,uM,Skip,3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cccagcttctgttagccactgacc,unmodified PMO,NA,1,uM,Skip,8.72,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cccagcttctgttagccactgacc,unmodified PMO,NA,3,uM,Skip,28.34,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cttgcttctgttagccactgaccc,unmodified PMO,NA,0.3,uM,Skip,2.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cttgcttctgttagccactgaccc,unmodified PMO,NA,1,uM,Skip,9.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cttgcttctgttagccactgaccc,unmodified PMO,NA,3,uM,Skip,35.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,15.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,58.98,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,3,uM,Skip,86.25,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctcagtgtctttctgag,unmodified PMO,NA,0.3,uM,Skip,5.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctcagtgtctttctgag,unmodified PMO,NA,1,uM,Skip,29.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctcagtgtctttctgag,unmodified PMO,NA,3,uM,Skip,73.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,0.3,uM,Skip,12.08,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,1,uM,Skip,43.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,3,uM,Skip,80.93,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,0.3,uM,Skip,7.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,1,uM,Skip,38.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,3,uM,Skip,77.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcctgttagccac,unmodified PMO,NA,0.3,uM,Skip,2.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcctgttagccac,unmodified PMO,NA,1,uM,Skip,11.49,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcctgttagccac,unmodified PMO,NA,3,uM,Skip,45.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,0.3,uM,Skip,7.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,1,uM,Skip,31.69,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,3,uM,Skip,75.51,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgttagccactga,unmodified PMO,NA,0.3,uM,Skip,7.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgttagccactga,unmodified PMO,NA,1,uM,Skip,37.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,atttgtgtctttctgttagccactga,unmodified PMO,NA,3,uM,Skip,65.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aaactgttcagcttctgtcaaatcgc,unmodified PMO,NA,0.3,uM,Skip,4.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aaactgttcagcttctgtcaaatcgc,unmodified PMO,NA,1,uM,Skip,6.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,aaactgttcagcttctgtcaaatcgc,unmodified PMO,NA,3,uM,Skip,37.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,acgccgccatttctcaggaatttgtg,unmodified PMO,NA,0.3,uM,Skip,4.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,acgccgccatttctcaggaatttgtg,unmodified PMO,NA,1,uM,Skip,19.82,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,acgccgccatttctcaggaatttgtg,unmodified PMO,NA,3,uM,Skip,71.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,18.56,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,53.49,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,3,uM,Skip,85.11,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtctttctgagccgccatttctc,unmodified PMO,NA,0.3,uM,Skip,5.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtctttctgagccgccatttctc,unmodified PMO,NA,1,uM,Skip,21.76,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtctttctgagccgccatttctc,unmodified PMO,NA,3,uM,Skip,68.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,5.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,1,uM,Skip,21.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,3,uM,Skip,59.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttctttgtgtctttctg,unmodified PMO,NA,0.3,uM,Skip,4.1,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttctttgtgtctttctg,unmodified PMO,NA,1,uM,Skip,32.33,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttctttgtgtctttctg,unmodified PMO,NA,3,uM,Skip,55.01,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttctttgtgtctttc,unmodified PMO,NA,0.3,uM,Skip,2.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttctttgtgtctttc,unmodified PMO,NA,1,uM,Skip,29.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttctttgtgtctttc,unmodified PMO,NA,3,uM,Skip,54.16,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttttgtgtctttc,unmodified PMO,NA,0.3,uM,Skip,2.9,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttttgtgtctttc,unmodified PMO,NA,1,uM,Skip,16.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttttgtgtctttc,unmodified PMO,NA,3,uM,Skip,56.09,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,9.07,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,56.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,3,uM,Skip,66.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtctttctgagcgccatttctc,unmodified PMO,NA,0.3,uM,Skip,2.11,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtctttctgagcgccatttctc,unmodified PMO,NA,1,uM,Skip,17.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtctttctgagcgccatttctc,unmodified PMO,NA,3,uM,Skip,57.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctcgccgccattt,unmodified PMO,NA,0.3,uM,Skip,1.86,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctcgccgccattt,unmodified PMO,NA,1,uM,Skip,18.01,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctcgccgccattt,unmodified PMO,NA,3,uM,Skip,60.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttcagcgccactgattac,unmodified PMO,NA,0.3,uM,Skip,0.66,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttcagcgccactgattac,unmodified PMO,NA,1,uM,Skip,1.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttcagcgccactgattac,unmodified PMO,NA,3,uM,Skip,9.84,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,0.3,uM,Skip,2.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,1,uM,Skip,15.08,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgacgccgccatttct,unmodified PMO,NA,3,uM,Skip,49.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactccgccatttc,unmodified PMO,NA,0.3,uM,Skip,0.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactccgccatttc,unmodified PMO,NA,1,uM,Skip,4.04,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactccgccatttc,unmodified PMO,NA,3,uM,Skip,17.05,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,0.3,uM,Skip,4.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,1,uM,Skip,35.63,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgtgttagccactga,unmodified PMO,NA,3,uM,Skip,68.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgtgtctttctgttagccac,unmodified PMO,NA,0.3,uM,Skip,1.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgtgtctttctgttagccac,unmodified PMO,NA,1,uM,Skip,6.23,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgtgtctttctgttagccac,unmodified PMO,NA,3,uM,Skip,24.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,5.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,24.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,3,uM,Skip,74.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtctttctgagccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,3.72,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,14.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtctttctgagccgccatttctca,unmodified PMO,NA,3,uM,Skip,60.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.1,uM,Skip,4.74,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,12.31,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,56.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,3,uM,Skip,89.17,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,10,uM,Skip,97.02,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,30,uM,Skip,98.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,0.1,uM,Skip,2.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,4.74,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,1,uM,Skip,16.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,3,uM,Skip,49.93,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,10,uM,Skip,88.5,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,30,uM,Skip,98.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,0.1,uM,Skip,10.55,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,0.3,uM,Skip,16.37,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,1,uM,Skip,57.78,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,3,uM,Skip,84.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,10,uM,Skip,94.45,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,30,uM,Skip,97.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,14.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,67.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,3,uM,Skip,84.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctc,unmodified PMO,NA,0.3,uM,Skip,10.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctc,unmodified PMO,NA,1,uM,Skip,54.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctc,unmodified PMO,NA,3,uM,Skip,93.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgaccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,5.34,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgaccgccatttctca,unmodified PMO,NA,1,uM,Skip,45.57,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgaccgccatttctca,unmodified PMO,NA,3,uM,Skip,71.17,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgaccgccatttctc,unmodified PMO,NA,0.3,uM,Skip,9.56,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgaccgccatttctc,unmodified PMO,NA,1,uM,Skip,35.72,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgaccgccatttctc,unmodified PMO,NA,3,uM,Skip,75.39,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgccgccatttctc,unmodified PMO,NA,0.3,uM,Skip,2.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgccgccatttctc,unmodified PMO,NA,1,uM,Skip,25.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgccgccatttctc,unmodified PMO,NA,3,uM,Skip,71.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,10.97,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,64.7,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,0.3,uM,Skip,93.53,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctcgccgccatttc,unmodified PMO,NA,0.3,uM,Skip,7.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctcgccgccatttc,unmodified PMO,NA,1,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctcgccgccatttc,unmodified PMO,NA,3,uM,Skip,84.31,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,0.3,uM,Skip,4.17,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,1,uM,Skip,33.75,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,3,uM,Skip,85,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,0.3,uM,Skip,12.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,1,uM,Skip,58.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,3,uM,Skip,91.39,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,0.3,uM,Skip,3.47,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,1,uM,Skip,16.39,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,3,uM,Skip,62.36,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcctgttagccac,unmodified PMO,NA,0.3,uM,Skip,2.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcctgttagccac,unmodified PMO,NA,1,uM,Skip,19.86,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcctgttagccac,unmodified PMO,NA,3,uM,Skip,54.58,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctcgccgccattt,unmodified PMO,NA,0.3,uM,Skip,2.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctcgccgccattt,unmodified PMO,NA,1,uM,Skip,13.61,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtgtctttctcgccgccattt,unmodified PMO,NA,3,uM,Skip,53.47,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgtgtcaaatcgcc,unmodified PMO,NA,0.3,uM,Skip,1.21,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgtgtcaaatcgcc,unmodified PMO,NA,1,uM,Skip,4.83,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgtgtcaaatcgcc,unmodified PMO,NA,3,uM,Skip,17.72,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtctttctgagtgtcaaatcgcc,unmodified PMO,NA,0.3,uM,Skip,0.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtctttctgagtgtcaaatcgcc,unmodified PMO,NA,1,uM,Skip,3.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgtctttctgagtgtcaaatcgcc,unmodified PMO,NA,3,uM,Skip,11.54,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctctgtcaaatcgcc,unmodified PMO,NA,0.3,uM,Skip,5.5,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctctgtcaaatcgcc,unmodified PMO,NA,1,uM,Skip,40.94,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctctgtcaaatcgcc,unmodified PMO,NA,3,uM,Skip,88.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttcagcttctgtcaaatcgcc,unmodified PMO,NA,0.3,uM,Skip,0.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttcagcttctgtcaaatcgcc,unmodified PMO,NA,1,uM,Skip,2.68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttcagcttctgtcaaatcgcc,unmodified PMO,NA,3,uM,Skip,20.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgtcaaatcgcc,unmodified PMO,NA,0.3,uM,Skip,0.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgtcaaatcgcc,unmodified PMO,NA,1,uM,Skip,6.44,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttagccactgtcaaatcgcc,unmodified PMO,NA,3,uM,Skip,28.72,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccatttctcgtcaaatcgcc,unmodified PMO,NA,0.3,uM,Skip,7.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccatttctcgtcaaatcgcc,unmodified PMO,NA,1,uM,Skip,25.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccatttctcgtcaaatcgcc,unmodified PMO,NA,3,uM,Skip,57.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,0.1,uM,Skip,1.03,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,0.3,uM,Skip,4.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,1,uM,Skip,31.23,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,3,uM,Skip,76.77,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,10,uM,Skip,96.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,30,uM,Skip,99.1,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,64.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctca/gtgtctttctgag,unmodified PMO,NA,1,uM,Skip,12.42,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctc,unmodified PMO,NA,1,uM,Skip,52.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctc/gtgtctttctgag,unmodified PMO,NA,1,uM,Skip,5.28,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,1,uM,Skip,15.22,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccattt/tctgttagcca,unmodified PMO,NA,1,uM,Skip,0.93,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,1,uM,Skip,52.33,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccac/ttgtgtctttct,unmodified PMO,NA,1,uM,Skip,0.93,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,1,uM,Skip,14.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccact/cgccgccatttc,unmodified PMO,NA,1,uM,Skip,1.23,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,actgttcagcgccactgatt,unmodified PMO,NA,3,uM,Skip,41.24,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,actgttcagcgccactgatt,unmodified PMO,NA,10,uM,Skip,75.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gccactgatt/actgttcagc,unmodified PMO,NA,3,uM,Skip,0.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gccactgatt/actgttcagc,unmodified PMO,NA,10,uM,Skip,0.69,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,1,uM,Skip,73.08,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttct/tctgttagccac,unmodified PMO,NA,1,uM,Skip,1.44,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttct,unmodified PMO,NA,1,uM,Skip,0.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccac,unmodified PMO,NA,1,uM,Skip,0.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,1,uM,Skip,88.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctca/gtgtctttctgag,unmodified PMO,NA,1,uM,Skip,32.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgag,unmodified PMO,NA,1,uM,Skip,2.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ccgccatttctca,unmodified PMO,NA,1,uM,Skip,4.08,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,1,uM,Skip,31.91,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagcca/cgccgccattt,unmodified PMO,NA,1,uM,Skip,1.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccattt,unmodified PMO,NA,1,uM,Skip,1.06,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagcca,unmodified PMO,NA,1,uM,Skip,0.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,1,uM,Skip,53.55,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccact/cgccgccatttca,unmodified PMO,NA,1,uM,Skip,3.55,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccact,unmodified PMO,NA,1,uM,Skip,1.24,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttc,unmodified PMO,NA,1,uM,Skip,0.71,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,gtgtctttctgagccgccatttctca,unmodified PMO,NA,10,uM,Skip,95.19,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,tctgttagccacgccgccattt,unmodified PMO,NA,10,uM,Skip,91.31,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgttagccactcgccgccatttc,unmodified PMO,NA,10,uM,Skip,95.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
journal article,Antisense Nucleic Acids,JP2020182459A,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttcttctgttagccac,unmodified PMO,NA,10,uM,Skip,95.96,NA,NA,NA,DNA,https://patents.google.com/patent/JP2020182459A,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,uauaguggggucguauucguccaca,2OMe,NA,unspecified,Null,Skip,68,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,uauaguggggucguauucguccaca,2OMe,NA,unspecified,Null,Skip,68,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,uauaguggggucguauucguccaca,2OMe,NA,unspecified,Null,Skip,44,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,uauaguggggucguauucguccaca,2OMe,NA,unspecified,Null,Skip,88,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,uauaguggggucguauucguccaca,2OMe,NA,unspecified,Null,Skip,47,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,uauaguggggucguauucguccaca,2OMe,NA,unspecified,Null,Skip,43,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,uauaguggggucguauucguccaca,2OMe,NA,unspecified,Null,Skip,13,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,uauaguggggucguauucguccaca,2OMe,NA,unspecified,Null,Skip,39,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,uauaguggggucguauucguccaca,2OMe,NA,unspecified,Null,Skip,52,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,79.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,32.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,49.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,37.5,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,50.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,25.6,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,45,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,34.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,91,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,52,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,70,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,54,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,32,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,67,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,68,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,42,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,32,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,T24 bladder cancer cells,Lipofectamine,NA,gggucuccugccccaccugccaagg,2OMe,NA,unspecified,Null,Skip,96,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
patent,Ras Exon 2 Skipping For Cancer Treatment,US/2017/0240900,"HRAS, KRAS , NRAS",exon,2,NA,human,HepG2 cancer cells,Lipofectamine,NA,uauaguggggucguauucguccaca,2OMe,NA,unspecified,Null,Skip,64,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0240900,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,60.13,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,30,uM,Skip,72.13,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.3,uM,Skip,18.89,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,1,uM,Skip,18.64,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,1,uM,Skip,8.52,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,3,uM,Skip,24.52,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,ccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,57.05,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,86.67,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,13.27,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,human DMD patient-derived fibroblasts (5017 cells),Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,37.95,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,fibroblasts from human DMD patient (with deletion of exons 48-52),Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,94.21,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,fibroblasts from human DMD patient (with deletion of exons 45-52),Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,88.81,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.3,uM,Skip,12.34,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,1,uM,Skip,22.17,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,3,uM,Skip,38.29,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,63.48,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,30,uM,Skip,73.05,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,fibroblasts from human DMD patient (with deletion of exons 45-52),Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,80.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,tccggttctgaaggtgttcttg,unmodified PMO,NA,10,uM,Skip,73.33,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,tgcctccggttctgaaggtgttctt,unmodified PMO,NA,10,uM,Skip,71.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,ccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,54.1,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,62.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,91.81,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,14.09,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,human DMD patient-derived fibroblasts (5017 cells),Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,37.01,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,fibroblasts from human DMD patient (with deletion of exons 45-52),Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,89.92,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,fibroblasts from human DMD patient (with deletion of exons 48-52),Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,94.75,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,fibroblasts from human DMD patient (with deletion of exons 45-52),Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,94.12,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.3,uM,Skip,3.1,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,3,uM,Skip,40.55,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,63.73,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,30,uM,Skip,73.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,gcctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,8.04,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,human DMD patient-derived fibroblasts (5017 cells),Null,NA,gcctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,18,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,human DMD patient-derived fibroblasts (5017 cells),Null,NA,gcctccggttctgaaggtgttcttg,unmodified PMO,NA,10,uM,Skip,19.02,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttctgaaggtg,unmodified PMO,NA,10,uM,Skip,18,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,human normal tissue-derived fibroblasts (TIG-119 cells),Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,10,uM,Skip,6.09,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,human DMD patient-derived fibroblasts (5017 cells),Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,10,uM,Skip,4.09,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,fibroblasts from human DMD patient (with deletion of exons 45-52),Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,79.89,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,0.3,uM,Skip,13.85,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,1,uM,Skip,16.88,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,3,uM,Skip,24.43,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,10,uM,Skip,29.47,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttcttgt,unmodified PMO,NA,30,uM,Skip,36.27,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,fibroblasts from human DMD patient (with deletion of exons 45-52),Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,71.75,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,0.3,uM,Skip,15.11,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,1,uM,Skip,10.83,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,3,uM,Skip,16.88,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,10,uM,Skip,28.97,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,cctccggttctgaaggtgttc,unmodified PMO,NA,30,uM,Skip,47.86,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,fibroblasts from human DMD patient (with deletion of exons 45-52),Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,10,uM,Skip,64.85,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,0.3,uM,Skip,1.29,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,1,uM,Skip,4.9,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,3,uM,Skip,12.65,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,10,uM,Skip,29.94,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,30,uM,Skip,52.38,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,0.3,uM,Skip,1.16,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,1,uM,Skip,2.5,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,3,uM,Skip,8.65,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,10,uM,Skip,18.32,NA,NA,NA,DNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,30,uM,Skip,39.74,NA,NA,NA,DNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,41.08,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,81.89,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,46.43,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,90.36,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,64.51,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,91.1,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,71.35,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,76.44,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucccacugauucugaauucuuucaa,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuucaucccacugauucugaauucu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuguacuucaucccacugauucuga,2OMe,NA,0.1,uM,Skip,22.31,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguucuuguacuucaucccacugau,2OMe,NA,0.1,uM,Skip,32.55,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gaagguguucuuguacuucauccca,2OMe,NA,0.1,uM,Skip,11.8,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guucugaagguguucuuguacuuca,2OMe,NA,0.1,uM,Skip,24.41,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuccgguucugaagguguucuugua,2OMe,NA,0.1,uM,Skip,42.39,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuccgguucugaagguguucuugua,2OMe,NA,0.1,uM,Skip,58.32,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guugccuccgguucugaagguguuc,2OMe,NA,0.1,uM,Skip,73.36,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guugccuccgguucugaagguguuc,2OMe,NA,0.1,uM,Skip,86.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caacuguugccuccgguucugaagg,2OMe,NA,0.1,uM,Skip,28.74,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caacuguugccuccgguucugaagg,2OMe,NA,0.1,uM,Skip,80.53,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucauucaacuguugccuccgguucu,2OMe,NA,0.1,uM,Skip,28.74,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,acauuucauucaacuguugccuccg,2OMe,NA,0.1,uM,Skip,1.51,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuuuaacauuucauucaacuguugc,2OMe,NA,0.1,uM,Skip,1.78,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gaauccuuuaacauuucauucaacu,2OMe,NA,0.1,uM,Skip,2.88,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guguugaauccuuuaacauuucauu,2OMe,NA,0.1,uM,Skip,2.88,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccauuguguugaauccuuuaacauu,2OMe,NA,0.1,uM,Skip,4.53,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uccagccauuguguugaauccuuua,2OMe,NA,0.1,uM,Skip,3.43,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uagcuuccagccauuguguugaauc,2OMe,NA,0.1,uM,Skip,6.72,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uagcuuccagccauuguguugaauc,2OMe,NA,0.1,uM,Skip,15.95,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuccuuagcuuccagccauuguguu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuccuuagcuuccagccauuguguu,2OMe,NA,0.1,uM,Skip,11.49,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuccuuagcuuccagccauuguguu,2OMe,NA,0.1,uM,Skip,14.12,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gcuucuuccuuagcuuccagccauu,2OMe,NA,0.1,uM,Skip,8.5,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gcuucuuccuuagcuuccagccauu,2OMe,NA,0.1,uM,Skip,9.75,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gcucagcuucuuccuuagcuuccag,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gaccugcucagcuucuuccuuagcu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuaagaccugcucagcuucuuccu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuguccuaagaccugcucagcuuc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucuggccuguccuaagaccugcuca,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuggcucuggccuguccuaagaccu,2OMe,NA,0.1,uM,Skip,27.27,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuggcucuggccuguccuaagaccu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caagcuuggcucuggccuguccuaa,2OMe,NA,0.1,uM,Skip,39.45,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caagcuuggcucuggccuguccuaa,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,caagcuuggcucuggccuguccuaa,2OMe,NA,0.1,uM,Skip,32.77,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugacucaagcuuggcucuggccugu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uuccaugacucaagcuuggcucugg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuccuuccaugacucaagcuuggc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gggacccuccuuccaugacucaagc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gggacccuccuuccaugacucaagc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guauagggacccuccuuccaugacu,2OMe,NA,0.1,uM,Skip,13.43,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guauagggacccuccuuccaugacu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guauagggacccuccuuccaugacu,2OMe,NA,0.1,uM,Skip,11.6,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuacuguauagggacccuccuucca,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugcaucuacuguauagggacccucc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uggauugcaucuacuguauagggac,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucuuuuggauugcaucuacuguaua,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gauuuucuuuuggauugcaucuacu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucugugauuuucuuuuggauugcau,2OMe,NA,0.1,uM,Skip,1.03,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugguuucugugauuuucuuuuggau,2OMe,NA,0.1,uM,Skip,1.71,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugguuucugugauuuucuuuuggau,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugguuucugugauuuucuuuuggau,2OMe,NA,0.1,uM,Skip,16.57,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuuagcuuccagccauuguguuga,2OMe,NA,0.1,uM,Skip,18.64,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ucuuccuuagcuuccagccauugug,2OMe,NA,0.1,uM,Skip,27.12,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ggcucuggccuguccuaagaccugc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,agcuuggcucuggccuguccuaaga,2OMe,NA,0.1,uM,Skip,22.18,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cucaagcuuggcucuggccuguccu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gacccuccuuccaugacucaagcuu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,auagggacccuccuuccaugacuca,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuguauagggacccuccuuccauga,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugugauuuucuuuuggauugcaucu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guuucugugauuuucuuuuggauug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuugguuucugugauuuucuuuugg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccgguucugaagguguucuuguacu,2OMe,NA,0.1,uM,Skip,57.44,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uccgguucugaagguguucuuguac,2OMe,NA,0.1,uM,Skip,67.59,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuccgguucugaagguguucuugu,2OMe,NA,0.1,uM,Skip,67.18,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gccuccgguucugaagguguucuug,2OMe,NA,0.1,uM,Skip,79,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gccuccgguucugaagguguucuug,2OMe,NA,0.1,uM,Skip,95.51,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugccuccgguucugaagguguucuu,2OMe,NA,0.1,uM,Skip,85.54,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugccuccgguucugaagguguucuu,2OMe,NA,0.1,uM,Skip,95.19,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uugccuccgguucugaagguguucu,2OMe,NA,0.1,uM,Skip,94.16,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uugccuccgguucugaagguguucu,2OMe,NA,0.1,uM,Skip,93.27,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguugccuccgguucugaagguguu,2OMe,NA,0.1,uM,Skip,83.59,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguugccuccgguucugaagguguu,2OMe,NA,0.1,uM,Skip,84.62,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuguugccuccgguucugaaggugu,2OMe,NA,0.1,uM,Skip,51.88,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,acuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,47.43,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,aacuguugccuccgguucugaaggu,2OMe,NA,0.1,uM,Skip,53.41,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguugccuccgguucugaagguguucuugu,2OMe,NA,0.1,uM,Skip,91.35,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,guugccuccgguucugaagguguuc,2OMe,NA,0.1,uM,Skip,78.37,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,gguucugaagguguucuugu,2OMe,NA,0.1,uM,Skip,9.46,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uccgguucugaagguguucu,2OMe,NA,0.1,uM,Skip,55.13,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ccuccgguucugaagguguu,2OMe,NA,0.1,uM,Skip,20.99,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uugccuccgguucugaaggu,2OMe,NA,0.1,uM,Skip,42.31,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguugccuccgguucugaag,2OMe,NA,0.1,uM,Skip,58.65,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uucugaagguguucuugu,2OMe,NA,0.1,uM,Skip,13.62,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cgguucugaagguguucu,2OMe,NA,0.1,uM,Skip,26.6,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuccgguucugaaggugu,2OMe,NA,0.1,uM,Skip,24.04,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,ugccuccgguucugaagg,2OMe,NA,0.1,uM,Skip,59.13,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uguugccuccgguucuga,2OMe,NA,0.1,uM,Skip,49.04,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uucugaagguguucu,2OMe,NA,0.1,uM,Skip,7.85,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uccgguucugaaggu,2OMe,NA,0.1,uM,Skip,5.13,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,uugccuccgguucug,2OMe,NA,0.1,uM,Skip,23.4,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
journal article,Antisense Nucleic Acids,JP2018027083A,DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuguugccuccgguucug,2OMe,NA,0.1,uM,Skip,53,NA,NA,NA,RNA,https://patents.google.com/patent/JP2018027083A,NA,NA,NA
journal article,Antisense Nucleic Acids,"JP2018027083A
",DMD,exon,53,NA,human,RD Cells,Lipofectamine2000,NA,cuguugccuccgguucug,2OMe,NA,0.1,uM,Skip,41.99,NA,NA,NA,RNA,"https://patents.google.com/patent/JP2018027083A
",NA,NA,NA
patent,Oligomers,US/2017/0204413,DMD,exon,46,NA,human,Healthy primary human myotubes,"Lipofectin (Invitrogen), 4 ?l/?g AO",NA,tgctgctcttttccaggttcaagtgggata,unmodified PMO,NA,0.5,uM,Skip,87.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2017/0204413,NA,NA,NA
patent,Oligomers,US/2017/0204413,DMD,exon,46,NA,human,Healthy primary human myotubes,"Lipofectin (Invitrogen), 4 ?l/?g AO",NA,cttttagttgctgctcttttccaggttcaa,unmodified PMO,NA,0.5,uM,Skip,87.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2017/0204413,NA,NA,NA
patent,Oligomers,US/2017/0204413,DMD,exon,46,NA,human,Healthy primary human myotubes,"Lipofectin (Invitrogen), 4 ?l/?g AO",NA,cttttcttttagttgctgctcttttccagg,unmodified PMO,NA,0.5,uM,Skip,76.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2017/0204413,NA,NA,NA
patent,Oligomers,US/2017/0204413,DMD,exon,46,NA,human,Healthy primary human myotubes,"Lipofectin (Invitrogen), 4 ?l/?g AO",NA,ttagttgctgctcttttccaggttcaagtg,unmodified PMO,NA,0.5,uM,Skip,74.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2017/0204413,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2017/0044534,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,ucuuuuccagguucaagugg,2OMe,NA,0.05,uM,Skip,21,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0044534,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2017/0044534,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,ucuuuuccagguucaagugg,2OMe,NA,0.15,uM,Skip,55,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0044534,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2017/0044534,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,gcuuuucuuuuaguugcugcucuuu,2OMe,NA,0.05,uM,Skip,53,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0044534,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2017/0044534,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,gcuuuucuuuuaguugcugcucuuu,2OMe,NA,0.15,uM,Skip,58,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0044534,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2017/0044534,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,ggauacuagcaauguuaucugcuuc,2OMe,NA,0.05,uM,Skip,46,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0044534,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2017/0044534,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,ggauacuagcaauguuaucugcuuc,2OMe,NA,0.15,uM,Skip,42,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0044534,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2017/0044534,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,agcaauguuaucugcuuccuccaac,2OMe,NA,0.05,uM,Skip,48,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0044534,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53",US/2017/0044534,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,agcaauguuaucugcuuccuccaac,2OMe,NA,0.15,uM,Skip,74,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0044534,NA,NA,NA
patent,Antisense Oligonucleotdes For Inducing Exon Skipping And Methods Of Use Thereof,US/2017/0009233,DMD,exon,46,NA,human,Healthy primary human myotubes,Null,NA,uuaccuugacuugcucaagc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009233,NA,NA,NA
patent,Antisense Oligonucleotdes For Inducing Exon Skipping And Methods Of Use Thereof,US/2017/0009233,DMD,exon,46,NA,human,Healthy primary human myotubes,Null,NA,uccagguucaagugggauac,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009233,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,6,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uacauuuuugaccuacauguggaaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,8,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuuccuggauggcuugaau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,8,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uguuguuguuuaugcucauu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,17,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccauuacaguugucuguguu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,19,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gccugagcugaucugcuggcaucuugc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,19,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucugcuggcaucuugc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccacaggcguugcacuuugcaaugc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cacaggcguugcacuuugcaaugcu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,acaggcguugcacuuugcaaugcug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caggcguugcacuuugcaaugcugc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aggcguugcacuuugcaaugcugcu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggcguugcacuuugcaaugcugcug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcguugcacuuugcaaugcugcugu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cguugcacuuugcaaugcugcuguc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guugcacuuugcaaugcugcugucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uugcacuuugcaaugcugcugucuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugcacuuugcaaugcugcugucuuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcacuuugcaaugcugcugucuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cacuuugcaaugcugcugucuucuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,acuuugcaaugcugcugucuucuug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuuugcaaugcugcugucuucuugc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugcaaugcugcugucuucuugcu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uugcaaugcugcugucuucuugcua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugcaaugcugcugucuucuugcuau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcaaugcugcugucuucuugcuaug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caaugcugcugucuucuugcuauga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aaugcugcugucuucuugcuaugaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,augcugcugucuucuugcuaugaau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugcugcugucuucuugcuaugaaua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcugcugucuucuugcuaugaauaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cugcugucuucuugcuaugaauaau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugcugucuucuugcuaugaauaaug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcugucuucuugcuaugaauaaugu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cugucuucuugcuaugaauaauguc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugucuucuugcuaugaauaauguca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gucuucuugcuaugaauaaugucaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucuucuugcuaugaauaaugucaau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuucuugcuaugaauaaugucaauc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uucuugcuaugaauaaugucaaucc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucuugcuaugaauaaugucaauccg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuugcuaugaauaaugucaauccga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uugcuaugaauaaugucaauccgac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugcuaugaauaaugucaauccgacc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcuaugaauaaugucaauccgaccu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuaugaauaaugucaauccgaccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uaugaauaaugucaauccgaccuga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,augaauaaugucaauccgaccugag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugaauaaugucaauccgaccugagc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gaauaaugucaauccgaccugagcu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aauaaugucaauccgaccugagcuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,auaaugucaauccgaccugagcuuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uaaugucaauccgaccugagcuuug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aaugucaauccgaccugagcuuugu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,augucaauccgaccugagcuuuguu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugucaauccgaccugagcuuuguug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gucaauccgaccugagcuuuguugu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaauccgaccugagcuuuguugua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caauccgaccugagcuuuguuguag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aauccgaccugagcuuuguuguaga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,auccgaccugagcuuuguuguagac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uccgaccugagcuuuguuguagacu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccgaccugagcuuuguuguagacua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gaccugagcuuuguuguagacuauc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,accugagcuuuguuguagacuauca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,43,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccugagcuuuguuguagacuauc,2OMe,NA,0.2,uM,Skip,46,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,44,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucagcuucuiuuagccacug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,44,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucagcuucuguuaiccacug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,44,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaicuucuguuagccacug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,44,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucagcuucuguuagccacui,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uugcagaccuccugccaccgcagauucaggcuuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccicugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcuicccaaugccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugcccaauiccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuuiccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccui,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,iuugccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uiugccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caauaguggucaguccaggagcuag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuigccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcigcccaaugccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugcccaiugccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugcccaaugcciuccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuuiccicugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugcccaaigccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugcccaaugccaiccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccig,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugccciaugccauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccaauaguggucaguccaggagcua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aauaguggucaguccaggagcuagg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,auaguggucaguccaggagcuaggu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uaguggucaguccaggagcuagguc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aguggucaguccaggagcuagguca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guggucaguccaggagcuaggucag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uggucaguccaggagcuaggucagg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggucaguccaggagcuaggucaggc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gucaguccaggagcuaggucaggcu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaguccaggagcuaggucaggcug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caguccaggagcuaggucaggcugc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aguccaggagcuaggucaggcugcu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guccaggagcuaggucaggcugcuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uccaggagcuaggucaggcugcuuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccaggagcuaggucaggcugcuuug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caggagcuaggucaggcugcuuugc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aggagcuaggucaggcugcuuugcc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggagcuaggucaggcugcuuugccc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gagcuaggucaggcugcuuugcccu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,agcuaggucaggcugcuuugcccuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcuaggucaggcugcuuugcccuca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cucagcucuugaaguaaacgguuua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cagcucuugaaguaaacgguuuacc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcucuugaaguaaacgguuuaccgc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuaggucaggcugcuuugcccucag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uaggucaggcugcuuugcccucagc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aggucaggcugcuuugcccucagcu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggucaggcugcuuugcccucagcuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gucaggcugcuuugcccucagcucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaggcugcuuugcccucagcucuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caggcugcuuugcccucagcucuug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aggcugcuuugcccucagcucuuga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggcugcuuugcccucagcucuugaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcugcuuugcccucagcucuugaag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cugcuuugcccucagcucuugaagu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugcuuugcccucagcucuugaagua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcuuugcccucagcucuugaaguaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuuugcccucagcucuugaaguaaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugcccucagcucuugaaguaaac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uugcccucagcucuugaaguaaacg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugcccucagcucuugaaguaaacgg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcccucagcucuugaaguaaacggu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cccucagcucuugaaguaaacgguu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cucagcucuugaaguaaacg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccucagcucuugaaguaaacgguuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucagcucuugaaguaaacgguuuac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,agcucuugaaguaaacgguuuaccg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,50,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cucuugaaguaaacgguuuaccgcc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucuaguuuggagauggcaguuuccu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuaguuuggagauggcaguuuccuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uaguuuggagauggcaguuuccuua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aguuuggagauggcaguuuccuuag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guuuggagauggcaguuuccuuagu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuuggagauggcaguuuccuuagua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuggagauggcaguuuccuuaguaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uggagauggcaguuuccuuaguaac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gagauggcaguuuccuuaguaacca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,agauggcaguuuccuuaguaaccac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gauggcaguuuccuuaguaaccaca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,auggcaguuuccuuaguaaccacag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uggcaguuuccuuaguaaccacagg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggcaguuuccuuaguaaccacaggu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcaguuuccuuaguaaccacagguu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caguuuccuuaguaaccacagguug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aguuuccuuaguaaccacagguugu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guuuccuuaguaaccacagguugug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuuccuuaguaaccacagguugugu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuccuuaguaaccacagguuguguc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uccuuaguaaccacagguuguguca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccuuaguaaccacagguugugucac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuuaguaaccacagguugugucacc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuaguaaccacagguugugucacca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uaguaaccacagguugugucaccag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aguaaccacagguugugucaccaga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guaaccacagguugugucaccagag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uaaccacagguugugucaccagagu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aaccacagguugugucaccagagua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,accacagguugugucaccagaguaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccacagguugugucaccagaguaac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cacagguugugucaccagaguaaca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,acagguugugucaccagaguaacag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cagguugugucaccagaguaacagu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,agguugugucaccagaguaacaguc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gguugugucaccagaguaacagucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guugugucaccagaguaacagucug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uugugucaccagaguaacagucuga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugugucaccagaguaacagucugag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gugucaccagaguaacagucugagu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugucaccagaguaacagucugagua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gucaccagaguaacagucugaguag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaccagaguaacagucugaguagg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caccagaguaacagucugaguagga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,accagaguaacagucugaguaggag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaigaagauggcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaagiaagauggcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaaiauggcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaagauigcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaagaugicauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,icaaggaagauggcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaagaiggcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaagauggcaiuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaagauggcauiucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaagauggcauuicu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaagauggcauuuci,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uciaggaagauggcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaiggaagauggcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggiagauggcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaigauggcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaagiuggcauuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,51,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaggaagauggciuuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,agccucuugauugcuggucuuguuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gccucuugauugcuggucuuguuuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccucuugauugcuggucuuguuuuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccucuugauugcuggucuug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucuugauugcuggucuuguuuuuca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuugauugcuggucuuguuuuucaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uugauugcuggucuuguuuuucaaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugauugcuggucuuguuuuucaaau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gauugcuggucuuguuuuucaaauu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gauugcuggucuuguuuuuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,auugcuggucuuguuuuucaaauuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uugcuggucuuguuuuucaaauuuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugcuggucuuguuuuucaaauuuug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcuggucuuguuuuucaaauuuugg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuggucuuguuuuucaaauuuuggg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uggucuuguuuuucaaauuuugggc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggucuuguuuuucaaauuuugggca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gucuuguuuuucaaauuuugggcag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucuuguuuuucaaauuuugggcagc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuuguuuuucaaauuuugggcagcg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuguuuuucaaauuuugggcagcgg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uguuuuucaaauuuugggcagcggu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guuuuucaaauuuugggcagcggua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuuuucaaauuuugggcagcgguaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuuucaaauuuugggcagcgguaau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuucaaauuuugggcagcgguaaug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uucaaauuuugggcagcgguaauga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaaauuuugggcagcgguaaugag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caaauuuugggcagcgguaaugagu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aaauuuugggcagcgguaaugaguu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aauuuugggcagcgguaaugaguuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,auuuugggcagcgguaaugaguucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuuugggcagcgguaaugaguucuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugggcagcgguaaugaguucuuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uugggcagcgguaaugaguucuucc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugggcagcgguaaugaguucuucca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gggcagcgguaaugaguucuuccaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggcagcgguaaugaguucuuccaac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcagcgguaaugaguucuuccaacu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cagcgguaaugaguucuuccaacug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,agcgguaaugaguucuuccaacugg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcgguaaugaguucuuccaacuggg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cgguaaugaguucuuccaacugggg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gguaaugaguucuuccaacugggga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guaaugaguucuuccaacuggggac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uaaugaguucuuccaacuggggacg,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aaugaguucuuccaacuggggacgc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,augaguucuuccaacuggggacgcc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugaguucuuccaacuggggacgccu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gaguucuuccaacuggggacgccuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aguucuuccaacuggggacgccucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guucuuccaacuggggacgccucug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uucuuccaacuggggacgccucugu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucuuccaacuggggacgccucuguu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuuccaacuggggacgccucuguuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uccaacuggggacgccucuguucca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccaacuggggacgccucuguuccaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caacuggggacgccucuguuccaaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aacuggggacgccucuguuccaaau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,acuggggacgccucuguuccaaauc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuggggacgccucuguuccaaaucc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uggggacgccucuguuccaaauccu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggggacgccucuguuccaaauccug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gggacgccucuguuccaaauccugc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggacgccucuguuccaaauccugca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,52,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gacgccucuguuccaaauccugcau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cucuggccuguccuaagaccugcuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucuggccuguccuaagaccugcuca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuggccuguccuaagaccugcucag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uggccuguccuaagaccugcucagc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ggccuguccuaagaccugcucagcu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gccuguccuaagaccugcucagcuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccuguccuaagaccugcucagcuuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuguccuaagaccugcucagcuucu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uguccuaagaccugcucagcuucuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guccuaagaccugcucagcuucuuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uccuaagaccugcucagcuucuucc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccuaagaccugcucagcuucuuccu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuaagaccugcucagcuucuuccuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uaagaccugcucagcuucuuccuua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aagaccugcucagcuucuuccuuag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,agaccugcucagcuucuuccuuagc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gaccugcucagcuucuuccuuagcu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccugcucagcuucuuccuuagcuuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cugcucagcuucuuccuuagcuucc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ugcucagcuucuuccuuagcuucca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcucagcuucuuccuuagcuuccag,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cucagcuucuuccuuagcuuccagc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucagcuucuuccuuagcuuccagcc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cagcuucuuccuuagcuuccagcca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,agcuucuuccuuagcuuccagccau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcuucuuccuuagcuuccagccauu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuucuuccuuagcuuccagccauug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uucuuccuuagcuuccagccauugu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucuuccuuagcuuccagccauugug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuuccuuagcuuccagccauugugu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuccuuagcuuccagccauuguguu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uccuuagcuuccagccauuguguug,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccuuagcuuccagccauuguguuga,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuuagcuuccagccauuguguugaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuagcuuccagccauuguguugaau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uagcuuccagccauuguguugaauc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,agcuuccagccauuguguugaaucc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gcuuccagccauuguguugaauccu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cuuccagccauuguguugaauccuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuccagccauuguguugaauccuuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uccagccauuguguugaauccuuua,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ccagccauuguguugaauccuuuaa,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cagccauuguguugaauccuuuaac,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,agccauuguguugaauccuuuaaca,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gccauuguguugaauccuuuaacau,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,53,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,cauuguguugaauccuuuaacauuu,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,65,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,gccauacguacgucaucauaaacauuc,2OMe,NA,0.2,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,73,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,72,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,63,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucaauguucugacaacaguuugccg,2OMe,NA,0.2,uM,Skip,9,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,caauguucugacaacaguuugccgc,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,aauguucugacaacaguuugccgcu,2OMe,NA,0.2,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,auguucugacaacaguuugccgcug,2OMe,NA,0.2,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uguucugacaacaguuugccgcugc,2OMe,NA,0.2,uM,Skip,20,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,guucugacaacaguuugccgcugcc,2OMe,NA,0.2,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,uucugacaacaguuugccgcugccc,2OMe,NA,0.2,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine  For Treating Dmd,US 20170204414 A1,DMD,exon,45,NA,human,Healthy primary human myotubes,"UNIfectylin (Prosensa Therapeutics BV, The Netherlands), 2 ?l/?g AO",NA,ucugacaacaguuugccgcugccca,2OMe,NA,0.2,uM,Skip,12,NA,NA,NA,RNA,https://patents.google.com/patent/US20170204414A1,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,48.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,75.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,25.5,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,69.5,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,4.3,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,36.5,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,10.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,11.3,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,9.5,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,40,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,15,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,66.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,39,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,1.3,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,33.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,0.8,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,28.5,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,0.8,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,0.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,5,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,6.7,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,1.2,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,ggccaaacctcggcttacctgaaat,Null,NA,2.84,uM/kg,Skip,54.3,NA,NA,NA,DNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,ggccaaacctcggcttacctgaaat,Null,NA,2.84,uM/kg,Skip,44.9,NA,NA,NA,DNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,ggccaaacctcggcttacctgaaat,Null,NA,2.84,uM/kg,Skip,68,NA,NA,NA,DNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,ggccaaacctcggcttacctgaaat,Null,NA,2.84,uM/kg,Skip,2.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Quadricep",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,21.3,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,ggccaaacctcggcttacctgaaat,Null,NA,2.84,uM/kg,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,ggccaaacctcggcttacctgaaat,Null,NA,2.84,uM/kg,Skip,0.4,NA,NA,NA,DNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,ggccaaacctcggcttacctgaaat,Null,NA,2.84,uM/kg,Skip,16.6,NA,NA,NA,DNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,ggccaaacctcggcttacctgaaat,Null,NA,2.84,uM/kg,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
journal article,Multiple Oligonucleotide Moieties On Peptide Carrier,JP2021063128A,DMD,exon,23,NA,mouse,"wild-type mice,Heart",Null,NA,unspecified,Null,NA,2.84,uM/kg,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/JP2021063128A,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcugcccaaugccauccuggaguuc,2OMe,NA,0.03,uM,Skip,34.84,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcugcccaaugccauccuggaguuc,2OMe,NA,0.1,uM,Skip,53.54,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugccgcugcccaaugccauccugg,2OMe,NA,0.01,uM,Skip,12.8,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugcauucaauguucugacaacagu,2OMe,NA,0.1,uM,Skip,12,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,cccaguugcauucaauguucugaca,2OMe,NA,0.03,uM,Skip,2.71,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.1,uM,Skip,26.97,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uucaauguucugacaacaguuugcc,2OMe,NA,0.1,uM,Skip,12,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugcauucaauguucugacaacagu,2OMe,NA,0.03,uM,Skip,1.94,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcugcccaaugccauccuggaguuc,2OMe,NA,0.01,uM,Skip,25.79,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.03,uM,Skip,36.26,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.1,uM,Skip,88.77,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcugcccaaugccauccuggaguuc,2OMe,NA,0.03,uM,Skip,62.97,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcugcccaaugccauccuggaguuc,2OMe,NA,0.1,uM,Skip,88.9,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugccgcugcccaaugccauccugg,2OMe,NA,0.03,uM,Skip,53.03,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugccgcugcccaaugccauccugg,2OMe,NA,0.1,uM,Skip,93.81,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,acaguuugccgcugcccaaugccau,2OMe,NA,0.03,uM,Skip,5.29,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,acaguuugccgcugcccaaugccau,2OMe,NA,0.1,uM,Skip,3.48,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,ugacaacaguuugccgcugcccaau,2OMe,NA,0.03,uM,Skip,1.16,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,ugacaacaguuugccgcugcccaau,2OMe,NA,0.1,uM,Skip,6.06,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uguucugacaacaguuugccgcugc,2OMe,NA,0.03,uM,Skip,11.74,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uguucugacaacaguuugccgcugc,2OMe,NA,0.1,uM,Skip,21.55,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uucaauguucugacaacaguuugcc,2OMe,NA,0.03,uM,Skip,9.42,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,cccaguugcauucaauguucugaca,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,ucuuccccaguugcauucaauguuc,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,ucuuccccaguugcauucaauguuc,2OMe,NA,0.1,uM,Skip,9.68,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuauuucuuccccaguugcauucaa,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuauuucuuccccaguugcauucaa,2OMe,NA,0.1,uM,Skip,3.48,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,cugaauuauuucuuccccaguugca,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,cugaauuauuucuuccccaguugca,2OMe,NA,0.1,uM,Skip,22.58,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gauugcugaauuauuucuuccccag,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gauugcugaauuauuucuuccccag,2OMe,NA,0.1,uM,Skip,2.45,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugaggauugcugaauuauuucuuc,2OMe,NA,0.03,uM,Skip,1.94,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugaggauugcugaauuauuucuuc,2OMe,NA,0.1,uM,Skip,6.32,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uguuuuugaggauugcugaauuauu,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uguuuuugaggauugcugaauuauu,2OMe,NA,0.1,uM,Skip,1.68,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcaucuguuuuugaggauugcugaa,2OMe,NA,0.03,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,gcaucuguuuuugaggauugcugaa,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uacuggcaucuguuuuugaggauug,2OMe,NA,0.03,uM,Skip,12.52,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uacuggcaucuguuuuugaggauug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.01,uM,Skip,10.04,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.03,uM,Skip,18.9,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugccgcugcccaaugccauccugg,2OMe,NA,0.03,uM,Skip,30.71,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Lipofectamine2000,NA,uugccgcugcccaaugccauccugg,2OMe,NA,0.1,uM,Skip,40.55,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,18.86,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,54.31,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,81.68,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttcctgt,unmodified PMO,NA,1,uM,Skip,14.22,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttcctgt,unmodified PMO,NA,3,uM,Skip,50.22,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttcctgt,unmodified PMO,NA,10,uM,Skip,84.27,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,9.31,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,31.92,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,54.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,1,uM,Skip,6.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,3,uM,Skip,26.48,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,10,uM,Skip,59.34,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,fibroblasts from human DMD patient (GM05017 cells),Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,59.31,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcagccucucgcucacucacc,2OMe,NA,0.03,uM,Skip,5.84,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcagccucucgcucacucacc,2OMe,NA,0.1,uM,Skip,22.97,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuuccaaagcagccucucg,2OMe,NA,0.03,uM,Skip,6.32,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuuccaaagcagccucucg,2OMe,NA,0.1,uM,Skip,33.63,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,aucuaugaguuucuuccaaag,2OMe,NA,0.03,uM,Skip,8.53,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,aucuaugaguuucuuccaaag,2OMe,NA,0.1,uM,Skip,13.42,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,cagggggaacuguugcaguaa,2OMe,NA,0.1,uM,Skip,4.89,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuuccagguccagggggaacu,2OMe,NA,0.03,uM,Skip,6.47,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuuccagguccagggggaacu,2OMe,NA,0.1,uM,Skip,6.32,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcaagaaacuuuuccaggucc,2OMe,NA,0.1,uM,Skip,17.21,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uguaagccaggcaagaaacuu,2OMe,NA,0.1,uM,Skip,1.26,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuucagcuucuguaagccagg,2OMe,NA,0.1,uM,Skip,2.21,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuggcaguuguuucagcuucu,2OMe,NA,0.1,uM,Skip,4.42,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,cuguaggacauuggcaguugu,2OMe,NA,0.1,uM,Skip,4.34,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ggguagcauccuguaggacau,2OMe,NA,0.1,uM,Skip,10.74,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,cuuuccuuacggguagcaucc,2OMe,NA,0.1,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuaggagccuuuccuuacg,2OMe,NA,0.1,uM,Skip,1.26,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uccuguaggacauuggcagu,2OMe,NA,0.1,uM,Skip,3.95,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcagccucucgcucacucacc,2OMe,NA,0.01,uM,Skip,1.4,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcagccucucgcucacucacc,2OMe,NA,0.03,uM,Skip,12.64,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,gcagccucucgcucacucacc,2OMe,NA,0.1,uM,Skip,23.5,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ccaaagcagccucucgcucac,2OMe,NA,0.03,uM,Skip,9.08,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,ccaaagcagccucucgcucac,2OMe,NA,0.1,uM,Skip,12.83,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuuccaaagcagccucucg,2OMe,NA,0.01,uM,Skip,6.84,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuuccaaagcagccucucg,2OMe,NA,0.03,uM,Skip,24.25,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uucuuccaaagcagccucucg,2OMe,NA,0.1,uM,Skip,31.18,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuuccagguccagggggaacu,2OMe,NA,0.01,uM,Skip,1.59,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuuccagguccagggggaacu,2OMe,NA,0.03,uM,Skip,6.65,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uuuccagguccagggggaacu,2OMe,NA,0.1,uM,Skip,12.08,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uccuguaggacauuggcagu,2OMe,NA,0.01,uM,Skip,1.22,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uccuguaggacauuggcagu,2OMe,NA,0.03,uM,Skip,1.59,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Lipofectamine2000,NA,uccuguaggacauuggcagu,2OMe,NA,0.1,uM,Skip,4.03,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agcagcctctcgctcactcac,unmodified PMO,NA,1,uM,Skip,0.89,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agcagcctctcgctcactcac,unmodified PMO,NA,3,uM,Skip,1.33,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agcagcctctcgctcactcac,unmodified PMO,NA,10,uM,Skip,1.78,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttccaaagcagcctctcgctc,unmodified PMO,NA,1,uM,Skip,13.11,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttccaaagcagcctctcgctc,unmodified PMO,NA,3,uM,Skip,29.11,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttccaaagcagcctctcgctc,unmodified PMO,NA,10,uM,Skip,56.67,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttcttccaaagcagcctctcg,unmodified PMO,NA,1,uM,Skip,31.33,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttcttccaaagcagcctctcg,unmodified PMO,NA,3,uM,Skip,52,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,ttcttccaaagcagcctctcg,unmodified PMO,NA,10,uM,Skip,84.67,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,36,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,59.56,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,90,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cucaacagaucugucaaaucgc,2OMe,NA,0.03,uM,Skip,46.61,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cucaacagaucugucaaaucgc,2OMe,NA,0.1,uM,Skip,51.07,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cauuucucaacagaucugucaa,2OMe,NA,0.03,uM,Skip,20.45,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cauuucucaacagaucugucaa,2OMe,NA,0.1,uM,Skip,45.12,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gccgccauuucucaacagaucu,2OMe,NA,0.03,uM,Skip,40.91,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gccgccauuucucaacagaucu,2OMe,NA,0.1,uM,Skip,61.98,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aaaacgccgccauuucucaaca,2OMe,NA,0.03,uM,Skip,16.12,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aaaacgccgccauuucucaaca,2OMe,NA,0.1,uM,Skip,58.51,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaaugaaaacgccgccauuucu,2OMe,NA,0.03,uM,Skip,39.55,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaaugaaaacgccgccauuucu,2OMe,NA,0.1,uM,Skip,53.06,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaucauaaugaaaacgccgcca,2OMe,NA,0.03,uM,Skip,37.93,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaucauaaugaaaacgccgcca,2OMe,NA,0.1,uM,Skip,61.98,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuuauaucauaaugaaaacgc,2OMe,NA,0.03,uM,Skip,29.26,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuuauaucauaaugaaaacgc,2OMe,NA,0.1,uM,Skip,50.08,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aauaucuuuauaucauaaugaa,2OMe,NA,0.1,uM,Skip,9.42,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gauuaaauaucuuuauaucaua,2OMe,NA,0.03,uM,Skip,5.95,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gauuaaauaucuuuauaucaua,2OMe,NA,0.1,uM,Skip,10.41,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,guuagccacugauuaaauaucu,2OMe,NA,0.03,uM,Skip,15.37,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,guuagccacugauuaaauaucu,2OMe,NA,0.1,uM,Skip,15.46,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuucuguuagccacugauuaaa,2OMe,NA,0.03,uM,Skip,25.29,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuucuguuagccacugauuaaa,2OMe,NA,0.1,uM,Skip,29.13,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uucagcuucuguuagccacuga,2OMe,NA,0.03,uM,Skip,46.24,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uucagcuucuguuagccacuga,2OMe,NA,0.1,uM,Skip,48.22,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aacuguucaguucuguuagcc,2OMe,NA,0.03,uM,Skip,36.45,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,aacuguucaguucuguuagcc,2OMe,NA,0.1,uM,Skip,38.93,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ugagaaacuguucagcuucugu,2OMe,NA,0.03,uM,Skip,30.87,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ugagaaacuguucagcuucugu,2OMe,NA,0.1,uM,Skip,37.19,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuucugagaaacuguucagcu,2OMe,NA,0.03,uM,Skip,52.69,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuucugagaaacuguucagcu,2OMe,NA,0.1,uM,Skip,41.16,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ugugucuuucugagaaacuguu,2OMe,NA,0.03,uM,Skip,34.96,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ugugucuuucugagaaacuguu,2OMe,NA,0.1,uM,Skip,50.33,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gaauuugugucuuucugagaaa,2OMe,NA,0.03,uM,Skip,21.82,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gaauuugugucuuucugagaaa,2OMe,NA,0.1,uM,Skip,26.53,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cucaggaauuugugucuuucug,2OMe,NA,0.03,uM,Skip,29.5,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cucaggaauuugugucuuucug,2OMe,NA,0.1,uM,Skip,54.92,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,caauucucaggaauuugugucu,2OMe,NA,0.03,uM,Skip,55.79,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,caauucucaggaauuugugucu,2OMe,NA,0.1,uM,Skip,34.21,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,guucccaauucucaggaauuug,2OMe,NA,0.03,uM,Skip,40.41,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,guucccaauucucaggaauuug,2OMe,NA,0.1,uM,Skip,55.29,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,agcauguucccaauucucagga,2OMe,NA,0.03,uM,Skip,27.02,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,agcauguucccaauucucagga,2OMe,NA,0.1,uM,Skip,41.53,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uauuuagcauguucccaauucu,2OMe,NA,0.03,uM,Skip,7.19,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uauuuagcauguucccaauucu,2OMe,NA,0.1,uM,Skip,17.23,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,auaccauuuguauuuagcaugu,2OMe,NA,0.1,uM,Skip,4.21,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ucagcuucuguuagccacug,2OMe,NA,0.03,uM,Skip,62.48,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,ucagcuucuguuagccacug,2OMe,NA,0.1,uM,Skip,51.07,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gccgccauuucucaacagaucu,2OMe,NA,0.01,uM,Skip,31.09,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gccgccauuucucaacagaucu,2OMe,NA,0.03,uM,Skip,62.01,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,gccgccauuucucaacagaucu,2OMe,NA,0.1,uM,Skip,46.46,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaaugaaaacgccgccauuucu,2OMe,NA,0.01,uM,Skip,23.06,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaaugaaaacgccgccauuucu,2OMe,NA,0.03,uM,Skip,15.37,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaaugaaaacgccgccauuucu,2OMe,NA,0.1,uM,Skip,60.44,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaucauaaugaaaacgccgcca,2OMe,NA,0.01,uM,Skip,23.76,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaucauaaugaaaacgccgcca,2OMe,NA,0.03,uM,Skip,49.78,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,uaucauaaugaaaacgccgcca,2OMe,NA,0.1,uM,Skip,60.79,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuucugagaaacuguucagcu,2OMe,NA,0.01,uM,Skip,19.56,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuucugagaaacuguucagcu,2OMe,NA,0.03,uM,Skip,29,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,cuuucugagaaacuguucagcu,2OMe,NA,0.1,uM,Skip,53.45,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,caauucucaggaauuugugucu,2OMe,NA,0.01,uM,Skip,17.29,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,caauucucaggaauuugugucu,2OMe,NA,0.03,uM,Skip,35.46,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Lipofectamine2000,NA,caauucucaggaauuugugucu,2OMe,NA,0.1,uM,Skip,33.36,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccattt,unmodified PMO,NA,1,uM,Skip,13.66,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccattt,unmodified PMO,NA,3,uM,Skip,27.52,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccattt,unmodified PMO,NA,10,uM,Skip,64.16,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,1,uM,Skip,15.64,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,3,uM,Skip,28.51,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,10,uM,Skip,74.85,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atatcataatgaaaacgccgc,unmodified PMO,NA,1,uM,Skip,8.32,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atatcataatgaaaacgccgc,unmodified PMO,NA,3,uM,Skip,23.76,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atatcataatgaaaacgccgc,unmodified PMO,NA,10,uM,Skip,48.51,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatatcataatgaaaacgccg,unmodified PMO,NA,1,uM,Skip,8.32,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatatcataatgaaaacgccg,unmodified PMO,NA,3,uM,Skip,30.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatatcataatgaaaacgccg,unmodified PMO,NA,10,uM,Skip,70.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,1,uM,Skip,37.03,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,3,uM,Skip,68.91,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,10,uM,Skip,92.08,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tcataatgaaaacgccgccat,unmodified PMO,NA,1,uM,Skip,23.15,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tcataatgaaaacgccgccat,unmodified PMO,NA,3,uM,Skip,61.42,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tcataatgaaaacgccgccat,unmodified PMO,NA,10,uM,Skip,91.65,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,1,uM,Skip,12.28,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,3,uM,Skip,45.59,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcca,unmodified PMO,NA,10,uM,Skip,80.79,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,29.53,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,54.09,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,93.78,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,ttatatcataatgaaaacgcc,unmodified PMO,NA,1,uM,Skip,3.78,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,ttatatcataatgaaaacgcc,unmodified PMO,NA,3,uM,Skip,9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,ttatatcataatgaaaacgcc,unmodified PMO,NA,10,uM,Skip,36.14,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,1,uM,Skip,38.74,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,3,uM,Skip,65.91,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,10,uM,Skip,95.67,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,tccagtatacttacaggctcc,unmodified PMO,NA,0.1,uM,Skip,1.02,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,tccagtatacttacaggctcc,unmodified PMO,NA,0.3,uM,Skip,2.04,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,tccagtatacttacaggctcc,unmodified PMO,NA,1,uM,Skip,7.25,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,atccagtatacttacaggctc,unmodified PMO,NA,0.1,uM,Skip,0.89,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,atccagtatacttacaggctc,unmodified PMO,NA,0.3,uM,Skip,3.56,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,atccagtatacttacaggctc,unmodified PMO,NA,1,uM,Skip,12.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gatccagtatacttacaggct,unmodified PMO,NA,0.1,uM,Skip,1.02,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gatccagtatacttacaggct,unmodified PMO,NA,0.3,uM,Skip,5.73,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gatccagtatacttacaggct,unmodified PMO,NA,1,uM,Skip,32.32,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacaggc,unmodified PMO,NA,0.1,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacaggc,unmodified PMO,NA,0.3,uM,Skip,10.81,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacaggc,unmodified PMO,NA,1,uM,Skip,59.54,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,5.85,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,83.72,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,99.24,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,cttacaggctccaatagtggtcagt,unmodified PMO,NA,0.1,uM,Skip,1.15,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,cttacaggctccaatagtggtcagt,unmodified PMO,NA,0.3,uM,Skip,6.11,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,cttacaggctccaatagtggtcagt,unmodified PMO,NA,1,uM,Skip,41.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.1,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,0.3,uM,Skip,53.94,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacaggctcc,unmodified PMO,NA,1,uM,Skip,97.58,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,1,uM,Skip,19.75,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,3,uM,Skip,59.12,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,caatgccatcctggagttcct,unmodified PMO,NA,10,uM,Skip,91.85,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcc,unmodified PMO,NA,1,uM,Skip,19.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcc,unmodified PMO,NA,3,uM,Skip,63.67,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcc,unmodified PMO,NA,10,uM,Skip,92.54,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,26.24,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,70.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,93.65,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,gcccaatgccatcctggagt,unmodified PMO,NA,1,uM,Skip,0.55,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,gcccaatgccatcctggagt,unmodified PMO,NA,3,uM,Skip,1.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,gcccaatgccatcctggagt,unmodified PMO,NA,10,uM,Skip,3.04,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,tgcccaatgccatcctggagt,unmodified PMO,NA,1,uM,Skip,0.55,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,tgcccaatgccatcctggagt,unmodified PMO,NA,3,uM,Skip,1.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,tgcccaatgccatcctggagt,unmodified PMO,NA,10,uM,Skip,5.66,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,1,uM,Skip,8.7,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,3,uM,Skip,33.43,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,10,uM,Skip,79.83,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,17.96,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,54.27,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,84.67,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,4.65,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,19.35,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,49.62,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttc,unmodified PMO,NA,1,uM,Skip,4.27,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttc,unmodified PMO,NA,3,uM,Skip,15.08,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttc,unmodified PMO,NA,10,uM,Skip,44.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagtt,unmodified PMO,NA,1,uM,Skip,4.15,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagtt,unmodified PMO,NA,3,uM,Skip,19.85,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,45,NA,human,RD Cells,Null,NA,cccaatgccatcctggagtt,unmodified PMO,NA,10,uM,Skip,46.48,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,tttcttccaaagcagcctctc,unmodified PMO,NA,1,uM,Skip,17.24,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,tttcttccaaagcagcctctc,unmodified PMO,NA,3,uM,Skip,36.91,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,tttcttccaaagcagcctctc,unmodified PMO,NA,10,uM,Skip,69.35,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctct,unmodified PMO,NA,1,uM,Skip,14.69,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctct,unmodified PMO,NA,3,uM,Skip,34.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctct,unmodified PMO,NA,10,uM,Skip,57.85,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,25.67,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,38.44,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,74.84,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtttcttccaaagcagcct,unmodified PMO,NA,1,uM,Skip,11.49,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtttcttccaaagcagcct,unmodified PMO,NA,3,uM,Skip,28.22,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtttcttccaaagcagcct,unmodified PMO,NA,10,uM,Skip,72.03,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,tgagtttcttccaaagcagcc,unmodified PMO,NA,1,uM,Skip,14.05,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,tgagtttcttccaaagcagcc,unmodified PMO,NA,3,uM,Skip,28.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,tgagtttcttccaaagcagcc,unmodified PMO,NA,10,uM,Skip,63.73,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,1,uM,Skip,0.89,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,3,uM,Skip,1.66,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,10,uM,Skip,1.66,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,17.23,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,32.77,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,67.66,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,6.36,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,19.77,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,44.92,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,1,uM,Skip,7.34,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,3,uM,Skip,24.29,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,10,uM,Skip,66.95,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,9.18,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,28.81,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,57.91,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,1,uM,Skip,0.56,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,3,uM,Skip,0.42,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,RD Cells,Null,NA,gagtcttctaggagcctt,unmodified PMO,NA,10,uM,Skip,1.41,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,12.97,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,27.95,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,68.73,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,11.82,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,18.3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,55.19,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgc,unmodified PMO,NA,1,uM,Skip,2.16,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgc,unmodified PMO,NA,3,uM,Skip,9.22,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgc,unmodified PMO,NA,10,uM,Skip,29.97,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,7.2,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,31.99,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,RD Cells,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,61.1,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,13.46,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,79.67,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,98.21,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,4.67,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,54.26,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,96.02,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,1.51,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,7.83,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,ggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,37.77,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacag,unmodified PMO,NA,0.1,uM,Skip,5.91,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacag,unmodified PMO,NA,0.3,uM,Skip,53.85,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,gggatccagtatacttacag,unmodified PMO,NA,1,uM,Skip,95.74,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,tgggatccagtatacttacag,unmodified PMO,NA,0.1,uM,Skip,7.01,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,tgggatccagtatacttacag,unmodified PMO,NA,0.3,uM,Skip,45.05,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,tgggatccagtatacttacag,unmodified PMO,NA,1,uM,Skip,96.43,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,atgggatccagtatacttaca,unmodified PMO,NA,0.1,uM,Skip,3.85,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,atgggatccagtatacttaca,unmodified PMO,NA,0.3,uM,Skip,32.42,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,RD Cells,Null,NA,atgggatccagtatacttaca,unmodified PMO,NA,1,uM,Skip,90.38,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,28.35,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,42.68,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,70.73,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,26.68,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,43.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,44,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,atcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,68.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,7.64,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,13.29,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,52.49,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,3,uM,Skip,67.11,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,10,uM,Skip,86.05,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,0.1,uM,Skip,1.33,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,0.3,uM,Skip,2.66,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,6.99,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,22.96,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon45(GM05112 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,59.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon 45 (GM05112cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,0.1,uM,Skip,4.99,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon 45 (GM05112cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,0.3,uM,Skip,1.33,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon 45 (GM05112cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,26.96,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon 45 (GM05112cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,3,uM,Skip,47.92,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon 45 (GM05112cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,70.88,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon 8-9 (11-0627cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,1.57,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon 8-9 (11-0627cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,19.75,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon 8-9 (11-0627cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,10,uM,Skip,76.8,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon 8-9 (11-0627cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.1,uM,Skip,35.33,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon 8-9 (11-0627cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,0.3,uM,Skip,49,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon 51-55 (GM04364 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,1,uM,Skip,70.67,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon 51-55 (GM04364 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,3,uM,Skip,82,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,50,NA,human,the fibroblasts from human DMD patient with deletion of exon 51-55 (GM04364 cells),Null,NA,gggatccagtatacttacagg,unmodified PMO,NA,10,uM,Skip,93,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon54 (04-035 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,0.1,uM,Skip,56.4,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon54 (04-035 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,1,uM,Skip,75.75,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon54 (04-035 cells),Null,NA,agtttcttccaaagcagcctc,unmodified PMO,NA,10,uM,Skip,78.47,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon54 (04-035 cells),Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,0.1,uM,Skip,31.88,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon54 (04-035 cells),Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,1,uM,Skip,55.59,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2013100190A1,DMD,exon,55,NA,human,the fibroblasts from human DMD patient with deletion of exon54 (04-035 cells),Null,NA,agtttcttccaaagcagcct,unmodified PMO,NA,10,uM,Skip,73.84,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,caccuaccacuuaccuccaauc,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,ccucugcauccuccccucucug,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,gcgagagaaauagcugccac,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,auacagaguuccucucuccc,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,cagcaauucaggaugccuaggaa,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,gccuaaacaagcucacauccaaa,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,auagcugccacccucccucu,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,gucuucugcaggugcgagagaaa,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,uaugugacuugaugacaucgga,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,cagaccccgguuuauaagugcaa,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,gugagugaccacaacuaacucaa,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,ggagacuggguccucacugcagg,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,uucaaaagcugcauuuccccaa,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,ugggagcucaucacuggccaggg,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,agcucgccagccccuggaacuca,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,gagguccugcgccagccccugga,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
patent,Compositions And Methods For Modulating Dysferlin Expression,US 2017/0101645 A1,DYSF,exon,44,NA,human,"Myogenic converted dermal fibroblasts, and myoblasts",Oligofectamine,NA,cugccccaucagcauuagccuga,2OMe,NA,600,nM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US2017/0101645A1,NA,NA,NA
journal article,Systemic Antisense Therapeutics For Dystrophin And Myostatin Exon Splice Modulation Improve Muscle Pathology Of Adult Mdx Mice,PMID 28325281,DMD/MSTN,exon,2,NA,mouse,Mdx mice (TA muscle),Null,NA,ggccaaacctcggcttacctgaaat/cagcccatcttctcctggtcctgggaaggt,modified PMO (BPMO),NA,10,mg/kg,Skip,55,NA,NA,NA,DNA,invalid,NA,NA,NA
journal article,Systemic Antisense Therapeutics For Dystrophin And Myostatin Exon Splice Modulation Improve Muscle Pathology Of Adult Mdx Mice,PMID 28325281,MSTN,exon,2,NA,mouse,Mdx mice (TA muscle),Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (BPMO),NA,10,mg/kg,Skip,20,NA,NA,NA,DNA,invalid,NA,NA,NA
journal article,Targeting Dmpk With Antisense Oligonucleotide Improves Muscle Strength In Myotonic Dystrophy Type 1 Mice.,PMID 28624222,DMPK,exon,CUG repeats,NA,mouse,DMSXL mice,Null,NA,acaataaataccgagg,Others (3-10-3 cEt gapmer),NA,25,mg/kg,reduction of nuclear foci [%],70,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/28624222,NA,NA,NA
journal article,Exon skipping of FcRI eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy,PMID 27872312,MS4A2,exon,3,NA,mouse,Mouse bone marrow-derived mast cells (BMMCs),Nucleofection,NA,gtgttgcctgtggaaaacatgaatt,unmodified PMO,NA,1,uM,Skip,80,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27872312,NA,NA,NA
journal article,Exon skipping of FcRI eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy,PMID 27872312,MS4A2,exon,3,NA,mouse,Mouse bone marrow-derived mast cells (BMMCs),Nucleofection,NA,gtgttgcctgtggaaaacatgaatt,unmodified PMO,NA,10,uM,Skip,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27872312,NA,NA,NA
journal article,Exon skipping of FcRI eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy,PMID 27872312,MS4A2,exon,3,NA,human,Human LAD-2 mast cells,Nucleofection,NA,cacaaatatggctccccagaatgga,unmodified PMO,NA,upto 1,nM,Skip,75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27872312,NA,NA,NA
journal article,Exon skipping of FcRI eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy,PMID 27872312,MS4A2,exon,3,NA,mouse,BALB/cAnN mice,"Intracutaneous injections on the dorsal and ventral left ear on days 1,7,14,21 and 27",NA,gtgttgcctgtggaaaacatgaatt,modified PMO (vivo morpholino),NA,10+10,ul,Skip,strong skipped band,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27872312,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Systemic Therapeutic Approach For Recessive Dystrophic Epidermolysis Bullosa,PMID 27754488,COL7A1,exon,105,NA,human,Keratinocytes from RDEB patient EB-23,Lipofectamine 2000,NA,gauaccaggcacuccauccu/caugaagccaacaucuccuu,2OMe,NA,250 (Combined),nM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27754488,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Systemic Therapeutic Approach For Recessive Dystrophic Epidermolysis Bullosa,PMID 27754488,COL7A1,exon,105,NA,human,Keratinocytes from RDEB patient EB-23,Lipofectamine 2000,NA,gauaccaggcacuccauccu,2OMe,NA,250,nM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27754488,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Systemic Therapeutic Approach For Recessive Dystrophic Epidermolysis Bullosa,PMID 27754488,COL7A1,exon,105,NA,human,Keratinocytes from RDEB patient EB-23,Lipofectamine 2000,NA,gauaccaggcacuccauccu,2OMe,NA,500,nM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27754488,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Systemic Therapeutic Approach For Recessive Dystrophic Epidermolysis Bullosa,PMID 27754488,COL7A1,exon,105,NA,human,Keratinocytes from RDEB patient EB-23,Lipofectamine 2000,NA,caugaa gccaacaucuccuu,2OMe,NA,250,nM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27754488,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Systemic Therapeutic Approach For Recessive Dystrophic Epidermolysis Bullosa,PMID 27754488,COL7A1,exon,105,NA,human,Keratinocytes from RDEB patient EB-23,Lipofectamine 2000,NA,caugaa gccaacaucuccuu,2OMe,NA,500,nM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27754488,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Systemic Therapeutic Approach For Recessive Dystrophic Epidermolysis Bullosa,PMID 27754488,COL7A1,exon,105,NA,human,Keratinocytes and fibroblasts from RDEB patient EB-24,Lipofectamine 2000,NA,gauaccaggcacuccauccu/caugaagccaacaucuccuu,2OMe,NA,250 (Combined),nM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27754488,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Systemic Therapeutic Approach For Recessive Dystrophic Epidermolysis Bullosa,PMID 27754488,COL7A1,exon,105,NA,human,Primary patient keratinocytes and fibroblasts grafted onto nude mice,subcutaneous injection,NA,gauaccaggcacuccauccu/caugaagccaacaucuccuu,2OMe,NA,50 each (100 total),mg/kg,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27754488,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,8,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gauaggugguaucaacaucuguaa,2OMe,NA,0.02,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,8,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gauaggugguaucaacaucug,2OMe,NA,0.04,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,8,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gauaggugguaucaacaucuguaag,2OMe,NA,0.04,uM,Null,Strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,8,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ggugguaucaacaucuguaa,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,8,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guaucaacaucuguaagcac,2OMe,NA,0.1,uM,Null,Patchy/weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,7,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugcauguuccagucguugugugg,2OMe,NA,0.02,uM,Null,Strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,7,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cacuauuccagucaaauaggucugg,2OMe,NA,0.1,uM,Null,Weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,7,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,auuuaccaaccuucaggaucgagua,2OMe,NA,0.3,uM,Null,Weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,7,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ggccuaaaacacauacacaua,2OMe,NA,0.3,uM,Null,Weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,6,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauuuuugaccuacaugugg,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,6,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuugaccuacauguggaaag,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,6,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacauuuuugaccuacauguggaaag,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,6,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,auuuuugaccuacaugggaaag,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,6,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacgaguugauugucggacccag,2OMe,NA,0.02,uM,Null,Strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,6,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guggucuccuuaccuaugacugugg,2OMe,NA,0.3,uM,Null,Weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,6,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ggucuccuuaccuauga,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,6,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugucucaguaaucuucuuaccuau,2OMe,NA,0.05,uM,Null,Weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,6,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuuaccuaugacuauggaugaga,2OMe,NA,0.3,uM,Null,Very weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,4,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gcaugaacucuuguggaucc,2OMe,NA,0.02,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,4,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uguucagggcaugaacucuuguggauccuu,2OMe,NA,0.02,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,4,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccaggguacuacuuacauua,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,4,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucgugugucacagcauccag,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,3,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaggaggcgccucccauccuguaggucacug,2OMe,NA,0.02 to 0.6,uM,Null,Moderate skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,3,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aggucuaggaggcgccucccauccuguaggu,2OMe,NA,0.3,uM,Null,Working,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,3,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gcgccucccauccuguaggucacug,2OMe,NA,002-0.6,uM,Null,Moderate,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,3,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuucgaggaggucuaggaggcgccuc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,3,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cucccauccuguaggucacug,2OMe,NA,0.02-0.6,uM,Null,Moderate,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,3,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaccaguuuuugcccugucagg,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,3,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucaauaugcugcuucccaaacugaaa,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,3,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaggaggcgccucccauccuguag,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,5,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuaugauuuccaucuacgaugucaguacuuc,2OMe,NA,0.1,uM,Null,Working,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,5,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuuaccugccaguggaggauuauauuccaaa,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,5,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caucaggauucuuaccugccagugg,2OMe,NA,0.3,uM,Null,Inconsistent,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,5,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cgaugucaguacuuccaauauucac,2OMe,NA,unspecified,Null,Null,Very weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,5,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accauucaucaggauucu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,5,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accugccaguggaggauu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,5,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccaauauucacuaaaucaaccuguuaa,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,5,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caggauucuuaccugccaguggaggauuau,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,5,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acgaugucaguacuuccaauauucacuaaau,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,5,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,auuuccaucuacgaugucaguacuuccaaua,2OMe,NA,0.3,uM,Null,working,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,10,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caggagcuuccaaaugcugca,2OMe,NA,Null,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,10,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuugucuucaggagcuuccaaaugcugca,2OMe,NA,Null,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,10,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccucagcagaaagaagccacg,2OMe,NA,Null,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,10,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuagaaaucucuccuugugc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,10,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaaauuggguguuacacaau,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,11,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cccugaggcauucccaucuugaau,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,11,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aggacuuacuugcuuuguuu,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,11,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuugaauuuaggagauucaucug,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,11,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caucuucugauaauuuuccuguu,2OMe,NA,0.05,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,11,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caucuucugauaauuuuccuguu,2OMe,NA,0.1,uM,Null,delivered,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,11,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cccugaggcauucccaucuugaau,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucuguuuuuguuagccaguca,2OMe,NA,0.005,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucuguuuuuguuagccaguca,2OMe,NA,0.025,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucuguuuuuguuagccaguca,2OMe,NA,0.05,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucuguuuuuguuagccaguca,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucuguuuuuguuagccaguca,2OMe,NA,0.2,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucuguuuuuguuagccaguca,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuauguaaacugaaaauuu,2OMe,NA,0.005,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucuggagauccauuaaaac,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucuggagauccauuaaaac,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucuggagauccauuaaaac,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucuggagauccauuaaaac,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucuggagauccauuaaaac,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,12,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucuggagauccauuaaaac,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cagcaguugcgugaucuccacuag,2OMe,NA,0.005,uM,Skip,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucaucaacuaccaccaccau,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucaucaacuaccaccaccau,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucaucaacuaccaccaccau,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucaucaacuaccaccaccau,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucaucaacuaccaccaccau,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucaucaacuaccaccaccau,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaagcaaaauaaucugaccuuaag,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaagcaaaauaaucugaccuuaag,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaagcaaaauaaucugaccuuaag,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaagcaaaauaaucugaccuuaag,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaagcaaaauaaucugaccuuaag,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,13,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaagcaaaauaaucugaccuuaag,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuuguaaaagaacccagcggucuucugu,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caucuacagauguuugcccauc,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caucuacagauguuugcccauc,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caucuacagauguuugcccauc,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caucuacagauguuugcccauc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caucuacagauguuugcccauc,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caucuacagauguuugcccauc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gaaggaugucuuguaaaagaacc,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gaaggaugucuuguaaaagaacc,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gaaggaugucuuguaaaagaacc,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gaaggaugucuuguaaaagaacc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gaaggaugucuuguaaaagaacc,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gaaggaugucuuguaaaagaacc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accuguucuucaguaagacg,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accuguucuucaguaagacg,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accuguucuucaguaagacg,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accuguucuucaguaagacg,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accuguucuucaguaagacg,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accuguucuucaguaagacg,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugacacaccuguucuucaguaa,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugacacaccuguucuucaguaa,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugacacaccuguucuucaguaa,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugacacaccuguucuucaguaa,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugacacaccuguucuucaguaa,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugacacaccuguucuucaguaa,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauuugagaaggaugucuug,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauuugagaaggaugucuug,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauuugagaaggaugucuug,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauuugagaaggaugucuug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauuugagaaggaugucuug,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauuugagaaggaugucuug,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucucccaauaccuggagaagaga,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucucccaauaccuggagaagaga,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucucccaauaccuggagaagaga,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucucccaauaccuggagaagaga,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucucccaauaccuggagaagaga,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,14,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucucccaauaccuggagaagaga,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccaugcacuaaaaaggcacugcaagacauu,2OMe,NA,0.005,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuuuaaagccaguugugugaauc,2OMe,NA,0.005,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuucugaaagccaugcacuaa,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuucugaaagccaugcacuaa,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuucugaaagccaugcacuaa,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuucugaaagccaugcacuaa,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuucugaaagccaugcacuaa,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuucugaaagccaugcacuaa,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccaugcacuaaaaaggcacugcaagacauu,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuuuuaaaaccuguuaaaacaa,2OMe,NA,0.005,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccaugcacuaaaaaggcacugcaagacauu,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccaugcacuaaaaaggcacugcaagacauu,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccaugcacuaaaaaggcacugcaagacauu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccaugcacuaaaaaggcacugcaagacauu,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccaugcacuaaaaaggcacugcaagacauu,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guacauacggccaguuuuugaagac,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guacauacggccaguuuuugaagac,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guacauacggccaguuuuugaagac,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guacauacggccaguuuuugaagac,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guacauacggccaguuuuugaagac,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,15,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guacauacggccaguuuuugaagac,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuuuuaaaaccuguuaaaacaa,2OMe,NA,0.01,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuuuucuagauccgcuuuuaaaaccuguua,2OMe,NA,0.005,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuuuucuagauccgcuuuuaaaaccuguua,2OMe,NA,0.01,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuagauccgcuuuuaaaaccuguua,2OMe,NA,0.025,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccgucuucugggucacugacuua,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuagauccgcuuuuaaaaccuguuaa,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuagauccgcuuuuaaaaccuguuaa,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuagauccgcuuuuaaaaccuguuaa,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccgcuuuuaaaaccuguuaa,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccgcuuuuaaaaccuguuaa,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccgcuuuuaaaaccuguuaa,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uggauugcuuuuucuuuucuagaucc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uggauugcuuuuucuuuucuagaucc,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uggauugcuuuuucuuuucuagaucc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugcuuccgucuucugggucacug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugcuuccgucuucugggucacug,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugcuuccgucuucugggucacug,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gaucuuguuugagugaauacagu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gaucuuguuugagugaauacagu,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gaucuuguuugagugaauacagu,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guuauccagccaugcuuccguc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guuauccagccaugcuuccguc,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guuauccagccaugcuuccguc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugauaauugguaucacuaaccugug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugauaauugguaucacuaaccugug,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugauaauugguaucacuaaccugug,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guaucacuaaccugugcuguac,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guaucacuaaccugugcuguac,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,16,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guaucacuaaccugugcuguac,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cagcaguaguugucaucugcuc,2OMe,NA,0.01,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cagcaguaguugucaucugcuc,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cagcaguaguugucaucugcuc,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cagcaguaguugucaucugcuc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cagcaguaguugucaucugcuc,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugauggggugguggguugg,2OMe,NA,0.01,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugauggggugguggguugg,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugauggggugguggguugg,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugauggggugguggguugg,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugauggggugguggguugg,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucugcauuaacacccucuagaaag,2OMe,NA,0.01,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucugcauuaacacccucuagaaag,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucugcauuaacacccucuagaaag,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucugcauuaacacccucuagaaag,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucugcauuaacacccucuagaaag,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccggcuguucaguuguucugaggc,2OMe,NA,0.01,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccggcuguucaguuguucugaggc,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccggcuguucaguuguucugaggc,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccggcuguucaguuguucugaggc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccggcuguucaguuguucugaggc,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucugcauuaacacccucuagaaagaaa,2OMe,NA,Not tested yet,Null,Null,Unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gaaggagaagagauucuuaccuuacaaa,2OMe,NA,Not tested yet,Null,Null,Unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuggcagaauucgauccaccggcuguuc/cagcaguaguugucaucugcuc,2OMe,NA,0.01-0.6,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,19+20,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccugagcugaucugcuggcaucuugcaguu/cuggcagaauucgauccaccggcuguuc/cagcaguaguugucaucugcuc,2OMe,NA,0.01-0.6,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,21,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccgguugacuucauccugugc,2OMe,NA,0.6,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,21,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugcauccaggaacaugggucc,2OMe,NA,0.05,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,21,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gucugcauccaggaacauggguc,2OMe,NA,0.05,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,21,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guugaagaucugauagccgguuga,2OMe,NA,0.3,uM,Null,Skips faintly to,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,21,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuuacugucuguagcucuuucu,2OMe,NA,0.005,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,21,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuuacugucuguagcucuuucu,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,21,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuuacugucuguagcucuuucu,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,21,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuuacugucuguagcucuuucu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,21,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuuacugucuguagcucuuucu,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,21,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuuacugucuguagcucuuucu,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cacucauggucuccugauagcgca,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cacucauggucuccugauagcgca,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cacucauggucuccugauagcgca,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cacucauggucuccugauagcgca,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugcaauuccccgagucucugc,2OMe,NA,0.05,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugcaauuccccgagucucugc,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugcaauuccccgagucucugc,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugcaauuccccgagucucugc,2OMe,NA,0.6,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acugcuggacccauguccugaug,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acugcuggacccauguccugaug,2OMe,NA,0.6,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaaguugagguauggagagu,2OMe,NA,0.05,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaaguugagguauggagagu,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaaguugagguauggagagu,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaaguugagguauggagagu,2OMe,NA,0.6,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uauucacagaccugcaauucccc,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uauucacagaccugcaauucccc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uauucacagaccugcaauucccc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,22,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uauucacagaccugcaauucccc,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acaguggugcugagauaguauaggcc,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acaguggugcugagauaguauaggcc,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acaguggugcugagauaguauaggcc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acaguggugcugagauaguauaggcc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acaguggugcugagauaguauaggcc,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaggccacuuuguugcucuugc,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaggccacuuuguugcucuugc,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaggccacuuuguugcucuugc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaggccacuuuguugcucuugc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaggccacuuuguugcucuugc,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucagagggcgcuuucuuc,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucagagggcgcuuucuuc,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucagagggcgcuuucuuc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucagagggcgcuuucuuc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,23,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucagagggcgcuuucuuc,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,24,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gggcaggccauuccuccuucaga,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,24,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucaggguuuguaugugauucu,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,25,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugggcugaauugucugaauaucacug,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,25,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuguuggcacaugugaucccacugag,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,25,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gucuauaccuguuggcacauguga,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,26,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugcuuucuguaauucaucuggaguu,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,26,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccuccuuucuggcauagaccuuccac,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,26,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugugucauccauucgugcaucucug,2OMe,NA,0.6,uM,Null,Faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,27,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuaaggccucuugugcuacaggugg,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,27,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gggccucuucuuuagcucucuga,2OMe,NA,0.6,uM,Null,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,27,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gggccucuucuuuagcucucuga,2OMe,NA,0.3,uM,Null,faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,27,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gacuuccaaagucuugcauuuc,2OMe,NA,0.6,uM,Null,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,27,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gacuuccaaagucuugcauuuc,2OMe,NA,0.3,uM,Null,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,28,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccaacaugcccaaacuuccuaag,2OMe,NA,0.6,uM,Null,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,28,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gccaacaugcccaaacuuccuaag,2OMe,NA,0.3,uM,Null,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,28,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cagagauuuccucagcuccgccagga,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,28,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuuacaucuagcaccucagag,2OMe,NA,0.6,uM,Null,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,28,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuuacaucuagcaccucagag,2OMe,NA,0.3,uM,Null,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,29,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccgccaucuguuagggucugugcc,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,29,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,auuuggguuauccucugaaugucgc,2OMe,NA,0.6,uM,Null,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,29,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,auuuggguuauccucugaaugucgc,2OMe,NA,0.3,uM,Null,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,29,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauaccucuucauguaguuccc,2OMe,NA,0.6,uM,Null,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,29,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauaccucuucauguaguuccc,2OMe,NA,0.3,uM,Null,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,30,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauuugagcugcguccaccuugucug,2OMe,NA,Needs testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,30,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccugggcagacuggaugcucuguuc,2OMe,NA,0.3,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,30,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccugggcagacuggaugcucuguuc,2OMe,NA,0.6,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,30,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uugccugggcuuccugaggcauu,2OMe,NA,0.3,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,30,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uugccugggcuuccugaggcauu,2OMe,NA,0.6,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,30,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uugccugggcuuccugaggcauu,2OMe,NA,0.3,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,31,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucugaaauaacauauaccugugc,2OMe,NA,0.3,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,31,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaguuucugaaauaacauauaccug,2OMe,NA,0.02,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,31,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaguuucugaaauaacauauaccug,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,31,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uaguuucugaaauaacauauaccug,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,31,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gacuugucaaaucagauugga,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,31,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gacuugucaaaucagauugga,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,31,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guuucugaaauaacauauaccugu,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,32,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caccagaaauacauaccaca,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,32,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caaugauuuagcugugacug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,32,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caaugauuuagcugugacug,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,32,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cgaaacuucauggagacaucuug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,32,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cgaaacuucauggagacaucuug,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,32,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuuguagacgcugcucaaaauuggc,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugcacacaccuuugcucc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugcacacaccuuugcucc,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,37,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cguguagaguccaccuuugggcgua,2OMe,NA,unspecified,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caugcacacaccuuugcucc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuguacaaucugacguccagucu,2OMe,NA,0.2,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuguacaaucugacguccagucu,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guguuuaucaccauuuccacuucagac,2OMe,NA,0.2,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guguuuaucaccauuuccacuucagac,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gcgucugcuuuuucuguacaaucug,2OMe,NA,0.01,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gcgucugcuuuuucuguacaaucug,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gcgucugcuuuuucuguacaaucug,2OMe,NA,0.2,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,33,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gcgucugcuuuuucuguacaaucug,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,34,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccauaucuguagcuggcagcc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,34,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccauaucuguagcuggcagcc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,34,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccaggcaacuucagaauccaaau,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,34,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccaggcaacuucagaauccaaau,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,34,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuucuguuaccugaaaagaauuauaaugaa,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,34,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauucauuuccuuucgcaucuuacg,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,34,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugaucucuuugucaauuccauaucug,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,34,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucagugauauagguuuuaccuuuccccag,2OMe,NA,Not tested,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,34,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuguagcugccagccauucugucaag,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,34,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuguagcugccagccauucugucaag,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,35,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucugcucgggaggugaca,2OMe,NA,0.02,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,35,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucugcucgggaggugaca,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,35,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucugcucgggaggugaca,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,35,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccaguuacuauucagaagac,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,35,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccaguuacuauucagaagac,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,35,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucaggugcaccuucugu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,35,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucuucaggugcaccuucugu,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,37,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuaauuuccugcaguggucacc,2OMe,NA,0.01,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,37,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucugugugaaauggcugcaaauc,2OMe,NA,0.01,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,38,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccuucaaaggaauggaggcc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,38,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugcugaauuucagccuccagugguu,2OMe,NA,0.01,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,38,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ugaagucuuccucuuucagauucac,2OMe,NA,0.01,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,39,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuggcuuucucucaucugugauuc,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,39,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,guuguaaguugucuccucuu,2OMe,NA,unspecified,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,39,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uugucuguaacagcugcugu,2OMe,NA,unspecified,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,39,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gcucuaauaccuugagagca,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,40,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuuugagaccucaaauccuguu,2OMe,NA,0.005,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,40,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuuuauuuuccuuucaucucugggc,2OMe,NA,0.005,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,42,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucguuucuucacggacaguguggugc,2OMe,NA,0.005,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,42,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gggcuugugagacaugagugauuu,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,42,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accuucagaggacuccucuugc,2OMe,NA,0.005,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,43,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uauguguuaccuacccuugucgguc,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,43,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ggagagagcuuccuguagcu,2OMe,NA,0.025,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,43,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ucacccuuuccacaggcguugca,2OMe,NA,0.2,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,44,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuugugucuuucugagaaac,2OMe,NA,under review,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,44,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aaagacuuaccuuaagauac,2OMe,NA,under review,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,44,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucugucaaaucgccugcag,2OMe,NA,under review,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,46,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuaccuugacuugcucaagc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,46,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccagguucaagugggauac,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,47,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gcucuucugggcuuaugggagcacu,2OMe,NA,yet to be prepared,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,47,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accuuuauccacuggagauuugucugc,2OMe,NA,yet to be prepared,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,47,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuccaccaguaacugaaacag,2OMe,NA,yet to be prepared,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,50,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccacucagagcucagaucuucuaacuucc,2OMe,NA,unspecified,Null,Null,a strong inducer,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,50,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuuccacucagagcucagaucuucuaa,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,50,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gggauccaguauacuuacaggcucc,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,46,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cucuuuuccagguucaagugggauacuagc,2OMe,NA,0.1,uM,Null,Good,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,46,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,caagcuuuucuuuuaguugcugcucuuuucc,2OMe,NA,0.1,uM,Null,Good,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,46,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uauucuuuuguucuucuagccuggagaaag,2OMe,NA,unspecified,Null,Null,Weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,46,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugcuuccuccaaccauaaaacaaauuc,2OMe,NA,unspecified,Null,Null,Weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,accagaguaacagucugaguaggagc,2OMe,NA,0.025-0.6,Null,Null,Faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cucauaccuucugcuugaugauc,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uucuguccaagcccgguugaaauc,2OMe,NA,Needs re? testing,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acaucaaggaagauggcauuucuaguuugg,2OMe,NA,0.025-0.6,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acaucaaggaagauggcauuucuag,2OMe,NA,0.025-0.6,uM,Null,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuccaacaucaaggaagauggcauuucuag,2OMe,NA,0.025-0.6,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucauuuuuucucauaccuucugcu,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucauuuuuucucauaccuucugcu,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucauuuuuucucauaccuucugcu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucauuuuuucucauaccuucugcu,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucauuuuuucucauaccuucugcu,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucauuuuuucucauaccuucugcuaggagcuaaaa,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucauuuuuucucauaccuucugcuaggagcuaaaa,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucauuuuuucucauaccuucugcuaggagcuaaaa,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucauuuuuucucauaccuucugcuaggagcuaaaa,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucauuuuuucucauaccuucugcuaggagcuaaaa,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cacccaccaucagccucugug,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cacccaccaucagccucugug,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cacccaccaucagccucugug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cacccaccaucagccucugug,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cacccaccaucagccucugug,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucaucucguugauauccucaa,2OMe,NA,0.025,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucaucucguugauauccucaa,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucaucucguugauauccucaa,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucaucucguugauauccucaa,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,51,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucaucucguugauauccucaa,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccugcauuguugccuguaag,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccugcauuguugccuguaag,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccugcauuguugccuguaag,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccugcauuguugccuguaag,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uccaacuggggacgccucuguuccaaaucc,2OMe,NA,0.05,uM,Null,Very strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acuggggacgccucuguucca,2OMe,NA,0.05,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acuggggacgccucuguucca,2OMe,NA,0.1,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acuggggacgccucuguucca,2OMe,NA,0.3,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,acuggggacgccucuguucca,2OMe,NA,0.6,uM,Null,Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccguaaugauuguucuagcc,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccguaaugauuguucuagcc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccguaaugauuguucuagcc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,ccguaaugauuguucuagcc,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uguuaaaaaacuuacuucga,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uguuaaaaaacuuacuucga,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uguuaaaaaacuuacuucga,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,52,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uguuaaaaaacuuacuucga,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauucaacuguugccuccgguucug,2OMe,NA,0.05,uM,Null,Faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuguugccuccgguucugaaggug,2OMe,NA,0.05,uM,Null,Faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.05,uM,Null,Strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Null,Strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.3,uM,Null,Strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.6,uM,Null,Strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuaaccuugguuucuguga,2OMe,NA,0.05,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuaaccuugguuucuguga,2OMe,NA,0.1,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuaaccuugguuucuguga,2OMe,NA,0.3,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uacuaaccuugguuucuguga,2OMe,NA,0.6,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugaagguguucuuguacuucaucc,2OMe,NA,0.05,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugaagguguucuuguacuucaucc,2OMe,NA,0.1,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugaagguguucuuguacuucaucc,2OMe,NA,0.3,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cugaagguguucuuguacuucaucc,2OMe,NA,0.6,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uguauagggacccuccuuccaugacuc,2OMe,NA,0.05,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uguauagggacccuccuuccaugacuc,2OMe,NA,0.1,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uguauagggacccuccuuccaugacuc,2OMe,NA,0.3,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uguauagggacccuccuuccaugacuc,2OMe,NA,0.6,uM,Null,Very faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,cuaaccuugguuucugugauuuucu,2OMe,NA,Not made yet,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gguaucuuugauacuaaccuugguuuc,2OMe,NA,0.6,uM,Null,Faint,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,auucuuucaacuagaauaaaag,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,auucuuucaacuagaauaaaag,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,auucuuucaacuagaauaaaag,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,auucuuucaacuagaauaaaag,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gauucugaauuguuucaacuagaau,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gauucugaauuguuucaacuagaau,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gauucugaauuguuucaacuagaau,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,gauucugaauuguuucaacuagaau,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucccacugauucugaauuc,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucccacugauucugaauuc,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucccacugauucugaauuc,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,aucccacugauucugaauuc,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuggcucuggccuguccuaaga,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuggcucuggccuguccuaaga,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuggcucuggccuguccuaaga,2OMe,NA,0.3,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof,"US/2017/0009234, US/2011/046203, WO/2006/000057, EP/3808845",DMD,exon,53,NA,human,normal primary myoblast cultures of human muscle biopsies,unspecified,NA,uuggcucuggccuguccuaaga,2OMe,NA,0.6,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US/2017/0009234US/2011/046203WO/2006/000057EP/3808845,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agaagcaacatttgggttttccatc,unmodified PMO,NA,1,uM,Skip,3.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agaagcaacatttgggttttccatc,unmodified PMO,NA,3,uM,Skip,9.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agaagcaacatttgggttttccatc,unmodified PMO,NA,10,uM,Skip,10.53,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tctcgacgggtctcaaatatatcca,unmodified PMO,NA,1,uM,Skip,3.51,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tctcgacgggtctcaaatatatcca,unmodified PMO,NA,3,uM,Skip,12.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tctcgacgggtctcaaatatatcca,unmodified PMO,NA,10,uM,Skip,20.61,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtctcg,unmodified PMO,NA,1,uM,Skip,27.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtctcg,unmodified PMO,NA,3,uM,Skip,67.11,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtctcg,unmodified PMO,NA,10,uM,Skip,88.16,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggaaggttacagcaagatcat,unmodified PMO,NA,3,uM,Skip,6.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggaaggttacagcaagatcat,unmodified PMO,NA,10,uM,Skip,32.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttctcctggtcctgggaaggttaca,unmodified PMO,NA,3,uM,Skip,2.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttctcctggtcctgggaaggttaca,unmodified PMO,NA,10,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccgtctttcataggtttgatgagtc,unmodified PMO,NA,1,uM,Skip,14.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccgtctttcataggtttgatgagtc,unmodified PMO,NA,3,uM,Skip,21.93,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccgtctttcataggtttgatgagtc,unmodified PMO,NA,10,uM,Skip,23.25,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaatcag,unmodified PMO,NA,1,uM,Skip,26.32,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaatcag,unmodified PMO,NA,3,uM,Skip,65.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaatcag,unmodified PMO,NA,10,uM,Skip,95.18,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttgtaggagtctcgacgggtctca,unmodified PMO,NA,1,uM,Skip,15.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttgtaggagtctcgacgggtctca,unmodified PMO,NA,3,uM,Skip,32.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttgtaggagtctcgacgggtctca,unmodified PMO,NA,10,uM,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgacgggtctca,unmodified PMO,NA,1,uM,Skip,7.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgacgggtctca,unmodified PMO,NA,3,uM,Skip,17.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgacgggtctca,unmodified PMO,NA,10,uM,Skip,25.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acactgttgtaggagtctcg,unmodified PMO,NA,1,uM,Skip,5.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acactgttgtaggagtctcg,unmodified PMO,NA,3,uM,Skip,18.86,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acactgttgtaggagtctcg,unmodified PMO,NA,10,uM,Skip,33.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtctcgacgggtctcaaat,unmodified PMO,NA,1,uM,Skip,4.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtctcgacgggtctcaaat,unmodified PMO,NA,3,uM,Skip,17.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtctcgacgggtctcaaat,unmodified PMO,NA,10,uM,Skip,31.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgttgtaggagtctcgacg,unmodified PMO,NA,1,uM,Skip,7.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgttgtaggagtctcgacg,unmodified PMO,NA,3,uM,Skip,23.25,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgttgtaggagtctcgacg,unmodified PMO,NA,10,uM,Skip,34.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aaacactgttgtaggagtctcg,unmodified PMO,NA,1,uM,Skip,4.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aaacactgttgtaggagtctcg,unmodified PMO,NA,3,uM,Skip,17.11,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aaacactgttgtaggagtctcg,unmodified PMO,NA,10,uM,Skip,38.6,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atttgcacaaacactgttgtaggag,unmodified PMO,NA,1,uM,Skip,3.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atttgcacaaacactgttgtaggag,unmodified PMO,NA,3,uM,Skip,11.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atttgcacaaacactgttgtaggag,unmodified PMO,NA,10,uM,Skip,20.18,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggag,unmodified PMO,NA,1,uM,Skip,10.09,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggag,unmodified PMO,NA,3,uM,Skip,32.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggag,unmodified PMO,NA,10,uM,Skip,58.33,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acactgttgtaggagtctcgacggg,unmodified PMO,NA,1,uM,Skip,7.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acactgttgtaggagtctcgacggg,unmodified PMO,NA,3,uM,Skip,23.25,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acactgttgtaggagtctcgacggg,unmodified PMO,NA,10,uM,Skip,37.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttgtaggagtctcgacggg,unmodified PMO,NA,1,uM,Skip,11.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttgtaggagtctcgacggg,unmodified PMO,NA,3,uM,Skip,27.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttgtaggagtctcgacggg,unmodified PMO,NA,10,uM,Skip,36.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtc,unmodified PMO,NA,1,uM,Skip,14.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtc,unmodified PMO,NA,3,uM,Skip,49.56,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtc,unmodified PMO,NA,10,uM,Skip,80.26,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,caacatttgggttttccatc,unmodified PMO,NA,1,uM,Skip,2.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,caacatttgggttttccatc,unmodified PMO,NA,3,uM,Skip,9.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,caacatttgggttttccatc,unmodified PMO,NA,10,uM,Skip,30.26,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gcattagaaaatcagctataaatga,unmodified PMO,NA,1,uM,Skip,5.26,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gcattagaaaatcagctataaatga,unmodified PMO,NA,3,uM,Skip,19.74,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gcattagaaaatcagctataaatga,unmodified PMO,NA,10,uM,Skip,57.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttttccatccacttgcattagaaa,unmodified PMO,NA,1,uM,Skip,19.74,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttttccatccacttgcattagaaa,unmodified PMO,NA,3,uM,Skip,49.56,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttttccatccacttgcattagaaa,unmodified PMO,NA,10,uM,Skip,77.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacttgcattagaaaatcagctata,unmodified PMO,NA,1,uM,Skip,13.16,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacttgcattagaaaatcagctata,unmodified PMO,NA,3,uM,Skip,35.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacttgcattagaaaatcagctata,unmodified PMO,NA,10,uM,Skip,74.12,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgacgggtctcaaatat,unmodified PMO,NA,1,uM,Skip,6.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgacgggtctcaaatat,unmodified PMO,NA,3,uM,Skip,15.35,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgacgggtctcaaatat,unmodified PMO,NA,10,uM,Skip,23.25,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aacactgttgtaggagtctcgacgg,unmodified PMO,NA,1,uM,Skip,3.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aacactgttgtaggagtctcgacgg,unmodified PMO,NA,3,uM,Skip,20.18,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aacactgttgtaggagtctcgacgg,unmodified PMO,NA,10,uM,Skip,34.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aaacactgttgtaggagtctcgacg,unmodified PMO,NA,1,uM,Skip,3.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aaacactgttgtaggagtctcgacg,unmodified PMO,NA,3,uM,Skip,11.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aaacactgttgtaggagtctcgacg,unmodified PMO,NA,10,uM,Skip,25.44,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acaaacactgttgtaggagtctcga,unmodified PMO,NA,1,uM,Skip,1.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acaaacactgttgtaggagtctcga,unmodified PMO,NA,3,uM,Skip,6.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acaaacactgttgtaggagtctcga,unmodified PMO,NA,10,uM,Skip,10.53,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,caaacactgttgtaggagtctcgac,unmodified PMO,NA,1,uM,Skip,3.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,caaacactgttgtaggagtctcgac,unmodified PMO,NA,3,uM,Skip,10.53,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,caaacactgttgtaggagtctcgac,unmodified PMO,NA,10,uM,Skip,20.61,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gcacaaacactgttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,5.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gcacaaacactgttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gcacaaacactgttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,22.81,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcacaaacactgttgtaggagtct,unmodified PMO,NA,1,uM,Skip,2.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcacaaacactgttgtaggagtct,unmodified PMO,NA,3,uM,Skip,7.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcacaaacactgttgtaggagtct,unmodified PMO,NA,10,uM,Skip,11.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccacttgcattagaaaatcagcta,unmodified PMO,NA,1,uM,Skip,5.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccacttgcattagaaaatcagcta,unmodified PMO,NA,3,uM,Skip,19.74,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccacttgcattagaaaatcagcta,unmodified PMO,NA,10,uM,Skip,51.32,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccacttgcattagaaaatcagctat,unmodified PMO,NA,1,uM,Skip,4.82,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccacttgcattagaaaatcagctat,unmodified PMO,NA,3,uM,Skip,16.23,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccacttgcattagaaaatcagctat,unmodified PMO,NA,10,uM,Skip,40.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atccacttgcattagaaaatcagct,unmodified PMO,NA,1,uM,Skip,7.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atccacttgcattagaaaatcagct,unmodified PMO,NA,3,uM,Skip,22.81,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atccacttgcattagaaaatcagct,unmodified PMO,NA,10,uM,Skip,54.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,catccacttgcattagaaaatcag,unmodified PMO,NA,1,uM,Skip,8.33,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,catccacttgcattagaaaatcag,unmodified PMO,NA,3,uM,Skip,27.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,catccacttgcattagaaaatcag,unmodified PMO,NA,10,uM,Skip,59.21,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttttccatccacttgcattagaaaa,unmodified PMO,NA,1,uM,Skip,8.33,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttttccatccacttgcattagaaaa,unmodified PMO,NA,3,uM,Skip,29.82,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttttccatccacttgcattagaaaa,unmodified PMO,NA,10,uM,Skip,64.91,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccatccacttgcattagaaaatca,unmodified PMO,NA,1,uM,Skip,10.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccatccacttgcattagaaaatca,unmodified PMO,NA,3,uM,Skip,32.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccatccacttgcattagaaaatca,unmodified PMO,NA,10,uM,Skip,58.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttccatccacttgcattagaaaat,unmodified PMO,NA,1,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttccatccacttgcattagaaaat,unmodified PMO,NA,3,uM,Skip,32.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttccatccacttgcattagaaaat,unmodified PMO,NA,10,uM,Skip,64.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttccatccacttgcattagaaaat,unmodified PMO,NA,1,uM,Skip,9.21,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttccatccacttgcattagaaaat,unmodified PMO,NA,3,uM,Skip,29.82,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttccatccacttgcattagaaaat,unmodified PMO,NA,10,uM,Skip,53.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cttgcattagaaaatcagctataaa,unmodified PMO,NA,1,uM,Skip,3.51,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cttgcattagaaaatcagctataaa,unmodified PMO,NA,3,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cttgcattagaaaatcagctataaa,unmodified PMO,NA,10,uM,Skip,33.33,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,caaacactgttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,4.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,caaacactgttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,14.91,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,caaacactgttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,30.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccacttgcattagaaaatcag,unmodified PMO,NA,1,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccacttgcattagaaaatcag,unmodified PMO,NA,3,uM,Skip,35.09,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccacttgcattagaaaatcag,unmodified PMO,NA,10,uM,Skip,67.98,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ggttttccatccacttgcattagaa,unmodified PMO,NA,1,uM,Skip,17.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ggttttccatccacttgcattagaa,unmodified PMO,NA,3,uM,Skip,43.42,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ggttttccatccacttgcattagaa,unmodified PMO,NA,10,uM,Skip,60.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaa,unmodified PMO,NA,1,uM,Skip,10.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaa,unmodified PMO,NA,3,uM,Skip,28.51,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaa,unmodified PMO,NA,10,uM,Skip,56.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttttccatccacttgcattagaa,unmodified PMO,NA,1,uM,Skip,3.51,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttttccatccacttgcattagaa,unmodified PMO,NA,3,uM,Skip,7.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttttccatccacttgcattagaa,unmodified PMO,NA,10,uM,Skip,13.16,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,21.05,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,56.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,82.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtct,unmodified PMO,NA,1,uM,Skip,17.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtct,unmodified PMO,NA,3,uM,Skip,48.25,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagtct,unmodified PMO,NA,10,uM,Skip,75.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atccacttgcattagaaaatcag,unmodified PMO,NA,1,uM,Skip,16.67,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atccacttgcattagaaaatcag,unmodified PMO,NA,3,uM,Skip,47.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atccacttgcattagaaaatcag,unmodified PMO,NA,10,uM,Skip,81.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaatc,unmodified PMO,NA,1,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaatc,unmodified PMO,NA,3,uM,Skip,33.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaatc,unmodified PMO,NA,10,uM,Skip,63.16,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttccatccacttgcattagaaaa,unmodified PMO,NA,1,uM,Skip,15.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttccatccacttgcattagaaaa,unmodified PMO,NA,3,uM,Skip,35.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttccatccacttgcattagaaaa,unmodified PMO,NA,10,uM,Skip,72.81,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cgacgggtctcaaatatatccatag,unmodified PMO,NA,1,uM,Skip,3.51,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cgacgggtctcaaatatatccatag,unmodified PMO,NA,3,uM,Skip,10.09,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cgacgggtctcaaatatatccatag,unmodified PMO,NA,10,uM,Skip,17.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtctcgacgggtctcaaatatatc,unmodified PMO,NA,1,uM,Skip,9.21,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtctcgacgggtctcaaatatatc,unmodified PMO,NA,3,uM,Skip,26.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtctcgacgggtctcaaatatatc,unmodified PMO,NA,10,uM,Skip,53.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgacgggtctcaaat,unmodified PMO,NA,1,uM,Skip,3.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgacgggtctcaaat,unmodified PMO,NA,3,uM,Skip,13.6,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgacgggtctcaaat,unmodified PMO,NA,10,uM,Skip,26.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgttgtaggagtctcgacgggtct,unmodified PMO,NA,1,uM,Skip,5.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgttgtaggagtctcgacgggtct,unmodified PMO,NA,3,uM,Skip,14.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgttgtaggagtctcgacgggtct,unmodified PMO,NA,10,uM,Skip,26.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaatcagc,unmodified PMO,NA,1,uM,Skip,10.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaatcagc,unmodified PMO,NA,3,uM,Skip,35.09,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccatccacttgcattagaaaatcagc,unmodified PMO,NA,10,uM,Skip,78.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccatccacttgcattagaaaatcag,unmodified PMO,NA,1,uM,Skip,17.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccatccacttgcattagaaaatcag,unmodified PMO,NA,3,uM,Skip,44.74,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccatccacttgcattagaaaatcag,unmodified PMO,NA,10,uM,Skip,80.26,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acaaacactgttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,3.51,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acaaacactgttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,10.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acaaacactgttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,25,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagt,unmodified PMO,NA,1,uM,Skip,10.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagt,unmodified PMO,NA,3,uM,Skip,29.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtaggagt,unmodified PMO,NA,10,uM,Skip,53.51,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcatcttgtaccgtctt,unmodified PMO,NA,1,uM,Skip,0.84,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcatcttgtaccgtctt,unmodified PMO,NA,3,uM,Skip,7.56,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcatcttgtaccgtctt,unmodified PMO,NA,10,uM,Skip,40.34,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggaaggttacacttgtaccgtctt,unmodified PMO,NA,1,uM,Skip,1.68,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggaaggttacacttgtaccgtctt,unmodified PMO,NA,3,uM,Skip,15.97,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggaaggttacacttgtaccgtctt,unmodified PMO,NA,10,uM,Skip,57.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttctcctggtcctcttgtaccgtctt,unmodified PMO,NA,3,uM,Skip,3.36,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttctcctggtcctcttgtaccgtctt,unmodified PMO,NA,10,uM,Skip,22.69,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttcatccacttgcat,unmodified PMO,NA,1,uM,Skip,10.08,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttcatccacttgcat,unmodified PMO,NA,3,uM,Skip,31.09,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttcatccacttgcat,unmodified PMO,NA,10,uM,Skip,56.3,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttttgggttttccat,unmodified PMO,NA,1,uM,Skip,5.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttttgggttttccat,unmodified PMO,NA,3,uM,Skip,18.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttttgggttttccat,unmodified PMO,NA,10,uM,Skip,49.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgcattagaaaatca,unmodified PMO,NA,1,uM,Skip,27.73,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgcattagaaaatca,unmodified PMO,NA,3,uM,Skip,52.52,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgcattagaaaatca,unmodified PMO,NA,10,uM,Skip,91.6,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgaagcaacatttg,unmodified PMO,NA,1,uM,Skip,4.62,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgaagcaacatttg,unmodified PMO,NA,3,uM,Skip,16.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgaagcaacatttg,unmodified PMO,NA,10,uM,Skip,42.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgcatccacttgcat,unmodified PMO,NA,1,uM,Skip,7.56,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgcatccacttgcat,unmodified PMO,NA,3,uM,Skip,25.21,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgcatccacttgcat,unmodified PMO,NA,10,uM,Skip,45.38,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acagcaagatcatcagtataccttgt,unmodified PMO,NA,3,uM,Skip,3.78,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,acagcaagatcatcagtataccttgt,unmodified PMO,NA,10,uM,Skip,22.69,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttcattagaaaatca,unmodified PMO,NA,1,uM,Skip,0.84,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttcattagaaaatca,unmodified PMO,NA,3,uM,Skip,3.36,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttcattagaaaatca,unmodified PMO,NA,10,uM,Skip,14.29,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttagttgggccttta,unmodified PMO,NA,1,uM,Skip,2.52,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttagttgggccttta,unmodified PMO,NA,3,uM,Skip,9.66,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttagttgggccttta,unmodified PMO,NA,10,uM,Skip,17.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgttgtaggagtccattagaaaatca,unmodified PMO,NA,3,uM,Skip,3.36,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgttgtaggagtccattagaaaatca,unmodified PMO,NA,10,uM,Skip,17.23,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cactgttgtaggacattagaaaatca,unmodified PMO,NA,3,uM,Skip,3.36,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cactgttgtaggacattagaaaatca,unmodified PMO,NA,10,uM,Skip,15.13,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttatatatccatagt,unmodified PMO,NA,1,uM,Skip,3.36,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttatatatccatagt,unmodified PMO,NA,3,uM,Skip,15.55,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttatatatccatagt,unmodified PMO,NA,10,uM,Skip,44.12,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttcgggtctcaaata,unmodified PMO,NA,1,uM,Skip,10.92,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttcgggtctcaaata,unmodified PMO,NA,3,uM,Skip,36.13,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttcgggtctcaaata,unmodified PMO,NA,10,uM,Skip,60.5,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgacttgcattagaa,unmodified PMO,NA,1,uM,Skip,8.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgacttgcattagaa,unmodified PMO,NA,3,uM,Skip,30.67,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgacttgcattagaa,unmodified PMO,NA,10,uM,Skip,66.81,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgacgcattagaaaatca,unmodified PMO,NA,1,uM,Skip,6.3,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgacgcattagaaaatca,unmodified PMO,NA,3,uM,Skip,21.85,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgacgcattagaaaatca,unmodified PMO,NA,10,uM,Skip,49.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttggagtctcgacgg,unmodified PMO,NA,1,uM,Skip,14.71,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttggagtctcgacgg,unmodified PMO,NA,3,uM,Skip,42.44,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttggagtctcgacgg,unmodified PMO,NA,10,uM,Skip,72.27,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaaggaagcaacatttg,unmodified PMO,NA,3,uM,Skip,2.52,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaaggaagcaacatttg,unmodified PMO,NA,10,uM,Skip,30.25,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaagcattagaaaatca,unmodified PMO,NA,1,uM,Skip,1.26,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaagcattagaaaatca,unmodified PMO,NA,3,uM,Skip,4.2,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaagcattagaaaatca,unmodified PMO,NA,10,uM,Skip,26.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcggaagcaacatttg,unmodified PMO,NA,1,uM,Skip,5.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcggaagcaacatttg,unmodified PMO,NA,3,uM,Skip,16.81,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcggaagcaacatttg,unmodified PMO,NA,10,uM,Skip,43.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccagtataccttgtgtaggagtctcg,unmodified PMO,NA,1,uM,Skip,6.3,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccagtataccttgtgtaggagtctcg,unmodified PMO,NA,3,uM,Skip,20.59,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccagtataccttgtgtaggagtctcg,unmodified PMO,NA,10,uM,Skip,52.52,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgtgcattagaaaat,unmodified PMO,NA,1,uM,Skip,18.49,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgtgcattagaaaat,unmodified PMO,NA,3,uM,Skip,36.55,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgtgcattagaaaat,unmodified PMO,NA,10,uM,Skip,61.34,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgccacttgcattag,unmodified PMO,NA,1,uM,Skip,5.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgccacttgcattag,unmodified PMO,NA,3,uM,Skip,19.33,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgccacttgcattag,unmodified PMO,NA,10,uM,Skip,35.29,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcggaaaatcagctat,unmodified PMO,NA,1,uM,Skip,1.26,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcggaaaatcagctat,unmodified PMO,NA,3,uM,Skip,10.92,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcggaaaatcagctat,unmodified PMO,NA,10,uM,Skip,33.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgtagaaaatcagct,unmodified PMO,NA,1,uM,Skip,9.66,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgtagaaaatcagct,unmodified PMO,NA,3,uM,Skip,31.09,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgtagaaaatcagct,unmodified PMO,NA,10,uM,Skip,76.05,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gaagcaacatttgcattagaaaatca,unmodified PMO,NA,1,uM,Skip,4.2,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gaagcaacatttgcattagaaaatca,unmodified PMO,NA,3,uM,Skip,18.91,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gaagcaacatttgcattagaaaatca,unmodified PMO,NA,10,uM,Skip,42.86,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccagtataccttgcattagaaaatca,unmodified PMO,NA,1,uM,Skip,3.36,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccagtataccttgcattagaaaatca,unmodified PMO,NA,3,uM,Skip,13.45,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccagtataccttgcattagaaaatca,unmodified PMO,NA,10,uM,Skip,36.13,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctccattagaaaatc,unmodified PMO,NA,1,uM,Skip,0.84,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctccattagaaaatc,unmodified PMO,NA,3,uM,Skip,5.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctccattagaaaatc,unmodified PMO,NA,10,uM,Skip,23.11,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaagtgtaggagtctcg,unmodified PMO,NA,1,uM,Skip,5.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaagtgtaggagtctcg,unmodified PMO,NA,3,uM,Skip,29.41,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaagtgtaggagtctcg,unmodified PMO,NA,10,uM,Skip,73.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggatgtaggagtctcg,unmodified PMO,NA,1,uM,Skip,21.85,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggatgtaggagtctcg,unmodified PMO,NA,3,uM,Skip,52.94,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggatgtaggagtctcg,unmodified PMO,NA,10,uM,Skip,80.67,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgattagaaaatca,unmodified PMO,NA,1,uM,Skip,3.36,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgattagaaaatca,unmodified PMO,NA,3,uM,Skip,11.34,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgattagaaaatca,unmodified PMO,NA,10,uM,Skip,34.45,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcattagaaaatca,unmodified PMO,NA,1,uM,Skip,1.27,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcattagaaaatca,unmodified PMO,NA,3,uM,Skip,5.06,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcattagaaaatca,unmodified PMO,NA,10,uM,Skip,20.68,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgcattagaaaatc,unmodified PMO,NA,1,uM,Skip,10.97,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgcattagaaaatc,unmodified PMO,NA,3,uM,Skip,33.33,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgcattagaaaatc,unmodified PMO,NA,10,uM,Skip,71.73,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cgggtctcaaatacattagaaaatca,unmodified PMO,NA,3,uM,Skip,2.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cgggtctcaaatacattagaaaatca,unmodified PMO,NA,10,uM,Skip,14.35,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcgacgggtctcacattagaaaatca,unmodified PMO,NA,1,uM,Skip,1.27,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcgacgggtctcacattagaaaatca,unmodified PMO,NA,3,uM,Skip,3.38,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcgacgggtctcacattagaaaatca,unmodified PMO,NA,10,uM,Skip,12.24,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtctcgacgggtcattagaaaatca,unmodified PMO,NA,1,uM,Skip,1.69,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtctcgacgggtcattagaaaatca,unmodified PMO,NA,3,uM,Skip,7.17,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtctcgacgggtcattagaaaatca,unmodified PMO,NA,10,uM,Skip,29.11,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtttcgacgggtctca,unmodified PMO,NA,1,uM,Skip,8.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtttcgacgggtctca,unmodified PMO,NA,3,uM,Skip,25.74,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtttcgacgggtctca,unmodified PMO,NA,10,uM,Skip,57.81,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtctcgacgggtc,unmodified PMO,NA,1,uM,Skip,9.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtctcgacgggtc,unmodified PMO,NA,3,uM,Skip,30.38,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttgtctcgacgggtc,unmodified PMO,NA,10,uM,Skip,60.76,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgttagaaaatcagc,unmodified PMO,NA,1,uM,Skip,15.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgttagaaaatcagc,unmodified PMO,NA,3,uM,Skip,43.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgttagaaaatcagc,unmodified PMO,NA,10,uM,Skip,81.86,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgattagaaaatca,unmodified PMO,NA,1,uM,Skip,9.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgattagaaaatca,unmodified PMO,NA,3,uM,Skip,30.38,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgattagaaaatca,unmodified PMO,NA,10,uM,Skip,62.45,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgcattagaaaatcag,unmodified PMO,NA,1,uM,Skip,30.38,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgcattagaaaatcag,unmodified PMO,NA,3,uM,Skip,69.62,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgcattagaaaatcag,unmodified PMO,NA,10,uM,Skip,92.83,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaatcag,unmodified PMO,NA,1,uM,Skip,17.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaatcag,unmodified PMO,NA,3,uM,Skip,52.32,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaatcag,unmodified PMO,NA,10,uM,Skip,87.76,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctccattagaaaatca,unmodified PMO,NA,1,uM,Skip,1.69,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctccattagaaaatca,unmodified PMO,NA,3,uM,Skip,7.59,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctccattagaaaatca,unmodified PMO,NA,10,uM,Skip,25.32,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttgtaggagtctcattagaaaatca,unmodified PMO,NA,1,uM,Skip,3.38,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttgtaggagtctcattagaaaatca,unmodified PMO,NA,3,uM,Skip,12.66,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gttgtaggagtctcattagaaaatca,unmodified PMO,NA,10,uM,Skip,35.86,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcggcattagaaaatc,unmodified PMO,NA,1,uM,Skip,13.92,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcggcattagaaaatc,unmodified PMO,NA,3,uM,Skip,43.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcggcattagaaaatc,unmodified PMO,NA,10,uM,Skip,83.12,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgaccattagaaaatca,unmodified PMO,NA,1,uM,Skip,1.69,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgaccattagaaaatca,unmodified PMO,NA,3,uM,Skip,5.91,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgaccattagaaaatca,unmodified PMO,NA,10,uM,Skip,20.68,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgacattagaaaatca,unmodified PMO,NA,1,uM,Skip,2.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgacattagaaaatca,unmodified PMO,NA,3,uM,Skip,11.81,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgacattagaaaatca,unmodified PMO,NA,10,uM,Skip,36.71,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgagcattagaaaatc,unmodified PMO,NA,1,uM,Skip,20.59,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgagcattagaaaatc,unmodified PMO,NA,3,uM,Skip,51.26,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgagcattagaaaatc,unmodified PMO,NA,10,uM,Skip,84.03,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctcgcattagaaaatc,unmodified PMO,NA,1,uM,Skip,12.61,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctcgcattagaaaatc,unmodified PMO,NA,3,uM,Skip,36.97,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctcgcattagaaaatc,unmodified PMO,NA,10,uM,Skip,75.63,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcattgtaggagtctcg,unmodified PMO,NA,1,uM,Skip,13.03,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcattgtaggagtctcg,unmodified PMO,NA,3,uM,Skip,47.9,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcattgtaggagtctcg,unmodified PMO,NA,10,uM,Skip,69.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtttgagccaattgtaggagtctcg,unmodified PMO,NA,1,uM,Skip,10.92,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtttgagccaattgtaggagtctcg,unmodified PMO,NA,3,uM,Skip,24.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtttgagccaattgtaggagtctcg,unmodified PMO,NA,10,uM,Skip,47.9,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgaattagaaaatcag,unmodified PMO,NA,1,uM,Skip,13.87,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgaattagaaaatcag,unmodified PMO,NA,3,uM,Skip,39.92,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgaattagaaaatcag,unmodified PMO,NA,10,uM,Skip,76.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctcattagaaaatca,unmodified PMO,NA,1,uM,Skip,5.04,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctcattagaaaatca,unmodified PMO,NA,3,uM,Skip,19.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctcattagaaaatca,unmodified PMO,NA,10,uM,Skip,52.1,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgattagaaaatca,unmodified PMO,NA,1,uM,Skip,2.52,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgattagaaaatca,unmodified PMO,NA,3,uM,Skip,11.76,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgattagaaaatca,unmodified PMO,NA,10,uM,Skip,35.29,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgcattagaaaatc,unmodified PMO,NA,1,uM,Skip,10.5,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgcattagaaaatc,unmodified PMO,NA,3,uM,Skip,31.93,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctcgcattagaaaatc,unmodified PMO,NA,10,uM,Skip,70.17,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgcattagaaaatca,unmodified PMO,NA,1,uM,Skip,13.45,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgcattagaaaatca,unmodified PMO,NA,3,uM,Skip,36.13,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgcattagaaaatca,unmodified PMO,NA,10,uM,Skip,77.73,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctccattagaaaatca,unmodified PMO,NA,1,uM,Skip,1.68,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctccattagaaaatca,unmodified PMO,NA,3,uM,Skip,5.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctccattagaaaatca,unmodified PMO,NA,10,uM,Skip,22.27,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggattgtaggagtctc,unmodified PMO,NA,1,uM,Skip,18.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggattgtaggagtctc,unmodified PMO,NA,3,uM,Skip,40.76,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggattgtaggagtctc,unmodified PMO,NA,10,uM,Skip,59.24,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggatgtaggagtctc,unmodified PMO,NA,1,uM,Skip,15.55,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggatgtaggagtctc,unmodified PMO,NA,3,uM,Skip,37.82,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggatgtaggagtctc,unmodified PMO,NA,10,uM,Skip,62.61,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggtgtaggagtctc,unmodified PMO,NA,1,uM,Skip,15.97,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggtgtaggagtctc,unmodified PMO,NA,3,uM,Skip,39.08,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggtgtaggagtctc,unmodified PMO,NA,10,uM,Skip,61.34,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggtaggagtctcgac,unmodified PMO,NA,1,uM,Skip,11.76,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggtaggagtctcgac,unmodified PMO,NA,3,uM,Skip,41.6,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggtaggagtctcgac,unmodified PMO,NA,10,uM,Skip,64.71,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggattgtaggagtctcga,unmodified PMO,NA,1,uM,Skip,26.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggattgtaggagtctcga,unmodified PMO,NA,3,uM,Skip,47.48,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggattgtaggagtctcga,unmodified PMO,NA,10,uM,Skip,67.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggataggagtctcgac,unmodified PMO,NA,1,uM,Skip,10.5,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggataggagtctcgac,unmodified PMO,NA,3,uM,Skip,31.93,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggataggagtctcgac,unmodified PMO,NA,10,uM,Skip,60.5,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggattgtaggagtctc,unmodified PMO,NA,1,uM,Skip,28.57,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggattgtaggagtctc,unmodified PMO,NA,3,uM,Skip,49.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggattgtaggagtctc,unmodified PMO,NA,10,uM,Skip,70.17,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgcattagaaaatc,unmodified PMO,NA,1,uM,Skip,3.36,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgcattagaaaatc,unmodified PMO,NA,3,uM,Skip,15.97,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgcattagaaaatc,unmodified PMO,NA,10,uM,Skip,47.06,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgagcattagaaaatc,unmodified PMO,NA,1,uM,Skip,8.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgagcattagaaaatc,unmodified PMO,NA,3,uM,Skip,23.53,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgagcattagaaaatc,unmodified PMO,NA,10,uM,Skip,52.94,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgtagaaaatcagc,unmodified PMO,NA,1,uM,Skip,7.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgtagaaaatcagc,unmodified PMO,NA,3,uM,Skip,20.59,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgtagaaaatcagc,unmodified PMO,NA,10,uM,Skip,51.68,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgattagaaaatcagc,unmodified PMO,NA,1,uM,Skip,5.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgattagaaaatcagc,unmodified PMO,NA,3,uM,Skip,24.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aggagtctcgattagaaaatcagc,unmodified PMO,NA,10,uM,Skip,57.98,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcggcattagaaaatc,unmodified PMO,NA,1,uM,Skip,13.87,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcggcattagaaaatc,unmodified PMO,NA,3,uM,Skip,43.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcggcattagaaaatc,unmodified PMO,NA,10,uM,Skip,79.83,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgttagaaaatcagc,unmodified PMO,NA,1,uM,Skip,10.5,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgttagaaaatcagc,unmodified PMO,NA,3,uM,Skip,40.76,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctcgttagaaaatcagc,unmodified PMO,NA,10,uM,Skip,69.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcatgtaggagtctc,unmodified PMO,NA,1,uM,Skip,16.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcatgtaggagtctc,unmodified PMO,NA,3,uM,Skip,45.38,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcatgtaggagtctc,unmodified PMO,NA,10,uM,Skip,77.31,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagtgcctgggttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,22.27,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagtgcctgggttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,53.78,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagtgcctgggttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,68.91,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaatca,unmodified PMO,NA,1,uM,Skip,7.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaatca,unmodified PMO,NA,3,uM,Skip,27.31,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaatca,unmodified PMO,NA,10,uM,Skip,66.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgttagaaaatcag,unmodified PMO,NA,1,uM,Skip,4.62,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgttagaaaatcag,unmodified PMO,NA,3,uM,Skip,18.49,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgttagaaaatcag,unmodified PMO,NA,10,uM,Skip,45.8,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaatcag,unmodified PMO,NA,3,uM,Skip,3.78,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaatcag,unmodified PMO,NA,10,uM,Skip,21.01,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ggtcctgggaaggttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,33.61,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ggtcctgggaaggttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,76.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ggtcctgggaaggttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,91.18,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaat,unmodified PMO,NA,1,uM,Skip,2.52,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaat,unmodified PMO,NA,3,uM,Skip,8.82,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaat,unmodified PMO,NA,10,uM,Skip,31.93,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaatc,unmodified PMO,NA,1,uM,Skip,5.04,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaatc,unmodified PMO,NA,3,uM,Skip,15.13,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcgcattagaaaatc,unmodified PMO,NA,10,uM,Skip,44.12,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcggcattagaaaatc,unmodified PMO,NA,1,uM,Skip,5.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcggcattagaaaatc,unmodified PMO,NA,3,uM,Skip,23.11,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,taggagtctcggcattagaaaatc,unmodified PMO,NA,10,uM,Skip,63.45,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcctgggaaggttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,10.53,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcctgggaaggttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,39.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcctgggaaggttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,77.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggaggagtctcgac,unmodified PMO,NA,1,uM,Skip,4.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggaggagtctcgac,unmodified PMO,NA,3,uM,Skip,15.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggaggagtctcgac,unmodified PMO,NA,10,uM,Skip,42.11,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtaggagtctcgac,unmodified PMO,NA,1,uM,Skip,10.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtaggagtctcgac,unmodified PMO,NA,3,uM,Skip,29.82,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtaggagtctcgac,unmodified PMO,NA,10,uM,Skip,59.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttaggagtctcga,unmodified PMO,NA,1,uM,Skip,13.16,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttaggagtctcga,unmodified PMO,NA,3,uM,Skip,34.21,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttaggagtctcga,unmodified PMO,NA,10,uM,Skip,58.33,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttaggagtctc,unmodified PMO,NA,1,uM,Skip,21.93,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttaggagtctc,unmodified PMO,NA,3,uM,Skip,50.44,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgttaggagtctc,unmodified PMO,NA,10,uM,Skip,77.63,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactggtaggagtctc,unmodified PMO,NA,1,uM,Skip,14.91,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactggtaggagtctc,unmodified PMO,NA,3,uM,Skip,41.23,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactggtaggagtctc,unmodified PMO,NA,10,uM,Skip,71.49,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtgtaggagtctc,unmodified PMO,NA,1,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtgtaggagtctc,unmodified PMO,NA,3,uM,Skip,36.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtgtaggagtctc,unmodified PMO,NA,10,uM,Skip,69.3,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agagatcggatgtaggagtctc,unmodified PMO,NA,1,uM,Skip,3.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agagatcggatgtaggagtctc,unmodified PMO,NA,3,uM,Skip,9.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agagatcggatgtaggagtctc,unmodified PMO,NA,10,uM,Skip,19.74,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggtaggagtctc,unmodified PMO,NA,1,uM,Skip,2.63,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggtaggagtctc,unmodified PMO,NA,3,uM,Skip,10.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggtaggagtctc,unmodified PMO,NA,10,uM,Skip,35.09,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcattgtaggagtctc,unmodified PMO,NA,1,uM,Skip,11.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcattgtaggagtctc,unmodified PMO,NA,3,uM,Skip,32.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcattgtaggagtctc,unmodified PMO,NA,10,uM,Skip,58.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcataggagtctcgac,unmodified PMO,NA,1,uM,Skip,3.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcataggagtctcgac,unmodified PMO,NA,3,uM,Skip,11.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgcctgggttcataggagtctcgac,unmodified PMO,NA,10,uM,Skip,35.53,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcctgggaaggtaggagtctcgac,unmodified PMO,NA,3,uM,Skip,4.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcctgggaaggtaggagtctcgac,unmodified PMO,NA,10,uM,Skip,30.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaatgtaggagtctc,unmodified PMO,NA,1,uM,Skip,2.63,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaatgtaggagtctc,unmodified PMO,NA,3,uM,Skip,14.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tggtcctgggaatgtaggagtctc,unmodified PMO,NA,10,uM,Skip,47.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgtaggagtctcgac,unmodified PMO,NA,1,uM,Skip,10.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgtaggagtctcgac,unmodified PMO,NA,3,uM,Skip,32.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgtaggagtctcgac,unmodified PMO,NA,10,uM,Skip,72.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,18.42,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,56.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,81.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtaggagtctcga,unmodified PMO,NA,1,uM,Skip,17.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtaggagtctcga,unmodified PMO,NA,3,uM,Skip,42.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtaggagtctcga,unmodified PMO,NA,10,uM,Skip,68.86,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtaggagtctc,unmodified PMO,NA,1,uM,Skip,18.42,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtaggagtctc,unmodified PMO,NA,3,uM,Skip,43.86,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgtaggagtctc,unmodified PMO,NA,10,uM,Skip,70.61,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggatgtaggagtctc,unmodified PMO,NA,1,uM,Skip,32.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggatgtaggagtctc,unmodified PMO,NA,3,uM,Skip,55.26,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggatgtaggagtctc,unmodified PMO,NA,10,uM,Skip,75.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccatccacttgagaaaatcagc,unmodified PMO,NA,1,uM,Skip,10.53,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccatccacttgagaaaatcagc,unmodified PMO,NA,3,uM,Skip,34.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tccatccacttgagaaaatcagc,unmodified PMO,NA,10,uM,Skip,68.86,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtctc,unmodified PMO,NA,1,uM,Skip,49.12,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtctc,unmodified PMO,NA,3,uM,Skip,84.21,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtctc,unmodified PMO,NA,10,uM,Skip,90.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtaggagtctc,unmodified PMO,NA,1,uM,Skip,49.56,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtaggagtctc,unmodified PMO,NA,3,uM,Skip,71.05,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtaggagtctc,unmodified PMO,NA,10,uM,Skip,89.04,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgtctgtaggagtctc,unmodified PMO,NA,1,uM,Skip,15.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgtctgtaggagtctc,unmodified PMO,NA,3,uM,Skip,32.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgtctgtaggagtctc,unmodified PMO,NA,10,uM,Skip,60.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtgtaggagtctc,unmodified PMO,NA,1,uM,Skip,36.84,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtgtaggagtctc,unmodified PMO,NA,3,uM,Skip,66.67,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtgtaggagtctc,unmodified PMO,NA,10,uM,Skip,82.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,21.05,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,68.86,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,93.86,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgttgtaggagtct,unmodified PMO,NA,1,uM,Skip,12.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgttgtaggagtct,unmodified PMO,NA,3,uM,Skip,44.3,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgttgtaggagtct,unmodified PMO,NA,10,uM,Skip,74.12,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgtgtaggagtctc,unmodified PMO,NA,1,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgtgtaggagtctc,unmodified PMO,NA,3,uM,Skip,31.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgtgtaggagtctc,unmodified PMO,NA,10,uM,Skip,44.74,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggattgtaggagtc,unmodified PMO,NA,1,uM,Skip,17.98,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggattgtaggagtc,unmodified PMO,NA,3,uM,Skip,44.74,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggattgtaggagtc,unmodified PMO,NA,10,uM,Skip,60.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcattgtaggagtctc,unmodified PMO,NA,1,uM,Skip,7.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcattgtaggagtctc,unmodified PMO,NA,3,uM,Skip,15.35,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcattgtaggagtctc,unmodified PMO,NA,10,uM,Skip,44.3,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,8.33,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,24.56,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,49.12,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgttaggagtctc,unmodified PMO,NA,1,uM,Skip,2.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgttaggagtctc,unmodified PMO,NA,3,uM,Skip,8.33,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgttaggagtctc,unmodified PMO,NA,10,uM,Skip,31.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgtcaggagtctcgac,unmodified PMO,NA,1,uM,Skip,6.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgtcaggagtctcgac,unmodified PMO,NA,3,uM,Skip,17.98,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgtcaggagtctcgac,unmodified PMO,NA,10,uM,Skip,42.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agagatcggatttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,7.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agagatcggatttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,17.11,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agagatcggatttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,30.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactggtaggagtct,unmodified PMO,NA,1,uM,Skip,8.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactggtaggagtct,unmodified PMO,NA,3,uM,Skip,28.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactggtaggagtct,unmodified PMO,NA,10,uM,Skip,57.46,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgaggagtctcgac,unmodified PMO,NA,1,uM,Skip,25.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgaggagtctcgac,unmodified PMO,NA,3,uM,Skip,64.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgaggagtctcgac,unmodified PMO,NA,10,uM,Skip,91.67,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtct,unmodified PMO,NA,1,uM,Skip,37.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtct,unmodified PMO,NA,3,uM,Skip,71.93,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtct,unmodified PMO,NA,10,uM,Skip,87.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtc,unmodified PMO,NA,1,uM,Skip,26.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtc,unmodified PMO,NA,3,uM,Skip,58.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtc,unmodified PMO,NA,10,uM,Skip,78.95,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattaggagtctc,unmodified PMO,NA,1,uM,Skip,19.3,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattaggagtctc,unmodified PMO,NA,3,uM,Skip,50.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattaggagtctc,unmodified PMO,NA,10,uM,Skip,75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgtaggagtctc,unmodified PMO,NA,1,uM,Skip,5.26,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgtaggagtctc,unmodified PMO,NA,3,uM,Skip,21.05,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatgtaggagtctc,unmodified PMO,NA,10,uM,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcagtaggagtctc,unmodified PMO,NA,1,uM,Skip,33.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcagtaggagtctc,unmodified PMO,NA,3,uM,Skip,72.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcagtaggagtctc,unmodified PMO,NA,10,uM,Skip,89.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacacttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacacttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,35.09,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacacttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,69.3,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgaggagtctcga,unmodified PMO,NA,1,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgaggagtctcga,unmodified PMO,NA,3,uM,Skip,33.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgaggagtctcga,unmodified PMO,NA,10,uM,Skip,64.91,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcggttgtaggagtc,unmodified PMO,NA,1,uM,Skip,10.96,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcggttgtaggagtc,unmodified PMO,NA,3,uM,Skip,24.56,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcggttgtaggagtc,unmodified PMO,NA,10,uM,Skip,46.49,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggattgtaggagtct,unmodified PMO,NA,1,uM,Skip,15.35,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggattgtaggagtct,unmodified PMO,NA,3,uM,Skip,30.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggattgtaggagtct,unmodified PMO,NA,10,uM,Skip,45.18,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgggagtctcgac,unmodified PMO,NA,1,uM,Skip,9.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgggagtctcgac,unmodified PMO,NA,3,uM,Skip,29.39,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactgggagtctcgac,unmodified PMO,NA,10,uM,Skip,62.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgtaggagtctcgac,unmodified PMO,NA,1,uM,Skip,13.6,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgtaggagtctcgac,unmodified PMO,NA,3,uM,Skip,47.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgggttcatgtaggagtctcgac,unmodified PMO,NA,10,uM,Skip,83.77,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcattaggagtctcgac,unmodified PMO,NA,1,uM,Skip,3.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcattaggagtctcgac,unmodified PMO,NA,3,uM,Skip,11.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcattaggagtctcgac,unmodified PMO,NA,10,uM,Skip,39.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcgtgtaggagtctc,unmodified PMO,NA,1,uM,Skip,3.51,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcgtgtaggagtctc,unmodified PMO,NA,3,uM,Skip,11.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcgtgtaggagtctc,unmodified PMO,NA,10,uM,Skip,32.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,55.26,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,89.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,97.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcattaggagtctc,unmodified PMO,NA,3,uM,Skip,2.63,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcattaggagtctc,unmodified PMO,NA,10,uM,Skip,16.23,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggattgtaggagtc,unmodified PMO,NA,1,uM,Skip,12.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggattgtaggagtc,unmodified PMO,NA,3,uM,Skip,26.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggattgtaggagtc,unmodified PMO,NA,10,uM,Skip,42.11,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcagtaggagtct,unmodified PMO,NA,1,uM,Skip,28.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcagtaggagtct,unmodified PMO,NA,3,uM,Skip,65.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcagtaggagtct,unmodified PMO,NA,10,uM,Skip,89.04,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcataggagtctc,unmodified PMO,NA,1,uM,Skip,32.89,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcataggagtctc,unmodified PMO,NA,3,uM,Skip,64.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcataggagtctc,unmodified PMO,NA,10,uM,Skip,84.21,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcgtaggagtctc,unmodified PMO,NA,1,uM,Skip,42.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcgtaggagtctc,unmodified PMO,NA,3,uM,Skip,78.51,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcgtaggagtctc,unmodified PMO,NA,10,uM,Skip,86.4,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcaggagtctcgac,unmodified PMO,NA,1,uM,Skip,28.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcaggagtctcgac,unmodified PMO,NA,3,uM,Skip,62.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcaggagtctcgac,unmodified PMO,NA,10,uM,Skip,90.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttgcacaaacactgttgtaggagt,unmodified PMO,NA,1,uM,Skip,34.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttgcacaaacactgttgtaggagt,unmodified PMO,NA,3,uM,Skip,69.3,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttgcacaaacactgttgtaggagt,unmodified PMO,NA,10,uM,Skip,89.04,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtaggagtct,unmodified PMO,NA,1,uM,Skip,24.56,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtaggagtct,unmodified PMO,NA,3,uM,Skip,59.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtaggagtct,unmodified PMO,NA,10,uM,Skip,84.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggatttgtaggagtct,unmodified PMO,NA,1,uM,Skip,14.04,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggatttgtaggagtct,unmodified PMO,NA,3,uM,Skip,28.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggatttgtaggagtct,unmodified PMO,NA,10,uM,Skip,42.11,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggttgtaggagtct,unmodified PMO,NA,1,uM,Skip,15.35,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggttgtaggagtct,unmodified PMO,NA,3,uM,Skip,32.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggttgtaggagtct,unmodified PMO,NA,10,uM,Skip,50.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggatttgtaggagtc,unmodified PMO,NA,1,uM,Skip,9.21,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggatttgtaggagtc,unmodified PMO,NA,3,uM,Skip,22.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tcagagatcggatttgtaggagtc,unmodified PMO,NA,10,uM,Skip,34.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,51.32,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,80.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,95.61,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atcggattccagtaggagtctc,unmodified PMO,NA,1,uM,Skip,2.63,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atcggattccagtaggagtctc,unmodified PMO,NA,3,uM,Skip,9.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,atcggattccagtaggagtctc,unmodified PMO,NA,10,uM,Skip,31.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtttcagagagtaggagtctc,unmodified PMO,NA,3,uM,Skip,1.32,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agtttcagagagtaggagtctc,unmodified PMO,NA,10,uM,Skip,10.53,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgagtctcgac,unmodified PMO,NA,1,uM,Skip,6.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgagtctcgac,unmodified PMO,NA,3,uM,Skip,14.04,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgagtctcgac,unmodified PMO,NA,10,uM,Skip,34.65,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatttgtaggagtc,unmodified PMO,NA,3,uM,Skip,3.51,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ctgggttcatttgtaggagtc,unmodified PMO,NA,10,uM,Skip,12.72,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gcacaaacactgtaggagtctc,unmodified PMO,NA,1,uM,Skip,3.49,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gcacaaacactgtaggagtctc,unmodified PMO,NA,3,uM,Skip,7.86,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gcacaaacactgtaggagtctc,unmodified PMO,NA,10,uM,Skip,15.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggattttgtaggagtc,unmodified PMO,NA,1,uM,Skip,11.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggattttgtaggagtc,unmodified PMO,NA,3,uM,Skip,25.76,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cagagatcggattttgtaggagtc,unmodified PMO,NA,10,uM,Skip,40.17,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccagtatacctgtaggagtctc,unmodified PMO,NA,3,uM,Skip,3.06,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ccagtatacctgtaggagtctc,unmodified PMO,NA,10,uM,Skip,14.41,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgcacaaacactgt,unmodified PMO,NA,1,uM,Skip,17.9,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgcacaaacactgt,unmodified PMO,NA,3,uM,Skip,44.98,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgcacaaacactgt,unmodified PMO,NA,10,uM,Skip,73.36,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtcagagatcgga,unmodified PMO,NA,1,uM,Skip,1.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtcagagatcgga,unmodified PMO,NA,3,uM,Skip,4.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcatgtcagagatcgga,unmodified PMO,NA,10,uM,Skip,13.54,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcagagtctcgac,unmodified PMO,NA,1,uM,Skip,10.04,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcagagtctcgac,unmodified PMO,NA,3,uM,Skip,25.76,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcagagtctcgac,unmodified PMO,NA,10,uM,Skip,42.79,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcgtaggagtctc,unmodified PMO,NA,3,uM,Skip,4.37,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcgtaggagtctc,unmodified PMO,NA,10,uM,Skip,28.38,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agatcggattcgtaggagtctc,unmodified PMO,NA,1,uM,Skip,16.16,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agatcggattcgtaggagtctc,unmodified PMO,NA,3,uM,Skip,37.12,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,agatcggattcgtaggagtctc,unmodified PMO,NA,10,uM,Skip,53.28,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttctaggagtctc,unmodified PMO,NA,1,uM,Skip,20.52,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttctaggagtctc,unmodified PMO,NA,3,uM,Skip,48.47,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctc/cacaaacactg,unmodified PMO,NA,3,uM,Skip,6.59,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttctaggagtctc,unmodified PMO,NA,10,uM,Skip,77.73,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcgtaggagtct,unmodified PMO,NA,1,uM,Skip,23.58,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcgtaggagtct,unmodified PMO,NA,3,uM,Skip,55.02,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcgtaggagtct,unmodified PMO,NA,10,uM,Skip,78.6,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcaggagtctc,unmodified PMO,NA,1,uM,Skip,12.66,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcaggagtctc,unmodified PMO,NA,3,uM,Skip,33.19,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcaggagtctc,unmodified PMO,NA,10,uM,Skip,61.14,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttctaggagtct,unmodified PMO,NA,1,uM,Skip,1.75,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttctaggagtct,unmodified PMO,NA,3,uM,Skip,5.68,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttctaggagtct,unmodified PMO,NA,10,uM,Skip,13.1,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttggattcaggttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,13.1,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttggattcaggttgtaggagtctc,unmodified PMO,NA,3,uM,Skip,56.33,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcagtaggagtctc,unmodified PMO,NA,1,uM,Skip,42.44,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttggattcaggttgtaggagtctc,unmodified PMO,NA,10,uM,Skip,91.7,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aagttggattcatgtaggagtctc,unmodified PMO,NA,1,uM,Skip,3.06,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aagttggattcatgtaggagtctc,unmodified PMO,NA,3,uM,Skip,8.3,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,aagttggattcatgtaggagtctc,unmodified PMO,NA,10,uM,Skip,20.09,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcggtgtaggagtct,unmodified PMO,NA,1,uM,Skip,7.42,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcggtgtaggagtct,unmodified PMO,NA,3,uM,Skip,18.34,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcggtgtaggagtct,unmodified PMO,NA,10,uM,Skip,31,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcgggttgtaggagt,unmodified PMO,NA,1,uM,Skip,6.11,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcgggttgtaggagt,unmodified PMO,NA,3,uM,Skip,12.66,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tttcagagatcgggttgtaggagt,unmodified PMO,NA,10,uM,Skip,28.82,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactggtaggagtctc,unmodified PMO,NA,3,uM,Skip,43.66,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctc,unmodified PMO,NA,3,uM,Skip,0.49,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cacaaacactg,unmodified PMO,NA,3,uM,Skip,0.24,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttca,unmodified PMO,NA,1,uM,Skip,0.73,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,gtaggagtctc/cctgggttca,unmodified PMO,NA,1,uM,Skip,16.1,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttcagagatcggattgtaggagtctc,unmodified PMO,NA,1,uM,Skip,31.07,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,0.34,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctc/ttcagagatcgga,unmodified PMO,NA,1,uM,Skip,0.68,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtctc,unmodified PMO,NA,1,uM,Skip,47.12,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctc,unmodified PMO,NA,1,uM,Skip,0.29,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttca,unmodified PMO,NA,1,uM,Skip,0.59,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,ttgtaggagtctc/cctgggttca,unmodified PMO,NA,1,uM,Skip,17.85,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcattgtaggagtctc,unmodified PMO,NA,1,uM,Skip,47.41,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctc,unmodified PMO,NA,1,uM,Skip,0.29,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,cctgggttcat,unmodified PMO,NA,1,uM,Skip,0.88,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
patent,Untisense Nucleic Acid For Treating Amyotrophy,US20200123546A1,MSTN,exon,2,NA,human,RD Cells,Null,NA,tgtaggagtctc/cctgggttcat,unmodified PMO,NA,1,uM,Skip,14.93,NA,NA,NA,DNA,https://patents.google.com/patent/US20200123546A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JPWO2017047707A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatctggagttcct,unmodified PMO,NA,1,uM,Skip,2.82,NA,NA,NA,DNA,https://patents.google.com/patent/JPWO2017047707A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JPWO2017047707A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatctggagttcct,unmodified PMO,NA,3,uM,Skip,16.35,NA,NA,NA,DNA,https://patents.google.com/patent/JPWO2017047707A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JPWO2017047707A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatctggagttcct,unmodified PMO,NA,10,uM,Skip,58.18,NA,NA,NA,DNA,https://patents.google.com/patent/JPWO2017047707A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JPWO2017047707A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatctggagttcct,unmodified PMO,NA,1,uM,Skip,0.55,NA,NA,NA,DNA,https://patents.google.com/patent/JPWO2017047707A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JPWO2017047707A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatctggagttcct,unmodified PMO,NA,3,uM,Skip,1.05,NA,NA,NA,DNA,https://patents.google.com/patent/JPWO2017047707A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JPWO2017047707A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ccgctgcccaatctggagttcct,unmodified PMO,NA,10,uM,Skip,9.54,NA,NA,NA,DNA,https://patents.google.com/patent/JPWO2017047707A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JPWO2017047707A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ttatttcttccccagttcctgtaaga,unmodified PMO,NA,1,uM,Skip,0.53,NA,NA,NA,DNA,https://patents.google.com/patent/JPWO2017047707A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JPWO2017047707A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ttatttcttccccagttcctgtaaga,unmodified PMO,NA,3,uM,Skip,0.63,NA,NA,NA,DNA,https://patents.google.com/patent/JPWO2017047707A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JPWO2017047707A1,DMD,exon,45,NA,human,RD Cells,Null,NA,ttatttcttccccagttcctgtaaga,unmodified PMO,NA,10,uM,Skip,6.15,NA,NA,NA,DNA,https://patents.google.com/patent/JPWO2017047707A1,NA,NA,NA
journal article,Antisense Nucleic Acids,JPWO2017047707A1,DMD,exon,45,NA,human,RD Cells,Null,NA,attcaggcttcccttccccagttgca,unmodified PMO,NA,0.1,uM,Skip,5.51,NA,NA,NA,DNA,https://patents.google.com/patent/JPWO2017047707A1,NA,NA,NA
patent,"Tricyclo-Dna Antisense Oligonucleotides, Compositions, And Methods For The Treatment Of Disease",EP 2417257 B1,DMD,exon,51,NA,human,hDMD mice muscle cells,Null,NA,agaaatgccatcttc,Others (tc-DNA),NA,10,ug,Skip,3.8,NA,NA,NA,DNA,https://patents.google.com/patent/EP2417257B1,NA,NA,NA
patent,"Tricyclo-Dna Antisense Oligonucleotides, Compositions, And Methods For The Treatment Of Disease",EP 2417257 B1,DMD,exon,51,NA,human,hDMD mice muscle cells,Null,NA,aaatgccatcttcct,Others (tc-DNA),NA,10,ug,Skip,15.2,NA,NA,NA,DNA,https://patents.google.com/patent/EP2417257B1,NA,NA,NA
patent,"Tricyclo-Dna Antisense Oligonucleotides, Compositions, And Methods For The Treatment Of Disease",EP 2417257 B1,DMD,exon,51,NA,human,hDMD mice muscle cells,Null,NA,tgccatcttccttga,Others (tc-DNA),NA,10,ug,Skip,5.9,NA,NA,NA,DNA,https://patents.google.com/patent/EP2417257B1,NA,NA,NA
journal article,Analysis Of The Functional Consequences Of Targeted Exon Deletion In Col7a1 Reveals Prospects For Dystrophic Pidermolysis Bullosa Therapy,PMID 27157667,COL7A1,exon,13,NA,human,Human dermal fibroblasts,Lipofectamine 2000,NA,gccugaacgucauccaagucg,2OMe,NA,250,nmol/l,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27157667,NA,NA,NA
journal article,Analysis Of The Functional Consequences Of Targeted Exon Deletion In Col7a1 Reveals Prospects For Dystrophic Pidermolysis Bullosa Therapy,PMID 27157667,COL7A1,exon,13,NA,human,Human dermal fibroblasts,Lipofectamine 2000,NA,gccugaacgucauccaagucg,2OMe,NA,500,nmol/l,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27157667,NA,NA,NA
journal article,Analysis Of The Functional Consequences Of Targeted Exon Deletion In Col7a1 Reveals Prospects For Dystrophic Pidermolysis Bullosa Therapy,PMID 27157667,COL7A1,exon,105,NA,human,Human dermal fibroblasts,Lipofectamine 2000,NA,cuccuuuuucuccucggauaccagg,2OMe,NA,250,nmol/l,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27157667,NA,NA,NA
journal article,Analysis Of The Functional Consequences Of Targeted Exon Deletion In Col7a1 Reveals Prospects For Dystrophic Pidermolysis Bullosa Therapy,PMID 27157667,COL7A1,exon,105,NA,human,Human dermal fibroblasts,Lipofectamine 2000,NA,cuccuuuuucuccucggauaccagg,2OMe,NA,500,nmol/l,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27157667,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,41,NA,human,Primary  human  myoblasts,ExGen500,NA,cuccucuuucuucuucugc,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,2,NA,human,Primary  human  myoblasts,ExGen500,NA,cccauuuugugaauguuuucuuuu,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,2,NA,human,Primary  human  myoblasts,ExGen500,NA,uugugcauuuacccauuuugug,2OMe,NA,1000,uM,Null,-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,29,NA,human,Primary  human  myoblasts,ExGen500,NA,uauccucugaaugucgcauc,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,29,NA,human,Primary  human  myoblasts,ExGen500,NA,gguuauccucugaaugucgc,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,40,NA,human,Primary  human  myoblasts,ExGen500,NA,gagccuuuuuucuucuuug,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,40,NA,human,Primary  human  myoblasts,ExGen500,NA,uccuuucgucucugggcuc,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,41,NA,human,Primary  human  myoblasts,ExGen500,NA,cuucgaaacugagcaaauuu,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,42,NA,human,Primary  human  myoblasts,ExGen500,NA,cuugugagacaugagug,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,42,NA,human,Primary  human  myoblasts,ExGen500,NA,cagagacuccucuugcuu,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,43,NA,human,Primary  human  myoblasts,ExGen500,NA,ugcugcugucuucuugcu,2OMe,NA,1000,uM,Null,?,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,43,NA,human,Primary  human  myoblasts,ExGen500,NA,uuguuaacuuuuucccauu,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,44,NA,human,Primary  human  myoblasts,ExGen500,NA,cgccgccauuucucaacag,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,44,NA,human,Primary  human  myoblasts,ExGen500,NA,uuuguauuuagcauguuccc,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,45,NA,human,Primary  human  myoblasts,ExGen500,NA,gcugaauuauuucuucccc,2OMe,NA,1000,uM,Null,?,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,45,NA,human,Primary  human  myoblasts,ExGen500,NA,gcccaaugccauccugg,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,46,NA,human,Primary  human  myoblasts,ExGen500,NA,cugcuuccuccaacc,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,46,NA,human,Primary  human  myoblasts,ExGen500,NA,gcuuuucuuuuaguugcugc,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,47,NA,human,Primary  human  myoblasts,ExGen500,NA,ucuugcucuucugggcuu,2OMe,NA,1000,uM,Null,?,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,47,NA,human,Primary  human  myoblasts,ExGen500,NA,cuugagcuuauuuucaaguuu,2OMe,NA,1000,uM,Null,?,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,48,NA,human,Primary  human  myoblasts,ExGen500,NA,uuucuccuuguuucuc,2OMe,NA,1000,uM,Null,?,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,48,NA,human,Primary  human  myoblasts,ExGen500,NA,ccauaaauuuccaacugauuc,2OMe,NA,1000,uM,Null,?,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,49,NA,human,Primary  human  myoblasts,ExGen500,NA,cuuccacauccgguuguuu,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,49,NA,human,Primary  human  myoblasts,ExGen500,NA,guggcugguuuuuccuugu,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,50,NA,human,Primary  human  myoblasts,ExGen500,NA,cucagagcucagaucuu,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,50,NA,human,Primary  human  myoblasts,ExGen500,NA,ggcugcuuugcccuc,2OMe,NA,1000,uM,Null,?,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,51,NA,human,Primary  human  myoblasts,ExGen500,NA,ucaaggaagauggcauuucu,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,51,NA,human,Primary  human  myoblasts,ExGen500,NA,ccucugugauuuuauaacuugau,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,53,NA,human,Primary  human  myoblasts,ExGen500,NA,cuguugccuuccgguucug,2OMe,NA,1000,uM,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Secondary Rna Structure,US/2016/168570,DMD,exon,53,NA,human,Primary  human  myoblasts,ExGen500,NA,uuggcucuggccuguccu,2OMe,NA,1000,uM,Null,?,NA,NA,NA,RNA,https://patents.google.com/patent/US/2016/168570,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,43,NA,human,Healthy primary human myotubes,oligofectamine,NA,ccugagcuuuguuguagacuauc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,43,NA,human,Healthy primary human myotubes,oligofectamine,NA,gagagagcuuccuguagcuucacc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,43,NA,human,Healthy primary human myotubes,oligofectamine,NA,guccuuguacauuuuguuaacuuuuuc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,43,NA,human,Healthy primary human myotubes,oligofectamine,NA,ugcacuuugcaaugcugcugucuucuugcuau,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,43,NA,human,Healthy primary human myotubes,oligofectamine,NA,ucauaaugaaaacgccgccauuucucaacagaucu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,43,NA,human,Healthy primary human myotubes,oligofectamine,NA,uuuagcauguucccaauucucaggaauuug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,45,NA,human,Healthy primary human myotubes,oligofectamine,NA,cgcugcccaaugcauccuggaguu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,50,NA,human,Healthy primary human myotubes,oligofectamine,NA,caguccaggagcuaggucagg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,50,NA,human,Healthy primary human myotubes,oligofectamine,NA,caguccaggagcuaggucaggcugcuuugc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,50,NA,human,Healthy primary human myotubes,oligofectamine,NA,ucuugaaguaaacgguuuaccgccuuccacucagagc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Means And Methods For Counteracting Muscle Disorders,US 9243245 B2,DMD,exon,52,NA,human,Healthy primary human myotubes,oligofectamine,NA,acuggggacgccucuguucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9243245B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,5,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,aaaccaagagucaguuuaugauuuccaucua,2OMe,NA,0.01,uM,Skip,great skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,11,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cuguuccaaucagcuuacuucccaauugua,2OMe,NA,0.0025,uM,Skip,faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,11,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cuguuccaaucagcuuacuucccaauugua,2OMe,NA,0.005,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,12,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cagucauucaacucuuucaguuucugau,2OMe,NA,0.0025,uM,Skip,faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,12,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cagucauucaacucuuucaguuucugau,2OMe,NA,0.01,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,17,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,gugguggugacagccugugaaaucugugag,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,17,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,uguucccuuguggucaccguaguuac,2OMe,NA,0.05,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,45,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,gcugcccaaugccauccuggaguuccuguaa,2OMe,NA,0.0025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,45,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,gcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,45,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,gcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.025,uM,Skip,100% skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,45,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,caaugccauccuggaguuccuguaagauacc,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,45,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,gcugcccaaugccauccuggaguuccug,2OMe,NA,0.0025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,46,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,uccagguucaagugggauacuagcaaugu,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,46,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,guugcugcucuuuuccagguucaaguggga,2OMe,NA,0.005,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,46,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,guugcugcucuuuuccagguucaaguggga,2OMe,NA,0.025,uM,Skip,100% skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,47,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,uggcgcaggggcaacucuuccaccaguaa,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,49,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,acaaaugcugcccuuuagacaaaauc,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,50,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,ggcugcuuugcccucagcucuugaagu,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,51,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,gguaccuccaacaucaaggaagauggcauu,2OMe,NA,0.005,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,54,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,uggucucaucugcagaauaaucccggagaag,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,55,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cagccucucgcucacucacccugcaaagga,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,56,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,ccaaacgucuuuguaacaggacugcau,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,56,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,ccacuugaaguucauguuauccaaacgucu,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,57,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,aacuggcuuccaaaugggaccugaaaaaga,2OMe,NA,0.3,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,59,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cuauuuuucucugccagucagcgga,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,58,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,uucguacagucucaagaguacucaugauuac,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,58,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,caauuaccucugggcuccugguag,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,60,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cgagcaaggucauugacguggcucacguuc,2OMe,NA,0.05,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,63,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,gagcucugucauuuugggauggucccagca,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,64,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cugcagucuucggaguuucauggcagucc,2OMe,NA,0.05,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,67,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,gcgcuggucacaaaauccuguugaacuugc,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,44,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cuguucagcuucuguuagccacugauu,2OMe,NA,0.005,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,52,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,uccaacuggggacgccucuguuccaaauccugc,2OMe,NA,0.0025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,53,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,uucaacuguugccuccgguucugaagguguucu,2OMe,NA,0.0025,uM,Skip,faint skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,53,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,uucaacuguugccuccgguucugaagguguucu,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,73,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cauugcuguuuuccauuucugguag,2OMe,NA,0.025,uM,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,62,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,uagggcacuuuguuuggcgagauggcucuc,2OMe,NA,0.1,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,21,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,cacaaagucugcauccaggaacauggguc,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,21,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,aaggccacaaagucugcauccaggaacaug,2OMe,NA,unspecified,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Antisense  Molecules And Methods For Treating Pathologies,US 9228187 B2,DMD,exon,43,NA,human,Healthy primary human myotubes,"Used cationic lipoplexes, other details unspecified",NA,gagagcuuccuguagcuucacccuuu,2OMe,NA,0.01,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US9228187B2,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,2.5,uM,Skip,4.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,5,uM,Skip,12.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,12.5,uM,Skip,20.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,unmodified PMO,NA,25,uM,Skip,34.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,42.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,45.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,56.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,68.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,8.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,15.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,46.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,73.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,17.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,48,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,46.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,81.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,2.5,uM,Skip,8.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,5,uM,Skip,16.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,12.5,uM,Skip,27.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,25,uM,Skip,32.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,2.5,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,5,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,12.5,uM,Skip,0.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,25,uM,Skip,8.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,2.5,uM,Skip,4.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,5,uM,Skip,12.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,12.5,uM,Skip,15.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,25,uM,Skip,22.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,12.5,uM,Skip,3.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,25,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgttgcctccggttctgaaggt,unmodified PMO,NA,2.5,uM,Skip,1.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgttgcctccggttctgaaggt,unmodified PMO,NA,5,uM,Skip,4.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgttgcctccggttctgaaggt,unmodified PMO,NA,12.5,uM,Skip,8.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgttgcctccggttctgaaggt,unmodified PMO,NA,25,uM,Skip,11.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,2.5,uM,Skip,13.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,5,uM,Skip,30.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,12.5,uM,Skip,46.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,25,uM,Skip,74.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,36.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,65.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,80.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,91.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,17.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,64.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,86.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,caactgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,94.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,52,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,48.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,92.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,95,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,2.5,uM,Skip,19.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,5,uM,Skip,41.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,12.5,uM,Skip,50.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,25,uM,Skip,65.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,12.5,uM,Skip,13.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,atttcattcaactgttgcctccggttct,unmodified PMO,NA,25,uM,Skip,32.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,2.5,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,5,uM,Skip,7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,12.5,uM,Skip,7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2015/361428,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttct,unmodified PMO,NA,25,uM,Skip,8.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2015/361428,NA,NA,NA
journal article,Combination Antisense Treatment For Destructive Exon Skipping Of Myostatin And Open Reading Frame Rescue Of Dystrophin In Neonatal Mdx Mice,PMID 25959011,DMD/MSTN,exon,unspecified,NA,human,Mdx neonates (TA muscle),Null,NA,ggccaaacctcggcttacctgaaat/agcccatcttctcctggtcctgggaagg,modified PMO (BPMO),NA,10,mg/kg,Skip,~30,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25959011,NA,NA,NA
journal article,Combination Antisense Treatment For Destructive Exon Skipping Of Myostatin And Open Reading Frame Rescue Of Dystrophin In Neonatal Mdx Mice,PMID 25959011,MSTN,exon,2,NA,mouse,Mdx neonates (TA muscle),Null,NA,ggccaaacctcggcttacctgaaat/agcccatcttctcctggtcctgggaagg,modified PMO (BPMO),NA,10,mg/kg,Skip,~6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25959011,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,aacuuccucuuuaacag,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,cttcctgtagcttcaccctttccacagg,unmodified PMO,NA,2.5,uM,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,gtcttcttgctatgaataatgtcaatcc,unmodified PMO,NA,2.5,uM,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,gtcttcttgctatgaataatgtcaatcc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gccatcctggagttcctgtaagatacc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ctgcccaatgccatcctgg,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ctgcccaatgccatcctgg,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,cagtttgccgctgcccaatgccatcc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,cagtttgccgctgcccaatgccatcc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,acagtttgccgctgcccaatgcca,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,acagtttgccgctgcccaatgcca,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ctgacaacagtttgccgctgcccaa,unmodified PMO,NA,2.5,uM,Skip,20.9,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ctgacaacagtttgccgctgcccaa,unmodified PMO,NA,2.5,uM,Skip,20.9,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gcattcaatgttctgacaac,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gcattcaatgttctgacaac,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gaattatttcttccccagttgcattcaatg,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,ccucuuuaacagaaaa,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,ccucuuuaacagaaaa,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,aacuuccucuuuaacagaaaag,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,aacuuccucuuuaacagaaaag,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,ccgacctgagctttgttgtagactatct,unmodified PMO,NA,20?g/40?L saline,Null,Skip,12.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,ccgacctgagctttgttgtagactatct,unmodified PMO,NA,2.5,uM,Skip,100,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,gctttgttgtagactatcttttatattc,unmodified PMO,NA,2.5,uM,Skip,75,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,gctttgttgtagactatcttttatattc,unmodified PMO,NA,2.5,uM,Skip,60,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,gctttgttgtagactatcttttatattc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,ccgacctgagctttgttgtagactatct,unmodified PMO,NA,2.5,uM,Skip,80,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,cttcctgtagcttcaccctttccacagg,unmodified PMO,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,cttcctgtagcttcaccctttccacagg,unmodified PMO,NA,20?g/40?L saline,Null,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,gctgggagagagcttcctgtagcttcac,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,gctgggagagagcttcctgtagcttcac,unmodified PMO,NA,2.5,uM,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,gctgggagagagcttcctgtagcttcac,unmodified PMO,NA,20?g/40?L saline,Null,Skip,2.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,tgttacctacccttgtcggtccttgtac,unmodified PMO,NA,2.5,uM,Skip,45,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,tgttacctacccttgtcggtccttgtac,unmodified PMO,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,tgttacctacccttgtcggtccttgtac,unmodified PMO,NA,20?g/40?L saline,Null,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,ctatgaataatgtcaatccgacctgagc,unmodified PMO,NA,2.5,uM,Skip,85,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,ctatgaataatgtcaatccgacctgagc,unmodified PMO,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,ctatgaataatgtcaatccgacctgagc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,ctgctgtcttcttgctatgaataatgtc,unmodified PMO,NA,2.5,uM,Skip,80,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,ctgctgtcttcttgctatgaataatgtc,unmodified PMO,NA,2.5,uM,Skip,48,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,ctgctgtcttcttgctatgaataatgtc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,55,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,ggcgttgcactttgcaatgctgctgtct,unmodified PMO,NA,2.5,uM,Skip,35,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,ggcgttgcactttgcaatgctgctgtct,unmodified PMO,NA,2.5,uM,Skip,48,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,ggcgttgcactttgcaatgctgctgtct,unmodified PMO,NA,20?g/40?L saline,Null,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,ttggaaatcaagctgggagagagcttcc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,ttggaaatcaagctgggagagagcttcc,unmodified PMO,NA,2.5,uM,Skip,48,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,ttggaaatcaagctgggagagagcttcc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,22.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,ctttttcccattggaaatcaagctggga,unmodified PMO,NA,2.5,uM,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,ctttttcccattggaaatcaagctggga,unmodified PMO,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,ctttttcccattggaaatcaagctggga,unmodified PMO,NA,20?g/40?L saline,Null,Skip,0.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,gtcggtccttgtacattttgttaacttt,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,gtcggtccttgtacattttgttaacttt,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,gtcggtccttgtacattttgttaacttt,unmodified PMO,NA,20?g/40?L saline,Null,Skip,2.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,ctacccttgtcggtccttgtacattttg,unmodified PMO,NA,2.5,uM,Skip,75,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,ctacccttgtcggtccttgtacattttg,unmodified PMO,NA,2.5,uM,Skip,48,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,ctacccttgtcggtccttgtacattttg,unmodified PMO,NA,20?g/40?L saline,Null,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,gacctgagctttgttgtagactatcttt,unmodified PMO,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,gacctgagctttgttgtagactatcttt,unmodified PMO,NA,2.5,uM,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,gacctgagctttgttgtagactatcttt,unmodified PMO,NA,20?g/40?L saline,Null,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,gtcaatccgacctgagctttgttgtaga,unmodified PMO,NA,2.5,uM,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,gtcaatccgacctgagctttgttgtaga,unmodified PMO,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,gtcaatccgacctgagctttgttgtaga,unmodified PMO,NA,20?g/40?L saline,Null,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,taatgtcaatccgacctgagctttgttg,unmodified PMO,NA,2.5,uM,Skip,25,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,taatgtcaatccgacctgagctttgttg,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,taatgtcaatccgacctgagctttgttg,unmodified PMO,NA,20?g/40?L saline,Null,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,cttgctatgaataatgtcaatccgacc,unmodified PMO,NA,2.5,uM,Skip,45,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,cttgctatgaataatgtcaatccgacc,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,cttgctatgaataatgtcaatccgacc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,aacuuccucuuuaacag,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,gtcttcttgctatgaataatgtcaatcc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,25,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,gcactttgcaatgctgctgtcttcttgc,unmodified PMO,NA,2.5,uM,Skip,35,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,gcactttgcaatgctgctgtcttcttgc,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,gcactttgcaatgctgctgtcttcttgc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,ccacaggcgttgcactttgcaatgctgc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,ccacaggcgttgcactttgcaatgctgc,unmodified PMO,NA,2.5,uM,Skip,100,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,ccacaggcgttgcactttgcaatgctgc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,agcttcaccctttccacaggcgttgcac,unmodified PMO,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,agcttcaccctttccacaggcgttgcac,unmodified PMO,NA,2.5,uM,Skip,45,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,agcttcaccctttccacaggcgttgcac,unmodified PMO,NA,20?g/40?L saline,Null,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,tcaccctttccacaggcgttgca,unmodified PMO,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,tcaccctttccacaggcgttgca,unmodified PMO,NA,2.5,uM,Skip,95,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,tcaccctttccacaggcgttgca,unmodified PMO,NA,20?g/40?L saline,Null,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,ggagagagcttcctgtagct,unmodified PMO,NA,2.5,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,ggagagagcttcctgtagct,unmodified PMO,NA,2.5,uM,Skip,95,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,ggagagagcttcctgtagct,unmodified PMO,NA,20?g/40?L saline,Null,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,tcccattggaaatcaagctgggagagag,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,tcccattggaaatcaagctgggagagag,unmodified PMO,NA,2.5,uM,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,tcccattggaaatcaagctgggagagag,unmodified PMO,NA,20?g/40?L saline,Null,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,Healthy human myoblast,Null,NA,tatatgtgttacctacccttgtcggtcc,unmodified PMO,NA,2.5,uM,Skip,65,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,human,DMD myoblast,Null,NA,tatatgtgttacctacccttgtcggtcc,unmodified PMO,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,43,NA,mouse,hDMD mice,Intramuscular injection,NA,tatatgtgttacctacccttgtcggtcc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,45,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gccatcctggagttcctgtaagatacc,unmodified PMO,NA,2.5,uM,Skip,81.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,gccatcctggagttcctgtaagatacc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,17.8,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gagttcctgtaagataccaaaaagg,unmodified PMO,NA,2.5,uM,Skip,59.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gagttcctgtaagataccaaaaagg,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,gagttcctgtaagataccaaaaagg,unmodified PMO,NA,20?g/40?L saline,Null,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gcccaatgccatcctggagttcctg,unmodified PMO,NA,2.5,uM,Skip,33.6,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gcccaatgccatcctggagttcctg,unmodified PMO,NA,2.5,uM,Skip,63.8,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,gcccaatgccatcctggagttcctg,unmodified PMO,NA,20?g/40?L saline,Null,Skip,59.6,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ccaatgccatcctggagttcct,unmodified PMO,NA,2.5,uM,Skip,51.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ccaatgccatcctggagttcct,unmodified PMO,NA,2.5,uM,Skip,58.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,ccaatgccatcctggagttcct,unmodified PMO,NA,20?g/40?L saline,Null,Skip,57.2,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,aatgccatcctggagttcctgtaa,unmodified PMO,NA,2.5,uM,Skip,59.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,aatgccatcctggagttcctgtaa,unmodified PMO,NA,2.5,uM,Skip,76.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,aatgccatcctggagttcctgtaa,unmodified PMO,NA,20?g/40?L saline,Null,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,cctggagttcctgtaagataccaaa,unmodified PMO,NA,2.5,uM,Skip,9,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,cctggagttcctgtaagataccaaa,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,tgccatcctggagttcctgtaagat,unmodified PMO,NA,2.5,uM,Skip,10.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,tgccatcctggagttcctgtaagat,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,tcctggagttcctgtaagatac,unmodified PMO,NA,2.5,uM,Skip,27.8,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,tcctggagttcctgtaagatac,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ccatcctggagttcctgtaagatac,unmodified PMO,NA,2.5,uM,Skip,67.2,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ccatcctggagttcctgtaagatac,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,cccaatgccatcctggagttcctgtaaga,unmodified PMO,NA,2.5,uM,Skip,54.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,cccaatgccatcctggagttcctgtaaga,unmodified PMO,NA,2.5,uM,Skip,52.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,cccaatgccatcctggagttcctgtaaga,unmodified PMO,NA,20?g/40?L saline,Null,Skip,61.3,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ccgctgccaatgccatcctggagttcc,unmodified PMO,NA,2.5,uM,Skip,66.6,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ccgctgccaatgccatcctggagttcc,unmodified PMO,NA,2.5,uM,Skip,72.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,ccgctgccaatgccatcctggagttcc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,55.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,caatgccatcctggagttcctgtaagatac,unmodified PMO,NA,2.5,uM,Skip,93.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,caatgccatcctggagttcctgtaagatac,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,caatgccatcctggagttcctgtaagatac,unmodified PMO,NA,20?g/40?L saline,Null,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,cccaatgccatcctggagttcctgtaagat,unmodified PMO,NA,2.5,uM,Skip,88.2,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,cccaatgccatcctggagttcctgtaagat,unmodified PMO,NA,2.5,uM,Skip,16,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,cccaatgccatcctggagttcctgtaagat,unmodified PMO,NA,20?g/40?L saline,Null,Skip,60,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gccgctgcccaatgccatcctggagttcct,unmodified PMO,NA,2.5,uM,Skip,38.7,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gccgctgcccaatgccatcctggagttcct,unmodified PMO,NA,2.5,uM,Skip,42.8,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,gccgctgcccaatgccatcctggagttcct,unmodified PMO,NA,20?g/40?L saline,Null,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,aatgccatcctggagttcctgtaagatacc,unmodified PMO,NA,2.5,uM,Skip,25.8,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,aatgccatcctggagttcctgtaagatacc,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ccgctgcccaatgccatcctggagttcctg,unmodified PMO,NA,2.5,uM,Skip,54.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ccgctgcccaatgccatcctggagttcctg,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,ccgctgcccaatgccatcctggagttcctg,unmodified PMO,NA,20?g/40?L saline,Null,Skip,44.2,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,tgccgctgcccaatgccatcctggagttcc,unmodified PMO,NA,2.5,uM,Skip,24.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,tgccgctgcccaatgccatcctggagttcc,unmodified PMO,NA,2.5,uM,Skip,32.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,tgccgctgcccaatgccatcctggagttcc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,tgcccaatgccatcctggagttcctgtaag,unmodified PMO,NA,2.5,uM,Skip,17,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,tgcccaatgccatcctggagttcctgtaag,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,tgcccaatgccatcctggagttcctgtaag,unmodified PMO,NA,20?g/40?L saline,Null,Skip,64.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,caatgccatcctggagttcctgtaagat,unmodified PMO,NA,2.5,uM,Skip,41.6,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,caatgccatcctggagttcctgtaagat,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,caatgccatcctggagttcctgtaagat,unmodified PMO,NA,20?g/40?L saline,Null,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,cccaatgccatcctggagttcctgtaag,unmodified PMO,NA,2.5,uM,Skip,24.3,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,cccaatgccatcctggagttcctgtaag,unmodified PMO,NA,2.5,uM,Skip,81.2,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,cccaatgccatcctggagttcctgtaag,unmodified PMO,NA,20?g/40?L saline,Null,Skip,42.8,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,tgcccaatgccatcctggagttcctgta,unmodified PMO,NA,2.5,uM,Skip,63.2,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,tgcccaatgccatcctggagttcctgta,unmodified PMO,NA,2.5,uM,Skip,88.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,tgcccaatgccatcctggagttcctgta,unmodified PMO,NA,20?g/40?L saline,Null,Skip,23,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gctgcccaatgccatcctggagttcctg,unmodified PMO,NA,2.5,uM,Skip,27.3,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gctgcccaatgccatcctggagttcctg,unmodified PMO,NA,2.5,uM,Skip,95.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,mouse,hDMD mice,Intramuscular injection,NA,gctgcccaatgccatcctggagttcctg,unmodified PMO,NA,20?g/40?L saline,Null,Skip,21,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,catcctggagttcctgtaagatacc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,catcctggagttcctgtaagatacc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gccatcctggagttcctgtaagatacc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gccatcctggagttcctgtaagatacc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gctgcccaatgccatcctggagttc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gctgcccaatgccatcctggagttc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gcccaatgccatcctggagt,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gcccaatgccatcctggagt,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,tgccgctgcccaatgccatcctgga,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,tgccgctgcccaatgccatcctgga,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gaattatttcttccccagttgcattcaatg,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ctggcatctgtttttgaggattgctgaatt,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ctggcatctgtttttgaggattgctgaatt,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ccagttgcattcaatgttctgacaac,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ccagttgcattcaatgttctgacaac,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ttgctgaattatttcttccccag,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ttgctgaattatttcttccccag,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,tttttgaggattgctgaattatttcttcc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,tttttgaggattgctgaattatttcttcc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,tttcctgtagaatactggcatctgt,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,tttcctgtagaatactggcatctgt,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,cttcccaatttttcctgtagaatactggcat,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,cttcccaatttttcctgtagaatactggcat,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ccaatttttcctgtagaatactggc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ccaatttttcctgtagaatactggc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,caggcttcccaatttttcctgtagaatac,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,caggcttcccaatttttcctgtagaatac,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ctcctgccaccgcagattcaggcttc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ctcctgccaccgcagattcaggcttc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gcagacctcctgccaccgcagattc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gcagacctcctgccaccgcagattc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,tgtttgcagacctcctgccaccgcagattc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,tgtttgcagacctcctgccaccgcagattc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gctgtttgcagacctcctgccacc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gctgtttgcagacctcctgccacc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,gtttgcagacctcctgccaccgcag,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,gtttgcagacctcctgccaccgcag,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,cttttttctgtctgacagctgtttgcagac,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,cttttttctgtctgacagctgtttgcagac,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ctgtctgacagctgtttgcag,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ctgtctgacagctgtttgcag,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,ctacctcttttttctgtctgacagc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,ctacctcttttttctgtctgacagc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,tattagatctgtcgccctacctctt,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,tattagatctgtcgccctacctctt,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,Healthy human myoblast,Null,NA,cctattagatctgtcgccctacctc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,45,NA,human,DMD myoblast,Null,NA,cctattagatctgtcgccctacctc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,cuuuaacagaaaagcauac,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,cuuuaacagaaaagcauac,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,ucuuuaacagaaaagcauac,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,ucuuuaacagaaaagcauac,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,ccucuuuaacagaaaagcauac,2OMe,NA,2.5,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,ccucuuuaacagaaaagcauac,2OMe,NA,2.5,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,aacuuccucuuuaacagaaaagcauac,2OMe,NA,2.5,uM,Skip,29,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,aacuuccucuuuaacagaaaagcauac,2OMe,NA,2.5,uM,Skip,21,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,mouse,hDMD mice,Intramuscular injection,NA,aacuuccucuuuaacagaaaagcauac,2OMe,NA,20?g/40?L saline,Null,Skip,34,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,cuucuaacuuccucuuuaacagaaaagcauac,2OMe,NA,2.5,uM,Skip,1,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,cuucuaacuuccucuuuaacagaaaagcauac,2OMe,NA,2.5,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,gcucagaucuucuaacuuccucuuuaacag,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,gcucagaucuucuaacuuccucuuuaacag,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,aacuuccucuuuaaca,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,aacuuccucuuuaaca,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,ccacucagagcucagaucuucuaacuucc,2OMe,NA,2.5,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,ccacucagagcucagaucuucuaacuucc,2OMe,NA,2.5,uM,Skip,8,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,mouse,hDMD mice,Null,NA,ccacucagagcucagaucuucuaacuucc,2OMe,NA,2.5,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,cucagagcucagaucuu,2OMe,NA,2.5,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,cucagagcucagaucuu,2OMe,NA,2.5,uM,Skip,2,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,gcucuugaaguaaacgg,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,gcucuugaaguaaacgg,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,mouse,hDMD mice,Intramuscular injection,NA,gcucuugaaguaaacgg,2OMe,NA,20?g/40?L saline,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,aauaguggucaguccagg,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,aauaguggucaguccagg,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,cuuacaggcuccaauagugguca,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,cuuacaggcuccaauagugguca,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,guauacuuacaggcuccaauagugguca,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,guauacuuacaggcuccaauagugguca,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,uccaguauacuuacaggcuccaauaguggu,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,uccaguauacuuacaggcuccaauaguggu,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,mouse,hDMD mice,Intramuscular injection,NA,uccaguauacuuacaggcuccaauaguggu,2OMe,NA,20?g/40?L saline,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,cuuacaggcuccaauagu,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,cuuacaggcuccaauagu,2OMe,NA,2.5,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,guauacuuacaggcuccaauagu,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,guauacuuacaggcuccaauagu,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,uccaguauacuuacaggcuccaauagu,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,uccaguauacuuacaggcuccaauagu,2OMe,NA,2.5,uM,Skip,1,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,uccaguauacuuacaggcucca,2OMe,NA,2.5,uM,Skip,1,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,uccaguauacuuacaggcucca,2OMe,NA,2.5,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,gggauccaguauacuuacaggcucc,2OMe,NA,2.5,uM,Skip,65,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,gggauccaguauacuuacaggcucc,2OMe,NA,2.5,uM,Skip,28,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,mouse,hDMD mice,Intramuscular injection,NA,gggauccaguauacuuacaggcucc,2OMe,NA,20?g/40?L saline,Null,Skip,62,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,uccaguauacuuacaggcu,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,uccaguauacuuacaggcu,2OMe,NA,2.5,uM,Skip,6,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,Healthy human myoblast,Null,NA,uccaguauacuuaca,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,50,NA,human,DMD myoblast,Null,NA,uccaguauacuuaca,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,ctccaacatcaaggaagatggcatttct,unmodified PMO,NA,2.5,uM,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,mouse,hDMD mice,Intramuscular injection,NA,ctccaacatcaaggaagatggcatttct,unmodified PMO,NA,20?g/40?L saline,Null,Skip,35,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,catcaaggaagatggcatttctagt,unmodified PMO,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,mouse,hDMD mice,Intramuscular injection,NA,catcaaggaagatggcatttctagt,unmodified PMO,NA,20?g/40?L saline,Null,Skip,18,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,ggagctaaaatattttgggtttttgc,unmodified PMO,NA,2.5,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,mouse,hDMD mice,Intramuscular injection,NA,ggagctaaaatattttgggtttttgc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,ttttctcataccttctgcttgatga,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,aggtacctccaacatcaaggaagatgg,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,ctccaacatcaaggaagatggcatt,unmodified PMO,NA,2.5,uM,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,mouse,hDMD mice,Intramuscular injection,NA,ctccaacatcaaggaagatggcatt,unmodified PMO,NA,20?g/40?L saline,Null,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,ctccaacatcaaggaagatggcatttct,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,aaggaagatggcatttctagtttgg,unmodified PMO,NA,2.5,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,mouse,hDMD mice,Intramuscular injection,NA,aaggaagatggcatttctagtttgg,unmodified PMO,NA,20?g/40?L saline,Null,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,cagtctgagtaggagctaaaatatt,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,51,NA,human,Healthy human myoblast,Null,NA,gagtaggagctaaaatattttgggt,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,human,Healthy human myoblast,Null,NA,cugaauucuuucaacuagaauaaaa,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,human,Healthy human myoblast,Null,NA,gccauuguguugaauccuuuaacauuuc,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,human,Healthy human myoblast,Null,NA,ccaugacucaagcuuggcucuggcc,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,human,Healthy human myoblast,Null,NA,cccuauacaguagaugcaau,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,human,Healthy human myoblast,Null,NA,uugauacuaaccuugguuucugug,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,human,Healthy human myoblast,Null,NA,caactgttgcctccggttctgaag,unmodified PMO,NA,2.5,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,mouse,hDMD mice,Intramuscular injection,NA,caactgttgcctccggttctgaag,unmodified PMO,NA,20?g/40?L saline,Null,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,human,Healthy human myoblast,Null,NA,ggaccctccttccatgactcaagc,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,mouse,hDMD mice,Intramuscular injection,NA,ggaccctccttccatgactcaagc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,human,Healthy human myoblast,Null,NA,ggtatctttgatactaaccttggtttc,unmodified PMO,NA,2.5,uM,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
patent,Antisense Oligonucleotides,US9078911B2,DMD,exon,53,NA,mouse,hDMD mice,Intramuscular injection,NA,ggtatctttgatactaaccttggtttc,unmodified PMO,NA,20?g/40?L saline,Null,Skip,6,NA,NA,NA,DNA,https://patents.google.com/patent/US9078911B2,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 7,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcag,Others (LNA with phosphodiester linkage),NA,5,nM,Inclusion [%],45.35,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 8,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcag,Others (LNA with phosphodiester linkage),NA,25,nM,Inclusion [%],43.37,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 9,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcag,Others (LNA with phosphodiester linkage),NA,125,nM,Inclusion [%],46.87,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 10,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagca,Others (LNA with phosphodiester linkage),NA,5,nM,Inclusion [%],42.55,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 11,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagca,Others (LNA with phosphodiester linkage),NA,25,nM,Inclusion [%],41.85,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 12,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagca,Others (LNA with phosphodiester linkage),NA,125,nM,Inclusion [%],37.07,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 13,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,5,nM,Inclusion [%],37.31,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 14,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,25,nM,Inclusion [%],33.11,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 15,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,125,nM,Inclusion [%],32.29,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 16,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagcag,Others (LNA with phosphodiester linkage),NA,5,nM,Inclusion [%],44.77,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 17,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagcag,Others (LNA with phosphodiester linkage),NA,25,nM,Inclusion [%],41.62,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL2 exon 18,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagcag,Others (LNA with phosphodiester linkage),NA,125,nM,Inclusion [%],35.67,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 7,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcag,Others (LNA with phosphodiester linkage),NA,5,nM,Inclusion [%],17.59,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 8,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcag,Others (LNA with phosphodiester linkage),NA,25,nM,Inclusion [%],18.31,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 9,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcag,Others (LNA with phosphodiester linkage),NA,125,nM,Inclusion [%],19.08,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 10,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagca,Others (LNA with phosphodiester linkage),NA,5,nM,Inclusion [%],19.03,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 11,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagca,Others (LNA with phosphodiester linkage),NA,25,nM,Inclusion [%],15.95,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 12,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagca,Others (LNA with phosphodiester linkage),NA,125,nM,Inclusion [%],13.74,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 13,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,5,nM,Inclusion [%],15.9,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 14,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,25,nM,Inclusion [%],14.05,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 15,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,125,nM,Inclusion [%],10.97,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 16,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagcag,Others (LNA with phosphodiester linkage),NA,5,nM,Inclusion [%],17.74,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 17,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagcag,Others (LNA with phosphodiester linkage),NA,25,nM,Inclusion [%],16.26,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 18,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagcag,Others (LNA with phosphodiester linkage),NA,125,nM,Inclusion [%],14.31,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 19,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,0.1,nM,Inclusion [%],34,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 20,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,1,nM,Inclusion [%],37,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 21,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,5,nM,Inclusion [%],44,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 22,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,25,nM,Inclusion [%],46,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 23,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,125,nM,Inclusion [%],47.5,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,Short Antisense-Locked Nucleic Acids (All-Lnas) Correct Alternative Splicing Abnormalities In Myotonic Dystrophy,PMID 25753670,DMPK,exon,CUG expansion (1000 repeats) MBNL1 exon 24,NA,human,"Human fibrobasts (DM1 patient derived, expressing 1000 CUG repeats)",Lipofectamine,NA,cagcagcagc,Others (LNA with phosphodiester linkage),NA,250,nM,Inclusion [%],47,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/25753670,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,53,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,gttcttgtacttcatcccactgattctgaa,unmodified PMO,NA,unspecified,Null,Skip,24.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,53,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,tctgaaggtgttcttgtacttcatcccact,unmodified PMO,NA,unspecified,Null,Skip,27.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,53,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,cctccggttctgaaggtgttcttgtacttc,unmodified PMO,NA,unspecified,Null,Skip,32.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,53,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,gttgcctccggttctgaaggtgttcttgta,unmodified PMO,NA,unspecified,Null,Skip,32.8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,53,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,tcattcaactgttgcctccggttctgaagg,unmodified PMO,NA,unspecified,Null,Skip,13.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,53,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,cattgtgttgaatcctttaacatttcattc,unmodified PMO,NA,unspecified,Null,Skip,2.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,53,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,ttggctctggcctgtcctaagacctgctca,unmodified PMO,NA,unspecified,Null,Skip,0.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,53,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,tatctttgatactaaccttggtttctgtga,unmodified PMO,NA,unspecified,Null,Skip,2.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,44,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,aaaacgccgccatttctcaacagatctgtc,unmodified PMO,NA,unspecified,Null,Skip,56.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,44,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,gccgccatttctcaacagatctgtcaaatc,unmodified PMO,NA,unspecified,Null,Skip,62.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,44,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,cataatgaaaacgccgccatttctcaacag,unmodified PMO,NA,unspecified,Null,Skip,54.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,44,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,cgccatttctcaacagatctgtcaaatcgc,unmodified PMO,NA,unspecified,Null,Skip,59.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,44,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,atatcataatgaaaacgccgccatttctca,unmodified PMO,NA,unspecified,Null,Skip,54.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,44,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,actgttcagcttctgttagccactgattaa,unmodified PMO,NA,unspecified,Null,Skip,54.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,44,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,cttaagataccatttgtatttagcatgttc,unmodified PMO,NA,unspecified,Null,Skip,38.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
journal article,In Silico Screening Based On Predictive Algorithms As A Design Tool For Exon Skipping Oligonucleotides In Duchenne Muscular Dystrophy,PMID 25816009,DMD,exon,44,NA,human,immortalized cell lines derived from muscle of two DMD patients harbouring appropriate mutations,unspecified,NA,attctcaggaatttgtgtctttctgagaaa,unmodified PMO,NA,unspecified,Null,Skip,34.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25816009,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,cggtaagttctgtcctcaaggaagatggca,unmodified PMO,NA,0.3,uM,Skip,8.68,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,cggtaagttctgtcctcaaggaagatggca,unmodified PMO,NA,1,uM,Skip,39.52,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,cggtaagttctgtcctcaaggaagatggca,unmodified PMO,NA,3,uM,Skip,83.98,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,cggtaagttctgtcctcaaggaagatggca,unmodified PMO,NA,10,uM,Skip,97.6,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,ctcataccttctgcttcaaggaagatggca,unmodified PMO,NA,0.3,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,ctcataccttctgcttcaaggaagatggca,unmodified PMO,NA,1,uM,Skip,6.29,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,ctcataccttctgcttcaaggaagatggca,unmodified PMO,NA,3,uM,Skip,36.53,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,ctcataccttctgcttcaaggaagatggca,unmodified PMO,NA,10,uM,Skip,83.53,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,0.3,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,1,uM,Skip,4.49,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,3,uM,Skip,12.28,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Antisense Nucleic Acids,WO2015137409A1,DMD,exon,51,NA,human,RD Cells,Null,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,10,uM,Skip,30.84,NA,NA,NA,DNA,https://patents.google.com/patent/WO2015137409A1,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,63.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,81.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,92.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,93.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttc,unmodified PMO,NA,2.5,uM,Skip,59.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttc,unmodified PMO,NA,5,uM,Skip,80.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttc,unmodified PMO,NA,12.5,uM,Skip,89.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttc,unmodified PMO,NA,25,uM,Skip,90.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,2.5,uM,Skip,12.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,5,uM,Skip,42.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,12.5,uM,Skip,51.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,ctccggttctgaaggtgttcttgta,unmodified PMO,NA,25,uM,Skip,79.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,2.5,uM,Skip,28.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,5,uM,Skip,38.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,12.5,uM,Skip,62.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,tgaaggtgttcttgtacttcatccc,unmodified PMO,NA,25,uM,Skip,84.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,2.5,uM,Skip,51.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,5,uM,Skip,48.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,12.5,uM,Skip,92.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,25,uM,Skip,94.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,2.5,uM,Skip,14.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,5,uM,Skip,32.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,12.5,uM,Skip,34.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/315977,DMD,exon,53,NA,human,RD Cells,Null,NA,gcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,25,uM,Skip,56.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/315977,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,ctatgaataatgtcaatccgacctgagc,2OMe,NA,2.5,uM,Skip,85,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctatgaataatgtcaatccgacctgagc,unmodified PMO,NA,20,ug,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,ctgctgtcttcttgctatgaataatgtc,2OMe,NA,2.5,uM,Skip,80,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctgctgtcttcttgctatgaataatgtc,unmodified PMO,NA,20,ug,Skip,55,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,ggcgttgcactttgcaatgctgctgtct,2OMe,NA,2.5,uM,Skip,35,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,ggcgttgcactttgcaatgctgctgtct,unmodified PMO,NA,20,ug,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,ttggaaatcaagctgggagagagcttcc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,ttggaaatcaagctgggagagagcttcc,unmodified PMO,NA,20,ug,Skip,22.5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,gctttgttgtagactatcttttatattc,2OMe,NA,2.5,uM,Skip,75,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,gctttgttgtagactatcttttatattc,unmodified PMO,NA,20,ug,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,ccgacctgagctttgttgtagactatct,2OMe,NA,2.5,uM,Skip,80,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccgacctgagctttgttgtagactatct,unmodified PMO,NA,20,ug,Skip,12.5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,cttcctgtagcttcaccctttccacagg,2OMe,NA,2.5,uM,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,cttcctgtagcttcaccctttccacagg,unmodified PMO,NA,20,ug,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,gctgggagagagcttcctgtagcttcac,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,gctgggagagagcttcctgtagcttcac,unmodified PMO,NA,20,ug,Skip,2.5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,tgttacctacccttgtcggtccttgtac,2OMe,NA,2.5,uM,Skip,45,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,tgttacctacccttgtcggtccttgtac,unmodified PMO,NA,20,ug,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,ctttttcccattggaaatcaagctggga,2OMe,NA,2.5,uM,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctttttcccattggaaatcaagctggga,unmodified PMO,NA,20,ug,Skip,0.5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,gtcggtccttgtacattttgttaacttt,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,gtcggtccttgtacattttgttaacttt,unmodified PMO,NA,20,ug,Skip,2.5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,ctacccttgtcggtccttgtacattttg,2OMe,NA,2.5,uM,Skip,75,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctacccttgtcggtccttgtacattttg,unmodified PMO,NA,20,ug,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,gacctgagctttgttgtagactatcttt,2OMe,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,gacctgagctttgttgtagactatcttt,unmodified PMO,NA,20,ug,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,gtcaatccgacctgagctttgttgtaga,2OMe,NA,2.5,uM,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,gtcaatccgacctgagctttgttgtaga,unmodified PMO,NA,20,ug,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,taatgtcaatccgacctgagctttgttg,2OMe,NA,2.5,uM,Skip,25,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,taatgtcaatccgacctgagctttgttg,unmodified PMO,NA,20,ug,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,cttgctatgaataatgtcaatccgacc,2OMe,NA,2.5,uM,Skip,45,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,cttgctatgaataatgtcaatccgacc,unmodified PMO,NA,20,ug,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,gtcttcttgctatgaataatgtcaatcc,2OMe,NA,2.5,uM,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,gtcttcttgctatgaataatgtcaatcc,unmodified PMO,NA,20,ug,Skip,25,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,gcactttgcaatgctgctgtcttcttgc,2OMe,NA,2.5,uM,Skip,35,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,gcactttgcaatgctgctgtcttcttgc,unmodified PMO,NA,20,ug,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,ccacaggcgttgcactttgcaatgctgc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccacaggcgttgcactttgcaatgctgc,unmodified PMO,NA,20,ug,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,agcttcaccctttccacaggcgttgcac,2OMe,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,agcttcaccctttccacaggcgttgcac,unmodified PMO,NA,20,ug,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,tcaccctttccacaggcgttgca,2OMe,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,tcaccctttccacaggcgttgca,unmodified PMO,NA,20,ug,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,ggagagagcttcctgtagct,2OMe,NA,2.5,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,ggagagagcttcctgtagct,unmodified PMO,NA,20,ug,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,tcccattggaaatcaagctgggagagag,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,tcccattggaaatcaagctgggagagag,unmodified PMO,NA,20,ug,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,human,Healthy human myotubes,Null,NA,tatatgtgttacctacccttgtcggtcc,2OMe,NA,2.5,uM,Skip,65,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,43,NA,mouse,hDMD mouse skeletal muscle,No,NA,tatatgtgttacctacccttgtcggtcc,unmodified PMO,NA,20,ug,Skip,45,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gccatcctggagttcctgtaagatacc,2OMe,NA,2.5,uM,Skip,81.4,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gccatcctggagttcctgtaagatacc,unmodified PMO,NA,20,ug,Skip,17.8,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gagttcctgtaagataccaaaaagg,2OMe,NA,2.5,uM,Skip,59.4,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gagttcctgtaagataccaaaaagg,unmodified PMO,NA,20,ug,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gcccaatgccatcctggagttcctg,2OMe,NA,2.5,uM,Skip,33.6,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gcccaatgccatcctggagttcctg,unmodified PMO,NA,20,ug,Skip,59.6,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ccaatgccatcctggagttcct,2OMe,NA,2.5,uM,Skip,51.4,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccaatgccatcctggagttcct,unmodified PMO,NA,20,ug,Skip,57.2,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,aatgccatcctggagttcctgtaa,2OMe,NA,2.5,uM,Skip,59.1,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,aatgccatcctggagttcctgtaa,unmodified PMO,NA,20,ug,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,cctggagttcctgtaagataccaaa,2OMe,NA,2.5,uM,Skip,9,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,cctggagttcctgtaagataccaaa,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,tgccatcctggagttcctgtaagat,2OMe,NA,2.5,uM,Skip,10.5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,tgccatcctggagttcctgtaagat,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,tcctggagttcctgtaagatac,2OMe,NA,2.5,uM,Skip,27.8,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,tcctggagttcctgtaagatac,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ccatcctggagttcctgtaagatac,2OMe,NA,2.5,uM,Skip,67.2,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,DMD human primary myotubes,Null,NA,ccatcctggagttcctgtaagatac,unmodified PMO,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccatcctggagttcctgtaagatac,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,cccaatgccatcctggagttcctgtaaga,2OMe,NA,2.5,uM,Skip,54.5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,cccaatgccatcctggagttcctgtaaga,unmodified PMO,NA,20,ug,Skip,61.3,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ccgctgcccaatgccatcctggagttcc,2OMe,NA,2.5,uM,Skip,66.6,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,DMD human primary myotubes,Null,NA,ccgctgcccaatgccatcctggagttcc,unmodified PMO,NA,2.5,uM,Skip,72.1,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccgctgcccaatgccatcctggagttcc,unmodified PMO,NA,20,ug,Skip,55.1,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,caatgccatcctggagttcctgtaagatac,2OMe,NA,2.5,uM,Skip,93.4,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,caatgccatcctggagttcctgtaagatac,unmodified PMO,NA,20,ug,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,cccaatgccatcctggagttcctgtaagat,2OMe,NA,2.5,uM,Skip,88.2,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,cccaatgccatcctggagttcctgtaagat,unmodified PMO,NA,20,ug,Skip,60,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gccgctgcccaatgccatcctggagttcct,2OMe,NA,2.5,uM,Skip,38.7,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gccgctgcccaatgccatcctggagttcct,unmodified PMO,NA,20,ug,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,aatgccatcctggagttcctgtaagatacc,2OMe,NA,2.5,uM,Skip,25.8,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,aatgccatcctggagttcctgtaagatacc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ccgctgcccaatgccatcctggagttcctg,2OMe,NA,2.5,uM,Skip,54.4,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,DMD human primary myotubes,Null,NA,ccgctgcccaatgccatcctggagttcctg,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccgctgcccaatgccatcctggagttcctg,unmodified PMO,NA,20,ug,Skip,44.2,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,tgccgctgcccaatgccatcctggagttcc,2OMe,NA,2.5,uM,Skip,24.5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,tgccgctgcccaatgccatcctggagttcc,unmodified PMO,NA,20,ug,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,tgcccaatgccatcctggagttcctgtaag,2OMe,NA,2.5,uM,Skip,17,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,tgcccaatgccatcctggagttcctgtaag,unmodified PMO,NA,20,ug,Skip,64.1,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,caatgccatcctggagttcctgtaagat,2OMe,NA,2.5,uM,Skip,41.6,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,cccaatgccatcctggagttcctgtaag,2OMe,NA,2.5,uM,Skip,24.3,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,cccaatgccatcctggagttcctgtaag,unmodified PMO,NA,20,ug,Skip,42.8,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,tgcccaatgccatcctggagttcctgta,2OMe,NA,2.5,uM,Skip,63.2,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,tgcccaatgccatcctggagttcctgta,unmodified PMO,NA,20,ug,Skip,23,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gctgcccaatgccatcctggagttcctg,2OMe,NA,2.5,uM,Skip,27.3,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gctgcccaatgccatcctggagttcctg,unmodified PMO,NA,20,ug,Skip,21,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,catcctggagttcctgtaagatacc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,catcctggagttcctgtaagatacc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gccatcctggagttcctgtaagatacc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gccatcctggagttcctgtaagatacc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gctgcccaatgccatcctggagttc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gctgcccaatgccatcctggagttc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gcccaatgccatcctggagt,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gcccaatgccatcctggagt,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,tgccgctgcccaatgccatcctgga,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,tgccgctgcccaatgccatcctgga,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ctgcccaatgccatcctgg,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctgcccaatgccatcctgg,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,cagtttgccgctgcccaatgccatcc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,cagtttgccgctgcccaatgccatcc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,acagtttgccgctgcccaatgcca,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,acagtttgccgctgcccaatgcca,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ctgacaacagtttgccgctgcccaa,2OMe,NA,2.5,uM,Skip,20.9,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctgacaacagtttgccgctgcccaa,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gcattcaatgttctgacaac,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gcattcaatgttctgacaac,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gaattatttcttccccagttgcattcaatg,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gaattatttcttccccagttgcattcaatg,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ctggcatctgtttttgaggattgctgaatt,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctggcatctgtttttgaggattgctgaatt,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ccagttgcattcaatgttctgacaac,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccagttgcattcaatgttctgacaac,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ttgctgaattatttcttccccag,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ttgctgaattatttcttccccag,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,tttttgaggattgctgaattatttcttcc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,DMD human primary myotubes,Null,NA,tttttgaggattgctgaattatttcttcc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,tttttgaggattgctgaattatttcttcc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,tttcctgtagaatactggcatctgt,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,DMD human primary myotubes,Null,NA,tttcctgtagaatactggcatctgt,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,tttcctgtagaatactggcatctgt,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,cttcccaatttttcctgtagaatactggcat,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,cttcccaatttttcctgtagaatactggcat,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ccaatttttcctgtagaatactggc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccaatttttcctgtagaatactggc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,caggcttcccaatttttcctgtagaatac,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,DMD human primary myotubes,Null,NA,caggcttcccaatttttcctgtagaatac,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,caggcttcccaatttttcctgtagaatac,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ctcctgccaccgcagattcaggcttc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctcctgccaccgcagattcaggcttc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gcagacctcctgccaccgcagattc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,DMD human primary myotubes,Null,NA,gcagacctcctgccaccgcagattc,unmodified PMO,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gcagacctcctgccaccgcagattc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,tgtttgcagacctcctgccaccgcagattc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,tgtttgcagacctcctgccaccgcagattc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gctgtttgcagacctcctgccacc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gctgtttgcagacctcctgccacc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,gtttgcagacctcctgccaccgcag,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,gtttgcagacctcctgccaccgcag,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,cttttttctgtctgacagctgtttgcagac,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,cttttttctgtctgacagctgtttgcagac,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ctgtctgacagctgtttgcag,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctgtctgacagctgtttgcag,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,ctacctcttttttctgtctgacagc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctacctcttttttctgtctgacagc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,tattagatctgtcgccctacctctt,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,tattagatctgtcgccctacctctt,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,human,Healthy human myotubes,Null,NA,cctattagatctgtcgccctacctc,2OMe,NA,2.5,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,45,NA,mouse,hDMD mouse skeletal muscle,No,NA,cctattagatctgtcgccctacctc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,cuuuaacagaaaagcauac,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,cuuuaacagaaaagcauac,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,ucuuuaacagaaaagcauac,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,ucuuuaacagaaaagcauac,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,ccucuuuaacagaaaagcauac,unmodified PMO,NA,2.5,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccucuuuaacagaaaagcauac,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,2.5,uM,Skip,21,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,aacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,20,ug,Skip,34,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,cuucuaacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,2.5,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,cuucuaacuuccucuuuaacagaaaagcauac,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,ccucuuuaacagaaaa,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccucuuuaacagaaaa,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,aacuuccucuuuaacagaaaag,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,aacuuccucuuuaacagaaaag,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,aacuuccucuuuaacag,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,aacuuccucuuuaacag,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,gcucagaucuucuaacuuccucuuuaacag,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,gcucagaucuucuaacuuccucuuuaacag,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,aacuuccucuuuaaca,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,aacuuccucuuuaaca,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,ccacucagagcucagaucuucuaacuucc,unmodified PMO,NA,2.5,uM,Skip,8,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccacucagagcucagaucuucuaacuucc,unmodified PMO,NA,20,ug,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,cucagagcucagaucuu,unmodified PMO,NA,2.5,uM,Skip,2,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,cucagagcucagaucuu,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,gcucuugaaguaaacgg,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,gcucuugaaguaaacgg,unmodified PMO,NA,20,ug,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,aauaguggucaguccagg,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,aauaguggucaguccagg,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,cuuacaggcuccaauagugguca,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,cuuacaggcuccaauagugguca,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,guauacuuacaggcuccaauagugguca,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,guauacuuacaggcuccaauagugguca,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,uccaguauacuuacaggcuccaauaguggu,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,uccaguauacuuacaggcuccaauaguggu,unmodified PMO,NA,20,ug,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,cuuacaggcuccaauagu,unmodified PMO,NA,2.5,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,cuuacaggcuccaauagu,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,guauacuuacaggcuccaauagu,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,guauacuuacaggcuccaauagu,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,uccaguauacuuacaggcuccaauagu,unmodified PMO,NA,2.5,uM,Skip,1,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,uccaguauacuuacaggcuccaauagu,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,uccaguauacuuacaggcucca,unmodified PMO,NA,2.5,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,uccaguauacuuacaggcucca,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,gggauccaguauacuuacaggcucc,unmodified PMO,NA,2.5,uM,Skip,28,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,gggauccaguauacuuacaggcucc,unmodified PMO,NA,20,ug,Skip,62,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,uccaguauacuuacaggcu,unmodified PMO,NA,2.5,uM,Skip,6,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,uccaguauacuuacaggcu,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,human,DMD human primary myotubes,Null,NA,uccaguauacuuaca,unmodified PMO,NA,2.5,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,50,NA,mouse,hDMD mouse skeletal muscle,No,NA,uccaguauacuuaca,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,ctccaacatcaaggaagatggcatttct,2OMe,NA,2.5,uM,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctccaacatcaaggaagatggcatttct,unmodified PMO,NA,20,ug,Skip,35,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,catcaaggaagatggcatttctagt,2OMe,NA,2.5,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,catcaaggaagatggcatttctagt,unmodified PMO,NA,20,ug,Skip,18,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,ggagctaaaatamtgggttmgc,2OMe,NA,2.5,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,DMD human primary myotubes,Null,NA,ggagctaaaatamtgggttmgc,unmodified PMO,NA,2.5,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,ggagctaaaatamtgggttmgc,unmodified PMO,NA,20,ug,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,ttttctcataccttctgcttgatga,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,ttttctcataccttctgcttgatga,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,aggtacctccaacatcaaggaagatgg,2OMe,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,aggtacctccaacatcaaggaagatgg,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,ctccaacatcaaggaagatggcatt,2OMe,NA,2.5,uM,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctccaacatcaaggaagatggcatt,unmodified PMO,NA,20,ug,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,ctccaacatcaaggaagatggcatttct,2OMe,NA,2.5,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctccaacatcaaggaagatggcatttct,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,ctccaacatcaaggaagatggcatttctag,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,aaggaagatggcatttctagtttgg,2OMe,NA,2.5,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,aaggaagatggcatttctagtttgg,unmodified PMO,NA,20,ug,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,cagtctgagtaggagctaaaatatt,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,cagtctgagtaggagctaaaatatt,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,human,Healthy human myotubes,Null,NA,gagtaggagctaaaatattttgggt,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,51,NA,mouse,hDMD mouse skeletal muscle,No,NA,gagtaggagctaaaatattttgggt,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,human,DMD human primary myotubes,Null,NA,cugaauucuuucaacuagaauaaaa,unmodified PMO,NA,2.5,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,mouse,hDMD mouse skeletal muscle,No,NA,cugaauucuuucaacuagaauaaaa,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,human,DMD human primary myotubes,Null,NA,gccauuguguugaauccuuuaacauuuc,unmodified PMO,NA,2.5,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,mouse,hDMD mouse skeletal muscle,No,NA,gccauuguguugaauccuuuaacauuuc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,human,DMD human primary myotubes,Null,NA,ccaugacucaagcuuggcucuggcc,unmodified PMO,NA,2.5,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,mouse,hDMD mouse skeletal muscle,No,NA,ccaugacucaagcuuggcucuggcc,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,human,DMD human primary myotubes,Null,NA,cccuauacaguagaugcaau,unmodified PMO,NA,2.5,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,mouse,hDMD mouse skeletal muscle,No,NA,cccuauacaguagaugcaau,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,human,DMD human primary myotubes,Null,NA,uugauacuaaccuugguuucugug,unmodified PMO,NA,2.5,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,mouse,hDMD mouse skeletal muscle,No,NA,uugauacuaaccuugguuucugug,unmodified PMO,NA,20,ug,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,human,Healthy human myotubes,Null,NA,caactgttgcctccggttctgaag,2OMe,NA,2.5,uM,Skip,20,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,mouse,hDMD mouse skeletal muscle,No,NA,caactgttgcctccggttctgaag,unmodified PMO,NA,20,ug,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,human,Healthy human myotubes,Null,NA,ggaccctccttccatgactcaagc,2OMe,NA,2.5,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,mouse,hDMD mouse skeletal muscle,No,NA,ggaccctccttccatgactcaagc,unmodified PMO,NA,20,ug,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,human,Healthy human myotubes,Null,NA,ggtatctttgatactaaccttggtttc,2OMe,NA,2.5,uM,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Antisense Oligonucleotides,KR20140052963A,DMD,exon,53,NA,mouse,hDMD mouse skeletal muscle,No,NA,ggtatctttgatactaaccttggtttc,unmodified PMO,NA,20,ug,Skip,6,NA,NA,NA,DNA,https://patents.google.com/patent/KR20140052963A,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcagg,unmodified PMO,NA,5,uM,Skip,15.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,unmodified PMO,NA,20,uM,Skip,58.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,unmodified PMO,NA,10,uM,Skip,34.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,unmodified PMO,NA,5,uM,Skip,19.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,unmodified PMO,NA,2.5,uM,Skip,14.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,caacagatctgtcaaatcgcctgcag,unmodified PMO,NA,20,uM,Skip,18.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,caacagatctgtcaaatcgcctgcag,unmodified PMO,NA,10,uM,Skip,9.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,caacagatctgtcaaatcgcctgcag,unmodified PMO,NA,5,uM,Skip,5.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,caacagatctgtcaaatcgcctgcag,unmodified PMO,NA,2.5,uM,Skip,2.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggta,unmodified PMO,NA,20,uM,Skip,68.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggta,unmodified PMO,NA,10,uM,Skip,54.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggta,unmodified PMO,NA,5,uM,Skip,42.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggta,unmodified PMO,NA,2.5,uM,Skip,20.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggt,unmodified PMO,NA,20,uM,Skip,67.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggt,unmodified PMO,NA,10,uM,Skip,60.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggt,unmodified PMO,NA,5,uM,Skip,50.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggt,unmodified PMO,NA,2.5,uM,Skip,24.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcag,unmodified PMO,NA,20,uM,Skip,66.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcag,unmodified PMO,NA,10,uM,Skip,50.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcag,unmodified PMO,NA,5,uM,Skip,38.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcag,unmodified PMO,NA,2.5,uM,Skip,23.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggt,unmodified PMO,NA,20,uM,Skip,65.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggt,unmodified PMO,NA,10,uM,Skip,52.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggt,unmodified PMO,NA,5,uM,Skip,41.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggt,unmodified PMO,NA,2.5,uM,Skip,22.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcag,unmodified PMO,NA,20,uM,Skip,69.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcag,unmodified PMO,NA,10,uM,Skip,53.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcag,unmodified PMO,NA,5,uM,Skip,34.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcag,unmodified PMO,NA,2.5,uM,Skip,10.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,unmodified PMO,NA,20,uM,Skip,14.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,unmodified PMO,NA,10,uM,Skip,11.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,unmodified PMO,NA,5,uM,Skip,8.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,unmodified PMO,NA,2.5,uM,Skip,6.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,unmodified PMO,NA,1.25,uM,Skip,2.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,unmodified PMO,NA,0.625,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,unmodified PMO,NA,20,uM,Skip,6.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,unmodified PMO,NA,10,uM,Skip,5.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,unmodified PMO,NA,5,uM,Skip,5.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,unmodified PMO,NA,2.5,uM,Skip,4.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,unmodified PMO,NA,1.25,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,unmodified PMO,NA,0.625,uM,Skip,0.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,caacagatctgtcaaatcgcctgcag,unmodified PMO,NA,20,uM,Skip,6.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,caacagatctgtcaaatcgcctgcag,unmodified PMO,NA,10,uM,Skip,3.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,caacagatctgtcaaatcgcctgcag,unmodified PMO,NA,5,uM,Skip,3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,caacagatctgtcaaatcgcctgcag,unmodified PMO,NA,2.5,uM,Skip,2.3,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,caacagatctgtcaaatcgcctgcag,unmodified PMO,NA,1.25,uM,Skip,0.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,caacagatctgtcaaatcgcctgcag,unmodified PMO,NA,0.625,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggta,unmodified PMO,NA,20,uM,Skip,14.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggta,unmodified PMO,NA,10,uM,Skip,13,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggta,unmodified PMO,NA,5,uM,Skip,15.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggta,unmodified PMO,NA,2.5,uM,Skip,10.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggta,unmodified PMO,NA,1.25,uM,Skip,3.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,cagatctgtcaaatcgcctgcaggta,unmodified PMO,NA,0.625,uM,Skip,1.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atcgcctgcaggtaaaagcatatgg,unmodified PMO,NA,20,uM,Skip,20.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atcgcctgcaggtaaaagcatatgg,unmodified PMO,NA,10,uM,Skip,17.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atcgcctgcaggtaaaagcatatgg,unmodified PMO,NA,5,uM,Skip,16.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atcgcctgcaggtaaaagcatatgg,unmodified PMO,NA,2.5,uM,Skip,11.5,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atcgcctgcaggtaaaagcatatgg,unmodified PMO,NA,1.25,uM,Skip,11.4,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atcgcctgcaggtaaaagcatatgg,unmodified PMO,NA,0.625,uM,Skip,3.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcaggtaaaag,unmodified PMO,NA,20,uM,Skip,15.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcaggtaaaag,unmodified PMO,NA,10,uM,Skip,15.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcaggtaaaag,unmodified PMO,NA,5,uM,Skip,7.6,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcaggtaaaag,unmodified PMO,NA,2.5,uM,Skip,8.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcaggtaaaag,unmodified PMO,NA,1.25,uM,Skip,6.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcaggtaaaag,unmodified PMO,NA,0.625,uM,Skip,2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaaaagc,unmodified PMO,NA,20,uM,Skip,20.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaaaagc,unmodified PMO,NA,10,uM,Skip,19.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaaaagc,unmodified PMO,NA,5,uM,Skip,11.1,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaaaagc,unmodified PMO,NA,2.5,uM,Skip,12.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaaaagc,unmodified PMO,NA,1.25,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaaaagc,unmodified PMO,NA,0.625,uM,Skip,4.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcagg,unmodified PMO,NA,20,uM,Skip,23,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcagg,unmodified PMO,NA,10,uM,Skip,20.2,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcagg,unmodified PMO,NA,2.5,uM,Skip,14.7,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcagg,unmodified PMO,NA,1.25,uM,Skip,7.9,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
patent,Exon Skipping Compositions For Treating Muscular Dystrophy,US/2014/323544,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcagg,unmodified PMO,NA,0.625,uM,Skip,5.8,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/323544,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,tgtcaccgcatgatactgccagggt/gacctcatcatctttggcgtaggat,unmodified PMO,NA,10,uM,Skip,9.09,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaacacctgatgatgggtgacaaaa/gaattggctgccttcacaattacgt,unmodified PMO,NA,10,uM,Skip,20.66,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaacacctgatgatgggtgacaaaa/ttccaaaatccagtttccaggccga,unmodified PMO,NA,10,uM,Skip,26.45,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaacacctgatgatgggtgacaaaa/gtactccacgtcatccagggaacgt,unmodified PMO,NA,10,uM,Skip,25.07,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaacacctgatgatgggtgacaaaa/tgtcaccgcatgatactgccagggt,unmodified PMO,NA,10,uM,Skip,11.57,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaattggctgccttcacaattacgt,unmodified PMO,NA,10,uM,Skip,10.25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,ttccaaaatccagtttccaggccga,unmodified PMO,NA,10,uM,Skip,13.87,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gtactccacgtcatccagggaacgt,unmodified PMO,NA,10,uM,Skip,3.68,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,tgtcaccgcatgatactgccagggt,unmodified PMO,NA,10,uM,Skip,1.23,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gacctcatcatctttggcgtaggat,unmodified PMO,NA,10,uM,Skip,1.66,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaacacctgatgatgggtgacaaaa,unmodified PMO,NA,10,uM,Skip,8.83,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,atgcagctttttgatcttacctctc,unmodified PMO,NA,10,uM,Skip,7.12,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaacacctgatgatgggtgacaaaa/atgcagctttttgatcttacctctc,unmodified PMO,NA,10,uM,Skip,17.73,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaacacctgatgatgggtgacaaaa/gacctcatcatctttggcgtaggat,unmodified PMO,NA,10,uM,Skip,17.63,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaattggctgccttcacaattacgt/ttccaaaatccagtttccaggccga,unmodified PMO,NA,10,uM,Skip,23.14,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaattggctgccttcacaattacgt/gtactccacgtcatccagggaacgt,unmodified PMO,NA,10,uM,Skip,35.26,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaattggctgccttcacaattacgt/tgtcaccgcatgatactgccagggt,unmodified PMO,NA,10,uM,Skip,13.77,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gaattggctgccttcacaattacgt/gacctcatcatctttggcgtaggat,unmodified PMO,NA,10,uM,Skip,6.89,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,ttccaaaatccagtttccaggccga/tgtcaccgcatgatactgccagggt,unmodified PMO,NA,10,uM,Skip,92.84,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,ttccaaaatccagtttccaggccga/gtactccacgtcatccagggaacgt,unmodified PMO,NA,10,uM,Skip,12.12,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,ttccaaaatccagtttccaggccga/gacctcatcatctttggcgtaggat,unmodified PMO,NA,10,uM,Skip,44.08,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gtactccacgtcatccagggaacgt/tgtcaccgcatgatactgccagggt,unmodified PMO,NA,10,uM,Skip,5.51,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
journal article,Highly Efficient In Vivo Delivery Of Pmo Into Regenerating Myotubes And Rescue In Laminin-A2 Chain-Null Congenital Muscular Dystrophy Mice,PMID 23882132,LAMA2,exon,4,NA,mouse,C2C12 myotubes,Null,NA,gtactccacgtcatccagggaacgt/gacctcatcatctttggcgtaggat,unmodified PMO,NA,10,uM,Skip,8.26,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23882132,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,55,NA,human,human rhabdomyosarcoma cell,Null,NA,uguugcaguaaucuaugaguu,2OMe,NA,30,nM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,55,NA,human,human rhabdomyosarcoma cell,Null,NA,uguugcaguaaucuaugaguu,2OMe,NA,100,nM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,55,NA,human,human rhabdomyosarcoma cell,Null,NA,ccuuggagucuucuaggagcc,2OMe,NA,30,nM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,55,NA,human,human rhabdomyosarcoma cell,Null,NA,ccuuggagucuucuaggagcc,2OMe,NA,100,nM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,55,NA,human,human rhabdomyosarcoma cell,Null,NA,ucuuuuacucccuuggagucu,2OMe,NA,30,nM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,55,NA,human,human rhabdomyosarcoma cell,Null,NA,ucuuuuacucccuuggagucu,2OMe,NA,100,nM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,55,NA,human,human rhabdomyosarcoma cell,Null,NA,uuucaucagcucuuuuacucc,2OMe,NA,30,nM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,55,NA,human,human rhabdomyosarcoma cell,Null,NA,uuucaucagcucuuuuacucc,2OMe,NA,100,nM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,55,NA,human,human rhabdomyosarcoma cell,Null,NA,uugccauuguuucaucagcu,2OMe,NA,30,nM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,55,NA,human,human rhabdomyosarcoma cell,Null,NA,uugccauuguuucaucagcu,2OMe,NA,100,nM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,44,NA,human,human rhabdomyosarcoma cell,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,1,uM,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,44,NA,human,human rhabdomyosarcoma cell,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,3,uM,Skip,50,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,44,NA,human,human rhabdomyosarcoma cell,Null,NA,tatcataatgaaaacgccgcc,unmodified PMO,NA,10,uM,Skip,90,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,50,NA,human,human rhabdomyosarcoma cell,Null,NA,cttacaggctccaatagtggt?agt,unmodified PMO,NA,0.1,uM,Skip,3,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,50,NA,human,human rhabdomyosarcoma cell,Null,NA,cttacaggctccaatagtggt?agt,unmodified PMO,NA,0.3,uM,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,50,NA,human,human rhabdomyosarcoma cell,Null,NA,cttacaggctccaatagtggt?agt,unmodified PMO,NA,1,uM,Skip,40,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,45,NA,human,human rhabdomyosarcoma cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,1,uM,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,45,NA,human,human rhabdomyosarcoma cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,3,uM,Skip,30,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
patent,Antisense Nucleic Acid,WO2013100190A1,DMD,exon,45,NA,human,human rhabdomyosarcoma cell,Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza),NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,10,uM,Skip,80,NA,NA,NA,DNA,https://patents.google.com/patent/WO2013100190A1,NA,NA,NA
journal article,In Vitro Antisense Therapeutics For A Deep Intronic Mutation Causing Neurofibromatosis Type 2,PMID 23188051,NF2,pseudoexon,pseudoexon 13,NA,human,Human fibroblast (c.1447-240T>A),Endoporter 6uM,NA,catccctcaaatctcttaccgttct,unmodified PMO,NA,5,uM,Skip,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23188051,NA,NA,NA
journal article,Design And Analysis Of Effects Of Triplet Repeat Oligonucleotides In Cell Models For Myotonic Dystrophy.,PMID 33530452,DMPK,exon,CUG repeats,NA,mouse,DM500 mouse myoblasts,polyethyleneimine,NA,cagcagcagcagcag,2OMe,NA,200,nmol/mL,mRNA reduction (RT-qPCR) [%],58.47,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/33530452,NA,NA,NA
journal article,Design And Analysis Of Effects Of Triplet Repeat Oligonucleotides In Cell Models For Myotonic Dystrophy.,PMID 33530452,DMPK,exon,CUG repeats,NA,mouse,DM500 mouse myoblasts,polyethyleneimine,NA,cagcagcagcagcagcag,2OMe,NA,200,nmol/mL,mRNA reduction (RT-qPCR) [%],63.12,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/33530452,NA,NA,NA
journal article,Design And Analysis Of Effects Of Triplet Repeat Oligonucleotides In Cell Models For Myotonic Dystrophy.,PMID 33530452,DMPK,exon,CUG repeats,NA,mouse,DM500 mouse myoblasts,polyethyleneimine,NA,cagcagcagcagcagcagcag,2OMe,NA,200,nmol/mL,mRNA reduction (RT-qPCR) [%],65.45,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/33530452,NA,NA,NA
journal article,Design And Analysis Of Effects Of Triplet Repeat Oligonucleotides In Cell Models For Myotonic Dystrophy.,PMID 33530452,DMPK,exon,CUG repeats,NA,mouse,DM500 mouse myoblasts,polyethyleneimine,NA,cagcagcagcagcagcagcagcag,2OMe,NA,200,nmol/mL,mRNA reduction (RT-qPCR) [%],84.05,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/33530452,NA,NA,NA
journal article,Design And Analysis Of Effects Of Triplet Repeat Oligonucleotides In Cell Models For Myotonic Dystrophy.,PMID 33530452,DMPK,exon,CUG repeats,NA,mouse,DM500 mouse myoblasts,polyethyleneimine,NA,cagcagcagcagcagcagcagcagcag,2OMe,NA,200,nmol/mL,mRNA reduction (RT-qPCR) [%],81.06,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/33530452,NA,NA,NA
journal article,Design And Analysis Of Effects Of Triplet Repeat Oligonucleotides In Cell Models For Myotonic Dystrophy.,PMID 33530452,DMPK,exon,CUG repeats,NA,mouse,DM500 mouse myoblasts,polyethyleneimine,NA,cagcagcagcagcagcagcagcagcagcag,2OMe,NA,200,nmol/mL,mRNA reduction (RT-qPCR) [%],73.09,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/33530452,NA,NA,NA
journal article,Design And Analysis Of Effects Of Triplet Repeat Oligonucleotides In Cell Models For Myotonic Dystrophy.,PMID 33530452,DMPK,exon,CUG repeats,NA,mouse,DM500 mouse myoblasts,polyethyleneimine,NA,cagcagcagcagcagcagcagcagcagcagcagcagcag,2OMe,NA,200,nmol/mL,mRNA reduction (RT-qPCR) [%],81.06,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/33530452,NA,NA,NA
journal article,Design And Analysis Of Effects Of Triplet Repeat Oligonucleotides In Cell Models For Myotonic Dystrophy.,PMID 33530452,DMPK,exon,CUG repeats,NA,mouse,DM500 mouse myoblasts,polyethyleneimine,NA,cigcigcigcigcigcigcig,2OMe,NA,200,nmol/mL,mRNA reduction (RT-qPCR) [%],82.72,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/33530452,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,51,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,ucaaggaagauggcauuucu,2OMe,NA,0.2,uM,Skip,12.78,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,51,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,ucaaggaagauggcauuucu,2OMe,NA,0.2,uM,Skip,16.76,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,23,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,ggccaaaccucggcuuaccu,2OMe,NA,Intramuscular injection of 20 ug,Null,Skip,2.5,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,44,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,ucagcuucuguuagccacug,2OMe,NA,0.2,uM,Skip,10.09,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,44,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,ucagcuucuguuagccacug,2OMe,NA,0.2,uM,Skip,29.7,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,53,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,guugccuccgguucugaagguguuc,2OMe,NA,0.1,uM,Skip,12.86,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,53,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,guugccuccgguucugaagguguuc,2OMe,NA,0.2,uM,Skip,23.33,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,53,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,guugccuccgguucugaagguguuc,2OMe,NA,0.4,uM,Skip,35.95,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,45,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.05,uM,Skip,6.73,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,45,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.1,uM,Skip,45.51,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,45,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,66.35,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,45,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.4,uM,Skip,79.45,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,45,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.8,uM,Skip,79.7,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,52,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,gguaaugaguucuuccaacugg,2OMe,NA,0.2,uM,Skip,23.82,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,52,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,gguaaugaguucuuccaacugg,2OMe,NA,0.2,uM,Skip,23.74,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,45,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugm5cm5cgm5cugm5cm5cm5caaugm5cm5caum5cm5cug,2OMe,NA,0.05,uM,Skip,62.98,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,45,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugm5cm5cgm5cugm5cm5cm5caaugm5cm5caum5cm5cug,2OMe,NA,0.1,uM,Skip,70.99,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,45,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugm5cm5cgm5cugm5cm5cm5caaugm5cm5caum5cm5cug,2OMe,NA,0.2,uM,Skip,69.07,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,45,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugm5cm5cgm5cugm5cm5cm5caaugm5cm5caum5cm5cug,2OMe,NA,0.4,uM,Skip,81.89,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,45,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugm5cm5cgm5cugm5cm5cm5caaugm5cm5caum5cm5cug,2OMe,NA,0.8,uM,Skip,88.3,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,51,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uca2aa2agga2aa2aga2auggca2auuucu,2OMe,NA,0.2,uM,Skip,64.74,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,53,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,guugm5cm5cum5cm5cgguum5cugaagguguum5c,2OMe,NA,0.1,uM,Skip,13.1,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,53,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,guugm5cm5cum5cm5cgguum5cugaagguguum5c,2OMe,NA,0.2,uM,Skip,44.29,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,53,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,guugm5cm5cum5cm5cgguum5cugaagguguum5c,2OMe,NA,0.4,uM,Skip,63.57,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,53,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,guugm5cm5cum5cm5cgguum5cugaagguguum5c,2OMe,NA,0.4,uM,Skip,64.3,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,51,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,m5ucaaggaagam5uggcam5um5um5ucm5u,2OMe,NA,0.2,uM,Skip,17.98,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,44,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uca2agcuucuguua2agcca2acug,2OMe,NA,0.2,uM,Skip,53.8,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,44,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,m5ucagcm5um5ucm5ugm5um5uagccacm5ug,2OMe,NA,0.2,uM,Skip,29.81,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,52,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,m5ucagcm5um5ucm5ugm5um5uagccacm5ug,2OMe,NA,0.2,uM,Skip,43.38,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,52,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,ggua2aa2auga2aguucuucca2aa2acugg,2OMe,NA,0.2,uM,Skip,73,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,23,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,ggccaaaccm5ucggcm5um5uaccm5u,2OMe,NA,Intramuscular injection of 20 ug,Null,Skip,7.26,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,51,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,m5um5caaggaagam5uggm5cam5um5um5um5cm5u,2OMe,NA,0.2,uM,Skip,23.5,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,44,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,m5um5cagm5cm5um5um5cm5ugm5um5uagm5cm5cam5cm5ug,2OMe,NA,0.2,uM,Skip,29.97,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,53,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,guugm5cm5cuccgguum5cugaagguguum5c,2OMe,NA,0.4,uM,Skip,47.27,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,53,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,guugm5cm5cuccgguucugaagguguuc,2OMe,NA,0.4,uM,Skip,36.36,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
patent,Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy,WO/2013/112053,DMD,exon,53,NA,human,Healthy primary human myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,guugcm5cuccgguum5cugaagguguum5c,2OMe,NA,0.4,uM,Skip,44.96,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2013/112053,NA,NA,NA
journal article,Dual Myostatin And Dystrophin Exon Skipping By Morpholino Nucleic Acid Oligomers Conjugated To A Cell-Penetrating Peptide Is A Promising Therapeutic Strategy For The Treatment Of Duchenne Muscular Dystrophy,PMID 23250360,DMD/MSTN,exon,2,NA,mouse,Mdx mice,Null,NA,ggccaaacctcggcttacctgaaat/agcccatcttctcctggtcctgggaagg,modified PMO (BPMO),NA,10,ug,Skip,11.65,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23250360,NA,NA,NA
journal article,Dual Myostatin And Dystrophin Exon Skipping By Morpholino Nucleic Acid Oligomers Conjugated To A Cell-Penetrating Peptide Is A Promising Therapeutic Strategy For The Treatment Of Duchenne Muscular Dystrophy,PMID 23250360,MSTN,exon,2,NA,mouse,Mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,modified PMO (BPMO),NA,10,ug,Skip,7.48,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23250360,NA,NA,NA
journal article,Deep-Intronic Atm Mutation Detected By Genomic Resequencing And Corrected In Vitro By Antisense Morpholino Oligonucleotide (Amo),PMID 23211698,ATM,pseudoexon,pseudoexon 11,NA,human,Human lymphoblastoid cell line (1236-405C>T),Endoporter,NA,gggcatggtggcacatacctggaat,unmodified PMO,NA,50,uM,Skip,26,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23211698,NA,NA,NA
patent,Therapeutic Muscular Dystrophy Drug Having Bubble Liposome Loaded With Morpholino As Active Ingredient,US/2014/0155813,DMD,exon,23,NA,mouse,Tibialis: upper hind limbs of 5 to 6-week-old mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,"ug, syringe pump (KDS 100, kdScientific) at a constant flow rate.",Skip,2.28,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/0155813,NA,NA,NA
patent,Therapeutic Muscular Dystrophy Drug Having Bubble Liposome Loaded With Morpholino As Active Ingredient,US/2014/0155813,DMD,exon,23,NA,mouse,Hamstring: upper hind limbs of 5 to 6-week-old mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,"ug, syringe pump (KDS 100, kdScientific) at a constant flow rate.",Skip,19.49,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/0155813,NA,NA,NA
patent,Therapeutic Muscular Dystrophy Drug Having Bubble Liposome Loaded With Morpholino As Active Ingredient,US/2014/0155813,DMD,exon,23,NA,mouse,Biceps: upper hind limbs of 5 to 6-week-old mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,"ug, syringe pump (KDS 100, kdScientific) at a constant flow rate.",Skip,7.59,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/0155813,NA,NA,NA
patent,Therapeutic Muscular Dystrophy Drug Having Bubble Liposome Loaded With Morpholino As Active Ingredient,US/2014/0155813,DMD,exon,23,NA,mouse,Gastrocnemius: upper hind limbs of 5 to 6-week-old mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,"ug, syringe pump (KDS 100, kdScientific) at a constant flow rate.",Skip,6.84,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/0155813,NA,NA,NA
patent,Therapeutic Muscular Dystrophy Drug Having Bubble Liposome Loaded With Morpholino As Active Ingredient,US/2014/0155813,DMD,exon,23,NA,mouse,Tibialis: upper hind limbs of 5 to 6-week-old mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,"ug, syringe pump (KDS 100, kdScientific) at a constant flow rate.",Skip,38.48,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/0155813,NA,NA,NA
patent,Therapeutic Muscular Dystrophy Drug Having Bubble Liposome Loaded With Morpholino As Active Ingredient,US/2014/0155813,DMD,exon,23,NA,mouse,Hamstring: upper hind limbs of 5 to 6-week-old mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,"ug, syringe pump (KDS 100, kdScientific) at a constant flow rate.",Skip,69.11,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/0155813,NA,NA,NA
patent,Therapeutic Muscular Dystrophy Drug Having Bubble Liposome Loaded With Morpholino As Active Ingredient,US/2014/0155813,DMD,exon,23,NA,mouse,Biceps: upper hind limbs of 5 to 6-week-old mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,"ug, syringe pump (KDS 100, kdScientific) at a constant flow rate.",Skip,19.49,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/0155813,NA,NA,NA
patent,Therapeutic Muscular Dystrophy Drug Having Bubble Liposome Loaded With Morpholino As Active Ingredient,US/2014/0155813,DMD,exon,23,NA,mouse,Gastrocnemius: upper hind limbs of 5 to 6-week-old mdx mice,Null,NA,ggccaaacctcggcttacctgaaat,unmodified PMO,NA,50,"ug, syringe pump (KDS 100, kdScientific) at a constant flow rate.",Skip,31.39,NA,NA,NA,DNA,https://patents.google.com/patent/US/2014/0155813,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,2,NA,human,normal human muscle cells,Null,NA,cuuuugaacaucuucucuuucauc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,2,NA,human,normal human muscle cells,Null,NA,uuuugugaauguuuucuuuugaacaucuucuc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,2,NA,human,normal human muscle cells,Null,NA,auuuugugaauguuuucuuuugaa,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,2,NA,human,normal human muscle cells,Null,NA,uagaaaauugugcauuuacccauuuugugaa,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,2,NA,human,normal human muscle cells,Null,NA,accauucuuaccuuagaaaauugugcauuu,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,2,NA,human,normal human muscle cells,Null,NA,aaaguaacaaaccauucuuaccuu,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,aggucacugaagagguucucaauau,2OMe,NA,0.01,uM,Skip,Moderate  skipping  to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,guaggucacugaagagguucu,2OMe,NA,0.05,uM,Skip,Strong skipping  to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,aggaggcgucucccauccuguaggucacugaagag,2OMe,NA,Null,Null,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,aggucuaggaggcgccuccca,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,cuucgaggaggucuaggaggcgccuc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,17,NA,human,normal human muscle cells,Null,NA,ggugacagccugugaaaucugugagaagua,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,17,NA,human,normal human muscle cells,Null,NA,gugguggugacagccugugaaaucugugag,2OMe,NA,0.025,uM,Skip,Skipping  at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,17,NA,human,normal human muscle cells,Null,NA,ugacagccugugaaaucugugag,2OMe,NA,0.2,uM,Skip,Skipping ex 17 + 18  at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,17,NA,human,normal human muscle cells,Null,NA,agugauggcugagugguggugacagc,2OMe,NA,Null,Null,Skip,Skipping   at 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,17,NA,human,normal human muscle cells,Null,NA,acaguugucuguguuaguga,2OMe,NA,Null,Null,Skip,inconsistent  skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,17,NA,human,normal human muscle cells,Null,NA,uguucccuuguggucaccguaguuac,2OMe,NA,0.05,uM,Skip,Skipping at 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,17,NA,human,normal human muscle cells,Null,NA,cagaauccacaguaaucugc,2OMe,NA,0.3,uM,Skip,skipping  at 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,2,NA,human,normal human muscle cells,Null,NA,ucucuuucaucuaaaaugcaaaau,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,gcccugucaggccuucgaggagguc,2OMe,NA,0.3,uM,Skip,Skipping   to 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,ucacauacaguuuuugcccugucag,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,uacaguuuuugcccugucagg,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,aagucacauacaguuuuugcccug,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,ucacauacaguuuuugccc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,uaggaggcgccucccauccuguaggucacug/gcccugucaggccuucgaggagguc,2OMe,NA,0.1,uM,Skip,Excellent  skipping   to 100 nM0.1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,uaggaggcgccucccauccuguaggucacug/gcccugucaggccuucgaggagguc,2OMe,NA,0.01,uM,Skip,skipping   to 10 nM Also taking  out 4 & 5 to 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,gcccugucaggccuucgaggagguc/gcgccucccauccuguaggucacug,2OMe,NA,0.05,uM,Skip,Very strong skipping  to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,3,NA,human,normal human muscle cells,Null,NA,gcccugucaggccuucgaggagguc/aggaggcgucucccauccuguaggucacugaagag,2OMe,NA,0.05,uM,Skip,Very strong skipping  to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,4,NA,human,normal human muscle cells,Null,NA,gauccuuuuucuuuuggcugagaac,2OMe,NA,0.01,uM,Skip,Weak skipping  down to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,4,NA,human,normal human muscle cells,Null,NA,ccgcagugccuuguugacauuguuc,2OMe,NA,0.01,uM,Skip,Good skipping  to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,4,NA,human,normal human muscle cells,Null,NA,guacuacuuacauuauuguucugca,2OMe,NA,0.01,uM,Skip,Very poor  skipping  to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,4,NA,human,normal human muscle cells,Null,NA,uguucagggcaugaacucuuguggauccuu/guacuacuuacauuauuguucugca,2OMe,NA,0.1,uM,Skip,Excellent skipping (100%  to 100 nM),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,4,NA,human,normal human muscle cells,Null,NA,uguucagggcaugaacucuuguggauccuu/guacuacuuacauuauuguucugca,2OMe,NA,0.005,uM,Skip,good  skipping    down to 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,5,NA,human,normal human muscle cells,Null,NA,aaaccaagagucaguuuaugauuuccaucua,2OMe,NA,0.01,uM,Skip,Great skipping   to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,5,NA,human,normal human muscle cells,Null,NA,cuuaccugccaguggaggauuauauuccaaa,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,6,NA,human,normal human muscle cells,Null,NA,uucauuacauuuuugaccuacaugug,2OMe,NA,0.6,uM,Skip,faint to 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,6,NA,human,normal human muscle cells,Null,NA,cuuuucacuguugguuuguugcaauc,2OMe,NA,0.025,uM,Skip,skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,6,NA,human,normal human muscle cells,Null,NA,aauuacgaguugauugucggacccagcuc,2OMe,NA,0.025,uM,Skip,skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,6,NA,human,normal human muscle cells,Null,NA,auaauuacgaguugauugucggacccag,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,6,NA,human,normal human muscle cells,Null,NA,ggugaaguugauuacauuaaccugug,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,6,NA,human,normal human muscle cells,Null,NA,ucuuaccuaugacuauggaugaga,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,6,NA,human,normal human muscle cells,Null,NA,caguaaucuucuuaccuaugac,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,6,NA,human,normal human muscle cells,Null,NA,ucaguaaucuucuuaccuaugac,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,6,NA,human,normal human muscle cells,Null,NA,ugucucaguaaucuucuuaccuau,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,7,NA,human,normal human muscle cells,Null,NA,ucaaauaggucuggccuaaaac,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,7,NA,human,normal human muscle cells,Null,NA,ccagucaaauaggucuggccua,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,7,NA,human,normal human muscle cells,Null,NA,uguuccagucguuguguggcuga,2OMe,NA,0.05,uM,Skip,skipping 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,7,NA,human,normal human muscle cells,Null,NA,ugcauguuccagucguuguguggcuga,2OMe,NA,0.025,uM,Skip,skipping 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,7,NA,human,normal human muscle cells,Null,NA,uguugaaugcauguuccagucguugugu,2OMe,NA,0.025,uM,Skip,skippking 25 nM  but weak,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,7,NA,human,normal human muscle cells,Null,NA,ugaaugcauguuccagucguugu,2OMe,NA,0.025,uM,Skip,good skipping  to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,uggauaggugguaucaacaucuguaagcac,2OMe,NA,0.01,uM,Skip,Very weak skipping   of 8 + 9 to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,aggugguaucaacaucuguaag,2OMe,NA,0.01,uM,Skip,"Very,very weak skipping of 8 + 9  to 10 nM",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,uaucuggauaggugguaucaacaucuguaa,2OMe,NA,0.01,uM,Skip,Weak skipping of  8 + 9 to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,gauaggugguaucaacaucugu,2OMe,NA,0.04,uM,Skip,works strongly  to 40 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,aaacuuggaagagugaugugaugua,2OMe,NA,0.01,uM,Skip,good skipping of  8 + 9 to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,gcucacuuguugaggcaaaacuuggaa,2OMe,NA,0.01,uM,Skip,"good skipping of 8 + 9 at high conc, down to 10 nM",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,gccuuggcaacauuuccacuuccug,2OMe,NA,0.3,uM,Skip,Weak skipping of 8 + 9 to 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,auguaacugaaaauguucuucuuua,2OMe,NA,0.1,uM,Skip,Weak skipping of  8 + 9 to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,uacacacuuuaccuguugagaauag,2OMe,NA,0.05,uM,Skip,Weakskippingof  8+9 to 50nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,uaucuggauaggugguaucaacaucuguaa/auguaacugaaaauguucuucuuua,2OMe,NA,0.01,uM,Skip,Good skipping to 10 nM (8 + 9) but  also 8 on its own,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,uaucuggauaggugguaucaacaucuguaa/uacacacuuuaccuguugagaauag,2OMe,NA,0.01,uM,Skip,Good skipping to 10 nM (8 + 9) but  also 8 on its own,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,uaucuggauaggugguaucaacaucuguaa/gcucacuuguugaggcaaaacuuggaa,2OMe,NA,0.01,uM,Skip,Good skipping to 10 nM (8 + 9) but  also 8 on its own,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,8,NA,human,normal human muscle cells,Null,NA,uaucuggauaggugguaucaacaucuguaa/gccuuggcaacauuuccacuuccug,2OMe,NA,0.01,uM,Skip,Good skipping to 10 nM (8 + 9) but  also 8 on its own,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,9,NA,human,normal human muscle cells,Null,NA,agcagccuguguguaggcauagcucuugaau,2OMe,NA,0.1,uM,Skip,working strongly  to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,9,NA,human,normal human muscle cells,Null,NA,agaccugugaaggaaaugggcuccguguag,2OMe,NA,0.2,uM,Skip,working strongly  to 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,10,NA,human,normal human muscle cells,Null,NA,caggagcuuccaaaugcugcacaau,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,10,NA,human,normal human muscle cells,Null,NA,ugacuugucuucaggagcuu,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,10,NA,human,normal human muscle cells,Null,NA,caaugaacugccaaaugacuug,2OMe,NA,0.1,uM,Skip,Skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,10,NA,human,normal human muscle cells,Null,NA,acucuccaucaaugaacugccaaau,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,10,NA,human,normal human muscle cells,Null,NA,cuguuugauaacgguccagguuuac,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,10,NA,human,normal human muscle cells,Null,NA,gccacgauaauacuucuucuaaag,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,10,NA,human,normal human muscle cells,Null,NA,uuaguuuaccucaugaguaugaaac,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,10,NA,human,normal human muscle cells,Null,NA,caggagcuuccaaaugcugca/uccucagcagaaagaagccacg,2OMe,NA,0.2,uM,Skip,Strong skipping at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,10,NA,human,normal human muscle cells,Null,NA,caggagcuuccaaaugcugca/uuagaaaucucuccuugugc,2OMe,NA,0.2,uM,Skip,Skipping  at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,11,NA,human,normal human muscle cells,Null,NA,ccaucauguaccccugacaa,2OMe,NA,0.3,uM,Skip,Skipping at 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,11,NA,human,normal human muscle cells,Null,NA,cccugaggcauucccaucuugaau,2OMe,NA,0.1,uM,Skip,Skipping  at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,11,NA,human,normal human muscle cells,Null,NA,auuaccaacccggcccugaugggcug,2OMe,NA,0.025,uM,Skip,skipping  to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,11,NA,human,normal human muscle cells,Null,NA,uccaaucagcuuacuucccaauuguagaau,2OMe,NA,0.025,uM,Skip,Strong skipping to 25 nM  hint at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,11,NA,human,normal human muscle cells,Null,NA,uccaaucagcuuacuucccaauugua,2OMe,NA,0.01,uM,Skip,Strong skipping  to 10 nM  faint at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,11,NA,human,normal human muscle cells,Null,NA,cuguuccaaucagcuuacuucccaauugua,2OMe,NA,0.005,uM,Skip,Strong skipping  to 5 nM  faint at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,11,NA,human,normal human muscle cells,Null,NA,aguuucuucaucuucugauaauuuuc,2OMe,NA,0.025,uM,Skip,Faint skipping   to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,11,NA,human,normal human muscle cells,Null,NA,auuuaggagauucaucugcucuuguacuuc,2OMe,NA,0.025,uM,Skip,Strong skipping  to 25 nM (20%),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,11,NA,human,normal human muscle cells,Null,NA,auuuaggagauucaucugcucuugua,2OMe,NA,0.025,uM,Skip,Strong skipping  to 25 nM (20%),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,11,NA,human,normal human muscle cells,Null,NA,uugaauuuaggagauucaucugcucuugua,2OMe,NA,0.025,uM,Skip,Strong skipping  to 25 nM (20%),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,12,NA,human,normal human muscle cells,Null,NA,cauaagauacaccuaccuuaug,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,12,NA,human,normal human muscle cells,Null,NA,ucuucuguuuuuguuagccaguca,2OMe,NA,Null,Null,Skip,Strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,12,NA,human,normal human muscle cells,Null,NA,cagucauucaacucuuucaguuucugau,2OMe,NA,0.01,uM,Skip,Strong skipping to 10 nM faint at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,12,NA,human,normal human muscle cells,Null,NA,uuccuuguucuuucuucuguuuuuguua,2OMe,NA,0.025,uM,Skip,Strong skipping to 25 nM faint at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,12,NA,human,normal human muscle cells,Null,NA,agaucagguccaagaggcucuuccucca,2OMe,NA,0.025,uM,Skip,Strong skipping to 25 nM (30%),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,12,NA,human,normal human muscle cells,Null,NA,uguuguuguacuuggcguuuuaggucuu,2OMe,NA,0.025,uM,Skip,Strong skipping  to 25 nM (30%),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,13,NA,human,normal human muscle cells,Null,NA,uucuugaagcaccugaaagauaaa,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,14,NA,human,normal human muscle cells,Null,NA,gaaggaugucuuguaaaagaacccagcgg,2OMe,NA,0.025,uM,Skip,Skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,16,NA,human,normal human muscle cells,Null,NA,cuagauccgcuuuuaaaaccuguuaa,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,16,NA,human,normal human muscle cells,Null,NA,gcuuuuucuuuucuagauccgcu,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,16,NA,human,normal human muscle cells,Null,NA,cacuaaccugugcuguacucuuuuc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,17,NA,human,normal human muscle cells,Null,NA,uguggucaccguaguuacuguuuccauucaa,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,17,NA,human,normal human muscle cells,Null,NA,guucccuuguggucaccguaguuacuguuuc,2OMe,NA,0.1,uM,Skip,Skipping   to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,18,NA,human,normal human muscle cells,Null,NA,caacauccuuccuaagacug,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,18,NA,human,normal human muscle cells,Null,NA,gcgaguaauccagcugugaa,2OMe,NA,Null,Null,Skip,Inconsistent  skipping of both exon  17 + 18,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,18,NA,human,normal human muscle cells,Null,NA,uucaggacucugcaacagagcuucugagcg,2OMe,NA,0.3,uM,Skip,Skipping exons 17 + 18 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,18,NA,human,normal human muscle cells,Null,NA,uugucugugaaguugccuuccuuccg,2OMe,NA,0.3,uM,Skip,Skipping exons  17 + 18 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,18,NA,human,normal human muscle cells,Null,NA,uuaaugcauaaccuacauug,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,19,NA,human,normal human muscle cells,Null,NA,ggcaucuugcaguuuucugaacuucucagc,2OMe,NA,0.025,uM,Skip,skipping  to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,19,NA,human,normal human muscle cells,Null,NA,ucugcuggcaucuugcaguuuucugaac,2OMe,NA,0.025,uM,Skip,skipping  to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,19,NA,human,normal human muscle cells,Null,NA,ucaacucguguaauuaccgu,2OMe,NA,Null,Null,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,20,NA,human,normal human muscle cells,Null,NA,guucaguuguucugaggcuuguuug,2OMe,NA,Null,Null,Skip,faint shadow  at 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,20,NA,human,normal human muscle cells,Null,NA,aguaguugucaucugcuccaauugu,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,23,NA,human,normal human muscle cells,Null,NA,cggcuaauuucagagggcgcuuucuuugac,2OMe,NA,0.025,uM,Skip,skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,24,NA,human,normal human muscle cells,Null,NA,caagggcaggccauuccuccuuc,2OMe,NA,0.025,uM,Skip,Strong skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,25,NA,human,normal human muscle cells,Null,NA,ugggcugaauugucugaauaucac,2OMe,NA,0.025,uM,Skip,strong at 25 nM   but did not reduce the full length product,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,25,NA,human,normal human muscle cells,Null,NA,gagauugucuauaccuguug,2OMe,NA,0.025,uM,Skip,very strong at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,25,NA,human,normal human muscle cells,Null,NA,agacugggcugaauugucugaauaucacu,2OMe,NA,0.005,uM,Skip,Strong skipping at 5 nM  faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,25,NA,human,normal human muscle cells,Null,NA,uugaguucuguucucaagucucgaag,2OMe,NA,0.025,uM,Skip,Strong skipping at 25 nM  faint 5 nM patient specific),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,25,NA,human,normal human muscle cells,Null,NA,gagauugucuauaccuguuggcacaug,2OMe,NA,0.01,uM,Skip,Strong skipping at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,ggcauagaccuuccacaaaacaaac,2OMe,NA,0.6,uM,Skip,Faint skipping  600 nM & 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,aaggccuccuuucuggcauagaccuuccac,2OMe,NA,0.3,uM,Skip,"Faint at 600,  300 nM, multiple   exons 26-29 or  27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,aaggccuccuuucuggcauagaccuuccac,2OMe,NA,0.6,uM,Skip,"Faint at 600,  300 nM, multiple   exons 26-29 or  27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,cuucaaggccuccuuucuggcauagaccuu,2OMe,NA,0.3,uM,Skip,"Faint at 600,  300 nM , multiple  exons 26-29 or  27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,cuucaaggccuccuuucuggcauagaccuu,2OMe,NA,0.6,uM,Skip,"Faint at 600,  300 nM , multiple  exons 26-29 or  27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,aaccucccuucaaggccuccuuucuggcau,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,cuuacaguuuucuccaaaccucccuuc,2OMe,NA,0.3,uM,Skip,"Faint at 600,  300 nM , multiple  exons 26-29 or  27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,cuuacaguuuucuccaaaccucccuuc,2OMe,NA,0.6,uM,Skip,"Faint at 600,  300 nM , multiple  exons 26-29 or  27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,uuucuuuuuuuuuuuuuaccuucau,2OMe,NA,0.6,uM,Skip,"Faint at 600, multiple exons 26-29 or 27-30",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,uuaccuucaucucuucaacugcuuu,2OMe,NA,Null,Null,Skip,multiple exons 26-29 or 27-30,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,uuuuuuuuaccuucaucucu,2OMe,NA,Null,Null,Skip,Not skipping 26  other bands,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,26,NA,human,normal human muscle cells,Null,NA,ccuccuuucuggcauagaccuuccac/cuuacaguuuucuccaaaccucccuuc/ugugucauccauucgugcaucucug,2OMe,NA,0.025,uM,Skip,strong skipping down to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,31,NA,human,normal human muscle cells,Null,NA,uucugaaauuucauauaccugugcaacauc,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,31,NA,human,normal human muscle cells,Null,NA,uaguuucugaaauaacauauaccugugcaa,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,31,NA,human,normal human muscle cells,Null,NA,cuuaguuucugaaauaacauauaccugugc,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,31,NA,human,normal human muscle cells,Null,NA,uaguuucugaaauaacauauaccu,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,31,NA,human,normal human muscle cells,Null,NA,ccuuaguuucugaaauaacauauacc,2OMe,NA,0.3,uM,Skip,strong skipping  at 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,32,NA,human,normal human muscle cells,Null,NA,acuuucuuguagacgcugcucaaaauuggc,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,34,NA,human,normal human muscle cells,Null,NA,uuucgcaucuuacgggacaauuuc,2OMe,NA,0.2,uM,Skip,skipping to 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,34,NA,human,normal human muscle cells,Null,NA,cauucauuuccuuucgcaucuuacgggaca,2OMe,NA,0.2,uM,Skip,skipping to 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,34,NA,human,normal human muscle cells,Null,NA,gacauucauuuccuuucgcaucuuacggga,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,34,NA,human,normal human muscle cells,Null,NA,ucugucaagacauucauuuccuuucgcauc,2OMe,NA,0.2,uM,Skip,skipping to 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,34,NA,human,normal human muscle cells,Null,NA,ugaucucuuugucaauuccauaucuguagc,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,34,NA,human,normal human muscle cells,Null,NA,cugaucucuuugucaauuccauaucugugg,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,34,NA,human,normal human muscle cells,Null,NA,ugaucucuuugucaauuccauaucug,2OMe,NA,0.025,uM,Skip,Faint to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,34,NA,human,normal human muscle cells,Null,NA,cugcugaucucuuugucaauuccauaucug,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,35,NA,human,normal human muscle cells,Null,NA,ucuucaggugcaccuucuguuucucaaucu,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,35,NA,human,normal human muscle cells,Null,NA,ucugugauacucuucaggugcaccuucugu,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,cugguauuccuuaauuguacagaga,2OMe,NA,Null,uM,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,ccauguguuucugguauucc,2OMe,NA,0.3,uM,Skip,very faint skipping 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,cacauucuggucaaaaguuuccauguguuu,2OMe,NA,0.025,uM,Skip,Skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,ugugaugugguccacauucuggucaaaagu,2OMe,NA,0.1,uM,Skip,Skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,ugugaugugguccacauucugguca,2OMe,NA,0.1,uM,Skip,Skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,cacuuugugaugugguccacauucugguca,2OMe,NA,0.3,uM,Skip,Skipping at 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,ugauccacuuugugaugugguccacauucu,2OMe,NA,0.025,uM,Skip,Skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,aagugugucagccugaauga,2OMe,NA,Null,uM,Skip,very weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,ucucugauucauccaaaagugugucagccu,2OMe,NA,0.025,uM,Skip,"100% skipping at 600 nM, skipping to 25 nM",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,ucucugauucauccaaaagugugucagccu,2OMe,NA,0.6,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,gcugggguuucuuuuucucugauucaucca,2OMe,NA,0.025,uM,Skip,"100% skipping  at 600 nM, skipping to 25 nM",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,gcugggguuucuuuuucucugauucaucca,2OMe,NA,0.6,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,uauuugcuaccuuaagcacgucuuc,2OMe,NA,Null,Null,Skip,very weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,36,NA,human,normal human muscle cells,Null,NA,cugguauuccuuaauuguacagaga/ugugaugugguccacauucuggucaaaagu,2OMe,NA,0.025,uM,Skip,good skipping down  to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,38,NA,human,normal human muscle cells,Null,NA,cuaaaaaaaaagauagugcua,2OMe,NA,0.025,uM,Skip,skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,38,NA,human,normal human muscle cells,Null,NA,aaaggaauggaggccuaaaaaaaaag,2OMe,NA,0.025,uM,Skip,skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,38,NA,human,normal human muscle cells,Null,NA,aaccaauuuaccauaucuuuauuga,2OMe,NA,0.025,uM,Skip,skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,39,NA,human,normal human muscle cells,Null,NA,acaguaccaucauugucuucauucugauc,2OMe,NA,0.6,uM,Skip,skipping to 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,39,NA,human,normal human muscle cells,Null,NA,acaguacccucauugucuucauucugauc,2OMe,NA,0.6,uM,Skip,skipping to 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,39,NA,human,normal human muscle cells,Null,NA,cucucgcuuucucucaucugugauucuuug,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,39,NA,human,normal human muscle cells,Null,NA,uccucucgcuuucucucaucugugauucuu,2OMe,NA,0.1,uM,Skip,skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,39,NA,human,normal human muscle cells,Null,NA,uauguuuugucuguaacagcugcug,2OMe,NA,0.6,uM,Skip,skipping to 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,41,NA,human,normal human muscle cells,Null,NA,auuuccuauugagcaaaacc,2OMe,NA,0.2,uM,Skip,Skipping down to 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,41,NA,human,normal human muscle cells,Null,NA,cauugcggccccauccucagacaag,2OMe,NA,0.1,uM,Skip,Skipping down to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,41,NA,human,normal human muscle cells,Null,NA,gcugagcuggaucugaguuggcuccacug,2OMe,NA,0.01,uM,Skip,Skipping down to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,41,NA,human,normal human muscle cells,Null,NA,guugagucuucgaaacugagcaaauuugc,2OMe,NA,Null,Null,Skip,No visible skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,41,NA,human,normal human muscle cells,Null,NA,ccaguaacaacucacaauuu,2OMe,NA,0.2,uM,Skip,Skipping down to 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,42,NA,human,normal human muscle cells,Null,NA,accuucagagacuccucuugc,2OMe,NA,Null,Null,Skip,strong skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,uccuguagcuucacccuuuccacaggcg,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,gagagcuuccuguagcuucacccuuu,2OMe,NA,0.01,uM,Skip,Skipping  at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,aaucagcugggagagagcuuccuguagcu,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,uguguuaccuacccuugucg,2OMe,NA,0.2,uM,Skip,Skipping down to 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,uagacuaucuuuuauauucuguaauau,2OMe,NA,0.025,uM,Skip,Faint skipping  to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,gagagcuuccuguagcuucacccuuucca,2OMe,NA,0.025,uM,Skip,Strong skipping at 25 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,uuccuguagcuucacccuuuccacaggcguu,2OMe,NA,0.05,uM,Skip,Strong skipping at 50 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,agcuuccuguagcuucacccuuu,2OMe,NA,0.0025,uM,Skip,Faint skipping to 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,ggagagagcuuccuguagcuucacccuuu,2OMe,NA,0.025,uM,Skip,Strong skipping at 10 nM faint 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,ggagagagcuuccuguagcuucacccuuu,2OMe,NA,0.01,uM,Skip,Strong skipping at 10 nM faint 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,gagagcuuccuguagcuucaccc,2OMe,NA,0.025,uM,Skip,Strong skipping at 25 nM faint 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,43,NA,human,normal human muscle cells,Null,NA,gagagcuuccuguagcuucaccc,2OMe,NA,0.01,uM,Skip,Strong skipping at 25 nM faint 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,uucucaacagaucugucaaaucgccugcag,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,gccacugauuaaauaucuuuauauc,2OMe,NA,0.1,uM,Skip,Skipping   at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,ucuguuagccacugauuaaauaucuuuaua,2OMe,NA,0.05,uM,Skip,Skipping  at 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,uguucagcuucuguuagccacuga,2OMe,NA,0.1,uM,Skip,Skipping  at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,gagaaacuguucagcuucuguuagccacuga,2OMe,NA,0.025,uM,Skip,Skipping  at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,uguucagcuucuguuagccacuga,2OMe,NA,0.01,uM,Skip,Skipping  at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,ucuuucugagaaacuguucagcuucuguuag,2OMe,NA,0.05,uM,Skip,weak at 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,cagaucugucaaaucgccugcaggua,2OMe,NA,0.01,uM,Skip,Faint skipping  to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,caacagaucugucaaaucgccugcag,2OMe,NA,0.0025,uM,Skip,Faint skipping  to 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,aaacuguucagcuucuguuagccacugauuaaa,2OMe,NA,0.0025,uM,Skip,Strong skipping  at 5 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,aaacuguucagcuucuguuagccacugauuaaa,2OMe,NA,0.005,uM,Skip,Strong skipping  at 5 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,cuguucagcuucuguuagccacugauu,2OMe,NA,0.05,uM,Skip,Strong skipping  at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,gaaacuguucagcuucuguuagccacugauu,2OMe,NA,0.01,uM,Skip,Faint skipping  to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,aaacuguucagcuucuguuagccacuga,2OMe,NA,0.025,uM,Skip,Faint skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,ugagaaacuguucagcuucuguuagcca,2OMe,NA,0.025,uM,Skip,Faint skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,uucugagaaacuguucagcuucuguuagccac,2OMe,NA,0.025,uM,Skip,Faint skipping  to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,uucugagaaacuguucagcuucuguu,2OMe,NA,0.05,uM,Skip,Faint skipping  to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcugcccaaugccauccuggaguuccuguaagauaccaa,2OMe,NA,Null,Null,Skip,Generates multiple bands,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,ccaaugccauccuggaguuccuguaagaua,2OMe,NA,0.001,uM,Skip,Skipping at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,uugccgcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.001,uM,Skip,Skipping at 10 nM (100% skipping at 25 nM),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.025,uM,Skip,Skipping at 10 nM (100% skipping at 25 nM),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,caaugccauccuggaguuccuguaaga,2OMe,NA,0.05,uM,Skip,Skipping  at 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcugcccaaugccauccuggaguuccuguaag,2OMe,NA,0.025,uM,Skip,Skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,caguuugccgcugcccaaugccaucc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,cuuccccaguugcauucaauguuc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,cuggcaucuguuuuugaggauug,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,uuagaucugucgcccuaccu,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcugcccaaugccauccuggaguuccuguaagauaccaa,2OMe,NA,Null,Null,Skip,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcccaaugccauccuggaguuccuguaagauacc,2OMe,NA,0.005,uM,Skip,Strong skipping  at 5 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcccaaugccauccuggaguuccuguaagauacc,2OMe,NA,0.0025,uM,Skip,Strong skipping  at 5 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,cauccuggaguuccuguaagauacc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,ugccauccuggaguuccuguaagauacc,2OMe,NA,0.005,uM,Skip,Strong skipping at 25 nM faint 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,ugccauccuggaguuccuguaagauacc,2OMe,NA,0.0025,uM,Skip,Strong skipping at 25 nM faint 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,ugccauccuggaguuccuguaagau,2OMe,NA,0.001,uM,Skip,skipping to 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,caaugccauccuggaguuccuguaagau,2OMe,NA,0.005,uM,Skip,Strong skipping at 25 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,caaugccauccuggaguuccuguaagau,2OMe,NA,0.0025,uM,Skip,Strong skipping at 25 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.0025,uM,Skip,Strong skipping at 10 nM faint 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.0025,uM,Skip,Strong skipping at 10 nM faint 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,uugccgcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.0025,uM,Skip,Strong skipping  at 5 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,uugccgcugcccaaugccauccuggaguuccuguaagau,2OMe,NA,0.005,uM,Skip,Strong skipping  at 5 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcugcccaaugccauccuggaguuccuguaag,2OMe,NA,0.0025,uM,Skip,Strong skipping at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcccaaugccauccuggaguuccuguaa,2OMe,NA,0.0025,uM,Skip,Strong skipping at 5 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcccaaugccauccuggaguuccuguaa,2OMe,NA,0.0025,uM,Skip,Strong skipping at 5 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,gcaauguuaucugcuuccuccaacc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gccgcugcccaaugacauccuggaguuccuguaa,2OMe,NA,0.0025,uM,Skip,Strong skipping  at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,caaugccauccuggaguuccug,2OMe,NA,0.0025,uM,Skip,Strong skipping at 5 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,caaugccauccuggaguuccug,2OMe,NA,0.0025,uM,Skip,Strong skipping at 5 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcccaaugccauccuggaguuccug,2OMe,NA,0.0025,uM,Skip,Strong skipping  at 10 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcccaaugccauccuggaguuccug,2OMe,NA,0.01,uM,Skip,Strong skipping  at 10 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcugcccaaugccauccuggaguuccug,2OMe,NA,0.0025,uM,Skip,Strong skipping  at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gccgcugcccaaugccauccuggaguuccug,2OMe,NA,0.0025,uM,Skip,Strong skipping  at 10 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gccgcugcccaaugccauccuggaguuccug,2OMe,NA,0.01,uM,Skip,Strong skipping  at 10 nM faint 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,auuagaucugucgcccuaccucuuuuuuc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,ugucgcccuaccucuuuuuucugucug,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,gcugcccaaugccauccuggaguuccuguaa,2OMe,NA,0.0025,uM,Skip,strong skipping  at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,caaugccauccuggaguuccuguaagauacc,2OMe,NA,0.025,uM,Skip,strong skipping  at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,auucuuuuguucuucuagccugga,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,ucucuuugaaauucugacaagauauuc,2OMe,NA,0.025,uM,Skip,"skipping to 25 nM, other bands",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,uuaaaucucuuugaaauucu,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,aaaacaaauucauuuaaaucucuuug,2OMe,NA,0.05,uM,Skip,very faint skipping to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,cugcuuccuccaaccauaaaac,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,uccagguucaagugggauacuagcaaugu,2OMe,NA,0.025,uM,Skip,strong skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,uucaagugggauacuagcaau,2OMe,NA,0.025,uM,Skip,skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,uccagguucaagugggauac,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,cugcucuuuuccagguucaagugggaua,2OMe,NA,0.025,uM,Skip,strong skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,guugcugcucuuuuccagguucaagugg,2OMe,NA,0.025,uM,Skip,strong skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,cuuuuaguugcugcucuuuuccagguuc,2OMe,NA,0.025,uM,Skip,strong skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,aagcuuuucuuuuaguugcugcuc,2OMe,NA,0.1,uM,Skip,skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,gcuuuucuuuuaguugcugc,2OMe,NA,0.1,uM,Skip,skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,gacuugcucaagcuuuucuuuuaguugcug,2OMe,NA,0.025,uM,Skip,strong skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,uucagaaaauaaaauuaccu,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,guugcugcucuuuuccagguucaaguggga,2OMe,NA,0.005,uM,Skip,strong,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,guugcugcucuuuuccagguucaaguggga,2OMe,NA,0.025,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,46,NA,human,normal human muscle cells,Null,NA,uaguugcugcucuuuuccagguucaagugg,2OMe,NA,0.025,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,44,NA,human,normal human muscle cells,Null,NA,agaaacuguucagcuucuguuagcca/ccaaugccauccuggaguuccuguaagaua,2OMe,NA,0.025,uM,Skip,Skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,ccaaugccauccuggaguuccuguaagaua/cugcucuuuuccagguucaggugggaua,2OMe,NA,0.025,uM,Skip,Skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,ccaaugccauccuggaguuccuguaagaua/caagcuuuucuuuuaguugcugcucuuuucc,2OMe,NA,0.025,uM,Skip,Skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,45,NA,human,normal human muscle cells,Null,NA,ccaaugccauccuggaguuccuguaagaua/agaaacuguucagcuucuguuagcca/cugcucuuuuccagguucaggugggaua,2OMe,NA,0.025,uM,Skip,Skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,47,NA,human,normal human muscle cells,Null,NA,gcaacucuuccaccaguaacugaaac,2OMe,NA,0.1,uM,Skip,Skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,47,NA,human,normal human muscle cells,Null,NA,uggcgcaggggcaacucuuccaccaguaa,2OMe,NA,0.025,uM,Skip,strong skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,47,NA,human,normal human muscle cells,Null,NA,gcacggguccuccaguuucauuuaauu,2OMe,NA,0.6,uM,Skip,Skipping at 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,47,NA,human,normal human muscle cells,Null,NA,gggcuuaugggagcacuuacaagca,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,47,NA,human,normal human muscle cells,Null,NA,cuugcucuucugggcuuaugggagcacuuac,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,47,NA,human,normal human muscle cells,Null,NA,cuugcucuucugggcuuaugggagcacu,2OMe,NA,0.2,uM,Skip,"Faint skipping at 200 nM, full length  product not reduced",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,47,NA,human,normal human muscle cells,Null,NA,aaugucuaaccuuuauccacuggagau,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,cucagguaaagcucuggaaaccugaaagga,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,cagguaaagcucuggaaaccugaaagg,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,uucucagguaaagcucuggaaaccugaaag,2OMe,NA,0.3,uM,Skip,"Skipping at 600, 300 nM",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,uucucagguaaagcucuggaaaccugaaag,2OMe,NA,0.6,uM,Skip,"Skipping at 600, 300 nM",NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,guuucucagguaaagcucuggaaaccugaa,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,cuuguuucucagguaaagcucuggaaac,2OMe,NA,0.05,uM,Skip,faint to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,uucuccuuguuucucagguaaagcucu,2OMe,NA,0.05,uM,Skip,faint to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,caagcugcccaaggucuuuuauuugagc,2OMe,NA,Null,Null,Skip,No skipping (sporadic),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,uuaacugcucuucaaggucuucaagc,2OMe,NA,1,uM,Skip,faint to 1000 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,gauaaccacagcagcagaugauuuaac,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,aguucccuaccugaacgucaaaugguc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,guucccuaccugaacgucaaauggu,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,48,NA,human,normal human muscle cells,Null,NA,cuuguuucucagguaaagcucuggaaac/caagcugcccaaggucuuuuauuugagc,2OMe,NA,0.025,uM,Skip,Strong skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,49,NA,human,normal human muscle cells,Null,NA,gaacugcuauuucaguuuccugggga,2OMe,NA,0.1,uM,Skip,Skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,49,NA,human,normal human muscle cells,Null,NA,aucucuuccacauccgguuguuuagc,2OMe,NA,0.025,uM,Skip,Skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,49,NA,human,normal human muscle cells,Null,NA,acaaaugcugcccuuuagacaaaauc,2OMe,NA,0.025,uM,Skip,Skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,49,NA,human,normal human muscle cells,Null,NA,uucauuaccuucacuggcugaguggc,2OMe,NA,0.1,uM,Skip,Skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,cucagaucuucuaacuuccucuuuaac,2OMe,NA,0.025,uM,Skip,Faint skipping 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,cucagagcucagaucuucuaacuuccucu,2OMe,NA,0.1,uM,Skip,faint skipping 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,cgccuuccacucagagcucagaucuuc,2OMe,NA,0.025,uM,Skip,skipping faintly to 25,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,ucagcucuugaaguaaacgguuuaccg,2OMe,NA,0.025,uM,Skip,strong skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,uuugcccucagcucuugaaguaaacgg,2OMe,NA,0.025,uM,Skip,reasonable skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,ggcugcuuugcccucagcucuugaagu,2OMe,NA,0.025,uM,Skip,strong skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,caggagcuaggucaggcugcuuugcc,2OMe,NA,Null,Null,Skip,strong skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,uccaauaguggucaguccaggagcu,2OMe,NA,Null,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,aaagagaaugggauccaguauacuuac,2OMe,NA,0.1,uM,Skip,faint skipping 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,aaauagcuagagccaaagagaauggga,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,ggcugcuuugcccucagcucuugaaguaaacgg,2OMe,NA,0.005,uM,Skip,Strong skipping to 10 nM faint at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,ggcugcuuugcccucagcucuugaaguaaacgg,2OMe,NA,0.01,uM,Skip,Strong skipping to 10 nM faint at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,aggcugcuuugcccucagcucuugaaguaa,2OMe,NA,0.005,uM,Skip,Strong skipping to 25 nM faint  at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,aggcugcuuugcccucagcucuugaaguaa,2OMe,NA,0.01,uM,Skip,Strong skipping to 25 nM faint  at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,gucaggcugcuuugcccucagcucuugaagu,2OMe,NA,0.005,uM,Skip,Strong skipping to 10 nM faint  at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,gucaggcugcuuugcccucagcucuugaagu,2OMe,NA,0.01,uM,Skip,Strong skipping to 10 nM faint  at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,aggucaggcugcuuugcccucagcucuuga,2OMe,NA,0.0025,uM,Skip,Strong skipping to 25 nM faint at   2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,50,NA,human,normal human muscle cells,Null,NA,aggucaggcugcuuugcccucagcucuuga,2OMe,NA,0.025,uM,Skip,Strong skipping to 25 nM faint at   2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,49,NA,human,normal human muscle cells,Null,NA,aagauaauucaugaacaucuuaaucca,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,uuuggguuuuugcaaaaagg,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,cuaaaauauuuuggguuuuugc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,ugaguaggagcuaaaauauuuugg,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,guuuccuuaguaaccacagguuguguc,2OMe,NA,0.025,uM,Skip,very faint skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,aguuuggagauggcaguuuccuuaguaa,2OMe,NA,0.025,uM,Skip,skipping to 25nM also skips 50 or 52 a well,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,uggcauuucuag,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,agauggcauuucuag,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,ggaagauggcauuucuag,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,cuccaacaucaaggaaga,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,cuccaacaucaagga,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,cuccaacaucaa,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,gaaaucugccagagcagguaccuccaa,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,gauggcauuucuaguuuggagauggca,2OMe,NA,0.025,uM,Skip,Strong skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,aaggaagauggcauuucuaguuuggagau,2OMe,NA,0.0025,uM,Skip,Strong skipping to 25 nM faint at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,aaggaagauggcauuucuaguuuggagau,2OMe,NA,0.025,uM,Skip,Strong skipping to 25 nM faint at 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,gguaccuccaacaucaaggaagauggcauu,2OMe,NA,0.005,uM,Skip,Strong skipping to 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,agcagguaccuccaacaucaaggaagaug,2OMe,NA,0.025,uM,Skip,Strong skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,ccugcauuguugccuguaagaacaa,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,gcauuguugccuguaagaac,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,gggacgccucuguuccaaauccugcau,2OMe,NA,0.005,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,guucuuccaacuggggacgccucuguucca,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,acuggggacgccucuguucca,2OMe,NA,0.025,uM,Skip,skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,ccucuugauugcuggucuuguuuuucaa,2OMe,NA,0.025,uM,Skip,vey very faint skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,51,NA,human,normal human muscle cells,Null,NA,uaccccuuaguaucaggguucuucagc,2OMe,NA,Null,Null,Skip,No skipping (SNP C or T),NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,aacuggggacgccucuguuccaaauccugc,2OMe,NA,0.0025,uM,Skip,Strong skipping to 2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,uccaacuggggacgccucuguuccaaauccugc,2OMe,NA,0.005,uM,Skip,Strong skipping to 5 nM faint  at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,ucuuccaacuggggacgccucuguuccaaa,2OMe,NA,0.005,uM,Skip,Strong skipping to 10 nM faint  at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,ucuuccaacuggggacgccucuguuccaaa,2OMe,NA,0.01,uM,Skip,Strong skipping to 10 nM faint  at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,auaguaguaaaugcuagucuggag,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,gaaaaauaaauauauaguaguaaaug,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,auaaaaggaaaaauaaauauauaguag,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,ucugaauucuuucaacuagaauaaaaggaa,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,caacuguugccuccgguucugaaggug,2OMe,NA,0.05,uM,Skip,skippping 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uucaacuguugccuccgguucugaaggug,2OMe,NA,0.1,uM,Skip,skippping 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,39,NA,human,normal human muscle cells,Null,NA,cguucaacuguugccuccgguucugaaggug,2OMe,NA,0.025,uM,Skip,skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,ucauucaacuguugccuccgguucugaaggu,2OMe,NA,0.05,uM,Skip,skippping 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,cauucaacuguugccuccgguucugaagg,2OMe,NA,0.05,uM,Skip,skippping 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,cauucaacuguugccuccgguucugaa,2OMe,NA,0.05,uM,Skip,skippping 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,cagccauuguguugaauccuuuaacauuuc,2OMe,NA,0.05,uM,Skip,Skipping at 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,52,NA,human,normal human muscle cells,Null,NA,uauauaguaguaaaugcuagucugg,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,ccuccgguucugaagguguucuuguacuuc,2OMe,NA,0.005,uM,Skip,strong skipping to 25 nM faint at  5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,ccuccgguucugaagguguucuuguacuuc,2OMe,NA,0.025,uM,Skip,strong skipping to 25 nM faint at  5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uugccuccgguucugaagguguucuuguacuuc,2OMe,NA,0.005,uM,Skip,strong skipping to 10 nM faint at  5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uugccuccgguucugaagguguucuuguacuuc,2OMe,NA,0.01,uM,Skip,strong skipping to 10 nM faint at  5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uugccuccgguucugaagguguucuuguac,2OMe,NA,Null,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,aacuguugccuccgguucugaagguguucuuguac,2OMe,NA,0.01,uM,Skip,strong skipping to 25 nM faint at   10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,aacuguugccuccgguucugaagguguucuuguac,2OMe,NA,0.025,uM,Skip,strong skipping to 25 nM faint at   10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,cauucaacuguugccuccgguucugaagguguucuuguac,2OMe,NA,0.005,uM,Skip,strong skipping to 25 nM faint at   5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,cauucaacuguugccuccgguucugaagguguucuuguac,2OMe,NA,0.025,uM,Skip,strong skipping to 25 nM faint at   5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,acuguugccuccgguucugaagguguucuug,2OMe,NA,0.005,uM,Skip,strong skipping to 25 nM faint at   5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,acuguugccuccgguucugaagguguucuug,2OMe,NA,0.025,uM,Skip,strong skipping to 25 nM faint at   5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uucaacuguugccuccgguucugaagguguucuug,2OMe,NA,0.005,uM,Skip,strong skipping to 50 nM faint at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uucaacuguugccuccgguucugaagguguucuug,2OMe,NA,0.05,uM,Skip,strong skipping to 50 nM faint at 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,caacuguugccuccgguucugaagguguucuug,2OMe,NA,0.0025,uM,Skip,strong skipping to 25 nM faint at   2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,caacuguugccuccgguucugaagguguucuug,2OMe,NA,0.025,uM,Skip,strong skipping to 25 nM faint at   2.5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uucaacuguugccuccgguucugaagguguucu,2OMe,NA,0.025,uM,Skip,strong skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uucaacuguugccuccgguucugaagguguu,2OMe,NA,0.025,uM,Skip,strong skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,ucauucaacuguugccuccgguucugaagguguuc,2OMe,NA,0.005,uM,Skip,reasonable sipping to 5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uucauucaacuguugccuccgguucugaaggug,2OMe,NA,0.025,uM,Skip,strong skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uucauucaacuguugccuccgguucugaag,2OMe,NA,0.005,uM,Skip,strong skipping to 100 nM faint at   5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,53,NA,human,normal human muscle cells,Null,NA,uucauucaacuguugccuccgguucugaag,2OMe,NA,0.1,uM,Skip,strong skipping to 100 nM faint at   5 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,54,NA,human,normal human muscle cells,Null,NA,uugucugccacuggcggagguc,2OMe,NA,0.3,uM,Skip,Skipping at 300 nM brings out 55 + 54,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,54,NA,human,normal human muscle cells,Null,NA,aucugcagaauaaucccggagaaguuucag,2OMe,NA,0.025,uM,Skip,Skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,54,NA,human,normal human muscle cells,Null,NA,ucugcagaauaaucccggagaag,2OMe,NA,0.04,uM,Skip,Weak skipping to 40nM - both 54 + 55,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,54,NA,human,normal human muscle cells,Null,NA,uggucucaucugcagaauaaucccggagaag,2OMe,NA,0.01,uM,Skip,Skipping at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,54,NA,human,normal human muscle cells,Null,NA,ggacuuuucugguaucaucugcagaauaau,2OMe,NA,0.05,uM,Skip,Skipping 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,54,NA,human,normal human muscle cells,Null,NA,uggucucaucugcagaauaaucccggagaag/cucgcucacucacccugcaaagga,2OMe,NA,0.01,uM,Skip,Specific for 54 & 55 Skipping at 10nM No additional bands,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,cucgcucacucacccugcaaagga,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,cagccucucgcucacucacccugcaaagga,2OMe,NA,0.01,uM,Skip,Skipping at 10nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,cagggggaacuguugcaguaauc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,ucuuuuacucccuuggagucuucuaggagcc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,ucuguaagccaggcaagaaac,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,ccuuacggguagcauccugauggacauuggc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,cuuacggguagcauccuguaggaca,2OMe,NA,0.1,uM,Skip,very weak skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,ccuuggagucuucuaggagccuuuccuuac,2OMe,NA,0.2,uM,Skip,Skipping at 200nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,cuuggagucuucuaggagcc,2OMe,NA,0.1,uM,Skip,Skipping at 100nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,cucuuuuacucccuuggagucuucuaggag,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,55,NA,human,normal human muscle cells,Null,NA,ccugacuuacuugccauugu,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,gcuucaauuucaccuuggagguccuacag,2OMe,NA,0.025,uM,Skip,Skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,uucaccuuggagguccuacag,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,guugugauaaacauguguguga,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,ccagggaucucaggauuuuuuggcug,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,cggaaccuuccagggaucucaggau,2OMe,NA,0.2,uM,Skip,Skipping at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,ccaaacgucuuuguaacaggacugcau,2OMe,NA,0.025,uM,Skip,skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,guuauccaaacgucuuuguaacagg,2OMe,NA,0.1,uM,Skip,skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,uucauguuauccaaacgucuuuguaacagg,2OMe,NA,0.025,uM,Skip,skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,ccacuugaaguucauguuauccaaacgucu,2OMe,NA,0.025,uM,Skip,skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,ucacuccacuugaaguucauguuauccaaa,2OMe,NA,0.025,uM,Skip,skipping weakly at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,cuccacuugaaguucauguuauc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,56,NA,human,normal human muscle cells,Null,NA,cuuuuccuaccaaauguugag,2OMe,NA,0.6,uM,Skip,Skipping at 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,57,NA,human,normal human muscle cells,Null,NA,cuggcuuccaaaugggaccugaaaaagaacagc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,57,NA,human,normal human muscle cells,Null,NA,cuggcuuccaaaugggaccugaaaaagaac,2OMe,NA,0.05,uM,Skip,Skipping at 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,57,NA,human,normal human muscle cells,Null,NA,aacuggcuuccaaaugggaccugaaaaaga,2OMe,NA,0.3,uM,Skip,Skipping at 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,57,NA,human,normal human muscle cells,Null,NA,ucagaacuggcuuccaaaugggaccugaaa,2OMe,NA,0.3,uM,Skip,Skipping at 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,57,NA,human,normal human muscle cells,Null,NA,ggugcagacgcuuccacuggucag,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,57,NA,human,normal human muscle cells,Null,NA,gcuguagccacaccagaaguuccugcagaga,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,57,NA,human,normal human muscle cells,Null,NA,cugccggcuuaauucaucaucuuuc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,57,NA,human,normal human muscle cells,Null,NA,cugcuggaaagucgccuccaauaggug,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,uccucaggaggcagcucuaaau,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,uccucgccugcuuucguagaagccgaguga,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,agguucaauuuuucccacucaguauu,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,cuauuuuucucugccagucagcgga,2OMe,NA,0.1,uM,Skip,Skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,cucaucuauuuuucucugccagucagcgga,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,cagggucucaucuauuuuucucugccaguca,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,cauccguggccucuugaaguuccug,2OMe,NA,0.2,uM,Skip,Skipping exon 58 & 59 at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,agguccagcucauccguggccucuu,2OMe,NA,0.3,uM,Skip,Skipping at 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,gcgcagcuugagguccagcucaucc,2OMe,NA,0.2,uM,Skip,weak skipping at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,gcuuggcgcagcuugagguccagcucaucc,2OMe,NA,0.1,uM,Skip,Skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,caccucagcuuggcgcagcuugagguc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,cccuugaucaccucagcuuggcgca,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,acgggcugccaggaucccuug,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,gagagagucaaugaggagaucgccc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,59,NA,human,normal human muscle cells,Null,NA,cucaucuauuuuucucugccagucagcggagugc,2OMe,NA,Null,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,gcaauuucuccucgaagugccugugugcaa,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,caauuucuccucgaagugccugugugc,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,caaggucauugacguggcucacguucucuu,2OMe,NA,0.05,uM,Skip,skipping to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,cgagcaaggucauugacguggcucacguuc,2OMe,NA,0.05,uM,Skip,strong skipping to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,cuggcgagcaagguccuugacguggcucac,2OMe,NA,0.1,uM,Skip,good skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,cuggcgagcaaggucauugacguggcucac,2OMe,NA,Null,Null,Skip,SNP,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,cuggcgagcaagguccuugacguggcuc,2OMe,NA,0.1,uM,Skip,good skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,ugguaagcuggcgagcaagguccuugacgug,2OMe,NA,0.1,uM,Skip,weak skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,agugguaagcuggcgugcaagguca,2OMe,NA,0.1,uM,Skip,weak skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,uuauacggugagagcugaaugcccaaagug,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,gagguuauacggugagagcugaaugcccaaa,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,ugcugagguuauacggugagagcugaa,2OMe,NA,0.1,uM,Skip,good skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,uccagagugcugagguuauacggugagagc,2OMe,NA,0.1,uM,Skip,weak skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,cuuuccugcagaagcuuccaucugguguuc,2OMe,NA,0.6,uM,Skip,weak skipping at 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,caauuucuccucgaagugccugugugc/cuggcgagcaagguccuugacguggcucac,2OMe,NA,0.01,uM,Skip,weak skipping at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,uccagagugcugagguuauacggugagagc/cuggcgagcaagguccuugacguggcucac,2OMe,NA,0.01,uM,Skip,skipping at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,gcaauuucuccucgaagugccugugugcaaugguaagcuggcgagcaagguccuugacgug,2OMe,NA,0.01,uM,Skip,skipping at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,60,NA,human,normal human muscle cells,Null,NA,cuggcgagcaagguccuugacguggcuc/gcaauuucuccucgaagugccugugugcaa,2OMe,NA,0.01,uM,Skip,skipping at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,61,NA,human,normal human muscle cells,Null,NA,cucgguccucgacggccaccugggag,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,61,NA,human,normal human muscle cells,Null,NA,caugcagcugccugacucgguccucgccgg,2OMe,NA,0.05,uM,Skip,skipping to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,61,NA,human,normal human muscle cells,Null,NA,gggcuucaugcagcugccugacucgguccuc,2OMe,NA,0.1,uM,Skip,Skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,61,NA,human,normal human muscle cells,Null,NA,gggcuucaugcagcugccugacucg,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,61,NA,human,normal human muscle cells,Null,NA,ccugugggcuucaugcagcugccugacucg,2OMe,NA,0.05,uM,Skip,skipping to 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,61,NA,human,normal human muscle cells,Null,NA,gcugagaugcuggaccaaagucccug,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,61,NA,human,normal human muscle cells,Null,NA,gcugaaaaugacuuacuggaaagaaa,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,62,NA,human,normal human muscle cells,Null,NA,gacccuggacagacgcugaaaagaagggag,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,62,NA,human,normal human muscle cells,Null,NA,ccagggacccuggacagacgcugaaaagaa,2OMe,NA,Null,Null,Skip,Noskipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,62,NA,human,normal human muscle cells,Null,NA,gacccuggacagacgcugaa,2OMe,NA,0.025,uM,Skip,Faint to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,62,NA,human,normal human muscle cells,Null,NA,cucucccagggacccuggacagacgcug,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,62,NA,human,normal human muscle cells,Null,NA,uggcucucucccagggacccuggacagacg,2OMe,NA,0.3,uM,Skip,almost 100% skipping to 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,62,NA,human,normal human muscle cells,Null,NA,gagauggcucucucccagggacccugg,2OMe,NA,0.3,uM,Skip,Skipping at 300 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,62,NA,human,normal human muscle cells,Null,NA,uuguuuggugagauggcucucucccagggac,2OMe,NA,0.025,uM,Skip,Faint to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,62,NA,human,normal human muscle cells,Null,NA,uagggcacuuuguuuggcgagauggcucuc,2OMe,NA,0.1,uM,Skip,Skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,62,NA,human,normal human muscle cells,Null,NA,uacuugauauaguagggcac,2OMe,NA,0.1,uM,Skip,Faint to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,62,NA,human,normal human muscle cells,Null,NA,cuuacuugauauaguagggcacuuuguuug,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,63,NA,human,normal human muscle cells,Null,NA,gagucucguggcuaaaacacaaaac,2OMe,NA,Null,Null,Skip,No visible skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,63,NA,human,normal human muscle cells,Null,NA,ugggauggucccagcaaguuguuug,2OMe,NA,0.6,uM,Skip,Possible skipping  at 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,63,NA,human,normal human muscle cells,Null,NA,gagcucugucauuuugggauggucccagca,2OMe,NA,0.1,uM,Skip,Skipping to 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,63,NA,human,normal human muscle cells,Null,NA,gacugguagagcucugucauuuugg,2OMe,NA,Null,Null,Skip,No visible skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,63,NA,human,normal human muscle cells,Null,NA,cuaaagacugguagagcucuguc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,63,NA,human,normal human muscle cells,Null,NA,cauggccauguccuuaccuaaagac,2OMe,NA,Null,Null,Skip,No visible skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,64,NA,human,normal human muscle cells,Null,NA,cugagaaucugacauuauucaggucagcug,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,64,NA,human,normal human muscle cells,Null,NA,cugcagucuucggaguuucauggcagucc,2OMe,NA,0.05,uM,Skip,Skipping at 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,64,NA,human,normal human muscle cells,Null,NA,aaagggccuucugcagucuucggaguuuca,2OMe,NA,0.05,uM,Skip,Skipping at 50 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,64,NA,human,normal human muscle cells,Null,NA,gcaaagggccuucugcagucuucggag,2OMe,NA,0.2,uM,Skip,Skipping at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,64,NA,human,normal human muscle cells,Null,NA,caauacuuacagcaaagggccuucu,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,65,NA,human,normal human muscle cells,Null,NA,uugaccaaauuguugugcucuugcuc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,66,NA,human,normal human muscle cells,Null,NA,gauccucccuguucguccccuauuaug,2OMe,NA,0.1,uM,Skip,Skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,66,NA,human,normal human muscle cells,Null,NA,caggacacggauccucccuguucguccccu,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,66,NA,human,normal human muscle cells,Null,NA,uaauauacacgacuuacaucuguacuuguc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,66,NA,human,normal human muscle cells,Null,NA,caggacacggauccucccuguucguccccu/uaauauacacgacuuacaucuguacuuguc,2OMe,NA,0.025,uM,Skip,skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,67,NA,human,normal human muscle cells,Null,NA,gcgcuggucacaaaauccuguugaacuugc,2OMe,NA,0.025,uM,Skip,strong skipping at 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,67,NA,human,normal human muscle cells,Null,NA,agcuccggacacuuggcucaauguuacu,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,67,NA,human,normal human muscle cells,Null,NA,gcagcuccggacacuuggcucaaug,2OMe,NA,0.6,uM,Skip,Skipping at 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,67,NA,human,normal human muscle cells,Null,NA,uaacuuacaaauuggaagcagcuccggaca,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,68,NA,human,normal human muscle cells,Null,NA,gaucucuggcuuauuauuagccugc,2OMe,NA,0.1,uM,Skip,Skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,68,NA,human,normal human muscle cells,Null,NA,cauccagucuaggaagagggccgcuuc,2OMe,NA,0.2,uM,Skip,Skipping at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,68,NA,human,normal human muscle cells,Null,NA,caccauggacugggguuccagucuc,2OMe,NA,0.2,uM,Skip,Skipping at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,68,NA,human,normal human muscle cells,Null,NA,cagcagccacucugugcaggacgggcagcc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,68,NA,human,normal human muscle cells,Null,NA,uaccugaauccaaugauuggacacuc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,68,NA,human,normal human muscle cells,Null,NA,caccauggacugggguuccagucuc/uaccugaauccaaugauuggacacuc,2OMe,NA,0.01,uM,Skip,skipping at 10 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,69,NA,human,normal human muscle cells,Null,NA,gugcuuuagacuccuguaccugauaaagagc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,69,NA,human,normal human muscle cells,Null,NA,uggcagaugucauaauuaaagugcuuuagac,2OMe,NA,0.2,uM,Skip,Skipping 68-71 at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,69,NA,human,normal human muscle cells,Null,NA,ccagaaaaaaagcagcuuuggcagauguc,2OMe,NA,0.2,uM,Skip,Skipping 68-71 at 200 nM also 68 + 69 & 69 + 70,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,69,NA,human,normal human muscle cells,Null,NA,ggccuuuugcaacucgaccagaaa,2OMe,NA,Null,Null,Skip,Skipping 68-71,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,69,NA,human,normal human muscle cells,Null,NA,uuuuauggccuuuugcaacucgaccagaaa,2OMe,NA,0.2,uM,Skip,~90% Skipping of 68-71 at 200 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,69,NA,human,normal human muscle cells,Null,NA,cuggcgucaaacuuaccggagugc,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,70,NA,human,normal human muscle cells,Null,NA,uucuccugauguagucuaaaaggg,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,70,NA,human,normal human muscle cells,Null,NA,cgaacaucuucuccugauguagucuaaaag,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,70,NA,human,normal human muscle cells,Null,NA,guaccuuggcaaagucucgaacauc,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,70,NA,human,normal human muscle cells,Null,NA,guuuuuuaguaccuuggcaaaguc,2OMe,NA,Null,Null,Skip,No Skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,70,NA,human,normal human muscle cells,Null,NA,gguucgaaauuuguuuuuuaguaccuugg,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,70,NA,human,normal human muscle cells,Null,NA,gcccauucggggaugcuucgcaaaauaccu,2OMe,NA,Null,Null,Skip,No skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,71,NA,human,normal human muscle cells,Null,NA,gaucagaguaacgggacugcaaaa,2OMe,NA,Null,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,71,NA,human,normal human muscle cells,Null,NA,acuggccagaaguugaucagagua,2OMe,NA,0.1,uM,Skip,weak skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,71,NA,human,normal human muscle cells,Null,NA,gcagaaucuacuggccagaaguug,2OMe,NA,0.1,uM,Skip,skipping at 100 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,71,NA,human,normal human muscle cells,Null,NA,cucacgcagaaucuacuggccaga,2OMe,NA,Null,Null,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,72,NA,human,normal human muscle cells,Null,NA,aagcugaggggacgaggcaggccuauaagg,2OMe,NA,0.6,uM,Skip,faint skipping  at 600 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,72,NA,human,normal human muscle cells,Null,NA,gugugaaagcugaggggacgaggcagg,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,72,NA,human,normal human muscle cells,Null,NA,agucucauaccugcuagcauaaug,2OMe,NA,Null,Null,Skip,no skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,73,NA,human,normal human muscle cells,Null,NA,augcuaucauuuagauaagauccau,2OMe,NA,Null,Null,Skip,weak skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,73,NA,human,normal human muscle cells,Null,NA,uucugcuagccugauaaaaaacguaa,2OMe,NA,0.025,uM,Skip,Faint to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,73,NA,human,normal human muscle cells,Null,NA,cauugcuguuuuccauuucugguag,2OMe,NA,0.025,uM,Skip,Strong to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,73,NA,human,normal human muscle cells,Null,NA,acaugcucucauuaggagagaugcu,2OMe,NA,0.025,uM,Skip,Skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,73,NA,human,normal human muscle cells,Null,NA,uaucauuuagauaagauccauugcug,2OMe,NA,0.025,uM,Skip,Faint skipping to 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,74,NA,human,normal human muscle cells,Null,NA,guucaaacuuuggcaguaaugcuggau,2OMe,NA,0.025,uM,Skip,skipping 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,74,NA,human,normal human muscle cells,Null,NA,gacuacgaggcuggcucaggggggaguc,2OMe,NA,0.025,uM,Skip,100,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,74,NA,human,normal human muscle cells,Null,NA,ccuccccucuuuccucacucucuaagg,2OMe,NA,0.025,uM,Skip,skipping 25 nM,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,76,NA,human,normal human muscle cells,Null,NA,cauucacuuuggccucugccuggggcu,2OMe,NA,Null,Null,Skip,no detectable skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Antisense Molecules And Methods For Treating Pathologies,US/2012/270925,DMD,exon,76,NA,human,normal human muscle cells,Null,NA,gacugccaaccacucggagcagcauag,2OMe,NA,Null,Null,Skip,no detectable skipping,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270925,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,24,NA,human,human control myoblasts,polyethyleneimine,NA,gcuucccacaauucuugcca,2OMe,NA,0.5,uM,Null,92,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,30,NA,human,human control myoblasts,polyethyleneimine,NA,ccgucuucuccaguggcucc,2OMe,NA,0.5,uM,Null,96,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,30,NA,human,human control myoblasts,polyethyleneimine,NA,cggcggaaggcaucugucuug,2OMe,NA,0.5,uM,Null,no skip,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,18,NA,human,human control myoblasts,polyethyleneimine,NA,cauagagguugauguagcag,2OMe,NA,0.5,uM,Null,no skip,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,18,NA,human,human control myoblasts,polyethyleneimine,NA,ggucugggaagccugugaac,2OMe,NA,0.5,uM,Null,no skip,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,19,NA,human,human control myoblasts,polyethyleneimine,NA,gaagccggccacgauaagcc,2OMe,NA,0.5,uM,Null,no skip,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,19,NA,human,human control myoblasts,polyethyleneimine,NA,ccuucuguucacugugcucc,2OMe,NA,0.5,uM,Null,15,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,uggcaucauccacauccugc,2OMe,NA,0.5,uM,Null,no skip,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,ggucaugucgaacuuguucc,2OMe,NA,0.5,uM,Null,no skip,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,ggcaggucaugucgaacuug,2OMe,NA,0.5,uM,Null,10,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,21,NA,human,human control myoblasts,polyethyleneimine,NA,accaccacagguuucacg,2OMe,NA,0.5,uM,Null,no skip,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,21,NA,human,human control myoblasts,polyethyleneimine,NA,gcagcugguucugagucucg,2OMe,NA,0.5,uM,Null,53,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,24,NA,human,human control myoblasts,polyethyleneimine,NA,gcauccagaugacgauguccg,2OMe,NA,0.5,uM,Null,24,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,31,NA,human,human control myoblasts,polyethyleneimine,NA,uggaaucuucacucuuguca,2OMe,NA,0.5,uM,Null,no skip,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,31,NA,human,human control myoblasts,polyethyleneimine,NA,ucgugggucuguucacaccg,2OMe,NA,0.5,uM,Null,17,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,32,NA,human,human control myoblasts,polyethyleneimine,NA,gcagcguagaugguagcggu,2OMe,NA,0.5,uM,Null,no skip,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,32,NA,human,human control myoblasts,polyethyleneimine,NA,gcguagaugguagcggu,2OMe,NA,0.5,uM,Null,25,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,32,NA,human,human control myoblasts,polyethyleneimine,NA,gaguccuuguccaucgcagc,2OMe,NA,0.5,uM,Null,40,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,34,NA,human,human control myoblasts,polyethyleneimine,NA,cgacggcuggcugccccucguc,2OMe,NA,0.5,uM,Null,25,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,34,NA,human,human control myoblasts,polyethyleneimine,NA,uccguuccagacucgguucac,2OMe,NA,0.5,uM,Null,15,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,43,NA,human,human control myoblasts,polyethyleneimine,NA,ggccuccacauucuccagcu,2OMe,NA,0.5,uM,Null,no skip,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,43,NA,human,human control myoblasts,polyethyleneimine,NA,ugucuccuccugcgucuugc,2OMe,NA,0.5,uM,Null,15,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,43,NA,human,human control myoblasts,polyethyleneimine,NA,uggaucuucugucuccuccu,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,uacuugcgccuccuaagguac,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,uacuugcgccuccuaaggua,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,uugcgccuccuaagguacu,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,augguggcugaguagaagg,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,gauggcaucauccacauccu,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,augcugaccucaaacuggau,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,ucgaacuuguucccguaguu,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,ucgaacuuguucccguaguuc,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,20,NA,human,human control myoblasts,polyethyleneimine,NA,ucaugucgaacuuguucccgu,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,21,NA,human,human control myoblasts,polyethyleneimine,NA,gguagguaguaguaguggca,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,21,NA,human,human control myoblasts,polyethyleneimine,NA,acagguuucacguuacccca,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,21,NA,human,human control myoblasts,polyethyleneimine,NA,ugauguccucccaguagga,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,21,NA,human,human control myoblasts,polyethyleneimine,NA,gauucuauggcugauguccuc,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,21,NA,human,human control myoblasts,polyethyleneimine,NA,cucgauucuauggcugauguc,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,21,NA,human,human control myoblasts,polyethyleneimine,NA,cugguucugagucucgauuc,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,21,NA,human,human control myoblasts,polyethyleneimine,NA,agcaaucccaagcagcugguu,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,US/2012/270930,DMD,exon,21,NA,human,human control myoblasts,polyethyleneimine,NA,caccacagguuucacguuac,2OMe,NA,0.5,uM,Null,n.d.,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/270930,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,cagguuucguagaaguucacucgg,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,acagcacucguugaaggccc,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,acuuacggauccuucccaguu,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,ggaaaacucauacuuacgga,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,guacuuagcagcugaaaugguggca,2OMe,NA,unspecified,Null,Null,+-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,cucgggcuccgucauagcagcauuu,2OMe,NA,unspecified,Null,Null,+-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,cacagguuucguagaaguucacucg,2OMe,NA,unspecified,Null,Null,+-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,gguaacccgggccacucgcuccuca,2OMe,NA,unspecified,Null,Null,+-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,cucguugaaggcccugaugcagaga,2OMe,NA,unspecified,Null,Null,-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,ccuucccaguuggacagguuuaugg,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,aaacucauacuuacggauccuuccc,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,gcucgcugcucacagguuuca,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,acacaacauucagugaaagcuuu,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,caggcuccaucguaacaacau,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,unspecified,unspecified,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,C5,exon,17,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,unspecified,unspecified,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,cuccagccaguaaacaugguaa,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,aaaaccacaggcgaguucuac,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,augacuacagcaaaugacaa,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,ccaaagugagcucgguaaaag,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,gcacacuuccaauacuuacc,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,uacuuaccaagaauugu,2OMe,NA,unspecified,Null,Null,+-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,gguaugacuacagcaaaugacaaaa,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,guaccuuggugguaugacuacagca,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,aaaaccacaggcgaguucuacugug,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,caguaaacaugguaaaccacaauga,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,aagaggaccaucuccagccaguaaa,2OMe,NA,unspecified,Null,Null,+-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,caaagugagcucgguaaaagaggac,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,agcacacuuccaauacuuaccaaga,2OMe,NA,unspecified,Null,Null,+-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,uguuacuuaccuaaaaugguuuc,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,uuucaucuguuccaaaaugag,2OMe,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,uagccaguaaacaugguaaacaa,2OMe,NA,unspecified,Null,Null,+-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,agaaucaccacuagcaggacugu,2OMe,NA,unspecified,Null,Null,-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,ucuuggagcuggcacuggaau,2OMe,NA,unspecified,Null,Null,+-,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,unspecified,unspecified,NA,0.05,uM,Skip,85,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,unspecified,unspecified,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Human embryonic kidney cells (HEK 293),Lipofectamine 2000,NA,unspecified,unspecified,NA,unspecified,Null,Null,+,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Null,Null,NA,?uguuacuuaccuaaaaugguuuc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Null,Null,NA,?uuucaucuguuccaaaaugag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Null,Null,NA,?uagccaguaaacaugguaaacaa,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Null,Null,NA,?agaaucaccacuagcaggacugu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,9,NA,human,Null,Null,NA,?ucuuggagcuggcacuggaau,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,17,NA,human,Null,Null,NA,?gcucgcugcucacagguuuca,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,17,NA,human,Null,Null,NA,?acacaacauucagugaaagcuuu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
patent,Molecule For Treating An Inflammatory Disorder,US/2012/0259002,IL1RAP,exon,17,NA,human,Null,Null,NA,?caggcuccaucguaacaacau,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/0259002,NA,NA,NA
journal article,Targeting Nuclear Rna For In Vivo Correction Of Myotonic Dystrophy,PMID 22859208,DMPK,exon,CUG repeats,NA,mouse,HSA-LR Tibialis anterior or flexor digitorum brevis injection,No,NA,agcagcagcagcagcagcagcagca,unmodified PMO,NA,20,ug,Skip,~50,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/22859208,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,CN102459595A,DMD,exon,45,NA,human,DMD human primary myotubes,"2 ul UNIFectylin per ug AON (Prosensa Therapeutics BV, Netherlands)",NA,ucaauguucugacaacaguuugccg,2OMe,NA,200,nM,Skip,9,NA,NA,NA,RNA,invalid,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,CN102459595A,DMD,exon,45,NA,human,DMD human primary myotubes,"2 ul UNIFectylin per ug AON (Prosensa Therapeutics BV, Netherlands)",NA,caauguucugacaacaguuugccgc,2OMe,NA,200,nM,Skip,25,NA,NA,NA,RNA,invalid,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,CN102459595A,DMD,exon,45,NA,human,DMD human primary myotubes,"2 ul UNIFectylin per ug AON (Prosensa Therapeutics BV, Netherlands)",NA,aauguucugacaacaguuugccgcu,2OMe,NA,200,nM,Skip,4,NA,NA,NA,RNA,invalid,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,CN102459595A,DMD,exon,45,NA,human,DMD human primary myotubes,"2 ul UNIFectylin per ug AON (Prosensa Therapeutics BV, Netherlands)",NA,auguucugacaacaguuugccgcug,2OMe,NA,200,nM,Skip,16,NA,NA,NA,RNA,invalid,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,CN102459595A,DMD,exon,45,NA,human,DMD human primary myotubes,"2 ul UNIFectylin per ug AON (Prosensa Therapeutics BV, Netherlands)",NA,uguucugacaacaguuugccgcugc,2OMe,NA,200,nM,Skip,20,NA,NA,NA,RNA,invalid,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,CN102459595A,DMD,exon,45,NA,human,DMD human primary myotubes,"2 ul UNIFectylin per ug AON (Prosensa Therapeutics BV, Netherlands)",NA,guucugacaacaguuugccgcugcc,2OMe,NA,200,nM,Skip,16,NA,NA,NA,RNA,invalid,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,CN102459595A,DMD,exon,45,NA,human,DMD human primary myotubes,"2 ul UNIFectylin per ug AON (Prosensa Therapeutics BV, Netherlands)",NA,uucugacaacaguuugccgcugccc,2OMe,NA,200,nM,Skip,16,NA,NA,NA,RNA,invalid,NA,NA,NA
patent,Oligonucleotide Comprising An Inosine For Treating Dmd,CN102459595A,DMD,exon,45,NA,human,DMD human primary myotubes,"2 ul UNIFectylin per ug AON (Prosensa Therapeutics BV, Netherlands)",NA,ucugacaacaguuugccgcugccca,2OMe,NA,200,nM,Skip,12,NA,NA,NA,RNA,invalid,NA,NA,NA
patent,Exon Skipping Therapy For Dysferlinopathies,US 2012/208865 A1,DYSF,exon,32,NA,human,Human myoblasts and fibroblasts,Oligofectamine,NA,gggaaccgctaccatctacgc,2OMe,NA,10,ug/uL,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US2012/208865A1,NA,NA,NA
patent,Exon Skipping Therapy For Dysferlinopathies,US 2012/208865 A1,DYSF,exon,32,NA,human,Human myoblasts and fibroblasts,Oligofectamine,NA,ctacatgtaccaggcccgggac,2OMe,NA,10,ug/uL,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US2012/208865A1,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,2,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,uguuuucuuuugaacaucuucucuuu,2OMe,NA,unspecified,Null,Skip,64.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,2,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,uacccauuuugugaauguuuucuuuuga,2OMe,NA,unspecified,Null,Skip,64.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,43,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,gagcuuuguuguagacuaucuuuuauauu,2OMe,NA,unspecified,Null,Skip,25.4,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,43,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,cuuccuguagcuucacccuuuccac,2OMe,NA,unspecified,Null,Skip,6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,45,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,uuauuucuuccccaguugcauucaauguucu,2OMe,NA,unspecified,Null,Skip,28.8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,45,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,ccaauuuuuccuguagaaua,2OMe,NA,unspecified,Null,Skip,13,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,45,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,cuuuuuucugucugacagcuguu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,46,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,ugacaagauauucuuuuguucuucuagc,2OMe,NA,unspecified,Null,Skip,33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,46,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,ucuuuuccagguucaagugggauacu,2OMe,NA,unspecified,Null,Skip,25.2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,47,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,acggguccuccaguuucauuuaauuguuug,2OMe,NA,0.1,uM,Skip,32.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,47,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,uuaucuugcucuucugggcuuauggga,2OMe,NA,0.1,uM,Skip,14,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,47,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,uuauccacuggagauuugucu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,50,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,acucagagcucagaucuucuaac,2OMe,NA,0.1,uM,Skip,37.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,51,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,gguugugucaccagaguaacagucugagua,2OMe,NA,0.1,uM,Skip,100,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,51,NA,human,Primary myoblast cells from DMD patients,Lipofectamine2000,NA,gguugugucaccagaguaacagucugagua,2OMe,NA,0.1,uM,Skip,56.7,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,51,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,uuucuaguuuggagauggcaguuuccuuagu,2OMe,NA,0.1,uM,Skip,100,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,51,NA,human,Primary myoblast cells from DMD patients,Lipofectamine2000,NA,uuucuaguuuggagauggcaguuuccuuagu,2OMe,NA,0.1,uM,Skip,32.3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,51,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,ccucugugauuuuauaacuug,2OMe,NA,0.1,uM,Skip,30.8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,51,NA,human,Primary myoblast cells from DMD patients,Lipofectamine2000,NA,ccucugugauuuuauaacuug,2OMe,NA,0.1,uM,Skip,1.7,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,53,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,guguucuuguacuucaucccacuga,2OMe,NA,0.1,uM,Skip,34.9,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,53,NA,human,Primary myoblast cells from DMD patients,Lipofectamine2000,NA,cgguucugaagguguucuuguacuuca,2OMe,NA,0.1,uM,Skip,59,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,53,NA,human,Primary myoblast cells from DMD patients,Lipofectamine2000,NA,cuguugccuccgguucugaagguguucuugu,2OMe,NA,0.1,uM,Skip,55.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,53,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,ugguuucugugauuuucuuuuggauu,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,57,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,gucagaacuggcuuccaaaugg,2OMe,NA,0.1,uM,Skip,25.4,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,57,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,uaauucaucaucuuucagcugua,2OMe,NA,0.1,uM,Skip,5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
journal article,A Prospective Study In The Rational Design Of Efficient Antisense Oligonucleotides For Exon Skipping In The Dmd Gene,PMID 22486275,DMD,exon,57,NA,human,primary human fibroblast cells from normal individual,Lipofectamine2000,NA,uguacaucguucugcuucuga,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/22486275,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,muscle cells (myotubes) from a patient,ExGen500 (MBI Fermentas),NA,gccauuucucaacagaucu,2OMe,NA,0.15,uM,Skip,72,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,muscle cells (myotubes) from a patient,ExGen500 (MBI Fermentas),NA,ucagcuucuguuagccacug,2OMe,NA,0.15,uM,Skip,84,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,muscle cells (myotubes) from a patient,ExGen500 (MBI Fermentas),NA,ucuguuagccacugauuaaau,2OMe,NA,0.15,uM,Skip,36,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,muscle cells (myotubes) from a patient,ExGen500 (MBI Fermentas),NA,cccuuguacgauuuauguuu,2OMe,NA,0.15,uM,Skip,84,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,muscle cells (myotubes) from a patient,ExGen500 (MBI Fermentas),NA,auucucaggaauuugugucuuuc,2OMe,NA,0.15,uM,Skip,86,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,muscle cells (myotubes) from a patient,ExGen500 (MBI Fermentas),NA,ucucaggaauuugugucuuuc,2OMe,NA,0.15,uM,Skip,94,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,muscle cells (myotubes) from a patient,ExGen500 (MBI Fermentas),NA,gccauuucucaacagaucuguca,2OMe,NA,0.15,uM,Skip,87,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,muscle cells (myotubes) from a patient,ExGen500 (MBI Fermentas),NA,gccgccauuucucaacag,2OMe,NA,0.15,uM,Skip,91,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,muscle cells (myotubes) from a patient,ExGen500 (MBI Fermentas),NA,guauuuagcauguuccca,2OMe,NA,0.15,uM,Skip,68,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,muscle cells (myotubes) from a patient,ExGen500 (MBI Fermentas),NA,caggaauuugugucuuuc,2OMe,NA,0.15,uM,Skip,35,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,gccgccauuucucaacag,2OMe,NA,0.15,uM,Skip,77.29,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,patient cell cultures,ExGen500 (MBI Fermentas),NA,gccgccauuucucaacag,2OMe,NA,0.15,uM,Skip,91.19,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,gccgccauuucucaacag,2OMe,NA,0.4,uM,Skip,42.03,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,gccauuucucaacagaucu,2OMe,NA,0.15,uM,Skip,56.61,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,patient cell cultures,ExGen500 (MBI Fermentas),NA,gccauuucucaacagaucu,2OMe,NA,0.15,uM,Skip,72.54,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,gccauuucucaacagaucu,2OMe,NA,0.4,uM,Skip,20.68,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,gccauuucucaacagaucuguca,2OMe,NA,0.15,uM,Skip,73.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,patient cell cultures,ExGen500 (MBI Fermentas),NA,gccauuucucaacagaucuguca,2OMe,NA,0.15,uM,Skip,87.12,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,gccauuucucaacagaucuguca,2OMe,NA,0.4,uM,Skip,4.41,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,guauuuagcauguuccca,2OMe,NA,0.15,uM,Skip,30.51,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,patient cell cultures,ExGen500 (MBI Fermentas),NA,guauuuagcauguuccca,2OMe,NA,0.15,uM,Skip,67.8,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,guauuuagcauguuccca,2OMe,NA,0.4,uM,Skip,17.63,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,cccuuguacgauuuauguuu,2OMe,NA,0.15,uM,Skip,27.46,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,patient cell cultures,ExGen500 (MBI Fermentas),NA,cccuuguacgauuuauguuu,2OMe,NA,0.15,uM,Skip,84.07,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,cccuuguacgauuuauguuu,2OMe,NA,0.4,uM,Skip,14.92,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,ccauuuguauuuagcauguuccc,2OMe,NA,0.15,uM,Skip,28.14,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,ccauuuguauuuagcauguuccc,2OMe,NA,0.4,uM,Skip,48.14,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,caggaauuugugucuuuc,2OMe,NA,0.15,uM,Skip,2.03,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,patient cell cultures,ExGen500 (MBI Fermentas),NA,caggaauuugugucuuuc,2OMe,NA,0.15,uM,Skip,35.25,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,auucucaggaauuugugucuuuc,2OMe,NA,0.15,uM,Skip,35.25,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,patient cell cultures,ExGen500 (MBI Fermentas),NA,auucucaggaauuugugucuuuc,2OMe,NA,0.15,uM,Skip,85.76,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,auucucaggaauuugugucuuuc,2OMe,NA,0.4,uM,Skip,41.02,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,ucucaggaauuugugucuuuc,2OMe,NA,0.15,uM,Skip,65.42,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,patient cell cultures,ExGen500 (MBI Fermentas),NA,ucucaggaauuugugucuuuc,2OMe,NA,0.15,uM,Skip,93.9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,ucucaggaauuugugucuuuc,2OMe,NA,0.4,uM,Skip,45.08,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,ucagcuucuguuagccacug,2OMe,NA,0.15,uM,Skip,59.32,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,patient cell cultures,ExGen500 (MBI Fermentas),NA,ucagcuucuguuagccacug,2OMe,NA,0.15,uM,Skip,84.07,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,ucagcuucuguuagccacug,2OMe,NA,0.4,uM,Skip,59.66,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,ucuguuagccacugauuaaau,2OMe,NA,0.15,uM,Skip,10.85,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,patient cell cultures,ExGen500 (MBI Fermentas),NA,ucuguuagccacugauuaaau,2OMe,NA,0.15,uM,Skip,36.95,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control cells from a healthy individual,ExGen500 (MBI Fermentas),NA,ucuguuagccacugauuaaau,2OMe,NA,0.4,uM,Skip,14.92,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control muscle cells,ExGen500 (MBI Fermentas),NA,guauuuagcauguuccca,2OMe,NA,0.15,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control muscle cells,ExGen500 (MBI Fermentas),NA,guauuuagcauguuccca,2OMe,NA,0.4,uM,Skip,9,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control muscle cells,ExGen500 (MBI Fermentas),NA,agauaccauuuguauuuagc,2OMe,NA,0.15,uM,Skip,1,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control muscle cells,ExGen500 (MBI Fermentas),NA,agauaccauuuguauuuagc,2OMe,NA,0.4,uM,Skip,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control muscle cells,ExGen500 (MBI Fermentas),NA,guucagcuucuguuagcc,2OMe,NA,0.15,uM,Skip,44,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control muscle cells,ExGen500 (MBI Fermentas),NA,guucagcuucuguuagcc,2OMe,NA,0.4,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control muscle cells,ExGen500 (MBI Fermentas),NA,cugauuaaauaucuuuauauc,2OMe,NA,0.15,uM,Skip,14,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,control muscle cells,ExGen500 (MBI Fermentas),NA,cugauuaaauaucuuuauauc,2OMe,NA,0.4,uM,Skip,12,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,"healthy human control muscle cells,",ExGen500 (MBI Fermentas),NA,ucagcuucuguuagccacug,2OMe,NA,0.05,uM,Skip,12.28,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,"healthy human control muscle cells,",ExGen500 (MBI Fermentas),NA,ucagcuucuguuagccacug,2OMe,NA,0.2,uM,Skip,29.82,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,"healthy human control muscle cells,",ExGen500 (MBI Fermentas),NA,ucagcuucuguuagccacug,2OMe,NA,0.3,uM,Skip,36.14,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Method For Efficient Exon (44) Skipping In Duchenne Muscular Dystrophy And Associated Means,US/2012/059042,DMD,exon,44,NA,human,"healthy human control muscle cells,",ExGen500 (MBI Fermentas),NA,ucagcuucuguuagccacug,2OMe,NA,0.4,uM,Skip,45.96,NA,NA,NA,RNA,https://patents.google.com/patent/US/2012/059042,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,gcctgagctgatctgctggcatcttgcagt,Others (mixed (see Appendix)),NA,10,ug,Skip,88,NA,NA,NA,DNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,gccgctgcccaatgc,Others (mixed (see Appendix)),NA,10,ug,Skip,29,NA,NA,NA,DNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,cgctgcccaatgccatcc,Others (mixed (see Appendix)),NA,10,ug,Skip,3,NA,NA,NA,DNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,cagtttgccgctgccaa,Others (mixed (see Appendix)),NA,10,ug,Skip,4,NA,NA,NA,DNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,gcttttcttttagttgctgc,Others (mixed (see Appendix)),NA,10,ug,Skip,92,NA,NA,NA,DNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,cttttagttgctgctcttttcc,Others (mixed (see Appendix)),NA,10,ug,Skip,5,NA,NA,NA,DNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,tgttctgacaacagtttg,Others (mixed (see Appendix)),NA,10,ug,Skip,39,NA,NA,NA,DNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,gttucagcutctgttagc,Others (mixed (see Appendix)),NA,10,ug,Skip,53,NA,NA,NA,RNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,tgtaggacattggcagtt,Others (mixed (see Appendix)),NA,10,ug,Skip,55,NA,NA,NA,DNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,tccttacgggtagcaucc,Others (mixed (see Appendix)),NA,10,ug,Skip,97,NA,NA,NA,RNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,agctcututactcccttg,Others (mixed (see Appendix)),NA,10,ug,Skip,55,NA,NA,NA,RNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Ena Nucleic Acid Drugs Modifying Splicing In Mrna Precursor,EP2374885,DMD,exon,19,NA,human,Human DMD myoblasts,Lipofectamine,NA,ccautgutucaucagctc,Others (mixed (see Appendix)),NA,10,ug,Skip,91,NA,NA,NA,RNA,https://patents.google.com/patent/EP2374885,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuaguugcugcucuu,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gaaauucugacaagauauucu,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Induction Of Exon Skipping In Eukaryotic Cells,US/7973015,DMD,exon,46,NA,human,unspecified,Null,NA,ctgcttcctccaacc,unmodified PMO,NA,20,ug/muscle,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US/7973015,NA,NA,NA
patent,Induction Of Exon Skipping In Eukaryotic Cells,US/7973015,DMD,exon,46,NA,human,unspecified,Null,NA,gttatctgcttcctccaacc,unmodified PMO,NA,20,ug/muscle,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US/7973015,NA,NA,NA
patent,Induction Of Exon Skipping In Eukaryotic Cells,US/7973015,DMD,exon,46,NA,human,unspecified,Null,NA,gcttttcttttagttgctgc,unmodified PMO,NA,20,ug/muscle,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US/7973015,NA,NA,NA
patent,Induction Of Exon Skipping In Eukaryotic Cells,US/7973015,DMD,exon,46,NA,human,unspecified,Null,NA,ttagttgctgctctt,unmodified PMO,NA,20,ug/muscle,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US/7973015,NA,NA,NA
patent,Induction Of Exon Skipping In Eukaryotic Cells,US/7973015,DMD,exon,46,NA,human,unspecified,Null,NA,ctgcttcctccaacc,unmodified PMO,NA,20,ug/muscle,Skip,10,NA,NA,NA,DNA,https://patents.google.com/patent/US/7973015,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cugcuuccuccaacc,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,guuaucugcuuccuccaacc,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gcuuuucuuuuaguugcugc,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uaaaacaaauucauu,2OMe,NA,0.2,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uccagguucaagugggauac,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuccagguucaagug,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ucaagcuuuucuuuuag,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cugacaagauauucuu,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Means And Method For Inducing Exon-Skipping,WO/2007/135105,DMD,exon,46,NA,human,Control and DMD patient-derived myotube cultures (specifics not provided),"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,agguucaagugggauacua,2OMe,NA,0.2,uM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO/2007/135105,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,34,NA,human,Human myoblasts,polyethyleneimine,NA,cgacggcuggcugccccucguc,2OMe,NA,500,nM,Skip,40,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,34,NA,human,Human myoblasts,polyethyleneimine,NA,uccguuccagacucgguucac,2OMe,NA,500,nM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,43,NA,human,Human myoblasts,polyethyleneimine,NA,ggccuccacauucuccagcu,2OMe,NA,500,nM,Skip,15,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,43,NA,human,Human myoblasts,polyethyleneimine,NA,uggaucuucugucuccuccu,2OMe,NA,500,nM,Skip,15,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,19,NA,human,Human myoblasts,polyethyleneimine,NA,ggagcacagtgaacagaagg,2OMe,NA,500,nM,Skip,15,NA,NA,NA,DNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,20,NA,human,Human myoblasts,polyethyleneimine,NA,ggcaggucaugucgaacuug,2OMe,NA,500,nM,Skip,10,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,24,NA,human,Human myoblasts,polyethyleneimine,NA,gcauccagaugacgauguccg,2OMe,NA,500,nM,Skip,53,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,24,NA,human,Human myoblasts,polyethyleneimine,NA,gcuucccacaauucuugcca,2OMe,NA,500,nM,Skip,24,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,30,NA,human,Human myoblasts,polyethyleneimine,NA,ccgucuucuccaguggcucc,2OMe,NA,500,nM,Skip,92,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,30,NA,human,Human myoblasts,polyethyleneimine,NA,cggcggaaggcaucugucuug,2OMe,NA,500,nM,Skip,96,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,32,NA,human,Human myoblasts,polyethyleneimine,NA,gcagcguagaugguagcggu,2OMe,NA,500,nM,Skip,17,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Compositions For Dysferlin Exon-Skipping,WO 2011/053144 A2,DYSF,exon,32,NA,human,Human myoblasts,polyethyleneimine,NA,gaguccuuguccaucgcagc,2OMe,NA,500,nM,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/WO2011/053144A2,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0,uM,skip[%],0,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.05,uM,skip[%],0,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.2,uM,skip[%],3,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.4,uM,skip[%],75,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.5,uM,skip[%],63,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,Null,NA,auucaauguucugacaacaguuugc,2OMe,NA,0.25,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,Null,NA,auucaauguucugacaacaguuugc,2OMe,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,Null,NA,ccaguugcauucaauguucugacaa,2OMe,NA,0.25,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,Null,NA,ccaguugcauucaauguucugacaa,2OMe,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,Null,NA,caguugcauucaauguucugac,2OMe,NA,0.25,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,Null,NA,caguugcauucaauguucugac,2OMe,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,Null,NA,aguugcauucaauguucuga,2OMe,NA,0.25,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,Null,NA,aguugcauucaauguucuga,2OMe,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,Null,NA,gauugcugaauuauuucuucc,2OMe,NA,0.25,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,Null,NA,gauugcugaauuauuucuucc,2OMe,NA,0.5,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,gauugcugaauuauuucuuccccag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,auugcugaauuauuucuuccccagu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uugcugaauuauuucuuccccaguu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ugcugaauuauuucuuccccaguug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,gcugaauuauuucuuccccaguugc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,cugaauuauuucuuccccaguugca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ugaauuauuucuuccccaguugcau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,gaauuauuucuuccccaguugcauu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,aauuauuucuuccccaguugcauuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,auuauuucuuccccaguugcauuca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uuauuucuuccccaguugcauucaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uauuucuuccccaguugcauucaau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,auuucuuccccaguugcauucaaug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uuucuuccccaguugcauucaaugu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uucuuccccaguugcauucaauguu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ucuuccccaguugcauucaauguuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,cuuccccaguugcauucaauguucu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uuccccaguugcauucaauguucug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uccccaguugcauucaauguucuga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ccccaguugcauucaauguucugac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,cccaguugcauucaauguucugaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ccaguugcauucaauguucugacaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,caguugcauucaauguucugacaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,aguugcauucaauguucugacaaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uccuguagaauacuggcauc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ugcagaccuccugccaccgcagauuca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uugcagaccuccugccaccgcagauucag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,guugcauucaauguucugacaacag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uugcauucaauguucugacaacagu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ugcauucaauguucugacaacaguu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,gcauucaauguucugacaacaguuu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,cauucaauguucugacaacaguuug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,auucaauguucugacaacaguuugc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ucaauguucugacaacaguuugccg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,caauguucugacaacaguuugccgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,aauguucugacaacaguuugccgcu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,auguucugacaacaguuugccgcug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uguucugacaacaguuugccgcugc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,guucugacaacaguuugccgcugcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uucugacaacaguuugccgcugccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ucugacaacaguuugccgcugccca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,cugacaacaguuugccgcugcccaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ugacaacaguuugccgcugcccaau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,gacaacaguuugccgcugcccaaug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,acaacaguuugccgcugcccaaugc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,caacaguuugccgcugcccaaugcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,aacaguuugccgcugcccaaugcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,acaguuugccgcugcccaaugccau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,caguuugccgcugcccaaugccauc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,aguuugccgcugcccaaugccaucc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,guuugccgcugcccaaugccauccu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uuugccgcugcccaaugccauccug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uugccgcugcccaaugccauccugg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ugccgcugcccaaugccauccugga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,gccgcugcccaaugccauccuggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,ccgcugcccaaugccauccuggagu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,cgcugcccaaugccauccuggaguu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uguuuuugaggauugcugaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Null,Null,NA,uguucugacaacaguuugccgcugcccaaugccauccugg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,gcccaaugccauccugg,2OMe,NA,0.2,uM,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,45,NA,human,Healthy human control myotubes,"PEI (ExGen 500, MBI Fermentas), 2 ?l/?g AO",NA,gcccaaugccauccugg,2OMe,NA,0.5,uM,skip[%],3,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,agagcagguaccuccaacaucaagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,gagcagguaccuccaacaucaagga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,agcagguaccuccaacaucaaggaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,gcagguaccuccaacaucaaggaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,cagguaccuccaacaucaaggaaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,agguaccuccaacaucaaggaagau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,gguaccuccaacaucaaggaagaug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,guaccuccaacaucaaggaagaugg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,uaccuccaacaucaaggaagauggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,accuccaacaucaaggaagauggca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,ccuccaacaucaaggaagauggcau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,cuccaacaucaaggaagauggcauu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,cuccaacaucaaggaagauggcauuucuag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,uccaacaucaaggaagauggcauuu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,ccaacaucaaggaagauggcauuuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,caacaucaaggaagauggcauuucu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,aacaucaaggaagauggcauuucua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,acaucaaggaagauggcauuucuag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,acaucaaggaagauggcauuucuaguuugg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,acaucaaggaagauggcauuucuag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,caucaaggaagauggcauuucuagu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,aucaaggaagauggcauuucuaguu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,ucaaggaagauggcauuucuaguuu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,ucaaggaagauggcauuucu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,caaggaagauggcauuucuaguuug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,aaggaagauggcauuucuaguuugg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,aggaagauggcauuucuaguuugga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,ggaagauggcauuucuaguuuggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,gaagauggcauuucuaguuuggaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,aagauggcauuucuaguuuggagau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,agauggcauuucuaguuuggagaug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,gauggcauuucuaguuuggagaugg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,auggcauuucuaguuuggagauggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,uggcauuucuaguuuggagauggca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,ggcauuucuaguuuggagauggcag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,gcauuucuaguuuggagauggcagu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,cauuucuaguuuggagauggcaguu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,auuucuaguuuggagauggcaguuu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,uuucuaguuuggagauggcaguuuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,51,NA,human,Null,Null,NA,uucuaguuuggagauggcaguuucc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,ccauuguguugaauccuuuaacauu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,ccauuguguugaauccuuuaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,auuguguugaauccuuuaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,ccuguccuaagaccugcuca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,cuuuuggauugcaucuacuguauag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,cauucaacuguugccuccgguucug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,cuguugccuccgguucugaaggug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,cauucaacuguugccuccgguucugaaggug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,cugaagguguucuuguacuucaucc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,uguauagggacccuccuuccaugacuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,aucccacugauucugaauuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,uuggcucuggccuguccuaaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,53,NA,human,Null,Null,NA,aagaccugcucagcuucuuccuuagcuuccagcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,7,NA,human,Null,Null,NA,ugcauguuccagucguugugugg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,7,NA,human,Null,Null,NA,cacuauuccagucaaauaggucugg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,7,NA,human,Null,Null,NA,auuuaccaaccuucaggaucgagua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,7,NA,human,Null,Null,NA,ggccuaaaacacauacacaua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,ucagcuucuguuagccacug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,uucagcuucuguuagccacu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,uucagcuucuguuagccacug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,ucagcuucuguuagccacuga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,uucagcuucuguuagccacuga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,ucagcuucuguuagccacuga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,uucagcuucuguuagccacuga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,ucagcuucuguuagccacugau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,uucagcuucuguuagccacugau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,ucagcuucuguuagccacugauu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,uucagcuucuguuagccacugauu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,ucagcuucuguuagccacugauua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,uucagcuucuguuagccacugaua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,ucagcuucuguuagccacugauuaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,uucagcuucuguuagccacugauuaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,ucagcuucuguuagccacugauuaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,uucagcuucuguuagccacugauuaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,cagcuucuguuagccacug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,cagcuucuguuagccacugau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agcuucuguuagccacugauu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,cagcuucuguuagccacugauu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agcuucuguuagccacugauua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,cagcuucuguuagccacugauua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agcuucuguuagccacugauuaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,cagcuucuguuagccacugauuaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agcuucuguuagccacugauuaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,cagcuucuguuagccacugauuaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agcuucuguuagccacugauuaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agcuucuguuagccacugau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,gcuucuguuagccacugauu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agcuucuguuagccacugauu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,gcuucuguuagccacugauua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agcuucuguuagccacugauua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,gcuucuguuagccacugauuaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agcuucuguuagccacugauuaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,gcuucuguuagccacugauuaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agcuucuguuagccacugauuaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,gcuucuguuagccacugauuaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,ccauuuguauuuagcauguuccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,agauaccauuuguauuuagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,gccauuucucaacagaucu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,gccauuucucaacagaucuguca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,auucucaggaauuugugucuuuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,ucucaggaauuugugucuuuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,guucagcuucuguuagcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,cugauuaaauaucuuuauauc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,gccgccauuucucaacag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,guauuuagcauguuccca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,44,NA,human,Null,Null,NA,caggaauuugugucuuuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,gcuuuucuuuuaguugcugcucuuu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,cuuuucuuuuaguugcugcucuuuu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uuuucuuuuaguugcugcucuuuuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uuucuuuuaguugcugcucuuuucc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uucuuuuaguugcugcucuuuucca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,ucuuuuaguugcugcucuuuuccag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,cuuuuaguugcugcucuuuuccagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uuuuaguugcugcucuuuuccaggu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uuuaguugcugcucuuuuccagguu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uuaguugcugcucuuuuccagguuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uaguugcugcucuuuuccagguuca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,aguugcugcucuuuuccagguucaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,guugcugcucuuuuccagguucaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uugcugcucuuuuccagguucaagu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,ugcugcucuuuuccagguucaagug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,gcugcucuuuuccagguucaagugg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,cugcucuuuuccagguucaaguggg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,ugcucuuuuccagguucaaguggga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,gcucuuuuccagguucaagugggac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,cucuuuuccagguucaagugggaua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,ucuuuuccagguucaagugggauac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,cuuuuccagguucaagugggauacu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uuuuccagguucaagugggauacua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uuuccagguucaagugggauacuag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uuccagguucaagugggauacuagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uccagguucaagugggauacuagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,ccagguucaagugggauacuagcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,cagguucaagugggauacuagcaau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,agguucaagugggauacuagcaaug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,gguucaagugggauacuagcaaugu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,guucaagugggauacuagcaauguu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uucaagugggauacuagcaauguua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,ucaagugggauacuagcaauguuau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,caagugggauacuagcaauguuauc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,aagugggauacuagcaauguuaucu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,agugggauacuagcaauguuaucug,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,gugggauacuagcaauguuaucugc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,ugggauacuagcaauguuaucugcu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,gggauacuagcaauguuaucugcuu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,ggauacuagcaauguuaucugcuuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,gauacuagcaauguuaucugcuucc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,auacuagcaauguuaucugcuuccu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uacuagcaauguuaucugcuuccuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,acuagcaauguuaucugcuuccucc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,cuagcaauguuaucugcuuccucca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uagcaauguuaucugcuuccuccaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,agcaauguuaucugcuuccuccaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,gcaauguuaucugcuuccuccaacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,caauguuaucugcuuccuccaacca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,aauguuaucugcuuccuccaaccau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,auguuaucugcuuccuccaaccaua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,uguuaucugcuuccuccaaccauaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,guuaucugcuuccuccaaccauaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,gcugcucuuuuccagguuc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,ucuuuuccagguucaagugg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,46,NA,human,Null,Null,NA,agguucaagugggauacua,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,59,NA,human,Null,Null,NA,caauuuuucccacucaguauu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,59,NA,human,Null,Null,NA,uugaaguuccuggagucuu,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,59,NA,human,Null,Null,NA,uccucaggaggcagcucuaaau,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,67,NA,human,Null,Null,NA,gcgcuggucacaaaauccuguugaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,67,NA,human,Null,Null,NA,cacuugcuugaaaaggucuacaaagga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,US/9926557,DMD,exon,67,NA,human,Null,Null,NA,ggugaauaacuuacaaauuuggaagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,RNA,https://patents.google.com/patent/US/9926557,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,MSTN,exon,2,NA,human,Human primary myoblasts (KM109),polyethyleneimine,NA,guuugaugagucucaggauu,2OMe,NA,500,nM,Skip,moderate skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,MSTN,exon,2,NA,human,Human primary myoblasts (KM109),polyethyleneimine,NA,guuugaugagucucaggauu,2OMe,NA,200,nM,Skip,strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,MSTN,exon,2,NA,human,Human primary myoblasts (KM109),polyethyleneimine,NA,guuugaugagucucaggauu,2OMe,NA,100,nM,Skip,strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,MSTN,exon,2,NA,human,Human immortalized myoblasts (7304.1),polyethyleneimine,NA,guuugaugagucucaggauu,2OMe,NA,500,nM,Skip,faint skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,MSTN,exon,2,NA,human,Human immortalized myoblasts (7304.1),polyethyleneimine,NA,guuugaugagucucaggauu,2OMe,NA,200,nM,Skip,faint skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,MSTN,exon,2,NA,human,Human immortalized myoblasts (7304.1),polyethyleneimine,NA,guuugaugagucucaggauu,2OMe,NA,100,nM,Skip,moderate skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,MSTN,exon,2,NA,human,DMD del51-55 primary myoblasts (DL589.2),polyethyleneimine,NA,guuugaugagucucaggauu,2OMe,NA,500,nM,Skip,faint skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,MSTN,exon,2,NA,human,DMD del51-55 primary myoblasts (DL589.2),polyethyleneimine,NA,guuugaugagucucaggauu,2OMe,NA,200,nM,Skip,faint skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Dual Exon Skipping In Myostatin And Dystrophin For Duchenne Muscular Dystrophy,PMID 21507246,MSTN,exon,2,NA,human,DMD del51-55 primary myoblasts (DL589.2),polyethyleneimine,NA,guuugaugagucucaggauu,2OMe,NA,100,nM,Skip,moderate skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/21507246,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,C2C12 myoblasts,Lipofectamine 2000,NA,sequence available on request. purchased from eurogentec,2OMe,NA,250,nmol/l,Skip,~100,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,C2C12 myoblasts,Lipofectamine 2000,NA,sequence available on request. purchased from eurogentec,2OMe,NA,250,nmol/l,Skip,~100,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,C2C12 myoblasts,Lipofectamine 2000,NA,sequence available on request. purchased from eurogentec,2OMe,NA,250,nmol/l,Skip,74,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,C2C12 myoblasts,Lipofectamine 2000,NA,sequence available on request. purchased from eurogentec,2OMe,NA,250,nmol/l,Skip,41,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,C2C12 myoblasts,Lipofectamine 2000,NA,sequence available on request. purchased from eurogentec,2OMe,NA,250,nmol/l,Skip,48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,MF1 or C57Bl10 mice,Intramuscular injection into the TA muscle,NA,sequence available on request. purchased from eurogentec,2OMe,NA,3,nmol,Skip,25.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,MF1 or C57Bl10 mice,Intramuscular injection into the TA muscle,NA,sequence available on request. purchased from eurogentec,2OMe,NA,3,nmol,Skip,54.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,MF1 or C57Bl10 mice,Intramuscular injection into the TA muscle,NA,sequence available on request. purchased from eurogentec,2OMe,NA,3,nmol,Skip,48.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,MF1 or C57Bl10 mice,Intramuscular injection into the TA muscle,NA,sequence available on request. purchased from eurogentec,2OMe,NA,3,nmol,Skip,24.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,C2C12 myoblasts,Lipofectamine 2000,NA,sequence available on request. purchased from gene tools,Others (Leashed PMOs (PMO hybridized to leash-oligonucleotides of natural negatively charged DNA chemistry),NA,250,nmol/l,Skip,skipping induced. % unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,C2C12 myoblasts,Lipofectamine 2000,NA,sequence available on request. purchased from gene tools,Others (Leashed PMOs (PMO hybridized to leash-oligonucleotides of natural negatively charged DNA chemistry),NA,250,nmol/l,Skip,skipping induced. % unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,C2C12 myoblasts,Lipofectamine 2000,NA,sequence available on request. purchased from gene tools,Others (Leashed PMOs (PMO hybridized to leash-oligonucleotides of natural negatively charged DNA chemistry),NA,250,nmol/l,Skip,skipping induced. % unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,C2C12 myoblasts,Lipofectamine 2000,NA,sequence available on request. purchased from gene tools,Others (Leashed PMOs (PMO hybridized to leash-oligonucleotides of natural negatively charged DNA chemistry),NA,250,nmol/l,Skip,skipping induced. % unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,MF1 or C57Bl10 mice soleus muscle,5 weekly intravenous injections,NA,sequence available on request. purchased from gene tools,Null,NA,6,mg/kg,Skip,79,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment,PMID 20924365,MSTN,exon,2,NA,mouse,MF1 or C57Bl10 mice EDL muscle,5 weekly intravenous injections,NA,sequence available on request. purchased from gene tools,Null,NA,6,mg/kg,Skip,9,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
patent,Antisense Oligonucleotides Capable Of Inducing Exon Skipping And The Use Thereof As A Medicament For The Treatment Of Duchenne Muscular Dystrophy (Dmd),US10781451B2,DMD,exon,10,NA,human,Human DMD myotubes,ExGen500 (2 ?l per ?g of AON),NA,guccucagcagaaagaagcc,2OMe,NA,100,nM,Skip,5.05,NA,NA,NA,RNA,https://patents.google.com/patent/US10781451B2,NA,NA,NA
patent,Antisense Oligonucleotides Capable Of Inducing Exon Skipping And The Use Thereof As A Medicament For The Treatment Of Duchenne Muscular Dystrophy (Dmd),US10781451B2,DMD,exon,10,NA,human,Human DMD myotubes,ExGen500 (2 ?l per ?g of AON),NA,guaugaaacugacuggucuu,2OMe,NA,100,nM,Skip,23.12,NA,NA,NA,RNA,https://patents.google.com/patent/US10781451B2,NA,NA,NA
patent,Antisense Oligonucleotides Capable Of Inducing Exon Skipping And The Use Thereof As A Medicament For The Treatment Of Duchenne Muscular Dystrophy (Dmd),US10781451B2,DMD,exon,16,NA,human,Human DMD myotubes,ExGen500 (2 ?l per ?g of AON),NA,ucuuuucuagauccgcuuuuaa,2OMe,NA,100,nM,Skip,5.15,NA,NA,NA,RNA,https://patents.google.com/patent/US10781451B2,NA,NA,NA
patent,Antisense Oligonucleotides Capable Of Inducing Exon Skipping And The Use Thereof As A Medicament For The Treatment Of Duchenne Muscular Dystrophy (Dmd),US10781451B2,DMD,exon,16,NA,human,Human DMD myotubes,ExGen500 (2 ?l per ?g of AON),NA,uucuggucacugacuuauucuu,2OMe,NA,100,nM,Skip,6.16,NA,NA,NA,RNA,https://patents.google.com/patent/US10781451B2,NA,NA,NA
patent,Antisense Oligonucleotides Capable Of Inducing Exon Skipping And The Use Thereof As A Medicament For The Treatment Of Duchenne Muscular Dystrophy (Dmd),US10781451B2,DMD,exon,26,NA,human,Human DMD myotubes,ExGen500 (2 ?l per ?g of AON),NA,ucuguaauucaucuggaguu,2OMe,NA,100,nM,Skip,5.94,NA,NA,NA,RNA,https://patents.google.com/patent/US10781451B2,NA,NA,NA
patent,Antisense Oligonucleotides Capable Of Inducing Exon Skipping And The Use Thereof As A Medicament For The Treatment Of Duchenne Muscular Dystrophy (Dmd),US10781451B2,DMD,exon,26,NA,human,Human DMD myotubes,ExGen500 (2 ?l per ?g of AON),NA,cucccuucaaggccuaauuuc,2OMe,NA,100,nM,Skip,8.51,NA,NA,NA,RNA,https://patents.google.com/patent/US10781451B2,NA,NA,NA
patent,Antisense Oligonucleotides Capable Of Inducing Exon Skipping And The Use Thereof As A Medicament For The Treatment Of Duchenne Muscular Dystrophy (Dmd),US10781451B2,DMD,exon,33,NA,human,Human DMD myotubes,ExGen500 (2 ?l per ?g of AON),NA,ccgucugcuuuuucuguaca,2OMe,NA,100,nM,Skip,32.47,NA,NA,NA,RNA,https://patents.google.com/patent/US10781451B2,NA,NA,NA
patent,Antisense Oligonucleotides Capable Of Inducing Exon Skipping And The Use Thereof As A Medicament For The Treatment Of Duchenne Muscular Dystrophy (Dmd),US10781451B2,DMD,exon,33,NA,human,Human DMD myotubes,ExGen500 (2 ?l per ?g of AON),NA,cuuuaucccauuuccacuucag,2OMe,NA,100,nM,Skip,32.22,NA,NA,NA,RNA,https://patents.google.com/patent/US10781451B2,NA,NA,NA
patent,Antisense Oligonucleotides Capable Of Inducing Exon Skipping And The Use Thereof As A Medicament For The Treatment Of Duchenne Muscular Dystrophy (Dmd),US10781451B2,DMD,exon,34,NA,human,Human DMD myotubes,ExGen500 (2 ?l per ?g of AON),NA,uccauaucuguagcugccag,2OMe,NA,100,nM,Skip,27.95,NA,NA,NA,RNA,https://patents.google.com/patent/US10781451B2,NA,NA,NA
patent,Antisense Oligonucleotides Capable Of Inducing Exon Skipping And The Use Thereof As A Medicament For The Treatment Of Duchenne Muscular Dystrophy (Dmd),US10781451B2,DMD,exon,34,NA,human,Human DMD myotubes,ExGen500 (2 ?l per ?g of AON),NA,gaucauaugacagauaugau,2OMe,NA,100,nM,Skip,6.94,NA,NA,NA,RNA,https://patents.google.com/patent/US10781451B2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ge2pce2pce2pte2pge2pampgmpcmpumpgmpampumpcmpumpgmpcmpumpgmpgmpcmpampumpcmpumpumpgmpce2pae2pge2pte2pte2p,2OMe,NA,0.04,uM,Skip,80,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ge2pce2pce2pte2pge2pampgmpcmpumpgmpampumpcmpumpgmpcmpumpgmpgmpcmpampumpcmpumpumpgmpce2pae2pge2pte2pte2p,2OMe,NA,0.04,uM,Skip,88,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ge2pae2pte2pce2pte2pgmpcmpumpgmpgmpce2pae2pte2pce2pte2p,2OMe,NA,0.04,uM,Skip,29,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ge2pae2pte2pce2pte2pgmpcmpumpgmpgmpcmpampumpcmpumpumpgmpce2pae2pge2pte2pte2p,2OMe,NA,0.04,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ge2pampte2pce2pte2pge2pcmpumpgmpgmpcmpampumpcmpte2pte2pge2pce2pampge2p,2OMe,NA,0.04,uM,Skip,4,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ampge2pce2pte2pge2pampte2pcmpumpgmpcmpumpgmpge2pce2pampte2pce2pte2p,2OMe,NA,0.04,uM,Skip,92,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ge2pce2pce2pte2pge2pampgmpcmpumpgmpampumpcmpumpgmpcmpumpgmpge2pce2pampte2pce2pte2p,2OMe,NA,0.04,uM,Skip,5,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ae2pge2pce2pte2pge2pae2pte2pce2pte2pge2pce2pte2pge2pge2pce2pae2pte2pce2pte2p,2OMe,NA,0.04,uM,Skip,83,NA,NA,NA,DNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ge2pae2pte2pce2pte2pgmpcmpumpgmpgmpcmpampumpce2pte2pte2pge2pce2p,2OMe,NA,0.04,uM,Skip,39,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ge2pae2pte2pce2pte2pge2pce2pue2pge2pge2pce2pae2pte2pce2pte2p,2OMe,NA,0.04,uM,Skip,14,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ampge2pce2pte2pge2pampte2pcmpumpgmpcmpumpgmpge2pce2pampte2pce2pte2p,2OMe,NA,0.04,uM,Skip,90,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,amsge2sce2ste2sge2samste2scmsumsgmscmsumsgmsge2sce2samste2sce2ste2s,2OMe,NA,1,uM,Skip,53,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,amsge2pce2pte2pge2pamste2pcmsumsgmscmsumsgmsge2pce2pamste2pce2pte2p,2OMe,NA,1,uM,Skip,55,NA,NA,NA,RNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,ampgmpce2pte2pgmpampte2pce2pte2pgmpce2pte2pgmpgmpce2pampte2pce2pte2p,2OMe,NA,0.04,uM,Skip,97,NA,NA,NA,DNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,amsgmsce2ste2sgmsamste2sce2ste2sgmsce2ste2sgmsgmsce2samste2sce2ste2s,2OMe,NA,1,uM,Skip,55,NA,NA,NA,DNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Ena Nucleic Acid Drug Modifying Splicing In Mrna Precursor,EP2392660A2,DMD,exon,17-20,NA,human,A primary culture of myoblast cells,Lipofectamine(GIBCO-BRL),NA,amsgmsce2pte2pgmsamste2pce2pte2pgmsce2pte2pgmsgmsce2pamste2pce2pte2p,2OMe,NA,1,uM,Skip,91,NA,NA,NA,DNA,https://patents.google.com/patent/EP2392660A2,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,WO2010050801A1,DMD,exon,45,NA,human,human control myotubes,"ExGen500, MBI Fermentas)",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2010050801A1,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,WO2010050801A1,DMD,exon,45,NA,human,human control myotubes,"ExGen500, MBI Fermentas)",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.05,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2010050801A1,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,WO2010050801A1,DMD,exon,45,NA,human,human control myotubes,"ExGen500, MBI Fermentas)",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/WO2010050801A1,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,WO2010050801A1,DMD,exon,45,NA,human,human control myotubes,"ExGen500, MBI Fermentas)",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.2,uM,Skip,42,NA,NA,NA,RNA,https://patents.google.com/patent/WO2010050801A1,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,WO2010050801A1,DMD,exon,45,NA,human,human control myotubes,"ExGen500, MBI Fermentas)",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.4,uM,Skip,75,NA,NA,NA,RNA,https://patents.google.com/patent/WO2010050801A1,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,WO2010050801A1,DMD,exon,45,NA,human,human control myotubes,"ExGen500, MBI Fermentas)",NA,gcccaaugccauccugg,2OMe,NA,0.5,uM,Skip,3,NA,NA,NA,RNA,https://patents.google.com/patent/WO2010050801A1,NA,NA,NA
patent,Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna,WO2010050801A1,DMD,exon,45,NA,human,human control myotubes,"ExGen500, MBI Fermentas)",NA,uuugccgcugcccaaugccauccug,2OMe,NA,0.5,uM,Skip,63,NA,NA,NA,RNA,https://patents.google.com/patent/WO2010050801A1,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,5,uM,Skip,0.54,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,10,uM,Skip,3.53,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,2,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,RD Cells,Null,NA,catcaaggaagatggcatttctagtt,modified PMO (PPMO),NA,3,uM,Skip,7.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,RD Cells,Null,NA,gagcaggtacctccaacatcaaggaa,modified PMO (PPMO),NA,3,uM,Skip,9.89,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,RD Cells,Null,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,3,uM,Skip,5.26,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,human primary skeletal muscle cells,Null,NA,atttctagtttggagatggcagtttc,modified PMO (PPMO),NA,3,uM,Skip,1.02,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,human primary skeletal muscle cells,Null,NA,catcaaggaagatggcatttctagtt,modified PMO (PPMO),NA,3,uM,Skip,1.12,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,human primary skeletal muscle cells,Null,NA,gagcaggtacctccaacatcaaggaa,modified PMO (PPMO),NA,3,uM,Skip,1.3,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,human primary skeletal muscle cells,Null,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,3,uM,Skip,1.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,human primary skeletal muscle cells,Null,NA,tcaaggaagatggcatttct,modified PMO (PPMO),NA,3,uM,Skip,0.14,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,1,uM,Skip,1.05,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,2,uM,Skip,1.72,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,3,uM,Skip,2.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,5,uM,Skip,2.62,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,10,uM,Skip,4.63,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,1,uM,Skip,4.83,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,2,uM,Skip,10.44,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,3,uM,Skip,17.28,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,5,uM,Skip,23.29,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,10,uM,Skip,57.67,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,1,uM,Skip,0.79,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,2,uM,Skip,1.98,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,3,uM,Skip,2.74,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,5,uM,Skip,4.18,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,10,uM,Skip,13.89,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,cattcaactgttgcctccggttctgaaggtg,modified PMO (PPMO),NA,3,uM,Skip,5.21,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,3,uM,Skip,20.09,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,3,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgttgcctccggttctg,modified PMO (PPMO),NA,3,uM,Skip,1.03,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,attctttcaactagaataaaag,modified PMO (PPMO),NA,3,uM,Skip,1.49,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,3,uM,Skip,16.49,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,human primary skeletal muscle cells,Null,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,3,uM,Skip,0.64,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,human primary skeletal muscle cells,Null,NA,ctgttgcctccggttctg,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,human primary skeletal muscle cells,Null,NA,attctttcaactagaataaaag,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,Null,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,3,uM,Skip,19,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,0.1,uM,Skip,3.14,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,0.3,uM,Skip,4.66,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,1,uM,Skip,7.56,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,3,uM,Skip,21.64,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,10,uM,Skip,64.9,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,0.1,uM,Skip,4.14,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,0.3,uM,Skip,6.69,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,1,uM,Skip,17.41,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,3,uM,Skip,39.74,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,10,uM,Skip,97.39,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,0.1,uM,Skip,3,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,0.3,uM,Skip,8.41,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,1,uM,Skip,21.48,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,3,uM,Skip,32.92,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,10,uM,Skip,88.47,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,0.1,uM,Skip,7.49,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,0.3,uM,Skip,16.01,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,1,uM,Skip,18.81,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,3,uM,Skip,46.71,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,10,uM,Skip,96.52,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,0.1,uM,Skip,2.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,0.3,uM,Skip,4.06,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,1,uM,Skip,9.01,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,3,uM,Skip,22.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,10,uM,Skip,69.38,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,tgttcagcttctgttagccactga,modified PMO (PPMO),NA,3,uM,Skip,44.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,tttgtgtctttctgagaaac,modified PMO (PPMO),NA,3,uM,Skip,20.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ctgtaagataccaaaaaggcaaaac,modified PMO (PPMO),NA,3,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,cgccgccatttctcaacag,modified PMO (PPMO),NA,3,uM,Skip,94,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,atctgtcaaatcgcctgcag,modified PMO (PPMO),NA,3,uM,Skip,97.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,3,uM,Skip,47.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,human primary skeletal muscle cells,Null,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,3,uM,Skip,8.85,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,human primary skeletal muscle cells,Null,NA,tgttcagcttctgttagccactga,modified PMO (PPMO),NA,3,uM,Skip,2.13,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,human primary skeletal muscle cells,Null,NA,tttgtgtctttctgagaaac,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,human primary skeletal muscle cells,Null,NA,cgccgccatttctcaacag,modified PMO (PPMO),NA,3,uM,Skip,6.42,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,Null,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,3,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,2,uM,Skip,0.43,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,3,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,5,uM,Skip,1.15,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,10,uM,Skip,4.17,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,1,uM,Skip,0.53,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,2,uM,Skip,1.99,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,3,uM,Skip,4.91,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,5,uM,Skip,14.25,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,10,uM,Skip,84.37,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,1,uM,Skip,3.05,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,2,uM,Skip,13.33,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,3,uM,Skip,31.12,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,5,uM,Skip,79.2,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,10,uM,Skip,97.68,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,2,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,3,uM,Skip,0.55,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,5,uM,Skip,1.63,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,10,uM,Skip,7.86,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,2,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,5,uM,Skip,0.78,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,10,uM,Skip,2.11,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,tgtttttgaggattgctgaa,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gctgaattatttcttcccc,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,3,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,gcccaatgccatcctgg,modified PMO (PPMO),NA,3,uM,Skip,1.19,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ccaatgccatcctggagttcctgtaa,modified PMO (PPMO),NA,3,uM,Skip,4.34,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,3,uM,Skip,38.59,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,human primary skeletal muscle cells,Null,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,human primary skeletal muscle cells,Null,NA,tgtttttgaggattgctgaa,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,human primary skeletal muscle cells,Null,NA,gctgaattatttcttcccc,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,human primary skeletal muscle cells,Null,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,human primary skeletal muscle cells,Null,NA,gcccaatgccatcctgg,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,human primary skeletal muscle cells,Null,NA,ccaatgccatcctggagttcctgtaa,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,Null,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,3,uM,Skip,38.59,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ataaaattaccttgacttgctcaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,agcctggagaaagaagaata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,cttctagcctggagaaagaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ttttgttcttctagcctggagaaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,attaccttgacttgctcaagctttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ttgttcttctagcctggaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ttcttttgttcttctagcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,tattcttttgttcttctagcctgga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,cttgacttgctcaagcttttctttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,ccatttctcaacagatctgtcaaat,modified PMO (PPMO),NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,ctgcaggtaaaagcatatggatcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,atcgcctgcaggtaaaagcatatgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,gtcaaatcgcctgcaggtaaaagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,0,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,0.1,uM,Skip,3.14,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,0.3,uM,Skip,4.66,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,1,uM,Skip,7.56,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,3,uM,Skip,21.6,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,10,uM,Skip,64.94,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,gatctgtcaaatcgcctgcaggtaa,modified PMO (PPMO),NA,Null,Null,EC50[?M],7.166,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,caacagatctgtcaaatcgcctgca,modified PMO (PPMO),NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,tttctcaacagatctgtcaaatcgc,modified PMO (PPMO),NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,0,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,0.1,uM,Skip,4.14,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,0.3,uM,Skip,6.69,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,1,uM,Skip,17.41,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,3,uM,Skip,39.74,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,10,uM,Skip,97.39,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ataatgaaaacgccgccatttctca,modified PMO (PPMO),NA,Null,Null,EC50[?M],3.024,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,aaatatctttatatcataatgaaaa,modified PMO (PPMO),NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,tgttagccactgattaaatatcttt,modified PMO (PPMO),NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,0,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,0.1,uM,Skip,3,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,0.3,uM,Skip,8.41,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,1,uM,Skip,21.48,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,3,uM,Skip,32.92,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,10,uM,Skip,88.47,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,aaactgttcagcttctgttagccac,modified PMO (PPMO),NA,Null,Null,EC50[?M],3.594,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,0,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,0.1,uM,Skip,7.49,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,0.3,uM,Skip,16.01,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,1,uM,Skip,18.81,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,3,uM,Skip,46.71,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,10,uM,Skip,96.52,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,Null,Null,EC50[?M],2.795,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,3,uM,Skip,47.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,human primary skeletal muscle cells,unspecified,NA,ttgtgtctttctgagaaactgttca,modified PMO (PPMO),NA,3,uM,Skip,8.86,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,0,uM,Skip,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,0.1,uM,Skip,2.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,0.3,uM,Skip,4.06,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,1,uM,Skip,9.01,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,3,uM,Skip,22.5,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,10,uM,Skip,69.38,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,ccaattctcaggaatttgtgtcttt,modified PMO (PPMO),NA,Null,Null,EC50[?M],6.277,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,gtatttagcatgttcccaattctca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,cttaagataccatttgtatttagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,cttaccttaagataccatttgtatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,aaagacttaccttaagataccattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,aaatcaaagacttaccttaagatac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,aaaacaaatcaaagacttaccttaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,Null,Null,NA,tcgaaaaaacaaatcaaagacttac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,ctgtaagataccaaaaaggcaaaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,cctgtaagataccaaaaaggcaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,agttcctgtaagataccaaaaaggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gagttcctgtaagataccaaaaagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,cctggagttcctgtaagataccaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,tcctggagttcctgtaagataccaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,0,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,2,uM,Skip,0.43,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,agaaaataaaattaccttgacttgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,3,uM,Skip,0.6,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,5,uM,Skip,1.15,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,10,uM,Skip,4.17,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gccatcctggagttcctgtaagata,modified PMO (PPMO),NA,Null,Null,EC50[?M],54.37,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,tgccatcctggagttcctgtaagat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,0,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,1,uM,Skip,0.53,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,2,uM,Skip,1.99,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,3,uM,Skip,4.91,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,5,uM,Skip,14.25,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,10,uM,Skip,84.37,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ccaatgccatcctggagttcctgta,modified PMO (PPMO),NA,Null,Null,EC50[?M],7.25,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,cccaatgccatcctggagttcctgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gctgcccaatgccatcctggagttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,cgctgcccaatgccatcctggagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,aacagtttgccgctgcccaatgcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,0,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,1,uM,Skip,3.05,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,2,uM,Skip,13.33,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,3,uM,Skip,31.12,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,5,uM,Skip,79.2,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,10,uM,Skip,97.68,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,Null,Null,EC50[?M],3.69,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,3,uM,Skip,38.59,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,human primary skeletal muscle cells,unspecified,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gttgcattcaatgttctgacaacag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gctgaattatttcttccccagttgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,attatttcttccccagttgcattca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,ggcatctgtttttgaggattgctga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,0,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,2,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,3,uM,Skip,0.55,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,5,uM,Skip,1.63,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,tttgaggattgctgaattatttctt,modified PMO (PPMO),NA,10,uM,Skip,7.86,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,aatttttcctgtagaatactggcat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,atactggcatctgtttttgaggatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,accgcagattcaggcttcccaattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,aatttttcctgtagaatactggcat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,ctgtttgcagacctcctgccaccgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,agattcaggcttcccaatttttcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,ctcttttttctgtctgacagctgtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,acctcctgccaccgcagattcaggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,cctacctcttttttctgtctgacag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,0,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,1,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,2,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,3,uM,Skip,0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ggagaaagaagaataaaatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,5,uM,Skip,0.78,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,10,uM,Skip,2.11,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gacagctgtttgcagacctcctgcc,modified PMO (PPMO),NA,Null,Null,EC50[?M],unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gtcgccctacctcttttttctgtct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gatctgtcgccctacctcttttttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,tattagatctgtcgccctacctctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,attcctattagatctgtcgccctac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,agataccaaaaaggcaaaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,aagataccaaaaaggcaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,cctgtaagataccaaaaagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gagttcctgtaagataccaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,tcctggagttcctgtaagat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,tgccatcctggagttcctgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,cccaatgccatcctggagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,cgctgcccaatgccatcctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,ctgacaacagtttgccgctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ttcttctagcctggagaaagaagaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gttgcattcaatgttctgac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,attatttcttccccagttgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,tttgaggattgctgaattat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,atactggcatctgtttttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,aatttttcctgtagaatact,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,agattcaggcttcccaattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,acctcctgccaccgcagatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gacagctgtttgcagacctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,ctcttttttctgtctgacag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,cctacctcttttttctgtct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gtcgccctacctcttttttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gatctgtcgccctacctctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,tattagatctgtcgccctac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,attcctattagatctgtcgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,gggggatttgagaaaataaaattac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,atttgagaaaataaaattaccttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ctagcctggagaaagaagaataaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,caagatattcttttgttcttctagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,cttttagttgctgctcttttccagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ccaggttcaagtgggatactagcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,atctctttgaaattctgacaagata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,agcaatgttatctgcttcctccaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,aacaaattcatttaaatctctttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ccaaccataaaacaaattcatttaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ttcctccaaccataaaacaaattca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,tttaaatctctttgaaattctgaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,tgacaagatattcttttgttcttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ttcaagtgggatactagcaatgtta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,agatattcttttgttcttctagcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ctgctcttttccaggttcaagtggg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ttcttttgttcttctagcctggaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,cttttcttttagttgctgctctttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ttgttcttctagcctggagaaagaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,cttctagcctggagaaagaagaata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,agcctggagaaagaagaataaaatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ctggagaaagaagaataaaattgtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,gaaagaagaataaaattgtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,tgacaagatattcttttgtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,atctctttgaaattctgaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,aacaaattcatttaaatctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ttcctccaaccataaaacaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,agcaatgttatctgcttcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ttcaagtgggatactagcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ctgctcttttccaggttcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,cttttcttttagttgctgct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,cttgacttgctcaagctttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,attaccttgacttgctcaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,ataaaattaccttgacttgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,agaaaataaaattaccttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,atttgagaaaataaaattac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,46,NA,human,Null,Null,NA,gggggatttgagaaaataaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ctgaaacagacaaatgcaacaacgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,agtaactgaaacagacaaatgcaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ccaccagtaactgaaacagacaaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ctcttccaccagtaactgaaacaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ggcaactcttccaccagtaactgaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,gcaggggcaactcttccaccagtaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ctggcgcaggggcaactcttccacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,tttaattgtttgagaattccctggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ttgtttgagaattccctggcgcagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,gcacgggtcctccagtttcatttaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,tccagtttcatttaattgtttgaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,gcttatgggagcacttacaagcacg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,tacaagcacgggtcctccagtttca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,agtttatcttgctcttctgggctta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,tctgcttgagcttattttcaagttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,atcttgctcttctgggcttatggga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ctttatccactggagatttgtctgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,cttattttcaagtttatcttgctct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ctaacctttatccactggagatttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,atttgtctgcttgagcttattttca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,aatgtctaacctttatccactggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,tggttaatgtctaacctttatccac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,agagatggttaatgtctaaccttta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,acggaagagatggttaatgtctaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,acagacaaatgcaacaacgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ctgaaacagacaaatgcaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,agtaactgaaacagacaaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ccaccagtaactgaaacaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ctcttccaccagtaactgaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ggcaactcttccaccagtaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ctggcgcaggggcaactctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ttgtttgagaattccctggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,tccagtttcatttaattgtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,tacaagcacgggtcctccag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,gcttatgggagcacttacaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,atcttgctcttctgggctta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,cttattttcaagtttatctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,atttgtctgcttgagcttat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ctttatccactggagatttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,ctaacctttatccactggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,aatgtctaacctttatccac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,tggttaatgtctaaccttta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,agagatggttaatgtctaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,47,NA,human,Null,Null,NA,acggaagagatggttaatgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ctgaaaggaaaatacattttaaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,cctgaaaggaaaatacattttaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,gaaacctgaaaggaaaatacatttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ggaaacctgaaaggaaaatacattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ctctggaaacctgaaaggaaaatac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,gctctggaaacctgaaaggaaaata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,taaagctctggaaacctgaaaggaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,gtaaagctctggaaacctgaaagga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,tcaggtaaagctctggaaacctgaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ctcaggtaaagctctggaaacctga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,gtttctcaggtaaagctctggaaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,tgtttctcaggtaaagctctggaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,aatttctccttgtttctcaggtaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,tttgagcttcaatttctccttgttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ttttatttgagcttcaatttctcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,aagctgcccaaggtcttttatttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,aggtcttcaagctttttttcaagct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ttcaagctttttttcaagctgccca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,gatgatttaactgctcttcaaggtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ctgctcttcaaggtcttcaagcttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,aggagataaccacagcagcagatga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,cagcagatgatttaactgctcttca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,atttccaactgattcctaataggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,cttggtttggttggttataaatttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,caactgattcctaataggagataac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,cttaacgtcaaatggtccttcttgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ttggttataaatttccaactgattc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,cctaccttaacgtcaaatggtcctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,tccttcttggtttggttggttataa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,agttccctaccttaacgtcaaatgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,caaaaagttccctaccttaacgtca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,taaagcaaaaagttccctaccttaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,atatttaaagcaaaaagttccctac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,aggaaaatacattttaaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,aaggaaaatacattttaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,cctgaaaggaaaatacattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ggaaacctgaaaggaaaata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,gctctggaaacctgaaagga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,gtaaagctctggaaacctga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ctcaggtaaagctctggaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,aatttctccttgtttctcag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ttttatttgagcttcaattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,aagctgcccaaggtctttta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ttcaagctttttttcaagct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ctgctcttcaaggtcttcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,cagcagatgatttaactgct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,aggagataaccacagcagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,caactgattcctaataggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,ttggttataaatttccaact,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,tccttcttggtttggttggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,cttaacgtcaaatggtcctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,cctaccttaacgtcaaatgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,agttccctaccttaacgtca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,caaaaagttccctaccttaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,taaagcaaaaagttccctac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,48,NA,human,Null,Null,NA,atatttaaagcaaaaagttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,ctggggaaaagaacccatatagtgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tcctggggaaaagaacccatatagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,gtttcctggggaaaagaacccatat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,cagtttcctggggaaaagaacccat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tttcagtttcctggggaaaagaacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tatttcagtttcctggggaaaagaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tgctatttcagtttcctggggaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,actgctatttcagtttcctggggaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tgaactgctatttcagtttcctggg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,cttgaactgctatttcagtttcctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tagcttgaactgctatttcagtttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tttagcttgaactgctatttcagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,ttccacatccggttgtttagcttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tgccctttagacaaaatctcttcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tttagacaaaatctcttccacatcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,gtttttccttgtacaaatgctgccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,gtacaaatgctgccctttagacaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,cttcactggctgagtggctggtttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,ggctggtttttccttgtacaaatgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,attaccttcactggctgagtggctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,gcttcattaccttcactggctgagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,aggttgcttcattaccttcactggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,gctagaggttgcttcattaccttca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,atattgctagaggttgcttcattac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,gaaaagaacccatatagtgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,gggaaaagaacccatatagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tcctggggaaaagaacccat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,cagtttcctggggaaaagaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tatttcagtttcctggggaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,actgctatttcagtttcctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,cttgaactgctatttcagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tttagcttgaactgctattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,ttccacatccggttgtttag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,tttagacaaaatctcttcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,gtacaaatgctgccctttag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,ggctggtttttccttgtaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,cttcactggctgagtggctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,attaccttcactggctgagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,gcttcattaccttcactggc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,aggttgcttcattaccttca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,gctagaggttgcttcattac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,49,NA,human,Null,Null,NA,atattgctagaggttgcttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ctttaacagaaaagcatacacatta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,tcctctttaacagaaaagcatacac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ttcctctttaacagaaaagcataca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,taacttcctctttaacagaaaagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ctaacttcctctttaacagaaaagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,tcttctaacttcctctttaacagaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,atcttctaacttcctctttaacaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,tcagatcttctaacttcctctttaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ctcagatcttctaacttcctcttta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,agagctcagatcttctaacttcctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,RD Cells,unspecified,NA,cagagctcagatcttctaacttcct,modified PMO (PPMO),NA,Null,Null,EC50[?M],1.741,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,cactcagagctcagatcttctact,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ccttccactcagagctcagatcttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,gtaaacggtttaccgccttccactc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ctttgccctcagctcttgaagtaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ccctcagctcttgaagtaaacggtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ccaggagctaggtcaggctgctttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ggtcaggctgctttgccctcagctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,aggctccaatagtggtcagtccagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,tcagtccaggagctaggtcaggctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,RD Cells,unspecified,NA,cttacaggctccaatagtggtcagt,modified PMO (PPMO),NA,Null,Null,EC50[?M],0.921,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,gtatacttacaggctccaatagtgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,atccagtatacttacaggctccaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,RD Cells,unspecified,NA,atgggatccagtatacttacaggct,modified PMO (PPMO),NA,Null,Null,EC50[?M],1.836,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,RD Cells,unspecified,NA,agagaatgggatccagtatacttac,modified PMO (PPMO),NA,Null,Null,EC50[?M],2.402,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,acagaaaagcatacacatta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,tttaacagaaaagcatacac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,tcctctttaacagaaaagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,taacttcctctttaacagaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,tcttctaacttcctctttaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,tcagatcttctaacttcctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ccttccactcagagctcaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,gtaaacggtttaccgccttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ccctcagctcttgaagtaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,ggtcaggctgctttgccctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,tcagtccaggagctaggtca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,aggctccaatagtggtcagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,cttacaggctccaatagtgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,gtatacttacaggctccaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,atccagtatacttacaggct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,atgggatccagtatacttac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,agagaatgggatccagtata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ctaaaatattttgggtttttgcaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,gctaaaatattttgggtttttgcaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,taggagctaaaatattttgggttttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,agtaggagctaaaatattttgggtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,tgagtaggagctaaaatattttggg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ctgagtaggagctaaaatattttggg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cagtctgagtaggagctaaaatatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,acagtctgagtaggagctaaaatatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,gagtaacagtctgagtaggagctaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cagagtaacagtctgagtaggagct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,caccagagtaacagtctgagtaggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,gtcaccagagtaacagtctgagtag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,aaccacaggttgtgtcaccagagtaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,gttgtgtcaccagagtaacagtctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,tggcagtttccttagtaaccacaggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,RD Cells,unspecified,NA,atttctagtttggagatggcagtttc,modified PMO (PPMO),NA,3,uM,skip[%],4.65,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,human primary skeletal muscle cells,unspecified,NA,atttctagtttggagatggcagtttc,modified PMO (PPMO),NA,3,uM,skip[%],1.02,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ggaagatggcatttctagtttggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,RD Cells,unspecified,NA,catcaaggaagatggcatttctagtt,modified PMO (PPMO),NA,3,uM,skip[%],7.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,human primary skeletal muscle cells,unspecified,NA,catcaaggaagatggcatttctagtt,modified PMO (PPMO),NA,3,uM,skip[%],1.12,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,RD Cells,unspecified,NA,gagcaggtacctccaacatcaaggaa,modified PMO (PPMO),NA,3,uM,skip[%],7.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,human primary skeletal muscle cells,unspecified,NA,gagcaggtacctccaacatcaaggaa,modified PMO (PPMO),NA,3,uM,skip[%],9.89,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,atctgccagagcaggtacctccaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,aagttctgtccaagcccggttgaaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cggttgaaatctgccagagcaggtac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,gagaaagccagtcggtaagttctgtc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,gtcggtaagttctgtccaagcccgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ataacttgatcaagcagagaaagcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,aagcagagaaagccagtcggtaagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,caccctctgtgattttataacttgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,caaggtcacccaccatcaccctctgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,catcaccctctgtgattttataact,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cttctgcttgatgatcatctcgttga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ccttctgcttgatgatcatctcgttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,atctcgttgatatcctcaaggtcacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,tcataccttctgcttgatgatcatct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,tcattttttctcataccttctgcttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ttttctcataccttctgcttgatgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ttttatcattttttctcataccttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ccaacttttatcattttttctcatac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,atattttgggtttttgcaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,aaaatattttgggtttttgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,gagctaaaatattttgggtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,agtaggagctaaaatatttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,gtctgagtaggagctaaaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,taacagtctgagtaggagct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cagagtaacagtctgagtag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cacaggttgtgtcaccagag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,agtttccttagtaaccacag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,tagtttggagatggcagttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ggaagatggcatttctagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,tacctccaacatcaaggaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,atctgccagagcaggtacct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ccaagcccggttgaaatctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,gtcggtaagttctgtccaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,aagcagagaaagccagtcgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ttttataacttgatcaagca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,catcaccctctgtgatttta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ctcaaggtcacccaccatca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,catctcgttgatatcctcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cttctgcttgatgatcatct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cataccttctgcttgatgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,tttctcataccttctgcttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cattttttctcataccttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,tttatcattttttctcatac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,caacttttatcattttttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,ctgtaagaacaaatatcccttagta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,tgcctgtaagaacaaatatccctta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,gttgcctgtaagaacaaatatccct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,attgttgcctgtaagaacaaatatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,gcattgttgcctgtaagaacaaata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,cctgcattgttgcctgtaagaacaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,atcctgcattgttgcctgtaagaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,caaatcctgcattgttgcctgtaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,tccaaatcctgcattgttgcctgta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,tgttccaaatcctgcattgttgcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,tctgttccaaatcctgcattgttgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,aactggggacgcctctgttccaaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,gcctctgttccaaatcctgcattgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,cagcggtaatgagttcttccaactg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,cttccaactggggacgcctctgttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,cttgtttttcaaattttgggcagcg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,ctagcctcttgattgctggtcttgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,ttttcaaattttgggcagcggtaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,ttcgatccgtaatgattgttctagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,gattgctggtcttgtttttcaaatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,cttacttcgatccgtaatgattgtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,ttgttctagcctcttgattgctggt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,aaaaacttacttcgatccgtaatga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,tgttaaaaaacttacttcgatccgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,atgcttgttaaaaaacttacttcga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,gtcccatgcttgttaaaaaacttac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,agaacaaatatcccttagta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,gtaagaacaaatatccctta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,tgcctgtaagaacaaatatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,attgttgcctgtaagaacaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,cctgcattgttgcctgtaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,caaatcctgcattgttgcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,gcctctgttccaaatcctgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,cttccaactggggacgcctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,cagcggtaatgagttcttcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,ttttcaaattttgggcagcg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,gattgctggtcttgtttttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,ttgttctagcctcttgattg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,ttcgatccgtaatgattgtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,cttacttcgatccgtaatga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,aaaaacttacttcgatccgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,tgttaaaaaacttacttcga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,atgcttgttaaaaaacttac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,52,NA,human,Null,Null,NA,gtcccatgcttgttaaaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctagaataaaaggaaaaataaatat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,aactagaataaaaggaaaaataaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ttcaactagaataaaaggaaaaata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctttcaactagaataaaaggaaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,attctttcaactagaataaaaggaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,gaattctttcaactagaataaaagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,0,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,1,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,2,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,3,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,5,uM,skip[%],0.54,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,10,uM,skip[%],3.53,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tctgaattctttcaactagaataaa,modified PMO (PPMO),NA,Null,Null,EC50[?M],unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,attctgaattctttcaactagaata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctgattctgaattctttcaactaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,cactgattctgaattctttcaacta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tcccactgattctgaattctttcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,catcccactgattctgaattctttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,0,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,1,uM,skip[%],1.05,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,2,uM,skip[%],1.72,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,3,uM,skip[%],2.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,5,uM,skip[%],2.62,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,10,uM,skip[%],4.63,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,tacttcatcccactgattctgaatt,modified PMO (PPMO),NA,Null,Null,EC50[?M],72.2,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,0,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,1,uM,skip[%],4.83,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,2,uM,skip[%],10.44,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,3,uM,skip[%],17.28,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,5,uM,skip[%],23.29,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,10,uM,skip[%],57.67,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,Null,Null,EC50[?M],9.3,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,3,uM,skip[%],16.49,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,cggttctgaaggtgttcttgtact,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,0,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,1,uM,skip[%],0.79,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,2,uM,skip[%],1.98,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,3,uM,skip[%],2.74,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,5,uM,skip[%],4.18,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,10,uM,skip[%],13.89,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgttgcctccggttctgaaggtgt,modified PMO (PPMO),NA,Null,Null,EC50[?M],25.3,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tttcattcaactgttgcctccggtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,taacatttcattcaactgttgcctc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ttgtgttgaatcctttaacatttca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,cttttatgaatgcttctccaagagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tcttccttagcttccagccattgtg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,cttagcttccagccattgtgttgaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,gtcctaagacctgctcagcttcttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctgctcagcttcttccttagcttcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctcaagcttggctctggcctgtcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ggcctgtcctaagacctgctcagct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tagggaccctccttccatgactcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tttggattgcatctactgtataggg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,accctccttccatgactcaagcttg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,cttggtttctgtgattttcttttgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,atctactgtatagggaccctccttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctaaccttggtttctgtgattttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tttcttttggattgcatctactgta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tgatactaaccttggtttctgtgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,atctttgatactaaccttggtttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,aaggtatctttgatactaaccttgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ttaaaaaggtatctttgatactaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ataaaaggaaaaataaatat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,gaataaaaggaaaaataaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,aactagaataaaaggaaaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctttcaactagaataaaagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,gaattctttcaactagaata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,attctgaattctttcaacta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tacttcatcccactgattct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctgaaggtgttcttgtact,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctgttgcctccggttctgaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,taacatttcattcaactgtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ttgtgttgaatcctttaaca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,cttagcttccagccattgtg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctgctcagcttcttccttag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ggcctgtcctaagacctgct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctcaagcttggctctggcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,accctccttccatgactcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,atctactgtatagggaccct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tttcttttggattgcatcta,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,cttggtttctgtgattttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctaaccttggtttctgtgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tgatactaaccttggtttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,atctttgatactaaccttgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,aaggtatctttgatactaac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ttaaaaaggtatctttgata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,ctatagatttttatgagaaagaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,aactgctatagatttttatgagaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,tggccaactgctatagatttttatg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,gtctttggccaactgctatagattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,cggaggtctttggccaactgctata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,actggcggaggtctttggccaactg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,tttgtctgccactggcggaggtctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,agtcatttgccacatctacatttgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,tttgccacatctacatttgtctgcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,ccggagaagtttcagggccaagtca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,gtatcatctgcagaataatcccgga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,taatcccggagaagtttcagggcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,ttatcatgtggacttttctggtatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,agaggcattgatattctctgttatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,atgtggacttttctggtatcatctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,atattctctgttatcatgtggactt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,cataccttttatgaatgcttctcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,ctccaagaggcattgatattctctg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,taattcataccttttatgaatgctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,atattctctgttatcatgtggactt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,taatgtaattcataccttttatgaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,agaaataatgtaattcatacctttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,gttttagaaataatgtaattcatac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,gatttttatgagaaagaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,ctatagatttttatgagaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,aactgctatagatttttatg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,tggccaactgctatagattt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,gtctttggccaactgctata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,cggaggtctttggccaactg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,tttgtctgccactggcggag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,tttgccacatctacatttgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,ttcagggccaagtcatttgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,taatcccggagaagtttcag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,gtatcatctgcagaataatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,atgtggacttttctggtatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,atattctctgttatcatgtg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,ctccaagaggcattgatatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,cttttatgaatgcttctcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,cataccttttatgaatgctt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,taattcataccttttatgaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,taatgtaattcatacctttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,agaaataatgtaattcatac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,54,NA,human,Null,Null,NA,gttttagaaataatgtaatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ctgcaaaggaccaaatgttcagatg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,tcaccctgcaaaggaccaaatgttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ctcactcaccctgcaaaggaccaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,tctcgctcactcaccctgcaaagga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cagcctctcgctcactcaccctgca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,caaagcagcctctcgctcactcacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,tcttccaaagcagcctctcgctcac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,tctatgagtttcttccaaagcagcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,gttgcagtaatctatgagtttcttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,gaactgttgcagtaatctatgagtt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ttccaggtccagggggaactgttgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,gtaagccaggcaagaaacttttcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ccaggcaagaaacttttccaggtcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,tggcagttgtttcagcttctgtaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ttcagcttctgtaagccaggcaaga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ggtagcatcctgtaggacattggca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,gacattggcagttgtttcagcttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,tctaggagcctttccttacgggtag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cttttactcccttggagtcttctag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,gagcctttccttacgggtagcatcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ttgccattgtttcatcagctctttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cttggagtcttctaggagcctttcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cttacttgccattgtttcatcagct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cagctcttttactcccttggagtct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cctgacttacttgccattgtttcat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,aaatgcctgacttacttgccattgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,agcggaaatgcctgacttacttgcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,gctaaagcggaaatgcctgacttac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,aaggaccaaatgttcagatg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ctgcaaaggaccaaatgttc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,tcaccctgcaaaggaccaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ctcactcaccctgcaaagga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,tctcgctcactcaccctgca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cagcctctcgctcactcacc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,caaagcagcctctcgctcac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,tctatgagtttcttccaaag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,gaactgttgcagtaatctat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ttccaggtccagggggaact,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ccaggcaagaaacttttcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ttcagcttctgtaagccagg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,gacattggcagttgtttcag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ggtagcatcctgtaggacat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,gagcctttccttacgggtag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cttggagtcttctaggagcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cagctcttttactcccttgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,ttgccattgtttcatcagct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cttacttgccattgtttcat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,cctgacttacttgccattgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,aaatgcctgacttacttgcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,agcggaaatgcctgacttac,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,55,NA,human,Null,Null,NA,gctaaagcggaaatgcctga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,RD Cells,unspecified,NA,ccactcagagctcagatcttctaacttcc,modified PMO (PPMO),NA,unspecified,Null,EC50[?M],0.921,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,RD Cells,unspecified,NA,gggatccagtatacttacaggctcc,modified PMO (PPMO),NA,unspecified,Null,EC50[?M],3.693,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,50,NA,human,Null,Null,NA,cttccactcagagctcagatcttctaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,acatcaaggaagatggcatttctagtttgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,RD Cells,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,3,uM,skip[%],5.26,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,human primary skeletal muscle cells,unspecified,NA,ctccaacatcaaggaagatggcatttctag,modified PMO (PPMO),NA,3,uM,skip[%],1.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ttctgtccaagcccggttgaaatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cacccaccatcaccctcygtg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,atcatctcgttgatatcctcaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,acatcaaggaagatggcatttctag,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,accagagtaacagtctgagtaggagc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,human primary skeletal muscle cells,unspecified,NA,tcaaggaagatggcatttct,modified PMO (PPMO),NA,3,uM,skip[%],0.14,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,cctctgtgattttataacttgat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,atcattttttctcataccttctgct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,51,NA,human,Null,Null,NA,ctcataccttctgcttgatgatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,unspecified,NA,human,Null,Null,NA,tggcatttctagtttgg,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,unspecified,NA,human,Null,Null,NA,ccagagcaggtacctccaacatc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,tgttcagcttctgttagccactga,modified PMO (PPMO),NA,3,uM,skip[%],44.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,human primary skeletal muscle cells,unspecified,NA,tgttcagcttctgttagccactga,modified PMO (PPMO),NA,3,uM,skip[%],2.13,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,tttgtgtctttctgagaaac,modified PMO (PPMO),NA,3,uM,skip[%],20.4,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,human primary skeletal muscle cells,unspecified,NA,tttgtgtctttctgagaaac,modified PMO (PPMO),NA,3,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,cgccgccatttctcaacag,modified PMO (PPMO),NA,3,uM,skip[%],94,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,human primary skeletal muscle cells,unspecified,NA,cgccgccatttctcaacag,modified PMO (PPMO),NA,3,uM,skip[%],6.42,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,44,NA,human,RD Cells,unspecified,NA,atctgtcaaatcgcctgcag,modified PMO (PPMO),NA,3,uM,skip[%],97.1,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,tgtttttgaggattgctgaa,modified PMO (PPMO),NA,3,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gctgaattatttcttcccc,modified PMO (PPMO),NA,3,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,gcccaatgccatcctgg,modified PMO (PPMO),NA,3,uM,skip[%],1.19,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,RD Cells,unspecified,NA,ccaatgccatcctggagttcctgtaa,modified PMO (PPMO),NA,3,uM,skip[%],4.34,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,human primary skeletal muscle cells,unspecified,NA,ctgacaacagtttgccgctgcccaa,modified PMO (PPMO),NA,3,uM,Skip,38.59,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,cattcaactgttgcctccggttctgaaggtg,modified PMO (PPMO),NA,3,uM,skip[%],5.21,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,3,uM,skip[%],20.09,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,human primary skeletal muscle cells,unspecified,NA,ctgaaggtgttcttgtacttcatcc,modified PMO (PPMO),NA,3,uM,skip[%],0.64,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,ctgttgcctccggttctg,modified PMO (PPMO),NA,3,uM,skip[%],1.03,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,human primary skeletal muscle cells,unspecified,NA,ctgttgcctccggttctg,modified PMO (PPMO),NA,3,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,attctttcaactagaataaaag,modified PMO (PPMO),NA,3,uM,skip[%],1.49,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,RD Cells,unspecified,NA,attctttcaactagaataaaag,modified PMO (PPMO),NA,3,uM,skip[%],0,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gccatcctggagttcctgtaagataccaaa,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,ccaatgccatcctggagttcctgtaagata,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gccgctgcccaatgccatcctggagttcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gtttgccgctgcccaatgccatcctggagt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,caacagtttgccgctgcccaatgccatcct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,ctgacaacagtttgccgctgcccaatgcca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,tgttctgacaacagtttgccgctgcccaat,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,caatgttctgacaacagtttgccgctgccc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,cattcaatgttctgac/aacagtttgccgct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,tatttcttccccagttgcattcaatgttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,gctgaattatttcttccccagttgcattca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,ggattgctgaattatttcttccccagttgc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,45,NA,human,Null,Null,NA,tttgaggattgctgaattatttcttcccca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,gtacttcatcccactgattctgaattcttt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tcttgtacttcatcccactgattctgaatt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tgttcttgtacttcatcccactgattctga,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,cggttctgaaggtgttcttgtacttcatcc,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ctccggttctgaaggtgttcttgtacttca,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tgcctccggttctgaaggtgttcttgtact,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,tgttgcctccggttctgaaggtgttcttgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,aactgttgcctccggttctgaaggtgttct,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
patent,Multiple Exon Skipping Compositions For Dmd,US9447416B2,DMD,exon,53,NA,human,Null,Null,NA,ttcaactgttgcctccggttctgaaggtgt,unspecified,NA,Null,Null,Null,Null,NA,NA,NA,DNA,https://patents.google.com/patent/US9447416B2,NA,NA,NA
journal article,Antisense Oligonucleotide Treatment For A Pseudoexon-Generating Mutation In The Npc1 Gene Causing Niemann-Pick Type C Disease.hum Mutat,PMID 19718781,NPC1,pseudoexon,pseudoexon 9,NA,human,Human fibroblast (c. 1554-1009G>A),Endoporter 9uL/mL,NA,unspecified,unmodified PMO,NA,10,uM,Skip,~100,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19718781,NA,NA,NA
journal article,Triplet-Repeat Oligonucleotide-Mediated Reversal Of Rna Toxicity In Myotonic Dystrophy,PMID 19667189,DMPK,exon,CUG repeats,NA,mouse,DM500 mouse myoblasts,polyethyleneimine 5uL per ug AON,NA,cagcagcagcagcagcagcag,2OMe,NA,Null,Null,Skip,~90,NA,NA,NA,Unknown,https://pubmed.ncbi.nlm.nih.gov/19667189,NA,NA,NA
journal article,Antisense Therapeutics For Neurofibromatosis Type 1 Caused By Deep Intronic Mutations.hum Mutat,PMID 19241459,NF1,pseudoexon,pseudoexon 3,NA,human,Human lymphocytes (c.288+2025T>G),Endoporter 10uM,NA,ctttcacttacatattccaactatg,unmodified PMO,NA,50,uM,Skip,66,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19241459,NA,NA,NA
journal article,Antisense Therapeutics For Neurofibromatosis Type 1 Caused By Deep Intronic Mutations.hum Mutat,PMID 19241459,NF1,pseudoexon,pseudoexon 30,NA,human,Human lymphocytes (c.5749+332A>G),Endoporter 10uM,NA,acatggatacttacgtggacttttc,unmodified PMO,NA,50,uM,Skip,40,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19241459,NA,NA,NA
journal article,Antisense Therapeutics For Neurofibromatosis Type 1 Caused By Deep Intronic Mutations.hum Mutat,PMID 19241459,NF1,pseudoexon,pseudoexon 45,NA,human,Human lymphocytes (c.7908-321C>G ),Endoporter 10uM,NA,ctgtctgctacttaccatgttttag,unmodified PMO,NA,50,uM,Skip,77,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19241459,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,43,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,cguugcacuuugcaaugcugcug,2OMe,NA,0.5,uM,Skip,36,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,43,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,cgaccugagcuuuguuguag,2OMe,NA,0.5,uM,Skip,66,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,43,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,cgaccugagcuuuguuguagacuau,2OMe,NA,0.5,uM,Skip,13,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,gcuuuucuuuuaguugcugcucuuu,2OMe,NA,0.05,uM,Skip,53,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,gcuuuucuuuuaguugcugcucuuu,2OMe,NA,0.15,uM,Skip,58,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,ucuuuuccagguucaagugg,2OMe,NA,0.05,uM,Skip,21,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,ucuuuuccagguucaagugg,2OMe,NA,0.15,uM,Skip,55,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,ggauacuagcaauguuaucugcuuc,2OMe,NA,0.05,uM,Skip,46,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,ggauacuagcaauguuaucugcuuc,2OMe,NA,0.15,uM,Skip,42,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,agcaauguuaucugcuuccuccaac,2OMe,NA,0.05,uM,Skip,48,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,46,NA,human,Ex45del primary patient myotubes,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,agcaauguuaucugcuuccuccaac,2OMe,NA,0.15,uM,Skip,74,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,50,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,auaguggucaguccaggagcu,2OMe,NA,0.5,uM,Skip,35,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,50,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,cucagcucuugaaguaaacg,2OMe,NA,0.5,uM,Skip,16,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,50,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,ccucagcucuugaaguaaacg,2OMe,NA,0.5,uM,Skip,14,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,50,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,ccucagcucuugaaguaaac,2OMe,NA,0.5,uM,Skip,14,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,52,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,cucuugauugcuggucuuguuuuuc,2OMe,NA,0.2,uM,Skip,50,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,52,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,cucuugauugcuggucuuguuuuuc,2OMe,NA,0.5,uM,Skip,59,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,52,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,uuccaacuggggacgccucuguucc,2OMe,NA,0.2,uM,Skip,88,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,52,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,uuccaacuggggacgccucuguucc,2OMe,NA,0.5,uM,Skip,91,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
patent,"Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Dystrophy Gene: 43, 46, 50-53",US20190100754A1,DMD,exon,53,NA,human,healthy control myotube cultures,"UNIFectylin (Prosensa), 2 ?l/?g AO",NA,accugcucagcuucuuccuuagcuu,2OMe,NA,unspecified,Null,Null,induced highest levels,NA,NA,NA,RNA,https://patents.google.com/patent/US20190100754A1,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,attgtgttgaatcctttaacatttc,unmodified PMO,NA,0.5,uM,skip[%],0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tgtcctaagacctgctcagcttctt,unmodified PMO,NA,0.5,uM,skip[%],0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tctggcctgtcctaagacctgctca,unmodified PMO,NA,0.5,uM,skip[%],0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ctcaagcttggctctggcctgtcct,unmodified PMO,NA,0.5,uM,skip[%],0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,atagggaccctccttccatgactca,unmodified PMO,NA,0.5,uM,skip[%],0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,45,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,gcttcccaatttttcctgtagaatactggc,unmodified PMO,NA,0.5,uM,skip[%],0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,45,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ctgtctgacagctgtttgcagacctcctgc,unmodified PMO,NA,0.5,uM,skip[%],0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,aatgttatctgcttcctccaaccat,unmodified PMO,NA,0.5,uM,skip[%],0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cttgctcaagcttttcttttagttgctgct,unmodified PMO,NA,0.5,uM,skip[%],0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,atctactgtatagggaccctccttc,unmodified PMO,NA,0.5,uM,skip[%],0.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tcaagcttttcttttagttgctgct,unmodified PMO,NA,0.5,uM,skip[%],0.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,catttcattcaactgttgcctccgg,unmodified PMO,NA,0.5,uM,skip[%],0.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,agcttccagccattgtgttgaatcc,unmodified PMO,NA,0.5,uM,skip[%],0.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,atttgagaaaataaaattaccttga,unmodified PMO,NA,0.5,uM,skip[%],0.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttgagaaaataaaattaccttgacttgctc,unmodified PMO,NA,0.5,uM,skip[%],1.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,45,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ctgtcgccctacctcttttttctgtctgac,unmodified PMO,NA,0.5,uM,skip[%],1.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,45,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tactggcatctgtttttgaggattgctgaa,unmodified PMO,NA,0.5,uM,skip[%],1.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,caactgttgcctccggttctgaagg,unmodified PMO,NA,0.5,uM,skip[%],2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ctttgaaattctgacaagatattct,unmodified PMO,NA,0.5,uM,skip[%],2.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cttcttccttagcttccagccattg,unmodified PMO,NA,0.5,uM,skip[%],3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cttttggattgcatctactgtatag,unmodified PMO,NA,0.5,uM,skip[%],3.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttctcaggaatttgtgtctttctgagaaac,unmodified PMO,NA,0.5,uM,skip[%],4.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tctgagaaactgttcagcttctgttagcca,unmodified PMO,NA,0.05,uM,skip[%],5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cttgacttgctcaagcttttctttt,unmodified PMO,NA,0.1,uM,skip[%],5.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tcctccaaccataaaacaaattcat,unmodified PMO,NA,0.5,uM,skip[%],5.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,45,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,atttcttccccagttgcattcaatgttctg,unmodified PMO,NA,0.5,uM,skip[%],6.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cttggtttctgtgattttcttttgg,unmodified PMO,NA,0.5,uM,skip[%],7.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttccaggttcaagtgggatactagc,unmodified PMO,NA,0.1,uM,skip[%],8.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttcattcaactgttgcctccggttc,unmodified PMO,NA,0.25,uM,skip[%],9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,caagatattcttttgttcttctagc,unmodified PMO,NA,0.5,uM,skip[%],9.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttcattcaactgttgcctccggttctgaag,unmodified PMO,NA,0.1,uM,skip[%],9.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ctgttgcctccggttctgaaggtgt,unmodified PMO,NA,0.1,uM,skip[%],9.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,attcaactgttgcctccggttctga,unmodified PMO,NA,0.5,uM,skip[%],10.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,45,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cagctgtttgcagacctcctgccaccgcag,unmodified PMO,NA,0.5,uM,skip[%],11.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttctgtgattttcttttggattgca,unmodified PMO,NA,0.5,uM,skip[%],12.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttgcctccggttctgaaggtgttct,unmodified PMO,NA,0.1,uM,skip[%],12.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,25,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tcaaggaagatggcatttctagttt,unmodified PMO,NA,0.25,uM,skip[%],14.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ctcttttccaggttcaagtgggata,unmodified PMO,NA,0.5,uM,skip[%],15.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,gggatttgagaaaataaaattaccttgact,unmodified PMO,NA,0.5,uM,skip[%],18.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cttttagttgctgctcttttccagg,unmodified PMO,NA,0.1,uM,skip[%],21.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,taccatttgtatttagcatgttcccaattc,unmodified PMO,NA,0.05,uM,skip[%],22,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,aggaatttgtgtctttctgagaaactgttc,unmodified PMO,NA,0.1,uM,skip[%],26,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,51,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ctccaacatcaaggaagatggcatttctag,unmodified PMO,NA,0.5,uM,skip[%],26.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tttgtgtctttctgagaaactgttcagctt,unmodified PMO,NA,0.5,uM,skip[%],32.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,taagataccatttgtatttagcatgttccc,unmodified PMO,NA,0.5,uM,skip[%],35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,agcttctgttagccactgattaaatatctt,unmodified PMO,NA,0.1,uM,skip[%],35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,catttcattcaactgttgcctccggttctg,unmodified PMO,NA,0.5,uM,skip[%],35.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,attcaactgttgcctccggttctgaaggtg,unmodified PMO,NA,0.1,uM,skip[%],38.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tttgtatttagcatgttcccaattctcagg,unmodified PMO,NA,0.1,uM,skip[%],42,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tgctgctcttttccaggttcaagtg,unmodified PMO,NA,0.1,uM,skip[%],49.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tatatcataatgaaaacgccgccatttctc,unmodified PMO,NA,0.25,uM,skip[%],52.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttgcctccggttctgaaggtgttcttgtac,unmodified PMO,NA,0.1,uM,skip[%],52.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,gaaactgttcagcttctgttagccactgat,unmodified PMO,NA,0.5,uM,skip[%],61,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,gtctttctgagaaactgttcagcttctgtt,unmodified PMO,NA,0.5,uM,skip[%],63.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,45,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttgccgctgcccaatgccatcctggagttc,unmodified PMO,NA,0.5,uM,skip[%],64.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttagttgctgctcttttccaggttcaagtg,unmodified PMO,NA,0.5,uM,skip[%],74.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ctcttttccaggttcaagtgggatactagc,unmodified PMO,NA,0.5,uM,skip[%],75.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cttttcttttagttgctgctcttttccagg,unmodified PMO,NA,0.5,uM,skip[%],76.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,caactgttgcctccggttctgaaggtgttc,unmodified PMO,NA,0.1,uM,skip[%],80.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tgttcagcttctgttagccactgattaaat,unmodified PMO,NA,0.5,uM,skip[%],80.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,53,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ctgttgcctccggttctgaaggtgttcttg,unmodified PMO,NA,0.1,uM,skip[%],87.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cttttagttgctgctcttttccaggttcaa,unmodified PMO,NA,0.5,uM,skip[%],87.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tgctgctcttttccaggttcaagtgggata,unmodified PMO,NA,0.5,uM,skip[%],87.9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,45,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cagtttgccgctgcccaatgccatcctgga,unmodified PMO,NA,0.5,uM,skip[%],91.4,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,cataatgaaaacgccgccatttctcaacag,unmodified PMO,NA,0.5,uM,skip[%],95,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,44,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,tgaaaacgccgccatttctcaacagatctg,unmodified PMO,NA,0.25,uM,skip[%],97,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Design Of Phosphorodiamidate Morpholino Oligomers (Pmos) For The Nduction Of Exon Skipping Of The Human Dmd Gene,PMID 19142179,DMD,exon,46,NA,human,Normal human pryimary skeletal muscle cell,"Lipofectin(Invitrogen,3.5 ?l/?g)",NA,ttccaggttcaagtgggatactagc,unmodified PMO,NA,0.1,uM,skip[%],8.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19142179,NA,NA,NA
journal article,Functional Analysis Of Three Splicing Mutations Identified In The Pmm2 Gene: Toward A New Therapy For Congenital Disorder Of Glycosylation Type Ia,PMID 19235233,PMM2,pseudoexon,pseudoexon 7,NA,human,Human fibroblast (c.640-15479C4T),Endoporter 8uL/mL,NA,atcacaaacacaacctacctcaggc,unmodified PMO,NA,20,uM,Skip,23,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/19235233,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,2,NA,human,Primary human myotubes,Lipofectamine2000,NA,ccauuuugugaauguuuucuuuugaacauc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,3,NA,human,Primary human myotubes,Lipofectamine2000,NA,guaggucacugaagagguucu,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,4,NA,human,Primary human myotubes,Lipofectamine2000,NA,uguucagggcaugaacucuuguggauccuu,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,5,NA,human,Primary human myotubes,Lipofectamine2000,NA,ucaguuuaugauuuccaucuacgaugucagu,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,6,NA,human,Primary human myotubes,Lipofectamine2000,NA,uacgaguugauugucggacccag,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,7,NA,human,Primary human myotubes,Lipofectamine2000,NA,ugcauguuccagucguugugugg,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,9,NA,human,Primary human myotubes,Lipofectamine2000,NA,cccugugcuagacugaccgugaucugcag,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,12,NA,human,Primary human myotubes,Lipofectamine2000,NA,ucuucuguuuuuguuagccaguca,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,13,NA,human,Primary human myotubes,Lipofectamine2000,NA,cagcaguugcgugaucuccacuag,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,14,NA,human,Primary human myotubes,Lipofectamine2000,NA,guaaaagaacccagcggucuucuguccauc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,15,NA,human,Primary human myotubes,Lipofectamine2000,NA,ucuuuaaagccaguugugugaauc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,18,NA,human,Primary human myotubes,Lipofectamine2000,NA,cagcuucugagcgaguaauccagcugugaa,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,19,NA,human,Primary human myotubes,Lipofectamine2000,NA,gccugagcugaucugcuggcaucuugcaguu,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,22,NA,human,Primary human myotubes,Lipofectamine2000,NA,cugcaauuccccgagucucugc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,23,NA,human,Primary human myotubes,Lipofectamine2000,NA,cggcuaauuucagagggcgcuuucuucgac,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,24,NA,human,Primary human myotubes,Lipofectamine2000,NA,caagggcaggccauuccuccuuc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,25,NA,human,Primary human myotubes,Lipofectamine2000,NA,uugaguucugucucaagucucgaag,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,27,NA,human,Primary human myotubes,Lipofectamine2000,NA,uuaaggccucuugugcuacaggugg,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,28,NA,human,Primary human myotubes,Lipofectamine2000,NA,cagagauuuccucagcuccgccagga,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,29,NA,human,Primary human myotubes,Lipofectamine2000,NA,uccgccaucuguuagggucugugcc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,30,NA,human,Primary human myotubes,Lipofectamine2000,NA,uccugggcagacuggaugcucuguuc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,31,NA,human,Primary human myotubes,Lipofectamine2000,NA,uaguuucugaaauaacauauaccug,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,32,NA,human,Primary human myotubes,Lipofectamine2000,NA,cuuguagacgcugcucaaaauuggcugguu,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,33,NA,human,Primary human myotubes,Lipofectamine2000,NA,ccgucugcuuuuucuguacaaucug,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,35,NA,human,Primary human myotubes,Lipofectamine2000,NA,ucugugauacucuucaggugcaccuucugu,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,37,NA,human,Primary human myotubes,Lipofectamine2000,NA,uucugugugaaauggcugcaaauc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,38,NA,human,Primary human myotubes,Lipofectamine2000,NA,ugaagucuuccucuuucagauucac,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,39,NA,human,Primary human myotubes,Lipofectamine2000,NA,uuuccucucgcuuucucucaucugugauuc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,41,NA,human,Primary human myotubes,Lipofectamine2000,NA,caagcccucagcuugccuacgcacug,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,42,NA,human,Primary human myotubes,Lipofectamine2000,NA,aucguuucuucacggacagugugcugg,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,47,NA,human,Primary human myotubes,Lipofectamine2000,NA,caggggcaacucuuccaccaguaacugaaa,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,49,NA,human,Primary human myotubes,Lipofectamine2000,NA,cugcuauuucaguuuccuggggaaaag,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,51,NA,human,Primary human myotubes,Lipofectamine2000,NA,acaucaaggaagauggcauuucuag,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,52,NA,human,Primary human myotubes,Lipofectamine2000,NA,uccaacuggggacgccucuguuccaaaucc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,53,NA,human,Primary human myotubes,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,72,NA,human,Primary human myotubes,Lipofectamine2000,NA,gugugaaagcugaggggacgaggcagg,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,74,NA,human,Primary human myotubes,Lipofectamine2000,NA,cgaggcuggcucaggggggaguccu,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,75,NA,human,Primary human myotubes,Lipofectamine2000,NA,ggacaggccuuuauguucgugcugc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,77,NA,human,Primary human myotubes,Lipofectamine2000,NA,cugugcuuguguccuggggaggacuga,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,78,NA,human,Primary human myotubes,Lipofectamine2000,NA,ucucauuggcuuuccagggguauuuc,2OMe,NA,0.3-0.6,uM,skip[%],30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,11,NA,human,Primary human myotubes,Lipofectamine2000,NA,caucuucugauaauuuuccuguu,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,21,NA,human,Primary human myotubes,Lipofectamine2000,NA,gucugcauccaggaacauggguc,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,36,NA,human,Primary human myotubes,Lipofectamine2000,NA,ugugaugugguccacauucuggucaaaagu,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,40,NA,human,Primary human myotubes,Lipofectamine2000,NA,cuuugagaccucaaauccuguu,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,43,NA,human,Primary human myotubes,Lipofectamine2000,NA,ggagagagcuuccuguagcu,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,44,NA,human,Primary human myotubes,Lipofectamine2000,NA,uguucagcuucuguuagccacuga,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,60,NA,human,Primary human myotubes,Lipofectamine2000,NA,cuggcgagcaagguccuugacguggcucac,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,61,NA,human,Primary human myotubes,Lipofectamine2000,NA,gggcuucaugcagcugccugacucgguccuc,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,68,NA,human,Primary human myotubes,Lipofectamine2000,NA,cauccagucuaggaagagggccgcuuc,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,70,NA,human,Primary human myotubes,Lipofectamine2000,NA,ccucuaagacagucugcacuggca,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,71,NA,human,Primary human myotubes,Lipofectamine2000,NA,aaguugaucagaguaacgggacug,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,73,NA,human,Primary human myotubes,Lipofectamine2000,NA,gauccauugcuguuuuccauuucug,2OMe,NA,0.3-0.6,uM,skip[%],10-30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,26,NA,human,Primary human myotubes,Lipofectamine2000,NA,ccuccuuucuggcauagaccuuccac,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,45,NA,human,Primary human myotubes,Lipofectamine2000,NA,ccaaugccauccuggaguuccuguaa,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,50,NA,human,Primary human myotubes,Lipofectamine2000,NA,ccacucagagcucagaucuucuaacuucc,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,55,NA,human,Primary human myotubes,Lipofectamine2000,NA,cuuggagucuucuaggagcc,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,56,NA,human,Primary human myotubes,Lipofectamine2000,NA,guuauccaaacgucuuuguaacagg,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,58,NA,human,Primary human myotubes,Lipofectamine2000,NA,acucaugauuacacguucuuuaguu,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,59,NA,human,Primary human myotubes,Lipofectamine2000,NA,uccucaggaggcagcucuaaau,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,62,NA,human,Primary human myotubes,Lipofectamine2000,NA,gagauggcucucucccagggacccugg,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,63,NA,human,Primary human myotubes,Lipofectamine2000,NA,ugggauggucccagcaaguuguuug,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,64,NA,human,Primary human myotubes,Lipofectamine2000,NA,gcaaagggccuucugcagucuucggag,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,66,NA,human,Primary human myotubes,Lipofectamine2000,NA,gauccucccuguucguccccuauuaug,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,67,NA,human,Primary human myotubes,Lipofectamine2000,NA,gcgcuggucacaaaauccuguugaac,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,69,NA,human,Primary human myotubes,Lipofectamine2000,NA,ugcuuuagacuccuguaccugaua,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,76,NA,human,Primary human myotubes,Lipofectamine2000,NA,gcugacugcugucggaccucuguagag,2OMe,NA,0.3-0.6,uM,skip[%],10,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,8,NA,human,Primary human myotubes,Lipofectamine2000,NA,gauaggugguaucaacaucuguaa,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,10,NA,human,Primary human myotubes,Lipofectamine2000,NA,caggagcuuccaaaugcugca,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,10,NA,human,Primary human myotubes,Lipofectamine2000,NA,uccucagcagaaagaagccacg,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,17,NA,human,Primary human myotubes,Lipofectamine2000,NA,ugacagccugugaaaucugugag,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,20,NA,human,Primary human myotubes,Lipofectamine2000,NA,cuggcagaauucgauccaccggcuguuc,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,20,NA,human,Primary human myotubes,Lipofectamine2000,NA,cagcaguaguugucaucugcuc,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,34,NA,human,Primary human myotubes,Lipofectamine2000,NA,cauucauuuccuuucgcaucuuacg,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,34,NA,human,Primary human myotubes,Lipofectamine2000,NA,aucucuuugucaauuccauaucugua,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,54,NA,human,Primary human myotubes,Lipofectamine2000,NA,ucugcagaauaaucccggagaag,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,65,NA,human,Primary human myotubes,Lipofectamine2000,NA,gcucaagagauccacugcaaaaaac,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,65,NA,human,Primary human myotubes,Lipofectamine2000,NA,ucugcaggauauccaugggcugguc,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Antisense Oligonucleotide-Induced Exon Skipping Across The Human Dystrophin Gene Transcript,PMID 17285139,DMD,exon,65,NA,human,Primary human myotubes,Lipofectamine2000,NA,gccauacguacguaucauaaacauuc,2OMe,NA,0.3-0.6,uM,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17285139,NA,NA,NA
journal article,Correction Of Prototypic Atm Splicing Mutations And Aberrant Atm Function With Antisense Morpholino Oligonucleotides,PMID 17389389,ATM,exon,55,NA,human,Human lymphoblastoid cell line TAT[C] (7865C>T),Endoporter 8uL/mL,NA,taagcatcacaaagtacctcaacac,unmodified PMO,NA,50,uM,Skip,36,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17389389,NA,NA,NA
journal article,Correction Of Prototypic Atm Splicing Mutations And Aberrant Atm Function With Antisense Morpholino Oligonucleotides,PMID 17389389,ATM,exon,7,NA,human,Human lymphoblastoid cell line IRAT9 (513C>T),Endoporter 8uL/mL,NA,agcctgaaatacacagagaacaatt,unmodified PMO,NA,50,uM,Skip,24,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17389389,NA,NA,NA
journal article,Correction Of Prototypic Atm Splicing Mutations And Aberrant Atm Function With Antisense Morpholino Oligonucleotides,PMID 17389389,ATM,exon,28,NA,human,Human lymphoblastoid cell line AT203LA (ivs28-159A>G),Endoporter 8uL/mL,NA,gacagctcaaaaggcatatattacc,unmodified PMO,NA,50,uM,Inclusion [%],56,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17389389,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,2,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cccauuuugugaauguuuucuuuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,2,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uugugcauuuacccauuuugug,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,2,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gaaaauugugcauuuacccauuuu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,8,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuuccuggauggcuucaau,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,8,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,guacauuaagauggacuuc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,17,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ccauuacaguugucuguguu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,17,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uaaucugccucuucuuuugg,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,19,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ucugcuggcaucuugc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,29,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uauccucugaaugucgcauc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,29,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gguuauccucugaaugucgc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,29,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ccaucuguuagggucugug,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,29,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ucugugccaauaugcgaauc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,29,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuaaaugucucaaguucc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,29,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,guaguucccuccaacg,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,29,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cauguaguucccucc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,40,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gagccuuuuuucuucuuug,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,40,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uccuuucgucucugggcuc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cugacaagauauucuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,41,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuccucuuucuucuucugc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,41,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuucgaaacugagcaaauuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,42,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuugugagacaugagug,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,42,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cagagacuccucuugcuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,43,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ugcugcugucuucuugcu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,43,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuguuaacuuuuucccauu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,43,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uguuaacuuuuucccauugg,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,43,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cauuuuguuaacuuuuuccc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,43,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuguagcuucacccuuucc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,44,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cgccgccauuucucaacag,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,44,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuuguauuuagcauguuccc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,45,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gcugaauuauuucuucccc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,45,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuuuucugucugacagcug,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,45,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ucuguuuuugaggauugc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,45,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ccaccgcagauucaggc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,45,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gcccaaugccauccugg,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,45,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuugcagaccuccugcc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cugcuuccuccaacc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,guuaucugcuuccuccaacc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gcuuuucuuuuaguugcugc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuaguugcugcucuu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gaaauucugacaagauauucu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uaaaacaaauucauu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uccagguucaagugggauac,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuccagguucaagug,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ucaagcuuuucuuuuag,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,agguucaagugggauacua,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,47,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ucuugcucuucugggcuu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,47,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuugagcuuauuuucaaguuu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,47,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uccaguuucauuuaauuguuug,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,47,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cugcuugagcuuauuuucaaguu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,47,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,agcacuuacaagcacgggu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,47,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uucaaguuuaucuugcucuuc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuucuccuuguuucuc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ccauaaauuuccaacugauuc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ggucuuuuauuugagcuuc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuucaagcuuuuuuucaagcu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gcuucaauuucuccuuguu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuuauuugagcuucaauuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gcugcccaaggucuuuu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuucaaggucuucaagcuuuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uaacugcucuucaaggucuuc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,49,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuuccacauccgguuguuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,49,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,guggcugguuuuuccuugu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,50,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cucagagcucagaucuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,50,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ggcugcuuugcccuc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,51,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ucaaggaagauggcauuucu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,51,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gaaagccagucgguaaguuc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,51,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cacccaccaucaccc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,51,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ccucugugauuuuauaacuugau,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,51,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ugauauccucaaggucaccc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,52,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uugcuggucuuguuuuuc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,52,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ccguaaugauuguucu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,53,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuguugccuccgguucug,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,53,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuggcucuggccuguccu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,54,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uacauuugucugccacugg,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,54,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cccggagaaguuucaggg,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,55,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuguugcaguaaucuaugag,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,55,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ugccauuguuucaucagcucuuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,55,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ugcaguaaucuaugaguuuc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,55,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uccuguaggacauuggcagu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,55,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gagucuucuaggagccuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,56,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuuuuuggcuguuuucaucc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,56,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,guucacuccacuugaaguuc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,56,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ccuuccagggaucucagg,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,57,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uaggugccugccggcuu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,57,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cugaacugcuggaaagucgcc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,57,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uucagcuguagccacacc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,58,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uucuuuaguuuucaauucccuc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,58,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gaguuucucuaguccuucc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,59,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,caauuuuucccacucaguauu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,59,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uugaaguuccuggagucuu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,60,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,guucucuuucagaggcgc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,60,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gugcugagguuauacggug,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,61,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gucccugugggcuucaug,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,61,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gugcugagaugcuggacc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,62,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uggcucucucccaggg,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,62,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gggcacuuuguuuggcg,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,63,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ggucccagcaaguuguuug,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,63,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,guagagcucugucauuuuggg,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,71,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gccagaaguugaucagagu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,71,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ucuacuggccagaaguug,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,72,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ugaguaucaucgugugaaag,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,72,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gcauaauguucaaugcgug,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,73,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gauccauugcuguuuucc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,73,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gagaugcuaucauuuagauaa,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,74,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cuggcucaggggggagu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,74,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uccccucuuuccucacucu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,75,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ccuuuauguucgugcugcu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,75,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ggcggccuuuguguugac,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,76,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gagagguagaaggagagga,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,76,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,auaggcugacugcugucgg,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,77,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,uuguguccuggggagga,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,77,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ugcuccaucaccuccucu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,78,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gcuuuccagggguauuuc,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,78,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,cauuggcuuuccagggg,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,gaaauucugacaagauauucu,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mrna By Interfering With The Binding Of Sr Proteins And By Interfering With Secondary Rna Structure.,US20160355810A1,DMD,exon,56,NA,human,healthy control myotube cultures,"PEI (ExGen 500, MBI Fermentas), 2-3.5 ?l/?g AO",NA,ccuuccagggaucucagg,2OMe,NA,unspecified,Null,Skip,25,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,2,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,cccauuuugugaauguuuucuuuu,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,2,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,uugugcauuuacccauuuugug,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,29,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,uauccucugaaugucgcauc,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,29,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,gguuauccucugaaugucgc,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,40,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,gagccuuuuuucuucuuug,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,40,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,uccuuucgucucugggcuc,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,41,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,cuccucuuucuucuucugc,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,41,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,cuucgaaacugagcaaauuu,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,42,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,cuugugagacaugagug,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,42,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,cagagacuccucuugcuu,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,43,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,ugcugcugucuucuugcu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,43,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,uuguuaacuuuuucccauu,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,44,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,cgccgccauuucucaacag,2OMe,NA,1,uM,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,44,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,uuuguauuuagcauguuccc,2OMe,NA,1,uM,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,45,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,gcugaauuauuucuucccc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,45,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,gcccaaugccauccugg,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,cugcuuccuccaacc,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,46,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,gcuuuucuuuuaguugcugc,2OMe,NA,unspecified,Null,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,47,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,ucuugcucuucugggcuu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,47,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,cuugagcuuauuuucaaguuu,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,uuucuccuuguuucuc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,48,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,uuauaaauuuccaacugauuc,2OMe,NA,unspecified,Null,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,49,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,cuuccacauccgguuguuu,2OMe,NA,1,uM,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,49,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,guggcugguuuuuccuugu,2OMe,NA,1,uM,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,50,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,cucagagcucagaucuu,2OMe,NA,1,uM,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,50,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,ggcugcuuugcccuc,2OMe,NA,1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,51,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,ucaaggaagauggcauuucu,2OMe,NA,1,uM,Null,induced,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Modulation Of Exon Recognition In Pre-Mena By Intesrrefering Wihh The Secondary Rna Structure.,US20160355810A1,DMD,exon,51,NA,human,Healthy primary human myblasts,"PEI (ExGen 500, MBI Fermentas), 3.5 ?l/?g AO",NA,ccucugugauuuuauaacuugau,2OMe,NA,1,uM,Skip,0,NA,NA,NA,RNA,https://patents.google.com/patent/US20160355810A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,43/ 46/ 53,NA,human,unspecified,Null,NA,agcaagaagacagcagcauugcaaag,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,43/ 46/ 53,NA,human,unspecified,Null,NA,ggaagcuaaggaagaagcugagcagg,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,19,NA,human,Lymphoblastoid cells,Lipofectamine,NA,gcaagatgccagcaga,2OMe,NA,0.2,uM,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,19,NA,human,Lymphoblastoid cells,Lipofectamine,NA,aactgcaagatgccagcagatcagctcaggc,2OMe,NA,0.2,uM,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,45,NA,human,unspecified,Null,NA,aggatggcattgggcagcggcaaactgttgt,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,45,NA,human,unspecified,Null,NA,cagaacattgaatgcaactggggaagaaataa,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,45,NA,human,unspecified,Null,NA,ttcagcaatcctcaaaaacagatgccagtattc,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,45,NA,human,unspecified,Null,NA,tacaggaaaaattgggaagcctgaatctgcgg,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,45,NA,human,unspecified,Null,NA,tggcaggaggtctgcaaacagctgtcagacagaaa,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,45,NA,human,unspecified,Null,NA,acagatgccagtattctacaggaaaaattggg,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,45,NA,human,unspecified,Null,NA,gatgccagtattctacaggaaaaattgggaag,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,45,NA,human,unspecified,Null,NA,aagcctgaatctgcggtggcaggaggtctgca,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
patent,Pharmaceutical Composition For Treatment Of Duchenne Muscular Dystrophy,US 20020055481 A1,DMD,exon,45,NA,human,unspecified,Null,NA,tgcagacctcctgccaccgcagattcaggctt,Others (unspecified?),NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://patents.google.com/patent/US20020055481A1,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,a(l)^a^t(l)^t^5(l)^c^5(l)^t^5(l)^t^t(l)^g^a(l)^a^g(l)^g^5(l)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,a(a)^a^t(a)^t^5(a)^c^5(a)^t^5(a)^t^t(a)^g^a(a)^a^g(a)^g^5(a)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),1.02,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,a(g)^a^t(g)^t^5(g)^c^5(g)^t^5(g)^t^t(g)^g^a(g)^a^g(g)^g^5(g)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),1.67,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,a^a(l)^t^t^5(l)^c^c^t(l)^c^t^t(l)^g^a^a(l)^g^g^5(l)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.934,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,a^a(a)^t^t^5(a)^c^c^t(a)^c^t^t(a)^g^a^a(a)^g^g^5(a)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),1.29,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,a^a(g)^t^t^5(g)^c^c^t(g)^c^t^t(g)^g^a^a(g)^g^g^5(g)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.67,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,t^5(l)^c^5(l)^t^5(l)^t^t(l)^g^a(l)^a^g(l)^g^5(l)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.77,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,t^5(a)^c^5(a)^t^5(a)^t^t(a)^g^a(a)^a^g(a)^g^5(a)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),1.21,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,t^5(g)^c^5(g)^t^5(g)^t^t(g)^g^a(g)^a^g(g)^g^5(g)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.85,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,t^5(l)^c^c^t(l)^c^t^t(l)^g^a^a(l)^g^g^5(l)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.61,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,t^5(a)^c^c^t(a)^c^t^t(a)^g^a^a(a)^g^g^5(a)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.13,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,t^5(g)^c^c^t(g)^c^t^t(g)^g^a^a(g)^g^g^5(g)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),1.15,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,c^5(l)^t^5(l)^t^t(l)^g^a(l)^a^g(l)^g^5(l)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.13,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,c^5(a)^t^5(a)^t^t(a)^g^a(a)^a^g(a)^g^5(a)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.84,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,c^5(g)^t^5(g)^t^t(g)^g^a(g)^a^g(g)^g^5(g)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),1.08,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,c^c^t(l)^c^t^t(l)^g^a^a(l)^g^g^5(l)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.02,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,c^c^t(a)^c^t^t(a)^g^a^a(a)^g^g^5(a)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.07,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,c^c^t(g)^c^t^t(g)^g^a^a(g)^g^g^5(g)^c,Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.67,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,a(m)^a(m)^u(m)^u(m)^c(m)^c(m)^c(m)^u(m)^c(m)^u(m)^u(m)^g(m)^a(m)^a (m)^g(m)^g(m)^c(m)^c(m),Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,u(m)^c(m)^c(m)^c(m)^u(m)^c(m)^u(m)^u(m)^g(m)^a(m)^a(m)^g(m)^g(m)^c (m)^c(m),Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.99,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,58,NA,human,stable-e58,Lipofectamine 2000,NA,c(m)^c(m)^u(m)^c(m)^u(m)^u(m)^g(m)^a(m)^a(m)^g(m)^g(m)^c(m)^c(m),Others,NA,10,nM,Relative expression levels of DMD exon 58 skipped mRNA (ratio),0.83,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,5(l)^t^t(l)^c^5(l)^a^5(l)^t^5(l)^a^g(l)^a^g(l)^c^t(l)^c^a(l)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.36,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,5(a)^t^t(a)^c^5(a)^a^5(a)^t^5(a)^a^g(a)^a^g(a)^c^t(a)^c^a(a)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.49,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,5(g)^t^t(g)^c^5(g)^a^5(g)^t^5(g)^a^g(g)^a^g(g)^c^t(g)^c^a(g)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.505,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c^t(l)^t^c^5(l)^a^c^t(l)^c^a^g(l)^a^g^5(l)^t^c^a(l)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),1.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c^t(a)^t^c^5(a)^a^c^t(a)^c^a^g(a)^a^g^5(a)^t^c^a(a)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),2.87,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c^t(g)^t^c^5(g)^a^c^t(g)^c^a^g(g)^a^g^5(g)^t^c^a(g)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.24,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c^5(l)^a^5(l)^t^5(l)^a^g(l)^a^g(l)^c^t(l)^c^a(l)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.14,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c^5(a)^a^5(a)^t^5(a)^a^g(a)^a^g(a)^c^t(a)^c^a(a)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.83,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c^5(g)^a^5(g)^t^5(g)^a^g(g)^a^g(g)^c^t(g)^c^a(g)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.09,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c^5(l)^a^c^t(l)^c^a^g(l)^a^g^5(l)^t^c^a(l)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.115,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c^5(a)^a^c^t(a)^c^a^g(a)^a^g^5(a)^t^c^a(a)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.72,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c^5(g)^a^c^t(g)^c^a^g(g)^a^g^5(g)^t^c^a(g)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.41,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,a^5(l)^t^5(l)^a^g(l)^a^g(l)^c^t(l)^c^a(l)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.01,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,a^5(a)^t^5(a)^a^g(a)^a^g(a)^c^t(a)^c^a(a)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.074,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,a^5(g)^t^5(g)^a^g(g)^a^g(g)^c^t(g)^c^a(g)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.01,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,a^c^t(l)^c^a^g(l)^a^g^5(l)^t^c^a(l)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.005,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,a^c^t(a)^c^a^g(a)^a^g^5(a)^t^c^a(a)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.033,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,a^c^t(g)^c^a^g(g)^a^g^5(g)^t^c^a(g)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.005,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c(m)^u(m)^u(m)^c(m)^c(m)^a(m)^c(m)^u(m)^c(m)^a(m)^ g(m)^a(m)^g(m)^c(m)^u(m)^c(m)^a(m)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.99,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c(m)^c(m)^a(m)^c(m)^u(m)^c(m)^a(m)^g(m)^a(m)^g(m)^ c(m)^u(m)^c(m)^a(m)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.11,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,a(m)^c(m)^u(m)^c(m)^a(m)^g(m)^a(m)^g(m)^c(m)^u(m)^ c(m)^a(m)^g,Others,NA,10,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.01,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,Stable-e50,Lipofectamine 2000,NA,c^g(l)^c^5(l)^t^t(l)^c^5(l)^a^5(l)^t^5(l)^a^g(l)^a^g(l)^c^ t(l)^c^a(l)^g,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.092,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,c^g(a)^c^5(a)^t^t(a)^c^5(a)^a^5(a)^t^5(a)^a^g(a)^a^g(a)^c^ t(a)^c^a(a)^g,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.62,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,c^g(g)^c^5(g)^t^t(g)^c^5(g)^a^5(g)^t^5(g)^a^g(g)^a^g(g)^ c^t(g)^c^a(g)^g,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.71,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,c^g(l)^c^c^t(l)^t^c^5(l)^a^c^t(l)^c^a^g(l)^a^g^5(l)^t^c^ a(l)^g,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),2.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,c^g(a)^c^c^t(a)^t^c^5(a)^a^c^t(a)^c^a^g(a)^a^g^5(a)^t^c^ a(a)^g,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),3.84,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,c^g(g)^c^c^t(g)^t^c^5(g)^a^c^t(g)^c^a^g(g)^a^g^5(g)^t^c^ a(g)^g,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),1.37,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,c(m)^g(m)^c(m)^c(m)^u(m)^u(m)^c(m)^c(m)^a(m)^c(m)^ u(m)^c(m)^a(m)^g(m)^a(m)^g(m)^c(m)^u(m)^c(m)^a(m)^g,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),3.04,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,c^a(l)^g^a(l)^t^5(l)^t^t(l)^c^t(l)^a^a(l)^c^t(l)^t,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,a^g(l)^c^t(l)^c^a(l)^g^a(l)^t^5(l)^t^t(l)^c^t(l)^a,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.79,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,t^5(l)^a^g(l)^a^g(l)^c^t(l)^c^a(l)^g^a(l)^t^5(l)^t,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.43,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,c^5(l)^t^t(l)^c^5(l)^a^5(l)^t^5(l)^a^g(l)^a^g(l)^c,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),1.1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,t^g(l)^g^t(l)^c^a(l)^g^t(l)^c^5(l)^a^g(l)^g^a(l)^g,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),3.66,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,a^t(l)^a^g(l)^t^g(l)^g^t(l)^c^a(l)^g^t(l)^c^5(l)^a,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),0.015,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,t^5(l)^c^a(l)^a^t(l)^a^g(l)^t^g(l)^g^t(l)^c^a(l)^g,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),2.28,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,stable-e50,Lipofectamine 2000,NA,a^g(l)^g^5(l)^t^5(l)^c^a(l)^a^t(l)^a^g(l)^t^g(l)^g,Others,NA,30,nM,Relative expression levels of DMD exon 50 skipped mRNA (ratio),1,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,HSMM myotube,Lipofectamine 2000,NA,c^t(l)^t^c^5(l)^a^c^t(l)^c^a^g(l)^a^g^5(l)^t^c^a(l)^g,Others,NA,30,nM,Skip,0.71,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,HSMM myotube,Lipofectamine 2000,NA,c^t(a)^t^c^5(a)^a^c^t(a)^c^a^g(a)^a^g^5(a)^t^c^a(a)^g,Others,NA,30,nM,Skip,0.67,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,HSMM myotube,Lipofectamine 2000,NA,c^t(g)^t^c^5(g)^a^c^t(g)^c^a^g(g)^a^g^5(g)^t^c^a(g)^g,Others,NA,30,nM,Skip,0.47,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,"Design And In Vitro Evaluation Of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, And Guanidine-Bridged Nucleic Acids",PMID 33805378,DMD,exon,50,NA,human,HSMM myotube,Lipofectamine 2000,NA,c(m)^u(m)^c(m)^a(m)^g(m)^a(m)^g(m)^c(m)^u(m)^c(m)^a(m)^g(m)^a(m)^u(m)^ c(m)^u(m)^u(m),Others,NA,30,nM,Skip,0.45,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33805378,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,aucaggucccacgaugaucccacuu,2OMe,NA,200,nM,Exon 52 skipped [%],41,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,aucaggucccacgaugaucccacuu,2OMe,NA,100,nM,Exon 52 skipped [%],38,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,aucaggucccacgaugaucccacuu,2OMe,NA,50,nM,Exon 52 skipped [%],34,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,atcaggtcccacgatgatcccactt,unmodified PMO,NA,250,nM,Exon 52 skipped [%],100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,atcaggtcccacgatgatcccactt,unmodified PMO,NA,50,nM,Exon 52 skipped [%],53,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,aucaggucccacaaugaucccacuu,2OMe,NA,200,nM,Exon 52 skipped [%],40,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,aucaggucccacaaugaucccacuu,2OMe,NA,100,nM,Exon 52 skipped [%],35,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,aucaggucccacaaugaucccacuu,2OMe,NA,50,nM,Exon 52 skipped [%],26,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,uaucuggcggaaggccucuguggug,2OMe,NA,200,nM,Exon 52 skipped [%],0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,uaucuggcggaaggccucuguggug,2OMe,NA,100,nM,Exon 52 skipped [%],0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,uaucuggcggaaggccucuguggug,2OMe,NA,50,nM,Exon 52 skipped [%],0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,caggcaacugaccaacugcugaauc,2OMe,NA,200,nM,Exon 52 skipped [%],37,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,caggcaacugaccaacugcugaauc,2OMe,NA,100,nM,Exon 52 skipped [%],34,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,caggcaacugaccaacugcugaauc,2OMe,NA,50,nM,Exon 52 skipped [%],27,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,cucugugguggagacacucauuaau,2OMe,NA,200,nM,Exon 52 skipped [%],0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,cucugugguggagacacucauuaau,2OMe,NA,100,nM,Exon 52 skipped [%],0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,cucugugguggagacacucauuaau,2OMe,NA,50,nM,Exon 52 skipped [%],0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,cauaaggacauaucuggcggaaggc,2OMe,NA,200,nM,Exon 52 skipped [%],22,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,cauaaggacauaucuggcggaaggc,2OMe,NA,100,nM,Exon 52 skipped [%],18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Proof-Of-Concept: Antisense Oligonucleotide Mediated Skipping Of Fibrillin-1 Exon 52,PMID 33801742,FBN1,exon,52,NA,human,fibroblasts,D-Nucleofector? & P3 nucleofection kits,NA,cauaaggacauaucuggcggaaggc,2OMe,NA,50,nM,Exon 52 skipped [%],19,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/33801742,NA,NA,NA
journal article,Development Of Antisense-Mediated Myostatin Knockdown For The Treatment Of Insulin Resistance,PMID 33452345,MSTN,exon,2,NA,mouse,Null,Null,NA,tcttgacgggtctgagatatatccacagtt,unmodified PMO,NA,first exp: 5; second exp:5; third exp:100,first exp: nmol/50 uL of saline weekly for 4 weeks; second exp: nmol per weekly injection of PMO; third exp: nmol injected weekly for five weeks,fl myostatin expression,38,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33452345,NA,NA,NA
journal article,Development Of Antisense-Mediated Myostatin Knockdown For The Treatment Of Insulin Resistance,PMID 33452345,MSTN,exon,2,NA,mouse,Null,Null,NA,ttttcagttatcacttaccagcccatcttc,unmodified PMO,NA,first exp: 5; second exp:5; third exp:101,first exp: nmol/50 uL of saline weekly for 4 weeks; second exp: nmol per weekly injection of PMO; third exp: nmol injected weekly for five weeks,fl myostatin expression,38,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33452345,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,actatgactggagtccatat,Others (ENA)/2OMe,NA,100,nM,exon skipping index,13.17,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,ttgcagtaggctgaagcgtt,Others (ENA)/2OMe,NA,100,nM,exon skipping index,16.89,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,caaacctgtgtttggatttg,Others (ENA)/2OMe,NA,100,nM,exon skipping index,6.44,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,aagaggtcctgtcctgtcca,Others (ENA)/2OMe,NA,100,nM,exon skipping index,1.57,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,ccaccaaacctgtgtttgga,Others (ENA)/2OMe,NA,100,nM,exon skipping index,0.85,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,ctgtccaaatcttccaccaa,Others (ENA)/2OMe,NA,100,nM,exon skipping index,6.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,gcgttgtcattgaaagaggt,Others (ENA)/2OMe,NA,100,nM,exon skipping index,51.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,actatgactggagtccatat,Others (ENA)/2OMe,NA,100,nM,exon skipping index,1.35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,ttgcagtaggctgaagcgtt,Others (ENA)/2OMe,NA,100,nM,exon skipping index,37,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,caaacctgtgtttggatttg,Others (ENA)/2OMe,NA,100,nM,exon skipping index,2.26,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,aagaggtcctgtcctgtcca,Others (ENA)/2OMe,NA,100,nM,exon skipping index,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,ccaccaaacctgtgtttgga,Others (ENA)/2OMe,NA,100,nM,exon skipping index,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,ctgtccaaatcttccaccaa,Others (ENA)/2OMe,NA,100,nM,exon skipping index,1.8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,Dual Fluorescence Splicing Reporter Minigene Identifies An Antisense Oligonucleotide To Skip Exon V8 Of The Cd44 Gene,PMID 33266296,CD44,exon,v8,NA,human,HeLa cells,Lipofectamine 3000,NA,gcgttgtcattgaaagaggt,Others (ENA)/2OMe,NA,100,nM,exon skipping index,48.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/33266296,NA,NA,NA
journal article,A Role For Alternative Splicing In Circadian Control Of Exocytosis And Glucose Homeostasis,PMID 32616519,CASK,exon,11,NA,human,Bmal1?/? and Clock?/? -TC6 cells,Null,NA,ctaggaggaaggcagcatatggaca,unmodified PMO,NA,2.5,uM,reduction in inclusion[%],81,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/32616519,NA,NA,NA
journal article,A Role For Alternative Splicing In Circadian Control Of Exocytosis And Glucose Homeostasis,PMID 32616519,MADD,exon,26,NA,human,Bmal1?/? and Clock?/? -TC6 cells,Null,NA,ttgtcccttcctgccaatttgtgag,unmodified PMO,NA,5,uM,reduction in inclusion[%],90,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/32616519,NA,NA,NA
journal article,A Role For Alternative Splicing In Circadian Control Of Exocytosis And Glucose Homeostasis,PMID 32616519,SNAP25A,exon,5a,NA,human,Bmal1?/? and Clock?/? -TC6 cells,Null,NA,ctggttaggacaaagggatgatagt,unmodified PMO,NA,1,uM,reduction in inclusion[%],90,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/32616519,NA,NA,NA
journal article,A Role For Alternative Splicing In Circadian Control Of Exocytosis And Glucose Homeostasis,PMID 32616519,SNAP25B,exon,5b,NA,human,Bmal1?/? and Clock?/? -TC6 cells,Null,NA,ccagttgttctgattaaacacaagt,unmodified PMO,NA,1,uM,reduction in inclusion[%],80,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/32616519,NA,NA,NA
journal article,A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity Of Splice Isoforms Of Spinal Muscular Atrophy Genes,PMID 23185376,SMN2,exon,3,NA,human,HeLa,Lipofectamine 2000,NA,uauccuuaccucuugagcau,2OMe,NA,100,nM,Skip,40.63,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23185376,NA,NA,NA
journal article,A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity Of Splice Isoforms Of Spinal Muscular Atrophy Genes,PMID 23185376,SMN2,exon,5,NA,human,HeLa,Lipofectamine 2000,NA,uuuacuuacuggugguccag,2OMe,NA,100,nM,Skip,51.11,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23185376,NA,NA,NA
journal article,A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity Of Splice Isoforms Of Spinal Muscular Atrophy Genes,PMID 23185376,SMN2,exon,7,NA,human,GM03813 fibroblasts,Lipofectamine 2000,NA,gcuggcag,2OMe,NA,50,nM,Skip,26.44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23185376,NA,NA,NA
journal article,A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity Of Splice Isoforms Of Spinal Muscular Atrophy Genes,PMID 23185376,SMN2,exon,7,NA,human,GM03813 fibroblasts,Lipofectamine 2000,NA,gcugucag,2OMe,NA,50,nM,Skip,36.42,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23185376,NA,NA,NA
journal article,A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity Of Splice Isoforms Of Spinal Muscular Atrophy Genes,PMID 23185376,SMN2,exon,7,NA,human,GM03813 fibroblasts,Lipofectamine 2000,NA,gcuggcag,2OMe,NA,50,nM,Skip,11.47,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23185376,NA,NA,NA
journal article,A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity Of Splice Isoforms Of Spinal Muscular Atrophy Genes,PMID 23185376,SMN2,exon,7,NA,human,GM03813 fibroblasts,Lipofectamine 2000,NA,gcugucag,2OMe,NA,50,nM,Skip,7.11,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23185376,NA,NA,NA
journal article,A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity Of Splice Isoforms Of Spinal Muscular Atrophy Genes,PMID 23185376,SMN2,exon,7,NA,human,GM03813 fibroblasts,Lipofectamine 2000,NA,gcuggcag,2OMe,NA,50,nM,Skip,13.09,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23185376,NA,NA,NA
journal article,A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity Of Splice Isoforms Of Spinal Muscular Atrophy Genes,PMID 23185376,SMN2,exon,7,NA,human,GM03813 fibroblasts,Lipofectamine 2000,NA,gcugucag,2OMe,NA,50,nM,Skip,17.58,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23185376,NA,NA,NA
journal article,AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?,PMID 31091803,CEP290,exon,36,NA,human,patient fibroblasts,Lipofectamine2000,NA,uagaaucuuacccaagccguuu,2OMe,NA,Null,Null,Relative expression of mRNA level,65.63,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31091803,NA,NA,NA
journal article,AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?,PMID 31091803,CEP290,exon,36,NA,human,patient fibroblasts,Lipofectamine2000,NA,uagaaucuuacccaagccguuu,2OMe,NA,Null,Null,Relative expression of mRNA level,62.36,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/31091803,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,JetMessenger,NA,ccucuuaccucaguuacda,2OMe,NA,0.2,uM,fold increase,4.45,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,ccucuuaccucaguuacda,2OMe,NA,0.6,uM,fold increase,11.3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,ccucuuaccucaguuacda,2OMe,NA,0.6,uM,fold increase,0.97,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s5-ccucuuaccucaguuacda,2OMe,NA,Null,uM,fold increase,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ccucuuaccucaguuacda,2OMe,NA,0.3,uM,fold increase,1.13,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ccucuuaccucaguuacda,2OMe,NA,0.4,uM,fold increase,1.59,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ccucuuaccucaguuacda,2OMe,NA,0.5,uM,fold increase,3.18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ccucuuaccucaguuacda,2OMe,NA,0.6,uM,fold increase,2.72,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ccucuuaccucaguuacda,2OMe,NA,0.4,uM,fold increase,2.62,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ccucuuaccucaguuacda,2OMe,NA,0.7,uM,fold increase,6.4,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ccucuuaccucaguuacda,2OMe,NA,1,uM,fold increase,10.97,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s20-ccucuuaccucaguuacda,2OMe,NA,0.3,uM,fold increase,1.18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s20-ccucuuaccucaguuacda,2OMe,NA,0.4,uM,fold increase,3.18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s20-ccucuuaccucaguuacda,2OMe,NA,0.5,uM,fold increase,13.86,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s20-ccucuuaccucaguuacda,2OMe,NA,0.6,uM,fold increase,39.3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s20-ccucuuaccucaguuacda,2OMe,NA,0.4,uM,fold increase,2.31,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s20-ccucuuaccucaguuacda,2OMe,NA,0.7,uM,fold increase,8.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s20-ccucuuaccucaguuacda,2OMe,NA,1,uM,fold increase,13.96,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s30-ccucuuaccucaguuacda,2OMe,NA,0.3,uM,fold increase,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ccucuuacaucaguuacda,2OMe,NA,Null,uM,fold increase,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-acuacccgauaucuccudc,2OMe,NA,0.3,uM,fold increase,6.81,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-acuacccgauaucuccudc,2OMe,NA,0.6,uM,fold increase,11.3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ugagacuuccacacugadt,2OMe,NA,0.3,uM,fold increase,9,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ugagacuuccacacugadt,2OMe,NA,0.6,uM,fold increase,13.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s15-ugagacuuccacacugadt,2OMe,NA,1,uM,fold increase,1.6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,ccucuuaccucaguuaca-f,2OMe,NA,0.4,uM,fold increase,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,ccucuuaccucaguuaca-f,2OMe,NA,1,uM,fold increase,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Cationic Oligospermine-Oligonucleotide Conjugates Provide Carrier-Free Splice Switching In Monolayer Cells And Spheroids,PMID 30388622,LUC,intron,705 splice site,NA,human,HeLa pLuc/705 cells,Null,NA,s20-ccucuuaccucaguuaca-f,2OMe,NA,0.7,uM,fold increase,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/30388622,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,gaactctgtcctgataggtc,Others (modified 2OMe),NA,200,nM,Skip,0,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,gctgttgctgcttttgctgctg,Others (modified 2OMe),NA,200,nM,Skip,43.07,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,ctgttgctgcttttgctgct,Others (modified 2OMe),NA,200,nM,Skip,49.99,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,ctagatcactcccaagtgct,Others (modified 2OMe),NA,200,nM,Skip,5.62,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,ataggtcccgctgctgct,Others (modified 2OMe),NA,200,nM,Skip,40.84,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,mouse,MJD84.2 mice,intracerebroventricularly injection,NA,gctgttgctgcttttgctgctg,Others (modified 2OMe),NA,500,?g,Skip,0,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,mouse,MJD84.2 mice,intracerebroventricularly injection,NA,gctgttgctgcttttgctgctg,Others (modified 2OMe),NA,500,?g,Skip,29.75,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,mouse,MJD84.2 mice,intracerebroventricularly injection,NA,gaactctgtcctgataggtc,Others (modified 2OMe),NA,500,?g,Skip,0,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,mouse,MJD84.2 mice,intracerebroventricularly injection,NA,gaactctgtcctgataggtc,Others (modified 2OMe),NA,500,?g,Skip,0,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,mouse,MJD84.2 mice,intracerebroventricularly injection,NA,ctagatcactcccaagtgct,Others (modified 2OMe),NA,500,?g,Skip,0,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,mouse,MJD84.2 mice,intracerebroventricularly injection,NA,ctagatcactcccaagtgct,Others (modified 2OMe),NA,500,?g,Skip,0,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,mouse,MJD84.2 mice,intracerebroventricularly injection,NA,ataggtcccgctgctgct,Others (modified 2OMe),NA,500,?g,Skip,34.76,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Removal Of The Polyglutamine Repeat In Spinocerebellar Ataxia Type 3 Mice,PMC5504086,ATXN3,exon,10,NA,mouse,MJD84.2 mice,intracerebroventricularly injection,NA,ataggtcccgctgctgct,Others (modified 2OMe),NA,500,?g,Skip,47.178,NA,NA,NA,DNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504086,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ggccaaaccucggcuuaccu,Others (modified 2OMe),NA,100,nM,Skip,52,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,100,nM,Skip,49,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclctlcggctluaccl,Others (modified 2OMe),NA,100,nM,Skip,51,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,100,nM,Skip,55,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,glclcaaaccucggcuuaclcl,Others (modified 2OMe),NA,100,nM,Skip,56,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,100,nM,Skip,23,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclctlcggctluacl,Others (modified 2OMe),NA,100,nM,Skip,44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,100,nM,Skip,48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,clclaaaccucggcuualcl,Others (modified 2OMe),NA,100,nM,Skip,50,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctlcggctlual,Others (modified 2OMe),NA,100,nM,Skip,33,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,100,nM,Skip,43,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,clalaaccucggcutlal,Others (modified 2OMe),NA,100,nM,Skip,37,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaacctcggcut,Others (modified 2OMe),NA,100,nM,Skip,6,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,100,nM,Skip,14,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggctt,Others (modified 2OMe),NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ggccaaaccucggcuuaccu,Others (modified 2OMe),NA,200,nM,Skip,57,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,200,nM,Skip,53,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclctlcggctluaccl,Others (modified 2OMe),NA,200,nM,Skip,61,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,200,nM,Skip,66,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,glclcaaaccucggcuuaclcl,Others (modified 2OMe),NA,200,nM,Skip,59,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,200,nM,Skip,30,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclctlcggctluacl,Others (modified 2OMe),NA,200,nM,Skip,53,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,200,nM,Skip,60,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,clclaaaccucggcuualcl,Others (modified 2OMe),NA,200,nM,Skip,59,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,200,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctlcggctlual,Others (modified 2OMe),NA,200,nM,Skip,44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,200,nM,Skip,57,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,clalaaccucggcutlal,Others (modified 2OMe),NA,200,nM,Skip,48,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,200,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaacctcggcut,Others (modified 2OMe),NA,200,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,200,nM,Skip,24,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggctt,Others (modified 2OMe),NA,200,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ggccaaaccucggcuuaccu,Others (modified 2OMe),NA,400,nM,Skip,65,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,400,nM,Skip,64,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclctlcggctluaccl,Others (modified 2OMe),NA,400,nM,Skip,65,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,400,nM,Skip,72,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,glclcaaaccucggcuuaclcl,Others (modified 2OMe),NA,400,nM,Skip,56,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,400,nM,Skip,39,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclctlcggctluacl,Others (modified 2OMe),NA,400,nM,Skip,61,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,400,nM,Skip,75,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,clclaaaccucggcuualcl,Others (modified 2OMe),NA,400,nM,Skip,63,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,400,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctlcggctlual,Others (modified 2OMe),NA,400,nM,Skip,58,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,400,nM,Skip,66,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,clalaaccucggcutlal,Others (modified 2OMe),NA,400,nM,Skip,56,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,400,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaacctcggcut,Others (modified 2OMe),NA,400,nM,Skip,9,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,400,nM,Skip,29,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggctt,Others (modified 2OMe),NA,400,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,12.5,nM,Skip,41,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,12.5,nM,Skip,50,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,12.5,nM,Skip,16,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,12.5,nM,Skip,44,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,12.5,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,12.5,nM,Skip,31,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,12.5,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,12.5,nM,Skip,20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,25,nM,Skip,55,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,25,nM,Skip,60,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,25,nM,Skip,32,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,25,nM,Skip,58,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,25,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,25,nM,Skip,54,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,25,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,25,nM,Skip,20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,50,nM,Skip,55,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,50,nM,Skip,74,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,50,nM,Skip,34,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,50,nM,Skip,68,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,50,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,50,nM,Skip,55,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,50,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,50,nM,Skip,7,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,100,nM,Skip,68,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,100,nM,Skip,76,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,100,nM,Skip,43,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,100,nM,Skip,77,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,100,nM,Skip,68,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,100,nM,Skip,19,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,12.5,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,12.5,nM,Skip,11,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,12.5,nM,Skip,3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,12.5,nM,Skip,20,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,12.5,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,12.5,nM,Skip,17,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,12.5,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,12.5,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,25,nM,Skip,16,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,25,nM,Skip,18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,25,nM,Skip,12,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,25,nM,Skip,8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,25,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,25,nM,Skip,16,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,25,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,25,nM,Skip,3,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,50,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,50,nM,Skip,19,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,50,nM,Skip,26,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,50,nM,Skip,16,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,50,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,50,nM,Skip,15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,50,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,50,nM,Skip,19,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaccucggcuuacc,Others (modified 2OMe),NA,100,nM,Skip,25,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,gccaaaclcucggctlualccl,Others (modified 2OMe),NA,100,nM,Skip,21,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaccucggcuuac,Others (modified 2OMe),NA,100,nM,Skip,18,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,ccaaaclcucggclutlacl,Others (modified 2OMe),NA,100,nM,Skip,11,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaccucggcuua,Others (modified 2OMe),NA,100,nM,Skip,19,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,caaaclctcgglcluual,Others (modified 2OMe),NA,100,nM,Skip,15,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcuu,Others (modified 2OMe),NA,100,nM,Skip,0,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro,PMID 29246294,DMD,exon,23,NA,human,H2K mdx cells,Lipofectin,NA,aaaccucggcut,Others (modified 2OMe),NA,100,nM,Skip,12,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/29246294,NA,NA,NA
journal article,A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model,PMID 28663100,SOD1,exon,2,NA,human,HEK293T,Oligofectamine,NA,cccacaccuucacuggucca,2OMe,NA,1,ug/uL,relative mRNA expression,0.233,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/28663100,NA,NA,NA
journal article,A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model,PMID 28663100,SOD1,exon,2,NA,human,HEK293T,Oligofectamine,NA,ggccuucagucaguccuuua,2OMe,NA,1,ug/uL,relative mRNA expression,0.494,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/28663100,NA,NA,NA
journal article,A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model,PMID 28663100,SOD1,exon,2,NA,human,HEK293T,Oligofectamine,NA,cugguccauuacuuuccuuu,2OMe,NA,1,ug/uL,relative mRNA expression,0.306,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/28663100,NA,NA,NA
journal article,A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model,PMID 28663100,SOD1,exon,2,NA,human,HEK293T,Oligofectamine,NA,ccaugcaggccuucagucag,2OMe,NA,1,ug/uL,relative mRNA expression,0.286,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/28663100,NA,NA,NA
journal article,A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model,PMID 28663100,SOD1,exon,2,NA,human,HEK293T,Oligofectamine,NA,cugcuguauuaucuccaaac,2OMe,NA,1,ug/uL,relative mRNA expression,0.562,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/28663100,NA,NA,NA
journal article,A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model,PMID 28663100,SOD1,exon,2,NA,human,HEK293T,Oligofectamine,NA,gcucauucgcuuucauucuu,2OMe,NA,1,ug/uL,relative mRNA expression,0.886,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/28663100,NA,NA,NA
journal article,Exon skipping of FcRI eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy,PMID 27872312,MS4A2,exon,3,NA,human,mouse BMMCs,Nucleofector II and Cell Line Kit V (Lonza) + X-001 program,NA,cacaaatatggctccccagaatgga,unmodified PMO,NA,10,uM,Skip,95,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27872312,NA,NA,NA
journal article,Exon skipping of FcRI eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy,PMID 27872312,MS4A2,exon,3,NA,mouse,LAD-2 human mast cells,Nucleofector II and Cell Line Kit V (Lonza) +U025 program,NA,gtgttgcctgtggaaaacatgaatt,unmodified PMO,NA,10,uM,Skip,75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/27872312,NA,NA,NA
journal article,"Synthesis Of A Morpholino Nucleic Acid (Mna)-Uridine Phosphoramidite, And Exon Skipping Using Mna/20 -O-Methyl Mixmer Antisense Oligonucleotide",PMID 27879669,DMD,exon,23,NA,mouse,myotubes,Lipofectin,NA,ggccaaaccucggcuuaccu,2OMe,NA,400,nM,Exon-skipping product [%],61,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27879669,NA,NA,NA
journal article,"Synthesis Of A Morpholino Nucleic Acid (Mna)-Uridine Phosphoramidite, And Exon Skipping Using Mna/20 -O-Methyl Mixmer Antisense Oligonucleotide",PMID 27879669,DMD,exon,23,NA,mouse,myotubes,Lipofectin,NA,ggccaaaccumcggcuuaccu,2OMe/Others (MNA modified uridine),NA,400,nM,Exon-skipping product [%],60,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27879669,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,gcccucugcaaauccuccuc,Others (modified 2OMe),NA,200,nM,Null,Null,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,cuugcauacuuagcugaauagcc,Others (modified 2OMe),NA,200,nM,Null,Null,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,cugcuuccucaucuuccaug,Others (modified 2OMe),NA,200,nM,Null,Null,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,ccucaucuucgucuaacauucc,Others (modified 2OMe),NA,200,nM,Null,Null,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,cacucguuccaggucuguuuu,Others (modified 2OMe),NA,200,nM,Null,Null,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,gagauauguuucuggaacuacc,Others (modified 2OMe),NA,200,nM,Null,Null,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,gcuucucgucucuuccgaagc,Others (modified 2OMe),NA,200,nM,Null,Null,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,ccgaagcucuucugaaguaa,Others (modified 2OMe),NA,200,nM,Null,Null,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,ccugaugucugugucauaucu,Others (modified 2OMe),NA,200,nM,Null,Null,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,cugcuuccucaucuuccaug/gagauauguuucuggaacuacc,Others (modified 2OMe),NA,200,nM,Skip,28,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,cugcuuccucaucuuccaug/gcuucucgucucuuccgaagc,Others (modified 2OMe),NA,200,nM,Skip,4.1,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Exon Skipping As A Strategy To Reduce Proteolytic Cleavage Of Ataxin-3,PMC5059676,ATXN3,exon,"8,9",NA,human,SCA3 patient fibroblast,"Lipofectamine, 0.3%",NA,cugcuuccucaucuuccaug/ccugaugucugugucauaucu,Others (modified 2OMe),NA,200,nM,Skip,12.3,NA,NA,NA,RNA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059676,NA,NA,NA
journal article,Antisense-Mediated Exon Skipping: A Therapeutic Strategy For Titin-Based Dilated Cardiomyopathy,PMID 25759365,TTN,exon,326,NA,human and mouse,iPSC,TransIT-LT1,NA,ugcauuugaaggugguccu,2OMe,NA,600 & 200,nM,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25759365,NA,NA,NA
journal article,Antisense-Mediated Exon Skipping: A Therapeutic Strategy For Titin-Based Dilated Cardiomyopathy,PMID 25759365,TTN,exon,326,NA,human and mouse,iPSC,TransIT-LT2,NA,ccgauuucuuggugguauca,2OMe,NA,600 & 200,nM,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25759365,NA,NA,NA
journal article,Antisense-Mediated Exon Skipping: A Therapeutic Strategy For Titin-Based Dilated Cardiomyopathy,PMID 25759365,TTN,exon,326,NA,human and mouse,iPSC,TransIT-LT3,NA,auccaggcaucaucuccuac,2OMe,NA,600 & 200,nM,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25759365,NA,NA,NA
journal article,Antisense-Mediated Exon Skipping: A Therapeutic Strategy For Titin-Based Dilated Cardiomyopathy,PMID 25759365,TTN,exon,326,NA,human and mouse,iPSC,TransIT-LT4,NA,uugauccaggcaucaucuccu,2OMe,NA,600 & 200,nM,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25759365,NA,NA,NA
journal article,Antisense-Mediated Exon Skipping: A Therapeutic Strategy For Titin-Based Dilated Cardiomyopathy,PMID 25759365,TTN,exon,326,NA,human and mouse,iPSC,TransIT-LT5,NA,uugaugcuccacgacauag,2OMe,NA,600 & 200,nM,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25759365,NA,NA,NA
journal article,Antisense-Mediated Exon Skipping: A Therapeutic Strategy For Titin-Based Dilated Cardiomyopathy,PMID 25759365,TTN,exon,326,NA,human and mouse,iPSC,TransIT-LT6,NA,ccaugccaaagaagcagauu,2OMe,NA,600 & 200,nM,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25759365,NA,NA,NA
journal article,Antisense-Mediated Exon Skipping: A Therapeutic Strategy For Titin-Based Dilated Cardiomyopathy,PMID 25759365,TTN,exon,326,NA,human and mouse,iPSC,TransIT-LT7,NA,agugacaugugcauuugaaggugguccu,2OMe,NA,600 & 200,nM,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25759365,NA,NA,NA
journal article,Antisense-Mediated Exon Skipping: A Therapeutic Strategy For Titin-Based Dilated Cardiomyopathy,PMID 25759365,TTN,exon,326,NA,mouse,HL-1,TransIT-LT1,NA,ugcauuugaaggugguccu/auccaggcaucaucuccuac,2OMe,NA,50,nM,Skip,11.682,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25759365,NA,NA,NA
journal article,Antisense-Mediated Exon Skipping: A Therapeutic Strategy For Titin-Based Dilated Cardiomyopathy,PMID 25759365,TTN,exon,326,NA,mouse,HL-1,TransIT-LT1,NA,ugcauuugaaggugguccu/auccaggcaucaucuccuac,2OMe,NA,100,nM,Skip,18.348,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25759365,NA,NA,NA
journal article,Antisense-Mediated Exon Skipping: A Therapeutic Strategy For Titin-Based Dilated Cardiomyopathy,PMID 25759365,TTN,exon,326,NA,mouse,HL-1,TransIT-LT1,NA,ugcauuugaaggugguccu/auccaggcaucaucuccuac,2OMe,NA,150,nM,Skip,45.866,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/25759365,NA,NA,NA
journal article,Ameliorating Pathogenesis By Removing An Exon Containing A Missense Mutation: A Potential Exon-Skipping Therapy For Laminopathies,PMID 25832542,LMNA,exon,5,NA,human,HeLa,TurboFect,NA,cagctggacaatgccaggca,2OMe,NA,150,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25832542,NA,NA,NA
journal article,Ameliorating Pathogenesis By Removing An Exon Containing A Missense Mutation: A Potential Exon-Skipping Therapy For Laminopathies,PMID 25832542,LMNA,exon,5,NA,human,HeLa,TurboFect,NA,caggcagtctgctgagagga,2OMe,NA,150,nM,Skip,13.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25832542,NA,NA,NA
journal article,Ameliorating Pathogenesis By Removing An Exon Containing A Missense Mutation: A Potential Exon-Skipping Therapy For Laminopathies,PMID 25832542,LMNA,exon,5,NA,human,HeLa,TurboFect,NA,aggagctgcagcagtcgcgc,2OMe,NA,150,nM,Skip,2.3,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25832542,NA,NA,NA
journal article,Ameliorating Pathogenesis By Removing An Exon Containing A Missense Mutation: A Potential Exon-Skipping Therapy For Laminopathies,PMID 25832542,LMNA,exon,5,NA,human,HeLa,TurboFect,NA,ctccagaagcaggtgatacc,2OMe,NA,150,nM,Skip,0,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25832542,NA,NA,NA
journal article,Ameliorating Pathogenesis By Removing An Exon Containing A Missense Mutation: A Potential Exon-Skipping Therapy For Laminopathies,PMID 25832542,LMNA,exon,5,NA,human,HeLa,TurboFect,NA,caggcagtctgctgagagga/aggagctgcagcagtcgcgc,2OMe,NA,75,nM,Skip,0.51,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25832542,NA,NA,NA
journal article,Ameliorating Pathogenesis By Removing An Exon Containing A Missense Mutation: A Potential Exon-Skipping Therapy For Laminopathies,PMID 25832542,LMNA,exon,5,NA,human,HeLa,TurboFect,NA,caggcagtctgctgagagga/aggagctgcagcagtcgcgc,2OMe,NA,100,nM,Skip,22.25,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25832542,NA,NA,NA
journal article,Ameliorating Pathogenesis By Removing An Exon Containing A Missense Mutation: A Potential Exon-Skipping Therapy For Laminopathies,PMID 25832542,LMNA,exon,5,NA,human,HeLa,TurboFect,NA,caggcagtctgctgagagga/aggagctgcagcagtcgcgc,2OMe,NA,150,nM,Skip,64.96,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25832542,NA,NA,NA
journal article,Ameliorating Pathogenesis By Removing An Exon Containing A Missense Mutation: A Potential Exon-Skipping Therapy For Laminopathies,PMID 25832542,LMNA,exon,5,NA,human,human dermal fibroblasts,TurboFect,NA,caggcagtctgctgagagga/aggagctgcagcagtcgcgc,2OMe,NA,60,nM,Skip,22.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25832542,NA,NA,NA
journal article,Ameliorating Pathogenesis By Removing An Exon Containing A Missense Mutation: A Potential Exon-Skipping Therapy For Laminopathies,PMID 25832542,LMNA,exon,5,NA,human,human dermal fibroblasts,TurboFect,NA,cag gca gtc tgc tga gag ga/agg agc tgc agc agt cgc gc,2OMe,NA,75,nM,Skip,40.06,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25832542,NA,NA,NA
journal article,Ameliorating Pathogenesis By Removing An Exon Containing A Missense Mutation: A Potential Exon-Skipping Therapy For Laminopathies,PMID 25832542,LMNA,exon,5,NA,human,human dermal fibroblasts,TurboFect,NA,caggcagtctgctgagagga/aggagctgcagcagtcgcgc,2OMe,NA,100,nM,Skip,72.63,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25832542,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Suppression Of Muscle Glycogen Synthase 1 Synthesis As An Approach For Substrate Reduction Therapy Of Pompe Disease,PMID 25350581,GYS1,intron,intron 7,NA,mouse,C57BL/6J mice,Null,NA,tcagggttgtggactcaatcatgcc,unmodified PMO,NA,15 or 30,mg/ kg bodyweight by tail vein injection once every 2 weeks for a total of 12 weeks,Gys1 mRNA remaining [%],111,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Suppression Of Muscle Glycogen Synthase 1 Synthesis As An Approach For Substrate Reduction Therapy Of Pompe Disease,PMID 25350581,GYS1,intron,intron 4,NA,mouse,C57BL/6J mice,Null,NA,aaggaccagggtaagactagggact,unmodified PMO,NA,15 or 30,mg/ kg bodyweight by tail vein injection once every 2 weeks for a total of 12 weeks,Gys1 mRNA remaining [%],99.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Suppression Of Muscle Glycogen Synthase 1 Synthesis As An Approach For Substrate Reduction Therapy Of Pompe Disease,PMID 25350581,GYS1,exon,8,NA,mouse,C57BL/6J mice,Null,NA,gtcctggacaaggattgctgaccat,unmodified PMO,NA,15 or 30,mg/ kg bodyweight by tail vein injection once every 2 weeks for a total of 12 weeks,Gys1 mRNA remaining [%],81,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Suppression Of Muscle Glycogen Synthase 1 Synthesis As An Approach For Substrate Reduction Therapy Of Pompe Disease,PMID 25350581,GYS1,exon,5,NA,mouse,C57BL/6J mice,Null,NA,ctgcttccttgtctacattgaactg,unmodified PMO,NA,15 or 30,mg/ kg bodyweight by tail vein injection once every 2 weeks for a total of 12 weeks,Gys1 mRNA remaining [%],89,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Suppression Of Muscle Glycogen Synthase 1 Synthesis As An Approach For Substrate Reduction Therapy Of Pompe Disease,PMID 25350581,GYS1,exon,14,NA,mouse,C57BL/6J mice,Null,NA,atacccggcccaggtacttccaatc,unmodified PMO,NA,15 or 30,mg/ kg bodyweight by tail vein injection once every 2 weeks for a total of 12 weeks,Gys1 mRNA remaining [%],79,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Suppression Of Muscle Glycogen Synthase 1 Synthesis As An Approach For Substrate Reduction Therapy Of Pompe Disease,PMID 25350581,GYS1,exon,8,NA,mouse,C57BL/6J mice,Null,NA,ctggacaaggattgctgaccatagt,unmodified PMO,NA,15 or 30,mg/ kg bodyweight by tail vein injection once every 2 weeks for a total of 12 weeks,Gys1 mRNA remaining [%],72,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Suppression Of Muscle Glycogen Synthase 1 Synthesis As An Approach For Substrate Reduction Therapy Of Pompe Disease,PMID 25350581,GYS1,exon,initiation codon,NA,mouse,C57BL/6J mice,Null,NA,aattcatcctcccagtcttccaatc,unmodified PMO,NA,15 or 30,mg/ kg bodyweight by tail vein injection once every 2 weeks for a total of 12 weeks,Gys1 mRNA remaining [%],71,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Suppression Of Muscle Glycogen Synthase 1 Synthesis As An Approach For Substrate Reduction Therapy Of Pompe Disease,PMID 25350581,GYS1,exon,7,NA,mouse,C57BL/6J mice,Null,NA,tcccaccgagcaggccttactctga,unmodified PMO,NA,15 or 30,mg/ kg bodyweight by tail vein injection once every 2 weeks for a total of 12 weeks,Gys1 mRNA remaining [%],83,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Suppression Of Muscle Glycogen Synthase 1 Synthesis As An Approach For Substrate Reduction Therapy Of Pompe Disease,PMID 25350581,GYS1,exon,5,NA,mouse,C57BL/6J mice,Null,NA,gaccacagctcagaccctacctggt,unmodified PMO,NA,15 or 30,mg/ kg bodyweight by tail vein injection once every 2 weeks for a total of 12 weeks,Gys1 mRNA remaining [%],8.7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Antisense Oligonucleotide-Mediated Suppression Of Muscle Glycogen Synthase 1 Synthesis As An Approach For Substrate Reduction Therapy Of Pompe Disease,PMID 25350581,GYS1,exon,6,NA,mouse,C57BL/6J mice,Null,NA,tcactgtctggctcacatacccata,modified PMO,NA,15 or 30,mg/ kg bodyweight by tail vein injection once every 2 weeks for a total of 12 weeks,Gys1 mRNA remaining [%],7.8,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,STAT3,exon,19,NA,mouse,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,gaagcccttgccagccatgt,Others (2-MOE gapmer),NA,50,nM,mRNA,6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,STAT3,exon,6,NA,human,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,atcaaagtcatcctggag,Others (uniform 2'-MOE),NA,50,nM,mRNA,97,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,STAT3,exon,6,NA,human,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,atagttgaaatcaaagtc,Others (uniform 2'-MOE),NA,50,nM,mRNA,88,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,STAT3,intron,intron 1,NA,human,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,ttttgcatgatgtaaccact,Others (2-MOE gapmer),NA,50,nM,mRNA,Null,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,STAT3,exon,24,NA,human,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,cagcagatcaagtccaggga,Others (2-MOE gapmer),NA,50,nM,mRNA,18,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,STAT3,exon,6,NA,mouse,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,agttgaaatcaaagtcgt,Others (uniform 2'-MOE),NA,50,nM,mRNA,71,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,STAT3,exon,6,NA,mouse,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,tcttgagggttttgtagt,Others (uniform 2'-MOE),NA,50,nM,mRNA,82,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,STAT3,exon,17,NA,mouse,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,ggcttagtgaagaagttc,Others (uniform 2'-MOE),NA,50,nM,mRNA,97,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,STAT3,exon,17,NA,mouse,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,gtggtggacgagaactgc,Others (uniform 2'-MOE),NA,50,nM,mRNA,73,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,STAT3,exon,3,NA,mouse,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,gactcttgcaggaatcggct,Others (2-MOE gapmer),NA,50,nM,mRNA,Null,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,SOD1,exon,2,NA,mouse,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,ggacgtggaacccatgct,Others (uniform 2'-MOE),NA,50,nM,mRNA,83,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,SOD1,exon,3,NA,mouse,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,cttagagtgaggattaaa,Others (uniform 2'-MOE),NA,50,nM,mRNA,77,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,SOD1,exon,1,NA,mouse,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,ccgtcgcccttcagcacgca,Others (2-MOE gapmer),NA,50,nM,mRNA,7,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,HNRNPH1,exon,4,NA,human,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,ccaccggcaatgttatcc,Others (uniform 2'-MOE),NA,50,nM,mRNA,34.615,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,HNRNPH1,exon,4,NA,human,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,agcaaactgcacgaaggc,Others (uniform 2'-MOE),NA,50,nM,mRNA,24.35,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Nonsense-Mediated Decay As A Terminating Mechanism For Antisense Oligonucleotides,PMID 25350581,HNRNPH1,exon,8,NA,human,CCL-2 HeLa Cells and CRL-2299 bEnd.3 Cells,Cytofectin,NA,agcttcactgttacatccta,Others (2-MOE gapmer),NA,50,nM,mRNA,1.923,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/25350581,NA,NA,NA
journal article,Antisense-Mediated Isoform Switching Of Steroid Receptor Coactivator-1 In The Central Nucleus Of The Amygdala Of The Mouse Brain,PMID 23294837,DMD,exon,22,NA,mouse,C57bl/6j,Null,NA,cgccgccauuucucaacag,2OMe,NA,400,pmol/ul,Relative expression of the SRC-a1/SRC-1e 3 ratio,2,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23294837,NA,NA,NA
journal article,Antisense-Mediated Isoform Switching Of Steroid Receptor Coactivator-1 In The Central Nucleus Of The Amygdala Of The Mouse Brain,PMID 23294837,SRC1,exon,22,NA,mouse,C57bl/6j,Null,NA,cuguagucaccacagagaag,2OMe,NA,400,pmol/ul,Relative expression of the SRC-a1/SRC-1e 3 ratio,1,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23294837,NA,NA,NA
journal article,Antisense-Mediated Isoform Switching Of Steroid Receptor Coactivator-1 In The Central Nucleus Of The Amygdala Of The Mouse Brain,PMID 23294837,DMD,exon,22,NA,mouse,C57bl/6j,Null,NA,cgccgccauuucucaacag,2OMe,NA,400,pmol/ul,Relative expression of the SRC-a1/SRC-1e 3 ratio,1.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23294837,NA,NA,NA
journal article,Antisense-Mediated Isoform Switching Of Steroid Receptor Coactivator-1 In The Central Nucleus Of The Amygdala Of The Mouse Brain,PMID 23294837,SRC1,exon,22,NA,mouse,C57bl/6j,Null,NA,cuguagucaccacagagaag,2OMe,NA,400,pmol/ul,Relative expression of the SRC-a1/SRC-1e 3 ratio,1,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23294837,NA,NA,NA
journal article,Aon-Mediated Exon Skipping Restores Ciliation In Fibroblasts Harboring The Common Leber Congenital Amaurosis Cep290 Mutation,PMID 23344081,CEP290,intron,intron 26,NA,human,patient fibroblasts,Lipofectamine2000,NA,gggauagguaugagauacucacaau,2OMe,NA,150,nmol/l,Relative expression of wt CEP290,0.7,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344081,NA,NA,NA
journal article,Aon-Mediated Exon Skipping Restores Ciliation In Fibroblasts Harboring The Common Leber Congenital Amaurosis Cep290 Mutation,PMID 23344081,CEP290,intron,intron 26,NA,human,patient fibroblasts,Lipofectamine2000,NA,guaugagauacucacaauuacaacuggggc,2OMe,NA,150,nmol/l,Relative expression of wt CEP291,0.5,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344081,NA,NA,NA
journal article,Aon-Mediated Exon Skipping Restores Ciliation In Fibroblasts Harboring The Common Leber Congenital Amaurosis Cep290 Mutation,PMID 23344082,CEP290,intron,intron 26,NA,human,patient fibroblasts,Lipofectamine2000,NA,ccgaggcggguggaucacgag,2OMe,NA,150,nmol/l,Relative expression of wt CEP292,0.7,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344082,NA,NA,NA
journal article,Aon-Mediated Exon Skipping Restores Ciliation In Fibroblasts Harboring The Common Leber Congenital Amaurosis Cep290 Mutation,PMID 23344083,CEP290,intron,intron 26,NA,human,patient fibroblasts,Lipofectamine2000,NA,gguaugagauacucacaauuac,2OMe,NA,150,nmol/l,Relative expression of wt CEP293,0.9,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344083,NA,NA,NA
journal article,Aon-Mediated Exon Skipping Restores Ciliation In Fibroblasts Harboring The Common Leber Congenital Amaurosis Cep290 Mutation,PMID 23344084,CEP290,intron,intron 26,NA,human,patient fibroblasts,Lipofectamine2000,NA,cugggccaggugcgguggcucacaucugua,2OMe,NA,150,nmol/l,Relative expression of wt CEP294,0.8,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23344084,NA,NA,NA
journal article,Rescue Of Refractory Splicing Of Cftr Exon 12 Pathological Mutations G576a/G48c Using Antisense Oligonucleotides,"Haque, A. (2011)",CFTR,exon,12,NA,human,HeLa cells,Oligofectamine,NA,asgsgsasgsgacggaggacggaggacagoucouaoauoaaoauoacoaaoauocaogco,2OMe/Others (LNA),NA,200,mM,Exon rescue,0,NA,NA,NA,RNA,invalid,NA,NA,NA
journal article,Rescue Of Refractory Splicing Of Cftr Exon 12 Pathological Mutations G576a/G48c Using Antisense Oligonucleotides,"Haque, A. (2011)",CFTR,exon,12,NA,human,HeLa cells,Oligofectamine,NA,asgsgsasgsgacggaggacggaggacagoucouaoauoaaoauoacoaaoauocaogco,2OMe/Others (LNA),NA,300,mM,Exon rescue,0,NA,NA,NA,RNA,invalid,NA,NA,NA
journal article,Rescue Of Refractory Splicing Of Cftr Exon 12 Pathological Mutations G576a/G48c Using Antisense Oligonucleotides,"Haque, A. (2011)",CFTR,exon,12,NA,human,HeLa cells,Oligofectamine,NA,asgsgsasgsgacggaggacggaggacagoucouaoauoaaoauoacoaaoauocaogco,2OMe/Others (LNA),NA,400,mM,Exon rescue,0,NA,NA,NA,RNA,invalid,NA,NA,NA
journal article,Rescue Of Refractory Splicing Of Cftr Exon 12 Pathological Mutations G576a/G48c Using Antisense Oligonucleotides,"Haque, A. (2011)",CFTR,exon,12,NA,human,HeLa cells,Oligofectamine,NA,asgsgsasgsgacggaggacggaggacagoucouaoauoaaoauoacoaaoauocaogco,2OMe/Others (LNA),NA,500,mM,Exon rescue,0,NA,NA,NA,RNA,invalid,NA,NA,NA
journal article,Rescue Of Refractory Splicing Of Cftr Exon 12 Pathological Mutations G576a/G48c Using Antisense Oligonucleotides,"Haque, A. (2011)",CFTR,exon,12,NA,human,HeLa cells,Oligofectamine,NA,goucouaoauoaaoauoacoaaoauocaogco,2OMe/Others (LNA),NA,200,mM,Exon rescue,4.25,NA,NA,NA,RNA,invalid,NA,NA,NA
journal article,Rescue Of Refractory Splicing Of Cftr Exon 12 Pathological Mutations G576a/G48c Using Antisense Oligonucleotides,"Haque, A. (2011)",CFTR,exon,12,NA,human,HeLa cells,Oligofectamine,NA,goucouaoauoaaoauoacoaaoauocaogco,2OMe/Others (LNA),NA,300,mM,Exon rescue,9.51,NA,NA,NA,RNA,invalid,NA,NA,NA
journal article,Rescue Of Refractory Splicing Of Cftr Exon 12 Pathological Mutations G576a/G48c Using Antisense Oligonucleotides,"Haque, A. (2011)",CFTR,exon,12,NA,human,HeLa cells,Oligofectamine,NA,goucouaoauoaaoauoacoaaoauocaogco,2OMe/Others (LNA),NA,400,mM,Exon rescue,13.8,NA,NA,NA,RNA,invalid,NA,NA,NA
journal article,Rescue Of Refractory Splicing Of Cftr Exon 12 Pathological Mutations G576a/G48c Using Antisense Oligonucleotides,"Haque, A. (2011)",CFTR,exon,12,NA,human,HeLa cells,Oligofectamine,NA,goucouaoauoaaoauoacoaaoauocaogco,2OMe/Others (LNA),NA,500,mM,Exon rescue,19.46,NA,NA,NA,RNA,invalid,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,tccacagttgggcttttact,2OMe,NA,250,nmol/l,Null,59.54,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,tctgagatatatccacagtt,2OMe,NA,250,nmol/l,Null,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,mouse,TA/C57BL10,Null,NA,tctgagatatatccacagtt,2OMe,NA,3,nmol/l,Null,25.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,mouse,TA/C57BL10,Null,NA,tctgagatatatccacagtt,2OMe,NA,3,nmol/l,Null,48.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,tcttgacgggtctgagatat,2OMe,NA,250,nmol/l,Null,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,tgatgagtctcaggatttgc,2OMe,NA,250,nmol/l,Null,64.78,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,ttcatgggtttgatgagtct,2OMe,NA,250,nmol/l,Null,57.51,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,ttgtaccgtctttcatgggt,2OMe,NA,250,nmol/l,Null,74,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,mouse,TA/C57BL10,Null,NA,ttgtaccgtctttcatgggt,2OMe,NA,3,nmol/l,Null,54.6,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,mouse,TA/C57BL10,Null,NA,ttgtaccgtctttcatgggt,2OMe,NA,3,nmol/l,Null,24.5,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,cagagatcggattccagtat,2OMe,NA,250,nmol/l,Null,50.06,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,tgtcaagtttcagagatcgg,2OMe,NA,250,nmol/l,Null,26.82,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,cctgggctcatgtcaagttt,2OMe,NA,250,nmol/l,Null,41,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,ctgggaaggttacagcaaga,2OMe,NA,250,nmol/l,Null,28.91,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,tctcctggtcctgggaaggt,2OMe,NA,250,nmol/l,Null,41.2,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,cagcccatcttctcctggtc,2OMe,NA,250,nmol/l,Null,48,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,tcttgacgggtctgagatatatccacagtt,unmodified PMO,NA,250,nmol/l,Null,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,tgtaccgtctttcatgggtttgatgagtct,unmodified PMO,NA,250,nmol/l,Null,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,cctgggctcatgtcaagtttcagagatcgg,unmodified PMO,NA,250,nmol/l,Null,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,Null,C2C12,Lipofectamine 2000,NA,cagcccatcttctcctggtcctgggaaggt,unmodified PMO,NA,250,nmol/l,Null,100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,mouse,Soleus/C57BL10,Null,NA,cagcccatcttctcctggtc,modified PMO,NA,6,mg/kg,Null,79,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-Induced Myostatin Exon Skipping Leads To Muscle Hypertrophy In Mice Following Octa Guanidine Morpholino Oligomer Treatment,PMID 20924365,MSTN,exon,2,NA,mouse,EDL/C57BL10,Null,NA,cagcccatcttctcctggtc,modified PMO,NA,6,mg/kg,Null,9,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/20924365,NA,NA,NA
journal article,Antisense-mediated exon skipping to correct IL-12R1 deficiency in T cells,PMID 19258592,IL12RB1,exon,2,NA,human,T-cells,VPA-1002,NA,ccugaaaacagcacucacuggu,2OMe,NA,20,ug/mL,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19258592,NA,NA,NA
journal article,Antisense-mediated exon skipping to correct IL-12R1 deficiency in T cells,PMID 19258592,IL12RB2,exon,2,NA,human,T-cells,VPA-1002,NA,gucugcauccggauauggcggg,2OMe,NA,20,ug/mL,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19258592,NA,NA,NA
journal article,Antisense-mediated exon skipping to correct IL-12R1 deficiency in T cells,PMID 19258592,IL12RB3,exon,2,NA,human,T-cells,VPA-1002,NA,ccuaaaaacagcacucacuggu,2OMe,NA,20,ug/mL,Skip,35.126,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19258592,NA,NA,NA
journal article,Antisense-mediated exon skipping to correct IL-12R1 deficiency in T cells,PMID 19258592,IL12RB4,exon,2,NA,human,T-cells,VPA-1002,NA,auauggcggguccugaaaaca,2OMe,NA,20,ug/mL,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19258592,NA,NA,NA
journal article,Antisense-mediated exon skipping to correct IL-12R1 deficiency in T cells,PMID 19258592,IL12RB5,exon,2,NA,human,T-cells,VPA-1002,NA,cugagucugcauccggauaugg,2OMe,NA,20,ug/mL,Skip,Null,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19258592,NA,NA,NA
journal article,Antisense-mediated exon skipping to correct IL-12R1 deficiency in T cells,PMID 19258592,IL12RB6,exon,2,NA,human,T-cells,VPA-1002,NA,agcacucacugguucugcaggc,2OMe,NA,20,ug/mL,Skip,64.157,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19258592,NA,NA,NA
journal article,Antisense-mediated exon skipping to correct IL-12R1 deficiency in T cells,PMID 19258592,IL12RB7,exon,2,NA,human,T-cells,VPA-1002,NA,ccuaaaaacagcacucacuggu/cugagucugcauccggauaugg,2OMe,NA,20,ug/mL,Skip,75.782,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19258592,NA,NA,NA
journal article,Antisense-mediated exon skipping to correct IL-12R1 deficiency in T cells,PMID 19258592,IL12RB8,exon,2,NA,human,T-cells,VPA-1002,NA,agcacucacugguucugcaggc/cugagucugcauccggauaugg,2OMe,NA,20,ug/mL,Skip,25.018,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/19258592,NA,NA,NA
journal article,"Qr-313, An Antisense Oligonucleotide,Shows Therapeutic Efficacy For Treatment Of Dominant And Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study",PMID 32946877,COL7A1,exon,73,NA,human,Immortalized pateint keratinocytes(c.6081delC; RDEBK-muE73-3),"INTERFERin (Polyplus Transfection, Illkirch, France) or lipofectamine-2000 (Thermo Fisher Scientific)",NA,cguucuccaggaaagccgaug,2OMe,NA,20,nM,Skip,strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/32946877,NA,NA,NA
journal article,"Qr-313, An Antisense Oligonucleotide,Shows Therapeutic Efficacy For Treatment Of Dominant And Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study",PMID 32946877,COL7A1,exon,73,NA,human,Immortalized pateint keratinocytes(c.6081delC; RDEBK-muE73-3),"INTERFERin (Polyplus Transfection, Illkirch, France) or lipofectamine-2000 (Thermo Fisher Scientific)",NA,cguucuccaggaaagccgaug,2OMe,NA,40,nM,Skip,strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/32946877,NA,NA,NA
journal article,"Qr-313, An Antisense Oligonucleotide,Shows Therapeutic Efficacy For Treatment Of Dominant And Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study",PMID 32946877,COL7A1,exon,73,NA,human,Immortalized pateint keratinocytes(c.6081delC; RDEBK-muE73-3),"INTERFERin (Polyplus Transfection, Illkirch, France) or lipofectamine-2000 (Thermo Fisher Scientific)",NA,cguucuccaggaaagccgaug,2OMe,NA,60,nM,Skip,strong skipped band,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/32946877,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,73,NA,human,F-RDEB (fibroblasts from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,50,nM,Skip,95,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,73,NA,human,F-RDEB (fibroblasts from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,100,nM,Skip,95,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,73,NA,human,F-RDEB (fibroblasts from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,200,nM,Skip,95,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,73,NA,human,K-RDEB (keratinocytes from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,50,nM,Skip,60,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,73,NA,human,K-RDEB (keratinocytes from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,100,nM,Skip,60,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,73,NA,human,K-RDEB (keratinocytes from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,200,nM,Skip,70,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,80,NA,human,F-RDEB (fibroblasts from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,50,nM,Skip,90,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,80,NA,human,F-RDEB (fibroblasts from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,100,nM,Skip,90,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,80,NA,human,F-RDEB (fibroblasts from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,200,nM,Skip,90,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,80,NA,human,K-RDEB (keratinocytes from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,50,nM,Skip,50,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,80,NA,human,K-RDEB (keratinocytes from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,100,nM,Skip,50,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Targeted Exon Skipping Restores Type Vii Collagen Expression And Anchoring Fibril Formation In An In Vivo Rdeb Model,PMID 27498345,COL7A1,exon,80,NA,human,K-RDEB (keratinocytes from RDEB-1 patient),Lipofectamine 2000,NA,unspecified,2OMe,NA,200,nM,Skip,50,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27498345,NA,NA,NA
journal article,Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients' Cells,PMID 27858744,DYSF,exon,32,NA,human,Miyoshi myopathy myoblasts c.[3477C>A]+[5979dupA]+[Ala1993 Glu1994insArg;Ser1995?],Oligofectamine,NA,gcguagaugguagcgguuccc,2OMe,NA,800,nM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27858744,NA,NA,NA
journal article,Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients' Cells,PMID 27858744,DYSF,exon,32,NA,human,Miyoshi myopathy myoblasts c.[3477C>A]+[5979dupA]+[Ala1993 Glu1994insArg;Ser1995?],Oligofectamine,NA,accuaccagaaaaagaguccuu,2OMe,NA,800,nM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27858744,NA,NA,NA
journal article,Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients' Cells,PMID 27858744,DYSF,exon,32,NA,human,LGMD2B myoblasts NM_0003498.3: c.[342+1G>A]+[3516 3517delTT]p.[Ser1173?],Oligofectamine,NA,accuaccagaaaaagaguccuu,2OMe,NA,800 upto 3 times,nM,Skip,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/27858744,NA,NA,NA
journal article,Megalencephalic Leukoencephalopathy With Subcortical Cysts Type 1 (Mlc1) Due To A Homozygous Deep Intronic Splicing Mutation (C.895-226t>G) Abrogated In Vitro Using An Antisense Morpholino Oligonucleotide.,PMID 22552818,MLC1,pseudoexon,pseudoexon 10,NA,human,Human lymphoblast (c.895-226T>G),Endoporter 8uL/mL,NA,atcagcttgtgttcaacataccgga,unmodified PMO,NA,10,uM,Skip,~100,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/22552818,NA,NA,NA
journal article,Ultrasound-Enhanced Delivery Of Morpholino With Bubble Liposomes Ameliorates The Myotonia Of Myotonic Dystrophy Model Mice,PMID 23873129,DMPK,exon,exon 7a,NA,monkey,COS-7 monkey fibroblasts,Polyethylenimine,NA,cugcccaggcacggucugcaacaga,2OMe,NA,0.1,ug,Skip,~65,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23873129,NA,NA,NA
journal article,Ultrasound-Enhanced Delivery Of Morpholino With Bubble Liposomes Ameliorates The Myotonia Of Myotonic Dystrophy Model Mice,PMID 23873129,DMPK,exon,exon 7a,NA,monkey,COS-7 monkey fibroblasts,Polyethylenimine,NA,ggagaucaagcugcccaggcacggu,2OMe,NA,0.1,ug,Skip,~75,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23873129,NA,NA,NA
journal article,Ultrasound-Enhanced Delivery Of Morpholino With Bubble Liposomes Ameliorates The Myotonia Of Myotonic Dystrophy Model Mice,PMID 23873129,DMPK,exon,exon 7a,NA,monkey,COS-7 monkey fibroblasts,Polyethylenimine,NA,acgcccacugcacaggcuggcacca,2OMe,NA,0.1,ug,Skip,~52,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23873129,NA,NA,NA
journal article,Ultrasound-Enhanced Delivery Of Morpholino With Bubble Liposomes Ameliorates The Myotonia Of Myotonic Dystrophy Model Mice,PMID 23873129,DMPK,exon,exon 7a,NA,monkey,COS-7 monkey fibroblasts,Polyethylenimine,NA,aucaggggcugcaaaguagcauccc,2OMe,NA,0.1,ug,Skip,~55,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23873129,NA,NA,NA
journal article,Ultrasound-Enhanced Delivery Of Morpholino With Bubble Liposomes Ameliorates The Myotonia Of Myotonic Dystrophy Model Mice,PMID 23873129,DMPK,exon,exon 7a,NA,monkey,COS-7 monkey fibroblasts,Polyethylenimine,NA,uagggaggaagugaaacuugccucc,2OMe,NA,0.1,ug,Skip,~52,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/23873129,NA,NA,NA
journal article,Ultrasound-Enhanced Delivery Of Morpholino With Bubble Liposomes Ameliorates The Myotonia Of Myotonic Dystrophy Model Mice,PMID 23873129,DMPK,exon,exon 7a,NA,monkey,COS-7 monkey fibroblasts,Endoporter,NA,ccaggcacggtctgcaacagagaag,unmodified PMO,NA,0.1,ug,Skip,~75,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23873129,NA,NA,NA
journal article,Ultrasound-Enhanced Delivery Of Morpholino With Bubble Liposomes Ameliorates The Myotonia Of Myotonic Dystrophy Model Mice,PMID 23873129,DMPK,exon,exon 7a,NA,monkey,COS-7 monkey fibroblasts,Endoporter,NA,ggagatcaagctgcccaggcacggt,unmodified PMO,NA,0.1,ug,Skip,~92,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/23873129,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,uuuaaaaccuguuaaaacaagaaag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,cuagauccgcuuuuaaaaccuguuaaaacaa,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,ccgcuuuuaaaaccuguuaa,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,cuagauccgcuuuuaaaaccuguua,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,ucuuuucuagauccgcuuuuaaaaccuguua,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,ucuuuucuagauccgcuuuuaaaac,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,cuuuuucuuuucuagauccgcuuuu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,gauugcuuuuucuuuucuagauccg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,uggauugcuuuuucuuuucuagaucc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,gaucuuguuugagugaauacagu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,ccgucuucugggucacugacuua,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,caugcuuccgucuucugggucacug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,guuauccagccaugcuuccguc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,guaucacuaaccugugcuguac,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,16,NA,human,Primary human myoblasts,Lipofectamine2000,NA,ugauaauugguaucacuaaccugug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,51,NA,human,Primary human myoblasts,Lipofectamine2000,NA,accagaguaacagucugaguaggagc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,51,NA,human,Primary human myoblasts,Lipofectamine2000,NA,acaucaaggaagauggcauuucuaguuugg,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,51,NA,human,Primary human myoblasts,Lipofectamine2000,NA,acaucaaggaagauggcauuucuag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,51,NA,human,Primary human myoblasts,Lipofectamine2000,NA,cacccaccaucacccucugug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,51,NA,human,Primary human myoblasts,Lipofectamine2000,NA,uucuguccaagcccgguugaaauc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,51,NA,human,Primary human myoblasts,Lipofectamine2000,NA,aucaucucguugauauccucaa,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,51,NA,human,Primary human myoblasts,Lipofectamine2000,NA,cucauaccuucugcuugaugauc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,51,NA,human,Primary human myoblasts,Lipofectamine2000,NA,aucauuuuuucucauaccuucugcu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,53,NA,human,Primary human myoblasts,Lipofectamine2000,NA,auucuuucaacuagaauaaaag,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,53,NA,human,Primary human myoblasts,Lipofectamine2000,NA,gauucugaauucuuucaacuagaau,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,53,NA,human,Primary human myoblasts,Lipofectamine2000,NA,ctgaaggtgttcttgtacttcatcc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,DNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,53,NA,human,Primary human myoblasts,Lipofectamine2000,NA,cuguugccuccgguucugaaggug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,53,NA,human,Primary human myoblasts,Lipofectamine2000,NA,cauucaacuguugccuccgguucugaaggug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,53,NA,human,Primary human myoblasts,Lipofectamine2000,NA,cauucaacuguugccuccgguucug,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,53,NA,human,Primary human myoblasts,Lipofectamine2000,NA,uuggcucuggccuguccuaaga,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,53,NA,human,Primary human myoblasts,Lipofectamine2000,NA,guauagggacccuccuuccaugacu,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,53,NA,human,Primary human myoblasts,Lipofectamine2000,NA,uacuaaccuugguuucuguga,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
journal article,The Influence Of Antisense Oligonucleotide Length On Dystrophin Exon Skipping,PMID 17164787,DMD,exon,53,NA,human,Primary human myoblasts,Lipofectamine2000,NA,gguaucuuugauacuaaccuugguuuc,2OMe,NA,unspecified,Null,Null,unspecified,NA,NA,NA,RNA,https://pubmed.ncbi.nlm.nih.gov/17164787,NA,NA,NA
